Document:

EX-4.10

 Exhibit 4.10 
 CONFIDENTIAL TREATMENT REQUESTED 
 21 November 2014

 GLAXOSMITHKLINE PLC 
 and 
 NOVARTIS AG 

 
  

 
 DEED OF AMENDMENT AND
RESTATEMENT 
 relating to the 
 SALE AND PURCHASE AGREEMENT 
 dated 22 April 2014, as amended and
restated on 29 May 2014 
  
  

 
  
  

 
 Freshfields. Bruckhaus Deringer LLP 

65 Fleet Street 

London EC4Y 1HS 

 Deed of Amendment and Restatement 

This Deed (the “Deed”) is made on 21 November 2014 between: 

 

	(1)	GLAXOSMITHKLINE PLC, a public limited company incorporated in England and Wales whose registered office is at 980 Great West Road, Brentford, Middlesex,
TW8 9GS (the “Seller”); and 

  

	(2)	NOVARTIS AG, a corporation (Aktiengesellschaft) incorporated in Switzerland whose registered office is at Lichtstrasse 35, 4056 Basel, Switzerland (the
“Purchaser”), 

 each a “party” and together the “parties”. 

Whereas: 
  

	(A)	The Seller and the Purchaser entered into the Original Agreement (as defined below) on 22 April 2014 (the “Signing Date”).

  

	(B)	The parties now wish to further amend and restate the Original Agreement, in the form of the Amended Agreement (as defined below). 

It is agreed as follows: 
  

	1.	Definitions and Interpretation 

 In this Deed, unless the context otherwise requires, the provisions in this clause 1 apply. 
  

	1.1	Incorporation of defined terms 

 Unless otherwise stated, terms defined in the Original Agreement shall have the same meaning in this Deed. 
  

	1.2	Definitions 

“Amended Agreement” means the Original Agreement, as amended and restated in the form set out in Schedule 1 to this Deed;
and 
 “Original Agreement” means the Sale and Purchase Agreement relating to the Seller’s oncology
business, dated 22 April 2014 as amended and restated on 29 May 2014. 
  

	1.3	Interpretation Clauses 

  

	 	1.3.1	The principles of interpretation set out in Clause 1 of the Original Agreement shall have effect as if set out in this Deed, save that references to “this
Agreement” shall be construed as references to “this Deed”. 

  

	 	1.3.2	References to this Deed include the Schedule. 

  

	2.	Amendment 

  

	2.1	In accordance with Clauses 16.4.3 and 16.5.1 of the Original Agreement, the parties agree that the Original Agreement shall be amended and restated as set out in
Schedule 1 to this Deed. 

  
 Page 2

	2.2	The amendment and restatement of the Original Agreement pursuant to clause 2.1 shall take effect from the Signing Date, as if the Amended Agreement had been
entered into on the Signing Date. Therefore, upon this Deed being entered into, the Amendment Agreement shall supersede the Original Agreement in its entirety. 

 

	3.	Miscellaneous 

  

	3.1	Each party represents and warrants that it has full power and authority to enter into this Deed and to perform its obligations under it.

  

	3.2	The provisions of Clauses 13, 16.2 to 16.5 and 16.11 to 16.15 of the Amended Agreement shall apply to this Deed as if set out in full in this Deed and as if
references in that clause to “this Agreement” are references to this Deed and references to “party” or “parties” are references to parties to this Deed. 

  
 Page 3

 In witness whereof this Deed has been delivered on the date first stated above. 

 

							
	Executed as a DEED by	 	)	 		 	
	GLAXOSMITHKLINE PLC acting by its	 	)	 		 	 /s/ Subesh Williams

	duly appointed attorney	 	)	 		 	(Signature of attorney)
		 	)	 		 	
	in the presence of:	 	)	 		 	
				
	Witness’s signature:	 		 		 	/s/ Emma Lloyd-Jones
				
	Name (print):	 		 		 	Emma Lloyd-Jones
				
	Occupation:	 		 		 	Trainee Solicitor
				
	Address:	 		 		 	980 Great West Road
		 		 		 	Brentford, TW8 9GS

  
 Page 4

					
	Executed as a DEED by	 	 }
  
	 	
	  
 Roland Altwegg and
	 	 	 /s/ Roland Altwegg

	  
 Jonathan Emery
	 	 	 /s/ Jonathan Emery

	on behalf of NOVARTIS AG	 	 	

  
 Page 5

 SCHEDULE 1 
 Amended Agreement 
  
  

 
 Freshfields. Bruckhaus Deringer LLP 

65 Fleet Street 

London EC4Y 1HS 

 Dated 22 April 2014 

as amended and restated on 29 May 2014, and as further amended and restated 

on 

21 November 2014 
 GLAXOSMITHKLINE PLC 
 and 

NOVARTIS AG 

	
	         
	  

 SALE AND PURCHASE AGREEMENT 

	
	         
	  

  
 1 

 Sale and Purchase Agreement 
 This Agreement is made on 22 April 2014, as amended and restated on 29 May 2014, and as further amended and restated on 21 November 2014 

Between: 
  

	(1)	GLAXOSMITHKLINE PLC, a public limited company incorporated in England and Wales whose registered office is at 980 Great West Road, Brentford TW8 9GS,
United Kingdom (the “Seller”); and 

  

	(2)	NOVARTIS AG, a corporation (Aktiengesellschaft) incorporated in Switzerland whose registered office is at Lichtstrasse 35, 4056 Basel, Switzerland (the
“Purchaser”), 

 each a “party” and together the “parties”. 

Whereas: 
  

	(A)	As of the date of this Agreement, the Seller and certain of the Seller’s Affiliates own or license certain assets and other rights relating to the Products and are
engaged in the Business; 

  

	(B)	The Seller has agreed, inter alia, to procure the sale of the Share and to sell or license (or cause the sale or licence of) certain assets and other rights
relating to the Products together with the Assumed Liabilities comprising the Business, and to assume the obligations imposed on the Seller under this Agreement; 

 

	(C)	The Purchaser has agreed, inter alia, to purchase or procure the purchase of the Share and to purchase or license certain assets and other rights relating to the
Products, together with the Assumed Liabilities comprising the Business, and to assume the obligations imposed on the Purchaser under this Agreement; 

  

	(D)	In connection with the transactions contemplated by this Agreement, the Purchaser and the Seller, or certain of their respective Affiliates, will enter into the
Ancillary Agreements; and 

  

	(E)	The Seller has notified the Purchaser of its intention to carry out the Pre-Closing Product Reorganisation and accordingly this Agreement has been amended to give
effect to it. 

 It is agreed as follows: 
  

	1.	Interpretation 

 In this
Agreement, unless the context otherwise requires, the provisions in this Clause 1 apply: 

	1.1	Definitions 

“Action” means the taking of any steps by any Governmental Entity to seek a Judgment which would have the effect of
preventing the consummation of the transactions contemplated by this Agreement by the Purchaser; 
 “Affiliate”
means: 
  

	 	(i)	with respect to any person (other than a party to this Agreement), any other person that Controls, is Controlled by or is under common Control with such person; or

  

	 	(ii)	with respect to a party to this Agreement, any other person that is Controlled by such party, 

and “Affiliates” shall be interpreted accordingly; 

“Agreed Terms” means, in relation to a document, such document in the terms agreed between the Seller and the Purchaser
and signed for identification purposes by the Seller’s Lawyers and the Purchaser’s Lawyers, with such alterations as may be agreed in writing between the Seller and the Purchaser from time to time; 

“Agreed UK Restructuring Arrangement” means the pension augmentation (or cash in lieu of augmentation) policy applying on
redundancy to UK employees of the Seller’s Group who joined service prior to 1 April 2005 as disclosed to the Purchaser prior to the date of this Agreement via a document which was signed on 22 April 2014 by Eleanor Hart of Slaughter
and May and Andrew Murphy of Freshfields Bruckhaus Deringer LLP for identification purposes; 
 “Agreement”
means this business sale and purchase agreement; 
 “Allocation Statement” means a statement prepared in
accordance with Schedule 10 allocating whole number percentages to each of the Products so that the aggregate of those percentages equals 100 per cent.; 
 “Allowance” means any amount payable or repayable to customers in respect of a contractual allowance or discount due on the sales of products; 

“Ancillary Agreements” means the Implementation Agreement, the Company Tax Indemnity, the Disclosure Letter, the
Manufacturing and Supply Agreement, the Transitional Distribution Services Agreement, the France Offer Letter, the France SPA, the Netherlands Offer Letter, the Netherlands APA, the Purchaser Tax Indemnity, the Transitional Services Agreement, the
Ofatumumab Intellectual Property Licence Agreement, the Oncology Intellectual Property Licence Agreement, the Intellectual Property Assignment, the Claims Management Agreement, the Quality Agreement, and the Pharmacovigilance Agreement; 

“Anti-Bribery Law” means any Applicable Law that relates to bribery or corruption, including the US Foreign Corrupt
Practices Act of 1977 and the UK Bribery Act 2010, in each case as amended, re-enacted or replaced from time to time; 

“Applicable Law” means any supra-national, federal, national, state, municipal or local statute, law, ordinance,
regulation, rule, code, order (whether executive, legislative, judicial or otherwise), judgment, injunction, notice, decree or other requirement or rule of law or legal process (including common law), or any other order of, or agreement issued,
promulgated or entered into by, any Governmental Entity or any rule or requirement of any national securities exchange, including all Healthcare Laws, and GCP, GLP, and GMP, each as may be amended from time to time; 

  
 3 

 “Aspen Agreements” means: (i) the Amended and Restated Sale and
Purchase Agreement dated 14 August 2012 and amended and restated on 30 November 2012, between Glaxo Group Limited and Aspen Global Incorporated; and (ii) the Principal Manufacturing and Supply Agreement dated 14 August 2002,
between GlaxoSmithKline Trading Services Limited and Aspen Global Incorporated; 
 “Assets” means the property,
rights and assets referred to in Clause 2.3.1, in each case excluding the Excluded Assets; 
 “Associated
Person” means, in relation to the Seller’s Group, a person (including any director, officer, employee, agent or other intermediary) who performs services for or on behalf of any member of the Seller’s Group or who holds shares of
capital stock, partnership interests, limited liability company membership interests and units, shares, interest and other participations in any member of the Seller’s Group (in each case when performing such services or acting in such
capacity); 
 “Assumed Liabilities” means the Liabilities of the Business other than: (i) the Excluded
Liabilities; (ii) any Relevant Pension and Employment Liability; and (iii) any Liabilities in respect of Tax; 

“Benefit Plans” means the US Benefit Plans and the Non-US Benefit Plans; 

“Business” means the business of the Seller’s Group (including the Company) of research and development (including
any studies or trials (whether or not undertaken with third parties)) relating to the Products and the Commercialisation of the Products but excluding (i) the Manufacturing of the Products and (ii) the Seller Pipeline; 

“Business Consideration” has the meaning set forth in Clause 3.1.1; 

“Business Day” means a day which is not a Saturday, a Sunday or a public holiday in the canton of Basel-Stadt
(Switzerland) or London; 
 “Business Goodwill” means the goodwill of the Business; 

“Business Product Intellectual Property Rights” means the Owned Product Intellectual Property Rights and the Transferred
Product Intellectual Property Rights; 
 “Business Sellers” means the members of the Seller’s Group that
own assets of or otherwise conduct any of the Business immediately prior to Closing, or for the purposes of the Seller’s Warranties, at the date of this Agreement; 
 “Cabilly Agreement” means the licence and settlement agreement dated 26 March 2012 between: 
  

	 	(i)	Genentech Inc.; 

  

	 	(ii)	City of Hope; 

  
 4 

	 	(iii)	Glaxo Group Limited; 

  

	 	(iv)	Lonza Biologics Inc.; and 

  

	 	(v)	Lonza Biologics plc; 

“Call for New Tender” means any calls for a tender (including any tender for a basket of products), whether a new tender
or the renewal of an existing tender, which includes the Products and which is published after Closing of which the Seller and/or any of the Seller’s Affiliates become aware and which relates in whole or in part to the sale of Products;

 “Certificate” means a certificate signed by a director, officer or an authorised signatory of the Seller in
the form set out in Schedule 16, to be provided to the Purchaser immediately prior to Closing; 
 “CFIUS” means
the Committee on Foreign Investment in the United States; 
 “CFIUS Approval” means written notice from CFIUS
that any review or investigation of the Transaction under Section 721 of the Defense Production Act of 1950, as amended (50 U.S.C. App. Section 2170), has been concluded and there are no unresolved national security concerns with respect
to the Transaction or the President of CFIUS shall have determined not to take action with respect to the Transaction; 

“CFIUS Filing” has the meaning set forth in Clause 4.2.3; 

“Claims Management Agreement” means the agreement between the Seller and the Purchaser, to be negotiated in good faith
between the parties and entered into at Closing, in respect of the management of claims or investigations by or against third parties (including by any Governmental Entity) which constitute or may constitute an Assumed Liability or an Excluded
Liability; 
 “Clinical Trials/Data Liability” means any Liability arising out of, relating to or resulting from
any breach of Applicable Law in connection with the conduct of, or reporting or data in relation to, clinical studies or trials (including post-approval studies) in relation to the Products or the Business; 

“Closing” means the completion of the sale of the Share and the Business pursuant to this Agreement; 

“Closing Date” means the date on which Closing takes place; 

“COBRA” means the Consolidated Omnibus Budget Reconciliation Act of 1985 of the United States, as amended, section 4980B
of the Code, Title I Part 6 of ERISA, and any similar US state group health plan continuation law, together with its implementing regulations; 
 “Code” means the U.S. Internal Revenue Code of 1986, as amended, together with its implementing regulations; 
 “Commercial Information” means information that is, as of the Closing Date, owned by the Seller and/or its Affiliates and relates exclusively to the Commercialisation of any Product;

  
 5 

 “Commercial Practices Liability” means any Liability arising out of,
relating to or resulting from any breach of Applicable Law in connection with the Commercialisation of products; 

“Commercialise” means to promote, market, distribute and/or sell a Product and “Commercialising” and
“Commercialisation” shall be construed accordingly; 
 “Company” has the meaning given to it in
Schedule 18; 
 “Company Intra-Group Debt” means all sums owed by the Company to GlaxoSmithKline Finance plc at
the Closing Date (immediately prior to Closing) as shall be notified by the Seller to the Purchaser in accordance with Clause 6.3.2; 
 “Company Tax Indemnity” has the meaning given to it in Schedule 18; 
 “Competing Product” has the meaning given to it in Clause 12.1; 

“Contract” means any binding contract, agreement, instrument, lease, licence or commitment, excluding any contract with
any Employee; 
 “Contracts Liabilities” means Liabilities relating to the: (i) Transferred Contracts;
(ii) Transferred Intellectual Property Contracts; and (iii) all other contracts or parts thereof transferred, assigned, novated or assumed by the Purchaser pursuant to this Agreement, and a “Contracts Liability” shall mean
any one of them; 
 “Control” means the power to direct the management and policies of a person (directly or
indirectly), whether through ownership of voting securities, by Contract or otherwise (and the term “Controlled” shall be interpreted accordingly); 
 “Co-Owned Business Product Intellectual Property Right” means any Business Product Intellectual Property Right that is owned in part by a third party; 

“Co-Owned Transferred Product Intellectual Property Right” means any Transferred Product Intellectual Property Right that
is owned in part by a third party; 
 “Copyright” means any works of authorship, copyrights, database rights,
mask work rights and registrations and applications therefor; 
 “Cork FDA Matter” means the deficiencies in GMP
noted in the observations made by the FDA in a Form FDA 483 following an inspection of the Cork Site between 18 and 23 October 2013 which are the subject of the Warning Letter dated 18 March 2014 issued by the FDA to a member of the
Seller’s Group; 
 “Data Room” means the electronic data room containing documents and information relating
to the Business made available by Intralinks on behalf of the Seller, the contents of which are listed in the Disclosure Letter; 

“Decision” means the issuing of any decision by a competition, antitrust, foreign investment, national, local,
supranational or supervisory or other government, governmental, quasi-governmental, trade, or regulatory body, agency, branch, subdivision, department, commission, official or authority, including any Tax Authority and any governmental department
and any court or other tribunal, that would have the effect of prohibiting the acquisition of the Business by the Purchaser; 

  
 6 

 “Deferred Employee” means any person to whom the Seller or any other member
of the Seller’s Group has made an offer of employment for a role within the Business in compliance with Clause 5 and whose employment in the Business will take effect on a date following the Closing Date, save that no person shall become a
Deferred Employee unless and until the Seller has provided to the Purchaser a copy of the offer letter setting out the agreed principal terms of employment and/or employment agreement (if executed) applicable to such person; 

“Development Plan” means the development plans and study protocols, including the target product profile, development
designs, timelines and costs of the studies and trials being undertaken by the Seller’s Group (whether or not approved by any Governmental Entity) in respect of each Product Expansion as at the date of this Agreement, including the Key Study
Plans; 
 “Disclosure Letter” means the letter dated on the same date as this Agreement from the Seller to the
Purchaser disclosing information constituting exceptions to the Seller’s Warranties; 
 “Divested Zofran
Product” means Zofran (Ondansetron) in Australia, following the divestment by the Seller or its Affiliates of its rights to Commercialise it in Australia only to Aspen Global Incorporated; 

“Election Date” has the meaning set forth in Clause 4.2.3; 

“Employee Benefit Indemnification Amount” has the meaning given to it in Schedule 9; 

“Employee Benefits” has the meaning given to it in Schedule 9; 

“Employees” means, other than Excluded Employees, the employees of any member of the Seller’s Group who work wholly
or substantially in the Business from time to time including the International Assignees and provided that, in relation to the Seller’s Warranties only, the words “from time to time” shall be deemed to be replaced by “at the date
of this Agreement”, and “Employee” means any one of them; 
 “Encumbrance” means any
claim, charge, mortgage, lien, option, equitable right, power of sale, pledge, hypothecation, usufruct, retention of title, right of pre-emption, right of first refusal or other security interest of any kind or an agreement, arrangement or
obligation to create any of the foregoing, and for the avoidance of doubt, shall exclude any licences of, or claims of infringement relating to, Intellectual Property Rights; 
 “ERISA” means the Employee Retirement Income Security Act of 1974 of the United States, as amended, together with its implementing regulations; 

“Estimated Employee Benefit Adjustment” means the Seller’s reasonable estimate (in so far as practicable), made in
good faith after consulting with the Purchaser, of 95 per cent. of the anticipated aggregate of the Employee Benefit Indemnification Amounts, to be notified by the Seller to the Purchaser pursuant to Clause 6.3.9; 

“Excluded Assets” means the property, rights and assets referred to in Clause 2.3.2; 

  
 7 

 “Excluded Contracts” means, collectively, each Contract: (i) which is
not Exclusively Related to the Business; or (ii) which is listed in Part 2 of Schedule 3; 
 “Excluded
Employees” means the employees of any member of the Seller’s Group who work in the Discovery organisation as operated by the Seller’s Group, together with such other employees of any member of the Seller’s Group as may be
agreed in writing between the Seller and the Purchaser after the date of this Agreement but before the Closing Date; 

“Excluded Liabilities” means all Liabilities relating to: 

 

	 	(i)	the Business to the extent they have arisen or arise (whether before or after Closing) as a result of, or otherwise relate to, an act, omission, fact, matter,
circumstance or event undertaken, occurring, in existence or arising before Closing, other than any Relevant Pension and Employment Liability; 

  

	 	(ii)	the Seller Group Retained Business; and 

  

	 	(iii)	any Seller Allowance, Rebate and Royalty Amount; 

 “Exclusively Related to the Business” means exclusively related to, or exclusively used or held for use exclusively in connection with, the Business; 

“Exploitation Arrangements” has the meaning given to it in Schedule 18; 

“FCA” means the Financial Conduct Authority; 
 “FDA” means the United States Food and Drug Administration (or its successor); 
 “France Assumed Liabilities” means the Assumed Liabilities to the extent they relate to the France Business; 
 “France Business” means that part of the Business, comprising the activities of the France Employees; 
 “France Closing” has the meaning given to it in the France SPA; 

“France Employees” means those of the Employees who are employed in France; 

“France Offer Letter” means the letter from the Purchaser to the Seller in respect of the binding offer from the
Purchaser to acquire the France Business dated on or around the date hereof; 
 “France Put Option Exercise” has
the meaning given to it in the France Offer Letter; 
 “France SPA” OR “France APA” has
the meaning given to it in the France Offer Letter; 
 “FSMA” means the Financial Services and Markets Act 2000;

 “Full Disclosure” means disclosure by the Seller to the Purchaser of the material terms, including financial
terms, of a Relevant Part of a Shared Business Contract; 
 “Full Title Guarantee” means on the basis that the
covenants implied under Part 1 of the Law of Property (Miscellaneous Provisions) Act 1994 where a disposition is expressed to be made with full title guarantee are deemed to be given by the Seller (on behalf of the relevant Share Seller or Business
Seller) on Closing; 

  
 8 

 “Genmab” means Genmab A/S, a Danish corporation having its principal office
at Toldbodgade 33, DK-1253 Copenhagen K, Denmark; 
 “Genmab Agreement” means the co-development and
collaboration agreement between Genmab and Glaxo Group Limited dated 19 December 2006 (as amended from time to time) relating to the development, manufacturing and commercialisation of pharmaceutical products containing Ofatumumab; 

“Good Clinical Practices” or “GCP” means the then-current standards, practices and procedures
promulgated or endorsed by (i) the ICH Harmonised Tripartite Guidelines for Good Clinical Practice (CPMP/ICH/135/95) and any other guidelines for good clinical practices for trials on medicinal products in the European Union; (ii) the FDA
as set forth in the guidelines entitled “Guidance for Industry E6 Good Clinical Practice: Consolidated Guidance,” including related regulatory requirements imposed by the FDA; and (iii) the equivalent Applicable Law in any relevant
country; 
 “Good Laboratory Practices” or “GLP” means the then-current standards, practices
and procedures promulgated or endorsed by: (i) the European Commission Directive 2004/10/EC relating to the application of the principles of good laboratory practices as well as “The rules governing medicinal products in the European
Union,” Volume 3, Scientific guidelines for medicinal products for human use (ex-OECD principles of GLP); (ii) the then-current standards, practices and procedures promulgated or endorsed by the FDA as defined in 21 C.F.R. Part 58; and
(iii) the equivalent Applicable Law in any relevant country; 
 “Good Manufacturing Practices” or
“GMP” means the then-current standards, practices and procedures promulgated or endorsed by: (i) the European Commission Directive 91/356/EEC, as amended by Directive 2003/94/EC and 91/412/EEC respectively, as well as “The
rules governing medicinal products in the European Union,” Volume 4, Guidelines for good manufacturing practices for medicinal products for human and veterinary use; (ii) the FDA and the provisions of 21 C.F.R. Parts 210 and 211;
(iii) the principles detailed in the ICH Q7A guidelines; and (iv) all Applicable Law with respect to each of (i) through (iii); 
 “Governmental Entity” means any supra-national, federal, national, state, county, local, municipal or other governmental, regulatory or administrative authority, agency, commission or
other instrumentality, any court, tribunal or arbitral body with competent jurisdiction, or any national securities exchange or automated quotation service including, any governmental regulatory authority or agency responsible for the grant
approval, clearance, qualification, licensing or permitting of any aspect of the research, development, manufacture, marketing, distribution or sale of the Products including the FDA, the European Medicines Agency, or any successor agency thereto;

 “Governmental Liability” means any Liability arising out of, relating to or resulting from any claim, demand,
action, suit, proceedings or investigation by a Governmental Entity (other than a Tax Authority) brought or undertaken in connection with products sold or developed by, or operations or practices of, the Seller’s Group prior to Closing;

  
 9 

 “GSK Break Fee” has the meaning given to it in the Implementation
Agreement; 
 “Headline Amount” has the meaning given to it in Clause 3.1.1; 

“Healthcare Laws” means the federal Anti-kickback Statute (42 U.S.C. § 1320a-7b(b)); the Anti-Inducement Law (42
U.S.C. § 1320a-7a (a)(5)); the civil False Claims Act (31 U.S.C. §§ 3729 et seq.); the administrative False Claims Law (42 U.S.C. § 1320a-7b(a)); the Exclusion Laws (42 U.S.C. § 1320a-7); the Medicare statute (Title XVIII of
the Social Security Act), including Social Security Act §§ 1860D-1 to 1860D-43 (relating to Medicare Part D and the Medicare Part D Coverage Gap Program); the Medicaid statute (Title XIX of the Social Security Act); the Physician Payment
Sunshine Act (42 U.S.C. § 1320a-7h) and any analogous state laws; the Health Insurance Portability and Accountability Act of 1996 (42 U.S.C. § 1320d et seq.), as amended by the Health Information Technology for Economic and Clinical Health
Act of 2009, and any other similar Law, including the price reporting requirements and the requirements relating to the processing of any applicable rebate, chargeback or adjustment, under applicable rules and regulations relating to the Medicaid
Drug Rebate Program (42 U.S.C. § 1396r-8), any state supplemental rebate program, Medicare average sales price reporting (42 U.S.C. § 1395w-3a), the Public Health Service Act (42 U.S.C. § 256b), the Veterans Health Care Act (38 U.S.C.
§ 8126), regulatory requirements applicable to sales on the Federal Supply Schedule or under any state pharmaceutical assistance program or United States Department of Veterans Affairs agreement, all legal requirements relating to the billing
or submission of claims, collection of accounts receivable, underwriting the cost of, or provision of management or administrative services in connection with, any and all of the foregoing, by the Seller’s Group and any successor government
programs, and all foreign equivalents of the foregoing; 
 “HSR Act” means the Hart-Scott-Rodino Antitrust
Improvements Act of 1976, as amended, together with its implementing regulations; 
 “Implementation Agreement”
means the implementation agreement dated the date of this Agreement between the Seller, and the Purchaser relating to, amongst other things, the implementation of the Transaction; 

“In-Market Inventory” means all inventory of Products for Commercialisation that, at any particular time: (i) is
beneficially owned by a member of the Seller’s Group; and (ii) is in finished packed form and released for Commercialisation; and (iii) is located: (a) in (or in transit to) the relevant Market; or (b) in (or in transit to)
a multi-market warehouse owned or operated by a member of the Seller’s Group or by a third party; or (c) at a primary or secondary manufacturing site pending despatch following release by the relevant qualified person to the relevant
market or multi-market warehouse; 
 “Information Technology” means computer, hardware, software and network;

  
 10 

 “Intellectual Property Assignment” means, collectively, the intellectual
property assignment agreements that may be entered into between the Seller, the Purchaser or their respective Affiliates at Closing on terms consistent with the Agreed Terms; 
 “Intellectual Property Rights” means all: (i) Patents; (ii) Know-How; (iii) Trademarks; (iv) internet domain names; (v) Copyrights; (vi) rights in designs;
(vii) database rights; and (viii) all rights or forms of protection, anywhere in the world, having equivalent or similar effect to the rights referred to in paragraphs (i) to (vii) above, in each case whether registered or
unregistered and including applications for registration of any such thing; 
 “International Assignees” means
the employees of any member of the Seller’s Group as may be agreed in writing between the Seller and the Purchaser after the date of this Agreement but before the Closing Date; 

“IP Liability” means any Liability arising out of, relating to or resulting from any actual or alleged infringement,
misappropriation or other violation of Intellectual Property Rights of third parties; 
 “JTI” means Japan
Tobacco Inc., a Japanese corporation having its principal office at 2-1Toranomon, 2-chome, Minato-ku, Tokyo 105-8422, Japan; 

“JTI Agreement” means the licence agreement between JTI and SmithKline Beecham Corporation (doing business as GSK) dated
18 April 2006 (as amended from time to time); 
 “Judgment” means any order, writ, judgment, injunction,
decree, stipulation, determination, decision or award entered by or with any Governmental Entity of competent jurisdiction; 

“Key Financial Information” means: (i) the gross profit (being net sales less standard costs, less third party
royalties) for each of the Key Products in respect of the financial year ended 31 December 2013; and (ii) the net sales for the Key Products in respect of the financial years ended 31 December 2012 and 31 December 2011, as set
out in an annex to the Disclosure Letter; 
 “Key Personnel” means the Employees listed in Schedule 20;

 “Key Products” means Tykerb, Promacta, Votrient, Arzerra, Tafinlar and Mekinist; 

“Key Study Plans” means the plans relating to certain combination studies involving the Products appended to this
Agreement at Schedule 17; 
 “Know-How” means all existing and available technical information, know-how and
data, including inventions (whether patentable or not), discoveries, trade secrets, specifications, instructions, processes and formulae, including all biological, chemical, pharmacological, biochemical, toxicological, pharmaceutical, physical,
safety, quality control, preclinical and clinical data; 
 “Liabilities” means all liabilities, claims, damages,
proceedings, demands, orders, suits, costs, losses and expenses of every description, whether deriving from contract, common law, statute or otherwise, whether present or future, actual or contingent, ascertained or unascertained or disputed and
whether owed or incurred severally or jointly or as principal or surety; 

  
 11 

 “LIBOR” means the London interbank offered rate, being the interest rate
offered in the London inter-bank market for three month US dollar deposits as displayed on pages LIBOR01 or LIBOR02 of the Reuters screen at 11 a.m. (London) on the second Business Day prior to the Closing Date; 

“Licensed Intellectual Property Contract” means any Contract under which Product Intellectual Property Rights have been
licensed by a third party to the Seller or any Affiliate thereof or to a third party by the Seller or any Affiliate thereof; 

“Licensed Product Intellectual Property Rights” means all Intellectual Property Rights licensed to the Seller or its
Affiliates under any Transferred Intellectual Property Contract; 
 “Listing Rules” means the listing rules made
by the FCA under section 73A of FSMA; 
 “Local Transfer Document” has the meaning given to it in
Clause 2.5; 
 “Long Stop Date” has the meaning given to it in Clause 4.3; 

“Losses” means all losses, liabilities, costs (including legal costs and experts’ and consultants’ fees),
charges, expenses, actions, proceedings, claims and demands; 
 “MA Costs” has the meaning given to it in
paragraph 4.1 of Part 2 of Schedule 6; 
 “MA Documentation” has the meaning given to it in
paragraph 1.5 of Part 2 of Schedule 6; 
 “Manufacture” or “Manufacturing” or
“Manufactured” means planning, purchasing of materials for, production, processing, compounding, storage, filling, packaging, labelling, leafleting, warehousing, quality control testing, waste disposal, quality release, sample
retention and stability testing of products; 
 “Manufacturing and Supply Agreement” means the manufacturing and
supply agreement to be entered into between the Seller and the Purchaser at Closing on terms consistent with the heads of terms in the Agreed Terms; 
 “Manufacturing Licences” means any certificates, permits, licences, consents and approvals issued by any Governmental Entity, used in the operation or conduct of Manufacturing any
Product, and “Manufacturing Licence” shall be construed accordingly; 
 “Marketing Authorisation
Data” means the existing and available dossiers containing the relevant Know-How used by the Seller and/or its Affiliates to obtain and maintain the Marketing Authorisations including with respect to any Product Expansion Application;

 “Marketing Authorisation Holder” means the holder of the relevant Marketing Authorisation; 

  
 12 

 “Marketing Authorisation Re-registration” has the meaning given to it in
paragraph 1.1.2 of Part 2 of Schedule 6; 
 “Marketing Authorisation Re-Registration Date” means the date
on which the relevant Governmental Entity approves, or is deemed to approve, the relevant Marketing Authorisation Re-registration; 
 “Marketing Authorisation Transfer” has the meaning given to it in paragraph 1.1.1 of Part 2 of Schedule 6; 
 “Marketing Authorisation Transfer Date” means the date on which the relevant Governmental Entity approves, or is deemed to approve, the relevant Marketing Authorisation Transfer;

 “Marketing Authorisation Transferee” means the member of the Purchaser’s Group or, where no member of
the Purchaser’s Group satisfies the requirements under Applicable Law to be transferred the relevant Marketing Authorisation, such Third Party as is nominated by the Purchaser, in either case to whom the relevant Marketing Authorisation is to
be transferred; 
 “Marketing Authorisations” means the marketing authorisations issued or applications for
Marketing Authorisations with respect to the Products and all supplements, amendments and revisions thereto including any pending Product Expansion Application; 
 “Markets” means the markets in which the Products are marketed and sold under the relevant Marketing Authorisation, and “Market” shall be construed accordingly;

 “Material Adverse Effect” means any matter, change, event or circumstance arising or discovered on or after
the date of this Agreement and prior to Closing (including a breach of the Seller’s obligations under Clause 5 or Clause 9.1) (a “Relevant Matter”) that, individually or in the aggregate with other Relevant Matters,
if known to the Purchaser prior to the date of this Agreement, could reasonably have expected to have resulted in the Purchaser offering to acquire the Business on the terms of this Agreement at a discount to the Headline Amount of 30 per cent.
or more, and, in determining such reduction, regard shall be had to the actual basis on which the Purchaser determined the Headline Amount. A Relevant Matter shall not constitute or count towards a “Material Adverse Effect” to the extent
resulting or arising from: 
  

	 	(i)	any change that is generally applicable to, or generally affects, the industries or markets in which the Business operates (including changes arising as a result of
usual seasonal variations) or arises from or relates to changes in Applicable Law or accounting rules or changes in any authoritative interpretation of any Applicable Law by any Governmental Entity; 

 

	 	(ii)	any change in financial, securities or currency markets or general economic or political conditions or changes in prevailing interest rates or exchange rates;

  

	 	(iii)	the execution of this Agreement, the public announcement thereof or the pendency or consummation of the transactions contemplated hereby (including any cancellations of
or delays in customer orders or other decreases in customer demand, any reduction in revenues and any disruption in supplier, distributor, customer or similar relationships); or 

  
 13 

	 	(iv)	the taking of any action expressly required by this Agreement or by any Ancillary Agreement or otherwise taken with the advance written consent of the Purchaser,

 except, in relation to either paragraph (i) or paragraph (ii) above, if that change adversely affects
the Business in a disproportionate manner relative to other comparable businesses operating in the same industry and geographic markets as the Business (in which case it may constitute or count towards a “Material Adverse Effect”);

 “Material Employee Jurisdictions” means France, Germany, Japan, the United Kingdom and the United States
of America; 
 “Medical Information” means information relating to clinical and technical matters, such as
therapeutic uses for the approved indications, drug-disease information, and other product characteristics Exclusively Related to the Business which is available to or used by the Seller and/or its Affiliates; 

[***] 
 [***]

 [***] 

[***] 

“Netherlands APA” has the meaning given to it in the Netherlands Offer Letter; 

“Netherlands Assumed Liabilities” means the Assumed Liabilities to the extent they relate to the Netherlands Business;

 “Netherlands Business” means that part of the Business, comprising the activities of Netherlands Employees;

 “Netherlands Closing” has the meaning given to it in the Netherlands APA; 

“Netherlands Employees” means those of the Employees who are employed in the Netherlands; 

“Netherlands Offer Letter” means the letter from the Purchaser to the Seller in respect of the binding offer from the
Purchaser to acquire the Netherlands Business dated on or around the date hereof; 
 “Netherlands Put Option
Exercise” has the meaning given to it in the Netherlands Offer Letter; 
  

	***	Note: Confidential treatment has been requested with respect to the information contained within the [***] marking. Such portions have been omitted from this filing and
have been filed separately with the Securities and Exchange Commission. 

  
 14 

 “New Marketing Authorisation” has the meaning given to it in
paragraph 3.1 of Part 2 of Schedule 6; 
 “Non-US Benefit Plans” has the meaning given to it in
paragraph 13.3.1 of Schedule 14; 
 “Notice” has the meaning given to it in Clause 16.11.1;

 “Novartis Break Fee” has the meaning given in the Implementation Agreement; 

“OIG” has the meaning given to it in Clause 4.1.12; 

“Ofatumumab Agreements” means the Transferred Contracts and the Transferred Intellectual Property Contracts that relate
to the Ofatumumab Compound, including but not limited to (i) the Genmab Agreement, (ii) the side letter to the Genmab Agreement dated 8 June 2012, and (iii) the Cabilly Agreement; 

“Ofatumumab Compound” means the compound Ofatumumab; 

“Ofatumumab Indications” means: (i) multiple sclerosis; (ii) rheumatoid arthritis; (iii) pemphigus; and
(iv) neuromyelitis optica; 
 “Ofatumumab Indications Data” means any data or other information owned by
any member of the Seller’s Group as at the date of Closing relating exclusively to the use of the Ofatumumab Compound for the Ofatumumab Indications; 
 “Ofatumumab Intellectual Property Licence Agreement” means the intellectual property licence agreement to be entered into between the Seller and the Purchaser or their respective
Affiliates at Closing on terms consistent with the heads of terms in the Agreed Terms in respect of the grant of a licence from the Purchaser to the Seller of certain Intellectual Property Rights related to the Ofatumumab Compound; 

“Oncology Intellectual Property Licence Agreement” means the intellectual property licence agreement to be entered into
between the Seller and the Purchaser or their respective Affiliates at Closing on terms consistent with the heads of terms in the Agreed Terms, in respect of the grant of licences from the Seller to the Purchaser of certain Intellectual Property
Rights; 
 “Ongoing Clinical Trials” means the ongoing clinical studies sponsored or supported by the Seller
Group (including post-approval studies) or otherwise recommended by a Governmental Entity, and regulatory commitments in respect of the Products, and “Ongoing Clinical Trial” shall mean any one of them; 

“Out of Scope Patent” means any Patent of the Seller’s Group at the date of Closing, but excluding: (i) the
Business Product Intellectual Property Rights; and (ii) any Patents licensed under the Oncology Intellectual Property Licence Agreement; 
 “Owned Product Intellectual Property Rights” means the Intellectual Property Rights listed at Part 1 of Schedule 2 and all other Intellectual Property Rights Exclusively Related to the
Business that, in each case, are owned by the Company, including the Registered Owned Product Intellectual Property Rights and, for the avoidance of doubt, excluding any Intellectual Property Rights in Seller Combination Compounds; 

  
 15 

 “PA Transfer Date” means, in relation to a Product, the date upon which the
relevant Governmental Entity approves and notifies the Product Approval (as applicable) naming the Purchaser or the relevant Affiliate of the Purchaser (or designee thereof) as the holder of such Product Approval in the relevant country or territory
covered by that Product Approval; 
 “Patents” means, patents, design patents, patent applications, and any
reissues, re-examinations, divisionals, continuations, continuations-in-part, provisionals, and extensions thereof or any counterparts to any of the foregoing (including rights resulting from any post-grant proceedings relating to any of the
foregoing); 
 “Patent Term Extensions” means any and all extension of the term of a Patent granted under the
Patent laws or regulations of any country, the European Union, or any other Governmental Entity; 
 “Pending Marketing
Authorisation” has the meaning given to it in paragraph 3.2 of Part 2 of Schedule 6; 
 “Permitted Cash
Receivable” means a debt owed to the Company by a member of the Seller’s Group other than GlaxoSmithKline Finance plc, payable on demand to the Company or as the Company directs, not exceeding £5 million multiplied by the
number of months from and including 29 September 2014 to Closing; 
 “Permitted Encumbrance” means:

  

	 	(i)	Encumbrances imposed by Applicable Law otherwise than in respect of Tax; 

  

	 	(ii)	Encumbrances imposed in the ordinary course of business which are not yet due and payable or which are being contested in good faith; 

 

	 	(iii)	Encumbrances which are listed in Schedule 5; and 

  

	 	(iv)	liens, title retention arrangements or deposits to secure the performance of bids, trade contracts (other than for borrowed money), conditional sales contracts, leases,
statutory obligations, surety and appeal bonds, performance bonds and other obligations of a like nature incurred in the ordinary course of the Business; 

 “Pharmacovigilance Agreement” means the agreement between the Seller and the Purchaser, to be entered into at Closing, in respect of pharmacovigilance and regulatory matters relating to
the Products; 
 “Pre-Closing Product Reorganisation” means the steps described in Part 1 of Schedule 18 as may
be amended from time to time in accordance with Part 3 of Schedule 18; 
 “Pre-Closing Receivables” means all
outstanding payments due to the Seller or any of its Affiliates as at Closing related to the period prior to Closing for goods or services supplied or rights licensed by it or on its behalf in the ordinary and usual course of carrying on the
Business other than any Permitted Cash Receivable; 
 “Proceedings” means any legal actions, proceedings, suits,
litigations, prosecutions, investigations, enquiries, mediations or arbitrations; 

  
 16 

 “Product Approvals” means all permits, licences, certificates, clearances,
registrations or other authorisations or consents issued by any Governmental Entity to the Seller or one of its Affiliates with respect to the Products or the Product Expansions, or the manufacture, use, research, development, marketing,
distribution or sale thereof, including the Marketing Authorisations; 
 “Product Expansion Applications” means
all of the applications or planned applications for Product Expansions set out in Schedule 1 including those listed in the column “Product Expansion Applications” in Part 1 of Schedule 1, with each individual application being a
“Product Expansion Application”; 
 “Product Expansion” means in relation to any Product:

  

	 	(i)	the expansion of the indications or formulations for such Product for use as monotherapy; and 

 

	 	(ii)	the expansion of the indications or formulations for such Product for use in combination with any other compound including without limitation those set out in Part 2 of
Schedule 1 but excluding any Seller Combination Compounds; 

 “Product Filings” means all filings,
written representations, declarations, listings, registrations, reports or submissions with or to any Governmental Entity, including adverse event reports and all submitted data relating to each Product; 

“Product Liabilities” means any Liability arising out of, relating to or resulting from actual or alleged harm, injury,
damage or death to persons in connection with the use of any product (including in any clinical trial or study); 

“Product Partners” means any third parties which pursuant to a Contract with Seller or any Affiliate of Seller
co-develop, co-promote, co-market, or otherwise have a licence or other right to research, develop, manufacture, promote, distribute, market, or sell any Product, including all manufacturers and suppliers of any such Product; 

“Products” means the products set out under the heading “Products” in Part 1 of Schedule 1 (but excluding the
Divested Zofran Product); 
 “Proprietary Information” means all confidential and proprietary information of the
Seller or its Affiliates that is Exclusively Related to the Business, including confidential Medical Information confidential Know-How and confidential Commercial Information; 
 “Product Intellectual Property Rights” means all Intellectual Property Rights related to, or used, or held for use in connection with the Products or the manufacture, use, research,
development, marketing, distribution or sale thereof; 
 “Purchaser’s Group” means the Purchaser and its
Affiliates from time to time, and includes the Company with effect from Closing; 
 “Purchaser’s Lawyers”
means Freshfields Bruckhaus Deringer LLP of 65 Fleet Street, London EC4Y 1HS, United Kingdom; 
 “Purchaser Tax
Indemnity” has the meaning given to it in Schedule 18; 

  
 17 

 “Quality Agreement” means the agreement between the Seller and the
Purchaser, to be entered into at Closing, in respect of regulatory compliance and product safety and quality with respect to the manufacture of the Products; 
 “Rebate” means any amount payable or repayable to customers or Governmental Entities in respect of a contractual rebate or other rebate including under applicable Healthcare Laws (or
under similar laws or regulations) due on sales of the Products; 
 “Reduction Amount” has the meaning given to
it in Clause 6.3; 
 “Registered Business Product Intellectual Property Rights” means all Business Product
Intellectual Property Rights that are Registered Intellectual Property Rights, including those set out at Part 1 of Schedule 2; 

“Registered Intellectual Property Product Rights” means all Registered Business Product Intellectual Property Rights,
Registered Licensed Product Intellectual Property Rights and Registered Shared Product Intellectual Property Rights; 

“Registered Intellectual Property Rights” means Intellectual Property Rights that are registered, issued, filed, or
applied for under the authority of any Governmental Entity; 
 “Registered Licensed Product Intellectual Property
Rights” means all Licensed Product Intellectual Property Rights that are Registered Intellectual Property Rights; 

“Registered Owned Product Intellectual Property Rights” means all Owned Product Intellectual Property Rights that are
Registered Intellectual Property Rights, including those set out at 1 of Schedule 2; 
 “Registered Shared Product
Intellectual Property Rights” means all Shared Product Intellectual Property Rights that are Registered Intellectual Property Rights; 
 “Registered Transferred Product Intellectual Property Rights” means all Transferred Product Intellectual Property Rights that are Registered Intellectual Property Rights, including those
set out at Part 1 0 of Schedule 2; 
 “Regulation” has the meaning given to it in Clause 4.1.1; 

“Relevant Development Product” has the meaning given to it in Clause 8.12; 

“Relevant Employees” means the Employees immediately prior to the Closing Date and “Relevant Employee”
means any one of them; 
 “Relevant Employers” means the Sellers and such other members of the Seller’s
Group who employ the Relevant Employees; 
 “Relevant Employer’s FSAs” has the meaning given to it in
paragraph 7.1 of Schedule 8; 
 “Relevant Part” means the relevant part of the Shared Business Contracts
which relates exclusively to the Business (or the relevant part of the Business that is transferred to the Purchaser at Closing); 

  
 18 

 “Relevant Pension and Employment Liability” means (i) any Liabilities
assumed by the Purchaser or a member of the Purchaser’s Group as contemplated by Schedule 8; and (ii) any Transferred Employee Benefit Liabilities (as defined in Schedule 9) which the Purchaser agrees to assume in accordance with Schedule
9; 
 “Relevant Period” means the period of two years prior to the date of this Agreement; 

“Relevant Purchaser Business” has the meaning given to it in Clause 4.1.12; 

“Reporting Accountants” means the London office of Ernst & Young or, if that firm is unable or unwilling to act
in any matter referred to them under this Agreement, the London office of Deloitte or, if that firm is also unable or unwilling to act in any matter referred to them under this Agreement, an internationally recognised and independent firm of
accountants who does not act as auditor to the Seller or the Purchaser, to be agreed by the Seller and the Purchaser within seven days of a notice by one to the other requiring such agreement or, failing such agreement, to be nominated on the
application of either of them by or on behalf of the Institute of Chartered Accountants of England and Wales; 

“Representatives” means, in relation to any party, any of its and/or any other member of the Purchaser’s
Group’s or Seller’s Group’s directors, officers, employees, agents, representatives, bankers, auditors, accountants, financial advisers, legal advisers and any other professional advisers; 

“Required Notifications” has the meaning given to it in Clause 4.2.1; 

“Restricted Group Employee” means any Transferred Employee who has access to trade secrets or other confidential
information relating to the Business with an annual basic salary in excess of US$150,000; 
 “Royalty” means any
royalty payable in respect of sales of the Products; 
 “SA Distribution Agreement” has the meaning given to it
in paragraph 1.1 of Part 2 of Schedule 19; 
 “Sanctions Law” has the meaning given to it in
paragraph 7 of Schedule 14; 
 “Seller Allowance, Rebate and Royalty Amount” means any Allowance, Rebate or
Royalty payable after Closing by the Purchaser or any member of the Purchaser’s Group, to the extent it relates to the sales of any Products made prior to Closing; 
 “Seller Articles of Association” means the articles of association of the Seller in force and effect from time to time; 

“Seller Combination Compounds” means any compounds owned by the Seller or a member of the Seller’s Group (other than
a Product) which are used in combination with the Products; 
 “Seller Marks” means any Trademark of the Seller
containing the marks listed in Schedule 23; 

  
 19 

 “Seller Pipeline” means: 

 

	 	(i)	any research and development activities relating to any compound (other than the Products) at any stage of development by or on behalf of the Seller that is not yet
approved for marketing for use in humans and all assets, rights and contracts relating to those activities (except where those assets, rights and contracts relate to the Products, save in relation to (ii) below); and 

 

	 	(ii)	subject to Clause 8.5.3, assets, rights and contracts relating to pre-clinical research which do not relate exclusively to the Products; 

“Seller Partner” shall mean any counterparty to a development, contract research, commercialisation, manufacturing,
distribution, sales, marketing, supply, consulting or other collaboration Contract with the Seller or any Affiliate of the Seller; 
 “Seller Shareholder Meeting” has the meaning given to it in Clause 4.1.8; 
 “Seller Shareholder Resolution” has the meaning given to it in Clause 4.1.8; 
 “Seller Shareholders” means the holders of ordinary shares in the capital of the Seller from time to time; 
 “Seller’s Group” means the Seller and its Affiliates from time to time but excluding from Closing, the Company; 

“Seller’s Group Insurance Policies” means all insurance policies (whether under policies maintained with third party
insurers or any member of the Seller’s Group) maintained by the Seller or any member of the Seller’s Group in relation to the Business or under which, immediately prior to Closing, the Seller or any member of the Seller’s Group in
relation to the Business is entitled to any benefit, and “Seller’s Group Insurance Policy” means any one of them; 
 “Seller’s Group Retained Business” means all businesses of the Seller’s Group, including the manufacture and/or supply of the Divested Zofran Product pursuant to the Aspen
Agreements, but excluding the Business; 
 “Seller’s Indian Business” means that part of the Business
conducted by any member of the Seller’s Group in the Republic of India; 
 “Seller’s Knowledge” has
the meaning given to it in Clause 9.1.4; 
 “Seller’s Lawyers” means Slaughter and May of One Bunhill
Row, London EC1Y 8YY; 
 “Seller’s Warranties” means the warranties given by the Seller pursuant to
Clause 9.1 and Schedule 14, and “Seller’s Warranty” means any one of them; 

“Separation” has the meaning given to it in paragraph 1.4 of Schedule 7; 

“Service Provider” means an Associated Person who is a legal person; 

“Share” means the entire issued share capital of the Company; 

  
 20 

 “Share Consideration” means, subject to Clause 6.3.3, an amount equal to
the product of: 
 (x) the Headline Amount less the aggregate of the Business Consideration, the amount of the Company
Intra-Group Debt, any Employee Benefit Indemnification Amount and any amount to be deducted pursuant to Clause 6.3.6; and 

(y) 100 divided by 100.5; 
 “Share Seller” means Glaxo Group Limited, a company incorporated in England and Wales with registered number 00305979; 

“Shared Business Contracts” means any Contract which relates both: 

 

	 	(i)	to the Business or any part of the Business to be transferred to the Purchaser at Closing; and 

 

	 	(ii)	to any part of the Seller’s Group Retained Business, any product other than the Products, or any Excluded Asset, 

and to which a member of the Seller’s Group is a party or in respect of which a member of the Seller’s Group has any liability
or obligation at Closing (including, for the avoidance of doubt, the Zofran Trade Mark and Domain Name Licence) and “Shared Business Contract” shall mean any of them; 

“Shared Product Intellectual Property Rights” means all Intellectual Property Rights which shall be licensed to the
Purchaser pursuant to the Oncology Intellectual Property Licence Agreement; 
 “Six-Month LIBOR” means the
London interbank offered rate, being the interest rate offered in the London inter-bank market for six month US dollar deposits as displayed on page LIBOR01 of the Reuters screen at 11 a.m. (London) on the second Business Day prior to the date
on which the Reduction Amount becomes payable; 
 “SSA Collaboration Agreement” has the meaning given to it in
paragraph 1.1 of Part 2 of Schedule 19; 
 “Stamp Duty Amount” means an amount equal to 0.5% of the Share
Consideration; 
 “Target Asset Agreements” has the meaning given to it in the Implementation Agreement;

 “Taxation” or “Tax” has the meaning given to it in the Company Tax Indemnity; 

“Tax Authority” means any taxing or other authority competent to impose any liability in respect of Taxation or
responsible for the administration and/or collection of Taxation or enforcement of any law in relation to Taxation; 

“Tax Group” has the meaning given to it in the Company Tax Indemnity; 

  
 21 

 “Tax Return” has the meaning given to it in the Company Tax Indemnity;

 “Tax Warranties” means the Seller’s Warranties set out in paragraph 11 of Schedule 14; 

“Third Party Claim” has the meaning given to it in Clause 11.4; 

“Third Party Consents” means all consents, licences, approvals, permits, authorisations or waivers required from third
parties: 
  

	 	(i)	in connection with any step of the Pre-Closing Products Reorganisation; and 

 

	 	(ii)	for the assignment or transfer to the Purchaser or any member of the Purchaser’s Group of any of the Transferred Contracts, Transferred Intellectual Property
Contracts, Co-Owned Transferred Product Intellectual Property Rights, or Shared Business Contracts, 

 and
“Third Party Consent” means any one of them; 
 “Time-Limited Excluded Liability” means an
Excluded Liability which is: 
  

	 	(i)	a Contracts Liability; or 

  

	 	(ii)	a Commercial Practices Liability; 

“Trademarks” means trademarks, service marks, trade names, certification marks, service names, industrial designs, brand
names, brand marks, trade dress rights, identifying symbols, logos, emblems, and signs or insignia; 

“Transaction” has the meaning given to it in Clause 4.1.1; 

“Transfer Regulations” means the relevant national measure by which the employment of a Relevant Employee automatically
transfers to the Purchaser or a relevant member of the Purchaser’s Group; 
 “Transferred Books and
Records” means all books, ledgers, files, reports, plans, records, manuals and other materials (in any form or medium) to the extent of, or maintained predominantly for, the Business by the Seller’s Group (other than emails), including
(without limitation) all books, records and other materials relating to the research, development and pre-clinical trials for each of the Products and the Product Expansions but excluding: 

 

	 	(i)	any such items to the extent that: (A) they are related to any Excluded Assets or Excluded Liabilities, (B) they are related to any corporate, Tax, human
resources or stockholder matters of the Seller or its Affiliates, (C) any Applicable Law prohibits their transfer or (D) any transfer thereof otherwise would subject the Seller or any of its Affiliates to any material liability;

  

	 	(ii)	any laboratory notebooks to the extent containing research and development information unrelated to the Business; and 

 

	 	(iii)	in relation to Products other than the Key Products, any books and records that are more than 5 years old containing, in whole or in part, research and development
information (other than any laboratory notebooks, books or records described in this paragraph (iii) that are maintained for the Business by the Seller’s Group); 

  
 22 

 “Transferred Contracts” means Contracts (other than the Transferred
Intellectual Property Contracts) that (i) are listed in Part 2 of Schedule 2 or (ii) are between the Seller or a member of the Seller’s Group on the one hand and any third party on the other hand and are Exclusively Related to the
Business, but excluding the Excluded Contracts, this Agreement and any Ancillary Agreement; 
 “Transferred
Employees” means (i) the Relevant Employees to whom the Purchaser (or a member of the Purchaser’s Group) offers employment and who accept such employment and become employed by the Purchaser (or a member of the Purchaser’s
Group) in accordance with Schedule 8; and (ii) any Relevant Employees who transfer to the Purchaser (or a member of the Purchaser’s Group) by operation of the Transfer Regulations and do not object to such transfer (to the extent permitted
by the Transfer Regulations) in accordance with Schedule 8; and “Transferred Employee” means any one of them; 

“Transferred Intellectual Property Contracts” means Contracts relating to Intellectual Property Rights Exclusively
Related to the Business that are between the Seller or a member of the Seller’s Group on the one hand and any third party on the other hand including any such Contracts set out in Part 2 of Schedule 2; 

“Transferred Product Intellectual Property Rights” means the Intellectual Property Rights listed at Part 1 of Schedule 2
(except where such Intellectual Property Rights are Owned Product Intellectual Property Rights) and all other Intellectual Property Rights Exclusively Related to the Business and owned by any member of the Seller’s Group (other than the
Company), including the Registered Transferred Product Intellectual Property Rights and, for the avoidance of doubt, excluding any Intellectual Property Rights in Seller Combination Compounds; 

“Transitional Services Agreement” means the transitional services agreement to be entered into between the Seller and the
Purchaser at Closing on terms consistent with the heads of terms in the Agreed Terms; 
 “Transitional Distribution and
Supply Agreement” means the transitional distribution and supply agreement to be entered into between the Seller and the Purchaser at Closing on terms consistent with the heads of terms in the Agreed Terms; 

“US Benefit Plans” means all United States “employee benefit plans” (within the meaning of section 3(3) of
ERISA), severance, change in control or employment, vacation, incentive, bonus, stock option, stock purchase, or restricted stock plans, programmes, agreements or policies benefiting the Employees; 

“US Transferred Employees” has the meaning given to it in paragraph 7.1 of Schedule 8; 

  
 23 

 “Vaccines Sale and Purchase Agreement” means the sale and purchase
agreement dated the date of this agreement between the Purchaser and the Seller relating to the sale and purchase of the Purchaser’s vaccines business; 
 “VAT” means within the European Union such Taxation as may be levied in accordance with (but subject to derogations from) Council Directive 2006/112/EC and outside the European Union any
Taxation levied by reference to added value or sales; 
 “WARN Act” means the Worker Adjustment and Retraining
Notification Act of 1988 of the United States; and 
 “Zofran Trade Mark and Domain Name Licence” means the
trade mark and domain name licence agreement dated 30 November 2012 between (i) Glaxo Group Limited; (ii) SmithKline Beecham (Australia) Pty Limited; (iii) GlaxoSmithKline Australia Pty Limited (together, as licensors); and
(iv) Aspen Global Incorporated (as licensee), relating to the licensing of certain Intellectual Property Rights in Australia. 
  

	1.2	Singular, plural, gender 

References to one gender include all genders and references to the singular include the plural and vice versa. 

 

	1.3	References to persons and companies 

 References to: 
  

	 	1.3.1	a person include any individual, company, partnership or unincorporated association (whether or not having separate legal personality); and

  

	 	1.3.2	a company include any company, corporation or any body corporate, wherever incorporated. 

 

	1.4	Schedules etc. 

References to this Agreement shall include any Recitals and Schedules to it and references to Clauses and Schedules are to Clauses of, and
Schedules to, this Agreement. References to paragraphs and Parts are to paragraphs and Parts of the Schedules. 
  

	1.5	Reference to documents 

References to any document (including this Agreement), or to a provision in a document, shall be construed as a reference to such document
or provision as amended, supplemented, modified, restated or novated from time to time. 
  

	1.6	References to enactments 

Except as otherwise expressly provided in this Agreement, any express reference to an enactment (which includes any legislation in any
jurisdiction) includes references (i) to that enactment as amended, consolidated or re-enacted by or under any other enactment before or after the date of this Agreement; (ii) any enactment which that enactment re-enacts (with or without
modification); and (iii) any subordinate legislation (including regulations) made before or after the date of this Agreement under that enactment as amended, consolidated or re-enacted as described in paragraph (i) or (ii) above,
except to the extent that any of the matters referred to in paragraphs (i) to (iii) occurs after the date of this Agreement and increases or alters the liability of the Seller or Purchaser under this Agreement. 

  
 24 

	1.7	Information 

 References
to books, records or other information mean books, records or other information in any form including paper, electronically stored data, magnetic media, film and microfilm. 

 

	1.8	References to “indemnify” 

 Unless specified to the contrary, references to “indemnify” and “indemnifying” any person against any circumstance include indemnifying and holding that person harmless on an after-Tax
basis and: 
  

	 	1.8.1	references to the Purchaser indemnifying each member of the Seller’s Group shall constitute undertakings by the Purchaser to the Seller for itself and on
behalf of each other member of the Seller’s Group; 

  

	 	1.8.2	references to the Seller indemnifying each member of the Purchaser’s Group shall constitute undertakings by the Seller to the Purchaser for itself and on
behalf of each other member of the Purchaser’s Group; 

  

	 	1.8.3	to the extent that the obligation to indemnify relates to the Share, the Company or any assets or liabilities transferred by a Business Seller or the Share
Seller (as the case may be) to a member of the Purchaser’s Group pursuant to this Agreement, references to the Seller indemnifying the Purchaser and references to the Seller indemnifying the Purchaser or any member of the Purchaser’s Group
shall constitute undertakings by the Seller to indemnify or procure indemnification of the relevant purchaser of the assets or liabilities or the Share transferred by that Business Seller or the Share Seller or the Company, and references to the
Purchaser indemnifying the Seller and references to the Purchaser indemnifying the Seller and each member of the Seller’s Group shall constitute undertakings by the Purchaser to indemnify or procure the indemnification of the relevant member of
the Seller’s Group; and 

  

	 	1.8.4	where under the terms of this Agreement one party is liable to indemnify or reimburse another party in respect of any costs, charges or expenses, the payment
shall include an amount equal to any VAT thereon not otherwise recoverable by the other party or any member of any group or consolidation of which it forms part for VAT purposes, subject to that party using reasonable endeavours to recover or
procure recovery of such amount of VAT as may be practicable. 

 For the purposes of this Clause, indemnifying and
holding harmless a person on an “after-Tax basis” means that the amount payable pursuant to the indemnity (the “Payment”) shall be calculated in such a manner as will ensure that, after taking into account: 

  
 25 

	 	(i)	any Tax required to be deducted or withheld from the Payment and any additional amounts required to be paid by the payer of the Payment in consequence of such
withholding; 

  

	 	(ii)	the amount and timing of any additional Tax which becomes (or would, but for the use of any credit or other relief which would otherwise have been available to reduce
the Tax liabilities of any member of the Seller’s Group (or a member of the Purchaser’s Group, as the case may be), have become) payable by the recipient of the Payment (or a member of the Seller’s Group or the Purchaser’s Group,
as the case may be) as a result of the Payments being subject to Tax in the hands of that person; and 

  

	 	(iii)	the amount and timing of any Tax benefit which is obtained by the recipient of the Payment (or a member of the Seller’s Group or the Purchaser’s Group, as the
case may be) to the extent that such Tax benefit is attributable to the matter giving rise to the indemnity payment or to the receipt of the Payment, 

 which amount and timing is to be determined by the auditors of the recipient at the shared expense of both relevant parties and is to be certified as such to the party making the Payment, the recipient of
the Payment is in no better and no worse after Tax position as that in which it would have been if the matter giving rise to the indemnity payment had not occurred, provided that if either party to this Agreement shall have assigned or novated the
benefit of this Agreement in whole or in part or shall, after the date of this Agreement, have changed its Tax residence or the permanent establishment to which the rights under this Agreement are allocated then no Payment to that party shall be
increased by reason of the operation of paragraphs (i) to (iii) above to any greater extent than would have been the case had no such assignment, novation or change taken place. 

 

	1.9	References to wholly or substantially in the Business 

 References to “wholly or substantially in the Business” in relation to any employee employed by a member of the Seller’s Group means that such employee spends more than 70 per cent. of
their time working in the Business at the relevant time. 
  

	1.10	Legal terms 

 References
to any English legal term shall, in respect of any jurisdiction other than England and Wales, be construed as references to the term or concept which most nearly corresponds to it in that jurisdiction. 

 

	1.11	Non-limiting effect of words 

 The words “including”, “include”, “in particular” and words of similar effect shall not be deemed to limit the general effect of the words that precede them. 

  
 26 

	1.12	Currency conversion 

Other than in relation to conversion of the Company Intra-Group Debt, where the provisions of Clause 1.13 shall apply, any amount to be
converted from one currency into another currency for the purposes of this Agreement shall be converted into an equivalent amount at the Conversion Rate prevailing at the Relevant Date. For the purposes of this Clause: 

“Conversion Rate” means the spot reference rate for a transaction between the two currencies in question as quoted by the
European Central Bank on the Business Day immediately preceding the Relevant Date or, if no such rate is quoted on that date, on the preceding date on which such rates are quoted; 

“Relevant Date” means, save as otherwise provided in this Agreement, the date on which a payment or an assessment is to
be made, save that, for the following purposes, the date shall mean: 
  

	 	(i)	for the purposes of Clause 5, the date of this Agreement; 

  

	 	(ii)	for the purposes of Clause 10, the date of this Agreement; and 

  

	 	(iii)	for the purposes of the monetary amounts set out in Schedule 14, the date of this Agreement. 

 

	1.13	US$ Spot Rate 

 For the
purposes of Clause 6.3.2, the amount of the Company Intra-Group Debt shall be converted from sterling to US$ at the spot rate of exchange for sterling into US$ on the Closing Date available at 8:00 am GMT on the Bloomberg screen (the Intraday
Chart) or where no such US$ rate is available for such date, at the rate quoted by Barclays Bank on such date. 
  

	2.	Sale and Purchase of the Business 

  

	2.1	Sale and Purchase of the Business 

 On and subject to the terms of this Agreement: 
  

	 	2.1.1	the Seller shall procure that the Business Sellers shall sell and assign that part of the Business which is not carried on by the Company immediately before
Closing; and 

  

	 	2.1.2	the Seller shall procure that the Share Seller shall sell the Share in accordance with Clause 2.2; 

 

	 	2.1.3	the Purchaser shall purchase and accept, or procure the purchase and acceptance by one or more other members of the Purchaser’s Group of that part of the
Business which is not carried on by the Company immediately before Closing; and 

  

	 	2.1.4	the Purchaser shall purchase and accept, or procure the purchase and acceptance by another member of the Purchaser’s Group of, the Share,

  
 27 

 such that the Seller shall directly or indirectly relinquish and the Purchaser shall
directly or indirectly acquire the Business as a going concern. 
  

	2.2	Sale of the Share 

  

	 	2.2.1	The Seller shall procure that: 

  

	 	(i)	the Share Seller shall sell the Share with Full Title Guarantee free from Encumbrances and together with all rights and advantages attaching to it as at Closing
(including the right to receive all dividends or distributions declared, made or paid on or after Closing); and 

  

	 	(ii)	on or prior to Closing, any and all rights of pre-emption over the Share and the equity interests in any subsidiaries are waived irrevocably by the person entitled
thereto. 

  

	 	2.2.2	If the Seller notifies the Purchaser under paragraph 4, Part 1 of Schedule 18 that it no longer wishes to proceed with the Pre-Closing Product Reorganisation,
then: 

  

	 	(i)	the provisions of sub-Clauses 2.1.2, 2.1.4 and 2.2.1 shall cease to have effect; and 

 

	 	(ii)	the parties acknowledge that amendments to this Agreement will be required to give effect to that notice such that, subject to any other amendments that may be agreed
by the parties that are not required to implement the Pre-Closing Product Reorganisation, the provisions of this Agreement will be the same as they were after it was amended and restated on 29 May 2014. 

 

	2.3	The Business, the Excluded Assets, the Assumed Liabilities and the Excluded Liabilities 

 

	 	2.3.1	The Assets to be sold under this Agreement, which shall be sold with Full Title Guarantee (save in respect of the Transferred Product Intellectual Property
Rights) and free from Encumbrances other than Permitted Encumbrances shall be: 

  

	 	(i)	the Transferred Books and Records; 

  

	 	(ii)	the Transferred Product Intellectual Property Rights; 

  

	 	(iii)	subject to and in accordance with Schedule 7, the Transferred Contracts, the Transferred Intellectual Property Contracts, Co-Owned Transferred Product Intellectual
Property Rights and if elected by the Purchaser in accordance with paragraph 1 of Schedule 7, the Relevant Parts of any Shared Business Contracts; 

  

	 	(iv)	subject to and in accordance with Schedule 6, all Product Approvals (other than those relating to manufacturing), Product Expansions and all other permits, licences,
certificates, registrations, marketing or other authorisations or consents issued by a Governmental Entity Exclusively Related to the Business; 

  
 28 

	 	(v)	subject to and in accordance with Schedule 6, all Marketing Authorisation Data; 

 

	 	(vi)	all Commercial Information; 

  

	 	(vii)	all Medical Information; 

  

	 	(viii)	all rights of the Purchaser or a member of the Purchaser’s Group as contemplated by Schedule 8 and Schedule 9; 

 

	 	(ix)	the Business Goodwill; and 

  

	 	(x)	all other property, rights and assets owned by any member of the Seller’s Group and Exclusively Related to the Business at Closing (other than any property, rights
and assets of the Business Sellers or the Company expressly excluded from the sale under this Agreement). 

  

	 	2.3.2	There shall be excluded from the sale of the Business under this Agreement the following: 

 

	 	(i)	the Seller’s Group Retained Business, including the Seller Pipeline, any Manufacturing, and any equipment, machinery, spare parts, tools and other tangible
property used by the Seller’s Group for Manufacturing products or in connection with the research and development of the Products or the Product Expansions and any rights or property related to the Seller Combination Compounds;

  

	 	(ii)	any Intellectual Property Right that is not a Business Product Intellectual Property Right, and any Contract relating to Intellectual Property Rights that is not a
Transferred Intellectual Property Contract or the Relevant Part of a Shared Business Contract; 

  

	 	(iii)	the Seller Marks; 

  

	 	(iv)	any product and any permits, licences, certificates, registrations, marketing or other authorisations or consents issued by any Governmental Entity in respect of any
products, or any applications therefor, other than the Products, Product Approvals and Product Expansion Applications; 

  

	 	(v)	the In-Market Inventory; 

  

	 	(vi)	any Information Technology; 

  

	 	(vii)	all cash, marketable securities and negotiable instruments, and all other cash equivalents, of the Seller and its Affiliates, other than the Share and any Permitted
Cash Receivable; 

  
 29 

	 	(viii)	all real property and any leases therefor and interests therein, together with all buildings, fixtures, and improvements erected thereon; 

 

	 	(ix)	the company seal, minute books, charter documents, stock or equity record books and such other books and records pertaining to the Seller or its Affiliates other than
the Company, as well as any other records or material relating to the Seller or its Affiliates generally and not involving or related to the Business; 

  

	 	(x)	any right of the Seller or its Affiliates to be indemnified in respect of Assumed Liabilities; 

 

	 	(xi)	all Tax assets (including Tax refunds and prepayments) other than those of the Company; 

 

	 	(xii)	all Tax Returns of the Seller’s Group other than the Company and all books and records (including working papers) related thereto; 

 

	 	(xiii)	any rights in respect of any insurance policies of the Seller’s Group as provided in Clause 14; 

 

	 	(xiv)	any rights in respect of Pre-Closing Receivables; 

  

	 	(xv)	any equity interest in any person other than the Company; 

  

	 	(xvi)	the Excluded Contracts; and 

  

	 	(xvii)	all rights of the Seller’s Group under this Agreement and the Ancillary Agreements. 

 

	 	2.3.3	The Seller agrees to procure the transfer (to the extent it is able so to do) and the Purchaser agrees to accept (or procure the acceptance by another member of
the Purchaser’s Group of) the transfer of, and to assume, duly and punctually pay, satisfy, discharge, perform or fulfil (or procure that another member of the Purchaser’s Group will assume, duly and punctually pay, satisfy, discharge,
perform or fulfil) the Assumed Liabilities with effect from Closing. 

  

	 	2.3.4	Clause 2.3.3 shall not apply to, and the Purchaser shall not be obliged to accept or procure the acceptance by another member of the Purchaser’s Group
of the transfer of or to assume, pay, satisfy, discharge, perform or fulfil, or procure that another member of the Purchaser’s Group will assume, duly and punctually pay, satisfy, discharge, perform or fulfil: 

 

	 	(i)	any Excluded Liability; or 

  

	 	(ii)	any Liability to the extent it relates to an Excluded Asset. 

  

	 	2.3.5	The parties acknowledge that the Seller has notified the Purchaser of its intention to carry out the Pre-Closing Product Reorganisation and that the Seller may,
at its discretion, carry out the Pre-Closing Product Reorganisation provided that: 

  
 30 

	 	(i)	the Seller shall, in good faith, consult with, and take into account the reasonable views of, and any reasonable requests made by the Purchaser in relation to the
Pre-Closing Product Reorganisation steps and documents, including any proposals to reduce or avoid Liability or cost being suffered or incurred by any member of the Purchaser’s Group; 

 

	 	(ii)	all fees, costs and expenses of implementing the Pre-Closing Product Reorganisation (or any part thereof) shall be borne by the Seller’s Group (other than the
Company); and 

  

	 	(iii)	any modification or amendment of the steps set out in Part 1 of Schedule 18 shall require the prior written consent of the Purchaser, not to be unreasonably withheld or
delayed. Without prejudice to any other exercise of a discretion whether or not to give consent, the Purchaser shall not be acting unreasonably if it withholds or delays its consent because it believes in good faith that the modification or
amendment would result in exposure of any member of the Purchaser’s Group to any additional cost, loss of benefit or Liability; and 

  

	 	(iv)	for the avoidance of doubt, nothing done or agreed to by the Purchaser to comply with the provisions of this Clause 2.3.5, Clause 2.3.6 and Schedule 18 shall in any
respect reduce or restrict any rights the Purchaser or any member of the Purchaser’s Group may have to make a claim against the Seller under Clause 2.3.6, the Company Tax Indemnity or the Purchaser Tax Indemnity. 

 

	 	2.3.6	The Seller undertakes to the Purchaser (for itself and as trustee for each other member of the Purchaser’s Group) that, with effect from Closing, the Seller
will indemnify on demand and hold harmless each member of the Purchaser’s Group against and in respect of the loss of any benefit (other than benefits in respect of Tax) and any and all Liabilities (other than Liabilities in respect of Tax),
including any and all Liabilities (other than Liabilities in respect of Tax) of any company whose shares are transferred to the Purchaser or a member of the Purchaser’s Group in connection with the Pre-Closing Product Reorganisation, arising in
connection with any Pre-Closing Product Reorganisation (or part thereof) including any such loss or Liability that would not have been suffered or incurred had such Pre-Closing Product Reorganisation (or part thereof) not been undertaken.

  

	2.4	Employees and Employee Benefits 

  

	 	2.4.1	The provisions of Schedule 8 shall apply in respect of the Employees. 

 

	 	2.4.2	The provisions of Schedule 9 shall apply in respect of Employee Benefits. 

 

	2.5	Local Transfer Documents 

  

	 	2.5.1	 On Closing or at such other time as agreed between the parties, the Seller shall procure that the Business Sellers or the Share Seller execute,
and the Purchaser shall execute (or procure the execution by one or more 

  
 31 

	 	
other members of the Purchaser’s Group of), such agreements, transfers, conveyances and other documents, as may be required pursuant to the relevant local law and otherwise as may be agreed
between the Seller and the Purchaser to implement the transfer of the Business or the Share on Closing (the “Local Transfer Documents” and each, a “Local Transfer Document”). Title shall be transferred by the
applicable Local Transfer Document. 

  

	 	2.5.2	To the extent that the provisions of a Local Transfer Document are inconsistent with or (except to the extent they implement a transfer in accordance with this
Agreement) additional to the provisions of this Agreement: 

  

	 	(i)	the provisions of this Agreement shall prevail; and 

  

	 	(ii)	so far as permissible under the laws of the relevant jurisdiction, the Seller and the Purchaser shall procure that the provisions of the relevant Local Transfer
Document are adjusted, to the extent necessary to give effect to the provisions of this Agreement or, to the extent this is not permissible, the Seller shall indemnify the Purchaser against all Liabilities suffered by the Purchaser or its Affiliates
or, as the case may be, the Purchaser shall indemnify the Seller against all Liabilities suffered by the Seller or its Affiliates, in either case through or arising from the inconsistency between the Local Transfer Document and this Agreement or the
additional provisions (except to the extent they implement a transfer in accordance with this Agreement). 

  

	 	2.5.3	The Seller shall not, and shall procure that none of its Affiliates shall bring any claim against the Purchaser or any member of the Purchaser’s Group in
respect of or based upon the Local Transfer Documents save to the extent necessary to implement any transfer of the Business as contemplated by this Agreement. To the extent that the Seller or a member of the Seller’s Group does bring a claim
in breach of this Clause, the Seller shall indemnify the Purchaser and each member of the Purchaser’s Group against all Liabilities which the Purchaser or that member of the Purchaser’s Group may suffer through or arising from the bringing
of such a claim. 

  

	 	2.5.4	The Purchaser shall not, and shall procure that none of its Affiliates shall, bring any claim against the Seller or any member of the Seller’s Group in
respect of or based upon the Local Transfer Documents save to the extent necessary to implement any transfer of the Business as contemplated by this Agreement. To the extent that the Purchaser or a member of the Purchaser’s Group does bring a
claim in breach of this Clause, the Purchaser shall indemnify the Seller and each member of the Seller’s Group against all Liabilities which the Seller or any member of the Seller’s Group may suffer through or arising from the bringing of
such a claim. 

  
 32 

	3.	Amounts Payable 

  

	3.1	Consideration 

  

	 	3.1.1	Subject to Clause 3.4.1, the consideration for the purchase of the Business (including the Share) under this Agreement shall be an amount equal to
US$16,000,000,000 (the “Headline Amount”) less the Stamp Duty Amount and, if applicable, any Employee Benefit Indemnification Amount paid in accordance with Schedule 9 and any Reduction Amount, and shall include:

  

	 	(i)	the consideration for the purchase of the Share under this Agreement, being the Share Consideration; 

 

	 	(ii)	the “Business Consideration”, being the consideration for the purchase of that part of the Business not owned directly by the Company as at the Closing
Date, as notified by the Seller to the Purchaser 5 Business Days prior to the Closing Date, and for the undertaking given by the Seller in Clause 12.1; and 

 

	 	(iii)	the amount of the Company Intra-Group Debt. 

  

	3.2	Allocation 

 The
provisions of Schedule 10 shall apply. 
  

	3.3	VAT 

  

	 	3.3.1	The provisions of Schedule 11 shall apply. 

  

	 	3.3.2	The Seller and the Purchaser agree that the amount payable in respect of the sales and purchases described in Clause 2.1 above is exclusive of any VAT.

  

	 	3.3.3	To the extent that VAT is chargeable in respect of those sales and purchases or any part thereof, the Purchaser shall, against delivery of a valid VAT invoice
(or equivalent, if any), in addition to any other amount expressed in the Agreement to be payable by the Purchaser, pay or procure the payment to the Seller (on behalf of the relevant Business Seller or the Share Seller as applicable) any amount of
any VAT so chargeable for which the Seller (or the relevant member of the Seller’s Group, as the case may be) is liable to account, in accordance with Schedule 11. 

 

	 	3.3.4	The Seller shall indemnify each member of the Purchaser’s Group against any VAT chargeable in connection with the transfer of the Share under this
Agreement. 

  

	3.4	Treatment of Payments 

  

	 	3.4.1	If any payment is made by a member of the Seller’s Group to a member of the Purchaser’s Group or by a member of the Purchaser’s Group to a member
of the Seller’s Group, in either case in respect of any claim under, or for any breach of this Agreement or pursuant to an indemnity (or equivalent covenant to pay) under this Agreement, the payment shall be treated, so far as possible, as an
adjustment of the consideration paid by the Purchaser for the Share, the Owned Product Intellectual Property Rights or the Assets to which the payment and/or claim relates under this Agreement and the consideration shall be deemed to be increased or
reduced (as applicable) by the amount of such payment. 

  
 33 

 PROVIDED THAT this Clause 3.4.1 shall not require any amount to be treated as an
amount in respect of the Share Consideration or the Business Consideration for the purposes of Clause 16.10 if it would not otherwise have been so treated. 
  

	 	3.4.2	If: 

  

	 	(i)	the payment and/or claim relates to more than one Asset, Owned Product Intellectual Property Rights or to the Share and one or more Assets or Owned Product Intellectual
Property Rights, it shall be allocated in a manner which reflects the impact of the matter to which the payment and/or claim relates, failing which it shall be allocated rateably to the Products concerned by reference to the percentages in which
amounts are to be allocated between the Products in accordance with Schedule 10; or 

  

	 	(ii)	the payment and/or claim relates to neither the Share nor any particular Assets, it shall be allocated rateably to the Products by reference to the percentages in which
amounts are to be allocated between the Products in accordance with Schedule 10, 

 and in each case the
consideration shall be deemed to have been reduced by the amount of such payment. 
  

	4.	Conditions 

  

	4.1	Conditions Precedent 

 The
sale and purchase of the Business, including the sale and purchase of the Share, is conditional upon satisfaction or, where applicable, waiver of the following conditions, or their satisfaction subject only to Closing: 

 

	 	4.1.1	to the extent that the proposed acquisition of all or any of the Business (the “Transaction”) either constitutes (or is deemed to constitute
under Article 4(5) or Article 5(2))) a concentration with a Community dimension within the meaning of Council Regulation (EC) 139/2004 (as amended) (the “Regulation”) or is to be examined by the European Commission as a result of a
decision under Article 22(3) of the Regulation: 

  

	 	(i)	the European Commission taking a decision (or being deemed to have taken a decision) under Article 6(1)(b) or, if the Commission has initiated proceedings pursuant to
Article 6(1)(c), under Article 8(1) or 8(2) of the Regulation declaring the Transaction compatible with the common market; or 

  
 34 

	 	(ii)	the European Commission taking a decision (or being deemed to have taken a decision) to refer the whole or part of the Transaction to the competent authorities of one
or more Member States under Articles 4(4) or 9(3) of the Regulation; and 

  

	 	(a)	each such authority taking a decision with equivalent effect to Clause 4.1.1(i) with respect to those parts of the Transaction referred to it; and

  

	 	(b)	the European Commission taking any of the decisions under Clause 4.1.1(i) with respect to any part of the Transaction retained by it; 

 

	 	4.1.2	any waiting period (and any extension thereof) under the HSR Act applicable to the Transaction having expired; 

 

	 	4.1.3	to the extent required or otherwise agreed between the parties as appropriate to permit the parties to consummate the Transaction in the jurisdictions listed in
Schedule 21, any additional clearances, approvals, waivers, no-action letters and consents having been obtained and any additional waiting periods having expired under applicable antitrust, merger control or foreign investment rules set forth in
Schedule 21; 

  

	 	4.1.4	receipt of CFIUS Approval if CFIUS has initiated a review of the transactions contemplated by this Agreement, whether pursuant to Clause 4.2.3 or otherwise;

  

	 	4.1.5	the unconditional consent of JTI to the assignment to the Purchaser of the rights and obligations of the relevant member of the Seller’s Group under the JTI
Agreement having been obtained; 

  

	 	4.1.6	the unconditional consent of Genmab to: 

  

	 	(i)	the assignment to the Purchaser of the rights and obligations of the relevant member of the Seller’s Group under the Genmab Agreement having been obtained; and

  

	 	(ii)	a waiver of all non-compete provisions in the Genmab Agreement that would otherwise prevent the Purchaser and any member of the Purchaser’s Group from [***] having
been obtained; 

  

	 	4.1.7	no Governmental Entity having enacted, issued, promulgated, enforced or entered any Applicable Law or Judgment (whether temporary, preliminary or permanent) that
is in effect at the Closing Date and that has the effect of making the transactions contemplated by this Agreement illegal or otherwise restraining or prohibiting the consummation of such transactions; 

 

	***	Note: Confidential treatment has been requested with respect to the information contained within the [***] marking. Such portions have been omitted from this filing and
have been filed separately with the Securities and Exchange Commission. 

  
 35 

	 	4.1.8	the passing at a duly convened and held general meeting of the Seller Shareholders of an ordinary resolution validly approving the Target Asset Agreements (as
defined in the Implementation Agreement) and any sale and purchase under the Put Option Agreement (as defined in the Implementation Agreement) in accordance with the Seller Articles of Association, the Listing Rules and all other Applicable Law
(such resolution being the “Seller Shareholder Resolution” and such meeting being the “Seller Shareholder Meeting”); 

  

	 	4.1.9	the Purchaser not delivering a Novartis AG Board Certificate (as defined in the Implementation Agreement), in accordance with clause 3 of the Implementation
Agreement, prior to the conclusion of the vote on the Seller Shareholder Resolution at the Seller Shareholder Meeting; 

  

	 	4.1.10	there having been no disruption in the Seller Group’s supply chain, for any reason, which has caused a stock out at any of the Seller Group’s relevant
distribution centres in a manner which had, or would be reasonably likely to have, a Material Adverse Effect; 

  

	 	4.1.11	each of the other Target Asset Agreements having become unconditional in accordance with its terms (save for any condition in those agreements relating to this
Agreement or the other of those agreements having become unconditional); and 

  

	 	4.1.12	the Office of Inspector General of the U.S. Department of Health and Human Services (“OIG”) not requiring that: 

 

	 	(i)	the full terms and conditions of the Corporate Integrity Agreement between OIG and GlaxoSmithKline LLC dated on or around 28 June 2012 (the “GSK
CIA”); or 

  

	 	(ii)	significant provisions of the GSK CIA which (a) are terms that are not currently applicable to the Relevant Purchaser Business under Novartis Pharmaceutical
Corporation’s own Corporate Integrity Agreement with the OIG, and (b) when applied to the Relevant Purchaser Business, would, in the aggregate, reasonably be expected to have an adverse effect on it, 

shall, by reason of the sale under this Agreement, bind or apply in respect of the Relevant Purchaser Business. 

In this Clause 4.1.12, the “Relevant Purchaser Business” means the entire (NPC) business and operations in the
United States of the pharmaceuticals division of the Purchaser. 
  

	4.2	Responsibility for Satisfaction 

  

	 	4.2.1	The Purchaser and the Seller shall prepare and file the notifications necessary for the fulfilment of the conditions in Clauses 4.1.1 to 4.1.3 (the
“Required Notifications”) as soon as reasonably practicable (with notifications under the HSR Act to be filed by 29 May 2014). Notwithstanding anything to the contrary contained in this Agreement, the Purchaser
shall     have primary responsibility for obtaining all consents, approvals or actions of any Governmental Entity which are required in connection with the Required Notifications. 

  
 36 

	 	4.2.2	The Purchaser shall be responsible for payment of all filing and other fees and expenses in connection with the Required Notifications and the satisfaction of
the conditions in Clauses 4.1.1 to 4.1.3. 

  

	 	4.2.3	CFIUS 

  

	 	(i)	The Seller and the Purchaser shall consult, cooperate and keep each other reasonably informed regarding communications with, and requests for additional information
from, CFIUS with respect to the Transaction. The Seller and the Purchaser shall use their respective reasonable best efforts to provide promptly all information that is pursuant to a request by CFIUS. 

 

	 	(ii)	Within 30 calendar days after the execution of this Agreement, any party wishing to submit a formal joint voluntary notice to CFIUS pursuant to 31 C.F.R.
Section 800.401, et. seq. (“CFIUS Filing”) shall provide the other party with written notice of its intent to make a CFIUS Filing (“Election Date”). Prior to making its election to submit a CFIUS Filing, the
party wishing to make a CFIUS Filing shall consult in good faith with senior executives of the other party. If neither the Seller nor the Purchaser provides notice to submit a formal joint voluntary notice to CFIUS, a CFIUS Filing will not be made
unless requested by CFIUS. 

  

	 	(iii)	If either the Seller or the Purchaser elects to make a CFIUS Filing following the procedures and consultations in Clause 4.2.3(ii) or if CFIUS requires a filing,
then: 

  

	 	(a)	the Seller and the Purchaser shall use their respective reasonable best efforts to submit a draft CFIUS Filing no later than 15 Business Days following the Election
Date, and a final CFIUS Filing the earlier of (1) five business days after submitting the draft CFIUS filing or (2) five calendar days after the receipt of any comments from CFIUS staff regarding the draft CFIUS Filing.

  

	 	(b)	the Seller and the Purchaser will provide each other with the reasonable opportunity to review and comment on any information provided to CFIUS to the extent permitted
by Applicable Law, with the exception of personal identifier information required under Section 800.402(c)(6)(vi)(B) of the CFIUS regulations, 31 C.F.R.. Competitively sensitive information, or information not related to the transactions
contemplated by this Agreement, may be restricted to each party’s external counsel to the extent reasonably considered necessary or advisable by the providing party; 

  
 37 

	 	(c)	the Seller and the Purchaser shall each have an opportunity to approve and mutually agree on the joint contents of the CFIUS Filing and shall be jointly responsible for
the accuracy of such contents. The Seller and the Purchaser respectively, shall each be responsible for the accuracy of contents of the CFIUS Filing that exclusively relate to itself, its business, and any subsidiaries, parents or other related
parties; and 

  

	 	(d)	the Seller and the Purchaser shall use their respective reasonable best efforts to obtain CFIUS Approval as promptly as practicable and shall consult with each other on
strategic matters related to obtaining such CFIUS Approval, provided that the Purchaser shall have no obligation to agree to any mitigation or other restrictive provision that could reasonably be considered to have a substantial impact on either the
Business or the Purchaser. 

  

	 	4.2.4	The party responsible for satisfaction of each condition pursuant to this Clause 4.2 shall give notice to the other party of the satisfaction of the
relevant condition within one Business Day of becoming aware of the same. 

  

	 	4.2.5	The parties shall cooperate with each other in connection with the satisfaction of the conditions in Clauses 4.1.1 to 4.1.3. The parties will consult and
cooperate reasonably with one another, consider in good faith the views of one another, and provide to the other party in advance any analyses, appearances, presentations, memoranda, briefs, arguments, opinions and proposals they or their agents
make or submit to a Governmental Entity. Without limiting the foregoing, the parties agree to (a) give each other reasonable advance notice of all meetings with any Governmental Entity, (b) give each other an opportunity to participate in
each of such meetings, (c) to the extent practicable, give each other reasonable advance notice of all substantive oral communications with any Governmental Entity, (d) if any Governmental Entity initiates a substantive oral communication
promptly notify the other party of the substance of such communication, (e) provide each other with a reasonable advance opportunity to review and comment upon all written communications (including any analyses, presentations, memoranda,
briefs, arguments, opinions and proposals) with a Governmental Entity, (f) provide each other with copies of all written communications to or from any Governmental Entity, and (g) not advance arguments in connection with any regulatory
review or litigation proceeding related to this Agreement (other than litigation between the parties) over the objection of the other party that would reasonably be likely to have a significant adverse impact on that other party, provided however,
that neither party shall be required to comply with subsection (b) to the extent that the Governmental Entity objects to the participation of a party, or with subsections (e) or (f) to the extent that such disclosure may raise
regulatory concerns (in which case, the disclosure may be made on an outside counsel basis). 

  

	 	4.2.6	Subject to sub-Clause 4.2.7 and Applicable Law: 

  
 38 

	 	(i)	the parties shall cooperate with each other in connection with the satisfaction of the condition in Clause 4.1.12; 

 

	 	(ii)	the parties will consult and cooperate reasonably with one another, consider in good faith the views of one another, and provide to the other party in advance any
analyses, appearances, presentations, memoranda, briefs, arguments, opinions and proposals they or their agents make or submit to the OIG; and 

  

	 	(iii)	without limiting paragraphs (i) and (ii) of this Clause 4.2.6, the parties agree to (a) give each other reasonable advance notice of all meetings
with the OIG, (b) consult to determine if it is in the parties’ mutual interest for both parties give each other an opportunity to participate in each of such meetings, (c) to the extent practicable, give each other reasonable advance
notice of all substantive oral communications with the OIG, (d) if the OIG initiates a substantive oral communication promptly notify the other party of the substance of such communication, (e) provide each other with a reasonable advance
opportunity to review and comment upon all written communications (including any analyses, presentations, memoranda, briefs, arguments, opinions and proposals) with the OIG, (f) provide each other with copies of all written communications to or
from the OIG, (g) not advance arguments in connection with any regulatory review or litigation proceeding related to this Agreement (other than litigation between the parties) over the objection of the other party that would reasonably be
likely to have a significant adverse impact on that other party, and (h) provide each other with such information, documents and data as may be reasonably requested in preparation for any communications (including any analyses, presentations,
memoranda, briefs, arguments, opinions and proposals) with the OIG, provided however, that neither party shall be required to permit the participation of the other party in a meeting with the OIG following the consultation required to comply with
subsection (b) to the extent that the parties fail to agree to such mutual participation or the OIG objects to the participation of a party, to comply with subsections (e), (f) or (g) to the extent that such disclosure may raise
regulatory concerns (in which case, the disclosure may be made on an outside counsel basis), or permit the disclosure or use of information, documents and data provided under subsection (h) in any communications with the OIG if the providing
party reasonably determines that the information is confidential or proprietary and disclosure or use would be reasonably likely to have a significant adverse impact on that party. 

 

	 	4.2.7	The Seller shall not, and shall procure that no member of the Seller’s Group (including but not limited to GlaxoSmithKline LLC) or their directors,
officers, employees, agents or advisors shall, make any material or substantive communication or notification to the OIG regarding the Transaction without consulting and taking into account the views of the Purchaser. 

  
 39 

	 	4.2.8	The Purchaser shall and, shall cause its Affiliates to, use its reasonable endeavours to procure the satisfaction of the conditions in Clauses 4.1.1 to
4.1.3 as soon as reasonably possible (and, in any event, not later than the Long Stop Date). Notwithstanding any other provision of this Agreement to the contrary, the Purchaser shall and, shall cause its Affiliates to use best endeavours to
propose, negotiate, offer to commit and effect (and if such offer is accepted, commit to and effect), by consent decree, undertaking, hold separate order, or otherwise, the sale, divestiture, licence or disposition of its LGX818 and MEK162 products
in development on a global basis (excluding existing manufacturing capabilities) as may be required or desirable in order to procure the satisfaction of the conditions in Clauses 4.1.1 to 4.1.3 as soon as reasonably possible (and, in any event,
not later than the Long Stop Date) and to avoid the commencement of any Action or the issuing of any Decision to prohibit the acquisition or any other transaction contemplated by this Agreement or, if such Action is already commenced, to avoid the
entry of, or to effect the dissolution of, any injunction, temporary restraining order or other order in any Action so as to enable the Closing to occur as soon as reasonably possible (and, in any event, not later than the Long Stop Date). Nothing
in this Clause shall require the Purchaser to divest any currently marketed product indicated for use in renal cell carcinoma or any currently marketed Product indicated for use in melanoma, including but not limited to Mekinist, Tafinlar, Votrient
and/or Afinitor. 

  

	 	4.2.9	The Seller shall, and shall cause the Seller’s Group, to use its reasonable endeavours to cooperate with the Purchaser in connection with procuring the
satisfaction of the conditions in Clauses 4.1.1 to 4.1.3 as soon as reasonably possible (and, in any event, not later than the Long Stop Date), including providing to the Purchaser such information with respect to the Business and the Products
as the Purchaser may reasonably require in connection with satisfaction of its obligations under this Clause. 

  

	 	4.2.10	The Purchaser and Seller shall cooperate to confirm, within 21 Business Days from signing of this Agreement, any additional merger notification requirements
reasonably required or advisable in respect of the Transaction in jurisdictions beyond those listed in Schedule 21, and shall cooperate with each other, within the meaning of Clause 4.2.5, in achieving any additional clearances, approvals,
consents, waivers, no- action letters or waiting period expirations in such jurisdictions. For the avoidance of doubt, Closing shall not be conditional upon such additional clearances, approvals and consents or waiting period expirations.

  

	 	4.2.11	The Purchaser and Seller shall cooperate, within the meaning of Clause 4.2.5, and use reasonable endeavours to ensure that no Governmental Entity shall
enact, issue, promulgate, enforce or enter any Applicable Law or Judgment as contemplated under Clause 4.1.7. In the event that any Governmental Entity enacts, issues, promulgates, enforces or enters any Applicable Law or Judgment as
contemplated under Clause 4.1.7, the Seller and the Purchaser shall cooperate and use reasonable endeavours to put in place arrangements that would allow the Transaction to complete to the greatest possible extent in compliance with the
relevant Applicable Law or Judgment. 

  
 40 

	 	4.2.12	The Seller shall use best efforts to obtain the consents referred to in Clauses 4.1.5 and 4.1.6 prior to the Closing Date. The cost of obtaining such
consents shall be borne by the Seller, including any payment or other incentive that may (whether required to be offered or not) be offered to JTI and/or Genmab or any of their respective Affiliates in order to obtain such consents. The Purchaser
shall, and shall cause its Affiliates to cooperate with the Seller in connection with obtaining the consents, referred to in Clauses 4.1.5 and 4.1.6 and use its reasonable endeavours to ensure that such conditions are satisfied at Closing,
including providing to the Seller such information as the Seller may reasonably require in connection with the satisfaction of its obligations under this Clause 4.2.12. 

 

	 	4.2.13	The Purchaser may at any time waive in whole or in part (and conditionally or unconditionally) the conditions set out in Clauses 4.1.5, 4.1.6, 4.1.10 and
4.1.12 by notice in writing to the Seller. 

  

	4.3	Non-Satisfaction by the Long Stop Date 

 If the conditions in Clause 4.1 are not satisfied (or waived in accordance with Clause 4.2.13) as of 22 October 2015 (the “Long Stop Date”), the Purchaser or the Seller
may, in its sole discretion, terminate this Agreement (other than Clauses 1, 13, and 16.2 to 16.15) and no party shall have any claim against the other under it, save for any claim arising from breach of any obligation contained in such Clauses
or Clause 4.2. Neither the Seller nor the Purchaser may terminate this Agreement after satisfaction or waiver of the conditions in Clause 4.1, except in accordance with this Agreement. 

 

	4.4	Termination 

  

	 	4.4.1	This Agreement may be terminated at any time prior to Closing: 

  

	 	(i)	by written consent of the Seller and the Purchaser; 

  

	 	(ii)	by either the Seller or the Purchaser by notice to the other party in the event that any Judgment restraining, enjoining or otherwise prohibiting the transactions
contemplated by this Agreement shall have become final and non-appealable, provided that the party seeking to terminate this Agreement pursuant to this Clause 4.4 has complied with the terms of the Implementation Agreement and this Agreement in
connection with having such Judgment vacated or denied; or 

  

	 	(iii)	by the Purchaser by notice to the Seller if: 

  

	 	(a)	a Material Adverse Effect occurs prior to Closing (which shall include any breach or breaches of Clause 9.1 which alone or together constitute a Material Adverse
Effect); or 

  
 41 

	 	(b)	the Seller fails to provide a Certificate immediately prior to Closing; or 

 

	 	(iv)	in accordance with the terms of the Implementation Agreement. 

  

	 	4.4.2	This Agreement shall terminate automatically at any time prior to Closing in the event that: 

 

	 	(i)	any other Target Asset Agreement terminates or is terminated in accordance with its terms; or 

 

	 	(ii)	the Novartis Break Fee and/or the GSK Break Fee becomes payable under clause 5.1 or clause 5.8 of the Implementation Agreement, respectively.

  

	 	4.4.3	Save as provided in this Clause 4, neither party shall be entitled to terminate or rescind this Agreement (whether before or after Closing). If this
Agreement is terminated pursuant to this Clause 4.4, this Agreement shall be of no further force and effect and there shall be no further liability under this Agreement or any of the Ancillary Agreements on the part of any party, except that
Clauses 1, 13, and 16.2 to 16.15, in each case, to the extent applicable, shall survive any termination. 

  

	 	4.4.4	Nothing in this Clause 4.4 shall be deemed to release any party from any liability for any breach by such party of the terms and provisions of this
Agreement prior to termination of this Agreement. 

  

	5.	Pre-Closing 

  

	5.1	The Seller’s Obligations in Relation to the Business 

  

	 	5.1.1	The Seller undertakes to procure that between the date of this Agreement and Closing, the relevant members of the Seller’s Group shall, so far as permitted
by Applicable Law, carry on the Business as carried on by the Seller Group as a going concern in the ordinary course as carried on immediately prior to the date of this Agreement save in so far as agreed in writing by the Purchaser (such consent not
to be unreasonably withheld or delayed). 

  

	 	5.1.2	Without prejudice to the generality of Clause 5.1.1 and subject to Clause 5.2, the Seller shall not, in each case with respect to the Business only,
between the date of this Agreement and Closing, and shall procure that each member of the Seller’s Group shall not, except as may be required to comply with this Agreement, without the prior written consent of the Purchaser (such consent not to
be unreasonably withheld or delayed), take any of the actions listed in Part 1 of Schedule 19. 

  

	 	5.1.3	Without prejudice to the generality of Clause 5.1.1, the Seller shall, in each case with respect to the Business only: (i) undertake to procure the
satisfaction of its obligations listed in paragraph 1, Part 2 of Schedule 19; and (ii) shall, and shall procure that each member of the Seller’s Group shall, between the date of this Agreement and Closing, comply with the requirements
of paragraph 2, Part 2 of Schedule 19. 

  
 42 

	5.2	Exceptions to Seller’s Obligations in Relation to the Conduct of Business 

Clause 5.1 shall not operate so as to prevent or restrict: 

 

	 	5.2.1	any matter undertaken by any member of the Seller’s Group to implement any Pre-Closing Product Reorganisation in accordance with Clauses 2.3.5 and
2.3.6; 

  

	 	5.2.2	any action to the extent it is required to be undertaken to comply with Applicable Law; or 

 

	 	5.2.3	any matter reasonably undertaken by any member of the Seller’s Group in an emergency or disaster situation with the intention of minimising any adverse
effect of such situation in relation to the Business and where any delay arising by virtue of having to give notice to the Purchaser and await consent would materially prejudice the Business, 

provided that the Seller shall notify the Purchaser as soon as reasonably practicable of any action taken or proposed to be taken as
described in Clause 5.2.3, shall provide to the Purchaser all such information as the Purchaser may reasonably request and shall use reasonable endeavours to consult with the Purchaser in respect of any such action. 

 

	5.3	Seller and Purchaser’s Rights and Obligations 

  

	 	5.3.1	Subject to Clause 5.3.2, the parties shall negotiate in good faith to agree definitive and legally binding documentation in respect of each of the Ancillary
Agreements for which the heads of terms are in the Agreed Terms, including the Manufacturing and Supply Agreement, on the date of this Agreement, and shall duly execute and deliver such definitive and legally binding documentation in respect of the
Ancillary Agreements at Closing. 

  

	 	5.3.2	In the event that the parties are unable to agree definitive and legally binding documentation in respect of an Ancillary Agreement referred to in
Clause 5.3.1 by Closing, the parties shall be subject to and shall adhere to the heads of terms in the Agreed Terms for that Ancillary Agreement, which terms shall be legally binding on the parties. 

 

	 	5.3.3	If required by the Seller, the Purchaser shall co-operate with the Seller and the relevant counterparty to procure the grant of a sub-licence or partial
assignment of certain rights under the Ofatumumab Agreements to the Seller for use in relation to the Ofatumumab Compound in the Ofatumumab Indications and in the field of autoimmune diseases under the Ofatumumab Intellectual Property Licence or
another agreement between the parties, effective from Closing. 

  

	 	5.3.4	If, at any time prior to Closing, the [***] determines that the terms and conditions of the [***] shall not bind or apply (in full or with respect to significant
provisions thereof) to the Relevant Purchaser Business, but does determine that they shall bind or apply in any respect to either all or part of the Business or the Employees, then, at any time prior to the date falling 5 Business Days prior to the
Closing Date, notwithstanding any provision in this Agreement to the contrary, the Purchaser shall be entitled not to make an offer of employment to any Employee who: 

 

	***	Note: Confidential treatment has been requested with respect to the information contained within the [***] marking. Such portions have been omitted from this filing and
have been filed separately with the Securities and Exchange Commission 

  
 43 

	 	(i)	is not expected to transfer by operation of law to the Purchaser or any member of the Purchaser’s Group on Closing; and 

 

	 	(ii)	is or would reasonably be expected to be a “Covered Person” (as defined in the [***]) or is otherwise subject to or bound by any material obligation or term
of the [***] as applied to the Purchaser or any member of the Purchaser’s Group following Closing, 

 and,
where no offer of employment with the Purchaser or any member of the Purchaser’s Group is made in accordance with this Clause 5.3.4, such Employee shall remain employed by the Seller or the relevant member of the Seller’s Group on and
following Closing. 
  

	 	5.3.5	At any time prior to the date falling 18 months after the Closing Date, each relevant member of the Purchaser’s Group shall be entitled to terminate the
employment of any Employee: 

  

	 	(i)	whose employment has transferred to the Purchaser or any member of the Purchaser’s Group either by operation of law or by way of offer and acceptance; and

  

	 	(ii)	who is or would reasonably be expected to be a “Covered Person” (as defined in the [***], as applied to the Purchaser’s Group) or is otherwise subject to
or bound by any material obligation or term of the [***] as applied to the Purchaser or any member of the Purchaser’s Group following Closing, 

 if the [***] has determined or determines that the terms and conditions of the [***] shall apply or be binding (in whole or in part) to the Relevant Purchaser Business. The relevant member of the
Purchaser’s Group may effect such termination either by giving notice or transferring the Employee to a member of the Seller’s Group by agreement to be concluded between the relevant member of the Purchaser’s Group, the Employee
concerned and the relevant member of the Seller’s Group. The Seller shall be responsible for and shall indemnify and keep indemnified the Purchaser (for itself and as trustee for any relevant member of the Purchaser’s Group) against all
Liabilities from time to time made, suffered or incurred by the Purchaser (or any other member of the Purchaser’s Group) as a result of: 
  

	 	(iii)	the transfer of employment of such Employee to the Purchaser or any member of the Purchaser’s Group and the employment of such Employee from the Closing Date until
the termination of employment of such Employee as referred to in this Clause 5.3.5(iii) (or any other employment liabilities relating to such person); and 

 

	***	Note: Confidential treatment has been requested with respect to the information contained within the [***] marking. Such portions have been omitted from this filing and
have been filed separately with the Securities and Exchange Commission 

  
 44 

	 	(iv)	the termination of such Employee’s employment. 

  

	 	5.3.6	Prior to Closing, the Seller shall be entitled to take and retain a full set of copies of the Ofatumumab Indications Data for use in accordance with the
Ofatumumab Intellectual Property Licence Agreement. For the avoidance of doubt, the Ofatumumab Indications Data constitutes part of the Arzerra Auto-Immune IP Rights for the purposes of the Ofatumumab Intellectual Property Licence Agreement (as such
term is defined in the Agreed Terms for the Ofatumumab Intellectual Property Licence Agreement). 

  

	6.	Closing 

  

	6.1	Date and Place 

 Subject
to paragraph 4.3 of Schedule 25, Closing shall take place simultaneously with closing under the other Target Asset Agreements at 11.59 p.m. (Central European Time) at the offices of Freshfields Bruckhaus Deringer, 65 Fleet Street, London EC4Y 1HS
(other than in respect of any Local Transfer Documents agreed between the parties to be executed in another jurisdiction) on the last Business Day of the month in which fulfilment or waiver of the last of the condition(s) set out in Clause 4.1
to be fulfilled or waived takes place, except that: 
  

	 	6.1.1	where the last day of such month is not a Business Day, Closing shall instead take place on the first Business Day of the following month; and

  

	 	6.1.2	where less than five Business Days remain between such fulfilment or waiver and the last Business Day of the month, Closing shall take place:

  

	 	(i)	on the last Business Day of the following month; 

  

	 	(ii)	where the last day of such month is not a Business Day, Closing shall instead take place on the first Business Day of the month following the month referred to in
Clause 6.1.2(i); or 

  

	 	(iii)	at such other location, time or date as may be agreed between the Purchaser and the Seller in writing, 

provided that: 
  

	 	(a)	Closing shall not take place and shall not be effective in any circumstances unless closing also takes place under and in accordance with the terms of the other Target
Asset Agreements at the same time; and 

  

	 	(b)	 in determining the date on which the last of the conditions set out in Clause 4.1 is fulfilled or waived, the date shall be the date on which the
last of the conditions set out in Clauses 4.1.1, 4.1.2, 4.1.3, 4.1.4, 4.1.5, 4.1.6, 4.1.8, 4.1.9 and 4.1.11 is fulfilled or waived unless any of the conditions set out in Clauses 4.1.7, 4.1.10 and 4.1.12 is not fulfilled or waived on that
date, in which case the date shall then be the first following date on which all of the conditions set out in Clauses 4.1.7, 4.1.10 and 4.1.12 are fulfilled or waived. 

  
 45 

	6.2	Closing Events 

  

	 	6.2.1	On Closing, but subject to paragraph 4.3 of Schedule 25, the parties shall comply with their respective obligations specified in Schedule 12. The Seller may
waive some or all of the obligations of the Purchaser as set out in Schedule 12 and the Purchaser may waive some or all of the obligations of the Seller as set out in Schedule 12. 

 

	 	6.2.2	The parties acknowledge that the transfer of Product Approvals to the Purchaser or other members of the Purchaser’s Group may be subject to the approval of
applicable Governmental Entities, and that, notwithstanding anything in this Agreement to the contrary, each Product Approval shall continue to be held by the relevant member of the Seller’s Group from the Closing Date until the relevant PA
Transfer Date. 

  

	 	6.2.3	The parties shall perform their respective obligations with respect to: 

 

	 	(i)	the transfer of the Product Approvals as set out in Schedule 6; 

  

	 	(ii)	the transfer of Contracts (other than Product Approvals) and the Transferred Intellectual Property Contracts as set out in Schedule 7; 

 

	 	(iii)	to the extent the Purchaser has elected to have the Relevant Part of a Shared Business Contract transferred to it, the separation of each Shared Business Contract as
set out in Schedule 7; and 

  

	 	(iv)	the Seller’s Indian Business as set out in Schedule 25. 

  

	6.3	Payment on Closing and the Reduction Amount 

  

	 	6.3.1	Subject to the remainder of this Clause 6.3, on Closing the Purchaser shall pay (for itself and on behalf of each relevant member of the Purchaser’s
Group, and in accordance with Clause 16.6): 

  

	 	(i)	an amount in cleared funds to the Seller which is equal to the Headline Amount less the sum of: 

 

	 	(a)	the amount of the Company Intra-Group Debt; and 

  

	 	(b)	any Estimated Employee Benefit Adjustment; and 

  

	 	(c)	any amount to be deducted pursuant to Clause 6.3.6; and 

  

	 	(d)	the amount that would be the Stamp Duty Amount assuming, for this purpose only, that: 

 

	 	(A)	the Employee Benefit Indemnification Amount is equal to the Estimated Employee Benefit Adjustment, if any; and 

  
 46 

	 	(B)	the Reduction Amount is equal to the amount referred to in limb (c), if any; and 

 

	 	(ii)	a further amount in cleared funds to the Seller which is equal to the amount of the Company Intra-Group Debt and which shall be applied as provided in paragraph 1.4 of
Schedule 12, 

 such that the total amount to be paid to the Seller and other members of the Seller’s Group
on Closing shall be the Headline Amount less the sum of the Stamp Duty Amount and, if applicable, any Estimated Employee Benefit Adjustment and, if applicable, any amount to be deducted under Clause 6.3.6. 

 

	 	6.3.2	On the Closing Date but immediately prior to Closing, the Seller shall deliver a written statement to the Purchaser in the form of Schedule 24 setting out the
amount of the Company Intra-Group Debt determined using the US$ Spot Rate, provided that such amount shall be no greater than the Headline Amount less the aggregate of the Business Consideration, the Stamp Duty Amount and if applicable, any
Reduction Amount and, if applicable, any Employee Benefit Indemnification Amount (the “Maximum Company Intra-Group Debt Amount”). If, after Closing, it is determined that the amount paid by the Purchaser pursuant to Clause 6.3.1(ii)
exceeded the Maximum Company Intra-Group Debt Amount, the Seller shall pay the Purchaser an amount equal to the difference on demand. 

  

	 	6.3.3	The amount of the Share Consideration shall be subject to the following: 

 

	 	(i)	in the event that, by the CombiD Outcome Longstop Date, neither the Category A Outcome nor the Category B Outcome is achieved, the Share Consideration shall be reduced
by $1.5 billion; and 

  

	 	(ii)	in the event that, by the CombiD Outcome Longstop Date, the Category A Outcome is not achieved but the Category B Outcome is achieved, the Share Consideration shall be
reduced by $1.0 billion, 

 the amount of any such applicable reduction being the “Reduction
Amount”. Clauses 6.3.5 and 6.3.6 below shall apply in respect of any Reduction Amount. 
  

	 	6.3.4	For the avoidance of doubt, in the event that, by the CombiD Outcome Longstop Date, the Category A Outcome is achieved, then (whether or not the Category B
Outcome is also achieved) no reduction or adjustment shall be made to the Share Consideration. 

  

	 	6.3.5	In the event that a reduction to the Share Consideration applies under Clause 6.3.3 above and the cause of such reduction occurs at or following Closing, the
Seller shall (against the Purchaser having paid the full amount of the Share Consideration at Closing) repay to the Purchaser: 

  

	 	(i)	an amount equal to the applicable Reduction Amount; and 

  
 47 

	 	(ii)	interest on the Reduction Amount at the rate of Six-Month LIBOR, such interest accruing on a daily basis from the Closing Date to (and including) the date of payment of
the Reduction Amount by the Seller to the Purchaser. 

 Any repayment to be made pursuant to this
Clause 6.3.5 shall be made within 5 Business Days of the CombiD Outcome Longstop Date, provided that, in circumstances where Conclusion of the CombiD Study has occurred and either or both of (a) the condition in Clause 6.3.7(i)(a) of
the Category A Outcome, and (b) the condition in Clause 6.3.7(ii)(a)(A) of the Category B Outcome are no longer capable of satisfaction, any resulting applicable reduction to the Share Consideration shall apply and take effect at (and any
payment in respect thereof made within the 5 Business Days following) the time at which the relevant condition or conditions are no longer capable of satisfaction. 
  

	 	6.3.6	In the event that a reduction applies under Clause 6.3.3 above and the cause of such reduction occurs prior to Closing, the Purchaser shall be entitled to
deduct an amount equal to the applicable Reduction Amount from the Share Consideration otherwise payable to the Seller at Closing. 

  

	 	6.3.7	The following terms used in this Clause 6.3 shall have the meaning ascribed below: 

 

	 	(i)	“Category A Outcome” means, in relation to the CombiD Study, all of the following: 

 

	 	(a)	that Statistical Significance is achieved for the Overall Survival Endpoint; 

 

	 	(b)	that the FDA accepts or agrees that Statistical Significance has been achieved for the Overall Survival Endpoint; and 

 

	 	(c)	the absence of a New Material Safety Signal; 

  

	 	(ii)	“Category B Outcome” means both of the following: 

  

	 	(a)	in relation to the CombiD Study, both: 

  

	 	(A)	achievement of a point estimate for the Hazard Ratio (HR) on the Overall Survival Endpoint that is [***] or better (that is, lower than [***]); and

  

	 	(B)	the absence of a New Material Safety Signal; and 

  

	 	(b)	the FDA not disallowing, within 12 months of Conclusion of the CombiD Study, continued use in the product insert of the claim that the Combination is more efficacious
than the constituent mono-therapies; 

  

	***	 Note: Confidential treatment has been requested with respect to the information contained within the [***] marking. Such portions have been omitted
from this filing and have been filed separately with the Securities and Exchange Commission. 

  
 48 

	 	(iii)	“CombiD Outcome Longstop Date” means the later of (i) the date that is 12 months after Conclusion of the CombiD Study, and
(ii) 31 December 2015; 

  

	 	(iv)	“CombiD Study” means the Phase III, randomized, double-blinded study comparing the combination of the BRAF inhibitor, dabrafenib and the MEK inhibitor,
trametinib to dabrafenib and placebo as first-line therapy in subjects with unresectable (Stage IIIC) or metastatic (Stage IV) BRAF V600E/K mutation-positive cutaneous melanoma (the “Combination”); 

 

	 	(v)	“Conclusion” means when the Overall Survival Endpoint is analysed and the CombiD Study is closed; 

 

	 	(vi)	“New Material Safety Signal” means a Safety Signal: 

  

	 	(a)	which is identified in the results of the CombiD Study; 

  

	 	(b)	which was not described in the approval of the Combination by the FDA or the respective approvals of the BRAF and MEK components of the Combination; and

  

	 	(c)	in respect of which, within 12 months of the Conclusion of the CombiD Study, the FDA requires inclusion of a “black box” on the product insert for the
Combination, the BRAF inhibitor and the MEK inhibitor; 

  

	 	(vii)	“Overall Survival Endpoint” means, as defined in the study protocol for the CombiD Study and the statistical analysis plan agreed with the FDA in
respect thereof, the time from randomization until death due to any cause, where: 

  

	 	(a)	all-cause mortality is used and censoring is performed using the date of the last known contact for those who were alive at the time of analysis; and

  

	 	(b)	overall survival is summarized using the Kaplan-Meier method and treatment comparisons are made using a stratified log rank test (stratified by LDH status and mutation
status); 

  

	 	(viii)	“Safety Signal” means information that arises from one or multiple sources that suggests a new, potentially causal association, or a new aspect of a
known association, between an intervention and event or set of related events, which is adverse; and 

  
 49 

	 	(ix)	“Statistical Significance” means a one-sided p-value less than [***]. 

 

	 	6.3.8	Notwithstanding any other provision in this Agreement or any Ancillary Agreement, the parties agree that the CombiD Study shall remain under the control of the
Seller until its Conclusion. 

  

	 	6.3.9	Five Business Days prior to Closing, the Seller shall notify the Purchaser of any Estimated Employee Benefit Adjustment and at the same time provide to the
Purchaser reasonable supporting calculations and information to enable the Purchaser to review the basis on which the estimate has been prepared. 

  

	6.4	Breach of Closing Obligations 

 If any party fails to comply with any material obligation in Clause 6.2 or 6.3 or Schedule 12 in relation to Closing, the Purchaser, in the case of non-compliance by the Seller, or the Seller, in the
case of non-compliance by the Purchaser, shall be entitled (in addition to and without prejudice to all other rights or remedies available) by written notice to the Seller or the Purchaser to fix a new date for Closing which, except as agreed by the
parties, shall be the last day of the month next ending or, if that day is not a Business Day, the first Business Day falling after that day, in which case the provisions of Schedule 12 shall apply to Closing as so deferred, but provided such
deferral may only occur once. In all circumstances Closing shall only occur simultaneously with closing under the other Target Asset Agreements. 
  

	7.	Development Plans 

  

	7.1	As at the date of this Agreement, the Seller or the relevant member of the Seller’s Group intends to implement the studies of the Products set out in the
Key Study Plans in accordance with the Key Study Plans. Prior to Closing, the Seller (or the relevant member(s) of the Seller Group) shall continue to implement the Development Plans in the same manner and to the same standards as it has done so
prior to the date of this Agreement. 

  

	7.2	The Seller shall (and shall ensure that the relevant member(s) of the Seller Group), maintain and preserve the laboratory notebooks and other records detailing
the experiments and studies (including of any clinical trials) conducted pursuant to the Development Plans (the “Development Plan Records”) and shall require any sub-contractors to similarly maintain and preserve Development Plan
Records of their respective activities. 

  

	7.3	So far as permitted by Applicable Law and at the Purchaser’s risk: 

 

	 	7.3.1	the Seller shall provide the Purchaser with such information about the progress of the Development Plans as the Purchaser may reasonably request and shall
provide the Purchaser with copies of substantive correspondence with any Governmental Entity with respect to any Product Expansion Application. 

 

	***	Note: Confidential treatment has been requested with respect to the information contained within the [***] marking. Such portions have been omitted from this filing and
have been filed separately with the Securities and Exchange Commission. 

  
 50 

	 	7.3.2	the Seller shall provide to the Purchaser monthly an update in relation to each Product Expansion with sufficient detail for the Purchaser to be able to assess
the progress of each Product Expansion against the relevant Development Plan and highlighting any areas, whether scientific, clinical or regulatory, which may have a material impact on the future development of the Product Expansion. The form of
update shall be agreed by the Seller and the Purchaser acting reasonably and in good faith. The Seller shall discuss matters relevant to the Product Expansion with representatives of the Purchaser and consult the Purchaser on the progress of the
Product Expansion and any material proposed amendments to the relevant Development Plan with respect to the particular Product Expansion; and 

  

	 	7.3.3	the Seller shall promptly inform the Purchaser of any material unforeseen results, problems or difficulties with regards to any Product Expansion including with
respect to any communication from any Governmental Entity which indicates that the Development Plan in relation to such Product Expansion requires material amendment in order for the Product Expansion to be approved. The Seller shall consult with
the Purchaser with respect to any such matters and shall take account of the views of the Purchaser for resolving any such unforeseen results, problems or difficulties. 

 

	8.	Post-Closing Obligations 

  

	8.1	Indemnities 

  

	 	8.1.1	Indemnity by the Purchaser against Assumed Liabilities 

 The Purchaser hereby undertakes to the Seller (for itself and on behalf of each other member of the Seller’s Group, and their respective directors, officers, employees and agents) that with effect
from Closing, the Purchaser will indemnify on demand and hold harmless each member of the Seller’s Group and their respective directors, officers, employees and agents against and in respect of any and all Assumed Liabilities. 

 

	 	8.1.2	Indemnities by the Seller 

  

	 	(i)	Subject to Clause 8.1.3, the Seller hereby undertakes to the Purchaser (for itself and on behalf of each other member of the Purchaser’s Group and their
respective directors, officers, employees and agents) that, with effect from Closing, the Seller will indemnify on demand and hold harmless each member of the Purchaser’s Group and their respective directors, officers, employees and agents
against and in respect of any and all: 

  

	 	(a)	Excluded Liabilities; and 

  

	 	(b)	 Liabilities, including legal fees, to the extent they have arisen or arise (whether before or after Closing) as a result of or otherwise relate to any
act, omission, fact, matter, 

  
 51 

	 	
circumstance or event undertaken, occurring or in existence or arising before Closing so far as related to: (A) any anti-bribery warranty, including without limitation those set forth in
paragraphs 7.1 through 7.6 of Schedule 14, not being true and correct when made; (B) any government inquiries or investigations involving the Seller, its Affiliates or their respective Associated Persons; (C) save to the extent in
existence as at the date of this Agreement, any limitation, restriction or other reduction in drug registrations, licenses, listings or marketing approvals, government pricing or reimbursement rates relating to the Products including specifically
the value of lost future profits as a result of any such limitation, restriction or reduction; or (D) any other claim, litigation, investigation or proceeding to the extent related to any of the foregoing (A) to (C), including but not
limited to costs of investigation and defense and legal fees. 

  

	 	(ii)	The Seller hereby undertakes to the Purchaser (for itself and on behalf of each other member of the Purchaser’s Group and their respective directors, officers,
employees and agents) that, with effect from Closing, the Seller will indemnify on demand and hold harmless each member of the Purchaser’s Group and their respective directors, officers, employees and agents against and in respect of any and
all Liabilities, including lost profits, arising from or in connection with any failure by the Seller or its Affiliates to Manufacture and supply Products in accordance with the terms of the Manufacturing and Supply Agreement or Transitional
Distribution Services Agreement, as applicable, to the extent such failure results from the Cork FDA Matter. 

  

	 	8.1.3	Limitations on Indemnities 

 Subject to Clause 8.1.4, the Seller shall not be liable under Clause 8.1.2(i) in respect of: 
  

	 	(i)	any Time-Limited Excluded Liability unless a notice of claim in respect of the matter giving rise to such Liability is given by the Purchaser to the Seller within ten
years of Closing, provided that this sub-Clause (i) shall not apply in respect of any claim by the Purchaser which relates to: 

  

	 	(a)	a Product Liability; 

  

	 	(b)	a Governmental Liability; 

  

	 	(c)	a Clinical Trials/Data Liability; 

  

	 	(d)	an Excluded Asset; or 

  

	 	(e)	an IP Liability; and 

  
 52 

	 	(ii)	any individual claim (or a series of claims arising from similar or identical facts or circumstances) where the Liability (disregarding the provisions of this
Clause 8.1.3(ii)) in respect of any such claim or series of claims does not exceed US$10 million, provided that, for the avoidance of doubt, where the Liability in respect of any such claim or series of claims exceeds US$10 million, the
Liability of the Seller shall be for the whole amount of such claim(s) and not just the excess. 

  

	 	8.1.4	Disapplication of limitations 

 None of the limitations contained in Clause 8.1.3 shall apply to any claim to the extent that such claim which arises or is increased, or to the extent to which it arises or is increased, as the
consequence of, or which is delayed as a result of, fraud by any member of the Seller’s Group or any director, officer or employee of any member of the Seller’s Group. 

 

	8.2	Conduct of Claims 

  

	 	8.2.1	Assumed Liabilities 

  

	 	(i)	If the Seller becomes aware after Closing of any claim by a third party which constitutes or may constitute an Assumed Liability, the Seller shall as soon as reasonably
practicable: 

  

	 	(a)	give written notice thereof to the Purchaser setting out such information as is available to the Seller as is reasonably necessary to enable the Purchaser to assess the
merits of the potential claim; 

  

	 	(b)	take all appropriate actions to preserve evidence; and 

  

	 	(c)	provide the Purchaser with periodic updates on the status of the claim upon request and shall not admit, compromise, settle, discharge or otherwise deal with such claim
without the prior written agreement of the Purchaser (such agreement not to be unreasonably withheld or delayed). 

  

	 	(ii)	The Seller shall, and shall procure that each Business Seller and the Share Seller shall, take such action as the Purchaser may reasonably request to avoid, dispute,
resist, appeal, compromise, defend or mitigate any claim which constitutes or may constitute an Assumed Liability subject to the Seller, the Share Seller and each Business Seller being indemnified and secured to their reasonable satisfaction by the
Purchaser against all Liabilities which may thereby be incurred. In connection therewith, the Seller shall make or procure to be made available to the Purchaser or their duly authorised agents on reasonable notice during normal business hours all
relevant books of account, records and correspondence relating to the Business which have been retained by the Seller’s Group (and shall permit the Purchaser to take copies thereof at its expense) for the purposes of enabling the Purchaser to
ascertain or extract any information relevant to the claim. 

  
 53 

	 	8.2.2	Liabilities Indemnified by the Seller 

  

	 	(i)	If the Purchaser becomes aware after Closing of any claim by a third party which constitutes or may constitute a Liability covered by Clause 8.1.2 or relates to a
Liability or any investigations related thereto, regardless of whether the Purchaser believes that such claim would be made against a member of the Purchaser’s Group or a member of the Seller’s Group, the Purchaser shall as soon as
reasonably practicable: 

  

	 	(a)	give written notice thereof to the Seller, setting out such information as is available to the Purchaser as is reasonably necessary to enable the Seller to assess the
merits of the potential claim; 

  

	 	(b)	take all appropriate actions to preserve evidence; and 

  

	 	(c)	provide the Seller with periodic updates on the status upon request and shall not admit, compromise, settle, discharge or otherwise deal with such claim without the
prior written agreement of the Seller (such agreement not to be unreasonably withheld or delayed). 

  

	 	(ii)	The Purchaser shall take such action as the Seller may reasonably request to avoid, dispute, resist, appeal, compromise, defend or mitigate any claim which constitutes
or may constitute a Liability covered by Clause 8.1.2 subject to the Purchaser being indemnified and secured to its reasonable satisfaction by the Seller against all Liabilities which may thereby be incurred. 

 

	 	(iii)	In addition, where any such claim or investigation involves a Governmental Entity, the Purchaser shall, subject to Applicable Law, the requirements of the relevant
Governmental Entity and the Seller providing an appropriate confidentiality undertaking in favour of the Purchaser’s Group, provide to the Seller, at least five Business Days in advance (or, where not possible, as soon as reasonably possible),
any analyses, appearances, presentations, memoranda, briefs, arguments, opinions and proposals they or their agents make or submit to a Governmental Entity. Without limiting the foregoing, the parties agree, subject to the Applicable Law and the
requirements of the relevant Governmental Entity and the Seller providing an appropriate confidentiality undertaking in favour of the Purchaser’s Group to: 

 

	 	(a)	give the Seller reasonable advance notice of all meetings with any Governmental Entity; 

  
 54 

	 	(b)	give the Seller an opportunity to participate in each of such meetings; 

  

	 	(c)	to the extent practicable, give the Seller reasonable advance notice of all substantive oral communications with any Governmental Entity; 

 

	 	(d)	if any Governmental Entity initiates a substantive oral communication, promptly notify the Seller of the substance of such communication; 

 

	 	(e)	provide the Seller with a reasonable advance opportunity to review and comment upon all substantive written communications (including any substantive correspondence,
analyses, presentations, memoranda, briefs, arguments, opinions and proposals) that the Purchaser or its agents intend to make or submit to a Governmental Entity in connection with such claim; 

 

	 	(f)	provide the Seller with copies of all substantive written communications to or from any Governmental Entity; and 

 

	 	(g)	not advance arguments with the Governmental Entity without prior agreement of the Seller that would reasonably be likely to have a significant adverse impact on the
Seller, provided however, that the Purchaser shall not be required to comply with paragraph (b) above to the extent that the Governmental Entity objects to the participation of a party, or with paragraph (e) or (f) above to the extent
that such disclosure may raise regulatory concerns (in which case, the disclosure may be made on an outside counsel basis). 

  

	 	(iv)	Other than in respect of any claim to the extent it relates to an IP Liability, a Commercial Practices Liability or a Governmental Liability (other than in respect of
any Liability arising solely by virtue of a breach of any Contract with any Governmental Entity which breach does not also constitute a breach of Applicable Law), the Seller shall be entitled at its own expense and in its absolute discretion, by
notice in writing to the Purchaser, to take such action as it shall deem necessary to avoid, dispute, deny, defend, resist, appeal, compromise or contest any such claim (including making counterclaims or other claims against third parties) in the
name of and on behalf of the Purchaser or other member of the Purchaser’s Group concerned and to have the conduct of any related proceedings, negotiations or appeals. In taking action on behalf of any member of the Purchaser’s Group as
permitted by this Clause 8.2, the Seller shall, in good faith, take into account and have due regard to any reputational matter or issue arising out of the claim for any member of the Purchaser’s Group or any of their respective directors,
officers, employees or agents which are brought to its attention by the Purchaser or a member of the Purchaser’s Group. 

  
 55 

	 	(v)	Without limitation to the Seller’s rights pursuant to Clause 8.7.2, the Purchaser shall make or procure to be made available to the Seller or its duly
authorised agents on reasonable notice during normal business hours full and free access to all relevant books of account, records and correspondence relating to the Business which are in the possession or control of the Purchaser or any member of
the Purchaser’s Group (and shall permit the Seller to take copies thereof) for the purposes of enabling the Seller to ascertain or extract any information relevant to the claim. 

 

	 	(vi)	The Purchaser shall, and shall procure that each other member of the Purchaser’s Group shall, on reasonable notice from the Seller, give such assistance to the
Seller as it may reasonably require in relation to the claim including providing the Seller or any member of the Seller’s Group and its representative and advisers with access to and assistance from directors, officers, managers, employees,
advisers, agents or consultants of the Purchaser and/or of each other member of the Purchaser’s Group (collectively, the “Relevant Persons”) and the Purchaser will use its reasonable endeavours to procure that such Relevant
Persons comply with any reasonable requests from the Seller and generally co-operates with and assists the Seller and other members of the Seller’s Group. 

 

	 	(vii)	When seeking assistance under Clauses 8.2.2(v) and (vi), the Seller, or any other relevant member of the Seller’s Group, shall use reasonable endeavours to
minimise interference with the Purchaser and the Purchaser’s Group’s conduct of the relevant business or the performance by the Relevant Persons of their employment duties. 

 

	8.3	Release of Guarantees 

  

	 	8.3.1	The Purchaser shall use reasonable endeavours to procure as soon as reasonably practicable after Closing, the release of the Sellers or any member of the
Seller’s Group from any securities, guarantees or indemnities given by or binding upon the Seller or any member of the Seller’s Group in respect of the Assumed Liabilities. Pending such release the Purchaser shall indemnify the Seller and
any member of the Seller’s Group against all amounts paid by any of them (acting reasonably) pursuant to any such securities, guarantees or indemnities in respect of such Assumed Liabilities. 

 

	 	8.3.2	The Seller shall use reasonable endeavours to procure by Closing or, to the extent not done by Closing, as soon as reasonably practicable after Closing, the
release of the Assets, the Owned Product Intellectual Property Rights and the Company from any securities, guaranties or indemnities given by or binding upon the Assets, the Owned Product Intellectual Property Rights and the Company in respect of
any liability of the Seller or any member of the Seller’s Group. Pending such release, the Seller shall indemnify the Purchaser and any member of the Purchaser’s Group against all amounts paid by any of them (acting reasonably) pursuant to
any such securities, guarantees and indemnities in respect of such liability of the Seller which arises after Closing. 

  
 56 

	8.4	Pre-Closing Receivables 

  

	 	8.4.1	The Purchaser shall not acquire the Pre-Closing Receivables, and accordingly the Seller or, as the case may be, the other relevant members of the Seller’s
Group (as applicable) shall remain entitled to the Pre-Closing Receivables in accordance with the terms of Clauses 8.4.2 and 8.4.3. 

  

	 	8.4.2	The Purchaser agrees that the Seller (or such other member(s) of the Seller’s Group as the Seller may nominate) (each, a “Collecting
Seller”) shall be responsible for the collection of any of the Pre-Closing Receivables and that: 

  

	 	(i)	each Collecting Seller shall be entitled to take such steps as it may think fit (having regard for maintaining good relationships with third parties from whom
Pre-Closing Receivables are being collected) to recover any Pre-Closing Receivables; 

  

	 	(ii)	the Purchaser shall not take, and shall procure that no other member of the Purchaser’s Group takes, any step to collect any of the Pre-Closing Receivables (unless
agreed in writing with the Seller or relevant Collecting Seller), and shall not do anything to hinder their collection by any Collecting Seller; and 

  

	 	(iii)	if the Purchaser or any other member of the Purchaser’s Group should receive any written communication or payment in respect of any Pre-Closing Receivable, the
Purchaser shall use reasonable efforts to give, or procure that there are given, written details of any such written communication or payment to the Seller as soon as reasonably practicable following receipt thereof. 

 

	 	8.4.3	In the event that, notwithstanding Clauses 8.4.1 and 8.4.2 above, a member of the Purchaser’s Group receives any monies in respect of any Pre-Closing
Receivables, then the Purchaser shall procure that those monies are paid by the recipient to the Seller or, as directed, its Affiliate, as soon as reasonably practicable after the amount is received. 

 

	8.5	Wrong Pockets Obligations and Pre-Clinical Research Licence 

  

	 	8.5.1	Except as provided in Schedule 6, Schedule 7, Schedule 8 and Schedule 9, if any property, right or asset forming part of the Business (other than any property,
right or asset expressly excluded from the sale under this Agreement) has not been transferred to the Purchaser, or to another member of the Purchaser’s Group and should have transferred pursuant to the terms of this Agreement, the Seller shall
procure that such property, right or asset (and any related liability which is an Assumed Liability) is transferred to the Purchaser, or to such other member of the Purchaser’s Group as the Purchaser may nominate reasonably acceptable to the
Seller, as soon as practicable and at no cost to the Purchaser. 

  
 57 

	 	8.5.2	If, following Closing, any property, right or asset not forming part of the Business (other than any property, right or asset expressly included in the sale
under this Agreement and any Permitted Cash Receivable) is found to have been transferred to the Purchaser or to another member of the Purchaser’s Group and should not have transferred pursuant to the terms of this Agreement, the Purchaser
shall procure that such property, right or asset is transferred to the transferor or another member of the Seller’s Group nominated by the Seller reasonably acceptable to the Purchaser as soon as practicable and at no cost to the Seller (save
that if such property, right or asset is or has been owned by the Company, the cost of transferring such property, right or asset to a member of the Seller’s Group shall be borne by the Seller, provided that the consideration paid for any such
transfer shall, unless otherwise required by Applicable Law, be of a nominal amount). 

  

	 	8.5.3	The Seller shall, with effect from Closing, grant (and shall procure the grant by members of the Seller’s Group) to the extent it has the right to grant or
procure the grant to the Purchaser of a non-exclusive, irrevocable, royalty-free licence for use solely in relation to the Products of all Intellectual Property Rights (excluding for the avoidance of doubt any Intellectual Property Rights to the
extent relating to new chemical entities owned by or licensed to the Seller which are not Products) owned by or licensed to the Seller’s Group as at Closing relating to pre-clinical research which relate to (but do not exclusively relate to)
the Products and which are necessary or reasonably useful to research, develop, manufacture or Commercialise the Products, which licence shall be (a) sub-licensable by the Purchaser (i) to members of its Group and (ii) to third
parties working with it on the development of the Products; and (b) sub-licensable and assignable to other third parties solely in connection with the license, sub-license or assignment of all of the rights of the Purchaser in the relevant
Product. 

  

	8.6	Covenant not to sue 

  

	 	8.6.1	The Seller hereby undertakes not to enforce, at any time after Closing, any Out of Scope Patent against the Purchaser’s Group in relation to the
Purchaser’s Group carrying on the Business as at the date of Closing. 

  

	 	8.6.2	The Purchaser hereby undertakes not to enforce, at any time after Closing, any Patents constituting Business Product Intellectual Property Rights against the
Seller’s Group in relation to the Seller’s Group carrying on the Seller’s Group Retained Business as at the date of Closing. 

  

	8.7	The Purchaser’s Continuing Obligations 

  

	 	8.7.1	Except as provided in the Ancillary Agreements, the Purchaser shall not, and shall procure that no member of the Purchaser’s Group shall, after Closing, use
any of the Seller Marks or any confusingly similar name or mark, any extensions thereof or developments thereto in any business which competes with the Seller’s business or any other business of the Seller or any member of the Seller’s
Group in which the Seller Marks are used for (i) a minimum period of five years following Closing; and (ii) thereafter for so long as any member of the Seller’s Group continues to retain an interest in the name.

  
 58 

	 	8.7.2	The Purchaser shall retain for a period of 10 years from Closing (and, upon notice from the Seller between 9 and 10 years from Closing, for a further period of 5
years), and not dispose of or destroy, the books, records and documents of the Business to the extent they relate to the period prior to Closing and shall, if reasonably requested by the Seller, allow the Seller reasonable access to such books,
records and documents (including the right to take copies at the Seller’s expense) and to the employees of the Business. 

  

	8.8	The Seller’s Continuing Obligations 

  

	 	8.8.1	For a period of 10 years from Closing (and, upon notice from the Purchaser between 9 and 10 years from Closing, for a further period of 5 years), the Seller
shall make or procure to be made available to the Purchaser or their duly authorised agents on reasonable notice during normal business hours: 

  

	 	(i)	all relevant books, accounts, other records and correspondence Exclusively Relating to the Business which have been retained by the Seller’s Group (and shall
permit the Purchaser to take copies thereof); and 

  

	 	(ii)	reasonable access to employees of the Seller’s Group who have knowledge relating to any of the Products (including any inventor of the Products) for the purposes
of the defence, prosecution or enforcement of any Business Product Intellectual Property Rights or Licensed Product Intellectual Property Rights) or as required by law or a Governmental Entity, provided that the Purchaser shall promptly reimburse
the Seller for expenses reasonably incurred by the Seller in relation to providing such access if it exceeds 25 man hours in aggregate per annum. 

  

	8.9	Transfer of Marketing Authorisations and Tenders 

  

	 	8.9.1	The transfer of the Marketing Authorisations following Closing shall take place in accordance with Part 2 of Schedule 6 and the terms of the Transitional
Distribution and Supply Agreement. 

  

	 	8.9.2	Between the Closing Date and the Marketing Authorisation Transfer Date, the Seller agrees to assist the Purchaser in accordance with Part 3 of Schedule 6 in
respect of any tenders relating to the Products. 

  

	8.10	Joint tax election 

 If,
following Closing, the Seller so requests in writing to the Purchaser, the Purchaser and the Seller shall, each acting reasonably and in good faith, discuss the making of a joint election under subsection 56.4(7) of the Income Tax Act (Canada) and
the corresponding provisions of any applicable Canadian provincial statute. Any such election shall be made using the applicable prescribed form, if any, or otherwise filed in a manner acceptable to the Canada Revenue Agency or the applicable
Canadian provincial Tax Authorities, as the case may be. 

  
 59 

	8.11	Clinical Trials and Safety Database 

 Arrangements in relation to the Clinical Trials and the safety database shall take place in accordance with the terms of the Transitional Services Agreement. 

 

	8.12	Ongoing collaboration 

  

	 	8.12.1	The Seller hereby grants to the Purchaser, as its preferred partner, with effect from Closing, the rights set out in Schedule 22 in relation to the
co-development and commercialisation of Relevant Development Products. “Relevant Development Products” means products in development for the treatment, palliation, diagnosis or prevention of any and all cancers, including without
limitation immunology, epigenetics and treatment of solid or hematologic tumours (but excluding in all cases vaccines). 

  

	 	8.12.2	In the event that the Seller elects to assign or sub-license the Ofatumumab Intellectual Property Licence Agreement in a transaction of the type described in
paragraph 1.1.1 of Schedule 22, then the provisions of Schedule 22 will apply to such assignment or sub-license (except where such assignment or sub-license is to a member of the Seller’s Group). For the avoidance of doubt, the Seller shall be
free at all times to pursue the co-development and commercialisation of the Ofatumumab Compound for use in relation to autoimmune diseases (including the Ofatumumab Indications), on its own or with third parties provided that if such co-development
or commercialisation falls within the activities described in paragraph 1.1.1 of Schedule 22, that schedule shall apply. 

  

	9.	Warranties 

  

	9.1	The Seller’s Warranties 

  

	 	9.1.1	Subject to Clause 9.2, the Seller warrants (on behalf of the relevant Business Sellers or the Share Seller as applicable) to the Purchaser and each member
of the Purchaser’s Group to which Assets, the Owned Product Intellectual Property Rights or the Share are transferred pursuant to this Agreement (whether directly or indirectly) that the statements set out in Schedule 14 are true and accurate
as of the date of this Agreement. 

  

	 	9.1.2	Each of the Seller’s Warranties shall be separate and independent and shall not be limited by reference to any other paragraph of Schedule 14 or by anything
in this Agreement. 

  

	 	9.1.3	The Seller does not give or make any warranty as to the accuracy of the forecasts, estimates, projections, statements of intent or statements of opinion provided
to the Purchaser or any of its directors, officers, employees, agents or advisers on or prior to the date of this Agreement. 

  
 60 

	 	9.1.4	Any Seller’s Warranty qualified by the expression “so far as the Seller is aware” or to the “Seller’s Knowledge” or
any similar expression shall, unless otherwise stated, be deemed to refer to the knowledge of the following persons: [***], such persons having made due and reasonable enquiry. 

 

	 	9.1.5	The Seller’s Warranties shall be deemed to be repeated immediately before Closing by reference to the facts, circumstances and knowledge then existing as if
references in the Seller’s Warranties to the date of this Agreement were references to the Closing Date. Without prejudice to the provisions of Clause 10, the Seller shall have no liability for any breach of any Seller’s Warranty
where the Seller’s Warranty was true as at the date of this Agreement unless the fact, event or circumstances giving rise to the breach constitutes a Material Adverse Effect. The Seller shall have no liability under this Clause 9.1.5 if
the Purchaser has exercised its termination right in accordance with Clause 4.4.1(iii). 

  

	9.2	Seller’s Disclosures 

  

	 	9.2.1	The Seller’s Warranties are subject to all matters which are fairly disclosed in this Agreement or in the Disclosure Letter. 

 

	 	9.2.2	References in the Disclosure Letter to paragraph numbers shall be to the paragraphs in Schedule 14 to which the disclosure is most likely to relate. Such
references are given for convenience only and, shall not limit the effect of any of the disclosures, all of which are made against the Seller’s Warranties as a whole. 

 

	9.3	The Purchaser’s Warranties 

 The Purchaser warrants to the Seller that the statements set out in Schedule 15 are true and accurate as of the date of this Agreement. 

 

	10.	Limitation of Liability 

  

	10.1	Time Limitation for Claims 

The Seller shall not be liable under this Agreement for breach of any Seller’s Warranty in respect of any claim unless a notice of
the claim is given by the Purchaser to the Seller specifying the matters set out in Clause 11.2: 
  

	 	10.1.1	in the case of a claim under paragraphs 1 and 2.2 of Schedule 14, within the applicable statutory limitations period; 

 

	 	10.1.2	in the case of a claim under paragraph 3 of Schedule 14, within 6 years of the Closing Date; 

 

	 	10.1.3	in respect of claims under the Tax Warranties, before the date falling six months after the expiry of the period specified by statute during which an assessment
of the relevant liability to Tax may be issued by the relevant Tax Authority; and 

  

	***	Note: Confidential treatment has been requested with respect to the information contained within the [***] marking. Such portions have been omitted from this filing and
have been filed separately with the Securities and Exchange Commission. 

  
 61 

	 	10.1.4	in the case of any other claim, within two years of the Closing Date. 

 

	10.2	Minimum Claims 

  

	 	10.2.1	The Seller shall not be liable under this Agreement for breach of any Seller’s Warranty in respect of any individual claim (or a series of claims arising
from similar or identical facts or circumstances) where the liability agreed or determined (disregarding the provisions of this Clause 10.2) in respect of any such claim or series of claims does not exceed 0.1 per cent of the Headline
Amount. 

  

	 	10.2.2	Where the liability agreed or determined in respect of any such claim or series of claims exceeds 0.1 per cent. of the Headline Amount, the liability of the
Seller shall be for the whole amount of such claim(s) and not just the excess. 

  

	10.3	Aggregate Minimum Claims 

  

	 	10.3.1	The Seller shall not be liable under this Agreement for breach of any Seller’s Warranty (other than any Tax Warranty) in respect of any claim unless the
aggregate amount of all claims for which the Seller would otherwise be liable under this Agreement for breach of any Seller’s Warranty (disregarding the provisions of this Clause 10.3) exceeds 1 per cent of the Headline Amount.

  

	 	10.3.2	Where the liability agreed or determined in respect of all claims exceeds 1 per cent of the Headline Amount, the Seller shall be liable for the aggregate
amount of all claims as agreed or determined and not just the excess. 

  

	 	10.3.3	For the avoidance of doubt, the Purchaser may give notice of any single claim in accordance with and for the purposes of Clause 10.1 above, irrespective of
whether, at the time the notice is given, the amount set out in Clause 10.3.1 has been exceeded. 

  

	10.4	Maximum Liability 

 The
aggregate liability of the Seller in respect of any breaches: 
  

	 	10.4.1	of the Seller’s Warranties (other than Tax Warranties and the Seller’s Warranties contained in paragraphs 1, 2.2 or 3 of Schedule 14) shall not
exceed an amount equal to 30 per cent. of the Headline Amount; 

  

	 	10.4.2	of the Seller’s Warranties contained in paragraph 3 of Schedule 14 shall not exceed an amount equal to 60 per cent. of the Headline Amount; and

  

	 	10.4.3	of the Seller’s Warranties contained in paragraphs 1 or 2.2 of Schedule 14 shall not exceed the Headline Amount. 

  
 62 

	10.5	Contingent Liabilities 

The Seller shall not be liable under this Agreement for breach of any Seller’s Warranties in respect of which the liability is
contingent, unless and until such contingent liability becomes an actual liability and is due and payable (but the Purchaser has the right under Clause 11.1 to give notice of such claim before such time). For the avoidance of doubt, the fact
that the liability may not have become an actual liability by the relevant date provided in Clause 10.1 shall not exonerate the Seller in respect of any claim properly notified before that date. 

 

	10.6	Matters Arising Subsequent to this Agreement 

 The Seller shall not be liable under this Agreement for breach of any Seller’s Warranty in respect of any matter, act, omission or circumstance (or any combination thereof) to the extent that the
same would not have occurred but for: 
  

	 	10.6.1	Agreed matters 

 any
matter or thing done or omitted to be done by the Seller or any member of the Seller’s Group before Closing pursuant to and in compliance with this Agreement or otherwise at the request in writing of the Purchaser; or 

 

	 	10.6.2	Changes in legislation 

the passing of, or any change in, after the Closing Date, any Applicable Law or administrative practice of any government, governmental
department, agency or regulatory body having the force of the law including (without prejudice to the generality of the foregoing) any increase in the rates of Taxation or any imposition of Taxation or any withdrawal of relief from Taxation not in
force at the Closing Date. 
  

	10.7	Insurance 

 Without
prejudice to Clause 14, the Seller’s Liability under this Agreement for breach of any Seller’s Warranty shall be reduced by an amount equal to any loss or damage to which such claim related which has actually been recovered under a
policy of insurance held by the Purchaser (after deducting any reasonable costs incurred in making such recovery including the amount of any excess or deductible). 
  

	10.8	Purchaser’s Right to Recover 

 If the Seller has paid an amount in discharge of any claim under this Agreement for breach of any Seller’s Warranty and subsequently the Purchaser recovers (whether by payment, discount, credit,
relief, insurance or otherwise) from a third party a sum which indemnifies or compensates the Purchaser (in whole or in part) in respect of the loss or liability which is the subject matter of the claim, the Purchaser shall pay to the Seller as soon
as practicable after receipt an amount equal to (i) the sum recovered from the third party less any costs and expenses incurred in obtaining such recovery and any Tax on any amounts recovered (or Tax that would have been payable on such amounts
but for the availability of any Tax relief), or if less (ii) the amount previously paid by the Seller to the Purchaser. Any payment made by the Purchaser to the Seller under this Clause shall be made or procured by way of further adjustment of
the consideration paid by the Purchaser and the provisions of Clause 3.3 to 3.4 shall apply mutatis mutandis. 

  
 63 

	10.9	No Double Recovery and no Double Counting 

 A party shall be entitled to make more than one claim under this Agreement arising out of the same subject matter, fact, event or circumstance but shall not be entitled to recover under this Agreement or
otherwise more than once in respect of the same Losses suffered or amount for which the party is otherwise entitled to claim (or part of such Losses or amount), regardless of whether more than one claim arises in respect of it. No amount (including
any relief) (or part of any amount) shall be taken into account, set off or credited more than once under this Agreement or otherwise, with the intent that there will be no double counting under this Agreement or otherwise. 

 

	10.10	Fraud 

 None of the
limitations contained in this Clause 10 shall apply to any claim to the extent that such claim which arises or is increased, or to the extent to which it arises or is increased, as the consequence of, or which is delayed as a result of, fraud
by any director or officer of any member of the Seller’s Group. 
  

	11.	Claims 

  

	11.1	Notification of Potential Claims 

 Without prejudice to the obligations of the Purchaser under Clause 11.2, if the Purchaser becomes aware of any fact, matter or circumstance that may give rise to a claim against the Seller under this
Agreement for breach of any Seller’s Warranty (ignoring for these purposes the application of Clauses 11.2 or 11.3), the Purchaser shall as soon as reasonably practicable give a notice in writing to the Seller of such facts, matters or
circumstances as are then available regarding the potential claim. Failure to give notice within such period shall not affect the rights of the Purchaser to make a relevant claim under this Agreement for breach of any Seller’s Warranty, except
that the failure shall be taken into account in determining the liability of the Seller for such claim to the extent the Seller establishes that the amount of it is increased, or is not reduced as a result of such failure. 

 

	11.2	Notification of Claims under this Agreement 

 Notices of claims under this Agreement for breach of Seller’s Warranty shall be given by the Purchaser to the Seller within the time limits specified in Clause 10.1 and shall specify information
(giving reasonable detail) in relation to the basis of the claim and setting out the Purchaser’s estimate of the amount of Losses which are, or are to be, the subject of the claim. 

 

	11.3	Commencement of Proceedings 

 Any claim notified pursuant to Clause 11.2 shall (if it has not been previously satisfied, settled or withdrawn) be deemed to be irrevocably withdrawn 9 months after the relevant time limit set out
in Clause 10.1 unless, at the relevant time, legal proceedings in respect of the relevant claim have been commenced by being both issued and served except: 

  
 64 

	 	11.3.1	where the claim relates to a contingent liability, in which case it shall be deemed to have been withdrawn unless legal proceedings in respect of it have been
commenced by being both issued and served with 9 months of it having become an actual liability; or 

  

	 	11.3.2	where the claim is a claim for breach of a Seller’s Warranty of which notice is given for the purposes of Clause 10.1 at a time when the amount set out
in Clause 10.3.1 has not been exceeded, in which case it shall be deemed to have been withdrawn unless legal proceedings in respect of it have been commenced by being both issued and served within 9 months of the date of any subsequent
notification to the Seller pursuant to Clause 11.1 above of one or more claims which result(s) in the total amount claimed in all claims notified to the Seller pursuant to Clause 10.1 exceeding the amount set out in Clause 10.3.1 for
the first time. 

  

	11.4	Conduct of Third Party Claims 

  

	 	11.4.1	If the matter or circumstance that may give rise to a claim against the Seller under this Agreement for breach of any Seller’s Warranty is a result of or in
connection with a claim by a third party (a “Third Party Claim”) then: 

  

	 	(i)	the Purchaser shall as soon as reasonably practicable give written notice thereof to the Seller and thereafter shall provide the Seller with periodic updates upon
reasonable request and shall consult with the Seller so far as reasonably practicable in relation to the conduct of the Third Party Claim and shall take reasonable account of the views of the Seller in relation to the Third Party Claim;

  

	 	(ii)	the Third Party Claim shall not be admitted, compromised, disposed of or settled without the written consent of the Seller (such consent not to be unreasonably withheld
or delayed); and 

  

	 	(iii)	subject to the Seller indemnifying the Purchaser or other member of the Purchaser’s Group concerned against all reasonable costs and expenses (including legal and
professional costs and expenses) that may be incurred thereby, the Purchaser shall, or the Purchaser shall procure that any other members of the Purchaser’s Group shall, take such action as the Seller may reasonably request to avoid, dispute,
deny, defend, resist, appeal, compromise or contest the Third Party Claim, provided that this Clause 11.4.1(iii) shall not apply where the claim by the third party relates to matters or circumstances referred to in paragraphs 3 or 7 of
Schedule 14 and the Purchaser shall then have the right to conduct the claim at its discretion (subject to Clauses 11.4.1(i) and (ii)), 

 provided that failure to give notice in accordance with Clause 11.4.1(i) shall not affect the rights of the Purchaser to make a relevant claim under this Agreement for breach of any Seller’s
Warranty, except that the failure shall be taken into account in determining the liability of the Seller for such claim to the extent the Seller establishes that the amount of it is increased, or is not reduced as a result of such failure.

  
 65 

	 	11.4.2	Notwithstanding the provisions of Clause 11.4.1, if a Third Party Claim may also give rise to an indemnity claim under Clause 8.1.2, the provisions of Clause
8.2.2 shall apply instead of the provisions of Clause 11.4.1. 

  

	12.	Restrictive Covenants 

  

	12.1	Non-Compete 

 In
consideration of the payment by the Purchaser of $1,600,000,000, the Seller will not, and undertakes to procure that each member of the Seller’s Group will not, do any of the following things: 

 

	 	12.1.1	for three years from the Closing Date, manufacture, sell, commercialise, market or licence (whether as a result of M&A activity or otherwise) any oncology
product which has or is proposed to have (i) the same mechanism of action as any Product; and/or (ii) the same indication as any Product or any Product Expansion (a “Competing Product”); or 

 

	 	12.1.2	for three years from the Closing Date, solicit the custom of any person to whom goods or services have been sold by any Business Seller in the course of the
Business during the two years before the Closing Date, in each case only to the extent that such solicitation is in respect of products referred to in Clause 12.1.1. 

 

	12.2	Exceptions to the non-compete 

 The restrictions in Clause 12.1 shall not apply to: 
  

	 	12.2.1	any activities of any nature undertaken or developed by the Seller’s Group in relation to vaccines; 

 

	 	12.2.2	any Affiliate of Seller in which a person who is not a member of the Seller’s Group holds equity interests and with respect to whom a member of the
Seller’s Group has existing contractual or legal obligations limiting its discretion to impose non-competition obligations; 

  

	 	12.2.3	the holding of shares in a company or other entity for investment purposes provided the Seller does not exercise, directly or indirectly, Control over that
company or entity; 

  

	 	12.2.4	any business activity that would otherwise violate Clause 12.1 that is acquired in connection with an acquisition so long as the relevant member of the
Seller’s Group divests all or substantially all of the business activity that would otherwise violate Clause 12.1 or otherwise terminates or disposes of such business activity, product line or assets of such acquired business that would
otherwise violate Clause 12.1 within nine months after the consummation of the relevant acquisition, or such longer period as may reasonably be necessary to comply with Applicable Law (provided that in those circumstances the Seller shall
procure that the such competing business activity is disposed of as soon as reasonably practicable); 

  
 66 

	 	12.2.5	passive investments by a pension or employee benefit plan or trust for present or former employees; 

 

	 	12.2.6	performance of any obligation of the Seller’s Group under this Agreement or any of the Ancillary Agreements, as amended from time to time in accordance with
their terms; 

  

	 	12.2.7	any manufacturing of products that are not Competing Products by any member of the Seller’s Group for the Seller’s Group or any third party;

  

	 	12.2.8	any manufacturing and supply of the Divested Zofran Product by any member of the Seller’s Group exclusively for or to the order of Aspen Global Incorporated
and its Affiliates for sale in Australia to the extent required under the Aspen Agreements; or 

  

	 	12.2.9	provision of data or other content to or in connection with business conducted by any person, in each case as required by Applicable Law.

  

	12.3	Non-solicit 

 The Seller
will not, and undertakes to procure that each member of the Seller’s Group will not, for a period of two years after the Closing Date, solicit or induce any Restricted Group Employee to become employed or engaged whether as employee, consultant
or otherwise by any member of the Seller’s Group. 
  

	12.4	Exceptions to the non-solicit 

 The restrictions in Clause 12.3 shall not apply to the solicitation, inducement or recruitment of any person: 
  

	 	12.4.1	through the placing of advertisements of posts available to the public generally; 

 

	 	12.4.2	through an employment agency, provided that no member of the Seller’s Group encourages or advises such agency to approach any such person; or

  

	 	12.4.3	who is no longer employed by the Purchaser’s Group. 

  

	12.5	Reasonableness of Restrictions 

 Each undertaking contained in this Clause 12 shall be construed as a separate undertaking and if one or more of the undertakings is held to be against the public interest or unlawful or in any way an
unreasonable restraint of trade, the remaining undertakings shall continue to bind the Seller. 

  
 67 

	13.	Confidentiality 

  

	13.1	Announcements 

 No
announcement, communication or circular concerning the existence or the subject matter of this Agreement shall be made or issued by or on behalf of any member of the Seller’s Group or the Purchaser’s Group without the prior written
approval of the Seller and the Purchaser (such consent not to be unreasonably withheld or delayed). This shall not affect any announcement, communication or circular required by law or any governmental or regulatory body or the rules of any stock
exchange on which the shares of any party (or its holding company) are listed but the party with an obligation to make an announcement or communication or issue a circular (or whose holding company has such an obligation) shall consult with the
other parties (or shall procure that its holding company consults with the other parties) insofar as is reasonably practicable before complying with such an obligation. 
  

	13.2	Confidentiality 

  

	 	13.2.1	Subject to Clause 13.1 and Clause 13.2.2, each of the parties shall treat as strictly confidential and not disclose or use any information received or
obtained as a result of entering into this Agreement, the Ancillary Agreements (or any other agreement entered into pursuant to this Agreement) which relates to: 

 

	 	(i)	the existence and provisions of this Agreement, the Ancillary Agreements and of any other agreement entered into pursuant to this Agreement; 

 

	 	(ii)	the negotiations relating to this Agreement, the Ancillary Agreements and any such other agreement; 

 

	 	(iii)	(in the case of the Seller) any information relating to the Business following Closing and any other information relating to the business, financial or other affairs
(including future plans and targets) of the Purchaser’s Group; or 

  

	 	(iv)	(in the case of the Purchaser) any information relating to the business, financial or other affairs (including future plans and targets) of the Seller’s Group
including, prior to Closing, any information relating to the Business. 

  

	 	13.2.2	Clause 13.2.1 shall not prohibit disclosure or use of any information if and to the extent: 

 

	 	(i)	the disclosure or use is required by law, any governmental or regulatory body or any stock exchange on which the shares of any party (or its holding company) are
listed; 

  

	 	(ii)	the disclosure or use is required to vest the full benefit of this Agreement or the Ancillary Agreements in any party; 

  
 68 

	 	(iii)	the disclosure or use is required for the purpose of any arbitral or judicial proceedings arising out of this Agreement, the Ancillary Agreements or any other agreement
entered into under or pursuant to this Agreement; 

  

	 	(iv)	the disclosure is made to a Tax Authority in connection with the Tax affairs of the disclosing party; 

 

	 	(v)	the disclosure is made to a ratings agency on a confidential basis in connection with the affairs of the disclosing party; 

 

	 	(vi)	the disclosure is made by the Purchaser to any of its Representatives, any member of the Purchaser’s Group and/or any of their respective Representatives, or by
the Seller to any of its Representatives, any member of the Seller’s Group and/or any of their respective Representatives, in each case on a “need-to-know” basis and provided they have a duty (contractual or otherwise) to keep such
information confidential; 

  

	 	(vii)	the information was lawfully in the possession of that party without any obligation of secrecy prior to its being received or held, in either case as evidenced by
written records; 

  

	 	(viii)	the information is or becomes publicly available (other than by breach of this Agreement); 

 

	 	(ix)	the other party has given prior written approval to the disclosure or use; or 

 

	 	(x)	the information is independently developed, 

 provided that prior to disclosure or use of any information pursuant to Clause 13.2.2(i), (ii) or (iii), the party concerned shall, where not prohibited by law, promptly notify the other parties
of such requirement with a view to providing the other parties with the opportunity to contest such disclosure or use or otherwise to agree the timing and content of such disclosure or use. 

 

	14.	Insurance 

  

	14.1	No cover under Seller’s Group Insurance Policies from Closing 

 The Purchaser acknowledges and agrees that following Closing: 
  

	 	14.1.1	the Purchaser shall not have or be entitled to the benefit of any Seller’s Group Insurance Policy in respect of any event, act or omission that takes place
after Closing and it shall be the sole responsibility of the Purchaser to ensure that adequate insurances are put in place in relation to the Business with effect from Closing; 

 

	 	14.1.2	neither the Seller nor any member of the Seller’s Group shall be required to maintain any Seller’s Group Insurance Policy in relation to the Business;
and 

  
 69 

	 	14.1.3	the Purchaser shall not be entitled to make or notify a claim under any Seller’s Group Insurance Policy in respect of any event, act or omission that
occurred prior to the Closing Date. 

  

	15.	France Business and Netherlands Business 

  

	15.1	France Business 

Notwithstanding any other provision of this Agreement, this Agreement shall not constitute a binding agreement to sell or purchase the
France Business, provided that: 
  

	 	15.1.1	in the event that the France Put Option Exercise occurs before Closing, this Clause 15.1 (other than this Clause 15.1.1) shall terminate and shall
cease to have effect and the sale of the France Business shall be subject to the provisions of this Agreement as if it were part of the Business to be sold as and from the date of this Agreement; 

 

	 	15.1.2	in the event that the France Put Option Exercise does not occur before Closing: 

 

	 	(i)	the provisions of Clauses 2 and 6 (the “Disapplied Provisions”) shall not apply to the France Business; 

 

	 	(ii)	prior to the France Closing, the provisions of Clause 12, Schedule 8 and Schedule 9 (the “Suspended Provisions”) shall not apply to the France
Business; and 

  

	 	(iii)	in respect of the Disapplied Provisions and, prior to the France Closing, the Suspended Provisions only: 

 

	 	(a)	the term “Business” shall be deemed to exclude the France Business; 

 

	 	(b)	the term “Assumed Liabilities” shall be deemed to exclude the France Assumed Liabilities; and 

 

	 	(c)	the term “Employees” shall be deemed to exclude the France Employees; 

 

	 	15.1.3	with effect from the France Closing, the Suspended Provisions shall apply to the France Business mutatis mutandis save that in respect of the Suspended
Provisions only (A) the term “Closing” shall be deemed to refer to the France Closing and (B) the term “Closing Date” shall be deemed to refer to the date of the France Closing; and

  

	 	15.1.4	the parties shall negotiate in good faith to agree any amendments to this Agreement and any of the Ancillary Agreements as are required in order to give effect
to the principles set forth in this Clause 15.1 for the purposes of complying with the information and consultation requirements in respect of the relevant works council in respect of the France Business; and 

  
 70 

	 	15.1.5	the provisions of Clause 10 shall apply to the France Business as if the remaining provisions of this Clause 15.1 did not have any force or effect.

  

	15.2	Netherlands Business 

Notwithstanding any other provision of this Agreement, this Agreement shall not constitute a binding agreement to sell or purchase the
Netherlands Business, provided that: 
  

	 	15.2.1	in the event that the Netherlands Put Option Exercise occurs before Closing, this Clause 15.2 (other than this Clause 15.2.1) shall terminate and shall
cease to have effect and the sale of the Netherlands Business shall be subject to the provisions of this Agreement as if it were part of the Business to be sold as and from the date of this Agreement; 

 

	 	15.2.2	in the event that the Netherlands Put Option Exercise does not occur before Closing: 

 

	 	(i)	the Disapplied Provisions shall not apply to the Netherlands Business; 

  

	 	(ii)	prior to the Netherlands Closing, the Suspended Provisions shall not apply to the Netherlands Business; and 

 

	 	(iii)	in respect of the Disapplied Provisions and, prior to the Netherlands Closing, the Suspended Provisions only: 

 

	 	(a)	the term “Business” shall be deemed to exclude the Netherlands Business; 

 

	 	(b)	the term “Assumed Liabilities” shall be deemed to exclude the Netherlands Assumed Liabilities; and 

 

	 	(c)	the term “Employees” shall be deemed to exclude the Netherlands Employees; 

 

	 	15.2.3	with effect from the Netherlands Closing, the Suspended Provisions shall apply to the Netherlands Business mutatis mutandis save that in respect of the Suspended
Provisions only (A) the term “Closing” shall be deemed to refer to the Netherlands Closing and (B) the term “Closing Date” shall be deemed to refer to the date of the Netherlands Closing; and

  

	 	15.2.4	the parties shall negotiate in good faith to agree any amendments to this Agreement and any of the Ancillary Agreements as are required in order to give effect
to the principles set forth in this Clause 15.2 for the purposes of complying with the information and consultation requirements in respect of the relevant works council in respect of the Netherlands Business; and 

 

	 	15.2.5	the provisions of Clause 10 shall apply to the Netherlands Business as if the remaining provisions of this Clause 15.2 did not have any force or
effect. 

  
 71 

	16.	Other Provisions 

  

	16.1	Further Assurances 

  

	 	16.1.1	Without prejudice to any restriction or limitation on the extent of any party’s obligations under this Agreement, each of the parties shall from time to
time, so far as each is reasonably able, do or procure the doing of all such acts and/or execute or procure the execution of all such documents in a form reasonably satisfactory to the party concerned as they consider necessary to transfer the
Business to the Purchaser or otherwise to give the other party the full benefit of this Agreement. 

  

	16.2	Whole Agreement 

  

	 	16.2.1	This Agreement and the Ancillary Agreements contain the whole agreement between the parties relating to the subject matter of this Agreement at the date hereof
to the exclusion of any terms implied by law which may be excluded by contract and supersedes any previous written or oral agreement between the parties in relation to the matters dealt with in this Agreement. 

 

	 	16.2.2	The Purchaser acknowledges that, in entering into this Agreement, it is not relying on any representation, warranty or undertaking not expressly incorporated
into it. 

  

	 	16.2.3	Each of the parties agrees and acknowledges that its only right and remedy in relation to any representation, warranty or undertaking made or given in connection
with this Agreement shall be for breach of the terms of this Agreement and each of the parties waives all other rights and remedies (including those in tort or arising under statute) in relation to any such representation, warranty or undertaking.

  

	 	16.2.4	In Clauses 16.2.1 to 16.2.3, “this Agreement” includes the Ancillary Agreements and all other documents entered into pursuant to this Agreement.

  

	 	16.2.5	Nothing in this Clause 16.2 excludes or limits any liability for fraud. 

 

	16.3	No Assignment 

 No party
may without the prior written consent of the other parties, assign, grant any security interest over, hold on trust or otherwise transfer the benefit of the whole or any part of this Agreement. 

 

	16.4	Third Party Rights 

  

	 	16.4.1	Subject to Clause 16.4.2, the parties to this Agreement do not intend that any term of this Agreement should be enforceable, by virtue of the Contracts
(Rights of Third Parties) Act 1999, by any person who is not a party to this Agreement. 

  

	 	16.4.2	Certain provisions of this Agreement confer benefits on the Affiliates of the Purchaser and the Affiliates of the Seller (each such Affiliate being, for the
purposes of this Clause 16.4, a “Third Party”) and, subject to Clause 16.4.3, are intended to be enforceable by each Third Party by virtue of the Contracts (Rights of Third Parties) Act 1999. 

  
 72 

	 	16.4.3	Notwithstanding Clause 16.4.2, this Agreement may be varied in any way and at any time without the consent of any Third Party. 

 

	16.5	Variation or waiver 

  

	 	16.5.1	No variation of this Agreement shall be effective unless in writing and signed by or on behalf of each of the parties. 

 

	 	16.5.2	No failure or delay by a party in exercising any right or remedy provided by Applicable Law or under this Agreement or any Ancillary Agreement shall impair such
right or remedy or operate or be construed as a waiver or variation of it or preclude its exercise at any subsequent time and no single or partial exercise of any such right or remedy shall preclude any further exercise of it or the exercise of any
other remedy. 

  

	16.6	Method of Payment and set off 

  

	 	16.6.1	Payments (including payments pursuant to an indemnity, compensation or reimbursement provision) made or expressed to be made by the Purchaser or the Seller
pursuant to this Agreement or any claim for breach of this Agreement shall, insofar as the payment or claim relates to or affects the Share (including the Company by reason of the transfer of the Share) or any assets or liabilities transferred
pursuant to this Agreement, be made or received (as the case may be) by: 

  

	 	(i)	the Seller, for itself or as agent on behalf of the relevant Business Seller or the Share Seller (each in respect of the assets and liabilities to be transferred by it
pursuant to this Agreement including, in the case of the Share Seller, the Share); and 

  

	 	(ii)	the Purchaser, for itself or as agent on behalf of the relevant members of the Purchaser’s Group (each in respect of the assets and liabilities to be transferred
to it pursuant to this Agreement, including the Share). 

  

	 	16.6.2	Payments pursuant to this Agreement shall be settled by payments between the Seller, on behalf of the relevant members of the Seller’s Group, and the
Purchaser, on behalf of the relevant members of the Purchaser’s Group. 

  

	 	16.6.3	Any payments pursuant to this Agreement shall be made in full, without any set-off, counterclaim, restriction or
condition and without any deduction or withholding (save as may be required by law or as otherwise agreed). 

  

	 	16.6.4	Any payments pursuant to this Agreement shall be effected by crediting for same day value the account specified by the Seller or the Purchaser (as the case may
be) on behalf of the party entitled to the payment (reasonably in advance and in sufficient detail to enable payment by telegraphic or other electronic means to be effected) on or before the due date for payment. 

  
 73 

	 	16.6.5	Payment of a sum in accordance with this Clause 16.6 shall constitute a payment in full of the sum payable and shall be a good discharge to the payer (and
those on whose behalf such payment is made) of the payer’s obligation to make such payment and the payer (and those on whose behalf such payment is made) shall not be obliged to see to the application of the payment as between those on whose
behalf the payment is received. 

  

	16.7	Costs 

  

	 	16.7.1	Subject to Clause 16.8, the Seller shall bear all costs incurred by it and its Affiliates in connection with the preparation and negotiation of, and the
entry into, this Agreement and the sale of the Business. 

  

	 	16.7.2	Subject to Clause 2.3.6 and to paragraph 3, Part 1 of Schedule 18, the Purchaser shall bear all such costs incurred by it and its Affiliates in
connection with the preparation and negotiation of, and the entry into, this Agreement and the purchase of the Business. 

  

	16.8	Notarial Fees, Registration, Stamp and Transfer Taxes and Duties 

 The Seller shall bear the cost of all notarial fees and all registration, stamp and transfer taxes and duties (including, for the avoidance of doubt, stamp duty reserve tax) or their equivalents
(“Transfer Taxes”) in all jurisdictions where such fees, taxes and duties are payable as a result of the transactions contemplated by this Agreement. The Purchaser shall be responsible for arranging the payment of all Transfer Taxes
payable as a result of transactions taking place at or after Closing, including fulfilling any administrative or reporting obligation imposed by the jurisdiction in question in connection with such payment. The Seller shall indemnify the Purchaser
or any other member of the Purchaser’s Group against any Transfer Taxes payable as a result of the transactions contemplated by this Agreement to the extent that such amounts have not already been deducted from the amount payable by the
Purchaser at Closing under Clause 6.3.1(i)(d). 
  

	16.9	Interest 

 If any party
defaults in the payment when due of any sum payable under this Agreement, the liability of that party shall be increased to include interest on such sum from the date when such payment is due until the date of actual payment (as well after as before
judgment) at a rate per annum of two per cent. above LIBOR. Such interest shall accrue from day to day. 
  

	16.10	Grossing-up 

  

	 	16.10.1	 All sums payable under this Agreement and the Local Transfer Documents shall be paid free and clear of all deductions, withholdings, set-offs or
counterclaims whatsoever save only as required by Applicable Law or as may be otherwise agreed. Subject to Clauses 16.10.2 to 16.10.7 if any deductions or withholdings are required by law the party making the payment shall (except in the case
of any interest payable under Clause 16.9) be obliged to pay to the other party such sum as will after such deduction or withholding has been made leave the other party with the same amount as it would have been entitled to receive in the
absence of any such 

  
 74 

	 	
requirement to make a deduction or withholding, provided that if either party to this Agreement shall have assigned or novated the benefit in whole or in part of this Agreement or shall, after
the date of this Agreement, have changed its tax residence or the permanent establishment to which the rights under this Agreement are allocated then the liability of the other party under this Clause 16.10.1 shall be limited to that (if any)
which it would have been had no such assignment, novation or change taken place. 

  

	 	16.10.2	If either party is or becomes aware of any facts making it reasonably likely that the Purchaser, or any relevant member of the Purchaser’s Group, will be
required to deduct or withhold any amount in respect of the Business Consideration and/or the Share Consideration (a “Relevant Tax Deduction”), then that party shall, as soon as reasonably practicable, give notice to the other party
(including details of the relevant facts and, so far as possible, details of the rate and basis of such withholding). 

  

	 	16.10.3	The Seller and the Purchaser shall, and shall procure that the members of their respective groups shall (at the Seller’s cost), co-operate with each other
in good faith and use all reasonable efforts to reduce or mitigate any Relevant Tax Deduction (or its amount) and/or to enable the Seller or the relevant Business Seller or Share Seller to obtain any available credit or refund in respect of such
Relevant Tax Deduction, including, without limitation, making any available claim under an applicable double taxation treaty. 

  

	 	16.10.4	Without prejudice to the generality of Clause 16.10.3, the Seller and the Purchaser shall co-operate in good faith to establish or agree the amount or basis
of calculation of any Relevant Tax Deduction prior to Closing (and in this regard the Purchaser shall consider reasonably any relevant information or evidence provided or obtained by the Seller) including, if requested by the Seller and at the
Seller’s expense, by seeking to obtain a ruling or confirmation from a relevant Tax Authority, or obtaining an opinion from reputable local tax counsel or a firm of accountants of international standing satisfactory to the Purchaser (acting
reasonably) and instructed jointly by the Seller and the Purchaser. 

  

	 	16.10.5	The Purchaser shall, or shall procure that the relevant member of the Purchaser’s Group shall, make any Relevant Tax Deduction in the minimum amount
required by Applicable Law, provided that: 

  

	 	(i)	if a double taxation treaty between the jurisdiction under the laws of which the Relevant Tax Deduction is required and the jurisdiction of residence of the Seller or
the relevant Share Seller or Business Seller is in force, the Purchaser shall (and shall procure that any relevant member of the Purchaser’s Group shall) make any Relevant Tax Deduction in an amount not exceeding the rate specified in such
double taxation treaty (which may be nil), provided that the Seller has provided the Purchaser with such evidence as is required under Applicable Law to establish the entitlement of the Seller (or relevant Share Seller or Business Seller) to the
benefit of the applicable treaty; and 

  
 75 

	 	(ii)	if an opinion from reputable local counsel or a firm of accountants of international standing has been obtained as envisaged by Clause 16.10.4, the Purchaser shall
(and shall procure that any relevant member of the Purchaser Group shall) make such Relevant Tax Deduction in an amount or on a basis which is consistent with that opinion (which may result in no withholding or deduction), provided that the Seller
has indemnified the Purchaser and any relevant member of the Purchaser’s Group, to the Purchaser’s reasonable satisfaction, against any Liabilities arising (including any interest and penalties) should such opinion be wholly or partly
incorrect. 

  

	 	16.10.6	The Purchaser shall promptly provide the Seller with evidence reasonably satisfactory to the Seller that a Relevant Tax Deduction has been made and an
appropriate amount paid to the relevant Tax Authority. 

  

	 	16.10.7	If any Relevant Tax Deduction is required, an additional sum shall be payable in accordance with Clause 16.10.1 only if and to the extent that such
deduction or withholding would not have been required had the Purchaser and each member of the Purchaser’s Group making such payment or to which such payment relates been resident for Tax purposes only in Switzerland. 

 

	16.11	Notices 

  

	 	16.11.1	Any notice or other communication in connection with this Agreement (each, a “Notice”) shall be: 

 

	 	(i)	in writing in English; and 

  

	 	(ii)	delivered by hand, fax, or by courier using an internationally recognised courier company. 

 

	 	16.11.2	A Notice to the Seller shall be sent to such party at the following address, or such other person or address as the Seller may notify to the Purchaser from time
to time: 

 GlaxoSmithKline plc 
 980 Great West Road 
 Brentford 

Middlesex TW8 9GS 
  

			
	Fax:	  	+44 (0)208 0476904
		
	Attention:	  	Company Secretary

 with a copy to the Seller’s Lawyers, marked for the urgent attention of Simon Nicholls
(delivery of such copy shall not itself constitute valid notice). 

  
 76 

	 	16.11.3	A Notice to the Purchaser shall be sent to such party at the following address, or such other person or address as the Purchaser may notify to the Seller from
time to time: 

 Novartis AG 
 Postfach 
 CH-4002 Basel 

Switzerland 
  

			
	Fax:	  	+41 613244300
		
	Attention:	  	Head Legal M&A, Novartis International AG

 with a copy to the Purchaser’s Lawyers, marked for the urgent attention of Jennifer Bethlehem
(delivery of such copy shall not itself constitute valid notice). 
  

	 	16.11.4	A Notice shall be effective upon receipt and shall be deemed to have been received: 

 

	 	(i)	at the time of delivery, if delivered by hand or courier; 

  

	 	(ii)	at the time of transmission in legible form, if delivered by fax. 

  

	16.12	Invalidity or Conflict 

  

	 	16.12.1	If any provision in this Agreement shall be held to be illegal, invalid or unenforceable, in whole or in part, the provision shall apply with whatever deletion
or modification is necessary so that the provision is legal, valid and enforceable and gives effect to the commercial intention of the parties. 

  

	 	16.12.2	To the extent it is not possible to delete or modify the provision, in whole or in part, under Clause 16.12.1, then such provision or part of it shall, to
the extent that it is illegal, invalid or unenforceable, be deemed not to form part of this Agreement and the legality, validity and enforceability of the remainder of this Agreement shall, subject to any deletion or modification made under
Clause 16.12.1, not be affected. 

  

	 	16.12.3	If there is any conflict between the terms of this Agreement and any of the Ancillary Agreements this Agreement shall prevail (as between the parties between
this Agreement and as between any member of the Seller’s Group and any member of the Purchaser’s Group) unless (i) such Ancillary Agreement expressly states that it overrides this Agreement in the relevant respect and (ii) the
Seller and the Purchaser are either also parties to that Ancillary Agreement or otherwise expressly agree in writing that such Ancillary Agreement shall override this Agreement in that respect. 

 

	16.13	Counterparts 

 This
Agreement may be entered into in any number of counterparts, all of which taken together shall constitute one and the same instrument. Any party may enter into this Agreement by executing any such counterpart. Delivery of a counterpart of this
Agreement by email attachment shall be an effective mode of delivery. 

  
 77 

	16.14	Governing Law and Submission to Jurisdiction 

  

	 	16.14.1	This Agreement and the documents to be entered into pursuant to it, save as expressly referred to therein, and any non-contractual obligations arising out of or
in connection with the Agreement and such documents shall be governed by and construed in accordance with English law. 

  

	 	16.14.2	Each of the parties irrevocably agrees that the courts of England and Wales are to have exclusive jurisdiction to settle any dispute which may arise out of or in
connection with this Agreement and the documents to be entered into pursuant to it, save as expressly referred to therein, and that accordingly any proceedings arising out of or in connection with this Agreement and the documents to be entered into
pursuant to it shall be brought in such courts. Each of the parties irrevocably submits to the jurisdiction of such courts and waives any objection to proceedings in any such court on the ground of venue or on the ground that proceedings have been
brought in an inconvenient forum. 

  

	16.15	Appointment of Process Agent 

  

	 	16.15.1	The Purchaser hereby irrevocably appoints Hackwood Secretaries Limited of One Silk Street, London EC2Y 8HQ as its agent to accept service of process in England
and Wales in any legal action or proceedings arising out of this Agreement, service upon whom shall be deemed completed whether or not forwarded to or received by the Purchaser. 

 

	 	16.15.2	The Purchaser agrees to inform the Seller in writing of any change of address of such process agent within 28 days of such change. 

 

	 	16.15.3	If such process agent ceases to be able to act as such or to have an address in England and Wales, the Purchaser irrevocably agrees to appoint a new process
agent in England and Wales and to deliver to the Seller within 14 days a copy of a written acceptance of appointment by the process agent. 

  

	 	16.15.4	Nothing in this Agreement shall affect the right to serve process in any other manner permitted by law. 

This Agreement has been entered into on the date stated at the beginning. 

  
 78 

			
	 SIGNED by
  
 AND
	 	}
	  
 for and on behalf of

NOVARTIS AG:
	 	}
	  
 SIGNED by

 
 for and on behalf of
 GLAXOSMITHKLINE PLC:
	 	}

 Schedule 1 
 Products 
 Part 1 Products 

[See overleaf] 
 Part
2 Product Expansions 
 [See overleaf] 

  
 80 

 Schedule 1 
 Part 1 
 Products 

 

															
	 No
	 	 Brand
name
	 	 Active
Ingredient
	  	 Product Description
	  	 Marketing
Authorisation details
(includes all countries
that have product
approval; NOTE;
for
products with multiple
indications, some
countries may not have
yet have approval for
all indications)
	  	 Product Expansion
Applications (includes
only those submitted or
currently under
regulatory
review)
	  	 ATC Code
	  	 Dosage

								
	1	 	Tafinlar	 	Dabrafenib	  	 Dabrafenib mesylate is a kinase inhibitor. The chemical name for dabrafenib mesylate is
N-{3-[5-(2-Amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-1,3-thiazol-4-yl]-2-fluorophenyl}-2,6-difluorobenzene sulfonamide, methanesulfonate salt. It has the molecular formula C23H20
F3N5O2S2•
 CH4O3S and a molecular weight of 615.68.
	  	Australia, Austria, Belgium, Bulgaria, Canada, Chile, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Italy, Latvia,
Luxembourg, Malta, Netherlands, Norway, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, Sweden, Switzerland, United Kingdom, United States	  	 Combination w/ MEK (regulatory reviews ongoing in certain markets, i.e. Switzerland); proposed indication below:

 
 TAFINLAR in combination with trametinib is indicated for the treatment of patients
with unresectable or metastatic melanoma with BRAF V600E or V600K mutations.
	  	 Antineoplastic agents, protein kinase inhibitor
 L01XE23
	  	The recommended dose of TAFINLAR is 150 mg orally twice daily as a single agent or in combination with trametinib 2 mg orally once daily.
								
	2	 	Mekinist	 	Trametinib	  	 Trametinib dimethyl sulfoxide is a kinase inhibitor. The chemical name is acetamide, N-[3-[3-cyclopropyl-5-[(2-fluoro-4-
iodophenyl)
 amino]-3,4,6,7-tetrahydro-6,8-dimethyl- 2,4,7-trioxopyrido[4,3-d]pyrimidin-1(2H)-yl]phenyl]-, compound with
1,1’-sulfinylbis[methane] (1:1). It has a molecular formula C26H23FIN5O4•C2H6

 OS with a molecular mass of 693.53.
	  	Australia, Canada, Switzerland, United States	  	 EU opinion for Mekinist monotherapy on track for April CHMP meeting:

 
 Trametinib is indicated in monotherapy for the treatment of adult patients with
unresectable or metastatic melanoma with a BRAF V600 mutation
	  	 Antineoplastic agents, protein kinase inhibitor
 L01XE23
	  	The recommended dosage regimens of MEKINIST are 2 mg orally once daily as a single agent or in combination with dabrafenib 150 mg orally twice
daily

															
								
	3	 	Votrient	 	Pazopanib	  	 VOTRIENT (pazopanib) is a tyrosine kinase inhibitor (TKI). Pazopanib is presented as

the hydrochloride salt, with the chemical name 5-[[4-[(2,3-dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]

amino]-2-methylbenzene
 sulfonamide
monohydrochloride. It has the molecular formula C21H23N7O2
S•HCl and a molecular weight of 473.99.
	  	Albania, Argentina, Aruba, Australia, Austria, Bahrain, Bangladesh, Belarus, Belgium, Bosnia and Herzegovina, Brazil, Brunei Darussalam, Bulgaria, Canada, Chile, Colombia, Costa
Rica, Croatia, Cuba, Curacao, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, El Salvador, Estonia, Finland, France, Germany, Greece, Guatemala, Guyana, Honduras, Hong Kong, Hungary, Iceland, India, Indonesia, Ireland, Israel, Italy,
Japan, Kazakhstan, Korea, Republic of, Kuwait, Latvia, Lebanon, Lithuania, Luxembourg, Macao, Macedonia, Malaysia, Malta, Mexico, Morocco, Netherlands, New Zealand, Nicaragua, Norway, Oman, Pakistan, Panama, Peru, Philippines, Poland, Portugal,
Qatar, Romania, Russian Federation, Saudi Arabia, Serbia, Singapore, Slovakia, Slovenia, Spain, Suriname, Sweden, Switzerland, Syrian Arab Republic, Taiwan, Thailand, Turkey, Ukraine, United Arab Emirates, United Kingdom, United States, Uruguay,
Venezuela, Yemen	  	EU withdrawal of maintenance treatment of women with FIGO stage II-IV epithelial ovarian, fallopian tube or primary peritoneal cancer who had not progressed after receiving
first-line chemotherapy.	  	 Antineoplastic agents, other antineoplastic agents, protein- kinase inhibitors,
 ATC code: L01XE11
	  	The recommended dose of pazopanib for the treatment of RCC or STS is 800 mg once daily.
								
	4	 	Tykerb/ Tyverb	 	Lapatinib	  	 Lapatinib is a small molecule and a member of the 4-anilinoquinazoline class of kinase inhibitors. It is present as the monohydrate of
the ditosylate salt, with chemical name N-(3
 chloro-4-{[(3-fluorophenyl)
 methyl]oxy}
 phenyl)-6-[5-({[2
 (methylsulfonyl)
 ethyl]amino}
 methyl)-2-furanyl]-4-quinazolinamine bis(4
 methylbenzene

sulfonate) monohydrate. It has the molecular formula C29H26
ClFN4O4S

(C7H8O3S)2
H2O and a molecular weight of 943.5.
	  	Albania, Argentina, Aruba, Australia, Austria, Azerbaijan, Bahrain, Bangladesh, Belgium, Brazil, Bulgaria, Cambodia, Chile, Colombia, Croatia, Cyprus, Czech Republic, Denmark,
Ecuador, Egypt, Finland, France, Germany, Greece, Guatemala, Guyana, Honduras, Hungary, Iceland, Indonesia, Ireland, Israel, Italy, Kazakhstan, Korea, Republic of, Latvia, Lithuania, Luxembourg, Malaysia, Malta, Mexico, Moldova, Morocco,
Netherlands, Norway, Oman, Pakistan, Paraguay, Peru, Poland, Portugal, Romania, Russian Federation,	  	Awaiting results of ALTTO to support submission along with NeoALTTO.	  	Antineoplastic agent, other antineoplastic agents, protein kinase inhibitor, ATC code: L01XE07	  	 Tyverb / capecitabine combination:
  

The recommended dose of Tyverb is 1250 mg (i.e. five tablets) once daily continuously.

 
 The recommended dose of capecitabine is 2000 mg/m2/day taken in 2 doses 12 hours
apart on days 1-14 in a 21 day cycle
  
 Tyverb / trastuzumab
combination:
  
 The recommended dose of Tyverb
is

  
 82 

															
		 		 		  		  	Serbia, Singapore, Slovakia, Slovenia, Spain, Sri Lanka, Sweden, Switzerland, Syrian Arab Republic, Turkey, Ukraine, United Kingdom, United States, Yemen, Algeria, Armenia, Belarus,
Bosnia and Herzegovina, Canada, China, Costa Rica, Curacao, Dominican Republic, El Salvador, Georgia, Hong Kong, India, Jamaica, Japan, Jordan, Kuwait, Lebanon, Macao, Macedonia, New Zealand, Nicaragua, Panama, Qatar, Saudi Arabia, South
Africa, Suriname, Taiwan, Thailand, Trinidad and Tobago, United Arab Emirates, Uruguay, Venezuela	  		  		  	 1000 mg (i.e. four tablets) once daily continuously.
  

The recommended dose of trastuzumab is 4 mg/kg administered as an intravenous (IV) loading dose, followed by 2 mg/kg IV weekly

 
 Tyverb / aromatase inhibitor combination:

 
 The recommended dose of Tyverb is 1500 mg (i.e. six tablets) once daily
continuously.
  
 U.S. FDA Label:

 
 HER2-Positive Metastatic

Breast Cancer:
  
 The recommended dose of TYKERB is 1,250 mg given orally once daily on Days 1-21 continuously in combination with capecitabine 2,000 mg/m2/day (administered orally in 2 doses approximately 12 hours apart)
on Days 1-14 in a repeating 21-day cycle.
  
 Hormone Receptor-Positive,
HER2-Positive Metastatic Breast Cancer:
  
 The recommended dose of
TYKERB is 1,500 mg given orally once daily continuously in combination with letrozole. When coadministered with TYKERB, the recommended dose of letrozole is 2.5 mg once daily.

  
 83 

															
								
	5	 	Promacta/ Revolade	 	Eltrombopag	  	 Eltrombopag olamine is a biphenyl hydrazone. The chemical name for eltrombopag olamine is
3’-{(2Z)-2-[1-(3,4-dimethylphenyl)-3-methyl-5-oxo-1,5-dihydro-4H-pyrazol-4-ylidene]hydrazino}
 -2’-hydroxy-3-biphenylcarboxylic acid -
2-aminoethanol (1:2). It has the molecular formula
C25H
22N4O4
•2
 (C2H7
NO). The molecular weight is 564.65 for eltrombopag olamine and 442.5 for eltrombopag free acid.
	  	Albania, Argentina, Aruba, Australia, Austria, Azerbaijan, Bahrain, Bangladesh, Belarus, Belgium, Bosnia and Herzegovina, Brazil, Brunei Darussalam, Bulgaria, Canada, Chile,
Colombia, Costa Rica, Croatia, Curacao, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, El Salvador, Estonia, Finland, France, Georgia, Germany, Greece, Guatemala, Guyana, Honduras, Hong Kong, Hungary, Iceland, India, Indonesia,
Ireland, Israel, Italy, Jamaica, Jordan, Kazakhstan, Korea Republic of, Kuwait, Latvia, Lebanon, Lithuania, Luxembourg, Macao, Macedonia, Malaysia, Malta, Mexico, Moldova, Morocco, Myanmar, Netherlands, New Zealand, Nicaragua, Norway, Oman,
Pakistan, Panama, Peru, Philippines, Poland, Portugal, Qatar, Romania, Russian Federation, Saudi Arabia, Serbia, Singapore, Slovakia, Slovenia, Spain, Sudan (North part), Suriname, Sweden, Switzerland, Syrian Arab Republic, Taiwan, Thailand,
Trinidad and Tobago, Turkey, United Arab Emirates, United Kingdom, United States, Uruguay, Yemen	  	 sNDA filed 27 Feb 2014: Proposed Indication below:

 
 PROMACTA is indicated for the treatment of cytopenias in patients with severe
aplastic anemia who have had an insufficient response to immunosuppressive therapy
	  	Antihemorrhagics, other systemic hemostatics. ATC code: B02BX 05	  	 US FDA Label:
  

Promacta has four FDA approved dosages: 12.5 mg, 25 mg, 50 mg, 75 mg, and 100 mg tablets.

								
	6	 	Arzerra	 	Ofatumumab	  	ARZERRA (ofatumumab) is an IgG1K human monoclonal antibody with a molecular weight of approximately 149 kDa. The antibody was generated via transgenic mouse and
hybridoma technology and is produced in a recombinant murine cell line (NS0) using	  	Argentina, Australia, Austria, Bahrain, Belgium, Bosnia and Herzegovina, Bulgaria, Canada, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece,
Hungary, Iceland, Ireland, Italy, Japan, Kazakhstan, Kuwait, Latvia, Lithuania, Luxembourg, Malta, Netherlands, Norway, Panama, Poland, Portugal, Qatar, Romania,	  	Arzerra in combination with alkylator (e.g. chlorambucil) is indicated for the treatment of chronic lymphocytic leukaemia (CLL) in previously untreated patients PDUFA date
(4/18)	  	monoclonal antibodies, ATC code: L01XC10	  	The recommended dose is 300 mg ofatumumab for the first infusion and 2,000 mg ofatumumab for all subsequent infusions. The infusion schedule is 8 consecutive weekly infusions,
followed 4-5 weeks later by 4 consecutive monthly (i.e. every 4 weeks) infusions.

  
 84 

															
		 		 		  	standard mammalian cell cultivation and purification technologies.	  	Russian Federation, Slovakia, Slovenia, Spain, Sweden, Switzerland, United Arab Emirates, United Kingdom, United States	  		  		  	 U.S. FDA Label:
  

Previously Untreated CLL:
  

The recommended dosage and schedule is:
  

•    300 mg on Day 1 followed 1 week later by 1,000 mg on Day 8 (Cycle 1) followed
by
  

•    1,000 mg on Day 1 of subsequent 28-day cycles for a minimum of 3 cycles until best
response or a maximum of 12 cycles.
  
 Refractory
CLL:
  
 The recommended dosage and schedule is 12 doses administered
as follows:
  

•    300 mg initial dose (Dose 1), followed 1 week later by

 
 •    2,000 mg
weekly for 7 doses (Doses 2 through 8), followed 4 weeks later by
  
 •    2,000 mg every 4 weeks for 4 doses (Doses 9 through 12).

								
	7	 	Hycamtin	 	Topotecan	  	 HYCAMTIN (topotecan hydrochloride) is a semi-synthetic derivative of camptothecin and is an anti-tumor drug with topoisomerase
I-inhibitory activity. HYCAMTIN for Injection is supplied as a sterile lyophilized, buffered, light yellow to greenish powder available in single-dose vials. Each vial contains topotecan hydrochloride equivalent to 4 mg of topotecan as free base.
The chemical name for topotecan hydrochloride is (S)-10-[(dimethylamino)
 methyl]-4
ethyl-4,9-dihydroxy-1H-pyrano[3’,4’:6,7] indolizino [1,2-b]quinoline-3,14-(4H,12H)-dione
	  	Albania, Argentina, Aruba, Australia, Austria, Bahrain, Belarus, Belgium, Bosnia and Herzegovina, Brazil, Brunei Darussalam, Bulgaria, Canada, Chile, China, Colombia, Costa Rica,
Croatia, Curacao, Cyprus, Denmark, Dominican Republic, Ecuador, Egypt, El Salvador, Estonia, Finland, France, Gabon, Germany, Greece, Guatemala, Honduras, Hong Kong, Hungary, Iceland, India, Indonesia, Ireland,	  	None	  	Other antineoplastic agents: ATC code: L01XX17	  	 Hycamtin IV infusion Ovarian & Small Cell Lung Cancer:

 
 The recommended dose of topotecan is 1.5 mg/m2 body surface area/day administered by intravenous

2 infusion over 30 minutes daily for five consecutive days with a three week interval between the start of each course.

 
 Cervical Carcinoma: The
recommended

  
 85 

															
		 		 		  	monohydrochloride. It has the molecular formula
C23H
23N3O5
•HCl and a molecular weight of 457.9.	  	Israel, Italy, Jamaica, Japan, Jordan, Kazakhstan, Kenya, Korea, Republic of Kuwait, Latvia, Lebanon, Lithuania, Luxembourg, Macedonia, Madagascar, Malaysia, Maldives, Malta,
Moldova, Morocco, Namibia, Netherlands, New Zealand, Nicaragua, Niger, Norway, Oman, Pakistan, Palestine, Panama, Peru, Philippines, Poland, Portugal, Qatar, Romania, Russian Federation, Saudi Arabia, Serbia, Singapore, Slovakia, Slovenia, South
Africa, Spain, Sri Lanka, Sweden, Switzerland, Syrian Arab Republic, Taiwan, Thailand, Trinidad and Tobago, Ukraine, United Arab Emirates, United Kingdom, United States, Uruguay	  		  		  	 dose of topotecan is 0.75 mg/m2/day administered as 30 minute intravenous infusion daily on days 1, 2 and 3. Cisplatin is administered as an
intravenous infusion on day 1 at a dose of 50 mg/m2/day and following the topotecan dose.
  
 Hycamtin Capsules (per US FDA label)
  
 The recommended dose of HYCAMTIN capsules is 2.3 mg/m2 /day once daily for 5 consecutive days repeated every 21 days. Round the calculated oral daily dose to the nearest 0.25 mg, and prescribe the minimum
number of 1 mg and 0.25 mg capsules. The same number of capsules should be prescribed for each of the 5 dosing days.

								
	8	 	Argatroban	 	Argatroban	  	 Argatroban is a synthetic direct thrombin inhibitor derived from L-arginine. The chemical name for Argatroban is
1-[5-[(aminoimino
 methyl)amino]-1-oxo-2-[[(1,2,3,4-tetrahydro-3-methyl-8quinolinyl)
 sulfonyl]amino]
 pentyl]-4-methyl-2-piperidinecarbox

ylic acid, monohydrate. Argatroban has 4 asymmetric carbons. One of the asymmetric
	  		  	None	  	B01AE03	  	 Heparin-Induced Thrombocytopenia (HIT/HITTS): Initial Dosage:

 
 Before administering Argatroban, discontinue heparin therapy and obtain a baseline
aPTT. The recommended initial dose of Argatroban for adult patients without hepatic impairment is 2 mcg/kg/min, administered as a continuous infusion

  
 86 

															
		 		 		  	 carbons has an R configuration (stereoisomer Type I) and an S configuration (stereoisomer Type II). Argatroban consists of
a mixture of R and S stereoisomers at a ratio of approximately 65:35.
  
 The molecular formula of Argatroban is C23H36N6O5S•
 H2O. Its molecular weight is 526.66.
	  		  		  		  	Percutaneous Coronary Interventions (PCI) in HIT/HITTS Patients: Initial Dosage: An infusion of Argatroban should be started at 25 mcg/kg/min and a bolus of 350
mcg/kg administered via a large bore intravenous (IV) line over 3 to 5 minutes (see Table 9). Activated clotting time (ACT) should be checked 5 to 10 minutes after the bolus dose is completed. The procedure may proceed if the ACT is greater than 300
seconds.
								
	9	 	Zofran	 	Ondansetron	  	 The active ingredient in ZOFRAN Injection is ondansetron hydrochloride (HCl), the racemic form of ondansetron and a selective blocking
agent of the serotonin 5-HT3 receptor type. Chemically it is (±) 1, 2, 3, 9-tetrahydro-9-methyl-3-[(2-methyl-1H-imidazol-1-yl)methyl]-4Hc o e o u
 The empirical formula is C18H19N3O•HCl•2
 H2O,
representing a molecular weight of 365.9.
	  		  	None	  	A04AA01	  	 Prevention of Chemotherapy-Induced Nausea and Vomiting: Adult Dosing: The recommended I.V. dosage of ZOFRAN for
adults is a single 32-mg dose or three 0.15-mg/kg doses. A single 32-mg dose is infused over 15 minutes beginning 30 minutes before the start of emetogenic chemotherapy.
  

The recommended infusion rate should not be exceeded (see OVERDOSAGE). With the three-dose (0.15-mg/kg) regimen, the first dose is infused over 15 minutes
beginning 30

  
 87 

															
		 		 		  		  		  		  		  	 minutes before the start of emetogenic chemotherapy. Subsequent doses (0.15 mg/kg) are administered 4 and 8 hours after the first dose
of ZOFRAN.
  
 Prevention of Postoperative Nausea and Vomiting:
Adult Dosing: The recommended
 I.V. dosage of ZOFRAN for adults is 4 mg undiluted administered intravenously in not less
than 30 seconds, preferably over 2 to 5 minutes, immediately before induction of anesthesia, or postoperatively if the patient experiences nausea and/or vomiting occurring shortly after surgery.

								
	10	 	Arranon/ Atriance	 	Nelarabine	  	 ARRANON (nelarabine) is a pro-drug of the cytotoxic deoxyguanosine analogue, 9-b-D­250
arabinofuranosyl
 guanine (ara-G).
  

The chemical name for nelarabine is 2-amino-9-b-D-arabinofuranosyl-6-methoxy-9H-

purine. It has the molecular formula C11H15
N5O5 and a
molecular weight of 297.27.
	  		  	None	  	 Antineoplastic agents, antimetabolites, purine analogues, ATC code:
 L01B B 07
	  	 Adults and adolescents (aged 16 years and older):
  

The recommended dose of nelarabine for adults is 1,500 mg/m2 administered intravenously over two hours on days 1, 3 and 5 and repeated every 21
days.
  
 Paediatric population: Children and adolescents
(aged 21 years and younger):
  
 The recommended dose of nelarabine
for children and adolescents is 650 mg/m2 administered
 intravenously over one hour daily for 5 consecutive days, repeated every 21
days.

  
 88 

															
								
	11	 	AKT GSK2141795	 	-	  	An orally bioavailable inhibitor of the serine/threonine protein kinase Akt (protein kinase B) with potential antineoplastic activity. Akt inhibitor GSK2141795 binds to and inhibits
the activity of Akt, which may result in inhibition of the PI3K/Akt signaling pathway and tumor cell proliferation and the induction of tumor cell apoptosis. Activation of the PI3K/Akt signaling pathway is frequently associated with tumorigenesis
and dysregulated PI3K/Akt signaling may contribute to tumor resistance to a variety of antineoplastic agents	  	None	  	None	  	Antineoplastic agents, protein kinase inhibitor	  	n/a
								
	12	 	GSK2110183	 	Afuresertib	  	An orally bioavailable inhibitor of the serine/threonine protein kinase Akt (protein kinase B) with potential antineoplastic activity. Afuresertib binds to and inhibits the activity
of Akt, which may result in inhibition of the	  	None	  	None	  	Antineoplastic agents, protein kinase inhibitor	  	n/a

  
 89 

															
		 		 		  	PI3K/Akt signaling pathway and tumor cell proliferation and the induction of tumor cell apoptosis. Activation of the PI3K/Akt signaling pathway is frequently associated with
tumorigenesis and dysregulated PI3K/Akt signaling may contribute to tumor resistance to a variety of antineoplastic agents.	  		  		  		  	

  
 90 

 Schedule 1 
 Part 2 
 Product Expansions – Combos 

[***] 
  

	***	Note: Confidential treatment has been requested with respect to the information contained within the [***] marking. Such portions, consisting of ten pages, have been
omitted from this filing and have been filed separately with the Securities and Exchange Commission. 

  
 91 

 Schedule 2 
 Certain Intellectual Property Rights Matters 
 (Clause 2.3.1)

 Part 1: Registered Transferred Product Intellectual Property Rights 
 Patents 
 [***] 
 Registered Trade Marks and Copyright 
 [***] 

Part 2: List of Transferred Contracts and Transferred IP Contracts 
 [***] 
  

	***	Note: Confidential treatment has been requested with respect to the information contained within the [***] marking. Such portions, consisting of 66, 72 and 3 pages,
respectively, have been omitted from this filing and have been filed separately with the Securities and Exchange Commission. 

  
 92 

 Schedule 3 
 Excluded Assets and Excluded Contracts 
 (Clause 2.3.2) 

Part 1 Excluded Assets 

None 
 Part 2 Excluded
Contracts 
 None 

  
 93 

 Schedule 4 
 Excluded Liabilities 
 (Clause 2.3.4) 

Not Used 

  
 94 

 Schedule 5 
 Permitted Encumbrances 
 (Clause 1.1) 

(i) Co-Owned Business Product Intellectual Property Rights listed at Part 1 of Schedule 2. 

  
 95 

 Schedule 6 
 Product Approvals 
 (Clause 6.2.2) 

Part 1 Terms relating to the Product Approvals 
  

	1.	General Provisions 

  

	1.1	The Purchaser shall do all things necessary to effect the transfer of each Product Approval, including complying with requirements and requests of Governmental
Entities with respect to the transfer of each Product Approval. 

  

	1.2	The Marketing Authorisations shall be transferred in accordance with Part 2 of this Schedule 6. 

 

	2.	Fees and expenses 

 From
and after the Closing Date, the Purchaser shall promptly reimburse the relevant members of the Seller’s Group for all maintenance and renewal fees and similar fees paid, and all out of pocket expenses reasonably incurred in connection with the
satisfaction of any commitments or obligations by such member of the Seller’s Group with respect to each Product Approval. 
  

	3.	Product Expansion Applications 

  

	3.1	The Purchaser shall file or cause to be filed applications for the transfer of each Product Expansion Application in each country or territory in which such
transfer is required to be submitted as soon as possible after the Closing Date. 

  

	3.2	Pending the transfer of each Product Expansion Application the Seller shall, and shall cause the relevant members of the Seller’s Group to:

  

	 	3.2.1	upon reasonable request from the Purchaser and at the Purchaser’s expense, reasonably cooperate and coordinate with the Purchaser in relation to the
transfer of the Product Expansion Applications, including by providing the Purchaser with regulatory documentation concerning the Products owned or controlled by Seller or its Affiliates; 

 

	 	3.2.2	perform such acts and services as may be requested by the Purchaser that are reasonably necessary or required by any Governmental Entity to maintain or renew any
Product Expansion Application or are reasonably necessary for the Purchaser to pursue the regulatory approval for any Product Expansion Application, including conducting any studies, including clinical and stability studies, concerning the Products
and the Product Expansions; and 

  

	 	3.2.3	notify the Purchaser as soon as is reasonably practicable of any written communication received by the Seller or any member of the Seller’s Group with
respect to any Product Expansion Application and shall consult with the Purchaser with respect to such communication and take into account the Purchaser’s views as to the form and content of any communication with any Governmental Entity
concerning such Product Expansion Application. 

  
 96 

 Part 2 Marketing Authorisation Transfer Provisions 

 

	1.	Transfer of Marketing Authorisations 

Marketing Authorisation Transfer and Marketing Authorisation Re-registration 

 

	1.1	The Seller and the Purchaser hereby agree they will each use, and will procure that their respective Affiliates will use, all reasonable endeavours to ensure
that, as soon as reasonably practicable after the Closing Date: 

  

	 	1.1.1	subject to paragraph 1.1.2, each Marketing Authorisation shall be transferred in accordance with Applicable Law by the Marketing Authorisation Holder to the
Marketing Authorisation Transferee (“Marketing Authorisation Transfer”); and 

  

	 	1.1.2	where Applicable Law does not permit Marketing Authorisation Transfer, a new marketing authorisation shall be registered in the name of the Marketing
Authorisation Transferee to replace the existing Marketing Authorisation (“Marketing Authorisation Re-registration”) and the Seller shall procure that the relevant Marketing Authorisation Holder takes all necessary steps to
withdraw, abandon, cancel or allow to lapse the superseded Marketing Authorisation as soon as practicable after the Marketing Authorisation Re-registration Date. 

 

	1.2	Without prejudice to any rights the Purchaser may have under the terms of this Agreement, to the extent that, before Closing, and in the event that, at Closing,
the Marketing Authorisation Holder of the Marketing Authorisation for Argatroban in the United States and Canada (the “Argatroban MA”) is not the Seller or a member of the Seller’s Group, the Seller shall use all reasonable
endeavours to procure or assist the Purchaser to procure the transfer of the Argatroban MA to the Marketing Authorisation Transferee as soon as reasonably practicable. 

 

	1.3	Any Marketing Authorisation Transfer or Marketing Authorisation Re-registration (as applicable) shall each be effected on a Market-by-Market basis (such that
there shall not be any staggered Marketing Authorisation Transfer or Marketing Authorisation Re-registration (as the case may be) on a Product-by-Product basis in any Market), unless otherwise agreed between the Seller and the Purchaser.

  

	1.4	With effect from the Closing Date until the Marketing Authorisation Transfer Date or the Marketing Authorisation Re-registration Date (as applicable), the Seller
shall procure that each Marketing Authorisation Holder shall hold the Marketing Authorisation(s) in its name but for the account, risk and benefit of the relevant Marketing Authorisation Transferee. 

Submission of MA Documentation 

  
 97 

	1.5	Without prejudice to paragraph 1.6, the Purchaser shall be responsible for preparing and submitting, or for procuring that there is prepared and submitted
(in any such case at the Purchaser’s cost and expense), all notices, applications, submissions, reports and any other instruments, documents, correspondence or filings necessary to complete Marketing Authorisation Transfer or Marketing
Authorisation Re-registration (as applicable) (the “MA Documentation”). The MA Documentation shall be prepared in accordance with Applicable Law as soon as reasonably practicable. 

 

	1.6	At the Seller’s election, the Purchaser shall procure that advanced drafts of the MA Documentation are submitted to the Seller so as to allow the Seller
and/or the Marketing Authorisation Holder a reasonable opportunity to provide comments on such MA Documentation before it is submitted to the relevant Governmental Entity. The Purchaser shall incorporate all comments on such drafts as may reasonably
be made by the Seller and/or the Marketing Authorisation Holder PROVIDED THAT the Purchaser shall not be obliged to incorporate any comments if the Purchaser considers, acting reasonably that to do so would materially delay Marketing Authorisation
Transfer or Marketing Authorisation Re-registration (as applicable). 

  

	1.7	Where under Applicable Law the MA Documentation is required to be submitted to the relevant Governmental Entity: 

 

	 	1.7.1	by the Marketing Authorisation Holder, the Purchaser shall procure that the finalised MA Documentation is provided to the Seller after such MA Documentation is
finalised in accordance with paragraph 1.6 above and the Seller shall, in turn, procure that the Marketing Authorisation Holder submits such MA Documentation to the relevant Governmental Entity (the timing and date of such submission to be
agreed with the Purchaser) and the Seller shall promptly thereafter advise the Purchaser of such submission and provide a copy of the relevant MA Documentation (in the form submitted) to the Purchaser; and 

 

	 	1.7.2	by the Marketing Authorisation Transferee, the Purchaser shall procure that the relevant Marketing Authorisation Transferee submits the finalised MA
Documentation to the relevant Governmental Entity as soon as reasonably practicable after such MA Documentation is finalised in accordance with paragraph 1.6 above and the Purchaser shall promptly thereafter advise the Seller of such submission
and provide a copy of the relevant MA Documentation (in the form submitted) to the Seller. 

  

	 	1.7.3	From the Closing Date, the Seller shall procure that the relevant Marketing Authorisation Holder shall, as soon as reasonably practicable, sign any notices,
applications, submissions, reports and other instruments, documents, correspondence or filings presented to it by the Purchaser or the relevant Marketing Authorisation Transferee that are necessary to effect Marketing Authorisation Transfer or
Marketing Authorisation Re-registration (as applicable). The Marketing Authorisation Holder shall: 

  

	 	(i)	provide notice of its consent to a Marketing Authorisation Transfer or Marketing Authorisation Re-registration if required by any Governmental Entity; and

  
 98 

	 	(ii)	provide to the Purchaser or the relevant Marketing Authorisation Transferee any information or other data or technical or other information in its possession that
relates to the relevant Marketing Authorisation and that is required by a relevant Governmental Entity or otherwise reasonably required by the Purchaser or the relevant Marketing Authorisation Transferee to assist the Purchaser or the relevant
Marketing Authorisation Transferee to effect the relevant Marketing Authorisation Transfer or Marketing Authorisation Re-registration; 

  

	 	(iii)	in the event of any request for information or any query from any relevant Governmental Entity in respect of Marketing Authorisation Transfer or the Marketing
Authorisation Re-registration (as applicable), the relevant party receiving such request or query shall provide copies of any such request or query to the Seller or, as the case may be, to the Purchaser. The Purchaser shall be responsible for
preparing, or shall be responsible for procuring that there is prepared, (at the Purchaser’s cost and expense) any response to such a request or query with the intention that such request or query shall be dealt with as promptly and efficiently
as possible. In advance of finalising any such response, the Purchaser shall procure that the relevant response is submitted to the Seller so as to allow the Seller and/or the relevant Marketing Authorisation Holder a reasonable opportunity to
provide comments on such response before it is submitted to the Governmental Entity. The Purchaser shall procure that relevant Marketing Authorisation Transferee (i) shall submit the response to the relevant Governmental Entity as soon as
reasonably practicable after the same has been finalised in accordance with this paragraph 1.7.3(iii) and (ii) shall provide a copy of the relevant response (in the form submitted) to the Seller. 

 

	2.	Obligations Pending Marketing Authorisation Transfer or Marketing Authorisation Re-Registration 

 

	2.1	Unless otherwise required by Applicable Law or a relevant Governmental Entity (or unless otherwise agreed in writing by the Seller and the Purchaser), from the
Closing Date until the applicable Marketing Authorisation Transfer Date or Marketing Authorisation Re-registration Date: 

  

	 	2.1.1	the Seller shall: 

  

	 	(i)	maintain in force (or procure that there is maintained in force) each Marketing Authorisation, and shall not voluntarily amend, cancel or surrender any Marketing
Authorisation unless requested to do so in writing by the Purchaser or required to do so by any Applicable Law or any Governmental Entity; 

  

	 	(ii)	with the Purchaser’s consent (not to be unreasonably withheld or delayed) progress (or procure that there is progressed) any registrations, variations or renewals
to Marketing Authorisations initiated by the Seller (or any other member of the Seller’s Group) prior to the Closing Date or withdraw them upon the request of the Purchaser; 

  
 99 

	 	(iii)	procure that each Marketing Authorisation Holder shall comply with the terms of any Marketing Authorisation and shall notify the Purchaser as soon as reasonably
practicable of the details of any variations or renewals initiated following the Closing Date; 

  

	 	(iv)	inform the Purchaser of any impending renewals of Marketing Authorisations as at the Closing Date and the parties shall discuss in good faith to what extent any such
renewal will be pursued or withdrawn (it being agreed that the Purchaser shall have the final decision in any such matter); 

  

	 	(v)	not without the consent of the Purchaser, initiate any additional variations or amendments to the Marketing Authorisations, except to the extent required by any
Governmental Entity or where failure to do so would breach Applicable Law; and 

  

	 	(vi)	consider in good faith any request by the Purchaser to apply for a new marketing authorisation in respect of a Product PROVIDED THAT if the Seller agrees to submit such
application, any costs or expenses incurred by the Seller in making such application shall be for the Purchaser’s account and shall constitute MA Costs; 

 

	 	2.1.2	without prejudice to the generality of the foregoing paragraph 2.1.1(iii), the Purchaser acknowledges and agrees that each Marketing Authorisation Holder
shall be entitled to do (or to procure that there is done) any or all of the following (and the Purchaser acknowledges that, where the relevant Marketing Authorisation Holder so chooses and unless otherwise agreed, responsibility for each of the
following activities shall rest with the relevant Marketing Authorisation Holder): 

  

	 	(i)	pharmacovigilance activities related to the Marketing Authorisations, which activities shall be conducted in accordance with the Applicable Law, the Pharmacovigilance
Agreement, and the standards, policies and procedures of the Seller’s Group from time to time in force; and 

  

	 	(ii)	conducting any and all communications with a Governmental Entity in respect of a Marketing Authorisation (including, without limitation to the generality of the
foregoing, attending any meetings with relevant Governmental Entities and filing and submitting all reports and other documents which it reasonably considers necessary to be submitted in order to comply with Applicable Law or its obligations under
this Agreement), PROVIDED THAT responsibility for (a) the costs of preparation of any such documents, reports and/or filings shall be borne by the Purchaser (or the relevant Marketing Authorisation Transferee) to the extent such costs are
reasonably necessary, and (b) the submission of MA Documentation shall be the responsibility of the Purchaser in accordance with paragraph 1.5 above, PROVIDED THAT the Seller shall ensure that the Purchaser is kept fully and promptly
informed of any such communications or submissions in advance, to the extent reasonably practicable; and 

  
 100

	 	2.1.3	the Seller shall procure that each Marketing Authorisation Holder shall act in accordance with the reasonable instructions of the Purchaser or the Marketing
Authorisation Transferee in respect of each Marketing Authorisation in respect of which such Marketing Authorisation Holder is the holder, PROVIDED THAT no Marketing Authorisation Holder shall be obliged to comply with such instructions to the
extent the same: (i) infringe the terms of the relevant Marketing Authorisation(s); or (ii) are otherwise inconsistent with the provisions of the Pharmacovigilance Agreement relating to the Seller; 

 

	 	2.1.4	the Purchaser shall only request artwork changes to the extent such changes are required in order to comply with Applicable Law; and 

 

	 	2.1.5	the Purchaser shall submit to the Seller (or shall procure that there is submitted) written details (in such form and with such supporting materials as the
Seller may reasonably request) of any new, amended or proposed advertising and promotional activity or training materials in respect of any Product Commercialised pursuant to any Marketing Authorisation (including (without limitation) any material
reasonably requested by the Seller in order to validate new and/or amended promotional or training materials), and the Purchaser acknowledges and agrees that no such advertising, promotional or training activity shall be implemented, undertaken or
otherwise commenced without the prior written consent of the Seller (for itself and on behalf of the relevant Marketing Authorisation Holder), such consent not to be unreasonably withheld. The Purchaser further agrees and acknowledges that, if it so
chooses, the Seller shall be entitled to assume responsibility for obtaining (or procuring that there is obtained) the consent(s) and approval(s) of any relevant Governmental Entity required for such new, amended or proposed advertising and
promotional activity or training activity; and 

  

	 	2.1.6	to the extent permitted by the terms of the relevant Marketing Authorisation and provided for in the Transitional Distribution Services Agreement, the Purchaser
or any other member of the Purchaser’s Group shall Commercialise the Product(s) which are the subject of such Marketing Authorisation (notwithstanding that such Marketing Authorisation is held in the name of the relevant Marketing Authorisation
Holder and, for the avoidance of doubt, the proceeds of any such Commercialisation shall be for the benefit of the Purchaser’s Group) and the Purchaser shall: 

 

	 	(i)	indemnify each member of the Seller’s Group against any and all actions, claims, demands, investigations, judgments, proceedings, liabilities, loss, damages,
payments, costs and expenses arising in relation to the Commercialisation of the Product(s) by the Purchaser or any other member of the Purchaser’s Group under this paragraph 2.1.6; and 

  
 101

	 	(ii)	procure that such Product(s) are Commercialised in compliance with the terms of the relevant Marketing Authorisation and/or the requirements of the relevant
Governmental Entity. 

  

	3.	New and Pending Marketing Authorisations in Respect of the Products 

 

	3.1	If, at any time prior to Closing, any member of the Seller’s Group is granted or otherwise comes to hold any marketing authorisation which relates
exclusively to one or more Products (a “New Marketing Authorisation”) then: 

  

	 	3.1.1	the Seller undertakes to the Purchaser to notify the Purchaser as soon as reasonably practicable following the date on which the relevant member of the
Seller’s Group is granted, or becomes entitled to, the New Marketing Authorisation; and 

  

	 	3.1.2	the provisions of paragraphs 1 and 2 above shall apply to that new Marketing Authorisation. 

 

	3.2	Where a member of the Seller’s Group has submitted to any Governmental Entity any application relating to the grant of a new marketing authorisation in
respect of the Business which is pending or in process as at the date of this Agreement (a “Pending Marketing Authorisation”): 

  

	 	3.2.1	the Seller shall continue to be responsible for preparation and submission of all documents required to register such Pending Marketing Authorisation but,
following Closing, it shall do so at the Purchaser’s cost and shall pass responsibility for such Pending Marketing Authorisation to the Purchaser (or such member of the Purchaser’s Group as the Purchaser may nominate) as soon reasonably
possible after Closing, subject to Applicable Law; 

  

	 	3.2.2	from the Closing Date, the provisions of paragraph 1 shall apply mutatis mutandis to any registration process for any Pending Marketing Approval.

  

	4.	MA Costs 

  

	4.1	From the Closing Date, the Purchaser shall be responsible for all necessary costs of preparation and submission of MA Documentation and, save as expressly
provided in this Agreement, any other necessary costs incurred by the Seller or a member of the Seller’s Group in connection with the maintenance and any variations, amendments and renewals of the Marketing Authorisations relating to the
Products or for any matter requested by the Purchaser pursuant to this Part 2 of Schedule 6 and for all fees and costs reasonably incurred by the relevant member of the Seller’s Group in complying with its obligations in respect of a Marketing
Authorisation Transfer or Marketing Authorisation Re-registration (“MA Costs”). 

  
 102

	5.	Obligations following Marketing Authorisation Transfer or Marketing Authorisation Re-Registration 

 

	5.1	On and from the relevant Marketing Authorisation Transfer Date or Marketing Authorisation Re-registration Date (as applicable), the Purchaser shall procure that
each Marketing Authorisation Transferee shall assume and be solely responsible for: 

  

	 	5.1.1	all obligations as the holder of such Marketing Authorisation including (subject to the terms of the Pharmacovigilance Agreement) pharmacovigilance activities
related to such Marketing Authorisation; 

  

	 	5.1.2	all activities and actions required by Applicable Law in connection with such Marketing Authorisation; and 

 

	 	5.1.3	any and all outstanding commitments and obligations to the relevant Governmental Entities with respect to the relevant Marketing Authorisation, save for any such
commitments or obligations arising from a breach of this Agreement by the Seller. 

  

	5.2	In the event that, following Marketing Authorisation Transfer or Marketing Authorisation Re-registration in respect of any Product, the Seller wishes to apply
for a marketing authorisation in respect of a retained product, the Purchaser shall (and shall procure that the relevant Marketing Authorisation Transferee shall) co-operate with and provide all reasonable assistance to the Seller (or the relevant
member of the Seller’s Group) at the Seller’s costs as may be reasonably required for the purposes of applying for such new marketing authorisation, including (without limitation) providing the Seller (or the relevant member of the
Seller’s Group) and/or any Governmental Entity with such access to Marketing Authorisation Data or such other data or technical or other information as is reasonably requested by the relevant Governmental Entity or is otherwise reasonably
required by the Seller or the relevant member of the Seller’s Group. 

  

	5.3	Except to the extent provided for in the Ofatumumab Intellectual Property Licence Agreement, nothing in paragraph 5.2 above shall require the Purchaser to
consent to or assist the Seller or any member of the Seller’s Group to apply for a marketing authorisation for any product which contains the same compound as any Product. 

Part 3 Tenders 
  

	1.1	From Closing until the Marketing Authorisation Transfer Date in any Market, the Seller shall, and shall procure that each member of the Seller’s Group and
the relevant Marketing Authorisation Holder shall, to the extent permitted by Applicable Law: 

  

	 	1.1.1	inform the Purchaser in writing of any Call for New Tender as soon as reasonably practicable following receipt; and 

 

	 	1.1.2	co-operate with and provide reasonable assistance to the Purchaser (or the relevant member of the Purchaser’s Group) for the purposes of responding to the
Call for New Tender or otherwise applying for a new tender; and 

  
 103

	 	1.1.3	where Applicable Law requires such responses or applications to be made by the Marketing Authorisation Holder, the Seller shall procure that the Marketing
Authorisation Holder submits such responses or applications on behalf of the Purchaser PROVIDED THAT the Purchaser shall indemnify the Seller and/or the relevant Marketing Authorisation Holder (as the case may be) for any and all costs, expenses and
liabilities suffered or reasonably incurred by the Seller and/or the Marketing Authorisation Holder in complying with or as a result of the provisions of this paragraph. 

  
 104

 Schedule 7 
 Transferred Contracts, Transferred Intellectual Property Contracts, Co-Owned 

Transferred Product Intellectual Property Rights, and 
 Shared Business Contracts 
 (Clause 2.3.1) 

 

	1.	Separation of Shared Business Contracts 

  

	1.1	Prior to Closing, the Seller and the Purchaser shall discuss and agree in good faith a process to identify all material Shared Business Contracts.

  

	1.2	The Seller shall use all reasonable efforts to maintain relationships under the Shared Business Contracts and continue to operate the Shared Business Contracts,
including without limitation fulfilling all its obligations under the Shared Business Contracts, in the same manner as it has for the twelve months prior to this Agreement. 

 

	1.3	The Purchaser may, by notice to the Seller at any time prior to the later of: 

 

	 	1.3.1	the date falling 90 days after the Closing Date or, if the Seller has not provided Full Disclosure of a Shared Business Contract on or prior to Closing, the date
falling 90 days after the date on which Full Disclosure of the relevant Shared Business Contract is made; and 

  

	 	1.3.2	the Marketing Authorisation Transfer Date in respect of the relevant Product in the relevant territory 

(the “Relevant Election Date”), 
 elect to take the rights and obligation of the Relevant Part of any Shared Business Contract. For the purposes of paragraph 1.3.2 above only, if a Shared Business Contract is in relation to more than one
Product and/or territory, the first Marketing Authorisation Transfer Date in respect of a Product covered by that Shared Business Contract shall be the relevant date. 
  

	1.4	If the Purchaser makes an election under paragraph 1.3 above: 

  

	 	1.4.1	the Seller and the Purchaser shall use all reasonable endeavours to procure that an arrangement is entered into with the relevant counterparty to each Shared
Business Contract, the effect of which shall be that, with effect from whichever is the later of Marketing Authorisation Transfer Date and the date of the relevant arrangement, the benefit and burden of the Relevant Part is severed from such Shared
Business Contract and an agreement or arrangement equivalent to such Shared Business Contract is entered into between the relevant counterparty and a member of the Purchaser’s Group (or the Relevant Part of the Shared Business Contract is
sub-licensed to such Purchaser) (a “Separation”). For the avoidance of doubt, no part of any such Shared Business Contract shall be severed and transferred to any Purchaser in so far as it relates to the Seller’s Retained
Business, any product other than the Products or any Excluded Asset; and 

  
 105

	 	1.4.2	in the event that the Marketing Authorisation Transfer Date occurs before the effective date of a Separation, the provisions of sub-paragraphs 3.2.1, 3.2.2 and
4.1 of this Schedule shall apply in respect of such Shared Business Contracts. 

  

	1.5	If no election is made by the Purchaser under paragraph 1.3 above by the Relevant Election Date, the provisions of sub-paragraphs 3.2.1 and 3.2.2 of this
Schedule shall apply in respect of the Relevant Part of such Shared Business Contract until: 

  

	 	1.5.1	in the case of any Shared Business Contract that is not a development contract or otherwise related to any Ongoing Clinical Trials, the earlier of 9 months from
the Relevant Election Date and the date on which the Purchaser notifies the Seller that an alternative arrangement has been put in place; and 

  

	 	1.5.2	in the case of any Shared Business Contract that is a development contract or which otherwise relates to any Ongoing Clinical Trials, the end of the period
specified in the Transitional Services Agreement which in any event shall be no less than 9 months from Closing. 

  

	1.6	For the avoidance of doubt, paragraphs 1.3, 1.4 and 1.5 shall not apply in respect of any Shared Business Contract which terminates before the Relevant Election
Date. 

  

	1.7	The parties acknowledge that the Purchaser has elected to take the rights and obligations of the Zofran Trade Mark and Domain Name Licence from Closing in so far
as such agreement relates to Business Product Intellectual Property Rights. 

  

	2.	Obligation to obtain Third Party Consents 

  

	2.1	Subject to paragraph 2.4, in relation to any Transferred Contract or Transferred Intellectual Property Contract (excluding, for the purposes of this Schedule,
any Product Approval) or rights in a Co-Owned Transferred Product Intellectual Property Right which is not assignable or sub-licensable without a Third Party Consent or
a Separation of a Shared Business Contract which is not separable without a Third Party Consent, this Agreement shall not be construed as an assignment, an attempted assignment, a sub-licensing or an attempted sub-licensing and the Seller and the
Purchaser shall each use reasonable endeavours both before and after Closing to obtain all necessary Third Party Consents as soon as possible and shall keep the other informed of progress in obtaining such Third Party Consents. The Seller shall
deliver to the Purchaser, on Closing or, if later, as soon as possible after receipt, any Third Party Consent. 

  

	2.2	In connection with the obtaining of any Third Party Consent referred to in paragraph 2.1, the Purchaser shall supply to the Seller such information as may
be reasonably requested by the Seller or any relevant third party. 

  

	2.3	Subject to paragraph 2.4, and save as otherwise provided in this Agreement, the cost of any fee demanded by the third party as consideration for giving the Third
Party Consent shall be borne by the Purchaser, provided that: 

  

	 	2.3.1	the cost is agreed in advance by the Purchaser (such agreement not to be unreasonably withheld or delayed); and 

  
 106

	 	2.3.2	no party shall be required to bear any internal or administrative costs of the other party in relation to any Third Party Consent. 

 

	2.4	In relation to any rights in a Co-Owned Transferred Product Intellectual Property Right for which a Third Party Consent is required for the satisfaction of any
step of the Pre-Closing Products Reorganisation, the following shall apply: 

  

	 	2.4.1	the Seller shall use reasonable endeavours to obtain all necessary Third Party Consents required for: 

 

	 	(i)	the satisfaction of any step of the Pre-Closing Products Reorganisation that takes place prior to the Closing Date; and 

 

	 	(ii)	the assignment or transfer to the Purchaser or any member of the Purchaser’s Group of the Co-Owned Transferred Product Intellectual Property Rights after the
Closing Date; 

  

	 	2.4.2	If the Seller has not, prior to the date on which Step 5 of the Pre-Closing Products Reorganisation takes effect, obtained all of the Third Party Consents
referred to in paragraphs 2.4.1(i) and (ii) above which are required for the transfer of any Co-Owned Transferred Product Intellectual Property Rights: 

 

	 	(i)	the legal title in that Co-Owned Transferred Product Intellectual Property Right shall not be transferred to the Company pursuant to Schedule 18; and

  

	 	(ii)	the terms of paragraphs 3 and 4 shall apply to that Co-Owned Transferred Product Intellectual Property Right; and 

 

	 	2.4.3	the cost of any fee demanded by the third party as consideration for giving any Third Party Consent in connection with paragraph 2.4.1 shall be paid by the
Seller and shall be allocated between the Seller and Purchaser as follows: 

  

	 	(i)	the Seller shall meet the cost of any fee demanded by the third party as consideration for giving any Third Party Consent in connection with 2.4.1(i);

  

	 	(ii)	the Purchaser shall meet the cost of any fee demanded by the third party as consideration for giving any Third Party Consent in connection with 2.4.1(ii) provided that:

  

	 	(a)	the cost is agreed in advance by the Purchaser (such agreement not to be unreasonably withheld or delayed); and 

 

	 	(b)	the Purchaser shall not be required to bear any internal or administrative costs of the other party in relation to any Third Party Consent]; and

  

	 	(iii)	if the cost of any fee demanded by the third party as consideration for giving any Third Party Consent does not distinguish between consent provided for the purposes of
paragraph 2.4.1(i) and 2.4.1(ii), the Seller and Purchaser shall discuss in good faith the allocation of the fee that should be payable by each in connection with any Third Party Consent. If the Seller and Purchaser are unable to agree on the
allocation within a period of 14 calendar days the allocation of the fee payable by each of the Seller and Purchaser shall be split equally. 

  
 107

	2.5	The parties agree that the provisions of any document entered into in connection with a Third Party Consent (including by way of novation) shall be without
prejudice to the provisions of Clauses 8.1, 8.2 and 13 of this Agreement. 

  

	3.	Obligations until Third Party Consents are obtained/where Third Party Consents are refused 

 

	3.1	Subject to paragraph 3.2, the Purchaser shall assume, carry out, perform and discharge the Seller’s and the Business Sellers’ obligations arising
under the Transferred Contracts, the Transferred Intellectual Property Contracts, the Co-Owned Transferred Product Intellectual Property Right, and the Relevant Part of the Shared Business Contracts as from Closing. 

 

	3.2	In respect of any Transferred Contract or Transferred Intellectual Property Contract, Relevant Part of any Shared Business Contract or Co-Owned Transferred
Product Intellectual Property Right from Closing until the relevant Third Party Consent has been obtained as contemplated by paragraphs 2.1 or 2.4 or where the Third Party Consent has been refused: 

 

	 	3.2.1	the relevant Business Seller shall hold on trust to the extent it is lawfully able to do so or, where it is not lawfully able to do so or where holding on trust
is not possible under local law or otherwise impracticable, the relevant Business Seller and the Purchaser shall make such other arrangements between themselves to provide to the Purchaser the benefits of the Contract (other than amounts
corresponding to any Tax payable by the relevant Business Seller in respect of amounts due under the Transferred Contract or Transferred Intellectual Property Contract or Relevant Part of the Shared Business Contract or Co-Owned Transferred Product
Intellectual Property Right), including the enforcement at the cost and for the account of the Purchaser of all rights of the relevant Business Seller against any other party thereto; 

 

	 	3.2.2	to the extent that the Purchaser is lawfully able to do so, the Purchaser shall perform the relevant Business Seller’s obligations under the Contract as
agent or sub-contractor and shall indemnify the Seller and the relevant Business Seller if the Purchaser fails to do so. To the extent that the Purchaser is not lawfully able to perform such obligations, the Seller shall procure that relevant
Business Seller shall, (subject to being indemnified by the Purchaser for any Losses the Seller or the relevant Business Seller may incur in connection therewith) do all such things as the Purchaser may reasonably require to enable due performance
of the Contract and the Purchaser shall indemnify the relevant Business Seller in respect thereof. 

  
 108

	4.	Failure to Obtain Third Party Consents 

  

	4.1	If a Third Party Consent is refused or otherwise not obtained on terms reasonably acceptable to the Purchaser within 18 months of Closing, or in the case of a
Separation, 18 months of the earliest Marketing Authorisation Transfer Date applicable to such Shared Business Contract: 

  

	 	4.1.1	the Seller shall be entitled to procure the termination of the Transferred Contract, Transferred Intellectual Property Contract or the Relevant Part of the
Shared Business Contract or Co-Owned Transferred Product Intellectual Property Right and the obligations of the parties under this Agreement in relation to such Transferred Contract, Transferred Intellectual Property Contract or Relevant Part of the
Shared Business Contract or Co-Owned Transferred Product Intellectual Property Right shall cease forthwith; 

  

	 	4.1.2	references in this Agreement to the Transferred Contracts, Transferred Intellectual Property Contracts or Relevant Part of the Shared Business Contract or
Co-Owned Transferred Product Intellectual Property Right (other than in this paragraph 4) shall be construed as excluding such Transferred Contract, Transferred Intellectual Property Contract or the Relevant Part of the Shared Business Contract
or Co-Owned Transferred Product Intellectual Property Right; and 

  

	 	4.1.3	the Seller and the Purchaser shall use all reasonable efforts to put in place alternative arrangements so as to give the Purchaser equivalent benefits or rights
as would have been enjoyed under the terminated Transferred Contract, Transferred Intellectual Property Contract, or the Relevant Part of the Shared Business Contract or Co-Owned Transferred Product Intellectual Property Right.

  
 109

 Schedule 8 
 Employees 
 (Clause 2.4.1) 

 

	1.	Information and consultation 

  

	1.1	At such time as the parties agree to be appropriate following the public announcement of the matters contemplated by this Agreement, the Seller and the Purchaser
or the relevant member of the Purchaser’s Group shall jointly communicate to the Employees an agreed notice which shall (other than to the extent the parties agree otherwise): 

 

	 	1.1.1	inform the Employees that following Closing those Employees who continue to be employed in the Business would be employed by the Purchaser or relevant member of
the Purchaser’s Group; and 

  

	 	1.1.2	comply with the requirements of any applicable national law. 

 For the avoidance of doubt, the parties may agree to issue such notice to different Employees or categories of Employees at different times and in different forms. 

 

	1.2	Notwithstanding the operation of paragraph 1.1 above, the Seller and the Purchaser agree to comply with any more onerous notice requirements imposed by
local laws. 

  

	1.3	The Purchaser (on its own behalf and on behalf of any relevant member of the Purchaser’s Group) shall provide the Seller (for itself and any relevant member
of the Seller’s Group) with such information and assistance at such times as the Seller may reasonably request or as may be reasonably necessary for the Seller or any other member of the Seller’s Group to comply with any formal or informal
requirement to inform or consult with the Employees, a relevant trade union, a relevant works council, or any other employee representatives in connection with the matters contemplated by this Agreement (which formal or informal requirements the
Seller hereby undertakes to comply or procure compliance with). Where reasonably necessary to ensure compliance with any formal or informal requirements or obligations to inform or consult with Employees, a relevant trade union, a relevant works
council or any other employee representatives in connection with the matters contemplated by this Agreement, the Seller (for itself and for each member of the Seller’s Group) and the Purchaser (for itself and for each member of the
Purchaser’s Group) agree that the Purchaser or relevant member of the Purchaser’s Group shall cooperate with and participate in any information, negotiation and/or consultation process as reasonably required by the Seller.

  

	1.4	As soon as practicable following the date of this Agreement, the Purchaser agrees to provide on a timely basis such information, in writing, in respect of its
existing terms and conditions of employment as may reasonably be required by the Seller so as to facilitate the Seller’s information and consultation exercise with its Employees in respect of the matters set out in this Agreement.

  
 110

	2.	Employees 

  

	2.1	General 

  

	 	2.1.1	The Purchaser shall (or shall procure that the relevant member of the Purchaser’s Group shall) fulfil all its duties and obligations under Applicable Law in
relation to the Employees. Where the provisions of local law do not provide for an automatic transfer of the employment of the Employees to the Purchaser or a relevant member of the Purchaser’s Group with effect from (and including) the Closing
Date, then paragraph 2.2 below shall apply. Where the provisions of local law do provide for an automatic transfer of employment of the Relevant Employees to the Purchaser or the relevant member of the Purchaser’s Group with effect from
(and including) the Closing Date, then paragraph 2.3 below shall apply. 

  

	 	2.1.2	The parties acknowledge and agree that: 

  

	 	(i)	any Deferred Employee shall be treated for all purposes under this Agreement as if such Deferred Employee were an Employee; and 

 

	 	(ii)	the Purchaser’s obligations under this Schedule 8 shall apply in respect of each Deferred Employee in the same way as they do to each Employee; and

  

	 	(iii)	if any Deferred Employee accepts an offer of employment made by the Purchaser under paragraph 2.2.1 below, such Deferred Employee shall further be treated for all
purposes under this Agreement as a Transferred Employee. 

  

	 	2.1.3	For the avoidance of doubt, this paragraph 2 shall not apply to any Excluded Employee, who will remain employed by the Seller or the relevant member of the
Seller’s Group. 

  

	2.2	Where no automatic transfer of employment 

  

	 	2.2.1	In such timescale as the parties may agree, but in any event at least 30 Business Days prior to the Closing Date, the Purchaser or relevant member of the
Purchaser’s Group shall make an offer to each Employee employed by the Seller or a member of the Seller’s Group to employ him or her under a new contract of employment to commence with effect from (and including) the Closing Date provided
that such employee continues to be an Employee until the Closing Date. Save as otherwise agreed with the Seller (such agreement not to be unreasonably withheld), the offer to be made will be on the same terms and conditions (including as to period
of continuous employment) as were provided to that Employee immediately prior to the Closing Date. The Purchaser shall keep the Seller updated throughout the offer process on when offers are made and accepted or rejected. 

 

	 	2.2.2	If the Employee wishes to accept the offer of employment from the Purchaser or the relevant member of the Purchaser’s Group, then the Seller shall (or shall
procure that the relevant member of Seller’s Group shall), insofar as it is permitted by Applicable Law, waive the requirement on the Employee concerned to give any period of notice of termination of his or her employment under the terms of his
or her employment so as to allow the Employee to commence employment with the Purchaser or relevant member of the Purchaser’s Group with effect from (and including) the Closing Date. 

  
 111

	2.3	Where automatic transfer of employment 

 If the Transfer Regulations do not or are found not to or are alleged not to apply to any person who is a Relevant Employee, and to whom paragraph 2.2 does not apply, the Purchaser agrees that
following Closing: 
  

	 	2.3.1	in consultation with the Seller, the Purchaser or relevant member of the Purchaser’s Group shall within 10 Business Days of being so requested by the Seller
(as long as the request is made no later than 3 months after Closing) (or if the Purchaser so chooses), make such Relevant Employee an offer in writing to employ him or her under a new contract of employment subject to, and to take effect upon, a
date agreed between the parties and such employee; and 

  

	 	2.3.2	save as otherwise agreed with the Seller (such agreement not to be unreasonably withheld), the offer to be made will be on the same terms and conditions
(including as to period of continuous employment) as were provided to that Relevant Employee immediately prior to the Closing Date. 

  

	3.	Wrong-pocket arrangements for persons other than Relevant Employees 

 

	3.1	If the contract of employment of any person other than a Relevant Employee is found or alleged to have effect upon Closing as if originally made with the
Purchaser or another member of the Purchaser’s Group as a consequence of this Agreement, the Seller agrees that following Closing: 

  

	 	3.1.1	in consultation with the Purchaser, the Seller or relevant member of the Seller’s Group may within 10 Business Days of being so requested by the Purchaser
(as long as the request is made no later than 3 months after Closing) (or if the Seller so chooses), make to that person an offer in writing to employ him or her under a new contract of employment subject to, and to take effect upon, the termination
referred to below; and 

  

	 	3.1.2	the offer to be made will be on the same terms and conditions (including as to period of continuous employment) as were provided to that person immediately prior
to the Closing Date. 

  

	3.2	After the expiry of the 10 Business Days referred to at paragraph 3.1 above, and provided that the relevant member of the Purchaser’s Group takes such
steps as are legally possible to terminate the employment of the person concerned as soon as reasonably practicable after becoming aware of the finding or allegation referred to at paragraph 3.1 above (either by giving notice or transferring
the person by agreement to be concluded between the relevant member of the Purchaser’s Group, the person concerned and the relevant member of the Seller’s Group), the Seller shall be responsible for and shall indemnify and keep indemnified
the Purchaser (for itself and as trustee for any relevant member of the Purchaser’s Group) against all Losses from time to time made, suffered or incurred by the Purchaser (or any other member of the Purchaser’s Group) as a result of:

  
 112

	 	3.2.1	the actual or alleged transfer to a member of the Purchaser’s Group and (regardless of whether there has been such a transfer) any employment liabilities
relating to such person; 

  

	 	3.2.2	employing such person on and from the Closing Date until such termination (up to the time reasonably expected to have achieved such termination in accordance
with the terms of the contract of employment and Applicable Law) but subject to a maximum period of 6 months unless prevented by the terms of the contract of employment or Applicable Law; and 

 

	 	3.2.3	such termination. 

  

	3.3	The parties agree to co-operate in good faith to minimise the Losses which are subject to the indemnity referred to in paragraph 3.2 above.

  

	4.	Employment liabilities 

  

	4.1	All wages, salaries, employer’s liabilities in respect of associated Taxes and other periodic outgoings in respect of the Transferred Employees which relate
to a period: 

  

	 	4.1.1	after the Closing Date shall be borne or discharged by the Purchaser or relevant member of the Purchaser’s Group; and 

 

	 	4.1.2	on or before the Closing Date shall be borne or discharged by the Seller or relevant member of the Seller’s Group. 

 

	4.2	The Seller shall (for itself and for each member of the Seller’s Group) indemnify and keep indemnified the Purchaser (for itself and as trustee for each
other member of the Purchaser’s Group) against all Losses (ignoring any amount in respect of Employee Benefits, as to which see Schedule 9) in respect of: 

 

	 	4.2.1	the employment of any Employee at any time prior to the Closing Date (excluding any Transferred Employee Benefit Liabilities (as defined in Schedule 9) which the
Purchaser agrees to assume in accordance with Schedule 9); 

  

	 	4.2.2	any termination of the employment of any Employees prior to the Closing Date including, but not limited to, all claims relating to severance, termination pay,
pay in lieu of notice of termination and similar obligations (excluding any liability arising directly as a result of any breach of the commitments set out in paragraph 5 or 6 below by the Purchaser or a member of the Purchaser’s Group and
any act or omission by the Purchaser or any member of the Purchaser’s Group in relation to any Employee before Closing as a result of which that Employee treats his employment as having been terminated prior to the Closing Date);

  
 113

	 	4.2.3	any amount which becomes payable to any Employee or benefit to which any Employee becomes entitled by reason of this Agreement or the matters it contemplates,
including any change of control or other payment or benefit (and including any enhancement of severance terms on a subsequent termination of employment but excluding any Losses relating to any share-based incentive schemes, as to which see
paragraph 10 below); 

  

	 	4.2.4	any failure by the Seller or any other member of the Seller’s Group to comply with any obligation to inform or consult with employee representatives in
connection with the matters contemplated by this Agreement (other than as a result of any failure set out in paragraph 4.3.3 below); and 

  

	 	4.2.5	any breach by the Seller or any other member of the Seller’s Group of paragraph 4.1.2 above or paragraph 4.4, 4.5 or 9 below.

  

	4.3	The Purchaser shall (for itself and for each member of the Purchaser’s Group) indemnify and keep indemnified the Seller (for itself and as trustee for each
other member of the Seller’s Group) against all Losses (ignoring any amount in respect of Employee Benefits, as to which see Schedule 9) in respect of: 

 

	 	4.3.1	the employment of any of the Transferred Employees on and after the Closing Date (including, without limitation, any changes to terms and conditions of
employment by the Purchaser or any other member of the Purchaser’s Group); 

  

	 	4.3.2	any termination of the employment of any Transferred Employees on and after the Closing Date including, but not limited to, all claims relating to severance,
termination pay, pay in lieu of notice of termination and similar obligations except as contemplated under paragraph 3.2 above; 

  

	 	4.3.3	any failure by the Purchaser or any other member of the Purchaser’s Group to provide information and reasonable assistance to the Seller to enable the
Seller or any other member of the Seller’s Group to comply with any obligation to inform or consult with employee representatives in connection with the matters contemplated by this Agreement; 

 

	 	4.3.4	any breach by the Purchaser or any other member of the Purchaser’s Group of paragraph 4.1.1 above or paragraph 4.4 or 4.5 below; and

  

	 	4.3.5	any act or omission by the Purchaser or any member of the Purchaser’s Group in relation to any Employee before Closing as a result of which that Employee
treats his employment as having been terminated prior to the Closing Date. 

  

	4.4	 Any amount payable to or in respect of any Transferred Employee after Closing (including without limitation amounts paid under
paragraph 4.5 below) which (ignoring vesting conditions and any amount payable in respect of Employee Benefits or otherwise in accordance with Schedule 9) is referable to the period prior to Closing is payable by the Seller (for itself or on
behalf of the relevant Business Seller). Responsibility for amounts payable which are only partly referable to the period prior to Closing (again ignoring vesting conditions) is to be shared between the Seller (for itself or on behalf of the
relevant 

  
 114

	 	
Business Seller) and the Purchaser (for itself or on behalf of the relevant member of the Purchaser’s Group) such that the Seller bears S per cent. of the cost and the Purchaser bears P per
cent., where S is the percentage of the period by reference to which the amount was earned which fell on or before the Closing Date and P is the percentage of that period which falls after the Closing Date. The Purchaser shall, or shall procure that
such other member of the Purchaser’s Group shall, pay such amounts when due to the relevant Transferred Employees on or after Closing and shall deduct and/or pay and account for any Tax payable or accountable for by the employer in respect of
such amounts. The Seller covenants to reimburse the Purchaser in respect of any such amount (or S per cent. of it where relevant), including any Tax payable or accountable for by the employer in respect of such amount, within 30 days of receiving
notification that it has been paid. The Seller will provide the Purchaser with all information and documentation reasonably necessary to allow such payments to be made. 

 

	4.5	Following the Closing Date: 

  

	 	4.5.1	the Purchaser shall, or shall procure that a member of the Purchaser’s Group shall, pay a pro-rated cash bonus of an amount advised by the Seller to the
Purchaser to each Transferred Employee who participated in an annual cash bonus plan immediately before the Closing Date in their first payroll payment after the Closing Date; and 

 

	 	4.5.2	where the Seller is able to determine performance, any such bonus payment made to such eligible employees by the Purchaser or a member of the Purchaser’s
Group will be based on the Seller’s determination of performance to the Closing Date and pro-rated to the Closing Date; or 

  

	 	4.5.3	where the Seller is unable to determine performance (either business or individual), for example, because the Closing Date occurs near the start of the bonus
year, the Seller shall calculate any such bonus payment based on a deemed achievement of performance conditions at target level pro-rated to the Closing Date; and 

 

	 	4.5.4	as soon as reasonably practicable after the Closing Date, the Purchaser shall, or shall procure that such other member of the Purchaser’s Group shall,
provide such information as the Seller requires in order for the Seller to calculate the Tax payable or accountable for by the employer in respect of such bonus payments; and 

 

	 	4.5.5	the Purchaser shall, or shall procure that such other member of the Purchaser’s Group shall, deduct and/or account for any Tax payable or accountable for by
the employer in respect of such bonus payments; and 

  

	 	4.5.6	the Seller shall reimburse the Purchaser for the aggregate bonuses advised by the Seller to the Purchaser which are paid pursuant to this paragraph 4.5
along with the employer’s social security contributions due in respect of such payments. 

  
 115

	5.	Protection of terms and conditions and termination rights post-Closing 

 

	5.1	Without prejudice to paragraph 5.4 below, the Purchaser shall procure that for a period of 24 months following the Closing Date: 

 

	 	5.1.1	each Transferred Employee will (for so long as such Transferred Employee continues in the same role with any member of the Purchaser’s Group save that the
Purchaser shall not seek to demote any Transferred Employee to avoid the application of this provision) continue to receive at least the same basic salary; and 

 

	 	5.1.2	each Transferred Employee will continue to receive contractual benefits (but excluding Employee Benefits and any share-based incentive schemes or other long-term
incentive plans) which the Purchaser reasonably considers to be substantially comparable, taken as a whole, to the contractual benefits (but excluding Employee Benefits and any share-based incentive schemes or other long-term incentive plans) of
such Transferred Employee immediately prior to the Closing Date; and 

  

	 	5.1.3	no Transferred Employee will suffer a change to his overall employment terms (whether contractual or otherwise) and including, without limitation, any related to
length of service (but excluding Employee Benefits and any share-based incentive schemes or other long-term incentive plans), which, when taken as a whole viewed in the round (including to the extent relevant alongside any other changes being made
at the same time to that Transferred Employee’s employment terms), would in the Purchaser’s reasonable opinion acting in good faith be regarded as materially detrimental. 

 

	5.2	The Purchaser confirms that, following the Closing Date and for so long as the Transferred Employees continue in the employment of any member of the
Purchaser’s Group, the Transferred Employees will be eligible to participate in those share-based incentive schemes or other long-term incentive plans that are operated by the Purchaser or relevant members of the Purchaser’s Group from
time to time for employees of equivalent status, subject always to the rules of such share-based incentive schemes or long-term incentive plans and any qualifying conditions. 

 

	5.3	The Seller shall provide or shall cause to be provided to any member of the Purchaser’s Group such information reasonably requested in writing by any member
of the Purchaser’s Group to enable the Purchaser to comply with its obligations in paragraph 5.1 above. 

  

	5.4	If the employment of any Transferred Employee is terminated by reason of redundancy within 24 months following the Closing Date, the Purchaser shall procure that
there shall be provided to such Transferred Employee benefits which are equivalent to those provided under such redundancy and severance policies and benefits (whether contractual or otherwise and giving due credit to the Transferred Employees for
any additional service or earnings from the Closing Date onwards) (but excluding Employee Benefits other than the Agreed UK Restructuring Arrangement) as were applicable in respect of the particular Transferred Employee immediately prior to the
Closing Date, to the extent that such policies and benefits are notified in writing to the Purchaser prior to the Closing Date. If, at any time during the 24 month period immediately following the Closing Date, the Purchaser places any Transferred
Employee into a redundancy selection process, the Purchaser undertakes that, in determining such selection, it will or will procure that the relevant member of the Purchaser’s Group will take no account of the costs of dismissal of any person
within the relevant selection pool (including such Transferred Employee). 

  
 116

	5.5	For the avoidance of doubt, the provisions of this paragraph 5 are without prejudice to the operation of any rule of law in relation to the terms and
conditions of employment of the Transferred Employees. 

  

	6.	Benefits arrangements/service continuity 

  

	6.1	Each Transferred Employee shall have their service with the Seller’s Group and their respective predecessors recognised under any employee benefit plans or
arrangements of the Purchaser’s Group for all purposes of eligibility, vesting and accrual of benefits to the extent past service was recognised for such Transferred Employee under a comparable plan or arrangement immediately prior to the
Closing Date. Notwithstanding the foregoing, nothing in this paragraph 6.1 shall be construed to require recognition of service for the purposes of calculation of Employee Benefits or that would result in: 

 

	 	6.1.1	any additional liability being assumed by the Purchaser’s Group in respect of Employee Benefits other than subject to and in accordance with the provisions
of Schedule 9; 

  

	 	6.1.2	duplication of benefit; 

  

	 	6.1.3	recognition of service for any purposes under any plan or arrangement for which participation, service and/or benefits accrual is frozen or any post-retirement
medical plan; or 

  

	 	6.1.4	recognition of service under a newly established plan or arrangement for which prior service is not taken into account for employees of the Purchaser’s
Group generally. 

  

	6.2	Without limiting the foregoing, with respect to the Transferred Employees, the Purchaser shall, or shall cause such other member of the Purchaser’s Group
to, be responsible for all paid time off benefits, including vacation pay, sick pay, banked leave, flexitime and other payments for time off of normal work hours accrued by the Transferred Employees up to the Closing Date provided that if the value
of such matters (excluding normal accrued but untaken annual leave for the year current as at Closing) would exceed US$7.5 million if accrued for in a balance sheet in accordance with IFRS then the Seller shall compensate the Purchaser for such
matters (again excluding normal accrued but untaken annual leave for the year current as at Closing) by paying the Purchaser an amount equal to that value, less any amount actually accrued and transferred to the Purchaser for such matters.

  

	6.3	With respect to any welfare plan maintained by the Purchaser or any other member of the Purchaser’s Group in which Transferred Employees are eligible to
participate after the Closing Date, the Purchaser shall: 

  
 117

	 	6.3.1	waive all limitations as to pre-existing conditions, exclusions, evidence of insurability provisions, waiting periods with respect to such participation and
coverage requirements or similar provisions under a Purchaser’s benefit plans that are welfare plans (as defined in section 3(1) of ERISA or any equivalent Applicable Law) applicable to such employees to the extent such conditions, exclusions
and waiting periods or other provisions were satisfied or did not apply to such employees under welfare plans maintained by the Seller or other members of the Seller’s Group prior to the Closing Date; and 

 

	 	6.3.2	provide each Transferred Employee with credit for any co-payments and deductibles paid prior to the Closing Date in satisfying any analogous deductible or
out-of-pocket requirements to the extent applicable under any such plan in the year in which Closing occurs, to the extent credited under the welfare plans maintained by the Seller or other members of the Seller’s Group prior to the Closing
Date. 

  

	7.	US Transferred Employees 

  

	7.1	To the extent the Purchaser or any other member of the Purchaser’s Group maintains a health care and dependent care flexible spending account arrangement
pursuant to section 125 or 129 of the Code (collectively, “FSAs”), the Purchaser will use commercially reasonable efforts to honour the elections of all Transferred Employees who are employed in the United States and/or covered by
US Benefit Plans (“US Transferred Employees”) under the FSAs of any relevant member of the Seller’s Group (“Relevant Employer’s FSAs”), as in effect immediately prior to the Closing Date, and the Purchaser
will use commercially reasonable efforts to assume responsibility for administering all reimbursement claims of US Transferred Employees with respect to the calendar year in which the Closing Date occurs that are submitted for payment on or after
the Closing Date, whether arising before, on or after the Closing Date, under the Purchaser’s FSAs. As soon as practicable but no more than 45 days following the Closing Date, the Seller will cause to be transferred to the Purchaser an amount
in cash equal to (i) the sum of all contributions to the Relevant Employer’s FSAs with respect to the calendar year in which the Closing Date occurs by or on behalf of the US Transferred Employees prior to the Closing Date, reduced by
(ii) the sum of all claims incurred in the calendar year in which the Closing Date occurs that are submitted to the Relevant Employer for payment prior to the Closing Date and paid by the Relevant Employer’s FSAs with respect to such US
Transferred Employees prior to the date of such cash transfer to the Purchaser; provided, however, if this calculation results in a negative number, then the Purchaser will pay to the Seller (on behalf of the Relevant Employer) as soon as
practicable following the end of the calendar year in which the Closing Date occurs, the amount by which (ii) exceeds (i). 

  

	7.2	With effect on and from the Closing Date, the Purchaser shall, or shall procure that such other members of the Purchaser’s Group shall, assume the
responsibility and obligation to provide COBRA continuation coverage to all US Transferred Employees whose employment is terminated after the Closing Date and their eligible dependents. 

  
 118

	8.	International Assignees 

Where Applicable Law does not provide for the automatic transfer of employment of any International Assignee and/or the other terms
governing their international assignment, the Purchaser shall assume and agree to be bound by the individual contract of employment and such other terms governing their international assignment including any tax equalisation agreement entered into
between an International Assignee and a member of the Seller’s Group provided that such employee becomes a Transferred Employee and the Seller has disclosed to the Purchaser the template international assignment terms of the Seller’s Group
prior to the Closing Date. 
  

	9.	Liability for retention arrangements 

 The Seller or any other member of the Seller’s Group has or will put in place certain retention arrangements (in the form of cash) to retain key employees in connection with the matters contemplated
by this Agreement. To the extent that details of such retention arrangements are disclosed to the Purchaser prior to the Closing Date, and in respect of arrangements put in place after the date of this Agreement, with the agreement of the Purchaser,
the Purchaser shall, or shall procure that such other member of the Purchaser’s Group shall, make the cash retention payments when due to the relevant Transferred Employees on or after Closing and shall deduct and/or pay and account for any Tax
payable or accountable for by the employer in respect of such cash payments. The Seller covenants to reimburse the Purchaser in respect of any cash retention payments, whether or not disclosed (including any Tax payable or accountable for by the
employer in respect of such payments), which are put in place prior to the Closing Date. The Seller acknowledges that the Purchaser may ask the Seller to put in place more generous retention arrangements than those proposed by the Seller (including,
where practicable, putting in place retention arrangements which last for a period of at least six months following Closing) and will not unreasonably withhold consent to such arrangements provided that any incremental cost of such arrangements over
and above the cost of the Seller’s own proposals will be for the Purchaser’s account. The Seller will provide the Purchaser with all information and documentation reasonably necessary to allow such payments to be made. 

 

	10.	Share-based incentive schemes 

  

	10.1	This paragraph 10 applies notwithstanding any other provision of this Agreement. 

 

	10.2	The Seller undertakes that share-based awards held by Transferred Employees pursuant to a share-based incentive scheme operated by the Seller or another member
of the Seller’s Group (“Relevant Awards”) shall be treated in a manner consistent with the “good leaver treatment” pursuant to the default position under those share-based incentive schemes. Where Relevant Awards are
subject to performance (or other) conditions and it is not possible to determine whether or not such conditions have been met at the applicable early vesting date (or within a reasonable period thereafter), the Seller and Purchaser agree that
performance shall be deemed “on target”. 

  
 119

 For the avoidance of doubt, such “good leaver treatment” provides that:

  

	 	10.2.1	Relevant Awards shall not lapse or be forfeited as a result of Closing except to the extent that they do not vest in accordance with paragraphs 10.2.2
and/or 10.2.3 below; 

  

	 	10.2.2	Relevant Awards shall vest early as a result of Closing and shall be time pro-rated to take account of the reduced period of time, as a proportion of the
original vesting period, that the relevant Transferred Employee worked within the Seller’s Group (calculated on the basis of the number of years of service as at the Closing Date, where part years of service are rounded up); and

  

	 	10.2.3	Relevant Awards that vest after the Closing Date shall remain subject to any relevant performance (or other) conditions, adjusted as necessary to take account of
Closing and measured up to the applicable early vesting date. 

 For the purposes of this paragraph 10.2,
“on target” performance shall not be construed as permitting share-based awards to vest in full. 
  

	10.3	The Seller agrees to indemnify the Purchaser (or relevant member of the Purchaser’s Group) for any Liabilities borne by the Purchaser’s Group in
connection with the Relevant Awards, including any Tax. The Purchaser agrees to use its best endeavours to seek any applicable Tax relief in respect of the Relevant Awards and to indemnify the Seller in respect of any Tax relief obtained, provided
always that the Seller provides the Purchaser with any information that the Purchaser may reasonably request in this respect in a timely manner. 

  

	10.4	Subject to paragraph 10.5, the Seller undertakes to inform the Purchaser of the vesting or exercise (as applicable) of the Relevant Awards and to provide,
in a timely manner, details of the Relevant Awards that so vest or are exercised so that the Purchaser’s Group can make any applicable withholdings for Tax and pay any Tax for which the Purchaser’s Group is liable in respect of the
Relevant Awards to the relevant Tax Authority within any applicable timescale. 

  

	10.5	To the extent permitted under the relevant plan rules and any Applicable Law, the Seller undertakes to sell such number of the shares underlying the Relevant
Awards as may be necessary for the sale proceeds to satisfy any applicable Tax withholdings and to pay such amounts to the Purchaser in sufficient time for the Purchaser to pay such Tax to the relevant Tax Authority within any applicable timescale,
provided always that the Purchaser provides the Seller with any information that the Seller may reasonably request in this respect in a timely manner. 

  

	10.6	The Seller undertakes to procure that each relevant member of the Seller’s Group will pay any Tax for which each member is liable in respect of the Relevant
Awards to the relevant Tax Authority within any applicable timescale. 

  

	10.7	The Seller undertakes to complete any relevant Tax Return in respect of the Relevant Awards and to submit any such Tax Return to the relevant Tax Authority
within any applicable timescale. 

  

	10.8	 This paragraph shall apply where Relevant Awards lapse or are forfeited (or will lapse or be forfeited) either in whole or in part as a result
of Closing. As soon as practicable following Closing (and, in any event, by the later of 30 days from the 

  
 120

	 	
Closing Date and 30 days from the first date after the Closing Date when the granting of share-based awards is not prevented by dealing restrictions, subject in both cases to the relevant plan
rules and any Applicable Law), the Purchaser (or member of the Purchaser’s Group) shall grant each relevant Transferred Employee a share-based award over shares in the capital of the Purchaser substantially equal in value (valued as at the date
of grant) to the value of the portion of their Relevant Awards which lapsed or was forfeited (or will lapse or be forfeited) as a result of Closing (valued as at the Closing Date), where relevant disregarding any loss (or expected loss) of
Tax-favourable treatment (each a “Compensation Award”). To the extent that (i) it could reasonably have been expected that any related matching share award and/or free share award would have been granted to a Transferred
Employee following Closing in connection with any Relevant Award which lapsed or was forfeited (or will lapse or be forfeited) as a result of Closing (each a “Relevant Matching Award”), and (ii) such Relevant Matching Award has
not been granted (or will not be granted) as a result of Closing, on or around the date on which such Relevant Matching Award would, in the ordinary course of business, have been made by the Seller (or member of the Seller’s Group), the
Purchaser (or member of the Purchaser’s Group) shall grant each relevant Transferred Employee a share-based award over shares in the capital of the Purchaser substantially equal in value (valued as at the date of grant) to the value of such
Relevant Matching Award (valued as at the date of grant of the related Matching Award, defined below), where relevant, disregarding any loss (or expected loss) of Tax-favourable treatment (each a “Matching Award”), subject to the
relevant plan rules and any Applicable Law. 

 Such Compensation Awards and Matching Awards shall be granted
pursuant to the rules of whichever share-based incentive plan operated by the Purchaser’s Group at the time of grant the Purchaser considers most closely aligned to the share-based incentive plan operated by the Seller’s Group pursuant to
which the related Relevant Award had been granted (or related Relevant Matching Award would have been granted) but will vest according to a vesting schedule substantially similar to the vesting schedule that would have otherwise applied to the
related Relevant Award or related Relevant Matching Award if Closing had not occurred. In such cases: 
  

	 	10.8.1	the Purchaser undertakes to seek any applicable Tax relief in respect of the Compensation Awards and Matching Awards and to indemnify the Seller in respect of
50 per cent. of any Tax relief obtained, provided always that the Seller provides the Purchaser with any information that the Purchaser may reasonably request in this respect in a timely manner; 

 

	 	10.8.2	where a Compensation Award or Matching Award is granted in the form of a restricted share award, the Purchaser undertakes to obtain a valid election pursuant to
section 431 of the Income Tax (Earnings and Pensions) Act 2003 (or, as applicable, any similar Tax election that is available pursuant to any Applicable Law in another jurisdiction), provided that, if either party makes representations to the other
party to waive this obligation in respect of certain Compensation Awards or certain Matching Awards and the other party consents to such waiver (such consent not to be unreasonably withheld), this paragraph 10.8.2 shall not apply in respect of
such Compensation Awards or Matching Awards; and 

  
 121

	 	10.8.3	the Seller agrees to indemnify the Purchaser (or relevant member of the Purchaser’s Group) for any Liabilities borne by the Purchaser’s Group in
connection with such Compensation Awards and Matching Awards, including any Tax, provided that: 

  

	 	(i)	the Seller shall not indemnify the Purchaser (or relevant member of the Purchaser’s Group) to the extent that the Purchaser (or member of the Purchaser’s
Group) compensates Transferred Employees for any loss (or expected loss) of Tax-favourable treatment in respect of Relevant Awards or for any Liabilities to Tax as contemplated in paragraph 10.9 below; 

 

	 	(ii)	the Seller only agrees to indemnify the Purchaser (or member of the Purchaser’s Group) to a maximum of 50 per cent. of the total of: (i) the value of the
portion of such Relevant Awards that lapsed or was forfeited (or will lapse or be forfeited) as a result of Closing, (ii) the value of the Relevant Matching Awards, and (iii) any related Liabilities, including any Tax; and

  

	 	(iii)	for the avoidance of doubt, the Seller shall not indemnify the Purchaser (or member of the Purchaser’s Group) for any lapse or forfeiture (or expected lapse or
forfeiture) due to a failure to meet any applicable performance (or other) conditions. 

 For these purposes, the
compensation in respect of the portion of a Relevant Award which lapsed or was forfeited (or will lapse or be forfeited) as a result of Closing shall not exceed the difference between (i) the value of the Relevant Award which could reasonably
have been expected to vest on the normal vesting date but for Closing (subject, where applicable, to performance (or other) conditions), and (ii) the value of the Relevant Award which actually vested (or will vest) as a result of Closing.

 For the purposes of this paragraph 10.8: 
  

	 	10.8.4	the portion of a Relevant Award which lapsed or was forfeited (or will lapse or be forfeited) as a result of Closing shall be valued on the basis of the average
price of an ordinary share in the capital of the Seller over the five trading days immediately prior to Closing; 

  

	 	10.8.5	the value of a Compensation Award to be granted shall be valued on the basis of the average price of an ordinary share in the capital of the Purchaser over the
five trading days immediately prior to the date of grant; 

  

	 	10.8.6	the value of a Relevant Matching Award shall be valued on the basis of the average price of an ordinary share in the capital of the Seller over the five trading
days immediately prior to the date of grant of the related Matching Award; 

  
 122

	 	10.8.7	the value of a Matching Award to be granted shall be valued on the basis of the average price of an ordinary share in the capital of the Purchaser over the five
trading days immediately prior to the date of grant; and 

  

	 	10.8.8	any currency conversion shall be made in accordance with Clause 1.12 of this Agreement. 

 

	10.9	To the extent that any payment to a Transferred Employee (whether by the Seller’s Group or by the Purchaser’s Group) would trigger Liabilities to Tax
under section 280G of the United States Internal Revenue Code (“Section 280G”), the relevant Transferred Employee shall be allowed to choose whether to accept the full payment (and pay any relevant Section 280G Tax) or to
receive such lower payment as may be necessary in order to fall below the Section 280G threshold for Tax. To the extent that any similar Tax would arise pursuant to any Applicable Law in another jurisdiction, this paragraph 10.9 shall
apply mutatis mutandis. 

  

	10.10	This paragraph shall apply where: (i) a Transferred Employee would, in the ordinary course of business, have been granted a share-based award pursuant to a
share-based incentive scheme operated by the Seller or another member of the Seller’s Group on the basis of performance criteria linked to the Seller’s Group’s 2014 financial year (which may, for the avoidance of doubt, be business
and/or individual performance criteria and assessment) (each a “2014 Performance Award”), and (ii) Closing occurs prior to the grant of such 2014 Performance Award. As soon as practicable following Closing (and, in any event,
by the later of 30 days from the Closing Date and 30 days from the date when the value of each 2014 Performance Award has been determined), the Seller shall notify the Purchaser in writing of the value of each 2014 Performance Award and under which
share-based incentive plan operated by the Seller’s Group the related 2014 Performance Award would have been granted. As soon as practicable following the receipt of such notice (and, in any event, by the later of 30 days from the receipt of
such notice and 30 days from the first date following the receipt of such notice when the granting of share-based awards is not prevented by dealing restrictions, subject in both cases to the relevant plan rules and any Applicable Law), the
Purchaser (or member of the Purchaser’s Group) shall grant each relevant Transferred Employee a share-based award over shares in the capital of the Purchaser substantially equal in value (valued as at the date of grant) to the value of the 2014
Performance Award which would have been granted but for the occurrence of Closing. Such 2014 Performance Awards shall be granted pursuant to the rules of whichever share-based incentive plan operated by the Purchaser’s Group at the time of
grant the Purchaser considers most closely aligned to the share-based incentive plan operated by the Seller’s Group pursuant to which the related 2014 Performance Award would have been granted. In such cases: 

 

	 	10.10.1	the Purchaser undertakes to seek any applicable Tax relief in respect of the 2014 Performance Awards and to indemnify the Seller in respect of any Tax relief
obtained, provided always that the Seller provides the Purchaser with any information that the Purchaser may reasonably request in this respect in a timely manner; 

 

	 	10.10.2	 where a 2014 Performance Award is granted in the form of a restricted share award, the Purchaser undertakes to obtain a valid election pursuant
to section 431 of the Income Tax (Earnings and Pensions) Act 2003 (or, as 

  
 123

	 	
applicable, any similar Tax election that is available pursuant to any Applicable Law in another jurisdiction), provided that, if either party makes representations to the other party to waive
this obligation in respect of certain 2014 Performance Awards and the other party consents to such waiver (such consent not to be unreasonably withheld), this paragraph 10.10.2 shall not apply in respect of such 2014 Performance Awards; and

  

	 	10.10.3	the Seller agrees to indemnify the Purchaser (or relevant member of the Purchaser’s Group) for any Liabilities borne by the Purchaser’s Group in
connection with such 2014 Performance Awards, including any Tax. 

 The grant of a 2014 Performance Award to a
Transferred Employee shall be taken into account by the Purchaser when determining the extent to which that Transferred Employee shall participate in incentive arrangements (other than any Compensation Award or Matching Award) operated by the
Purchaser’s Group following Closing. 
 For the purposes of this paragraph 10.10: 

 

	 	10.10.4	the value of a 2014 Performance Award to be granted shall: (i) be determined by the Seller acting reasonably and in good faith, (ii) be consistent with
past practice, (iii) take into account the relevant business and/or individual performance criteria linked to the Seller’s Group’s 2014 financial year, and (iv) if Closing occurs before 31 December 2014, be time pro-rated to
take account of the reduced period of time, as a proportion of the Seller’s Group’s 2014 financial year, that the relevant Transferred Employee worked within the Seller’s Group (calculated on the basis of the number of complete months
of service as at the Closing Date); 

  

	 	10.10.5	the number of shares to be placed under a 2014 Performance Award shall be valued on the basis of the average price of an ordinary share in the capital of the
Purchaser over the five trading days immediately prior to the date of grant; and 

  

	 	10.10.6	any currency conversion shall be made in accordance with Clause 1.12 of this Agreement. 

  
 124

 Schedule 9 
 Employee Benefits 
 (Clause 2.4.2) 

In this Schedule 9: 
 “Employee
Benefits” means benefits to or in respect of any current or former employee, including without limitation, any pension, early retirement, disability, death benefit, long service awards, termination indemnity (such as Italian TFR) or
post-retirement medical benefits or deferred compensation linked to retirement, disability or death benefits or old age part-time benefits (such as German ATZ) and jubilee payments. 
 “Employee Benefit Liabilities” means liabilities and obligations (whether funded or unfunded) in respect of any employee benefit promise, scheme, plan, fund, program, policy, practice or
other individual or collective arrangement providing Employee Benefits. 
 “Purchaser Funding Assumptions” means, in relation
to any Transferred Employee Benefits, where a member of the Purchaser’s Group provides, in the same country, a similar or comparable benefit programme to the programme to which the Transferred Employee Benefits relate (regardless of differences
in the terms of entitlement of accrual etc.), and there is a local obligation or practice prior to the date of this Agreement to pre-fund or externally fund those similar or comparable benefits to a funding target which is determined by reference to
a method and assumptions other than IFRS (such as would, for example, be the case in relation to UK HMRC-registered defined benefit pension obligations), then that method and those assumptions as in force in relation to those similar or comparable
benefits immediately prior to the date of this Agreement (so, taking the example of UK defined benefit obligations, this would be the method and assumptions used to determine the relevant plan’s technical provisions as at the date of this
Agreement – regardless of whether the plan is in fact fully funded on that basis at any relevant time). 
 “Purchaser IFRS
Assumptions” means, in relation to any Transferred Employee Benefits, where a member of the Purchaser’s Group provides, in the same country, a similar or comparable benefit programme to the programme to which the Transferred Employee
Benefits relate (regardless of differences in the terms of entitlement of accrual etc.), the method and assumptions used most recently prior to the date of this Agreement to value those similar or comparable benefits by the Purchaser’s Group
(or any relevant member thereof) for IFRS accounting purposes. 
 “Seller Funding Assumptions” means, in relation to any
Transferred Employee Benefits, if there is a local obligation or practice prior to the date of this Agreement to pre-fund or externally fund those Transferred Employee Benefits to a funding target which is determined by reference to a method and
assumptions other than IFRS (such as would, for example, be the case in relation to UK HMRC-registered defined benefit pension obligations), then that method and those assumptions as in force in relation to those Transferred Employee Benefits
immediately prior to the date of this Agreement (so, taking the example of UK defined benefit obligations, this would be the method and assumptions used to determine the relevant plan’s technical provisions as at the date of this Agreement
– regardless of whether the plan is in fact fully funded on that basis at any relevant time). 

  
 125

 “Seller IFRS Assumptions” means, in relation to any Transferred Employee Benefits, the
method and assumptions used by the Seller’s Group (or the most relevant member thereof) most recently prior to the date of this Agreement to value those Transferred Employee Benefits for IFRS accounting purposes. 

“Swiss Actuary” means an actuary: (a) who can reasonably be viewed: (i) as independent of both the Purchaser and the Seller;
and (ii) as familiar with Swiss pension issues; and (b) whom the Purchaser and the Seller have agreed should be jointly appointed by them for the purposes of determining the Swiss Assumptions or who in default of such agreement has been
appointed by the Swiss Association of Actuaries or other industry body of actuaries in Switzerland as agreed by the Seller and the Purchaser. 

“Swiss Assumptions” means, in relation to any Transferred Employee Benefits in Switzerland, the Seller IFRS Assumptions adjusted:

 (i) by replacing any assumed “cash balance” annuity conversion rate in the Seller IFRS Assumptions with a conversion rate which the
Swiss Actuary certifies to the Purchaser and the Seller as representing a reasonable estimate of the likely effective overall blended conversion rate which will apply in relation to the Transferred Employee Benefits in question, having regard to the
changes to the rate which can (having regard to longevity projections, legal and governance constraints around Swiss pension structures and such other matters as the Swiss Actuary considers relevant) in the Swiss Actuary’s opinion reasonably be
expected to occur during the expected service lives of the Transferred Employees to whom the Transferred Employee Benefits relate, and weighting the impact of those changes by reference to the ages of the relevant employees (and so the extent to
which the changes will in fact operate to reduce the effective liability on the Purchaser); and 
 (ii) by removing any reserve for death or
disability benefits to the extent that the Swiss Actuary certifies to the Purchaser and the Seller that it constitutes a reserve for liabilities to and in respect of the relevant Transferred Employees which could reasonably be externally insured by
the Purchaser without introducing a new ongoing cost on the Purchaser which was not reflected in the Seller’s ongoing cost base prior to the date of this Agreement. 
 “Vaccines Funding Assumptions” means, in relation to any Transferred Employee Benefits which are similar or comparable to benefits in the same country which are Transferred Employee
Benefits under the Vaccines Sale and Purchase Agreement (the “Equivalent Vaccines Benefits”), the method and assumptions used under the Vaccines Sale and Purchase Agreement to value those Equivalent Vaccines Benefits. For the
avoidance of doubt, the Vaccines Funding Assumptions are only available in respect of Transferred Employee Benefits for which there are Equivalent Vaccines Benefits. 
 For the purposes of each of the Purchaser Funding Assumptions, the Purchaser IFRS Assumptions, the Seller Funding Assumptions, the Seller IFRS Assumptions, the Swiss Assumptions (and, for the
avoidance of doubt, the Vaccines Funding Assumptions), any economic and financial assumptions which are based (whether expressly or implicitly) on yields, rates or indices shall be updated for the purposes of such definitions to take account of
those yields, rates or indices as at Closing (or the latest practicable time prior to Closing). 

  
 126

	1.	Except to the extent otherwise requested by the Seller and expressly agreed by the Purchaser before Closing (such Purchaser agreement not to be unreasonably
withheld to the extent that it is not reasonably possible for the Seller or its Affiliates to retain the relevant Employee Benefit Liabilities – for example, where liability unavoidably transfers by operation of law under European Council
Directive 2001/23/EC or its local implementing legislation), any Employee Benefit Liabilities in respect of service in the Business or with any member of the Seller’s Group or in any plan or arrangement in which any member of the Seller’s
Group participates or has participated: 

  

	 	(i)	(in the case of a Transferred Employee) prior to Closing; or 

  

	 	(ii)	(in the case of any other person) at any time, 

 (together, “Pre-Closing EB Liabilities”) will stay with or be assumed by the Seller or its Affiliates and the Seller shall fully indemnify the Purchaser and its Affiliates against any
such Employee Benefit Liabilities and against any liabilities and obligations to or in respect of any plan or arrangement for the provision of Employee Benefits in which any member of the Seller’s Group participates or participated prior to
Closing. For the avoidance of doubt, the Purchaser’s agreement under this paragraph 1 may, if the Purchaser so determines, relate only to certain specified categories or tranches of Pre-Closing EB Liabilities under a particular benefit
programme (in other words, it does not need to be “all or nothing”), in which case it is only those specified Pre-Closing EB Liabilities which are excluded from the scope of the Purchaser’s indemnity entitlement hereunder. 

 

	2.	Where and to the extent that the Purchaser agrees under paragraph 1 that any Pre-Closing EB Liabilities may transfer to or remain with the Purchaser and/or
its Affiliates (such Pre-Closing EB Liabilities being the “Transferred Employee Benefit Liabilities” and the benefits to which they relate being the “Transferred Employee Benefits”), the Purchaser will be
compensated in respect of such Transferred Employee Benefit Liabilities as set out in the rest of this Schedule 9. Subject to being so compensated but without prejudice to paragraphs 9 and 11, the Purchaser shall, or shall procure that its
relevant Affiliate shall, assume, with a full discharge for the Seller and its Affiliates, the Transferred Employee Benefit Liabilities. Without limiting the Purchaser’s obligation not unreasonably to withhold consent under paragraph 1 of
this Schedule 9 above, the Purchaser acknowledges its agreement to the principle that the post-retirement medical healthcare plan to which it admits US Transferred Employees who immediately before Closing were members of such a plan will take
account of periods of employment with the Seller’s Group to the extent previously recognised under the equivalent Seller’s Group plan for the purposes of determining eligibility, contributions, and vesting; again, therefore, subject to
appropriate identification during the period before Closing of such liabilities and to the operation of the compensation mechanism set out in this Schedule 9, they will become Transferred Employee Benefit Liabilities. 

  
 127

	3.	The value of the Transferred Employee Benefit Liabilities shall be determined on employee census data and plan provision as at Closing on the Vaccines Funding
Assumptions if available, but if not available then on: 

  

	3.1	in relation to any Transferred Employee Benefits in Switzerland, the Swiss Assumptions; and 

 

	3.2	in relation to any other Transferred Employee Benefits, the Seller IFRS Assumptions, PROVIDED that if any of the following values is available and is greater
than the value derived using the Seller IFRS Assumptions then that value will be used instead (and if more than one of these values is available then the one which would place the greatest value on the relevant Transferred Employee Benefit
Liabilities will be used): 

  

	 	3.2.1	if a member of the Purchaser’s Group provides, in the same country, a similar or comparable benefit programme to the programme to which the Transferred
Employee Benefits relate (regardless of differences in the terms of entitlement of accrual etc.), the value which is midway between the value based on the Seller IFRS Assumptions and the Purchaser IFRS Assumptions; 

 

	 	3.2.2	if there is a local obligation or practice prior to the date of this Agreement to pre-fund or externally fund the Transferred Employee Benefits to a funding
target which is determined by reference to a method and assumptions other than IFRS, the value derived using the Seller Funding Assumptions; and 

  

	 	3.2.3	if there is both: (i) a local obligation or practice prior to the date of this Agreement to pre-fund or externally fund the Transferred Employee Benefits to
a funding target which is determined by reference to a method and assumptions other than IFRS; and (ii) a member of the Purchaser’s Group provides, in the same country, a similar or comparable benefit programme to the programme to which
the Transferred Employee Benefits relate (regardless of differences in the terms of entitlement of accrual etc.), the value which is midway between the value based on the Seller Funding Assumptions and the Purchaser Funding Assumptions.

 The market value as at Closing of any underlying assets related to the Transferred Employee Benefit Liabilities
which are or are to be transferred as per paragraph 8 below will be deducted from the value of the Transferred Employee Benefit Liabilities to the extent such assets are or will be available to the Purchaser or its Affiliates to meet such
liabilities and the remaining value of the Transferred Employee Benefit Liabilities (if any) is the “Employee Benefit Indemnification Amount”. Such determination shall be carried out on a country-by-country basis and, where
necessary, on a plan-by-plan basis. If any Employee Benefit Indemnification Amount is greater than the estimate of such amount determined for the purposes of the Estimated Employee Benefit Adjustment (or, where no such estimate was made, greater
than zero), the Seller shall pay or procure payment (by way of a reduction in the Share Consideration) an amount equal to the difference (or, where no such estimate was made, such amount) to the Purchaser, or at the request of the Purchaser to an
Affiliate of the Purchaser, as compensation for the Transferred Employee Benefit Liabilities. If any Employee Benefit Indemnification Amount is less than the estimate of such amount determined for the purposes of the Estimated Employee Benefit
Adjustment (if any), the Purchaser shall pay an amount equal to the difference to the Seller. 

  
 128

	4.	The Seller and its Affiliates shall, within 45 days after Closing, provide its actuary, the Swiss Actuary and the actuary chosen by the Purchaser with all
relevant plan, asset, assumptions and employee census information needed to calculate the Employee Benefit Indemnification Amounts in respect of any Transferred Employees. The actuary chosen by the Seller shall provide the actuary chosen by the
Purchaser with its calculation of the Employee Benefit Indemnification Amounts (including, but not limited to, any supporting documentation on which it relied as well as the methodologies it employed in calculating the Employee Benefit
Indemnification Amounts), on a plan-by-plan basis, within 90 days following Closing. The actuary chosen by the Purchaser shall review the calculation of the Employee Benefit Indemnification Amounts of the Seller’s actuary within 120 days
following Closing. The Employee Benefit Indemnification Amounts shall be determined, on a plan-by-plan basis, by mutual agreement between the parties within 180 days following the Closing Date. 

 

	5.	If the parties cannot agree on any Employee Benefit Indemnification Amount within the 180-day period referred to in paragraph 4, the parties shall appoint
within 5 days an independent actuary acceptable to both parties, or such actuary shall be selected by the President of the Institute and Faculty of Actuaries in the UK if they cannot agree, and the independent actuary thus appointed shall review
their calculations and, within 75 days after appointment, render a final and binding decision on the amount of that Employee Benefit Indemnification Amount, and, in making such decision, shall be limited to adopting the position taken by either one
of the parties. The cost of any independent actuary shall be borne jointly by the parties. 

  

	6.	In connection with the procedures referred to in this Schedule 9, the parties shall provide each other and the actuaries referred to in this Schedule 9 with
access to the relevant business records and other relevant documents and information as may reasonably be requested. All documents, records and information provided for the purposes of this Schedule 9 must be accurate and complete in all material
respects. 

  

	7.	 Subject to Paragraph 3.2 of this Schedule, each Employee Benefit Indemnification Amount shall be paid by the Seller (by way of a reduction in
the Share Consideration) within 14 days following its final determination. The Seller may make an accelerated or advance payment at its own discretion (which, for the avoidance of doubt, includes in relation to each Employee Benefit Indemnification
Amount so much (if any) of the Estimated Employee Benefit Adjustment as the Seller notified pursuant to Clause 6.3.8 was intended to relate to that Employee Benefit Indemnification Amount). Each Employee Benefit Indemnification Amount shall
include interest calculated from (and including) the Closing Date to (and including) the date of payment at a rate per annum of LIBOR (but where amounts are prepaid or paid in stages or treated as

  
 129

	 	
paid via inclusion in the Estimated Employee Benefit Adjustment then the interest will cease to accrue on so much of the Employee Benefit Indemnification Amount as has been paid). Such interest
shall accrue from day to day. Any such payment shall be made in US dollars (and any underlying values shall be expressed in US dollars) and any currency other than US dollars shall be converted into US dollars at the exchange rates determined in
accordance with Clause 1.12 of this Agreement on the Closing Date. 

  

	8.	To the extent (if any) that there are any Transferred Employee Benefit Liabilities which prior to Closing were externally funded by assets held in a trust or
other vehicle established for the purposes of meeting such Transferred Employee Benefit Liabilities, the Purchaser will, if requested by the Seller before Closing and unless it is not reasonably practicable to do so, establish or nominate a trust or
other vehicle which is capable of receiving a transfer of assets from the pre-Closing trust or other vehicle to the extent that such assets relate to the Transferred Employee Benefit Liabilities. 

 

	9.	If, within one year of Closing, the Seller or the Purchaser notifies the other that the membership or other benefit data (the “Data”) used for
calculating any Employee Benefit Indemnification Amount may be inaccurate, then a “Data Dispute” has arisen and the following provisions shall apply: 

 

	 	(i)	On such notification, the Seller shall procure that its actuary and the Purchaser shall procure that its actuary consult each other with a view to agreeing whether the
Data is inaccurate and if so, what the accurate Data should be. If the Seller’s actuary and the Purchaser’s actuary agree that the Data is inaccurate, they will jointly certify this to be the case and advise on what the accurate Data
should be. The notification is deemed to have occurred on the date of the certification. 

  

	 	(ii)	If the Seller’s actuary and the Purchaser’s actuary fail to agree whether the Data is inaccurate within 60 days of the notification by one party to the other
that the Data may be inaccurate, paragraph 5 shall apply mutatis mutandis. The notification is deemed to have occurred when the independent actuary advises that the Data is inaccurate and what the accurate Data should be.

  

	 	(iii)	On the occurrence of the Data Dispute, the Seller and the Purchaser shall respectively procure that a valuation of the relevant Employee Benefit Indemnification Amount
is carried out in accordance with paragraphs 3 and 4 (mutatis mutandis) but on the basis of the accurate Data as agreed under sub-paragraph (i) or determined under sub-paragraph (ii). 

 

	 	(iv)	 If as a consequence of sub-paragraph (iii), the Seller has paid to the Purchaser an amount which on the basis of the further valuation is not
payable, such amount (the “Overpayment”) shall be repaid within 21 days of the amount of the Overpayment being agreed or determined. Any such payment 

  
 130

	 	
shall bear interest calculated from (and including) the date the Overpayment was made to (and including) the date the payment is made in full in accordance with this sub-paragraph (iv) at a
rate per annum of LIBOR. Such interest shall accrue from day to day. 

  

	 	(v)	If as a consequence of sub-paragraph (iii), the Seller has not paid to the Purchaser an amount which on the basis of the further valuation is payable, such amount
(the “Outstanding Amount”) shall be paid within 21 days of the amount of the Outstanding Amount being agreed or determined. Any such payment shall bear interest calculated from (and including) the Closing Date to (and including) the
date the payment is made in full in accordance with this sub-paragraph (v) at a rate per annum of LIBOR. Such interest shall accrue from day to day. 

  

	10.	Except as otherwise agreed by the Seller, the Purchaser shall where a trust or other vehicle has been established under paragraph 8, procure that all of the
assets transferred as envisaged by paragraph 8 are paid into such trust or other vehicle. If, after such payment or transfer, or after payment of an Employee Benefit Indemnification Amount or after making an Estimated Employee Benefit
Adjustment, the Purchaser and/or its Affiliates achieves a reduction in its liability to any Tax in respect of or in connection with the payment or transfer, the Purchaser shall pay to Seller (for itself or on behalf of the relevant Business Seller
or Share Seller as applicable), within 30 days after the Purchaser would otherwise have been liable to pay the saved Tax, a sum equal to the amount of that Tax reduction by way of an increase in the Share Consideration. This paragraph 10
applies for a period of four years following the later of the date on which a transfer of assets is made, or payment of any Employee Benefit Indemnification Amount or Estimated Employee Benefit Adjustment is made to the Purchaser.

  

	11.	The Seller covenants with the Purchaser to pay to the Purchaser an amount equal to any cost, claim or liability incurred by any member of the Purchaser’s
Group which it is or becomes liable to make on or at any time after Closing by reason of any change or purported change made to the terms of any Transferred Employee Benefits prior to Closing proving to be or have been legally ineffective or by
reason of such terms and/or benefits failing to comply with any mandatory legal requirements (excluding any obligation to equalise guaranteed minimum pensions in the United Kingdom). The Seller shall not be liable under this paragraph 11
in respect of any individual claim (or a series of claims arising from similar or identical facts or circumstances) unless the liability in respect of such claim or series of claims exceeds US$100,000. If the Purchaser becomes aware of any fact,
matter or circumstance that may give rise to a claim against the Seller under this paragraph 11 the Purchaser shall as soon as reasonably practicable give notice in writing to the Seller of such facts, matters or circumstances as are then
available regarding the potential claim. Failure to give such notice within such period shall not affect the rights of the Purchaser to make a relevant claim under this paragraph 11, except that the Seller shall not be liable for any increase
in the amount of such claim arising from such failure. The latest date on which the Purchaser may give notice of a claim under this paragraph 11 is the fourth anniversary of the Closing Date. 

  
 131

	12.	Notwithstanding any general provision to the contrary in Schedule 8 and subject to being compensated in accordance with this Schedule 9, the Purchaser shall
admit Transferred Employees in the United States who participated in a post-retirement medical plan immediately prior to Closing to its own post-retirement medical plan. Subject to being compensated in accordance with this Schedule 9, periods of
employment with the Seller’s Group (including, without limitation, any current or former Affiliate of the Seller, to the extent previously recognised under the applicable benefit plan arrangement provided by the Seller’s Group), shall be
taken into account for the purposes of determining, as applicable, the eligibility for participation, contributions, and vesting for any employee under such post-retirement medical plan. 

 

	13.	Notwithstanding any general provision to the contrary in Schedule 8, the US Transferred Employees shall, as of the Closing Date, become eligible to participate
in a US tax-qualified defined contribution plan to the extent such plan is sponsored by the Purchaser or a relevant member of the Purchaser’s Group. The Purchaser agrees that it will use commercially reasonable efforts to cause such plan to
accept rollovers of the account balances of the US Transferred Employees (including participant loan promissory notes) from the relevant employer’s tax-qualified retirement plans; provided that (i) the Purchaser will not be required to
accept any such rollovers that might result in material liability to the Purchaser or may otherwise cause the relevant plan to cease to qualify under Section 401(a) of the Code and (ii) the Purchaser will not be required to amend any plan
to permit participant loans. 

  

	14.	By way of exception to the general principle at paragraph 1, where a UK Transferred Employee who had joined service with the Seller’s Group before
1 April 2005 is made redundant within 24 months of Closing, then the Purchaser shall pay the Seller an amount equal to the cost of applying the Agreed UK Restructuring Arrangement to an employee of the employee’s actual age at the date he
is made redundant, but only to so much of the employee’s benefits in a Seller’s Group plan as were accrued prior to Closing; and provided further that the Purchaser’s aggregate liability under this paragraph in respect of all such UK
Transferred Employees who are so made redundant is capped at £1 million. This cost shall be calculated on a basis consistent with that which is used across the Seller’s Group retained business for internal cost-charging purposes in
relation to the Agreed UK Restructuring Arrangement, and the Seller shall supply the Purchaser with such evidence as the Purchaser may reasonably require to verify that. Subject to receipt of such payment, the Seller shall apply the Agreed UK
Restructuring Arrangement to the relevant employee’s Seller’s Group plan benefits. This provision shall cease to apply 24 months after Closing, whereafter the Purchaser shall procure that neither it nor its Affiliates offers or indicates
the availability of the Agreed UK Restructuring Arrangement to any Transferred Employee. 

  
 132

	15.	The parties agree that where any Transferred Employee has accrued defined contribution benefits prior to Closing in a Seller’s Group arrangement then:

  

	 	(i)	the Seller shall use commercially reasonable efforts to procure the vesting of those benefits (if they would otherwise lapse as a result of Closing);

  

	 	(ii)	the parties shall, provided this will not impose unreasonable administrative burdens on the Purchaser’s Group, co-operate in good faith to procure a transfer of
the account balances of such Transferred Employee from the Seller’s Group arrangement to a Purchaser’s Group arrangement; and 

  

	 	(iii)	for the avoidance of doubt, the Purchaser will comply with the provisions of paragraph 6.1 of Schedule 8. 

  
 133

 Schedule 10 
 Allocation 
 (Clause 3.2) 

 

	1.	The Seller and the Purchaser agree that to the extent it is necessary for Tax purposes to allocate any amount as between: 

 

	1.1	all of the Products, such amount shall be allocated for those Tax purposes as between the Products in proportions reflected as whole number percentages, to be
agreed in accordance with the remaining paragraphs of this Schedule 10; or 

  

	1.2	some but not all of the Products, such amount shall be allocated for those Tax purposes as between those particular Products in accordance with the relative
proportions reflected in the whole number percentages agreed in accordance with the remaining paragraphs of this Schedule 10. 

  

	2.	The Seller shall prepare, or procure the preparation of, a draft of the Allocation Statement, which shall be delivered to the Purchaser within 105 Business Days
of the date of this Agreement (the “Draft Allocation Statement”). 

  

	3.	The Purchaser shall have a period of 20 Business Days (the “Review Period”) after the delivery to it of the Draft Allocation Statement to review
the Draft Allocation Statement and may at any time during the Review Period request (in writing to the Seller) an adjustment to be made to any amount set out therein (an “Adjustment Request”). 

 

	4.	If no Adjustment Request is presented to the Seller within the Review Period, the Draft Allocation Statement shall be deemed to have been agreed and approved by
the Seller and the Purchaser, shall be final and binding upon them and shall constitute the “Allocation Statement” for the purposes of this Agreement. 

 

	5.	If an Adjustment Request is presented to the Seller within the Review Period: 

 

	5.1	the Purchaser and the Seller shall attempt to resolve the matter in dispute between them in good faith negotiations and before the date falling 20 Business Days
before Closing; and 

  

	5.2	in the event that the Purchaser and the Seller fail to agree the matter in dispute between them within 10 Business Days following delivery to the Seller of the
Adjustment Request, and unless the Seller and the Purchaser agree in writing to extend the period in which they may agree such allocation (subject to such extension not falling past Closing), the matter will be referred to the Reporting Accountants,
to be instructed jointly by the Purchaser and the Seller to determine the relevant allocation as soon as practicable and in any case before the date falling five Business Days before Closing. 

  
 134

	6.	If following agreement or determination of the Allocation Statement in accordance with paragraphs 4 and 5, the consideration payable by the Purchaser under
this Agreement is adjusted in accordance with any provision of this Agreement or any Ancillary Agreement: 

  

	6.1	if the adjustment of the consideration payable by the Purchaser relates specifically to one or more, but not all, of the Products, or relates to all of the
Products but to some more than others, the Purchaser and the Seller shall discuss in good faith the extent to which the percentage proportion allocated to the Products shall be adjusted and the Allocation Statement shall be amended to reflect the
outcome of those discussions (unless no agreement is reached, in which case paragraph 5.2 shall apply mutatis mutandis). 

  

	7.	The agreed or determined allocation set out in the Allocation Statement (as adjusted, where applicable) at Closing shall be binding on the parties and the
Purchaser and the Seller, or as the case may be, the Company, the Share Seller, the relevant Business Seller and the Purchaser, shall: 

  

	7.1	not in any Tax Return, or other document or filing, or in any Tax proceeding, take a position in relation to any of the allocation set out therein which is
inconsistent with the agreed or determined allocation; and 

	7.2	where reasonably necessary, make joint elections or otherwise cooperate in good faith to have the agreed or determined allocation respected for applicable Tax
purposes by any relevant Tax Authority. 

  

	8.	For the avoidance of doubt, it is understood and agreed by the parties that any valuation of the Products used in order to determine the allocation pursuant to
this Schedule 10 is not intended to be, and shall not be interpreted as, any assurance by any party as to the value of the Products (including the related assets and liabilities) being transferred. 

  
 135

 Schedule 11 
 VAT 
  

	1.	VAT: Records 

  

	1.1	The Seller, the Share Seller or any Business Seller may, on or before the Closing Date, obtain a direction from the relevant Tax Authority for the retention and
preservation by it of any VAT records relating to its period of ownership of the Business or the Share (as the case may be) and, where any such direction is obtained, the Seller undertakes to, or to procure that the relevant Business Seller or the
Share Seller (as the case may be) will: 

  

	 	1.1.1	preserve the records to which that direction relates in such a manner and for such period as may be required by the direction or by Applicable Law; and

  

	 	1.1.2	allow the Purchaser, upon the Purchaser giving reasonable notice, reasonable access to and copies of such records where reasonably required by the Purchaser for
its Tax purposes. 

  

	1.2	If no such direction as is referred to in paragraph 1.1 above is obtained before the Closing Date and any documents in the possession or control of a member
of the Seller’s Group are required by law to be preserved by the Purchaser, the Seller shall, as soon as reasonably practicable after Closing, deliver such documents to the Purchaser. 

 

	2.	VAT: Going Concern - EU Member States 

  

	2.1	The Seller and the Purchaser shall use reasonable endeavours (including, for the avoidance of doubt, the making of an election or application in respect of VAT
to any Tax Authority or entering into a written agreement) to secure that, to the extent reasonably possible, the sale of all or any part of the Business, so far as carried on in the European Union, is treated as neither a supply of goods nor a
supply of services for the purposes of the laws governing VAT in each relevant member state. 

  

	2.2	Each Business Seller shall have the right to seek a ruling from the relevant Tax Authority as to whether the sale of all or part of the Business, so far as
carried on in the relevant member state, should be treated as neither a supply of goods nor a supply of services for the purposes of the laws governing VAT in that member state and to account for VAT (and accordingly to seek an additional payment
from the Purchaser under Clause 3.3.3) in accordance with that ruling. The Seller shall not be obliged to challenge (or to procure that any relevant Business Seller challenges) that ruling unless required to do so by the Purchaser. If the
Purchaser wishes to challenge, or to require the relevant Business Seller to challenge, any such ruling it may do so, provided that it bears the full cost of, and agrees to indemnify the relevant Business Seller in respect of any loss arising from
or in connection with, that challenge and that such challenge shall not affect the date on which VAT must be paid to the Seller under paragraph 4 below. 

  
 136

	2.3	Insofar as no ruling has been obtained from a relevant Tax Authority prior to Closing, the Seller shall determine in good faith if (or the extent to which) VAT
is payable in respect of the sale of the Business and shall be entitled to charge (or not to charge) VAT to the Purchaser in accordance with such determination. 

 

	3.	VAT: Going Concern - non-EU Jurisdictions 

 

	3.1	To the extent that any state outside the European Union provides for relief or exemption from VAT on the transfer of a business or a company or treats such a
transaction as being non-taxable for VAT purposes, the Seller and the Purchaser shall use reasonable endeavours (including, for the avoidance of doubt, the making of an election or application in respect of VAT to any Tax Authority or entering into
a written agreement) to secure such relief, exemption or treatment, to the extent reasonably possible, as regards the sale of all or part of the Business (insofar as carried on in the relevant state) under this Agreement. 

 

	3.2	The relevant Business Seller shall have the right to seek a ruling from the relevant Tax Authority as to whether the sale of all or part of the Business, so far
as carried on in the relevant state, is eligible for a relief or exemption or is otherwise eligible to be treated as non-taxable for the purposes of the laws governing VAT in that state and to account for VAT (and accordingly seek an additional
payment from the Purchaser under Clause 3.3.3 in accordance with that ruling). The Seller shall not be obliged to challenge (or to procure then the relevant Business Seller challenges) that ruling unless required to do so by the Purchaser. If
the Purchaser wishes to challenge, or to require the relevant Business Seller to challenge, any ruling it may do so, provided that it bears the full cost of, and agrees to indemnify the relevant Business Seller in respect of any loss arising from or
in connection with, that challenge and that such challenge shall not affect the date on which VAT must be paid to the Seller under paragraph 4 below. Insofar as no ruling has been obtained from a relevant Tax Authority prior to Closing, the
Seller shall determine in good faith if (or the extent to which) VAT is payable in respect of the sale of the Business and shall be entitled to charge (or not to charge) VAT to the Purchaser in accordance with such determination.

  

	4.	VAT: Time, Manner and Currency of Payment 

  

	4.1	Any amounts which the Purchaser is obliged to pay to the Seller under this Agreement in respect of VAT shall be paid by the Purchaser, on its own account or on
behalf of another member of the Purchaser’s Group, to the Seller or to such member of the Seller’s Group as the Seller may direct. Such amounts shall be paid in the currency in which the VAT in question must be accounted for to the
relevant Tax Authority. 

  

	4.2	Subject to any provision or express agreement to the contrary, any amounts in respect of VAT payable in any jurisdiction in respect of the transfer at Closing of
any of the Business shall be paid in accordance with paragraph 4.1 above at Closing against production of a valid VAT invoice (or equivalent, if any). 

  
 137

	4.3	Notwithstanding any other provision of this Agreement, the Purchaser shall not be liable to account to the Seller or any member of the Seller’s Group for or
in respect of penalties or interest arising solely from the failure of the Seller or any other member of the Seller’s Group to account promptly for VAT to the relevant Tax Authority following the Seller having been placed in the appropriate
amount of funds for that purpose by the Purchaser. 

  
 138

 Schedule 12 
 Closing Obligations 
  

	1.	General Obligations 

  

	1.1	The Seller’s Obligations 

 On Closing, the Seller shall deliver or make available to the Purchaser the following: 
  

	 	1.1.1	the Ancillary Agreements (other than the France SPA and the Netherlands APA and any other Ancillary Agreements that have not been agreed and are subject to
Clause 5.3.2) duly executed by the relevant members of the Seller’s Group (save that, without prejudice to any other applicable provisions of this Agreement including without limitation paragraph 1.3, Part 2 of Schedule 19, no Intellectual
Property Assignment Agreements shall be required in respect of Owned Product Intellectual Property Rights); 

  

	 	1.1.2	a valid power of attorney or such other evidence reasonably satisfactory to the Purchaser that the Seller, and each of its relevant Affiliates, are authorised to
execute this Agreement, the Ancillary Agreements and the Local Transfer Documents (including, where relevant, any notarial deeds referred to in this Schedule 12), in each case to the extent that they are parties thereto; 

 

	 	1.1.3	the Certificate duly executed by the Seller; 

  

	 	1.1.4	a duly executed transfer in respect of the Share in favour of the Purchaser (or its Affiliate or its nominee); 

 

	 	1.1.5	a power of attorney in the terms agreed between the Seller and the Purchaser to allow the Purchaser (or its Affiliate or its nominee) to vote the Share;

  

	 	1.1.6	the statutory books of the Company (which shall be written up to but not including the Closing Date), the certificate of incorporation of the Company and share
certificate in respect of all the issued share capital of the Company; 

  

	 	1.1.7	indemnities directly in favour of the Company in the form of Clause 2.3.6 and of the Company Tax Indemnity, mutatis mutandis; and 

 

	 	1.1.8	the interim accounts of the Company as at the Closing Date which reflect the Company Intra-Group Debt. 

 

	1.2	In addition, the Seller shall procure: 

  

	 	1.2.1	any then present directors and officers (if any) of the Company resign their offices to take effect at the Closing Date as such and to relinquish any rights
which they may have under any contract with the Company or under any statutory provisions (including any right to damages or compensation for breach of contract, loss of office, redundancy or unfair dismissal or on any other account whatsoever) and
to confirm that no agreement or arrangement is outstanding under which the Company has or could have any obligation to any of them including in respect of remuneration or expenses; 

  
 139

	 	1.2.2	the present auditors of the Company to resign their office as such, such resignations to take effect as at the Closing Date; and 

 

	 	1.2.3	a board meeting of the Company is held, or written resolutions of the board are passed, at or by which: 

 

	 	(i)	it shall be resolved that the transfer relating to the Share shall, so far as possible, be approved for registration; and 

 

	 	(ii)	any person nominated by the Purchaser shall be appointed director, such appointments to take effect on the Closing Date. 

 

	1.3	The Purchaser’s Obligations 

 On Closing, the Purchaser shall deliver or make available to the Seller the following: 
  

	 	1.3.1	the Ancillary Agreements (other than the France SPA and the Netherlands APA and any other Ancillary Agreements that have not been agreed and are subject to
Clause 5.3.2) duly executed by the relevant members of the Purchaser’s Group; and 

  

	 	1.3.2	a valid power of attorney or such other evidence reasonably satisfactory to the Seller that the Purchaser, and each of its relevant Affiliates, are authorised to
execute this Agreement and the Ancillary Agreements (as appropriate), in each case to the extent that they are parties thereto. 

  

	1.4	Discharge of the Company Intra-Group Debt 

 Immediately following the above, the amount held by the Seller as a result of the payment by the Purchaser pursuant to Clause 6.3.1(ii) shall be applied to the settlement by the Purchaser (as agent for
the Company) of the Company Intra-Group Debt. 
  

	2.	Transfer of the Assets 

  

	2.1	General Transfer Obligations 

 On Closing or such other date as agreed between the parties, the Seller shall procure that the Business Sellers shall, and the Purchaser shall, take such steps as are required to transfer the Assets and
Assumed Liabilities not held by the Company in accordance with this Agreement. 

  
 140

 Schedule 13 
 Not Used 

  
 141

 Schedule 14 
 Warranties given under Clause 9.1 
  

	1.	Authority and Capacity 

  

	1.1	Incorporation 

  

	 	1.1.1	The Seller and each Business Seller is validly existing and is a company duly incorporated and registered under the law of its jurisdiction of incorporation.

  

	 	1.1.2	The Company is duly incorporated, validly existing and in good standing, under the laws of its jurisdiction of organisation. 

 

	1.2	Authority to enter into Agreement 

  

	 	1.2.1	The Seller has the legal right and full power and authority to enter into and perform this Agreement and the Seller, the Share Seller, each Business Seller and
the Company has the legal right and full power and authority to enter into and perform any other documents to be executed by it pursuant to or in connection with this Agreement. 

 

	 	1.2.2	The documents referred to in paragraph 1.2.1 will, when executed, constitute valid and binding obligations on the Seller, the Share Seller, each Business
Seller and the Company in accordance with their respective terms. 

  

	 	1.2.3	Except as referred to in this Agreement the Seller: 

  

	 	(i)	is not required to make any announcement, consultation, notice, report or filing; and 

 

	 	(ii)	does not require any consent, approval, registration, authorisation or permit, in each case in connection with the performance of this Agreement or any other document
referred to in paragraph 1.2.1. 

  

	 	1.2.4	The execution and delivery of the documents referred to in paragraph 1.2.1 and the performance by the Seller, the Share Seller, each Business Seller and the
Company of their respective obligations under them, will not: 

  

	 	(i)	result in a breach of any provision of the memorandum or articles of association or by laws or equivalent constitutional document of the relevant member of the
Seller’s Group; 

  

	 	(ii)	result in a breach of, or constitute a default under, any instrument or contract to which the relevant member of the Seller’s Group is party or by which the
relevant member of the Seller’s Group is bound where such breach is material to their ability to perform their obligations under such documents; 

  

	 	(iii)	result in a breach of any existing order, judgment or decree of any court, Governmental Entity by which the relevant member of the Seller’s Group is bound and
where such breach is material to their ability to perform their obligations under such documents. 

  
 142

	1.3	Authorisation 

 The
Seller, the Share Seller, each Business Seller and the Company has taken, or will have taken by Closing, all corporate action required by it to authorise it to enter into and to perform this Agreement, any Ancillary Agreement to which it is a party
and any other documents to be executed by it pursuant to or in connection with this Agreement or any Ancillary Agreement. 
  

	2.	Warranties relating to the Business 

  

	2.1	Organisation and Standing of the Assets 

  

	 	2.1.1	Schedule 1 sets out a complete and accurate list of each of the Products, together with details of each Product Expansion which is a combination study and which
is the subject of a phase II or later clinical trial. 

  

	 	2.1.2	The summary details relating to the Products set out in Schedule 1 are true and accurate. 

 

	2.2	The Assets and the Share 

  

	 	2.2.1	Save in relation to the Transferred Product Intellectual Property Rights, either the Seller or one of the Business Sellers has good and valid title to the
Assets, free and clear of all Encumbrances other than Permitted Encumbrances. 

  

	 	2.2.2	GGL is the legal and beneficial owner of the Share. 

  

	 	2.2.3	There is no option, right to acquire, mortgage, charge, pledge, lien or other form of security or Encumbrance or equity on, over or affecting the Share and there
is no agreement or commitment to give or create any. 

  

	 	2.2.4	The Share has been duly authorised and validly issued and is fully paid and non-assessable. There are no options, warrants, rights, convertible, exercisable or
exchangeable securities, “phantom” stock rights, stock appreciation rights, stock-based performance units, commitments, Contracts, arrangements or undertakings of any kind to which any member of the Seller Group is a party or by which it
is bound obligating any member of the Seller Group to issue, deliver or sell, or cause to be issued, delivered or sold, additional shares of capital stock or other equity interests in, or any security convertible into, or exercisable or exchangeable
for, any capital stock of, or other equity interest in, the Company. 

  

	 	2.2.5	There are no outstanding Contracts to which any member of the Seller Group is a party or is otherwise bound to repurchase, redeem or otherwise acquire any
shares, capital stock or other equity interest of the Company. 

  

	 	2.2.6	The Share is not subject to and was not issued in violation of any purchase option, call option, right of first refusal, pre-emptive right, subscription right or
similar right or any provision of Applicable Law or the constitutional documents of the Company. 

  
 143

	2.3	Key Financial Information 

  

	 	2.3.1	The Key Financial Information has been prepared by the Seller: 

 

	 	(i)	in good faith and with all due care and attention; 

  

	 	(ii)	in a manner applying the accounting policies and practices of the Seller’s Group on a consistent basis; 

 

	 	(iii)	in accordance with International Financial Reporting Standards as adopted by the European Union; 

 

	 	(iv)	is based on information properly extracted from the Seller’s Group accounting records without adjustment; and 

 

	 	(v)	having regard to the purpose for which they were prepared, the Key Financial Information presents fairly, in all material respects, the gross profit and revenue in
respect of each of the Key Products. 

  

	2.4	Changes Since 31 December 2013 

 Except as a result of the execution and delivery of this Agreement from 31 December 2013 to the date of this Agreement: 

 

	 	2.4.1	the Business has been conducted in all material respects in the ordinary and usual course; 

 

	 	2.4.2	no member of the Seller’s Group has entered into any material contract or commitment outside the ordinary course of business in respect of the Business as
conducted prior to 31 December 2013; and 

  

	 	2.4.3	to the Seller’s knowledge, there has been no event or circumstance arising which is reasonably likely to have had a Material Adverse Effect (as if reference
in the definition of “Material Adverse Effect” to the date of this Agreement were to 31 December 2013). 

  

	3.	Intellectual Property 

  

	3.1	Part 1 of Schedule 2 sets out a complete and accurate list of each item of Registered Business Product Intellectual Property Rights, including for each such
item, as applicable, (i) the identity of the record owner, (ii) the registration or application number, and (iii) the jurisdiction of issuance or registration. To the Seller’s Knowledge, all Patents forming part of Registered
Business Product Intellectual Property Rights for the Key Products and all Patents forming part of Registered Licensed Product Intellectual Property Rights for the Key Products are subsisting, valid and enforceable and have not lapsed or been
abandoned. 

  

	3.2	All documents and instruments necessary to maintain and preserve any extension of patent terms (including any Patent Term Extensions and Patent Term Adjustments)
in relation to (i) Registered Business Product Intellectual Property Rights with respect to the Key Products; and (ii) Registered Licensed Product Intellectual Property Rights with respect to the Key Products where the Seller or its
Affiliates controls prosecution and maintenance; and in each case, where such applications have a reasonable prospect of success, have been validly executed, delivered, and filed in a timely manner with the appropriate Governmental Entity. For the
purposes of this warranty, the Patent Term Extension application relating to patent number US7378423 shall be deemed to have a reasonable prospect of success. 

  
 144

	3.3	Each of the patents and patent applications included in the Registered Business Product Intellectual Property Rights for the Key Products and, to the
Seller’s Knowledge, in the Registered Licensed Product Intellectual Property Rights for the Key Products, correctly identifies by name each inventor thereof as determined in accordance with the Applicable Law of each jurisdiction in which such
patent issued and/or patent application is pending. 

  

	3.4	All renewal, application and registry fees required for the maintenance, prosecution and enforcement of the Business Product Intellectual Property Rights
relating to the Key Products have been paid. 

  

	3.5	Part 2 of Schedule 2 sets out a complete and accurate list of each material Transferred Intellectual Property Contract. No member of the Seller’s Group is
in default under any such Transferred Intellectual Property Contract and, to the Seller’s Knowledge, no third party is in default under any such material Transferred Intellectual Property Contract nor has the Seller nor any of its Affiliates
given, or received, written notice to terminate any such Transferred Intellectual Property Contract. 

  

	3.6	The Seller and its Affiliates between them own all Business Product Intellectual Property Rights free of all Encumbrances except Permitted Encumbrances.

  

	3.7	To the Seller’s Knowledge, the manufacture, use, research, development, marketing, distribution, and sale of the Products does not infringe or
misappropriate any Intellectual Property Rights of any third party and neither the Seller nor any of its Affiliates is a party to any Proceeding (public or private) in relation to such infringement or misappropriation under which the same is
alleged. Neither the Seller nor any of its Affiliates has received any written notice of such infringement or misappropriation. 

  

	3.8	To the Seller’s Knowledge, no person (including any employees and former employees of the Seller or its Affiliates) is infringing or misappropriating any
Business Product Intellectual Property Rights, Registered Licensed Product Intellectual Property Rights under the Genmab Agreement, Registered Licensed Product Intellectual Property Rights under the JTI Agreement or Proprietary Information, and
neither Seller nor any of its Affiliates have made any such claims against any such person nor, to the Seller’s Knowledge, is there any basis for such a claim. 

 

	3.9	The Business Product Intellectual Property Rights, the Shared Product Intellectual Property Rights and the Licensed Product Intellectual Property Rights
constitute all the material Intellectual Property Rights used in the manufacture, use, research, development, marketing, distribution and sale of the Products as currently conducted by the Seller and its Affiliates on a worldwide basis, provided
however that the foregoing is not a representation of non-infringement, non-misappropriation or any other non-violation of Intellectual Property Rights of any third party, which representation is solely set out in paragraph 3.7 above.

  
 145

	3.10	Each of the Seller and its Affiliates has taken reasonable steps to protect the confidentiality of Proprietary Information and Know-How relating to the Products.

  

	3.11	Except to the extent the Seller is prohibited from doing so under Applicable Law, all material information relating to the COMBI-D trial has been disclosed to
the Purchaser and there are no material omissions or inaccuracies in such material. 

  

	4.	Contracts 

  

	4.1	No Business Seller nor the Company is a party to or subject to any contract, transaction, arrangement, understanding or obligation (other than in relation to any
property, lease, contract of employment, Information Technology or Intellectual Property Right) which is material to the manufacture, use, research, development, marketing, distribution and sale of the Products and which: 

 

	 	4.1.1	is not in the ordinary course of business or is unduly onerous; 

  

	 	4.1.2	is not on an arm’s length basis; 

  

	 	4.1.3	has an unexpired term or likely duration of 5 years or more; 

  

	 	4.1.4	restricts its freedom to carry on its business in any part of the world in such manner as it thinks fit; 

 

	 	4.1.5	involves an aggregate outstanding expenditure by it of more than US$50 million, exclusive of VAT; or 

 

	 	4.1.6	involves the sale of goods and services, the aggregate sales value of which (exclusive of VAT) will be more than 5 per cent of turnover of the Business
(exclusive of VAT) for the preceding financial year. 

  

	4.2	Save in relation to a Transferred Intellectual Property Contract, no member of the Seller’s Group is in material default under any material Contract which
is relevant to the Business and to which it is party, and no third party is in material default under any material Contract which is relevant to the Business to which a member of the Seller’s Group is a party, and to the Seller’s
Knowledge, there are no circumstances in either case likely to give rise to such a default. 

  

	4.3	Other than the Contracts entered into by the Company pursuant to the Pre-Closing Product Reorganisation, Transferred Contracts and Shared Business Contracts (and
excluding the Transferred Intellectual Property Contracts) there are no other Contracts which are material to the Business. 

  

	5.	Agreements with Connected Parties 

  

	5.1	There are no existing contracts or arrangements material to the Business between, on the one hand, any Business Seller or the Company and, on the other hand, the
Seller or any member of the Seller’s Group other than on normal commercial terms in the ordinary course of business. 

  
 146

	6.	Sufficiency of Assets 

  

	6.1	Each of the Assets and the Owned Product Intellectual Property Rights is owned both legally and beneficially by a Business Seller or the Company and each of
those Assets and the Owned Product Intellectual Property Rights capable of possession is, save where in the possession of third parties in the ordinary course of business, in the possession of a Business Seller or the Company.

  

	6.2	Save for Permitted Encumbrances, no option, right to acquire, mortgage, charge, pledge, line or other form of security or Encumbrance (excluding licences of
Intellectual Property or Know-How) or equity on, over or affecting the whole or any part of the Assets or the Owned Product Intellectual Property Rights is outstanding and, save in relation to Permitted Encumbrances, there is no agreement or
commitment entered into by any member of the Seller’s Group to give or create any and no claim has been made against any member of the Seller’s Group by any person entitled to any. 

 

	6.3	The Assets and the Owned Product Intellectual Property Rights, when taken together with the rights and services under the Ancillary Agreements and for the
respective terms thereof: 

  

	 	6.3.1	comprise all of the assets required to carry out the Business in substantially the same manner as it has been during the twelve months prior to the date of this
Agreement; and 

  

	 	6.3.2	are sufficient in all material respects to carry out the Business after Closing substantially as conducted by the Seller and its Affiliates as of the date of
this Agreement, 

 provided however, that the foregoing is not a warranty of non-infringement, non-misappropriation
or any other non-violation of Intellectual Property Rights of any third party, which warranty is solely set out in paragraph 3.7. 
  

	7.	Compliance with Laws, Permits and Anti-Bribery 

  

	7.1	Neither the Seller nor any of its Affiliates is in breach of any Applicable Law where such breach is reasonably likely to be material to the Business.

  

	7.2	Neither the Seller nor any of its Affiliates has received any written notice from any Governmental Entity that it is not in compliance (or any warning letter
that it may not be in compliance) with any Applicable Law or is not in possession of any permits, licences, certificates or other authorisations or consents of a Governmental Entity in each case as is necessary for the conduct of the Business in all
material respects as presently conducted (each a “Permit” and, collectively, the “Permits”), except where such non-compliance or non-possession does not remain outstanding or uncured as of Closing or would not
reasonably be expected to have a material effect on the Business. 

  
 147

	7.3	With respect to the Business, since 1 January 2009, neither the Seller nor any of its Affiliates, nor any of their respective directors, officers or
employees and, to the Seller’s Knowledge, no Seller Partner has, directly or indirectly: (i) used any corporate funds for any unlawful contribution, gift, entertainment or other unlawful expense relating to political activity or to
influence official action; (ii) made or offered to make any unlawful payment to any foreign or domestic government official or employee, or agent, political party or any official of such party, or political candidate from corporate funds;
(iii) made or offered to make any bribe, rebate, payoff, influence payment, money laundering, kickback or other unlawful payment; or (iv) violated or is in violation of any provision of any applicable Anti-Bribery Law; and with respect to
the Business, the Seller and its relevant Affiliates have instituted and maintain policies and procedures reasonably designed to ensure compliance with applicable Anti-Bribery Law. 

 

	7.4	With respect to the Business, neither the Seller nor any of its Affiliates, nor any of their respective directors, officers or employees and, to the
Seller’s Knowledge, no Seller Partner: (i) is currently the subject of, nor has it been since 1 January 2009, the subject of, any action alleging a violation, or possible violation, of any Anti-Bribery Law, or been since
1 January 2009, the recipient of a subpoena, letter of investigation or other document alleging a violation, or possible violation, of any Anti-Bribery Law, or (ii) has, since 1 January 2009, improperly or inaccurately recorded in any
books and records (A) any payments, cash, contributions, gifts, hospitalities or entertainment to a foreign or domestic government official, employee of an enterprise owned or controlled in whole or in part by any foreign government, official
of a foreign or domestic political party or campaign, or a foreign or domestic candidate for political office; or (B) other expenses related to political activity or lobbying. 

 

	7.5	With respect to the Business, since 1 January 2009, neither the Seller nor any of its Affiliates, nor any of their respective directors or officers, and, to
the Seller’s Knowledge, none of their respective employees has received notice that any such person is or has been alleged to be in violation of any sanctions administered by the Office of Foreign Assets Control of the U.S. Department of the
Treasury or by the U.S. Department of State or equivalent measures of the United Kingdom, European Union, or the United Nations (the “Sanctions Law”). With respect to the Business, neither the Seller nor any of its Affiliates,
nor any of their respective directors or officers, and, to the Seller’s Knowledge, none of their respective employees has conducted any of their business activities whatsoever with, or for the benefit of, a government, national or legal entity
to the extent such actions would violate any Sanctions Law. None of the execution, delivery and performance of this Agreement and the direct or indirect use of proceeds from any transaction contemplated hereby or the fulfilment of the terms hereof
will result in a violation by any person of any Sanctions Law. 

  

	7.6	Each member of the Seller’s Group, in connection with the Products, the Product Approvals, the Transferred Contracts, the Shared Business Contracts and the
Transferred Intellectual Property Contracts requires its Service Providers to act in accordance with the requirements of applicable Anti-Bribery Law and uses all reasonable endeavours to procure that they do so. Each such Service Provider has in
place policies, systems, controls and procedures designed to prevent, and which are reasonably expected to continue to prevent, it and its Associated Persons from violating applicable Anti-Bribery Law. 

  
 148

	8.	Product Approvals 

  

	8.1	The Seller or one of its Affiliates is the registered holder of each of the Product Approvals. All material Product Approvals held by Seller or its Affiliates
are in full force and effect. No material deficiencies have been asserted by any applicable Government Entity with respect to any Product Approval or Product Filing, nor, to the Seller’s knowledge, are there any facts or circumstances that
would be likely to lead to such assertions being made. 

  

	8.2	Each Product was and is being researched, developed, manufactured, marketed or sold in all material respects in accordance with the specifications and standards
contained in the relevant Product Approval and the related Marketing Authorisation Data and in accordance with Applicable Law. 

  

	8.3	Neither the Seller or any of its Affiliates has received any written notice that any Governmental Entity with jurisdiction over the Products has commenced or
will commence any action: (i) to withdraw the approval of any Product or otherwise revoke or materially amend any Product Approval or Marketing Authorisation Data or (ii) enjoin production, marketing or sale of any Product and, to the
Seller’s knowledge, no such action has been threatened. 

  

	8.4	All application and renewal fees due and payable with respect to all material Product Approvals have been paid. 

 

	8.5	All preclinical and clinical investigations with respect to the Products are being and have been conducted in compliance with Applicable Law in all material
respects. The Seller and its Affiliates have not, and to the Seller’s Knowledge, none of its Product Partners or any other third party under any Licensed Intellectual Property Contract has received since 1 January 2009, any written notices
or other correspondence from any Governmental Entity with respect to any on-going clinical or pre-clinical studies or tests of any Product requiring the termination, suspension or material modification of such studies or tests.

  

	8.6	None of the Seller or its Affiliates or, to the Seller’s Knowledge, any Product Partner or any other third parties pursuant to any Licensed Intellectual
Property Contract, has any knowledge of any adverse event, arising since the date three years prior to the date of this Agreement, reportable with respect to the safety or efficacy of any Product which is or would reasonably be expected to be
material. 

  

	9.	Product Recall 

 No
Product (or any component thereof) has been recalled, suspended, withdrawn, seized, discontinued or the subject of a refusal to file, clinical hold, deficiency or similar action letter (including any correspondence questioning data integrity) as a
result of any action by any Governmental Entity, by the Seller or any of its Affiliates; nor are any such actions pending or under consideration (or any facts, conditions, or circumstance known) by the Seller or any of its Affiliates, or, to the
Seller’s Knowledge, by any Governmental Entity. There is not, to the Seller’s Knowledge, pending or threatened litigation anywhere in the world seeking the recall, withdrawal, suspension, seizure or discontinuance of any of the Products.

  
 149

	10.	Product Liability 

 The
Products sold by the Business during the Relevant Period have complied in all material respects with all applicable product specifications and have been Manufactured in all material respects in accordance with applicable requirements of then current
GMP and any Applicable Law, except for any such non-compliance that is not, and would not reasonably be expected to have, a materially adverse impact on the relevant Product. 

 

	11.	Taxes 

  

	11.1	The Company, each Business Seller and (in either case) each Tax Group to which it belongs has, and every member of the Seller’s Group with an interest in
the Business has in respect of the Business, duly, and within any appropriate time limits, filed all Tax Returns required to be filed and has maintained all records required to be maintained for tax purposes in relation to the assets comprised in
the Business; all such information was and remains complete and accurate in all material respects and all such Tax Returns were complete and accurate in all material respects and were made on the proper basis. 

 

	11.2	There are no Tax liens on the Share, any Asset or any Owned Product Intellectual Property Rights comprised in the Business (other than Permitted Encumbrances).

  

	11.3	No member of the Seller’s Group with an interest in the Business (including the Company) has received notice from a Tax Authority of, and so far as the
Seller is aware, there is not any dispute or disagreement outstanding at the date of this Agreement with any Tax Authority regarding the proper method of computing the profits of the Business (or any part of it) or of the Company for Tax purposes or
the proper treatment for VAT purposes of any supplies of goods or services made (or treated as made) in the course of the Business or by the Company and, so far as the Seller is aware, there are no circumstances which make it likely that any such
dispute or disagreement will commence. 

  

	11.4	So far as the Seller is aware, no Tax Authority has within the past three years operated or agreed to operate any special arrangement (being an arrangement which
is not based on relevant legislation or any published practice) in relation to any Assets or Owned Product Intellectual Property Rights comprised in the Business or in relation to the Company or the Share. 

 

	11.5	In respect of all documents which establish or are necessary to establish the title of the relevant member of the Seller’s Group to the Share and to each
material asset comprised in the Business, or by virtue of which the relevant member of the Seller’s Group has any right in respect of each such asset, all applicable stamp duties, transfer taxes, registration charges or similar duties or
charges have been duly paid. 

  
 150

	12.	Employees 

  

	12.1	The Disclosure Letter contains a true, complete and correct list of the following information in respect of each Employee as of 31 March 2014 (organised by
country): (A) employee identification details; (B) date of birth; (C) employment status (part-time or full-time); (D) employment start date; (E) base salary; (F) target annual incentive for 2014 (and actual bonus for
2013); and (G) target long-term incentive for 2014 (and actual long-term incentive for 2013). 

  

	12.2	In each of the Material Employee Jurisdictions except as would not be reasonably expected to have a Material Adverse Effect: 

 

	 	12.2.1	as of the date of this Agreement there is not, and in the two years prior to the date of this Agreement there has not been, nor to the Seller’s Knowledge is
there pending or threatened, any labour strike, dispute, work stoppage or lockout by any group of Employees; 

  

	 	12.2.2	no trade union or works council is recognised in any way for bargaining, information or consultation purposes in relation to any of the Employees and no
collective bargaining negotiations, whether voluntary or mandatory, are currently taking place with respect to any of the Employees and, as of the date of this Agreement, no Business Seller is a party to any agreement (whether legally binding or
not) with any trade union or works council affecting any Employee and there is no existing dispute with any such representative body (or, to the Seller’s Knowledge, pending or threatened) in relation to the Business; 

 

	 	12.2.3	there is no material litigation, claim or other dispute existing, nor, to the Seller’s Knowledge, pending or threatened by or in respect of any Employees in
respect of their employment or any matter arising from their employment; and 

  

	 	12.2.4	no Business Seller has, within the 2 years prior to the date of this Agreement, closed any plant or facility, effectuated any layoffs of employees or implemented
any early retirement, separation or similar programme in each case in violation of the WARN Act, nor has any Business Seller announced any such action or programme for the future. 

 

	12.3	No Key Personnel has given notice terminating his or her contract of employment, nor is under notice of dismissal. 

 

	12.4	The severance costs disclosed in the Data Room at document 2.2.1.11 represent the Seller’s estimation, calculated in good faith, of the indicative severance
cost for a full-time employee at middle-management level in each of the countries listed therein. 

  

	12.5	Since 31 December 2013, no material change has been made, announced or proposed to the emoluments or other terms of employment of any Employee, and no such
change, and no negotiation or request for such a change, is due or expected within 12 months from the date of this Agreement, and the employing company is under no obligation to make such a change (with or without retrospective operation) other than
any arrangement relating to the share-based incentive schemes of the Seller’s Group pursuant to paragraph 10 of Schedule 8. 

  
 151

	12.6	The Company has no employees and has never had any, and nor has it ever entered into any service contract or similar arrangements (whether formal or otherwise)
with any person. 

  

	13.	Employee Benefits 

  

	13.1	The Disclosure Letter contains a true, complete and correct list of all bonus, staff incentives (including any share-based incentive schemes), redundancy or
other benefits payable on termination of employment (whether voluntary or involuntary but excluding arrangements required in accordance with Applicable Law), ill-health, Employee Benefits or other benefits which are the material benefits available
to the Employees in the Material Employee Jurisdictions. To the Seller’s Knowledge, other than any arrangement relating to the share-based incentive schemes of the Seller’s Group pursuant to paragraph 10 of Schedule 8, no Business
Seller has made any promises or commitments to make available any additional benefits to the Employees in the Material Employee Jurisdictions, or to modify or change in any material way any existing benefits in the Material Employee Jurisdictions,
or to continue or maintain the level of any existing benefits generally for any period, which in each case could reasonably be expected to have a Material Adverse Effect. 

 

	13.2	The Disclosure Letter contains true and complete copies of all documents of any written benefit schemes, plans or arrangements referred to in paragraph 13.1
above applicable to Employees in the Material Employee Jurisdictions containing material terms (including governing documents, and for benefit plans that are not share-based incentive schemes, related trust agreements or other funding documents) and
a true, complete and correct summary of the material terms of any unwritten benefit schemes, plans or arrangements referred to in paragraph 13.1 above. 

 

	13.3	Benefit Plans 

  

	 	13.3.1	 In the Material Employee Jurisdictions, all benefit and compensation schemes, plans, funds, contracts, policies, agreements or arrangements
(other than the US Benefit Plans and any schemes, plans, funds, contracts, policies, agreements or arrangements operated by any Governmental Entity) (A) operated by or on behalf of a Business Seller, with respect to Employees, (B) in
respect of which any Business Seller, with respect to Employees, the Seller or any member of the Seller’s Group contributes or has contributed or (C) in respect of which any Business Seller, with respect to Employees, has any liability
(whether actual or contingent), including, but not limited to, plans providing Employee Benefits or during periods of sickness or disablement, or any deferred or incentive compensation, welfare, healthcare, medical, stock or stock-related award
plans, including individual pension commitments, “jubilee” pension benefits and retirement and termination indemnity arrangements, and in relation to Switzerland, all plans, funds, contracts, policies, agreements or arrangements providing
pension or other benefits on retirement (such schemes, plans, funds, contracts, policies, agreements and arrangements hereinafter being referred to as “Non-US Benefit Plans”) and the

  
 152

	 	
US Benefit Plans have been administered in accordance with their terms and are in compliance with Applicable Law, except for any failures to so administer or be in compliance that, individually
and in the aggregate, would not reasonably be expected to have a Material Adverse Effect. All required filings for all Benefit Plans have been made on time and with the appropriate Governmental Entity, except for any failures to timely file that,
individually and in the aggregate, would not reasonably be expected to have a Material Adverse Effect. As of the date of this Agreement there is no existing, pending or, to the Seller’s Knowledge, threatened material litigation, claim or other
dispute relating to Benefit Plans. 

  

	 	13.3.2	The Business Sellers, with respect to Employees in each Material Employee Jurisdiction, (A) are in material compliance with all Applicable Law respecting
employment, employment practices, terms and conditions of employment, occupational health, safety, wages and hours, (B) have withheld all amounts required by Applicable Law, collective bargaining agreements or the Benefit Plans to be withheld
from the wages, salaries or other payments to the Employees, (C) in respect of the Employees, are not liable under any applicable provisions of the Benefit Plans and any Applicable Law for any arrears, wages, Taxes, other than payments not yet
due, or any penalty for failure to comply with the foregoing and (D) are not liable under any applicable provisions of the Benefit Plans and any Applicable Law for any payment to any trust or other fund or to any Governmental Entity with
respect to unemployment compensation benefits, workers compensation, social security or other benefits for Employees, other than payments not yet due, except, in each case, for any failures to comply, failures to withhold or liabilities that,
individually and in the aggregate, would not reasonably be expected to have a Material Adverse Effect. 

  

	 	13.3.3	All material contributions that the Business Sellers, with respect to Employees in a Material Employee Jurisdiction, and Switzerland, are required to make to any
Benefit Plan in respect of the period on or before the date of this Agreement have been fully and timely paid when due. 

  

	13.4	The Company has never established, sponsored, participated in or contributed to any arrangement or agreed to do so for providing pensions or other benefits on,
or in anticipation of, the retirement, death, accident or sickness of any current or former director or employee of any company. 

  

	14.	Litigation 

  

	14.1	No Business Seller nor the Company is involved whether as claimant or defendant or other party in any claim or Proceeding (other than as claimant in the
collection of debts arising in the ordinary course of its business none of which exceeds US$5 million) which is material to the Business or a Key Product. 

  

	14.2	To the Seller’s Knowledge, no such claim or Proceeding of material importance is pending or threatened by or against any Business Seller or the Company.

  
 153

	15.	Insolvency 

  

	15.1	No order has been made and no resolution has been passed for the winding up of any Business Seller, the Share Seller or the Company or for the appointment of any
administrator, receiver (including administrative receiver) or liquidator (provisional or otherwise) over the whole or any part of the property, assets and/or undertaking of any Business Seller, the Share Seller or the Company.

  

	15.2	No petition has been presented or meeting convened for the purpose of considering a resolution or resolution circulated for the winding up of any Business
Seller, the Share Seller or the Company, or for the appointment of any administrator, receiver (including administrative receiver) or liquidator (provisional or otherwise) over the whole or any part of the property, assets and/or undertaking of any
Business Seller, the Share Seller or the Company. 

  

	15.3	Each of the Business Sellers, the Share Seller and the Company has not stopped payment or suspended payment of its debts generally, is not insolvent or deemed
unable to pay its debts as they fall due. 

  

	16.	Insurance 

 All material
insurance policies relating to the Business are in full force and effect and, to the Seller’s Knowledge, no notice of cancellation, termination or default has been received with respect to any such insurance policy. All premiums due and payable
on such policies covering periods up to Closing have been paid in full or accrued. 
  

	17.	Consents and Licences 

  

	17.1	All governmental and quasi-governmental licences, consents, permissions, waivers, exceptions and approvals required for carrying on the Business, the absence of
which, individually or in the aggregate, would be material to the Business, are in force and, to the Seller’s Knowledge, no written notice has been received by the Seller or any member of the Seller’s Group which indicates that any such
licence, consent, permission, waiver, exception or approval is likely to be revoked or which may confer a right of revocation. 

  

	18.	Delinquent and Wrongful Acts 

  

	18.1	To the Seller’s Knowledge, no member of the Seller’s Group has, during the Relevant Period, committed any criminal or illegal act which relates to the
Business. 

  

	18.2	No member of the Seller’s Group has, during the Relevant Period, received notification that any investigation or inquiry is being or has been conducted by
any supranational, national or local authority or governmental agency specifically related to the Business, which is material in respect of the Business. 

  
 154

	19.	Compliance 

  

	19.1	No member of the Seller’s Group has received in the Relevant Period any written notification or written claim (in each case, which remains outstanding) that
it has conducted the Business with respect to the research, development, manufacturing, distribution and sale of the Products in a manner which does not in any respect comply with all Applicable Law, or which in any respect is defective or
dangerous, where the pursuit of any such notification or claim is, or would reasonably be expected to be, material in respect of the Business or any of the Key Products. 

 

	19.2	So far as the Seller is aware, the Business has, and has during the Relevant Period been, operated in all material respects in compliance with all Applicable Law
or standards and to the Seller’s Knowledge there are no circumstances that could involve or lead to a material violation of any material Applicable Laws or standards. 

 

	20.	Pipeline Products 

  

	20.1	The information set out in Schedule 1 with respect to the Product Expansions is true and accurate. 

 

	20.2	The Seller or one of its Affiliates is the registered holder of each of the Product Expansion Applications, and each Product Expansion Application can be
transferred to the Purchaser (or another member of the Purchaser’s Group) regardless as to whether such transfer occurs directly (whether by way of transfer, reissuance or any other equivalent mechanism under Applicable Law of the relevant
jurisdiction) or indirectly (through the transfer to a member of the Purchaser Group). 

  

	20.3	All development activities in relation to the Product Expansions have been conducted in the ordinary course and in accordance with Applicable Law and standards
and to the Seller’s Knowledge there are no circumstances relating to the development of the Product Expansions that could involve or lead to a material violation of any material Applicable Law or standards. 

 

	20.4	No material regulatory, clinical or safety event has occurred in relation to the Products and no member of the Seller’s Group has received any notification
or claim from any person of any such event (or the possibility of any such event). 

  

	21.	Manufacturing Licences and Manufacture 

  

	21.1	All Manufacturing Licences which are material to the manufacture of the Products, are in effect and are validly held by a member of the Seller’s Group and
during the Relevant Period, to the Seller’s Knowledge, no member of the Seller’s Group has received any written notice of any suit, action or proceeding regarding the revocation or modification of any such Manufacturing Licence.

  

	21.2	No directive, order or notice has been given to the Seller or any member of the Seller’s Group by any relevant regulatory authority to update, modify,
amend, vary, supplement or delete any process and/or methodology relevant to the manufacture of any Product and, so far as the Seller is aware, no such directive, order or notice is pending. 

  
 155

	22.	The Company 

  

	22.1	The Company does not have outstanding any borrowing or indebtedness with any person who is not a member of the Seller’s Group. 

 

	22.2	The Company does not have any derivative, hedging or swap arrangements or contracts or anything similar in nature to such documentation.

  
 156

 Schedule 15 
 Warranties given by the Purchaser under Clause 9.3 
  

	1.	Authority and Capacity 

  

	1.1	Incorporation 

 The
Purchaser is validly existing and is a company duly incorporated and registered under the law of its jurisdiction of incorporation. 
  

	1.2	Authority to enter into Agreement 

  

	 	1.2.1	The Purchaser has the legal right and full power and authority to enter into and perform this Agreement and any other documents to be executed by it pursuant to
or in connection with this Agreement. 

  

	 	1.2.2	The documents referred to in paragraph 1.2.1 will, when executed, constitute valid and binding obligations on the Purchaser in accordance with their
respective terms. 

  

	 	1.2.3	Except as referred to in this Agreement, the Purchaser: 

  

	 	(i)	is not required to make any announcement, consultation, notice, report or filing; and 

 

	 	(ii)	does not require any consent, approval, registration, authorisation or permit, 

 in each case in connection with the performance of this Agreement or any other document referred to in paragraph 1.2.1. 

 

	 	1.2.4	The execution and delivery of the documents referred to in paragraph 1.2.1 and the performance by the Purchaser and each member of its Group of their
respective obligations under them, will not: 

  

	 	(i)	result in a breach of any provision of the memorandum or articles of association or by laws or equivalent constitutional document of the relevant member of the
Purchaser’s Group; 

  

	 	(ii)	result in a breach of, or constitute a default under, any instrument or contract to which the relevant member of the Purchaser’s Group is party or by which the
relevant member of the Purchaser’s Group is bound where such breach is material to their ability to perform their obligations under such documents; 

  

	 	(iii)	result in a breach of any existing order, judgment or decree of any court, Governmental Entity by which the relevant member of the Purchaser’s Group is bound and
where such breach is material to their ability to perform their obligations under such documents. 

  
 157

	1.3	Authorisation 

 The
Purchaser has taken, or will have taken by Closing, all corporate action required by it to authorise it to enter into and to perform this Agreement, any Ancillary Agreement to which it is a party and any other documents to be executed by it pursuant
to or in connection with this Agreement or any Ancillary Agreement. 

  
 158

 Schedule 16 
 Certificate 
 (Clause 4.4) 

To: Novartis AG 
 [Date] 

Certificate 
 This Certificate is issued in
accordance with Clause 4.4.1(iii)(b) and paragraph 1.1.3 of Schedule 12 of the sale and purchase agreement between Novartis AG and GlaxoSmithKline plc dated 22 April 2014 (the “Agreement”). Unless otherwise defined,
capitalised words used in this Certificate shall have the meanings given to them in the Agreement. 
 We confirm that: 

1. no Material Adverse Effect has occurred between the date of the Agreement and the date of this Certificate; 

2. having made due and careful enquiry, we are not aware of any breach or breaches of Clause 9.1 which alone or together give rise to a Material
Adverse Effect; and 
 [either] 

3. having made due and careful enquiry, we are not aware of any breach or breaches of the Seller’s Warranties that would have occurred and that
would, alone or together, have given rise to a Material Adverse Effect had the Seller’s Warranties been repeated immediately before Closing by reference to the facts, circumstances and knowledge then existing as if references in the
Seller’s Warranties to the date of this Agreement were references to the Closing Date. 
 [or] 

3. having made due and careful enquiry, we are aware of the following material breaches of the Seller’s Warranties that would, alone or together, be
material and have occurred had the Seller’s Warranties been repeated immediately before Closing by reference to the facts, circumstances and knowledge then existing as if references in the Seller’s Warranties to the date of this Agreement
were references to the Closing Date. 
 [description of material breaches.] 

 
 For and on behalf of GlaxoSmithKline
plc 

  
 159

 Schedule 17 
 Key Study Plans 
 [***] 

 

	***	Note: Confidential treatment has been requested with respect to the information contained within the [***] marking. Such portions, consisting of eleven pages, have been
omitted from this filing and have been filed separately with the Securities and Exchange Commission. 

  
 160

 Schedule 18 
 Pre-Closing Product Reorganisation 
 Part 1 Description of the
Pre-Closing Product Reorganisation 
  

	1.	For the purposes of this Schedule: 

 “Category 1A Assets” means: 
  

	 	(i)	all the Transferred Product Intellectual Property Rights which are owned directly by GIPL and relate to Votrient, which shall include full legal title to such
Transferred Product Intellectual Property Rights or the right to call for such legal title for no consideration; and 

  

	 	(ii)	for so long as the Votrient LLC Licence remains in force, the licensed interest in all Transferred Product Intellectual Property Rights licensed under the Votrient LLC
Licence, 

 and which for the avoidance of doubt shall not include any Transferred Intellectual Property Contracts;

 “Category 1B Assets” means: 
  

	 	(i)	all the Transferred Product Intellectual Property Rights which are owned directly by SmithKline Beecham (Cork) Limited and relate to Tykerb, which shall include full
legal title to such Transferred Product Intellectual Property Rights or the right to call for such legal title for no consideration; and 

  

	 	(ii)	for so long as the Tykerb LLC Licence remains in force, the licensed interest in all the Transferred Product Intellectual Property Rights licensed under the Tykerb LLC
Licence, 

 and which for the avoidance of doubt shall not include any Transferred Intellectual Property Contracts;

 “Category 2 Assets” means full legal and beneficial economic ownership of all the Transferred Product
Intellectual Property Rights other than the Category 1A Assets and Category 1B Assets, and which for the avoidance of doubt shall not include any Transferred Intellectual Property Contracts; 

“Company” means Leo Osprey Limited, a company incorporated in England and Wales on 16 April 2014 under company
number 9000270, whose registered office is 980 Great West Road, Brentford, TW8 9GS, United Kingdom, which has an issued share capital of one share of £1 and whose sole shareholder is Glaxo Group Limited; 

“Company Intra-Group Debt” means all sums owed by the Company to GlaxoSmithKline Finance plc at the Closing Date
(immediately prior to Closing) as shall be notified by the Seller to the Purchaser in accordance with Clause 6.3.2; 

  
 161

 “Company Tax Indemnity” means the deed of tax covenant relating to the
Company, in the Agreed Terms; 
 “GFplc” means GlaxoSmithKline Finance plc; 

“GGL” means Glaxo Group Limited; 
 “GIPL” means GlaxoSmithKline Intellectual Property Limited; 

“GIPL B Share” means one share in GIPL carrying a right to a preferential special dividend by GIPL of the Category 1A
Assets, whereupon the GIPL B Share shall convert into a deferred share having no voting rights and economic rights typical of deferred shares created in a B share scheme implemented by an English public limited company; 

“GIPL Estimated Value” means £2,934,000,000; 

“GSKHIL” means GlaxoSmithKline Holdings (Ireland) Limited; 

“GSKHIL B Share” means one share in GSKHIL carrying a right to a preferential dividend by GSKHIL of the Category 1B
Assets, whereupon the GSKHIL B Share shall convert into a deferred share having no voting rights and economic rights typical of deferred shares created in a B share scheme implemented by an English public limited company; 

“GSKHIL Estimated Value” means £147,000,000; 

“Purchaser Tax Indemnity” means the deed of tax covenant relating to the Purchaser’s Group, in the Agreed Terms;

 “Setfirst” means Setfirst Limited; 
 “Share” means the entire issued share capital of the Company; 

“Tykerb LLC Licence” means the licence agreement dated 1 January 2004 between GlaxoSmithKline LLC and SmithKline
Beecham (Cork) Limited relating to Tykerb (as amended from time to time); and 
 “Votrient LLC Licence” means
the licence agreement dated 1 July 2008 between GlaxoSmithKline LLC and GIPL relating to Votrient (as amended from time to time). 
  

	2.	Subject to paragraphs 3 and 4 below, and to Part 4 of this Schedule, the Pre-Closing Product Reorganisation shall consist of all of the following steps.

  

	2.1	The Seller shall procure that the following steps are taken in the order set out below. 

  
 162

 Preliminary step(s) 

 

	 	(A)	Any steps necessary to procure that GGL has full legal and beneficial ownership of the Share. 

Step 1 
  

	 	(B)	The Company shall receive funding sufficient to carry out Step 3 and Step 3A in the form of (i) an intra-group interest-bearing loan from GFplc on terms standard
within the Seller’s Group, and (ii) a subscription for ordinary shares by GGL. 

  

	 	(C)	GFplc shall provide the Company with an interest-bearing on demand loan facility (which shall terminate at Closing) on terms standard within the Seller’s Group,
under which the Company can draw down any further funds it requires to pay any purchase price adjustment on the GIPL B Share or the GSKHIL B Share, as required under paragraph (F)(ii) or (I)(ii) below. 

The loans referred to in paragraphs (B)(i) and (C) shall take the form of a single facility. 

Step 2 
  

	 	(D)	GIPL shall reclassify one ordinary share in its capital, held by GGL, as the GIPL B Share. 

Step 3 
  

	 	(E)	Promptly after completion of Step 2, the Company shall purchase the GIPL B Share from GGL for consideration reflecting the percentage allocated to Votrient in
accordance with Schedule 10 less the fair market value of (i) all the royalty rights in respect of Votrient which are held by members of the Seller’s Group other than the Company and (ii) any Transferred Intellectual Property
Contracts to the extent relating to Votrient, as at Closing (the “GIPL Agreed Value”). 

  

	 	(F)	The sale terms in respect of the sale and purchase of the GIPL B Share shall provide that: 

 

	 	(i)	the GIPL B Share shall be transferred to the Company for the GIPL Estimated Value; and 

 

	 	(ii)	as soon as reasonably practicable after the GIPL Agreed Value has been agreed or determined pursuant to Schedule 10, the Company or GGL shall pay the other an amount
equal to the difference between the GIPL Agreed Value and the GIPL Estimated Value, as appropriate, to ensure that the total amount paid for the GIPL B Share is equal to the GIPL Agreed Value. 

 

	 	(G)	The Seller shall procure that, at the Seller’s cost (such that, if any such costs are paid by the Purchaser, the Seller shall reimburse the Purchaser for the
amount of such costs): (i) all steps are taken which are necessary to pay any stamp duty and/or stamp duty reserve tax in respect of the sale of the GIPL B Share under this Step 3, and (ii) the GIPL B Share is registered in the name of the
Company. 

  
 163

 The Company shall subsequently (but before Step 4) enter into arrangements with another
member of the Seller’s Group for the exploitation and management of any intellectual property that it may come to hold (the “Exploitation Arrangements”). The material terms of the Exploitation Arrangements will be provided to
the Purchaser in advance in the form of summaries. 
 Step 3A 

 

	 	(H)	Promptly after completion of Step 2, the Company shall purchase the GSKHIL B Share from Setfirst for consideration reflecting the percentage allocated to Tykerb in
accordance with Schedule 10 less the fair market value of (i) all the royalty rights in respect of Tykerb which are held by members of the Seller’s Group other than the Company and (ii) any Transferred Intellectual Property Contracts
to the extent relating to Tykerb, as at Closing (the “GSKHIL Agreed Value”). At the time at which the Company acquires the GSKHIL B Share, a wholly-owned subsidiary of GSKHIL will hold all of the Category 1B Assets. Full beneficial
and economic ownership of the Category 1B Assets will be transferred to GSKHIL by its wholly-owned subsidiary by way of dividend. 

  

	 	(I)	The sale terms in respect of the sale and purchase of the GSKHIL B Share shall provide that: 

 

	 	(i)	the GSKHIL B Share shall be transferred to the Company for the GSKHIL Estimated Value; and 

 

	 	(ii)	as soon as reasonably practicable after the GSKHIL Agreed Value has been agreed or determined pursuant to Schedule 10, the Company or GSKHIL shall pay the other an
amount equal to the difference between the GSKHIL Agreed Value and the GSKHIL Estimated Value, as appropriate, to ensure that the total amount paid for the GSKHIL B Share is equal to the GSKHIL Agreed Value. 

 

	 	(J)	The Seller shall procure that, at the Seller’s cost (such that, if any such costs are paid by the Purchaser, the Seller shall reimburse the Purchaser for the
amount of such costs): (i) all steps are taken which are necessary to pay any stamp duty and/or stamp duty reserve tax in respect of the sale of the GSKHIL B Share under this Step 3, and (ii) the GSKHIL B Share is registered in the name of
the Company. 

  
 164

 Step 4 

 

	 	(K)	After completion of Step 3, GIPL shall declare a special dividend of the Category 1A Assets on the GIPL B Share and full beneficial and economic ownership of the
Category 1A Assets shall be assigned to the Company (the “GIPL Distribution”). GIPL shall not carry out a capital reduction in connection with such special dividend. The assignment of the Category 1A Assets will become effective at
exactly the same time as the assignment of the Category 1B Assets under Step 4A. 

 Step 4A 

 

	 	(L)	On 29 August 2014, GSKHIL shall become resident solely in the UK for UK Tax purposes and shall thereafter remain solely resident in the UK for UK Tax purposes
until at least Closing. 

  

	 	(M)	After having become resident in the UK for Tax purposes in accordance with paragraph (L) above, GSKHIL shall: 

 

	 	(i)	carry out a reduction of capital in order to create distributable reserves; and 

 

	 	(ii)	declare a special dividend of the Category 1B Assets on the GSKHIL B Share, to be paid solely out of profits available for distribution at the time the dividend is paid
that arose on or after the Company’s acquisition of the GSKHIL B Share, 

 and full beneficial and economic
ownership of the Category 1B Assets shall be assigned to the Company (the “GSKHIL Distribution”). The assignment of the Category 1B Assets will become effective at exactly the same time as the assignment of the Category 1A Assets
under Step 4. 
  

	2.2	After Step 4 and Step 4A and on or before the Business Day before Closing, the Seller shall procure that the following steps are taken. 

Step 5 
  

	 	(A)	The Company shall sell the GIPL B Share for a nominal amount to a company that is UK resident for UK Tax purposes and is in the same group (within the meaning of
section 170 of the Taxation of Chargeable Gains Act 1992) as the Company. 

  

	 	(B)	The Company shall exercise its rights under the Transferred Intellectual Property Rights falling with limb (i) of the definition of “Category 1A Assets”
to procure that registered legal title to the Category 1A Assets is transferred to the Company for no consideration. If all Third Party Consents relevant to any particular Category 1A Asset are not obtained, that Category 1A Asset shall be treated
in accordance with paragraph 2.4 below. 

  
 165

 Step 5A 

 

	 	(C)	The Company shall sell the GSKHIL B Share for a nominal amount to a company that is UK resident for UK Tax purposes and is in the same group (within the meaning of
section 170 of the Taxation of Chargeable Gains Act 1992) as the Company. 

  

	 	(D)	The Company shall exercise its rights under the Transferred Intellectual Property Rights falling with limb (i) of the definition of “Category 1B Assets”
to procure that registered legal title to the Category 1B Assets is transferred to the Company for no consideration. If all Third Party Consents relevant to any particular Category 1B Asset are not obtained, that Category 1B Asset shall be treated
in accordance with paragraph 2.4 below. 

  

	2.3	After completion of Step 5 and Step 5A and on or before the Business Day before Closing the Seller shall procure the following actions are taken.

 Step 6 
  

	 	(A)	The Company shall acquire the Category 2 Assets from the relevant members of the Seller’s Group for consideration in cash reflecting, in respect of each Category 2
Asset, the percentage allocated to the Product to which that Category 2 Asset is attributable in accordance with Schedule 10 less that part attributable to that Product other than that Category 2 Asset. If all Third Party Consents relevant to any
particular Category 2 Asset are not obtained, that Category 2 Asset shall be treated in accordance with paragraph 2.4 below. 

  

	 	(B)	In order to acquire the Category 2 Assets, the Company shall be funded in the form of (i) an intra-group interest-bearing loan from GFplc on terms standard within
the Seller’s Group, (ii) an ordinary share subscription from GGL, or (iii) a combination of both. 

  

	2.4	If a Third Party Consent has not been obtained in respect of any Category 1A Asset, Category 1B Asset or Category 2 Asset before the date on which Step 5 takes effect:

  

	 	(A)	the legal title in the relevant Category 1A Asset, Category 1B Asset or Category 2 Asset affected by the Third Party Consent shall not be transferred to the Company
pursuant to Step 5, Step 5A or Step 6; and 

  

	 	(B)	the relevant Category 1A Asset, Category 1B Asset or Category 2 Asset affected by the Third Party Consent will be dealt with in accordance with paragraphs 2 to 4 of
Schedule 7. 

  

	2.5	After completion of Step 6, the Votrient LLC Licence and the Tykerb LLC Licence shall terminate in so far as such licences relate to Business Product Intellectual
Property Rights owned by or transferred to the Company. In the event that such termination does not terminate the Tykerb LLC Licence and the Votrient LLC Licence entirely, the licensee interest in the Votrient LLC Licence and the licensee interest
in the Tykerb LLC Licence shall then be assigned by the Company to another member of the Seller’s Group. 

  
 166

 Step 7 

 

	 	(A)	The Company shall: 

  

	 	(i)	distribute to GGL an amount equal to the lower of (a) the sum of any after-Tax profits generated in respect of the Category 1A Assets since the GIPL Distribution
and any after-Tax profits generated in respect of the Category 1B Assets since the GSKHIL Distribution, and (b) the distributable reserves of the Company at the time of this step; and 

 

	 	(ii)	sell to another member of the Seller’s Group any rights to receive future adjustment payments under the Exploitation Arrangements in respect of the use of its
assets prior to Closing, in consideration of the payment of £1 and the assumption of any obligations to make payments in respect of the use of such assets prior to Closing, 

and may effect a reduction of capital in order to be able validly to effect any distributions to be made. 

 

	2.6	On: 

  

	 	(A)	the day before Closing, the Seller shall procure that the then current accounting period of the Company is terminated on that day; and 

 

	 	(B)	the Closing Date but prior to Closing, the Company’s debts to GFplc shall be refinanced into interest-free debts denominated in US dollars in accordance with
Clause 6.3.2. 

 Step 8(a) 
  

	2.7	On Closing: 

  

	 	(A)	the Seller shall procure that GGL will sell; and 

  

	 	(B)	the Purchaser shall purchase, or shall procure that a member of the Purchaser Group, will purchase, 

the Share in accordance with the terms of this Agreement (and whichever member of the Purchaser’s Group acquires the Share shall be
the “Novartis Purchaser” for the purposes of this Schedule). 
  

	2.8	On Closing, the Purchaser shall procure that the Company will discharge the Company Intra-Group Debt. 

Step 8(b) 

  
 167

	2.9	For the purpose of discharging its debt to GFplc in paragraph 2.6, the Company shall receive funding in the form of: (i) a loan from a member of the
Purchaser’s Group; (ii) a subscription for ordinary shares in the Company by the Novartis Purchaser; or (iii) a combination of both. Subject to those constraints, the Purchaser shall be free to decide the form in which this funding is
provided to the Company at Closing. 

 Step 9 

 

	2.10	Within four weeks after Closing, the relevant member of the Purchaser’s Group shall waive or convert into ordinary shares in the Company any loan provided to the
Company under paragraph 2.9, which step may be preceded by a transfer of such loan within the Purchaser’s Group. The loan may be converted into ordinary shares (rather than being waived) only if the Novartis Purchaser is the creditor under
the loan at the time of such conversion. 

 Step 10 

 

	2.11	By the later of (a) four weeks after Closing and (b) two weeks after the Seller provides any material which it is required to provide under paragraph 3, the
Company shall effect a reduction of share capital using the method prescribed in sections 642-644 of the Companies Act 2006 (reduction of share capital supported by solvency statement) to create an amount of additional distributable reserves at
least sufficient for it to distribute the Category 1A Assets and the Category 1B Assets. Prior to Closing, the Seller shall enter into indemnities directly in favour of the Company in the form of Clause 2.3.6 of this Agreement and of the Company Tax
Indemnity, mutatis mutandis. 

 Step 11 

 

	2.12	By the later of (a) four weeks after Closing and (b) two weeks after the Seller provides any material which it is required to provide under paragraph 3, the
Company shall declare a distribution in specie of the Category 1A Assets and the Category 1B Assets and accordingly transfer the Category 1A Assets and the Category 1B Assets to the Novartis Purchaser. 

Step 12 
  

	2.13	By the later of (a) six weeks after Closing and (b) four weeks after the Seller provides any material which it is required to provide under paragraph 3, the
Company shall either: 

  

	 	(A)	sell the Category 2 Assets to the Novartis Purchaser for consideration in cash or one or more debt instruments reflecting, in respect of each Category 2 Asset, the
percentage allocated to that Category 2 Asset in accordance with Schedule 10; or 

  

	 	(B)	declare a distribution in specie of the Category 2 Assets and transfer the Category 2 Assets to the Novartis Purchaser. 

  
 168

	3.	The parties shall co-operate in good faith, and the Seller shall provide any assistance reasonably requested by the Purchaser, in connection with the
implementation of any of Steps 9 to 12. In particular, the parties shall consult before Closing on whether any interim accounts or other material are required to support the reduction of capital at Step 10 and/or the distribution in specie at Step
11. If the Purchaser considers (acting reasonably and in good faith) that any such material is required, and notifies the Seller of this, then the Seller shall, at its own cost, procure the preparation of this material, with the input and
cooperation of the Purchaser, by the later of (a) thirty Business Days after receipt of such notice and (b) ten Business Days before Closing. 

  

	4.	The Seller may notify the Purchaser in writing, at any time up to five Business Days before Closing, that the Seller no longer wishes to proceed with the
Pre-Closing Product Reorganisation set out in this Schedule. If the Seller notifies the Purchaser to this effect, then: 

  

	 	(A)	the Seller shall not be entitled to sell the Share to the Purchaser at Closing; and 

 

	 	(B)	the Seller shall reimburse the whole of any reasonable out of pocket costs and expenses incurred by the Purchaser and/or any other member of the Purchaser’s Group
in connection with their assessment of the Pre-Closing Product Reorganisation or with any preparation undertaken for Steps 8 to 12 (to the extent that those costs and expenses would not have been incurred had the sale and purchase of the Category 1A
Assets, the Category 1B Assets and the Category 2 Assets always been structured as a direct sale of those assets from a member of the Seller’s Group to a member of the Purchaser’s Group). 

 

	5.	The Seller acknowledges that any decision to proceed with Steps 9 to 12 shall be a matter for the Purchaser and for the then directors of the Company, and that
neither the Purchaser nor the Company shall be under any obligation to implement all or any of those steps. 

Part 2 Seller undertakings 
  

	1.	The Seller undertakes to procure that, between the date of this Agreement and Closing: 

 

	 	(A)	the Company will not acquire any assets which are not the Category 1A Assets, Category 1B Assets, Category 2 Assets or assets arising under or pursuant to the
Exploitation Arrangements; 

  

	 	(B)	the Company will not carry on any business or other activities, other than the acquisition, management and exploitation of the Category 1A Assets, the Category 1B
Assets and Category 2 Assets; 

  

	 	(C)	the Company will not have any employees; 

  
 169

	 	(D)	any agreements which the Company enters into in connection with the management and exploitation of the Category 1A Assets, the Category 1B Assets and Category 2 Assets
shall be terminated, with immediate effect, by the Company immediately before Closing; and 

  

	 	(E)	the Company will not be a member of any VAT group, party to any group payment arrangement or otherwise party to any Tax allocation, contribution, indemnification or
sharing arrangement, Tax consolidation or fiscal unity, 

 except as may be required in connection with the
provisions listed in Part 1 of this Schedule or as agreed by the parties. 
  

	2.	The Seller undertakes that the Company will have no Third Party Indebtedness at Closing, except as agreed by the parties. 

 

	3.	The Seller shall procure that on Closing the Company will have no debts (other than the Company Intra-Group Debt). 

 

	4.	For the avoidance of doubt, the Seller acknowledges that the indemnity in Clause 2.3.6 of this Agreement shall apply to the Pre-Closing Product
Reorganisation set out in this Schedule. 

  

	5.	The Seller shall procure that, at Closing, the Company will have a Permitted Cash Receivable equal to the amount for which the Seller would be liable under
clause 2 of the Company Tax Indemnity in the absence of clause 3.1(A) of the Company Tax Indemnity. 

 Part 3
Co-operation between the parties; modifications 
  

	1.	At any time, the parties shall, on the request of the Seller and at the Seller’s expense, cooperate in good faith to identify and, subject to
paragraph 4 below, to implement any reasonable steps which can be taken to mitigate or remove any risk in relation to Swiss Tax which will result in a liability or potential liability for the Seller under clause 2 of the Purchaser Tax
Indemnity. For the avoidance of doubt, a step shall not be considered “reasonable” for the purposes of this Part 3 of this Schedule if it may have the effect on increasing an unindemnified Liability of the Purchaser’s Group.

  

	2.	Subject to paragraph 4 below, such reasonable steps may include: 

 

	 	(A)	the Purchaser seeking a ruling from the Swiss Tax authorities, with both parties having input into the drafting of any ruling application and subsequent correspondence,
and with the Seller being consulted in good faith on the approach which should be taken at any discussion, meetings or negotiations with the Swiss Tax authorities to discuss the ruling application, so far as permitted under Swiss law and being
informed within a reasonable time thereafter of the outcome of any such discussion, meeting or negotiation (but without giving the Seller any rights to attend); and 

  
 170

	 	(B)	amending the steps set out in Part 1 of this Schedule (at the Seller’s sole expense and risk) if, pursuant to their good faith cooperation under paragraph 1
of this Part 3, the parties identify any alternative or additional reasonable steps for implementing the Pre-Closing Product Reorganisation set out in this Schedule in a way which reduces or removes any risk indemnified under the Purchaser Tax
Indemnity. 

  

	3.	The parties shall co-operate in good faith in relation to the Company’s affairs with a view to minimising the Company’s balance sheet assets and
liabilities, and winding the Company up as soon as commercially practicable, in each case following completion of Step 8 and, if undertaken, Steps 9 to 12 and any agreed modifications to any of those Steps. 

 

	4.	Any modification or amendment of (including any addition to) the steps set out in Part 1 of this Schedule (other than the Seller electing at any time not to
proceed with the Pre-Closing Product Reorganisation) shall require the prior written consent of the Purchaser, not to be unreasonably withheld or delayed. Without prejudice to any other exercise of a discretion whether or not to give consent, the
Purchaser shall not be acting unreasonably if: 

  

	 	(A)	it withholds or delays its consent because it believes in good faith that the modification or amendment would result in exposure of any member of the Purchaser’s
Group to cost, loss of benefit or Liability; and 

  

	 	(B)	the relevant member or members of the Purchaser’s Group would not be indemnified (and the Seller does not agree to indemnify them), in each case to the
Purchaser’s reasonable satisfaction, in respect of that cost, loss of benefit or Liability. 

  

	5.	Nothing done by or at the request of the Seller pursuant to this Part 3 of this Schedule shall in any respect reduce or restrict any rights the Purchaser may
have to make a claim against the Seller under the Company Tax Indemnity or the Purchaser Tax Indemnity. 

  
 171

 Part 4 Definitions 

 

	1.	In this Schedule, the following expressions shall have the following meanings: 

“Indebtedness” means all loans and other financing liabilities and obligations in the nature of borrowed moneys and
overdrafts and moneys borrowed, but excluding trade debt and liabilities arising in the ordinary course of business; 

“Third Party Indebtedness” means any Indebtedness owed by the Company to any third party and, for the purposes of this
definition, third party shall exclude any member of the Seller’s Group; 
 Part 5 Details of the Company 

 

			
	Name of Company:	  	Leo Osprey Limited (the “Company”)
		
	Registered Number:	  	9000270
		
	Registered Office:	  	 980 Great West Road,

Brentford, TW8 9GS
 United
Kingdom

		
	Date and place of incorporation:	  	16 April 2014, United Kingdom
		
	Issued share capital:	  	one share of £1
		
	Shareholders and shares held:	  	Glaxo Group Limited             1 (100%)

  
 172

 Schedule 19 
 Pre-Closing Obligations 
 (Clause 5) 

Part 1 Seller’s Group Restrictions 
 The actions for the purposes of Clause 5.1.2 are: 
  

	1.1	(a) terminate, materially amend (or amend in any respect in relation to a Key Product) or grant any material waiver under (or any waiver in relation to a Key Product)
any Transferred Intellectual Property Contract, or (b) terminate any Transferred Contract other than in the ordinary course of business; 

  

	1.2	fail to comply in all material respects with all Applicable Law, Product Approvals and Marketing Authorisations applicable to the operation of the Business;

  

	1.3	assign, dispose of, license (save in respect of non-exclusive licences relating to the Seller’s research, development or Commercialisation of the Products)
or abandon any material Business Product Intellectual Property Rights (or any Business Product Intellectual Property Rights in respect of a Key Product) or cease to prosecute or fail to maintain, defend, or pursue applications for any material
Business Product Intellectual Property Rights (or any Business Product Intellectual Property Rights in respect of a Key Product); 

  

	1.4	save where requested in writing by the Purchaser or required by any applicable Governmental Entity, cancel, surrender or materially amend (or amend in any
respect in relation to a Key Product) any applications, submissions or filings with respect to Registered Business Product Intellectual Property Rights; 

  

	1.5	take any further steps to abandon US patent with publication number 2012/0202822; 

 

	1.6	terminate (except for good cause) the employment of any Key Personnel; 

 

	1.7	take any steps to increase or reduce the proportion of time spent working in the Business by any employee of any member of the Seller’s Group or to transfer
the employment of any Employee to another member of the Seller’s Group or to employ or offer to employ or engage any new persons in the Business other than in the ordinary course of business consistent with past practice and subject to an
aggregate increase of not more than 2.5 per cent. in total staff costs of the Business per annum; 

  

	1.8	make, or commit to make, any changes to the terms and conditions of employment (including pension fund commitments or any increase to remuneration) or to any
employee benefit plan of any Employee, other than (a) those required by Applicable Law or (b) pursuant to normal annual pay reviews in the ordinary course of business consistent with past practice and subject to an aggregate increase of
not more than 5 per cent. in total staff costs of the Business per annum or (c) retention arrangements (in the form of cash or shares) to retain key employees in connection with the matters contemplated by this Agreement as described in
paragraphs 9 and 10 of Schedule 8 or (d) those changes to share-based incentive schemes made for the purpose of complying with paragraph 10 of Schedule 8; 

  
 173

	1.9	make any promises or commitment to any Employees or employee representative body concerning the matters contemplated by this Agreement or offer or otherwise give
any assurances to any Employees as to the possibility of continued employment with the Purchaser’s Group after Closing; 

  

	1.10	make any change or commitment to make any change to the terms of any redundancy policy or practice applying to the Employees (including amounts payable on
redundancy); 

  

	1.11	enter into (where there is no existing agreement) or materially amend any collective bargaining agreement or other contract with a labour organisation, works
council or employee organisation to create new or additional obligations for any member of the Seller’s Group, in each case in relation to the Business; 

 

	1.12	instigate, cease, compromise or settle any litigation or arbitration proceedings related to the Business or the Company in relation to a claim for which the
potential liability attaching thereto is in excess of US$5 million; 

  

	1.13	make any material amendment to any Marketing Authorisation, except to the extent required by: (a) Applicable Law; (b) any Governmental Entity, or
(c) the standards, policies and procedures of the Seller’s Group as then in force; 

  

	1.14	enter into or amend in any material respect any Transferred Contract, or incur any commitment, which is not capable of being terminated without compensation at
any time with twelve months’ notice or less or which is not in the ordinary course of business, or which involves or may involve total annual expenditure in excess of US$10 million, exclusive of VAT; 

 

	1.15	enter into any contract which would materially restrict the freedom of the Business to operate in any part of the world; 

 

	1.16	save in respect of Intellectual Property Rights, sell, lease, license, transfer or dispose of, or create any Encumbrance (other than a Permitted Encumbrance)
over, any material assets (other than any Excluded Asset) of the Business; 

  

	1.17	undertake any recall or withdrawal of any Product (other than in the ordinary course of business or to comply with Applicable Law); 

 

	1.18	amend or otherwise modify the constitutional documents of the Company other than minor or administrative amendments or modifications which are not adverse to the
Business or to the Purchaser or any member of the Purchaser’s Group; 

  

	1.19	create, allot or issue, or grant an option or right to subscribe for or purchase, any share capital or other securities or loan capital of the Company;

  

	1.20	repay, redeem or repurchase any share capital, or other securities of the Company; and 

 

	1.21	cause or permit the Company to be subject to Tax in any jurisdiction other than in the United Kingdom. 

  
 174

 Part 2 Seller’s Group Obligations 

 

	1.	Obligations to be satisfied prior to the Closing Date 

  

	1.1	The Seller shall procure that the relevant member of the Seller Group shall notify, Pharmacare Limited in writing, in relation to: 

1.1.1 the distribution agreement dated 27 November 2009 between Pharmacare Limited and Glaxo South Africa (Proprietary) Limited
(the “SA Distribution Agreement”); and 
 1.1.2 the SSA Collaboration Agreement dated 27 November 2009
between Pharmacare Limited, Glaxo Export Limited (the “SSA Collaboration Agreement”), 
 of the withdrawal of
the Products to the extent relevant from the agreements set out in the SA Distribution Agreement and the SSA Collaboration Agreement, in each case with effect from Closing. 

 

	1.2	The Seller shall procure that the relevant member(s) of the Seller’s Group shall use best efforts to: 

1.2.1 obtain the unconditional consent of [***] to the assignment to the Purchaser of the rights and obligations of the relevant
member of the Seller’s Group under each of the [***] (at the Seller’s cost); and 
 1.2.2 obtain the
unconditional consent of [***] to the assignment to the Purchaser of the rights and obligations of the relevant member of the Seller’s Group under the [***] (at the Seller’s cost). 

 

	1.3	At least 5 Business Days prior to the Closing Date, the Seller shall provide the Purchaser with a list of any required actions that must be taken by the
Purchaser within three (3) months after Closing with respect to the payment of any registration, maintenance, or renewal fees or the filing of any documents, applications or certificates in order to maintain Registered Intellectual Property
Product Rights in full force and effect. Upon the Purchaser’s reasonable request, the Seller shall execute and deliver assignment agreements and other transfer documentation, including duly executed assignments of the Registered Business
Product Intellectual Property Rights for recording with the applicable Governmental Entity, and to take such further actions, in each case, subject to Clause 2.3.5(ii), at the Purchaser’s reasonable cost and expense and as may be required, to
give effect to the foregoing assignments. 

  

	2.	Obligations from the date of the Agreement to the Closing Date 

 The requirements for the purposes of Clause 5.1.3 are: 
  

	2.1	so far as permitted by Applicable Law, inform the Purchaser promptly if it becomes aware of, or has reasonable grounds for suspecting any violation of
Anti-Bribery Law which is reasonably likely to have an impact on the Business; 

  

	2.2	maintain in force all Seller’s Group Insurance Policies for the benefit of the Business; 

 

	2.3	allow the Purchaser and its respective agents, upon reasonable notice, reasonable access to personnel, and such information as the Seller considers reasonable,
provided that the obligations of the Seller under this Clause shall not extend to allowing access to information which is (i) reasonably regarded as confidential to the activities of the Seller and the Seller’s Group otherwise than in
relation to the Business or (ii) commercially sensitive or other information which is related to the Business if such information cannot be shared with the Purchaser prior to Closing in compliance with Applicable Law; 

  
 175

	2.4	in so far as it relates to the Business, continue to take such steps as are currently planned by the Seller’s Group in relation to the remediation of the
manufacturing site operated by the Seller’s Group in Cork, Ireland; 

  

	2.5	maintain and keep any Business Product Intellectual Property Rights and ensure that all filings and notifications required to be made in respect of the same are
made in accordance with past practice; 

  

	2.6	progress, in accordance with past practice, any applications, submissions, filings or other correspondence relating to the grant of new Business Product
Intellectual Property Rights; 

  

	2.7	continue to conduct the Ongoing Clinical Trials in accordance with GCP and the Seller Group’s policies and procedures; 

 

	2.8	notify the Purchaser in writing of any actual safety or quality issue in respect of any Product or the manufacture of any Product (as soon as reasonably
practicable after becoming aware of the same) which issue the relevant member of the Seller’s Group, acting reasonably and in good faith, considers material in the context of the manufacture or commercialisation of such Product;

  

	2.9	so far as permitted by Applicable Law, report periodically to the Purchaser concerning the status of the Business, including delivering to the Purchaser as soon
as reasonably practicable each month: 

  

	 	2.9.1	an update on material commercial developments in relation to the Business and the Products during the previous month; 

 

	 	2.9.2	the gross profit for each Product in respect of the previous month; and 

 

	 	2.9.3	a report on the month-end in-trade inventory in respect of each Product for the previous month prepared in the ordinary course of business consistent with past
practice, together with a comparison against the comparable period of trading for the prior year; 

  

	2.10	not discontinue or cease to operate or materially reduce the resources applied to any part of the Business related to the Products or the Product Expansions;

  

	2.11	continue to promote, market and Commercialise the Products in a manner consistent with past practice; 

 

	2.12	maintain levels of in-trade inventory in accordance with past practice and not materially accelerate or increase the quantity of the Products distributed to the
relevant distributors and/or wholesalers, except in respect of a bona fide increase in demand for the relevant Product by the relevant distributor and/or wholesaler which has not been stimulated in any way by discounts, rebates, claw-backs or the
like outside of the ordinary course or the grant of preferred terms offered by the Seller’s Group outside of the ordinary course; and 

  
 176

	2.13	continue to respond to any Call For New Tender in accordance with past practices in the relevant market. 

  
 177

 Schedule 20 
 Key Personnel 
 [***] 

 

	***	Note: Confidential treatment has been requested with respect to the information contained within the [***] marking. Such portions, consisting of two pages, have been
omitted from this filing and have been filed separately with the Securities and Exchange Commission. 

  
 178

 Schedule 21 
 Regulatory Approvals 
  

	1.	The following table provides the additional jurisdictions and applicable antitrust, merger control, or foreign investment rules referenced in Clause 4.1.3
of the Agreement. 

  

	2.	This list of jurisdictions and statutes is not meant to be indicative of a known filing or approval requirement in these jurisdictions. To the extent that
clearances, approvals, waivers, no action letters or consents are not required to be obtained or not otherwise agreed by the parties to be appropriate and waiting periods are not required to have expired in these jurisdictions prior to closing of
the transactions contemplated by the Agreement, such clearances, approvals, waivers, no action letters, consents, and waiting period expirations will not be conditions precedent to closing of the transactions contemplated by the Agreement.

  

			
	 Country
	  	 Statute Under Which Filing/Approval Is Required

		
	Australia	  	The Competition and Consumer Act of 2010
		
	Brazil	  	Law No. 12,529 of November 30, 2011
		
	Canada	  	The Competition Act
		
	China	  	The Chinese Anti-Monopoly Law
		
	India	  	The Competition Act of 2002, as amended by The Competition (Amendment) Act of 2007
		
	Israel	  	The Restrictive Trade Practices Law, 5748-1988
		
	Japan	  	The Act on Prohibition of Private Monopolisation and Maintenance of Fair Trade No. 54 of 1947
		
	Mexico	  	The Federal Law on Economic Competition
		
	New Zealand	  	The Commerce Act of 1986
		
	Russia	  	Federal Law No. 135-FZ of July 16, 2006 on Protection of Competition
		
	South Africa	  	The Competition Act 89 of 1998
		
	South Korea	  	The Monopoly Regulation and Fair Trade Act
		
	Taiwan	  	The Fair Trade Law of 1991

  
 179

			
	Turkey	  	The Law on Protection of Competition No. 4054 of 1994

  
 180

 Schedule 22 
 Ongoing Collaboration 
  

	1.	Subject to paragraph 4 below, in the event that: 

  

	 	1.1.1	any member of the Seller’s Group decides in its applicable governance committee (and in any event before approaching any third party) to seek a third party
partner for global or major market (that is, pan-EU, Spain, Italy, UK, Germany, France, US, a group of emerging markets, Switzerland, Japan, Canada or China) co-development or commercialisation of, or to whom to divest rights to, any Relevant
Development Product (the “In-scope Relevant Development Product”); or 

  

	 	1.1.2	any member of the Seller’s Group proposes to seek a marketing authorisation in a major market (that is, EU, US, Switzerland, Japan, Canada or China) for an
In-Scope Relevant Development Product, 

 the Seller shall (prior to (in the case of paragraph 1.1.1 above)
entering into any such discussions with any third party or (in the case of paragraph 1.1.2 above) filing an application for any such marketing authorisation) first notify the Purchaser of the same, including in such notification details of the
geographic markets in which it would intend to explore opportunities with the third party. The Purchaser shall then have a period of 30 days to confirm whether or not it is in principle interested in pursuing discussions regarding the co-development
and commercialisation or acquisition of the In-scope Relevant Development Product, and shall specify to the Seller the geographic markets in which it is interested in the opportunity (which need not be limited to the markets specified by the Seller
and may be worldwide). If the Purchaser declines the same or confirms in writing that it is not interested, then the provisions of this Schedule shall cease to apply with respect to such In-scope Relevant Development Product for the following 24
months. 
  

	2.	If the Purchaser confirms its interest in pursuing discussions, then, during the 6 month period from the date of such notification (the “Negotiation
Period”): 

  

	2.1	the Seller shall not (and shall procure that no other member of its Group shall) enter into any discussions or negotiations with any third party in relation to
possible co-development and commercialisation arrangements in respect of or the divestment of the In-scope Relevant Development Product in all territories specified by the Seller and/or the Purchaser in the foregoing notifications;

  

	2.2	the Seller shall make available to the Purchaser, subject to reasonable obligations and appropriate arrangements of confidence and compliance, all information
reasonably necessary for the Purchaser to assess the opportunity, including information regarding project budgets and costs, timelines and relevant clinical plans and data; and 

 

	2.3	 the Seller and the Purchaser (or the relevant members of their respective Groups) shall negotiate in good faith, the terms and conditions of a
co-development and commercialisation arrangement for or divestment of the In-Scope Relevant 

  
 181

	 	
Development Product, including (without limitation) financial terms, allocation of costs and responsibilities, project governance arrangements and appropriate intellectual property licences,
which terms and conditions shall include (without limitation), exclusive commercialization rights in favour of the Purchaser with respect to the In-Scope Relevant Development Product and otherwise be reasonable and customary (for similarly situated
products). 

  

	3.	In the event that the Negotiation Period expires and the Seller and the Purchaser (or the relevant members of their respective Groups) have not entered into a
binding agreement in relation to the co-development or commercialisation or acquisition of the In-scope Relevant Development Product, then the Seller (or the relevant member of its Group) shall be free: 

 

	 	3.1.1	to pursue the continued internal development and commercialisation of such In-scope Relevant Development Product; or 

 

	 	3.1.2	at any time thereafter, to enter into discussions and/or negotiations with a third party in relation to the same, provided that for a period of 18 months after
such expiration, the Seller shall not enter into an agreement with a third party involving any such co-development and/or commercialisation arrangement for or divestment of the In-scope Relevant Development Product on terms that are more favourable
to the third party than those last offered by the Seller to the Purchaser without first notifying the Purchaser of the material terms thereof and offering the Purchaser the right to match the offer by entering into an agreement on such terms (or
substantially similar terms if any of such terms are unique to the third party). In the event that such an offer is made by the Seller, the Purchaser shall have a period of 30 days to accept it. If the Purchaser does not do so within such period,
then the Seller shall be free to proceed with the agreement with the third party on substantially such terms without further restrictions hereunder; provided, that, in the spirit of partnership, the Seller will in any event notify the Purchaser at
least 5 days prior to entering into an agreement with a third party regarding such an arrangement or divestment, including (where not restricted by law or contract from doing so) the material terms thereof (it being understood that, other than as
provided above, no match right will apply), 

 and, save as provided in paragraph 3.1.2 above, the provisions
of this Schedule shall cease to apply with respect to such In-scope Relevant Development Product. 
  

	4.	The provisions of this Schedule: 

  

	4.1	shall expire 12 years and six months after Closing unless renewed by mutual agreement; 

 

	4.2	shall apply subject to the Seller’s existing written agreements with third parties, provided that the Seller represents and warrants that neither it nor any
member of its Group is party to any agreement or arrangement with a third party which would materially impact the expected benefit to the Purchaser of the arrangement set out in this Schedule; 

  
 182

	4.3	shall apply notwithstanding Clause 12.1 (Non-compete) and, subject to the provisions of this Schedule, shall not restrict any activities of the
Seller’s Group in relation to the research and development (including manufacturing for development) of or relating to Relevant Development Products; 

  

	4.4	shall not apply to situations where the Seller is seeking a third party partner for the co-development or commercialisation of a broad portfolio of products
where the majority of such portfolio is not comprised of Relevant Development Products; and 

  

	4.5	for the avoidance of doubt, shall not apply to situations where the Seller is seeking a third party contractor to provide research or development services.

  
 183

 Schedule 23 
 Seller Marks 
 GLAXOSMITHKLINE 
 GLAXO 
 GSK 
 SMITHKLINE 
 SMITHKLINE BEECHAM 
 SB 
 STERLING 
 STIEFEL 
 WELLCOME 
 GLAXO WELLCOME 
 GSK Logo 
 GLAXOSMITHKLINE Logo 
 STIEFEL Logo 

  
 184

 Schedule 24 
 Statement of Company Intra-Group Debt 
 Amount of the Company Intra-Group Debt in US$, as
determined by the Seller using the US$ Spot Rate: 
 US$             

Agreed and accepted: 
  

	
	  

 For and on behalf of the Seller 
  

	
	  

 For and on behalf of the Purchaser 
  

	
	  

 For and on behalf of the Purchaser 

  
 185

 Schedule 25 
 Seller’s Indian Business 
  

	1.	The parties acknowledge and agree that the Seller’s Indian Business cannot be transferred to the Purchaser without the approval of the Indian Foreign Investment
Promotion Board (“FIPB Approval”) and therefore this Agreement shall not be construed as a transfer or attempted transfer of the Seller’s Indian Business without FIPB Approval. 

 

	2.	The Purchaser agrees to use its reasonable endeavours to obtain FIPB Approval prior to Closing. Without prejudice to the generality of the foregoing, the Purchaser
shall, as soon as reasonably practicable following the date of this Agreement: 

  

	 	(i)	commence the process in relation to the obtaining of the FIPB Approval; and 

 

	 	(ii)	give the Seller a reasonable opportunity to take part in the process of, and to review and comment on any material documentation in relation to (with the Purchaser to
take reasonable account of any such comments), the obtaining of FIPB Approval. 

  

	3.	The Seller shall cooperate with the Purchaser in connection with obtaining the FIPB Approval and shall promptly provide the Purchaser with information reasonably
required by the Purchaser in respect of the Seller’s Indian Business to seek and obtain FIPB Approval. 

  

	4.	In the event that FIPB Approval is not obtained prior to Closing, such that the Seller’s Indian Business cannot be transferred to the Purchaser upon Closing in
accordance with the provisions of this Agreement: 

  

	4.1	the parties shall use reasonable endeavours to obtain FIPB Approval and to procure that the Seller’s Indian Business is transferred to the Purchaser as soon as
reasonably practicable after Closing; 

  

	4.2	until FIPB Approval is obtained, the Seller shall continue to operate and run the Seller’s Indian Business and provide the Purchaser with full details of the sales
of each Product made by the Seller’s Indian Business on a monthly basis between Closing and the date of India Closing (as defined below); 

  

	4.3	prompty following receipt of the FIPB Approval, the transfer of any assets or rights comprising the Seller’s Indian Business shall be effected, and Closing in
respect of the Seller’s Indian Business shall otherwise take place in accordance with the terms of this Agreement (“India Closing”); and 

 

	4.4	 the Seller shall remit to the Purchaser an amount for the sales made by the Seller’s Indian Business in respect of the Products during the period
from Closing until India Closing, as calculated in accordance with the provisions of the 

  
 186

	 	
Transitional Distribution Services Agreement related to the remittance of sales of the Products made by the Seller’s Group post-Closing and payable on the first date following India Closing
on which such amounts are to be remitted to the Purchaser or a member of the Purchaser’s Group under the Transitional Distribution Services Agreement. 

  
 187

							
	1.	 	INTERPRETATION	  	 	2	  
			
	2.	 	SALE AND PURCHASE OF THE BUSINESS	  	 	27	  
			
	3.	 	AMOUNTS PAYABLE	  	 	33	  
			
	4.	 	CONDITIONS	  	 	34	  
			
	5.	 	PRE-CLOSING	  	 	42	  
			
	6.	 	CLOSING	  	 	45	  
			
	7.	 	DEVELOPMENT PLANS	  	 	50	  
			
	8.	 	POST-CLOSING OBLIGATIONS	  	 	51	  
			
	9.	 	WARRANTIES	  	 	60	  
			
	10.	 	LIMITATION OF LIABILITY	  	 	61	  
			
	11.	 	CLAIMS	  	 	64	  
			
	12.	 	RESTRICTIVE COVENANTS	  	 	66	  
			
	13.	 	CONFIDENTIALITY	  	 	68	  
			
	14.	 	INSURANCE	  	 	69	  
			
	15.	 	FRANCE BUSINESS AND NETHERLANDS BUSINESS	  	 	70	  
			
	16.	 	OTHER PROVISIONS	  	 	72	  
		
	 SCHEDULE 1 PRODUCTS
	  	 	80	  
		
	 SCHEDULE 2 CERTAIN INTELLECTUAL PROPERTY RIGHTS MATTERS (CLAUSE 2.3.1)
	  	 	92	  
		
	 SCHEDULE 3 EXCLUDED ASSETS AND EXCLUDED CONTRACTS (CLAUSE 2.3.2)
	  	 	93	  
		
	 SCHEDULE 4 EXCLUDED LIABILITIES (CLAUSE 2.3.4)
	  	 	94	  
		
	 SCHEDULE 5 PERMITTED ENCUMBRANCES (CLAUSE 1.1)
	  	 	95	  
		
	 SCHEDULE 6 PRODUCT APPROVALS (CLAUSE 6.2.2)
	  	 	96	  
		
	 SCHEDULE 7 TRANSFERRED CONTRACTS, TRANSFERRED INTELLECTUAL PROPERTY CONTRACTS, CO-OWNED TRANSFERRED PRODUCT
INTELLECTUAL PROPERTY RIGHTS, AND SHARED BUSINESS CONTRACTS (CLAUSE 2.3.1)
	  	 	105	  
		
	 SCHEDULE 8 EMPLOYEES (CLAUSE 2.4.1)
	  	 	110	  
		
	 SCHEDULE 9 EMPLOYEE BENEFITS (CLAUSE 2.4.2)
	  	 	125	  
		
	 SCHEDULE 10 ALLOCATION (CLAUSE 3.2)
	  	 	134	  
		
	 SCHEDULE 11 VAT
	  	 	136	  
		
	 SCHEDULE 12 CLOSING OBLIGATIONS
	  	 	139	  
		
	 SCHEDULE 13 NOT USED
	  	 	141	  

					
	 SCHEDULE 14 WARRANTIES GIVEN UNDER CLAUSE 9.1
	  	 	142	  
		
	 SCHEDULE 15 WARRANTIES GIVEN BY THE PURCHASER UNDER CLAUSE 9.3
	  	 	157	  
		
	 SCHEDULE 16 CERTIFICATE (CLAUSE 4.4)
	  	 	159	  
		
	 SCHEDULE 17 KEY STUDY PLANS
	  	 	160	  
		
	 SCHEDULE 18 PRE-CLOSING PRODUCT REORGANISATION
	  	 	161	  
		
	 SCHEDULE 19 PRE-CLOSING OBLIGATIONS
	  	 	173	  
		
	 SCHEDULE 20 KEY PERSONNEL
	  	 	178	  
		
	 SCHEDULE 21 REGULATORY APPROVALS
	  	 	179	  
		
	 SCHEDULE 22 ONGOING COLLABORATION
	  	 	181	  
		
	 SCHEDULE 23 SELLER MARKS
	  	 	184	  
		
	 SCHEDULE 24 STATEMENT OF COMPANY INTRA-GROUP DEBT
	  	 	185	  
		
	 SCHEDULE 25 SELLER’S INDIAN BUSINESS
	  	 	186EX-4.11

 Exhibit 4.11 

CONFIDENTIAL TREATMENT REQUESTED 

EXECUTION VERSION 
 29 May 2014 

NOVARTIS AG 
 and 

GLAXOSMITHKLINE PLC 
 DEED OF
AMENDMENT AND RESTATEMENT 
 relating to the 

PUT OPTION DEED 
 relating to all
or part of the Influenza Business of the Novartis Group, dated 22 April 2014 
 Linklaters 

Linklaters LLP 
 One Silk Street 

London EC2Y 8HQ 
 Telephone (+44) 20 7465 2000 

Facsimile (+44) 20 7456 2222 
 Ref L-220595 

 This Deed (the “Deed”) is made on 29 May 2014 between: 

 

	(1)	NOVARTIS AG, a corporation (Aktiengesellschaft) incorporated in Switzerland whose registered office is at Lichtstrasse 35, 4056 Basel, Switzerland (“Novartis”); and 

 

	(2)	GLAXOSMITHKLINE PLC, a public limited company incorporated in England and Wales whose registered office is at 980 Great West Road Brentford, Middlesex, TW8 9GS (the “Purchaser”),

 each a “party” and together the “parties”.  

Whereas: 
  

	 	(A)	Novartis and the Purchaser entered into the Original Deed (as defined below) on 22 April 2014 (the “Signing Date”). 

 

	 	(B)	In connection with the Original Deed, Novartis provided the Original Disclosure Letter (as defined below) to the Purchaser. 

  

	 	(C)	Novartis and the Purchaser now wish to amend and restate: 

  

	 	(i)	the Original Deed, in the form of the Amended Deed (as defined below); and 

  

	 	(ii)	the Original Disclosure Letter, in the form of the Amended Disclosure Letter (as defined below). 

 It is
agreed as follows: 
  

	1	Definitions and Interpretation 

  

	    	In this Deed, unless the context otherwise requires, the provisions in this Clause 1 apply. 

  

	1.1	Incorporation of defined terms 

  

	    	Unless otherwise stated, terms defined in the Original Deed shall have the same meaning in this Deed. 

  

	1.2	Definitions 

  

	    	“Amended Deed” means the Original Deed, as amended and restated in the form set out in Schedule 1 to this Deed; 

 

	    	“Amended Disclosure Letter” means the Original Disclosure Letter, as amended and restated in the form set out in Schedule 2 to this Deed; 

 

	    	“Original Deed” means the Put Option Deed relating to all or part of the Influenza Business of the Novartis Group, dated 22 April 2014; and 

 

	    	“Original Disclosure Letter” means the letter given on the Signing Date from Novartis to the Purchaser disclosing information constituting exceptions to Novartis’s Warranties.

  

	1.3	Interpretation clauses 

  

	 	1.3.1	The principles of interpretation set out in Clause 1 of the Original Deed shall have effect as if set out in this Deed, save that references to “this Deed” shall be construed as references to this Deed.

  

	 	1.3.2	References to this Deed include the Schedules. 

  

	2	Amendment 

  

	2.1	In accordance with Paragraphs 15.4.3 and 15.5.1 of Schedule 1 of the Original Deed, the parties agree that the Original Deed shall be amended and restated as set out in Schedule 1 to this Deed. 

 

	2.2	The parties agree that the Original Disclosure Letter shall be amended and restated as set out in Schedule 2 to this Deed. 

  

	2.3	The amendment and restatement of the Original Deed pursuant to clause 2.1 and the amendment and restatement of the Original Disclosure Letter pursuant to clause 2.2 shall take effect from the Signing Date, as if the
Amended Deed and the Amended Disclosure Letter had been entered into on the Signing Date. Therefore, upon this Deed being entered into: 

  

	 	2.3.1	the Amended Deed shall supersede the Original Deed in its entirety; and 

  

	 	2.3.2	the Amended Disclosure Letter shall supersede the Original Disclosure Letter in its entirety. 

  

	3	Miscellaneous 

  

	3.1	Each party represents and warrants that it has full power and authority to enter into this Deed and to perform its obligations under it. 

 

	3.2	The provisions of Paragraphs 13, 15.2 to 15.5 and 15.11 to 15.15 of Schedule 1 of the Amended Deed shall apply to this Deed as if set out in full in this Deed and as if references in those Paragraphs to “this
Deed” are references to this Deed and references to “party” or “parties” are references to parties to this Deed. 

In witness whereof this Deed has been delivered on the date first stated above. 

 

					
	 Executed as a DEED by

Roy Papatheodorou
  

 
 AND
		 }
		 /s/ Roy Papatheodorou

	 Jonathan Emery

on

behalf of

NOVARTIS AG
			 /s/ Jonathan Emery

  

					
	Executed as a DEED by		)		
	GLAXOSMITHKLINE PLC		)		/s/ David Redfern
	acting by its duly appointed attorney		)		(Signature of attorney)
			)		
	in the presence of:		)		
			
	Witness’s signature:				/s/ Claire Jackson
			
	Name (print):				Claire Jackson
			
	Occupation:				Solicitor
			
	Address:				One Bunhill Row, London

 Schedule 1 

Amended Agreement 

 EXECUTION VERSION 

Dated 22 April 2014 
 as
amended and restated on 29 May 2014 
 NOVARTIS AG 

and 
 GLAXOSMITHKLINE PLC 

PUT OPTION DEED 
 relating to all
or part of the Influenza Business of the Novartis Group 

 Execution Version 
  

Table of Contents 
  

							
	Contents	  	 	  	Page	 
			
	 1
	  	Interpretation	  	 	2	  
			
	 2
	  	Put Option	  	 	7	  
			
	 3
	  	Termination	  	 	9	  
			
	 4
	  	Payment of Compensation / Disposal after Payment of Compensation	  	 	10	  
			
	 5
	  	Sale to Third Party Purchaser and Separation	  	 	12	  
			
	 6
	  	Application of provisions of Schedule 1	  	 	13	  
		
	 Schedule 1 Influenza Business – Terms and Conditions of Sale and Purchase
	  	 	16	  
		
	 Schedule 2 Option 2 Assets
	  	 	4	  
		
	 Schedule 3 Option 3
	  	 	8	  
		
	 Schedule 4 Option 4 Products Terms
	  	 	9	  

  
  

1 

 Execution Version 
  

Put Option Deed 
 This Deed is made on 22 April
2014 and amended and restated on 29 May 2014 between: 
  

	(1)	Novartis AG a corporation (Aktiengesellschaft) incorporated in Switzerland whose registered office is at Lichstrasse 35, 4056 Basel, Switzerland (“Novartis”); and

  

	(2)	GlaxoSmithKline plc a company incorporated in England and Wales whose registered office is at 980 Great West Road, Brentford, Middlesex, United Kingdom (the “Purchaser”),

 each a “party” and together the “parties”. 

Whereas: 
 The parties wish to provide Novartis with a
right to require the Purchaser to purchase the influenza business of the Novartis Group or a part of that business subject to the terms and conditions set out in this Deed. 

It is agreed as follows: 
  

	1	Interpretation 

 In this Deed (including its Schedules and Appendices), unless the
context requires otherwise, the provisions in this Clause 1 apply: 
  

	1.1	Definitions 

 “Affiliate” means: 

 

	 	(i)	with respect to any person (other than a party to this Deed), any other person that Controls, is Controlled by or is under common Control with such person; or 

 

	 	(ii)	with respect to a party to this Deed, any other person that is Controlled by such party, 

 and
“Affiliates” shall be interpreted accordingly; 
 “Applicable Law” means any supra-national, federal,
national, state, municipal or local statute, law, ordinance, regulation, rule, code, order (whether executive, legislative, judicial or otherwise), judgment, injunction, notice, decree or other requirement or rule of law or legal process (including
common law), or any other order of, or agreement issued, promulgated or entered into by, any Governmental Entity or any rule or requirement of any national securities exchange, including all Healthcare Laws, and GCP, GLP and GMP, each as may be
amended from time to time; 
 “Business” has the meaning given in Schedule 1; 

“Business Day” means a day which is not a Saturday, a Sunday or a public holiday in the canton of Basel-Stadt (Switzerland) or
London; 
 “Cell-based Influenza Business” has the meaning given in Schedule 1; 

“Class 1 Transaction” means a transaction requiring shareholder approval under Chapter 10 of the Listing Rules; 

“Compensation Amount” has the meaning given in Clause 4.1.1; 

  
  

2 

 Execution Version 
  

“Consumer Contribution Agreement” means the contribution agreement dated the date of this Deed between Novartis and the
Purchaser relating to the establishment of a joint venture between Novartis and the Purchaser; 
 “Contract” means any
binding contract, agreement, instrument, lease, licence or commitment, excluding (i) any lease or other related or similar agreements, undertakings and arrangements with respect to the leasing or ownership of the Properties (to which the
provisions set out in Appendix 3 to Schedule 1 shall apply); and (ii) any contract with any Employee; 
 “Control”
means the power to direct the management and policies of a person (directly or indirectly), whether through ownership of voting securities, by Contract or otherwise (and the term “Controlled” shall be interpreted accordingly); 

“Egg-based Influenza Business” has the meaning given in Schedule 1; 

“Exercise Period” has the meaning given in Clause 2.2.1; 

“FCA” means the Financial Conduct Authority; 

“FSMA” means the Financial Services and Markets Act 2000; 

“Good Clinical Practices” or “GCP” means the then-current standards, practices and procedures promulgated or
endorsed by (i) the ICH Harmonised Tripartite Guidelines for Good Clinical Practice (CPMP/ICH/135/95) and any other guidelines for good clinical practices for trials on medicinal products in the European Union; (ii) the FDA as set forth in
the guidelines entitled “Guidance for Industry E6 Good Clinical Practice: Consolidated Guidance,” including related regulatory requirements imposed by the FDA; and (iii) the equivalent Applicable Law in any relevant country; 

“Good Laboratory Practices” or “GLP” means the then-current standards, practices and procedures promulgated
or endorsed by: (i) the European Commission Directive 2004/10/EC relating to the application of the principles of good laboratory practices as well as “The rules governing medicinal products in the European Union,” Volume 3,
Scientific guidelines for medicinal products for human use (ex - OECD principles of GLP); (ii) the then-current standards, practices and procedures promulgated or endorsed by the FDA as defined in 21 C.F.R. Part 58; and (iii) the
equivalent Applicable Law in any relevant country; 
 “Good Manufacturing Practices” or “GMP” means the
then-current standards, practices and procedures promulgated or endorsed by: (i) the European Commission Directive 91/356/EEC, as amended by Directive 2003/94/EC and 91/412/EEC respectively, as well as “The rules governing medicinal
products in the European Union,” Volume 4, Guidelines for good manufacturing practices for medicinal products for human and veterinary use; (ii) the FDA and the provisions of 21 C.F.R. Parts 210 and 211; (iii) the principles detailed
in the ICH Q7A guidelines; and (iv) all Applicable Law with respect to each of (i) through (iii); 
 “Governmental
Entity” means any supra-national, federal, national, state, county, local, municipal or other governmental, regulatory or administrative authority, agency, commission or other instrumentality, any court, tribunal or arbitral body with
competent jurisdiction, or any national securities exchange or automated quotation service including any governmental regulatory authority or agency responsible for the grant, approval, clearance, qualification, licensing or permitting of any aspect
of the research, development, manufacture, marketing distribution or sale of the Products including the FDA, the European Medicines Agency, or any successor agency hereto; 

  
  

3 

 Execution Version 
  

“Healthcare Laws” means the federal Anti-kickback Statute (42 U.S.C. § 1320a-7b(b)); the Anti-Inducement Law (42 U.S.C.
§ 1320a-7a (a)(5)); the civil False Claims Act (31 U.S.C. §§ 3729 et seq.); the administrative False Claims Law (42 U.S.C. § 1320a-7b(a)); the Exclusion Laws (42 U.S.C. § 1320a-7); the Medicare statute (Title XVIII of the
Social Security Act), including Social Security Act §§ 1860D-1 to 1860D-43 (relating to Medicare Part D and the Medicare Part D Coverage Gap Program); the Medicaid statute (Title XIX of the Social Security Act); the Physician Payment
Sunshine Act (42 U.S.C. § 1320a-7h) and any analogous state laws; the Health Insurance Portability and Accountability Act of 1996 (42 U.S.C. § 1320d et seq.), as amended by the Health Information Technology for Economic and Clinical Health
Act of 2009, and any other similar law, including the price reporting requirements and the requirements relating to the processing of any applicable rebate, chargeback or adjustment, under applicable rules and regulations relating to the Medicaid
Drug Rebate Program (42 U.S.C. § 1396r-8), any state supplemental rebate program, Medicare average sales price reporting (42 U.S.C. § 1395w-3a), the Public Health Service Act (42 U.S.C. § 256b), the Veterans Health Care Act (38 U.S.C.
§ 8126), regulatory requirements applicable to sales on the Federal Supply Schedule or under any state pharmaceutical assistance program or United States Department of Veterans Affairs agreement, all legal requirements relating to the billing
or submission of claims, collection of accounts receivable, underwriting the cost of, or provision of management or administrative services in connection with, any and all of the foregoing, by the Novartis Group and any successor government
programs, and all foreign equivalents of the foregoing; 
 “Implementation Agreement” means the implementation agreement
dated the date of this Deed between Novartis and the Purchaser relating to, among other things, the transactions contemplated by this Deed; 

“Intellectual Property Rights” has the meaning given in Schedule 1; 

“Listing Rules” means the Listing Rules made by the FCA under section 73A of FSMA, as from time to time amended; 

“Novartis Group” means Novartis and its Affiliates from time to time; 

“Oncology Group Businesses” has meaning given in the Oncology SAPA; 

“Oncology SAPA” means the Share and Business Sale Agreement dated the date of this Deed between Novartis and the Purchaser
relating to the Oncology Group Businesses; 
 “Option Assets” means the Option 1 Assets; the Option 2 Assets; the Option 3
Assets; the Option 4 Assets or any combination thereof specified in accordance with Clause 2.1, as the case may be; 
 “Option 1
Assets” means the Business; 
 “Option 2 Assets” means the assets comprising the Cell-based Influenza Business;

 “Option 3 Assets” means the assets comprising the Egg-based Influenza Business; 

“Option 4 Assets” means the assets of the Novartis Group set out in Schedule 4; 

“Option Closing” means the completion of the sale of the Relevant Option Assets on the terms and subject to the conditions set
out in Schedule 1; 
 “Option Closing Date” means the date on which Option Closing takes place; 

  
  

4 

 Execution Version 
  

“Option Exercise Date” has the meaning given in Clause 2.2.2; 

“Option Long Stop Date” has meaning given in Clause 3.4.2; 

“Option Price” means the consideration payable by the Purchaser to Novartis at Option Closing for the Relevant Option Assets
in accordance with the terms of this Deed; 
 “Purchaser’s Group” means the Purchaser and its Affiliates from time to
time; 
 “Put Option” has the meaning given in Clause 2.1; 

“Put Option Deed” means this deed; 

“Put Option Price” has the meaning given in Clause 2.1; 

“Relevant Event” has the meaning given in Clause 4.2.2; 

“Relevant Option Assets” has the meaning given in Clause 2.3; 

“Relevant Payment” has the meaning given in Clause 4.1.4; 

“Relevant Period” means the period from and including the day on which any Compensation Amount is paid by the Purchaser
pursuant to Clause 4.1.2 and ending on and including the date falling 18 months after such date; 
 “Taxation” or
“Tax” means all supra-national, federal, state, county, local, municipal, foreign and other taxes, assessments, duties or similar charges of any kind whatsoever (other than deferred tax), including all corporate franchise, income,
gross receipts, sales, use, ad valorem, receipts, value added, profits, licence, withholding, payroll, employment, excise, premium, property, net worth, capital gains, transfer, stamp, documentary, social security, alternative minimum, occupation,
recapture and other taxes regardless as to whether any such taxes, assessments, duties or similar charges are chargeable directly or primarily against or attributable directly or primarily to a member of the Novartis Group or any other person, and
including all interest, penalties and additions imposed with respect to such amounts by any Tax Authority or with respect to any failure to file any Tax Return; 

“Tax Authority” means any taxing or other authority competent to impose any liability in respect of Taxation or responsible
for the administration and/or collection of Taxation or enforcement of any law in relation to Taxation; 
 “Third Party
Purchaser” means any person who is not a member of the Novartis Group; 
 “Third Party Purchaser Intellectual Property
Rights” has the meaning given in Clause 5.1.3; 
 “VAT” means within the European Union such Taxation as may be
levied in accordance with (but subject to derogations from) Council Directive 2006/112/EC and outside the European Union any Taxation levied by reference to added value or sales; 

“Vaccines Group Businesses” has the meaning given in the Vaccines SAPA; 

“Value Received” has the meaning given in Clause 4.2.1; and 

“Vaccines SAPA” means the Share and Business Sale Agreement dated the date of this Deed between Novartis and the Purchaser
relating to the Vaccines Group Businesses. 

  
  

5 

 Execution Version 
  

 

	1.2	Singular, plural, gender 

 References to one gender include all genders and references to
the singular include the plural and vice versa. 
  

	1.3	References to persons and companies 

 References to: 

 

	 	1.3.1	a person include any individual, company, partnership or unincorporated association (whether or not having separate legal personality); and 

 

	 	1.3.2	a company include any company, corporation or any body corporate, wherever incorporated. 

  

	1.4	Schedules etc. 

 References to this Deed shall include any Recitals and Schedules to it
and references to “Clauses” and “Schedules” are to Clauses of, and Schedules to, this Deed. References to “Paragraphs”, “Parts” and “Appendices” are to paragraphs and parts of, and appendices to, the
Schedules. References to “paragraphs” are to paragraphs of appendices to the Schedules. 
  

	1.5	Reference to documents 

 References to any document (including this Deed), or to a
provision in a document, shall be construed as a reference to such document or provision as amended, supplemented, modified, restated or novated from time to time. 
  

	1.6	References to enactments 

 Except as otherwise expressly provided in this Deed, any
express reference to an enactment (which includes any legislation in any jurisdiction) includes references (i) to that enactment as amended, consolidated or re-enacted by or under any other enactment before or after the date of this Deed;
(ii) any enactment which that enactment re-enacts (with or without modification); and (iii) any subordinate legislation (including regulations) made before or after the date of this Deed under that enactment as amended, consolidated or
re-enacted as described in (i) or (ii) above, except to the extent that any of the matters referred to in (i) to (iii) occurs after the date of this Deed and increases or alters the liability of Novartis or the Purchaser under
this Deed. 
  

	1.7	Information 

 References to books, records or other information mean books, records or
other information in any form including paper, electronically stored data, magnetic media, film and microfilm. 
  

	1.8	Legal Terms 

 References to any English legal term shall, in respect of any jurisdiction
other than England and Wales, be construed as references to the term or concept which most nearly corresponds to it in that jurisdiction. 

  
  

6 

 Execution Version 
  

 

	1.9	Non-limiting effect of words 

 The words “including”, “include”,
“in particular” and words of similar effect shall not be deemed to limit the general effect of the words that precede them. 
  

	1.10	Currency conversion 

 Any amount to be converted from one currency into another currency
for the purposes of this Deed shall be converted into an equivalent amount at the Conversion Rate prevailing at the Relevant Date. For the purposes of this Clause 1.10: 

“Conversion Rate” means the spot reference rate for a transaction between the two currencies in question as quoted by the
European Central Bank on the Business Day immediately preceding the Relevant Date or, if no such rate is quoted on that date, on the preceding date on which such rates are quoted; 

“Relevant Date” means, save as otherwise provided in this Deed, the date on which a payment or an assessment is to be made,
save that, for the following purposes, the date shall mean: 
  

	 	(i)	for the purposes of paragraph 5 of Schedule 1, the date of this Deed; 

  

	 	(ii)	for the purposes of paragraph 7 of Schedule 1 and Appendices 16 (Post Option Closing) and 22 (Statement of Net Assets) to Schedule 1, the Option Closing Date; 

 

	 	(iii)	for the purposes of paragraph 10 of Schedule 1, the date of this Deed; or 

  

	 	(iv)	for the purposes of the monetary amounts set out in Appendix 18 (Warranties given under paragraph 9.1) to Schedule 1, the date of this Deed. 

 

	2	Put Option 

  

	2.1	The Option 

 The Purchaser irrevocably grants to Novartis (for itself and on behalf of
the relevant members of the Novartis Group), in consideration for the payment of US$5 million (the “Put Option Price”) in accordance with Clause 2.4, an option (the “Put Option”) to require the Purchaser to
purchase, or procure the purchase by one or more other members of the Purchaser’s Group of, any one of the following asset combinations as specified by Novartis at its sole discretion: 

 

	 	2.1.1	the Option 1 Assets; 

  

	 	2.1.2	the Option 2 Assets; 

  

	 	2.1.3	the Option 3 Assets; 

  

	 	2.1.4	the Option 2 Assets and some or all of the Option 4 Assets; 

  

	 	2.1.5	the Option 3 Assets and some or all of the Option 4 Assets; or 

  

	 	2.1.6	some or all of the Option 4 Assets, 

 from Novartis or the relevant members of the
Novartis Group on the terms and subject to the conditions of this Deed. 

  
  

7 

 Execution Version 
  

 

	2.2	Exercise 

  

	 	2.2.1	The Put Option is exercisable by notice in writing from Novartis to the Purchaser given at any time during the period which: 

  

	 	(i)	starts on (and includes) the earlier of: (A) the date falling nine months following the date of this Deed or, if a Class 1 Transaction for the Purchaser is then pending completion, the day after such Class 1
Transaction has completed; and (B) the date falling 18 months after the date of this Deed; and 

  

	 	(ii)	ends on (and includes) the date falling 18 months later, 

 (the “Exercise
Period”). Such notice shall specify (in accordance with Clause 2.1) in respect of which combination of assets the Put Option is being exercised, including in the case of any combination which includes Option 4 Assets, which specific
products (from the list in Schedule 4). 
  

	 	2.2.2	The date on which the Purchaser is deemed, pursuant to Paragraph 15.11 of Schedule 1, to receive the notice served by Novartis pursuant to Clause 2.2.1 shall be the “Option Exercise Date”.

  

	 	2.2.3	The Put Option may be exercised only once. 

  

	2.3	Sale and Purchase 

 Service of a notice by Novartis pursuant to Clause 2.2.1 shall,
subject to the conditions set out in Schedule 1, oblige the Purchaser to purchase or procure the purchase by a member of the Purchaser’s Group and Novartis to sell or procure the sale of the Option Assets as specified by Novartis in the notice
of exercise pursuant to Clause 2.1 and Clause 2.2 (the “Relevant Option Assets”) on the terms set out in Schedule 1. 
  

	2.4	Payment of Put Option Price 

  

	 	2.4.1	Novartis shall pay the Option Price to the Purchaser as follows: 

  

	 	(i)	US$1 million within 60 Business Days of the date of this Deed; and 

  

	 	(ii)	US$4 million within 5 Business Days of the start of the Exercise Period, 

 in each case in
immediately available funds to the bank account notified to Novartis by the Purchaser. 
  

	 	2.4.2	If Novartis exercises its termination right in Clause 3.2(ii) prior to one or both of the payments in Clause 2.4.1 being made, it shall pay the amount of the Option Price not paid in immediately available funds
(and without any deduction or withholding, save as required by law) to the bank account notified to Novartis by the Purchaser within five Business Days of it exercising such termination right. 

 

	 	2.4.3	If Novartis makes any payments pursuant to Clause 2.4.2 and the Vaccines SAPA then terminates or is terminated in accordance with its terms, the Purchaser shall refund any such payment to Novartis within 5
Business Days of termination of the Vaccines SAPA. 

  

	 	2.4.4	The provisions of paragraphs 3.4.2 (VAT) and 15.10 (Grossing up) of Schedule 1 shall apply to payments of the Put Option Price mutatis mutandis, treating references to the “Purchase
Price” as references to such payment, and references to Belgium as references to the United Kingdom. 

  
  

8 

 Execution Version 
  

	3	Termination 

  

	3.1	Termination for non-exercise or transaction failure 

 The Put Option will terminate with
immediate effect if: 
  

	 	3.1.1	the Put Option is not validly exercised during the Exercise Period; or 

  

	 	3.1.2	any of the Implementation Agreement, the Vaccines SAPA, the Oncology SAPA or the Consumer Contribution Agreement terminates or is terminated in accordance with its terms. 

 

	3.2	Other termination rights 

 This Deed may be terminated at any time, with immediate
effect, prior to Option Closing: 
  

	 	(i)	by written consent of Novartis and the Purchaser; or 

  

	 	(ii)	by Novartis giving written notice to the Purchaser. 

  

	3.3	If this Deed is terminated pursuant to Clause 3.1 or 3.2, this Deed shall be of no further force and effect and there shall be no further liability on the part of any party (and in particular, the Purchaser shall
have no liability under Clause 4), except that Clauses 1, 2.4 and this Clause 3, and Paragraphs 13 and 15 of Schedule 1 in each case, to the extent applicable, shall survive any termination. 

 

	3.4	Termination upon non-satisfaction of conditions 

 If: 

 

	 	3.4.1	Novartis has validly exercised the Put Option in accordance with Clause 2.2; and 

  

	 	3.4.2	the conditions set out in paragraph 4 of Schedule 1 are not satisfied or waived on or before the date falling 18 months after the Option Exercise Date (the “Option Long Stop Date”),

 this Deed shall automatically terminate and there shall be no further liability on the part of any party, except that
Clauses 1, 2.4, this Clause 3, Clause 4 and Paragraphs 13 and 15 of Schedule 1, in each case to the extent applicable, shall survive any termination. 
  

	3.5	Nothing in this Clause 3 shall be deemed to release any party from any liability for any breach by such party of the terms and provisions of this Deed prior to termination of this Deed. 

  
  

9 

 Execution Version 
  

 

	4	Payment of Compensation / Disposal after Payment of Compensation 

  

	4.1	Payment of Compensation 

  

	 	4.1.1	If: 

  

	 	(i)	Novartis has validly exercised the Put Option in accordance with Clause 2.2; 

  

	 	(ii)	any of the conditions in paragraph 4.1 of Schedule 1 are not satisfied or waived on or before the Option Long Stop Date; 

  

	 	(iii)	Novartis has complied with its obligations under paragraph 4.2 of Schedule 1, other than in any respect which is immaterial in its contribution to the non-satisfaction of such conditions; and 

 

	 	(iv)	had all of the conditions in paragraph 4.1 of Schedule 1 been satisfied or waived, Novartis would have been capable of performing its obligations at Option Closing had it occurred in accordance with Schedule 1,

 the Purchaser shall pay to Novartis or to such member of the Novartis Group as Novartis may direct by way of compensation
the full amount of the Headline Price for the Relevant Option Assets which would have been payable to Novartis at Option Closing pursuant to Paragraph 3 of Schedule 1 had the relevant condition(s) been satisfied (the “Compensation
Amount”). 
  

	 	4.1.2	In the event that the Compensation Amount becomes payable, the Purchaser shall pay or procure the payment of the Compensation Amount within five Business Days of the Option Long Stop Date in immediately available
funds (and without any deduction or withholding, save as required by law) to the bank account notified to the Purchaser by Novartis. 

  

	 	4.1.3	If any deduction or withholding is required by law to be made from any payment required to be made pursuant to Clause 4.1.2 then the Purchaser shall be obliged to pay to Novartis such sum as will, after the
deduction or withholding has been made, leave Novartis with the same amount as it would have been entitled to receive in the absence of any such requirement to make a deduction or withholding. If the Purchaser thus makes an increased payment and
Novartis, in respect of the Tax that gave rise to such increased payment, receives and utilises a loss, relief, allowance or credit in respect of any Tax or any deduction in computing its income, profits or gains for the purposes of any Tax,
Novartis shall reimburse the Purchaser with such amount as shall leave Novartis in the same position as Novartis would have been in had no such deduction or withholding been required to be made. 

 

	 	4.1.4	The parties anticipate that any payment to be made pursuant to Clause 4.1.2 would not be treated as the consideration for a taxable supply for VAT purposes. If any Tax Authority determines that any such payment
(the “Relevant Payment”) is the consideration for a taxable supply then the Relevant Payment shall be inclusive of any amounts in respect of VAT but shall be subject to adjustment on the following basis: 

 

	 	(i)	if the Purchaser (or the representative member of its VAT group) is liable to account for VAT under a reverse charge mechanism, to the extent that the Purchaser (or such representative member) is not entitled to recover
such VAT from the relevant Tax Authority, the Relevant Payment shall be reduced such that the aggregate of the reduced payment and any irrecoverable VAT in respect thereof equals the original amount of the Relevant Payment; and 

  
  

10 

 Execution Version 
  

 

	 	(ii)	if Novartis (or the representative member of its VAT group) is liable to account for VAT, Novartis shall issue a valid VAT invoice to the Purchaser and the amount of the Relevant Payment (inclusive of amounts in respect
of VAT) shall be increased by the amount which the Purchaser (or the representative member of its VAT group) is entitled to recover as an input tax in respect thereof. 

 

	 	4.1.5	The parties agree that in the event the Compensation Amount becomes payable pursuant to Clause 4.1.1, Novartis shall not have any other rights or remedies under, or in connection with, this Deed against the
Purchaser. 

  

	 	4.1.6	The parties agree that nothing in Clauses 4.1.1 and (if applicable) 4.1.3 and 4.1.4 of this Deed shall oblige the Purchaser to pay an aggregate amount under such Clause which is more than the maximum amount
permitted under the Listing Rules. 

  

	4.2	Disposal after payment of compensation 

  

	 	4.2.1	If: 

  

	 	(i)	one or more Relevant Events occurs during the Relevant Period; and 

  

	 	(ii)	Novartis or any member of the Novartis Group has received from the Purchaser payment of the Compensation Amount pursuant to Clause 4.1.1, 

Novartis agrees to pay or procure payment to the Purchaser by way of a refund of the Compensation Amount an amount equal to the value of any
cash or non-cash consideration received by Novartis or any member of the Novartis Group in connection with such Relevant Event or Relevant Events (net of any Taxes or out-of-pocket costs or expenses incurred by Novartis and any member of the
Novartis Group in connection with such Relevant Event or Relevant Events) (the “Value Received”) up to an amount equal to the Compensation Amount received, (net of any Taxes incurred by the Novartis Group in respect thereof),
provided that Novartis shall not be required to make any payment pursuant to this Clause 4.2.1 unless the Value Received is equal to or in excess of US$7.5 million (or the equivalent in another currency). Where the Value Received is equal to or in
excess of US$7.5 million (or the equivalent in another currency), the liability of Novartis shall be for an amount equal to the whole of the Value Received and not just the excess. Clauses 4.1.3 and 4.1.4 shall apply to any payment to be made
pursuant to this Clause 4.2.1, mutatis mutandis. 
  

	 	4.2.2	Each of the following shall constitute a “Relevant Event” for the purposes of Clause 4.2.1: 

  

	 	(i)	the sale of any (or any part of any) of the Relevant Option Assets to a Third Party Purchaser either as a single transaction or by a number of transactions, excluding a sale of any (or any part of any) of the Relevant
Option Assets to another member of the Purchaser’s Group; 

  

	 	(ii)	any transaction, or series of transactions, the effect of which is to transfer ownership, or the ability to direct or control the use of, or to transfer the economic benefit of, any (or any part of any) of the Relevant
Option Assets from the Novartis Group to one or more Third Party Purchasers; 

  
  

11 

 Execution Version 
  

 

	 	(iii)	the grant of any option or the making or signing of or entry into any agreement to effect any of the foregoing; or 

  

	 	(iv)	any other transaction entered into or arrangement or agreement made by Novartis or any member of the Novartis Group that has substantially the same effect as any of the foregoing. 

 

	 	4.2.3	As soon as reasonably practicable after becoming aware that a Relevant Event will or is reasonably likely to occur in the Relevant Period, Novartis shall, unless prohibited by Applicable Law, give written notice
to the Purchaser setting out such details as the Purchaser may reasonably require regarding the identity of the Third Party Purchaser or Third Party Purchasers and the timetable upon which it is envisaged that the Relevant Event will or may occur.

  

	 	4.2.4	Any payment to be made pursuant to this Clause 4.2 shall be made by Novartis in immediately available funds (and without any deduction or withholding, save as required by law or provided for in Clause 4.2.1) to
the bank account notified to Novartis by the Purchaser within five Business Days of Novartis having received the relevant consideration. It is acknowledged that more than one payment may be required by this Clause 4.2. 

 

	 	4.2.5	Novartis undertakes to the Purchaser that it shall act in good faith in relation to this Clause 4.2. 

  

	5	Sale to Third Party Purchaser and Separation 

  

	5.1	No Restriction 

  

	 	5.1.1	The Purchaser acknowledges and agrees that, subject to Clause 5.2.1, Novartis shall not be subject to any restrictions on selling any of the Option Assets to a Third Party Purchaser after the date of this Deed.

  

	 	5.1.2	Novartis agrees to use its reasonable endeavours to sell the Option Assets to one or more Third Party Purchasers prior to the start of the Exercise Period on such terms as Novartis may in its sole discretion
determine. 

  

	 	5.1.3	If, otherwise than pursuant to the sale of the Option 1 Assets to a Third Party Purchaser, any member of the Novartis Group disposes of or transfers (or agrees to dispose of or transfer) any Intellectual Property
Rights used in or held for use in relation to any of the Option Assets to a Third Party Purchaser prior to the Option Exercise Date (“Third Party Purchaser Intellectual Property Rights”) and, after the signing of the relevant
disposal or transfer agreement, Novartis exercises the Put Option in respect of any of the Option Assets (excluding the Option 1 Assets), Novartis (and any relevant member(s) of the Novartis Group) shall, or shall procure (under the relevant
disposal or transfer agreement(s) or otherwise) that the Third Party Purchaser shall, upon the Option Closing Date, grant the Purchaser and each relevant member of the Purchaser’s Group a non-exclusive irrevocable, perpetual, fully paid-up,
royalty-free, freely-assignable, worldwide licence or sub-licence (to the extent permissible under any relevant intellectual property rights contract), with a right to sub-license, to use the Third Party Purchaser Intellectual Property Rights in
relation to the Relevant Option Assets in the manner (if any), and to the extent, that such Third Party Purchaser Intellectual Property Rights were used in relation to the Relevant Option Assets as at the earlier of the date of closing of the
relevant disposal or transfer agreement or the Option Closing Date. 

  
  

12 

 Execution Version 
  

 

	 	5.1.4	If the terms of any relevant intellectual property rights contract do not permit the sub-licensing to the Purchaser’s Group as contemplated in Clause 5.1.3 above, Novartis and the Purchaser shall discuss in
good faith and each use reasonable endeavours to agree an arrangement for giving the Purchaser’s Group the benefits of any such contract that would have been enjoyed by the Purchaser’s Group but for the terms of the contract not permitting
such sub-licensing. 

  

	5.2	Notification 

  

	 	5.2.1	In respect of a sale of any Option Assets by Novartis or a member of the Novartis Group to a Third Party Purchaser, Novartis agrees subject to Applicable Laws, to keep the Purchaser updated as to the progress of
any such sale to a Third Party Purchaser by: 

  

	 	(i)	providing updates to the Purchaser, at such times as the Purchaser may reasonably request, as to the status of Novartis’s endeavours to sell the Option Assets; 

 

	 	(ii)	giving notice to the Purchaser of Novartis or any of its Affiliates providing access to business information relating to the Option Assets to a Third Party Purchaser in contemplation of a sale of any Option Assets, but
without providing information as to the identity of the Third Party Purchaser; 

  

	 	(iii)	providing updates to the Purchaser following the entry into force of this Deed as to the number of Third Party Purchasers that have access from time to time to business information relating to the Option Assets in
contemplation of a sale of any Option Assets, but without providing information as to the identity of those Third Party Purchasers; and 

  

	 	(iv)	giving notice to the Purchaser of a firm intention by Novartis or any of its Affiliates to enter into an agreement with a Third Party Purchaser in relation to the sale of any Option Assets, together with the identity of
the Option Assets that are intended to form the subject of the sale and the identity of that Third Party Purchaser. 

  

	6	Application of provisions of Schedule 1 

  

	 	6.1.1	The provisions of Schedule 1 shall become effective as if set out in this Deed and on the basis set out in Clause 6.1.2 from and including the Option Exercise Date (or as stated expressly or impliedly in Schedule
1), except that: 

  

	 	(i)	Paragraph 15 shall apply with effect from and including the date of this Deed and shall govern the operative Clauses of this Deed, as well as the provisions of Schedule 1; and 

 

	 	(ii)	Paragraph 1 shall apply with effect from the date of this Deed to the extent that it contains defined terms and interpretive provisions relating to the Paragraphs of Schedule 1 that shall apply with effect from and
including the date of this Deed in accordance with Clause 6.1.1.(i); and 

  
  

13 

 Execution Version 
  

 

	 	(iii)	Paragraphs 2.3.5, 2.3.6, 2.4.1 (only to the extent that such paragraph applies to Paragraph 10 of Appendix 10), 5.1, 5.2, 5.3, 5.4, 9, 10, 11 and 13 shall apply with effect from and including the date of this Deed.

  

	 	6.1.2	If the Put Option is exercised in respect of the asset combination set out in Clause 2.1.1 (the Option 1 Assets), Schedule 1 shall apply without amendment. 

 

	 	6.1.3	If the Put Option is exercised in respect of any of the asset combinations set out in Clauses 2.1.2 to 2.1.6, with effect from the Option Exercise Date Schedule 1 shall be amended as follows (more than one may apply):

  

	 	(i)	if the asset combination includes the Option 2 Assets, Schedule 1 shall apply as amended on the basis set out in Schedule 2; 

  

	 	(ii)	if the asset combination includes the Option 3 Assets, Schedule 1 shall apply as amended on the basis set out in Schedule 3; and 

  

	 	(iii)	if the asset combination includes the Option 4 Assets, Schedule 1 shall apply as amended on the basis set out in Schedule 4. 

  

	 	6.1.4	References in this Deed to Schedule 1 shall, where applicable, be construed as references to Schedule 1 as amended in accordance with Clause 6.1.3. 

  
  

14 

 Execution Version 
  

IN WITNESS of which this document has been executed and delivered as a deed on the date which first appears on page 1 above. 

 

							
	Executed as a Deed by		)				
	GLAXOSMITHKLINE PLC		)				
	acting by its duly appointed attorney in the presence of:		)		  
		
			)		Attorney		
				
	Witness’s signature:				  
		
				
	Name (print):				  
		
				
	Occupation:				  
		
				
	Address:				  
		
				
	SIGNED by
                                         
       		 }
		  
		
	  
 and
                                        
on behalf of NOVARTIS AG and thereby executed by it as a DEED
			  

     
		
					

  
  

  
  

15 

 Execution Version 
  

Schedule 1 
 Influenza
Business – Terms and Conditions of Sale and Purchase 

  
  

16 

 Execution Version 
  

Schedule 1 
 Influenza
Business – Terms and Conditions of Sale and Purchase 
  

	1	Interpretation and amendment post signing 

 Clause 1 of this Deed shall apply to this
Schedule 1 and, as such, capitalised terms used in this Deed shall have the meanings given to them in this Deed. In this Deed, unless the context requires otherwise, the further interpretative provisions of this Paragraph 1 apply: 

 

	1.1	Definitions 

 “Accounts” means the audited financial statements of each
of the Company and Novartis Vaccines and Diagnostics Limited, prepared in accordance with legislation as in force and applicable to each respective company for the accounting reference period ended on the Accounts Date, comprising the balance sheet,
the profit and loss account and the notes to the accounts; 
 “Accounts Date” means 31 December 2012; 

“Action” means the taking of any steps by any Governmental Entity to seek a Judgment which would have the effect of preventing
the consummation of the transactions contemplated by this Deed by the Purchaser; 
 “Affiliate Contract” means a Contract
between or among any member of the Novartis Group (other than the Influenza Group Companies) on the one hand, and any Influenza Group Company on the other hand, but excluding any Ancillary Agreement; 

“Agreed Terms” means, in relation to a document, such document in the terms agreed between Novartis and the Purchaser and
signed for identification purposes by the Novartis’s Lawyers and the Purchaser’s Lawyers, with such alterations as may be agreed in writing between Novartis and the Purchaser from time to time; 

“Allocation” has the meaning given to it in paragraph 1 of Appendix 13; 

“Ancillary Agreements” means the Local Transfer Documents, Disclosure Letter, the Option Exercise Date Disclosure Letter, the
Tax Indemnity, the Transitional Services Agreement, the Manufacturing and Supply Agreement, the Manufacturing, Supply and Distribution Agreement, the Purchaser Intellectual Property Licence Agreement, the Intellectual Property Assignment Agreements
and the Pharmacovigilance Agreement; 
 “Anti-Bribery Law” means any Applicable Law that relates to bribery or corruption,
including the US Foreign Corrupt Practices Act of 1977 and the UK Bribery Act 2010, in each case as amended, re-enacted or replaced from time to time; 

“Applicable Law” means any supra-national, federal, national, state, municipal or local statute, law, ordinance, regulation,
rule, code, order (whether executive, legislative, judicial or otherwise), judgment, injunction, notice, decree or other requirement or rule of law or legal process (including common law), or any other order of, or agreement issued, promulgated or
entered into by, any Governmental Entity or any rule or requirement of any national securities exchange, including all Healthcare Laws, and GCP, GLP, and GMP, each as may be amended from time to time; 

“Appointment Notice” has the meaning given to it in paragraph 1.4 of Appendix 16; 

  
  

17 

 Execution Version 
  

“Associated Person” means, in relation to the Novartis Group, a person (including any director, officer, employee, agent or
other intermediary) who performs services for or on behalf of any member of the Novartis Group or who holds shares of capital stock, partnership interests, limited liability company membership interests and units, shares, interest and other
participations in any member of the Novartis Group (in each case when performing such services or acting in such capacity); 

“Assumed Liabilities” means all Liabilities relating to the Influenza Group Businesses other than: (i) the Excluded
Liabilities; (ii) any Relevant Pension and Employment Liability; and (iii) any Liabilities in respect of Tax (other than Tax which has been provided for or reflected in the Option Closing Statement) or which have been assumed by the
Purchaser’s Group under an express provision of this Deed; 
 “Benefit Plans” means the US Benefit Plans and the Non-US
Benefit Plans; 
 “Business” means the Cell-based Influenza Business and the Egg-based Influenza Business, taken together;

 “Business Information” means: (i) Commercial Information; (ii) Medical Information; and (iii) any other
information Predominantly Related to the Business; 
 “Business Sellers” means the members of the Novartis Group (other than
the Influenza Group Companies) that own assets of or otherwise conduct any of the Influenza Group Businesses; 
 “Call for New
Tender” means any calls for a tender (including any tender for a basket of products), whether a new tender or the renewal of an existing tender, which includes the Products and which is published after Option Closing of which Novartis
and/or any of Novatis’s Affiliates become aware and which relates in whole or in part to the sale of Products; 
 “Cash
Balances” means cash in hand or credited to any account with a financial institution and securities which are readily convertible into cash; 

“Cash Pooling Arrangements” means the cash pooling arrangements of members of the Novartis Group in which the Influenza Group
Companies participate; 
 “Cell-based Influenza Business” means: 

 

	 	(v)	the business conducted by the Novartis Group from time to time of research, development, manufacture, sales, distribution, marketing and commercialisation of: 

 

	 	(a)	influenza Vaccines using cell-based technologies, including such business conducted at the Holly Springs Site; 

  

	 	(b)	adjuvants conducted at the Holly Springs Site; and 

  

	 	(c)	other Vaccines products to the extent that such business is conducted or contemplated to be conducted by the Novartis Group at the Holly Springs Site in accordance with its obligations to, or as requested by, the US
government or regulatory authorities; and 

  

	 	(vi)	technical development, manufacturing and supply of Enoxaparin, Copaxone or any other pharmaceutical or biological products (other than Vaccines) at the Holly Springs Site, including, but not limited to, pursuant to
agreements or arrangements with Sandoz Inc. or its Affiliates; 

  
  

18 

 Execution Version 
  

“CFIUS” means the Committee on Foreign Investment in the United States; 

“CFIUS Approval” means written notice from CFIUS that any review or investigation of the Transaction under Section 721 of
the Defense Production Act of 1950, as amended (50 U.S.C. App. Section 2170), has been concluded and there are no unresolved national security concerns with respect to the Transaction or the President shall have determined not to take action
with respect to the Transaction; 
 “CFIUS Filing” has the meaning given to it in Paragraph 4.2.3(ii); 

“Clinical Trials/Data Liability” means any Liability arising out of, relating to or resulting from any breach of Applicable
Law in connection with the conduct of, or reporting or data in relation to, clinical studies or trials (including post-approval studies) in relation to the Influenza Group; 

“COBRA” means the Consolidated Omnibus Budget Reconciliation Act of 1985 of the United States, as amended, section 4980B of
the Code, Title I Part 6 of ERISA, and any similar US state group health plan continuation law, together with its implementing regulations; 

“Code” means the U.S. Internal Revenue Code of 1986, as amended, together with its implementing regulations; 

“Commercial Information” means information that is, as of the Option Closing Date, owned by Novartis and/or its Affiliates and
relates predominantly to the Commercialisation of any Product; 
 “Commercial Practices Liability” means any Liability
arising out of, relating to or resulting from any breach of Applicable Law in connection with the Commercialisation of products; 

“Commercialise” means to promote, market, distribute and/or sell a Product and “Commercialising” and
“Commercialisation” shall be construed accordingly; 
 “Company” means Novartis Vaccines Holdings Limited,
details of which are set out in paragraph 1 of Appendix 2; 
 “Company Lease” has the meaning given to it in paragraph 1.1
of Part 3 of Appendix 3; 
 “Company Leased Real Properties” has the meaning given to it in paragraph 1.1 of Part 3 of
Appendix 3; 
 “Company Owned Real Properties” has the meaning given to it in paragraph 1.1 of Part 3 of Appendix 3; 

“Company Real Properties” means the Company Owned Real Properties and the Company Leased Real Properties, and “Company
Real Property” means any one of them; 
 “Contracts Liabilities” means Liabilities relating to the:
(i) Transferred Contracts; (ii) Transferred Intellectual Property Contracts; and (iii) all other contracts or parts thereof transferred, assigned, novated or assumed by the Purchaser pursuant to this Deed or to which an Influenza
Group Company is or was a party or under which an Influenza Group Company has any Liability, and a “Contracts Liability” shall mean any one of them; 

  
  

19 

 Execution Version 
  

“Co-Owned Influenza Group Intellectual Property Right” means any Influenza Group Intellectual Property Rights or any MF59® Intellectual Property Rights that are owned in part by a third party; 

“Copyright” means any works of authorship, copyrights, database rights, mask work rights and registrations and applications
therefor; 
 “Decision” means the issuing of any decision by a competition, antitrust, foreign investment, national, local,
supranational or supervisory or other government, governmental, quasi-governmental, trade, or regulatory body, agency, branch, subdivision, department, commission, official or authority, including any Tax Authority and any governmental department
and any court or other tribunal, that would have the effect of prohibiting the acquisition of the Influenza Group by the Purchaser; 

“Deferred Employee” means any person to whom Novartis, any Influenza Group Company or any other member of the Novartis Group
has made an offer of employment for a role in the Business in compliance with Paragraph 5 and whose employment in the Business will take effect on a date following the Option Closing Date, save that no person shall become a Deferred Employee unless
and until Novartis has provided to the Purchaser a copy of the offer letter setting out the agreed principal terms of employment and/or employment agreement (if executed) applicable to such person; 

“Disclosure Letter” means the letter dated on the same date as this Deed from Novartis to the Purchaser disclosing information
constituting exceptions to Novartis’s Warranties; 
 “Draft Option Closing Statement” has the meaning given to it in
Paragraph 7.1; 
 “Effective Time” means 11.59 p.m. (local time in the relevant location) on the Option Closing Date or, if
the Option Closing Date is not the last day of a month but the first Business Day of a month, 11.59 p.m. on the last day of the immediately preceding month; 

“Egg-based Influenza Business” means the business conducted by the Novartis Group from time to time of research, development,
manufacture, sales, distribution, marketing and commercialisation of influenza Vaccines and other products using egg-based technologies and related adjuvant technologies; 

“Election Date” has the meaning given in Paragraph 4.2.3(ii); 

“Employee Benefit Indemnification Amount” has the meaning given to it in Appendix 11; 

“Employee Benefits” has the meaning given to it in Appendix 11; 

“Employees” means the Influenza Business Employees and the Influenza Group Company Employees, and “Employee”
means any one of them; 
 “Encumbrance” means any claim, charge, mortgage, lien, option, equitable right, power of sale,
pledge, hypothecation, usufruct, retention of title, right of pre-emption, right of first refusal or other security interest of any kind or an agreement, arrangement or obligation to create any of the foregoing, and for the avoidance of doubt, shall
exclude any licences of or claims of infringement relating to, Intellectual Property Rights; 
 “Environmental Laws” means
any and all Applicable Law regulating or imposing Liability or standards of conduct concerning pollution or protection of the environment (including surface water, groundwater or soil); 

  
  

20 

 Execution Version 
  

“Environmental Liabilities” means any Liability arising out of, relating to or resulting from any Environmental Law or
environmental, health or safety matter or condition, including natural resources, but excluding any Product Liability; 

“Environmental Permit” means any permit, licence, consent or authorisation required by Environmental Laws issued by any
relevant competent authority and used in relation to the operation or conduct of Manufacturing at each Property, and “Environmental Permit” shall be construed accordingly; 

“ERISA” means the Employee Retirement Income Security Act of 1974 of the United States, as amended, together with its
implementing regulations; 
 “Estimated Influenza Group Companies’ Cash Balances” means Novartis’s reasonable
estimate of the aggregate of the Influenza Group Companies’ Cash Balances, to be notified by Novartis to the Purchaser pursuant to Paragraph 6.4; 

“Estimated Employee Benefit Adjustment” means Novartis’s reasonable estimate (in so far as practicable), made in good
faith after consulting with the Purchaser, of 95 per cent. of the anticipated aggregate of the Employee Benefit Indemnification Amounts, to be notified by Novartis to the Purchaser pursuant to Paragraph 6.4; 

“Estimated Intra-Group Non-Trade Payables” means Novartis’s reasonable estimate of the Intra-Group Non-Trade Payables, to
be notified by Novartis to the Purchaser pursuant to Paragraph 6.4; 
 “Estimated Intra-Group Non-Trade Receivables” means
Novartis’s reasonable estimate of the Intra-Group Non-Trade Receivables, to be notified by Novartis to the Purchaser pursuant to Paragraph 6.4; 

“Estimated Tax Adjustment” means Novartis’s reasonable estimate of the Tax Adjustment, to be notified by Novartis to the
Purchaser pursuant to Paragraph 6.4; 
 “Estimated Third Party Indebtedness” means Novartis’s reasonable
estimate of the Third Party Indebtedness, to be notified by Novartis to the Purchaser pursuant to Paragraph 6.4; 
 “Excluded
Assets” means the property, rights and assets referred to in Paragraph 2.3.2; 
 “Excluded Contracts” means,
collectively, each Contract which is not Predominantly Related to the Business; 
 “Excluded Employees” means any Influenza
Group Company Employees who do not work wholly or substantially in the Business, and such other employees as may be agreed in writing between Novartis and the Purchaser after the date of this Deed but before the Option Closing Date; 

“Excluded Liabilities” means: 
  

	 	(vii)	all Liabilities 

  

	 	(a)	relating to the Influenza Group Businesses other than to the extent taken into account in the Option Closing Statement; and 

  

	 	(b)	of the Influenza Group Companies (other than Liabilities in respect of Tax), 

 in either case,
to the extent that they have arisen or arise (whether before or after Option Closing) as a result of, or otherwise relate to, an act, omission, fact, matter, circumstance or event undertaken, occurring, in existence or arising before Option Closing,
other than any Relevant Pension and Employment Liability and any Liabilities in respect of Tax provided for or reflected in the Option Closing Statement; and 

  
  

21 

 Execution Version 
  

 

	 	(viii)	all Liabilities relating to the Novartis Group Retained Business and the Excluded Assets; 

“Exclusively Related to the Business” means exclusively related to, or exclusively used or held for use exclusively, in
connection with the Business; 
 “FDA” means the United States Food and Drug Administration (or its successor); 

“Final Allocation Schedule” has the meaning given to it in paragraph 4 of Appendix 13; 

“Final Payment Date” means five Business Days after the date on which the process described in Part 1 of Appendix 16 for the
preparation of the Option Closing Statement is complete; 
 “FSAs” has the meaning given to it in paragraph 7.1 of Appendix
10; 
 “FSMA” means the Financial Services and Markets Act 2000; 

“Full Title Guarantee” means on the basis that the covenants implied under Part 1 of the Law of Property (Miscellaneous
Provisions) Act 1994 where a disposition is expressed to be made with full title guarantee are deemed to be given by Novartis (on behalf of the relevant Share Seller or Business Seller) on Option Closing; 

“Governmental Entity” means any supra-national, federal, national, state, county, local, municipal or other governmental,
regulatory or administrative authority, agency, commission or other instrumentality, any court, tribunal or arbitral body with competent jurisdiction, or any national securities exchange or automated quotation service including, any governmental
regulatory authority or agency responsible for the grant approval, clearance, qualification, licensing or permitting of any aspect of the research, development, manufacture, marketing distribution or sale of the Products including the FDA, the
European Medicines Agency, or any successor agency thereto; 
 “Governmental Liability” means any Liability arising out of,
relating to or resulting from any claim, demand, action, suit, proceedings or investigation by a Governmental Entity (other than a Tax Authority) brought or undertaken in connection with products sold or developed by, or operations or practices of,
the Influenza Group prior to Option Closing; 
 “Hazardous Substance” means any gasoline or petroleum products,
polychlorinated biphenyls, urea-formaldehyde insulation, hazardous wastes, toxic substances, asbestos, pollutants, or contaminants defined as such in or regulated under any applicable Environmental Law; 

“Headline Price” has the meaning given to it in Paragraph 3.1.1(i); 

“Holly Springs Site” means the Properties located in Holly Springs, North Carolina, United States of America at which the
Business undertakes Manufacturing activities; 
 “HSR Act” means the Hart-Scott Rodino Antitrust Improvements Act of 1976,
as amended, together with its implementing regulations; 

  
  

22 

 Execution Version 
  

“IFRS” means International Financial Reporting Standards, comprising the accounting standards and interpretations issued,
adopted and/or approved by the International Accounting Standards Board; 
 “In-Market Inventory” means all inventory of
Products for Commercialisation that, at any particular time: (i) is beneficially owned by a member of the Novartis Group; and (ii) is in finished packed form and released for Commercialisation; and (iii) is located: (a) in (or in
transit to) the relevant Market; or (b) in (or in transit to) a multi-market warehouse owned or operated by a member of the Novartis Group or by a third party; or (c) at a Property pending despatch following release by the relevant
qualified person to the relevant market or multi-market warehouse; 
 “Indebtedness” means all loans and other financing
liabilities and obligations in the nature of borrowed moneys and overdrafts and moneys borrowed, but excluding trade debt and liabilities arising in the ordinary course of business; 

“Influenza Business Employees” means the employees of any member of the Novartis Group who work wholly or substantially in the
Business from time to time including, for the avoidance of any doubt, the International Assignees other than the Influenza Group Company Employees, the Excluded Employees and the Shared Employees and provided that, in relation to Novartis’s
Warranties only, the words “from time to time” shall be deemed to be replaced by “at the date of this Deed” or “at the Option Exercise Date” (as applicable) and “Influenza Business Employee” means any
one of them; 
 “Influenza Group” means the Influenza Group Companies and the Influenza Group Businesses, taken as a whole;

 “Influenza Group Businesses” means the assets of the Business as set out in Paragraph 2.3.1, but subject always to
Paragraph 2.3.2; 
 “Influenza Group Companies” means the Company and the Subsidiaries, and “Influenza Group
Company” means any one of them; 
 “Influenza Group Companies’ Cash Balances” means the aggregate amount of
the Cash Balances held by or on behalf of the Influenza Group Companies at the Effective Time; 
 “Influenza Group Company
Employees” means the employees from time to time of any of the Influenza Group Companies other than the Excluded Employees, and provided that, in relation to Novartis’s Warranties only, the words “from time to time” shall be
deemed to be replaced by “at the date of this Deed” or “at the Option Exercise Date” (as applicable), and “Influenza Group Company Employee” means any one of them; 

“Influenza Group Goodwill” means all goodwill of the Influenza Group Businesses, but excluding any Trademark goodwill; 

“Influenza Group Information Technology” means the Transferred Information Technology and the Owned Information
Technology; 
 “Influenza Group Insurance Policies” means all insurance policies held exclusively by and for the benefit of
the Influenza Group Companies and “Influenza Group Insurance Policy” means any one of them; 
 “Influenza Group
Intellectual Property Contracts” means the Transferred Intellectual Property Contracts and the Owned Intellectual Property Contracts; 

  
  

23 

 Execution Version 
  

“Influenza Group Intellectual Property Rights” means the Transferred Intellectual Property Rights and the Owned Intellectual
Property Rights; 
 “Influenza Patent” means any Influenza Group Intellectual Property Right which is a Patent; 

“Information Technology” means computer, hardware, software and network; 

“Intellectual Property Assignment Agreements” means the assignments between Novartis and/or one or more of its Affiliates and
the Purchaser and/or one or more of its Affiliates on terms consistent with the Agreed Terms, to be entered into at Option Closing, in respect of the transfer of certain Intellectual Property Rights in each of the relevant jurisdictions; 

“Intellectual Property Rights” means all (i) Patents; (ii) Know-How; (iii) Trademarks; (iv) internet
domain names; (v) Copyrights; (vi) rights in designs; (vii) database rights; and (viii) all rights or forms of protection, anywhere in the world, having equivalent or similar effect to the rights referred to in paragraphs
(i) to (vii) above, in each case, whether registered or unregistered and including applications for registration of any such thing; 

“International Assignees” means such employees as may be agreed in writing between Novartis and the Purchaser after the date
of this Deed but before the Option Closing Date; 
 “Intra-Group Non-Trade Payables” means all outstanding loans or other
financing liabilities or obligations (including, for the avoidance of doubt, interest accrued, dividends declared or payable but not paid) owed by an Influenza Group Company to a member of the Novartis Group (other than an Influenza Group Company)
as at the Effective Time as derived from the Option Closing Statement, but excluding: (i) Intra-Group Trading Balances; and (ii) any item which falls to be included in calculating the Influenza Group Companies’ Cash Balances or the
Third Party Indebtedness; 
 “Intra-Group Non-Trade Receivables” means all outstanding loans or other financing liabilities
or obligations (including, for the avoidance of doubt, interest accrued, dividends declared or payable but not paid) owed by a member of the Novartis Group (other than an Influenza Group Company) to an Influenza Group Company as at the Effective
Time as derived from the Option Closing Statement, but excluding: (i) Intra-Group Trading Balances; and (ii) any item which falls to be included in calculating the Influenza Group Companies’ Cash Balances or the Third Party
Indebtedness; 
 “Intra-Group Trading Balances” means all trade accounts and notes receivable or payable arising in the
ordinary course between any two members of the Novartis Group, in each case to the extent related to the Business, to which lines “BS01_630 Payables Other BU’s”, “BS01_140 Receivables Other BU’s”, “BS01_620
Payables Own BU” and “BS01_130 Receivables Own BU” of the Statement of Net Assets apply, together with any unpaid financing charges accrued thereon; 

“IP Liability” means any Liability arising out of, relating to or resulting from any actual or alleged infringement,
misappropriation or other violation of Intellectual Property Rights of third parties; 
 “Judgment” means any order, writ,
judgment, injunction, decree, stipulation, determination, decision or award entered into by or with any Governmental Entity of competent jurisdiction; 

“Key Sites” means the Holly Springs Site and the Liverpool Site, each being a “Key Site”; 

  
  

24 

 Execution Version 
  

“Know-How” means all existing and available technical information, know-how and data, including inventions (whether patentable
or not), discoveries, trade secrets, specifications, instructions, processes and formulae, including all biological, chemical, pharmacological, biochemical, toxicological, pharmaceutical, physical, safety, quality control, preclinical and clinical
data; 
 “Lease” has the meaning given to it in paragraph 1.1 of Part 4 of Appendix 3; 

“Liabilities” means all liabilities, claims, damages, proceedings, demands, orders, suits, costs, losses and expenses of every
description, whether deriving from contract, common law, statute or otherwise, whether present or future, actual or contingent, ascertained or unascertained or disputed and whether owed or incurred severally or jointly or as principal or surety;

 “LIBOR” means the London interbank offered rate, being the interest rate offered in the London inter-bank market for
three month US dollar deposits as displayed on pages LIBOR01 or LIBOR02 of the Reuters screen at 11 a.m. (London) on the second Business Day prior to the Option Closing Date; 

“Licensed Intellectual Property Contract” means any Influenza Group Intellectual Property Contract constituting or containing
a licence of Intellectual Property Rights in respect of the Business or Products; 
 “Liverpool Site” means the Properties
located at Liverpool, United Kingdom at which the Influenza Group undertakes Manufacturing activities; 
 “Local Transfer
Document” has the meaning given to it in Paragraph 2.6.1; 
 “Losses” means all losses, liabilities, costs
(including legal costs and experts’ and consultants’ fees), charges, expenses, actions, proceedings, claims and demands; 

“MA Costs” has the meaning given to it in paragraph 4 of Part 2 of Appendix 8; 

“MA Documentation” has the meaning given to it in paragraph 1.4 of Part 2 of Appendix 8; 

“Manufacture”, “Manufacturing” or “Manufactured” means the planning, purchasing of materials
for, production, processing, compounding, storage, filling, packaging, labelling, leafleting, warehousing, quality control testing, waste disposal, quality release, sample retention and stability testing of products; 

“Manufacturing and Supply Agreement” has the meaning given in the Vaccines SAPA to the term “Influenza Business
Manufacturing and Supply Agreement”; 
 “Manufacturing Inventory” means any packed inventory of Products and/or
products for Commercialisation that is: (i) in finished form (save for any secondary packaging undertaken outside of a Property); (ii) beneficially owned by any member of the Novartis Group; (iiii) held at a Property; and
(iv) not yet released by the qualified person at a Property; and excluding in each case, for the avoidance of doubt, any In-Market Inventory and Manufacturing Stocks; 

“Manufacturing Liability” means any Liability arising out of, relating to or resulting from any breach of Applicable Law in
connection with the manufacturing of products; 
 “Manufacturing Licences” means any certificates, permits, licences,
consents and approvals issued by any Governmental Entity, used in the operation or conduct of Manufacturing at each Property, and “Manufacturing Licence” shall be construed accordingly; 

  
  

25 

 Execution Version 
  

“Manufacturing Stocks” means, as at Option Closing, all stocks of raw materials, active pharmaceutical ingredients,
ingredients, adjuvants, drug substances, intermediates, packaging materials, components, devices and other production and pre-production consumables and work-in-progress that are beneficially owned by any member of the Novartis Group for use in the
Manufacture of Products or Pipeline Products and held at a Property; 
 “Manufacturing, Supply and Distribution Agreement”
means the manufacturing, supply and distribution agreement between Novartis and/or one or more of its Affiliates and the Purchaser and/or one or more of its Affiliates, expected to be entered into at Option Closing on the heads of terms in the
Agreed Terms for the “Manufacturing, Supply and Distribution Agreement” as defined in the Vaccines SAPA (with any necessary amendments) or, if the “Manufacturing, Supply and Distribution Agreement” as defined in the Vaccines SAPA
is entered into before Option Closing, on the terms of the “Manufacturing, Supply and Distribution Agreement” as defined in the Vaccines SAPA (with any necessary amendments); 

“Marketing Authorisation Data” means the existing and available dossiers containing the relevant Know-How used by Novartis
and/or its Affiliates to obtain and maintain the Marketing Authorisations; 
 “Marketing Authorisation Holder” means the
holder of the relevant Marketing Authorisation; 
 “Marketing Authorisation Re-registration” has the meaning given to it in
paragraph 1.1.2 of Part 2 of Appendix 8; 
 “Marketing Authorisation Re-Registration Date” means the date on which the
relevant Governmental Entity approves, or is deemed to approve, the relevant Marketing Authorisation Re-registration; 
 “Marketing
Authorisation Transfer Date” means the date on which the relevant Governmental Entity approves, or is deemed to approve, the relevant Marketing Authorisation Transfer; 

“Marketing Authorisation Transfer” has the meaning given to it in paragraph 1.1.1 of Part 2 of Appendix 8; 

“Marketing Authorisation Transferee” means the member of the Purchaser’s Group or, where no member of the
Purchaser’s Group satisfies the requirements under Applicable Law to be transferred the relevant Marketing Authorisation, such Third Party as is nominated by the Purchaser, in either case, to whom the relevant Marketing Authorisation is to be
transferred; 
 “Marketing Authorisations” means the marketing authorisations issued or applications for Marketing
Authorisations with respect to the Products and all supplements, amendments and revisions thereto; 
 “Markets” means the
markets in which the Products are marketed and sold under the relevant Marketing Authorisation, and “Market” shall be construed accordingly; 

  
  

26 

 Execution Version 
  

“Material Employee Jurisdictions” means the United Kingdom and the United States of America; 

“Medical Information” means information relating to clinical and technical matters, such as therapeutic uses for the approved
indications, drug-disease information, and other product characteristics Predominantly Related to the Business which is available to or used by Novartis and/or its Affiliates as of the Option Closing Date; 

“MF59® Intellectual Property Rights” means the Intellectual Property
Rights owned by the Novartis Group comprised within the MF59® Rights including the Intellectual Property Rights of any member of the Novartis Group set out in Part 3 of Appendix 4; 

“MF59® Intellectual Property Rights Contracts” means the Contracts
held by the Novartis Group relating to the Intellectual Property Rights comprised within the MF59® Rights including any such Contracts set out in Part 4 of Appendix 4; 

“MF59® Rights” means all rights in the MF59® Adjuvant owned by or licensed to Novartis or its Affiliates including: (a) all stocks of the adjuvant and materials used in its production; (b) all Intellectual Property Rights in and
relating to the MF59® Adjuvant; and (c) all Intellectual Property Rights in and relating to the manufacture and production or fill finish process relating to the MF59® Adjuvant; 
 “Novartis Group” means Novartis and its Affiliates from
time to time; 
 “Novartis Group Insurance Policies” means all insurance policies (whether under policies maintained with
third party insurers or any member of the Novartis Group), other than Influenza Group Insurance Policies, maintained by Novartis or any member of the Novartis Group in relation to the Influenza Group or under which, immediately prior to Option
Closing, any Influenza Group Company or Novartis or member of the Novartis Group in relation to the Influenza Group Businesses is entitled to any benefit, and “Novartis Group Insurance Policy” means any one of them; 

“Novartis Group Retained Business” means, from time to time, all businesses of the Novartis Group, excluding the Business;

 “Novartis Marks” means any of the marks (including in either or both logo and local script form) “Novartis”,
“Sandoz”, “Alcon” and “Ciba Vision” used alone or in combination with other words or marks; 

“Novartis Restricted Marks” means any of the marks (including in either or both logo and local script form)
“Novartis”, “Sandoz”, “Alcon” and “Ciba Vision”; 
 “Novartis’s Disagreement
Notice” has the meaning given to it in paragraph 1.5 of Appendix 16; 
 “Novartis’s Knowledge” has the meaning
given to it in Paragraph 9.1.6; 
 “Novartis’s Lawyers” means Linklaters LLP of One Silk Street, London EC2Y 8HQ,
United Kingdom; 
 “Novartis’s Warranties” means the warranties given by Novartis pursuant to Paragraph 9 and Appendix
18, and “Novartis’s Warranty” means any one of them; 
 “Non-US Benefit Plans” has the meaning given
to it in paragraph 16.3.1 of Appendix 18; 
 “Notice” has the meaning given to it in Paragraph 15.11.1; 

  
  

27 

 Execution Version 
  

“Ongoing Clinical Trials” means the ongoing clinical studies sponsored or supported by Novartis Group (including post-approval
studies) or otherwise recommended by a Governmental Entity, and regulatory commitments in respect of the Products and the Pipeline Products, listed in Appendix 21 and “Ongoing Clinical Trial” shall mean any one of them; 

“Option Closing” means the completion of the sale of the Shares and the Influenza Group Businesses pursuant to this Deed and
any Ancillary Agreement; 
 “Option Closing Date” means the date on which Option Closing takes place; 

“Option Closing Statement” means the statement setting out the Influenza Group Companies’ Cash Balances, the Intra-Group
Non-Trade Receivables, the Third Party Indebtedness, the Intra-Group Non-Trade Payables and the Tax Adjustment, to be prepared by Novartis and agreed or determined in accordance with Paragraph 7 and Appendix 16; 

“Option Exercise Date Disclosure Letter” has the meaning given in Paragraph 9.1.3; 

“Out-Licensing Programme” means the out-licensing and enforcement of Intellectual Property Rights that are not used in or
developed for the Business and generally relate to base technology useful in drug discovery and/or manufacturing processes, including any contracts or Intellectual Property Rights related thereto; 

“Out-Licensing Programme Intellectual Property Rights” means the Intellectual Property Rights used in relation to the
Out-Licensing Programme; 
 “Out of Scope Patent” means any Patent of the Novartis Group at the date of Option Closing, but
excluding (i) the Transferred Intellectual Property Rights; (ii) any Patents licensed under the Purchaser Intellectual Property Licence Agreement; and (iii) Out-Licensing Programme Intellectual Property Rights; 

“Owned Information Technology” means all Information Technology of any Influenza Group Company to the extent Exclusively
Related to the Business; 
 “Owned Intellectual Property Contracts” means the Contracts Exclusively Related to the Business
which relate to Intellectual Property Rights and that are held by the Influenza Group Companies, including any such Contracts set out in Part 2 of Appendix 4; 

“Owned Intellectual Property Rights” means the Intellectual Property Rights of any Influenza Group Company to the extent
Exclusively Related to the Business, including the Intellectual Property Rights of any Influenza Group Company set out in Part 1 of Appendix 4; 

“Owned Plant and Equipment” means: 
  

	 	(ix)	the Owned Information Technology; and 

  

	 	(x)	all plant, furniture, furnishings, vehicles, equipment, tools and other tangible personal property (other than Owned Information Technology) of the Novartis Group that are Predominantly Related to the Business and held
by the Influenza Group Companies; 

 “Patent Term Extensions” means any and all extensions of a term of a
Patent granted under the Patent laws or regulations of any country, the European Union, or any other Governmental Entity; 

  
  

28 

 Execution Version 
  

“Patents” means patents, design patents, patent applications and any reissues, re-examinations, divisionals, continuations,
continuations-in-part, provisionals, and extensions thereof or any counterparts to any of the foregoing (including rights resulting from any post-grant proceedings relating to any of the foregoing); 

“PA Transfer Date” means, in relation to a Product or Product Application, the date upon which the relevant Governmental
Entity approves and notifies the Product Approval or Product Application (as applicable) naming the Purchaser or the relevant Affiliate of the Purchaser (or designee thereof) as the holder of such Product Approval or Product Application in the
relevant country or territory covered by that Product Approval or Product Application; 
 “Payment” has the meaning given to
it in Paragraph 1.4; 
 “Permit” has the meaning given to it in paragraph 9.2 of Appendix 18; 

“Permitted Encumbrance” means: 
  

	 	(xi)	Encumbrances imposed by Applicable Law; 

  

	 	(xii)	Encumbrances imposed in the ordinary course of business which are not yet due and payable or which are being contested in good faith; 

 

	 	(xiii)	Encumbrances which are listed in Appendix 7; 

  

	 	(xiv)	pledges or deposits to secure obligations under Applicable Law relating to workers’ compensation, unemployment insurance or to secure public or statutory obligations; and 

 

	 	(xv)	liens, title retention arrangements or deposits to secure the performance of bids, trade contracts (other than for borrowed money), conditional sales contracts, leases, statutory obligations, surety and appeal bonds,
performance bonds and other obligations of a like nature incurred in the ordinary course of the Business; 

 “Personal
Property” means all tangible personal property legally and beneficially owned by the Novartis Group which is Predominantly Related to the Business and is located at a Property at Option Closing; 

“Pharmacovigilance Agreement” means the agreement between Novartis and the Purchaser, to be entered into at Option Closing, in
respect of pharmacovigilance and regulatory matters relating to the Products; 
 “Pipeline Product” means: 

 

	 	(xvi)	each product in development by the Business set out under the heading “Pipeline Products” in Part 3 of Appendix 8; and 

  

	 	(xvii)	any other product in development which is Exclusively Related to the Business; 

“Pipeline Product Approvals” means the approvals in relation to the Pipeline Products; 

“Predominantly Related to the Business” means exclusively or predominantly related to, or used or held for use exclusively or
predominantly, in connection with the Business; 
 “Proceedings” means any legal actions, proceedings, suits, litigations,
prosecutions, investigations, enquiries, mediations or arbitrations; 

  
  

29 

 Execution Version 
  

“Product Applications” means all applications for Product Approval filed with respect to Products Under Registration, with
each individual application being a “Product Application”; 
 “Product Approvals” means all permits,
licences, certificates, clearances, registrations or other authorisations or consents issued by any Governmental Entity to Novartis or one of its Affiliates with respect to the Products or the use, research, development, marketing, distribution or
sale thereof, including the Marketing Authorisations; 
 “Product Filings” means all filings, written representations,
declarations, listings, registrations, reports or submissions with or to any Governmental Entity, including adverse event reports and all submitted data relating to each Product; 

“Product Liabilities” means any Liability arising out of, relating to or resulting from actual or alleged harm, injury, damage
or death to persons in connection with the use of any product (including in any clinical trial or study); 
 “Product Liability
Relevant Period” means the period of two years prior to the date of this Deed; 
 “Product Partners” means any
third parties which pursuant to a Contract with Novartis or any Affiliate of Novartis co-develop, co-promote, co-market, or otherwise have a licence or other right to research, develop, manufacture, promote, distribute, market, or sell any Product,
including all manufacturers and suppliers of any such Product; 
 “Products” means: (i) the products set out under the
heading “Products” in Part 3 of Appendix 8; and (ii) any other products Exclusively Related to the Business; 

“Products Under Registration” means: 
  

	 	(xviii)	the products set out under the heading “Products Under Registration” in Part 3 of Appendix 8, which are pending Product Approval as of the date hereof; and 

 

	 	(xix)	any other product under registration Exclusively Related to the Business; 

“Properties” means the Company Real Properties and the Transferred Real Properties, and “Property” means any
one of them; 
 “Proprietary Information” means all confidential and proprietary information of Novartis or its Affiliates
that is Predominantly Related to the Business, including confidential Medical Information, confidential Know How and confidential Commercial Information; 

“Purchase Price” has the meaning given to it in Paragraph 3.1.1; 

“Purchase Price Bank Account” means the account notified by Novartis to the Purchaser no later than two Business Days prior to
the Option Closing Date; 
 “Purchaser Intellectual Property Licence Agreement” means the agreement between Novartis and/or
one or more of its Affiliates and the Purchaser and/or one or more of its Affiliates on terms consistent with the Agreed Terms attached to this Deed as Attachment 1, expected to be entered into on Option Closing, in respect of the grant of licences
from Novartis to the Purchaser of certain Intellectual Property Rights; 
 “Purchaser’s Disagreement Notice” has the
meaning given to it in paragraph 1.4 of Part 1 of Appendix 16; 

  
  

30 

 Execution Version 
  

“Purchaser’s Lawyers” means Slaughter and May of One Bunhill Row, London EC1Y 8YY, United Kingdom; 

“Purchaser Shareholders” means the holders of ordinary shares in the capital of the Purchaser from time to time; 

“Registered Intellectual Property Rights” means Intellectual Property Rights that are registered, issued, filed, or applied
for under the authority of any Governmental Entity; 
 “Registered Influenza Group Intellectual Property Rights” means all
Influenza Group Intellectual Property Rights that are Registered Intellectual Property Rights; 
 “Registered MF59® Intellectual Property Rights” means all MF59® Intellectual Property Rights that are Registered Intellectual Property Rights; 

“Regulation” has the meaning given to it in Paragraph 4.1.1; 

“Relevant Employees” means the Relevant Influenza Business Employees and the Relevant Influenza Group Company Employees and
“Relevant Employee” means any one of them; 
 “Relevant Employers” means the Business Sellers and such
other members of the Novartis Group who employ the Relevant Influenza Business Employees; 
 “Relevant Employer’s FSAs”
has the meaning given to it in paragraph 7.1 of Appendix 10; 
 “Relevant Influenza Business Employees” means the Influenza
Business Employees immediately prior to the Option Closing Date and “Relevant Influenza Business Employee” means any one of them; 

“Relevant Influenza Group Company Employees” means the Influenza Group Company Employees immediately prior to the Option
Closing Date (excluding any who do not work wholly or substantially in the Business) and “Relevant Influenza Group Company Employee” means any one of them; 

“Relevant Part” means the relevant part of the Shared Business Contracts which relates exclusively to the Business (or the
relevant part of the Business that is transferred to the Purchaser at Option Closing); 
 “Relevant Pension and Employment
Liability” means (i) any Liabilities assumed by the Purchaser or a member of the Purchaser’s Group as contemplated by Appendix 10; and (ii) any Transferred Employee Benefit Liabilities (as defined in Appendix 11) which the
Purchaser agrees to assume in accordance with Appendix 11; 
 “Relevant Persons” has the meaning given to it in Paragraph
8.2.2; 
 “Reorganisation” has the meaning given to it in Paragraph 2.3.5; 

“Reporting Accountants” means the London office of Ernst & Young or, if that firm is unable or unwilling to act in
any matter referred to them under this Deed, the London office of Deloitte or, if that firm is also unable or unwilling to act in any matter referred to them under this Deed, an internationally recognised and independent firm of accountants who does
not act as auditor to Novartis or the Purchaser, to be agreed by Novartis and the Purchaser within seven days of a notice by one to the other requiring such agreement or, failing such agreement, to be nominated on the application of either of them
by or on behalf of the Institute of Chartered Accountants of England and Wales; 

  
  

31 

 Execution Version 
  

“Required Item” has the meaning given to it in paragraph 2 of Appendix 13; 

“Required Notifications” has the meaning given to it in Paragraph 4.2.1; 

“Sanctions Laws” has the meaning given to it in paragraph 9.5 of Appendix 18; 

“Seller Partner” means any counterparty to a development, contract research, commercialisation, manufacturing, distribution,
sales, marketing, supply, consulting or other collaboration Contract with Novartis or any Affiliate of Novartis; 
 “Service
Provider” means an Associated Person who is a legal person; 
 “Share Seller” means, in relation to the Company,
Novartis Pharma AG, as set out in Appendix 1; 
 “Shared Business Contracts” means any Contract which relates both: 

 

	 	(xx)	to the Business or any part of the Business to be transferred to the Purchaser at Option Closing; and 

  

	 	(xxi)	to any part of the Novartis Group Retained Business, any product other than the Products, or any Excluded Asset, 

and to which a member of the Novartis Group is a party or in respect of which a member of the Novartis Group has any liability or obligation at
Option Closing, and “Shared Business Contract” shall mean any of them; 
 “Shared Employees” means
employees of any member of the Novartis Group who work wholly or substantially in the Business pursuant to service level agreements with the Influenza Group Companies and other members of the Novartis Group but excluding, for the avoidance of any
doubt, any Influenza Group Company Employee and any employees included on the list of employees provided pursuant to paragraph 15.2 of Appendix 18; 

“Shares” means the shares in the capital of the Company specified in Appendix 2; 

“Sinergium Arrangements” means agreements and arrangements relating to the business and activities of the Sinergium
Consortium, including agreements and arrangements between: (i) any of the Sinergium Consortium Members; (ii) any of the Sinergium Consortium Members (and/or the Sinergium Consortium) and the Argentinian Ministry of Health; and
(iii) any member of the Novartis Group and any Sinergium Consortium Member (and/or the Sinergium Consortium); 
 “Sinergium
Consortium Members” means the shareholders of Sinergium Biotech - Consorcio de Cooperación (taken together, the “Sinergium Consortium”), who as at the date of this Deed are Novartis Argentina, S.A., Biogénesis
Bago, S.A., Laboratorio ELEA S.A.C.I.F. y A. and Sinergium Biotech, S.A.; 
 “Statement of Net Assets” has the meaning given
to it in Appendix 22; 
 “Statement of Net Assets Date” means 31 December 2013; 

“Statement of Net Assets Rules” means the rules in accordance with which the Statement of Net Assets was prepared, as set out
in Part 2 of Appendix 22; 
 “Subsidiaries” means the companies listed in paragraph 2 of Appendix 2 and
“Subsidiary” means any one of them; 

  
  

32 

 Execution Version 
  

“Surviving Affiliate Contracts” means any of the agreements or arrangements referred to in Paragraph 5.3.1(iii); 

“Tax Adjustment” means the amount by which: 
  

	 	(i)	the aggregate amount of the income taxes and sales taxes payable by the Influenza Group Companies, as at the Effective Time and as derived from the Option Closing Statement; 

exceeds or is less than 
  

	 	(ii)	the aggregate amount of the current income tax and, sales tax receivables of the Influenza Group Companies, as at the Effective Time and as derived from the Option Closing Statement, 

and any such excess amount shall be treated as a positive number and any shortfall shall be treated as a negative amount; 

“Tax Consolidation” means any group, consolidation, fiscal unity or other arrangement (whether in place by law, agreement or
otherwise and including any group for the purposes of VAT) under which a person is primarily responsible for paying or discharging Tax liabilities on behalf of, or attributable to the income, profits or gains of, or events affecting, one or more
other persons; 
 “Tax Group” means any group, consolidation or fiscal unity for the purposes of any Tax, including any
group for the purposes of VAT and any Tax Consolidation; 
 “Tax Indemnity” means the deed of covenant against taxation, in
a form that applies the provisions of the “Tax Indemnity” as defined in the Vaccines SAPA in relation to the Influenza Group Companies as those provisions apply in relation to the Vaccines Group Companies, mutatis mutandis, to be
entered into by Novartis and the Purchaser on the Option Closing Date; 
 “Tax Return” means any return, declaration, claim
for refund, information return or statement, including any schedule or attachment thereto, which must be filed or lodged with, or submitted to, any Tax Authority in relation to the assessment, notification, collection or administration of any Tax,
or which a taxpayer must prepare and retain; 
 “Tax Warranties” means Novartis’s Warranties set out in paragraph 13 of
Appendix 18; 
 “Third Party” has the meaning given to it in Paragraph 15.4.2; 

“Third Party Claim” has the meaning given to it in Paragraph 11.4; 

“Third Party Consents” means all consents, licences, approvals, permits, authorisations or waivers required from third parties
for the assignment or transfer to the Purchaser of any of the Transferred Contracts, Transferred Intellectual Property Contracts, MF59® Intellectual Property Rights Contracts or Shared
Business Contracts or Co-Owned Influenza Group Intellectual Property Rights or Transferred Plant and Equipment and “Third Party Consent” means any one of them; 

“Third Party Indebtedness” means the aggregate amount as at the Effective Time of all outstanding Indebtedness owed by the
Influenza Group Companies to any third party less any Indebtedness owed by any third party to any Influenza Group Company as derived from the Option Closing Statement (but excluding any item included in respect of any Influenza Group Companies’
Cash Balances or Intra-Group Non-Trade Payables), and, for the purposes of this definition, third party shall exclude any member of the Novartis Group; 

  
  

33 

 Execution Version 
  

“Time-Limited Excluded Liability” means an Excluded Liability which is: 

 

	 	(xxii)	a Contracts Liability; 

  

	 	(xxiii)	an Environmental Liability; 

  

	 	(xxiv)	a Manufacturing Liability; or 

  

	 	(xxv)	a Commercial Practices Liability, 

 “Trademarks” means trademarks, service
marks, trade names, certification marks, service names, industrial designs, brand names, brand marks, trade dress rights, identifying symbols, logos, emblems, and signs or insignia and all goodwill of the business in relation to which any of the
foregoing are used (but no other or greater goodwill); 
 “Transaction” has the meaning given to it in Paragraph 4.1.1; 

“Transfer Regulations” means the relevant national measure by which the employment of a Relevant Influenza Business Employee
automatically transfers to the Purchaser or a relevant member of the Purchaser’s Group; 
 “Transferred Accounts
Payable” means all trade accounts and notes payable arising in the ordinary course of the Novartis Group (other than any Influenza Group Company) to the extent related to the Business, and outstanding at the Effective Time, together with
any unpaid financing charges accrued thereon; 
 “Transferred Accounts Receivable” means all trade accounts and notes
receivable arising in the ordinary course of the Novartis Group (other than any Influenza Group Company) to the extent related to the Business, and outstanding at the Effective Time, together with any unpaid financing charges accrued thereon; 

“Transferred Books and Records” means all books, ledgers, files, reports, plans, records, manuals and other materials (in any
form or medium) to the extent of, or maintained predominantly for, the Business by the Novartis Group (excluding the Influenza Group Companies) (other than emails), but excluding: 

 

	 	(xxvi)	any such items to the extent that: (A) they are related to any Excluded Assets or Excluded Liabilities, (B) they are related to any corporate, Tax, human resources or stockholder matters of Novartis or its
Affiliates (other than the Influenza Group Companies), (C) any Applicable Law prohibits their transfer or (D) any transfer thereof otherwise would subject Novartis or any of its Affiliates to any material liability; and 

 

	 	(xxvii)	any laboratory notebooks to the extent containing research and development information unrelated to the Business; 

“Transferred Contracts” means: 
  

	 	(i)	the Contracts, other than Transferred Intellectual Property Contracts and the US Government Contracts, that are Predominantly Related to the Business between a member of the Novartis Group (excluding the Influenza Group
Companies), on the one hand, and any third party, on the other hand (other than this Deed and any Ancillary Agreement), but excluding any Excluded Contract; and 

  
  

34 

 Execution Version 
  

 

	 	(ii)	subject to paragraph 1 of Appendix 9, the Relevant Part of the Shared Business Contracts; 

“Transferred Employees” means (i) the Influenza Business Employees to whom the Purchaser (or a member of the
Purchaser’s Group) offers employment and who accept such employment and become employed by the Purchaser (or a member of the Purchaser’s Group) in accordance with Appendix 10; (ii) any Relevant Influenza Business Employees who
transfer to the Purchaser (or a member of the Purchaser’s Group) by operation of the Transfer Regulations and do not object to such transfer (to the extent permitted by the Transfer Regulations) in accordance with Appendix 10; and
(iii) the Relevant Influenza Group Company Employees, and “Transferred Influenza Business Employees” means the employees in (i) and (ii), “Transferred Influenza Group Company Employees” means the employees
in (iii) and “Transferred Employee”, “Transferred Influenza Business Employee” and “Transferred Influenza Group Company Employee” respectively means any one of them; 

“Transferred Information Technology” means all Information Technology of any member of the Novartis Group (other than an
Influenza Group Company) to the extent Exclusively Related to the Business; 
 “Transferred Intellectual Property Contracts”
means Contracts Exclusively Related to the Business which relate to Intellectual Property Rights (but excluding the rights under any such Contracts that are held by the Influenza Group Companies), including any such Contracts set out in Part 2 of
Appendix 4; 
 “Transferred Intellectual Property Rights” means the Intellectual Property Rights of any member of the
Novartis Group (other than an Influenza Group Company) Exclusively Related to the Business, including the Intellectual Property Rights of any member of the Novartis Group (other than an Influenza Group Company) set out in Part 1 of Appendix 4; 

“Transferred Inventory” means all inventories (including Manufacturing Inventory and Manufacturing Stocks and In-Market
Inventory), wherever located, including all raw materials, work in progress, finished Products and packaging and labelling material in respect of the Products and otherwise Predominantly Related to the Business (but excluding any such items held by
the Influenza Group Companies) whether held at any location or facility of a member of the Novartis Group or in transit to a member of the Novartis Group, in each case as of the Effective Time; 

“Transferred Leased Real Properties” has the meaning given to it in paragraph 1.1 of Part 4 of Appendix 3; 

“Transferred Owned Real Properties” has the meaning given to it in paragraph 1.1 of Part 4 of Appendix 3; 

“Transferred Plant and Equipment” means: 
  

	 	(xxviii)	the Transferred Information Technology; and 

  

	 	(xxix)	all plant, furniture, furnishings, vehicles, equipment, tools and other tangible personal property (other than Transferred Inventory or Transferred Information Technology) of the Novartis Group that are Predominantly
Related to the Business (but excluding any such items owned by the Influenza Group Companies); 

 “Transferred Real
Properties” means: 

  
  

35 

 Execution Version 
  

 

	 	(xxx)	the Transferred Owned Real Properties; 

  

	 	(xxxi)	the Transferred Leased Real Properties; and 

  

	 	(xxxii)	all other freehold, leasehold or other immovable property Predominantly Related to the Business, other than any freehold, leasehold or other immovable property within the definition of “Excluded Assets”,

 and “Transferred Real Property” means any one of them; 

“Transitional Services Agreement” means the transitional services agreement expected to be entered into between Novartis and
the Purchaser at Option Closing on the heads of terms in the Agreed Terms for the “Transitional Services Agreement” as defined in the Vaccines SAPA (with any necessary amendments) or, if the “Transitional Services Agreement” as
defined in the Vaccines SAPA is entered into before Option Closing, on the terms of the “Transitional Services Agreement” as defined in the Vaccines SAPA (with any necessary amendments); 

“US Benefit Plans” means all United States “employee benefit plans” (within the meaning of section 3(3) of ERISA),
severance, change in control or employment, vacation, incentive, bonus, stock option, stock purchase, or restricted stock plans, programmes, agreements or policies benefiting the Influenza Business Employees; 

“US Government Contracts” means: (i) the Contracts of Novartis Vaccines & Diagnostics, Inc. set out in Part 1 of
Appendix 17; and (ii) any other Contracts that are Predominantly Related to the Business between a member of the Novartis Group (excluding the Influenza Group Companies), on the one hand, and a Governmental Entity in the United States of
America on the other hand, but excluding any Excluded Contract; 
 “US Transferred Employees” has the meaning given to it in
paragraph 7.1 of Appendix 10; 
 “Vaccines” means a preparation comprising (i) an antigen, (ii) an epitope of an
antigen, or (iii) a polynucleotide encoding an antigen derived directly or indirectly from, or mimicking, an agent (including, but not limited to, a compound, a toxin, a microbe including a pathogen or component thereof), wherein such
preparation may further comprise a composition capable of modulating an immune response, including preparations intended to improve a human’s immune response to a microbe that has been linked to cancer, wherein said preparation is intended for
purposes of inducing an immune response in a human, including, but not limited to, a functional immune response or immunological memory to the particular or related antigen or agent, thereby causing or improving an immune response to a challenge by
the particular or related agent. “Vaccines” shall not include preparations intended to improve a human’s immune response to or to treat other non-infectious conditions, whether or not related to pathogens, such as certain autoimmune
diseases, Alzheimer’s disease and certain cancers, or non-antigen preparations comprising immune system components intended to function analogous to corresponding native components within the patient, such as antibodies or white blood cells
(both unmodified or modified to better treat disease); 
 “Vaccines Group Companies” has the meaning given in the Vaccines
SAPA; and 
 “WARN Act” means the Worker Adjustment and Retraining Notification Act of 1988 of the United States. 

  
  

36 

 Execution Version 
  

 

	1.2	Shares 

 References to shares shall include, where relevant, quotas. 

 

	1.3	Reference to documents 

 References to any document (including this Deed), or to a
provision in a document, shall be construed as a reference to such document or provision as amended, supplemented, modified, restated or novated from time to time. 
  

	1.4	References to “indemnify” 

 Unless specified to the contrary, references to
“indemnify” and “indemnifying” any person against any circumstance include indemnifying and holding that person harmless on an after-Tax basis and: 
  

	 	1.4.1	references to the Purchaser indemnifying each member of the Novartis Group shall constitute undertakings by the Purchaser to Novartis for itself and on behalf of each other member of the Novartis Group;

  

	 	1.4.2	references to Novartis indemnifying each member of the Purchaser’s Group shall constitute undertakings by Novartis to the Purchaser for itself and on behalf of each other member of the Purchaser’s
Group; 

  

	 	1.4.3	to the extent that the obligation to indemnify relates to any Shares (including any Influenza Group Companies) or other assets or liabilities transferred by a Share Seller or Business Seller (as the case may be)
to a member of the Purchaser’s Group pursuant to this Deed, references to Novartis indemnifying the Purchaser and references to Novartis indemnifying the Purchaser or any member of the Purchaser’s Group shall constitute undertakings by
Novartis, to indemnify or procure the indemnification of the relevant purchaser of the Shares transferred by that Share Seller or the relevant purchaser of the assets or liabilities transferred by that Business Seller (as the case may be), and
references to the Purchaser indemnifying Novartis and references to the Purchaser indemnifying Novartis and each member of the Novartis Group shall constitute undertakings by the Purchaser to indemnify or procure the indemnification of the relevant
member of the Novartis Group; and 

  

	 	1.4.4	where under the terms of this Deed one party is liable to indemnify or reimburse another party in respect of any costs, charges or expenses, the payment shall include an amount equal to any VAT thereon not
otherwise recoverable by the other party or any member of any group or consolidation of which it forms part for VAT purposes, subject to that party using reasonable endeavours to recover or to procure recovery of such amount of VAT as may be
practicable. 

 For the purposes of this Paragraph 1.4, indemnifying and holding harmless a person on an “after-Tax
basis” means that the amount payable pursuant to the indemnity (the “Payment”) shall be calculated in such a manner as will ensure that, after taking into account: 

 

	 	(i)	any Tax required to be deducted or withheld from the Payment and any additional amounts required to be paid by the payer of the Payment in consequence of such withholding; 

  
  

37 

 Execution Version 
  

 

	 	(ii)	the amount and timing of any additional Tax which becomes (or would, but for the use of any credit or other relief which would otherwise have been available to reduce the Tax liabilities of any member of the Novartis
Group, have become) payable by the recipient of the Payment (or a member of the Novartis Group or the Purchaser’s Group, as the case may be) as a result of the Payments being subject to Tax in the hands of that person; and 

 

	 	(iii)	the amount and timing of any Tax benefit which is obtained by the recipient of the Payment (or a member of the Novartis Group or the Purchaser’s Group, as the case may be) to the extent that such Tax benefit is
attributable to the matter giving rise to the indemnity payment or to the receipt of the Payment, 

 which amount and timing is
to be determined by the auditors of the recipient at the shared expense of both relevant parties and is to be certified as such to the party making the Payment, the recipient of the Payment is in no better and no worse after Tax position as that in
which it would have been if the matter giving rise to the indemnity payment had not occurred, provided that if either party to this Deed shall have assigned or novated the benefit of this Deed in whole or in part or shall , after the date of this
Deed, have changed its Tax residence or the permanent establishment to which the rights under this Deed are allocated then no Payment to that party shall be increased by reason of the operation of paragraphs (i) to (iii) above to any
greater extent than would have been the case had no such assignment, novation or change taken place. 
  

	1.5	References to wholly or substantially in the Business 

 References to “wholly or
substantially in the Business” in relation to any employee employed by a member of the Novartis Group means that such employee spends more than 70 per cent. of their time working in the Business at the relevant time. 

 

	2	Sale and Purchase of the Influenza Group 

  

	2.1	Sale and Purchase of the Influenza Group 

 Subject to the valid exercise of the Put
Option in accordance with Clause 2.2 of this Deed, and on and subject to the terms and conditions of this Deed and the Local Transfer Documents: 
  

	 	2.1.1	Novartis shall procure that the Share Sellers and Business Sellers shall sell, and 

  

	 	2.1.2	the Purchaser shall purchase, or shall procure the purchase by one or more members of the Purchaser’s Group, of 

the Influenza Group as a going concern. 
  

	2.2	Sale of the Shares 

  

	 	2.2.1	Novartis shall procure that the Share Seller shall sell the Shares, which shall be sold with Full Title Guarantee free from Encumbrances and together with all rights and advantages attaching to them as at Option
Closing (including the right to receive all dividends or distributions declared, made or paid on or after Option Closing). 

  
  

38 

 Execution Version 
  

 

	 	2.2.2	Novartis shall procure that, on or prior to Option Closing, any and all rights of pre-emption over the Shares, and over the shares or equity interests in any Subsidiaries, are waived irrevocably by the persons
entitled thereto. 

  

	2.3	Sale of the Influenza Group Businesses 

  

	 	2.3.1	Novartis shall procure that the Business Sellers shall sell the Influenza Group Businesses to be sold under this Deed or under the Local Transfer Documents, in each case with Full Title Guarantee (save in respect
of the Transferred Intellectual Property Rights which are not Registered Intellectual Property Rights) and free from Encumbrances other than Permitted Encumbrances (save for the Transferred Real Properties, which shall be sold free from Encumbrances
other than as provided in paragraph 1.9 of Part 4 of Appendix 3), such Influenza Group Businesses comprising: 

  

	 	(i)	the Transferred Real Properties; 

  

	 	(ii)	the Transferred Plant and Equipment; 

  

	 	(iii)	the Transferred Inventory; 

  

	 	(iv)	the Transferred Accounts Receivable; 

  

	 	(v)	the Transferred Books and Records; 

  

	 	(vi)	subject to and in accordance with Appendix 9, the Transferred Intellectual Property Rights and the MF59® Intellectual Property Rights; 

 

	 	(vii)	subject to and in accordance with Appendix 9, the Transferred Intellectual Property Contracts and the MF59® Intellectual Property Rights Contracts;

  

	 	(viii)	subject to and in accordance with Appendix 9, the Transferred Contracts; 

  

	 	(ix)	the US Government Contracts; 

  

	 	(x)	the Manufacturing, production and research activity carried on by the Novartis Group at the Holly Springs Site; 

  

	 	(xi)	the interest of the Novartis Group in the Sinergium Arrangements; 

  

	 	(xii)	the Manufacturing and Supply Agreement; 

  

	 	(xiii)	subject to and in accordance with Appendix 8, all Product Approvals and all Product Applications and all other permits, licences, certificates, registrations, marketing or other authorisations or consents issued by a
Governmental Entity Predominantly Related to the Business and not held by the Influenza Group Companies; 

  

	 	(xiv)	subject to and in accordance with Appendix 8, all Marketing Authorisation Data not held by the Influenza Group Companies; 

  

	 	(xv)	all Business Information not held at Option Closing by the Influenza Group Companies; 

  

	 	(xvi)	all rights of the Purchaser, its Affiliates and the Influenza Group Companies as contemplated by Appendix 10 and Appendix 11; 

  

	 	(xvii)	the MF59® Rights (to the extent not included within (vi) and (vii) above); 

  
  

39 

 Execution Version 
  

 

	 	(xviii)	the Influenza Group Goodwill; and 

  

	 	(xix)	all other property, rights and assets owned or held by the Novartis Group (other than the Influenza Group Companies) and Predominantly Related to the Business at Option Closing (other than any property, rights and
assets of the Influenza Group expressly excluded from the sale under this Deed). 

  

	 	2.3.2	There shall be excluded from the sale of the Influenza Group under this Deed and the Local Transfer Documents the following: 

  

	 	(i)	the Novartis Group Retained Business; 

  

	 	(ii)	Zhejiang Tianyuan Bio-Pharmaceutical Co., Ltd. and any business carried on by or on behalf of Zhejiang Tianyuan Bio-Pharmaceutical Co., Ltd.; 

 

	 	(iii)	the Out-Licensing Programme; 

  

	 	(iv)	any Intellectual Property Right that is not an Influenza Group Intellectual Property Right or MF59® Intellectual Property Right (subject to the Purchaser
Intellectual Property Licence Agreement) and any Contract relating to Intellectual Property Rights that is not an Influenza Group Intellectual Property Contract or MF59® Intellectual Property
Rights Contract or the Relevant Part of a Shared Business Contract; 

  

	 	(v)	any Information Technology other than Influenza Group Information Technology; 

  

	 	(vi)	the Novartis Marks; 

  

	 	(vii)	any product and any permits, licences, certificates, registrations, marketing or other authorisations or consents issued by any Governmental Entity in respect of any products, or any applications therefor, other than
(a) the Products, Product Approvals, Products Under Registration and Pipeline Product Approvals; and (b) Permits Predominantly Related to the Business; 

  

	 	(viii)	all cash, marketable securities and negotiable instruments, and all other cash equivalents, of the Novartis Group (other than the Influenza Group Companies); 

 

	 	(ix)	all real property and any leases thereof and interests therein other than the Properties; 

  

	 	(x)	the land and buildings of the Novartis Group at 4560 Horton Street, Emeryville CA, United States of America; 

  

	 	(xi)	the land and buildings of the Novartis Group at Jaboatão dos Guararapes, State of Pernambuco (Brazil), together with all, buildings, fixtures and improvements erected thereon and any other assets, rights and
Contracts related thereto; 

  

	 	(xii)	the company seal, minute books, charter documents, stock or equity record books and such other books and records pertaining to Novartis or its Affiliates (other than the Influenza Group Companies and the Transferred
Books and Records), as well as any other records or material relating to Novartis or its Affiliates (other than Influenza Group Companies) generally and not involving or related to the Influenza Group; 

  
  

40 

 Execution Version 
  

 

	 	(xiii)	any right of Novartis or its Affiliates to be indemnified in respect of Assumed Liabilities; 

  

	 	(xiv)	all Tax assets (including Tax refunds and prepayments), other than Tax Assets of any Influenza Group Company; 

  

	 	(xv)	all Tax Returns of the Novartis Group (other than the Influenza Group Companies) and all Tax Returns relating to Tax Groups of which persons other than Influenza Group Companies are members and, in each case, all books
and records (including working papers) related thereto; 

  

	 	(xvi)	any rights in respect of any insurance policies of the Novartis Group, as provided in Paragraph 14; 

  

	 	(xvii)	all artwork, paintings, drawings, sculptures, prints, photographs, lithographs and other artistic works of the Novartis Group that are not embodiments of Influenza Group Intellectual Property Rights; 

 

	 	(xviii)	any rights of the Novartis Group (other than the Influenza Group Companies) under any Intra-Group Non-Trade Payables or Intra-Group Non-Trade Receivables (excluding Transferred Accounts Receivable); 

 

	 	(xix)	any rights of Novartis or its Affiliates (other than the Influenza Group Companies) contemplated by Appendix 10 and Appendix 11; 

  

	 	(xx)	any equity interest in any person other than an Influenza Group Company; 

  

	 	(xxi)	the Excluded Contracts; 

  

	 	(xxii)	all rights of the Novartis Group under this Deed and the Ancillary Agreements; and 

  

	 	(xxiii)	the Purchase Price Bank Account; and 

  

	 	(xxiv)	the lease in respect of the 884 rentable square feet located at 7030 Kit Creek Road, Research Triangle Park, North Carolina, US. 

  

	 	2.3.3	Novartis agrees to procure the transfer (to the extent it is able so to do) and the Purchaser agrees to accept (or procure the acceptance by another member of the Purchaser’s Group of) the transfer of, and to
assume, pay, satisfy, discharge, perform or fulfil (or procure that another member of the Purchaser’s Group will assume, pay, satisfy, discharge, perform or fulfil) the Assumed Liabilities with effect from Option Closing. 

 

	 	2.3.4	Paragraph 2.3.3 shall not apply to, and the Purchaser shall not be obliged to accept (or procure the acceptance by another member of the Purchaser’s Group of), the transfer of or to assume, pay, satisfy, discharge,
perform or fulfil, or procure that another member of the Purchaser’s Group will assume, pay, satisfy, discharge, perform or fulfil: 

  

	 	(i)	any Excluded Liability; or 

  

	 	(ii)	any Liability to the extent it relates to an Excluded Asset. 

  

	 	2.3.5	Without prejudice to Clauses 2.1 to 2.3 and Paragraphs 2.1, 2.2, 2.3.1 to 2.3.4, 2.4 and 2.5 of this Deed, on or prior to Option Closing, Novartis may: 

  
  

41 

 Execution Version 
  

 

	 	(i)	assign or otherwise transfer assets, liabilities and (only where in compliance with Paragraph 5 (other than Paragraph 5.3.1(ii)) employees between members of the Novartis Group as may be reasonably required to
facilitate the separation of the Business from any other business or activities of the Novartis Group; and 

  

	 	(ii)	otherwise, carry out or procure one or more reorganisations of the Novartis Group (including assigning or otherwise transferring assets and liabilities between members of the Novartis Group but excluding assigning or
otherwise transferring assets or liabilities to Influenza Group Companies) as may reasonably be required to facilitate the Transaction, 

  

	 	  	each, a “Reorganisation”, 

  

	 	2.3.6	In respect of any Reorganisation: 

  

	 	(i)	Novartis shall notify the Purchaser of any proposed Reorganisation, the steps proposed to be implemented and such other information as the Purchaser may reasonably request regarding the proposed Reorganisation in
advance of it being implemented; 

  

	 	(ii)	Novartis shall, in good faith, consult with, and take into account the reasonable views of, and any reasonable requests made by the Purchaser in relation to any Reorganisation before it is implemented, including any
proposals to reduce or avoid Liability or cost being suffered or incurred by any member of the Purchaser’s Group or any Influenza Group Company; and 

  

	 	(iii)	all fees, costs and expenses of implementing any Reorganisation (or any part thereof) shall be borne by the Novartis Group. 

  

	 	2.3.7	Novartis undertakes to the Purchaser (for itself and as trustee for each other member of the Purchaser’s Group and each Influenza Group Company) that, with effect from Option Closing, Novartis will indemnify on
demand and hold harmless the relevant member of the Purchaser’s Group (including each Influenza Group Company) against and in respect of any and all Liabilities arising in connection with any Reorganisation (or part thereof) undertaken by
Novartis, other than: 

  

	 	(i)	any Liabilities of any Influenza Group Company in respect of Tax (which shall be dealt with under the Tax Indemnity); and 

  

	 	(ii)	any Liabilities in connection with this Deed or any document entered into as provided by this Deed or any Ancillary Agreement. 

  

	2.4	Employees and Employee Benefits 

  

	 	2.4.1	The provisions of Appendix 10 shall apply in respect of the Employees. 

  

	 	2.4.2	The provisions of Appendix 11 shall apply in respect of Employee Benefits. 

  

	2.5	Properties 

 The provisions of Appendix 3 shall apply in respect of the Properties. 

  
  

42 

 Execution Version 
  

	2.6	Local Transfer Documents 

  

	 	2.6.1	On Option Closing or at such other time as agreed between the parties, Novartis shall procure that the Share Seller and Business Sellers execute, and the Purchaser shall execute (or procure the execution by one or more
other members of the Purchaser’s Group of), such agreements, transfers, conveyances and other documents, as may be required pursuant to the relevant local law and otherwise as may be agreed between Novartis and the Purchaser to implement the
transfer of (i) the Shares and (ii) the Influenza Group Businesses, in each case on Option Closing (the “Local Transfer Documents” and each, a “Local Transfer Document”). The parties do not intend this
Deed to transfer title to any of the Shares. Title shall be transferred by the applicable Local Transfer Document. 

  

	 	2.6.2	To the extent that the provisions of a Local Transfer Document are inconsistent with or (except to the extent they implement a transfer in accordance with Deed) additional to the provisions of this Deed:

  

	 	(i)	the provisions of this Deed, shall prevail; and 

  

	 	(ii)	so far as permissible under the laws of the relevant jurisdiction, Novartis and the Purchaser shall procure that the provisions of the relevant Local Transfer Document are adjusted, to the extent necessary to give
effect to the provisions of this Deed or, to the extent this is not permissible, Novartis shall indemnify the Purchaser against all Liabilities suffered by the Purchaser or its Affiliates or, as the case may be, the Purchaser shall indemnify
Novartis against all Liabilities suffered by Novartis or its Affiliates, in either case through or arising from the inconsistency between the Local Transfer Document and this Deed or the additional provisions (except to the extent they implement a
transfer in accordance with this Deed). 

  

	 	2.6.3	If there is an adjustment to the Purchase Price under Paragraph 7.3 which relates to a part of the Influenza Group which is the subject of a Local Transfer Document, then, if required to implement the adjustment and so
far as permissible under Applicable Law, the Purchaser shall (or shall procure that the relevant member of the Purchaser’s Group will), and Novartis shall procure that its relevant Affiliate shall, enter into a supplemental agreement reflecting
such adjustment and the allocation of such adjustment. 

  

	 	2.6.4	Novartis shall not, and shall procure that none of its Affiliates shall, bring any claim against the Purchaser or any member of the Purchaser’s Group in respect of or based upon the Local Transfer Documents save to
the extent necessary to implement any transfer of the Shares or Influenza Group Businesses as contemplated by this Deed. To the extent that Novartis or a member of the Novartis Group does bring a claim in breach of this Paragraph, Novartis shall
indemnify the Purchaser and each member of the Purchaser’s Group against all Liabilities which the Purchaser or that member of the Purchaser’s Group may suffer through or arising from the bringing of such a claim. 

 

	 	2.6.5	The Purchaser shall not, and shall procure that none of its Affiliates shall, bring any claim against Novartis or any member of the Novartis Group in respect of or based upon the Local Transfer Documents save to the
extent necessary to implement any transfer of the Shares or Influenza Group Businesses as contemplated by this Deed. To the extent that the Purchaser or a member of the Purchaser’s Group does bring a claim in breach of this Paragraph, the
Purchaser shall indemnify Novartis and each member of the Novartis Group against all Liabilities which Novartis or any member of the Novartis Group may suffer through or arising from the bringing of such a claim. 

  
  

43 

 Execution Version 
  

 

	3	Consideration 

  

	3.1	Amount 

  

	 	3.1.1	The aggregate consideration for the purchase of the Influenza Group under this Deed and the Local Transfer Documents (the “Purchase Price”) shall be an amount in US dollars equal to the sum of:

  

	 	(i)	US$250,000,000 (the “Headline Price”); 

  

	 	  	plus 

  

	 	(ii)	the Influenza Group Companies’ Cash Balances and the Intra-Group Non-Trade Receivables; 

  

	 	  	minus 

  

	 	(iii)	the Third Party Indebtedness; 

  

	 	  	minus 

  

	 	(iv)	the Intra-Group Non-Trade Payables; 

  

	 	  	minus 

  

	 	(v)	any Employee Benefit Indemnification Amount paid in accordance with Appendix 11; 

  

	 	  	minus 

  

	 	(vi)	the Tax Adjustment. 

  

	3.2	Payment of Purchase Price 

 The Purchase Price shall be paid by the Purchaser (for itself
and on behalf of each relevant member of the Purchaser’s Group) by way of cash payments to the Purchase Price Bank Account pursuant to Paragraphs 6.3 and 7.6. 
  

	3.3	Allocation of Purchase Price 

 The Purchase Price shall be allocated in accordance with
Appendix 13. 
  

	3.4	VAT 

  

	 	3.4.1	The provisions of Appendix 14 shall apply in respect of VAT. 

  

	 	3.4.2	Novartis and the Purchaser agree that the consideration given under this Deed in respect of the sale of the Influenza Group Businesses and the Shares is exclusive of any VAT. 

  
  

44 

 Execution Version 
  

 

	 	3.4.3	To the extent that VAT is chargeable in respect of that sale or any part thereof, the Purchaser shall, against delivery of a valid VAT invoice (or equivalent, if any), in addition to any other amount expressed in this
Deed to be payable by the Purchaser, pay or procure the payment to Novartis (on behalf of the relevant Business Seller or Share Seller as applicable) any amount of any VAT so chargeable for which Novartis (or the relevant Share Seller or Business
Seller, as the case may be) is liable to account, in accordance with Appendix 14. 

  

	3.5	Treatment of Payments 

  

	 	3.5.1	If any payment is made or procured (i) by Novartis to the Purchaser or relevant member of the Purchaser’s Group, or (ii) by a Purchaser to Novartis or a member of the Novartis Group, in either case in
respect of any claim under or for any breach of this Deed, or pursuant to an indemnity (or equivalent covenant to pay) under this Deed, the payment shall be treated, so far as possible, as an adjustment of the consideration paid by the relevant
member of the Purchaser’s Group for the Shares or the particular part of the Influenza Group to which the payment and/or claim relates under this Deed and the consideration shall be deemed to be increased or reduced (as applicable) by the
amount of such payment, provided that this Paragraph 3.5.1 shall not require any amount to be treated as an amount in respect of the Purchase Price for the purposes of Paragraph 15.10 if it would not otherwise have been so treated.

  

	 	3.5.2	If: 

  

	 	(i)	the payment and/or claim relates to the shares in more than one Influenza Group Company or to more than one category of Influenza Group Business, it shall be allocated in a manner which reflects the impact of the matter
to which the payment and/or claim relates, failing which it shall be allocated rateably to the shares in the Influenza Group Companies or Influenza Group Businesses concerned by reference to the proportions in which the consideration is allocated in
accordance with Appendix 13; or 

  

	 	(ii)	the payment and/or claim relates to no particular shares in any Influenza Group Company or no particular category of Influenza Group Business, it shall be allocated rateably to all the Shares and all the Influenza Group
Businesses by reference to the proportions in which the consideration is allocated in accordance with Appendix 13, 

  

	 	  	and in each case the consideration shall be deemed to have been reduced by the amount of such payment. 

  
  

45 

 Execution Version 
  

 

	4	Conditions 

  

	4.1	Conditions Precedent 

 The sale and purchase of the Influenza Group is conditional upon
satisfaction or, where applicable, waiver of the following conditions, or their satisfaction subject only to Option Closing: 
  

	 	4.1.1	to the extent that the proposed acquisition of all or any of the Shares or Influenza Group Businesses (the “Transaction”) either constitutes (or is deemed to constitute under Article 4(5) and/or Article
5(2)) a concentration with a Community dimension within the meaning of Council Regulation (EC) 139/2004 (as amended) (the “Regulation”) or is to be examined by the European Commission as a result of a decision under Article 22(3) of
the Regulation: 

  

	 	(i)	the European Commission taking a decision (or being deemed to have taken a decision) under Article 6(1)(b) or, if the Commission has initiated proceedings pursuant to Article 6(1)(c), under Article 8(1) or 8(2) of the
Regulation declaring the Transaction compatible with the common market; or 

  

	 	(ii)	the European Commission taking a decision (or being deemed to have taken a decision) to refer the whole or part of the Transaction to the competent authorities of one or more Member States under Article 4(4) or 9(3) of
the Regulation; and 

  

	 	(a)	each such authority taking a decision with equivalent effect to Paragraph 4.1.1(i) with respect to those parts of the Transaction referred to it; and 

 

	 	(b)	the European Commission taking any of the decisions under Paragraph 4.1.1(i) with respect to any part of the Transaction retained by it; 

 

	 	4.1.2	any waiting period (and any extension thereof) under the HSR Act applicable to the Transaction having expired; 

  

	 	4.1.3	any additional clearances, approvals, waivers, no-action letters and consents required or otherwise agreed between the Parties as appropriate to be obtained having been obtained, or any waiting periods required to have
expired having expired, in each case under applicable antitrust, merger control or foreign investment rules and which are, in each case: (i) necessary (or mutually agreed as appropriate) to permit Novartis and the Purchaser to consummate the
Transaction; and (ii) following consultation with Novartis, notified by the Purchaser to Novartis in the period from and including the Option Exercise Date and ending on and including the twentieth Business Day after the Option Exercise Date;

  

	 	4.1.4	any additional clearances, approvals and consents having been obtained from any Governmental Entity, which are mandatory and necessary to permit Novartis and the Purchaser to lawfully consummate the Transaction;

  

	 	4.1.5	receipt of CFIUS Approval if CFIUS has initiated a review of the transactions contemplated by this Deed, whether pursuant to Paragraph 4.2.3 or otherwise; 

 

	 	4.1.6	in relation to all US Government Contracts which require formal novation pursuant to 48 C.F.R. Subpart 42.12 in connection with the consummation of the Transaction, no relevant Governmental Entity within the United
States Government having stated that it will not, or intends not to, grant such consents, unless such statement or indication has been withdrawn as at the proposed Option Closing Date; 

 

	 	4.1.7	no Governmental Entity having enacted, issued, promulgated, enforced or entered any Applicable Law or Judgment (whether temporary, preliminary or permanent) that is in effect at the Option Closing Date and that has the
effect of making the transactions contemplated by this Deed illegal or otherwise restraining or prohibiting the consummation of such transactions; and 

  
  

46 

 Execution Version 
  

 

	 	4.1.8	the passing at a duly convened and held general meeting of the Purchaser Shareholders of an ordinary resolution as contemplated by clause 2.1 of the Implementation Agreement. 

 

	4.2	Responsibility for Satisfaction 

  

	 	4.2.1	The Purchaser and Novartis shall prepare and file the notifications necessary for the fulfilment of the conditions in Paragraphs 4.1.1 to 4.1.4 (the “Required Notifications”) as soon as reasonably
practicable after the Option Exercise Date (with any necessary notifications under the HSR Act to be filed within 15 Business Days after the Option Exercise Date). Notwithstanding anything to the contrary contained in this Deed, the Purchaser shall
have primary responsibility for obtaining all consents, approvals or actions of any Governmental Entity which are required in connection with the Required Notifications. 

 

	 	4.2.2	The Purchaser shall be responsible for payment of all filing and other fees and expenses in connection with the Required Notifications and the satisfaction of the conditions in Paragraphs 4.1.1 to 4.1.4.

  

	 	4.2.3	CFIUS: 

  

	 	(i)	Novartis and the Purchaser shall consult, cooperate and keep each other reasonably informed regarding communications with, and requests for additional information from, CFIUS with respect to the Transaction. Novartis
and the Purchaser shall use their respective reasonable best efforts to provide promptly all information that is pursuant to a request by CFIUS. 

  

	 	(ii)	Within 60 calendar days after the Option Exercise Date, any party wishing to submit a formal joint voluntary notice to CFIUS pursuant to 31 C.F.R. Section 800.401, et. seq. (“CFIUS Filing”) shall
provide the other party with written notice of its intent to make a CFIUS Filing (“Election Date”). Prior to making its election to submit a CFIUS Filing, the party wishing to make a CFIUS Filing shall consult in good faith with
senior executives of the other party. If neither Novartis nor the Purchaser provides notice to submit a formal joint voluntary notice to CFIUS, a CFIUS Filing will not be made unless requested by CFIUS. 

 

	 	(iii)	If either Novartis or the Purchaser elects to make a CFIUS Filing following the procedures and consultations in Clause 4.2.3(i) or if CFIUS requires a filing, then: 

 

	 	(a)	Novartis and the Purchaser shall use their respective reasonable best efforts to submit a draft CFIUS Filing no later than 15 Business Days following the Election Date, and a final CFIUS Filing the earlier of
(1) five business days after submitting the draft CFIUS filing or (2) five calendar days after the receipt of any comments from CFIUS staff regarding the draft CFIUS Filing; 

 

	 	(b)	Novartis and the Purchaser will provide each other with the reasonable opportunity to review and comment on any information provided to CFIUS to the extent permitted by Applicable Law, with the exception of personal
identifier information required under Section 800.402(c)(6)(vi)(B) of the CFIUS regulations, 31 C.F.R.. Competitively sensitive information, or information not related to the transactions contemplated by this Deed, may be restricted to each
party’s external counsel to the extent reasonably considered necessary or advisable by the providing party; 

  
  

47 

 Execution Version 
  

 

	 	(c)	Novartis and the Purchaser shall each have an opportunity to approve and mutually agree on the joint contents of the CFIUS Filing and shall be jointly responsible for the accuracy of such contents. Novartis and the
Purchaser respectively, shall each be responsible for the accuracy of contents of the CFIUS Filing that exclusively relate to itself, its business, and any subsidiaries, parents or other related parties; and 

 

	 	(d)	Novartis and the Purchaser shall use their respective reasonable best efforts to obtain CFIUS Approval as promptly as practicable and shall consult with each other on strategic matters related to obtaining such CFIUS
Approval, provided that the Purchaser shall have no obligation to agree to any mitigation or other restrictive provision that could reasonably be considered to have a substantial impact on either the Business or the Purchaser. 

 

	 	4.2.4	The party responsible for satisfaction of each condition pursuant to this Paragraph 4 shall give notice to the other party of the satisfaction of the relevant condition within one Business Day of becoming aware of the
same. 

  

	 	4.2.5	The parties shall cooperate with each other in connection with the satisfaction of the conditions in Paragraphs 4.1.1 to 4.1.4. The parties will consult and cooperate reasonably with one another, consider in good
faith the views of one another, and provide to the other party in advance any analyses, appearances, presentations, memoranda, briefs, arguments, opinions and proposals they or their agents make or submit to a Governmental Entity. Without limiting
the foregoing, the parties agree to: (a) give each other reasonable advance notice of all meetings with any Governmental Entity; (b) give each other an opportunity to participate in each of such meetings; (c) to the extent
practicable, give each other reasonable advance notice of all substantive oral communications with any Governmental Entity; (d) if any Governmental Entity initiates a substantive oral communication, promptly notify the other party of the
substance of such communication; (e) provide each other with a reasonable advance opportunity to review and comment upon all written communications (including any analyses, presentations, memoranda, briefs, arguments, opinions and proposals)
with a Governmental Entity; (f) provide each other with copies of all written communications to or from any Governmental Entity; and (g) not advance arguments in connection with any regulatory review or litigation proceeding related to
this Deed, (other than litigation between the parties) over the objection of the other party that would reasonably be likely to have a significant adverse impact on that other party, provided however, that neither party shall be required to comply
with sub-Paragraph (b) above to the extent that the Governmental Entity objects to the participation of a party, or with sub-Paragraph (e) or (f) above to the extent that such disclosure may raise regulatory concerns (in which case,
the disclosure may be made on an outside counsel basis). 

  
  

48 

 Execution Version 
  

 

	 	4.2.6	The Purchaser shall and, shall cause its Affiliates to use reasonable endeavours to procure the satisfaction of the conditions in Paragraphs 4.1.1 to 4.1.4 as soon as reasonably possible (and, in any event, not later
than the Option Long Stop Date). For the avoidance of doubt, nothing in this Deed shall require the Purchaser to propose, negotiate, offer to commit or effect any sale, divestiture, licence or other remedy in order to procure the satisfaction of the
conditions in Paragraphs 4.1.1 to 4.1.4. 

  

	 	4.2.7	Novartis shall, and shall cause the Influenza Group to use reasonable endeavours to cooperate with the Purchaser in connection with procuring the satisfaction of the conditions in Paragraphs 4.1.1 to 4.1.4 as soon as
reasonably possible (and, in any event, not later than the Longstop Date), including providing to the Purchaser such information with respect to the Influenza Group as the Purchaser may reasonably require in connection with satisfaction of its
obligations under this Paragraph. 

  

	 	4.2.8	The Purchaser and Novartis shall cooperate, in the manner contemplated in Paragraph 4.2.5, and use reasonable endeavours to ensure that no Governmental Entity shall enact, issue, promulgate, enforce or enter any
Applicable Law or Judgment as contemplated under Paragraph 4.1.7. In the event that any Governmental Entity enacts, issues, promulgates, enforces or enters any Applicable Law or Judgment as contemplated under Paragraph 4.1.7, the Purchaser and
Novartis shall cooperate and use reasonable endeavours to put in place arrangements that would allow the Transaction to complete to the greatest possible extent in compliance with the relevant Applicable Law or Judgment. 

 

	4.3	Waiver 

  

	 	4.3.1	The Purchaser may at any time in whole or in part (and conditionally or unconditionally) waive the conditions set out in Paragraph 4.1.4, in each case with Novartis’s prior written consent, such consent not to be
unreasonably withheld or delayed. 

  

	 	4.3.2	The Purchaser may at any time in whole or in part (and conditionally or unconditionally) waive the condition set out in Paragraph 4.1.6 by notice in writing to Novartis. 

 

	5	Pre-Option Closing 

  

	5.1	General 

 Subject to the terms and conditions of this Deed and subject to the Put Option
being exercised, Novartis and the Purchaser shall use reasonable endeavours to cooperate with each other on and after the date of this Deed to consummate the transactions contemplated in it. 

 

	5.2	Novartis’s Obligations in Relation to the Business 

  

	 	5.2.1	Novartis undertakes to procure that between the date of this Deed and Option Closing, so far as permitted by Applicable Law, the Business is carried on by the Influenza Group as a going concern in the ordinary course as
carried on immediately prior to the date of this Deed, save in so far as agreed in writing by the Purchaser (such consent not to be unreasonably withheld or delayed) or as provided in Paragraph 5.3. 

  
  

49 

 Execution Version 
  

 

	 	5.2.2	Without prejudice to the generality of Paragraph 5.2.1 and subject to Paragraph 5.3, Novartis undertakes to procure that, with respect to the Business, between the date of this Deed and Option Closing, no member of the
Novartis Group shall, except as may be required to comply with this Deed, without the prior written consent of the Purchaser (such consent not to be unreasonably withheld or delayed), take any of the actions listed in Part 1 of Appendix 20.

  

	 	5.2.3	Without prejudice to the generality of Paragraph 5.2.1 and subject to Paragraph 5.3, Novartis shall, in each case with respect to the Business: (i) undertake to procure the satisfaction of its obligations listed in
paragraph 1, Part 2 of Appendix 20; and (ii) procure that the Influenza Group shall, between the date of this Deed and Option Closing, comply with the requirements of paragraph 2, Part 2 of Appendix 20. 

 

	5.3	Exceptions to Novartis’s Obligations in Relation to the Conduct of Business 

  

	 	5.3.1	Paragraphs 5.1 and 5.2 shall not operate so as to prevent or restrict: 

  

	 	(i)	subject to Paragraph 5.3.2, the disposal or transfer by Novartis or any other member of the Novartis Group of all or any part of the Business to a Third Party Purchaser or to another member of the Novartis Group;

  

	 	(ii)	any matter undertaken by any member of the Novartis Group to facilitate or implement any Reorganisation in accordance with Paragraph 2.3.5; 

 

	 	(iii)	the entry into of any agreements or arrangements on arm’s length terms with respect to the supply by the Influenza Group of Enoxaparin, Copaxone and any other products to Sandoz Inc. or its Affiliates;

  

	 	(iv)	the closure of any production lines or facilities where the manufacture or production is transferred to another site within the Novartis Group, provided that such closure does not adversely affect (i) the ability
of the Business to operate in a similar form as at the date of this Deed or (ii) the Purchaser’s rights under this Deed; 

  

	 	(v)	the technology transfer of any production line between manufacturing sites, provided that such transfer does not adversely affect (i) the ability of the Business to operate in a similar form as at the date of this
Deed or (ii) the Purchaser’s rights under this Deed; 

  

	 	(vi)	any matter undertaken by any member of the Influenza Group that is set out in Part 3 of Appendix 20; 

  

	 	(vii)	any action relating to the Business required to be undertaken to comply with Applicable Law or requests from, and any dealings or other arrangements with, any Governmental Entity including, for the avoidance of doubt,
the tender for, or re-negotiation of, Contracts with Governmental Entities in the ordinary course of business; 

  

	 	(viii)	any matter reasonably undertaken in relation to the Business in an emergency or disaster situation with the intention of minimising any adverse effect of such situation on the Business, provided that Novartis shall
notify the Purchaser as soon as reasonably practicable of any action taken or proposed to be taken as described in this Paragraph (viii), shall provide to the Purchaser all such information as the Purchaser may reasonably request and use reasonable
endeavours to consult with the Purchaser in respect of any such action; or 

  
  

50 

 Execution Version 
  

 

	 	(ix)	anything provided for under Clause 5 of this Deed. 

  

	 	5.3.2	Notwithstanding any other provision of this Deed if, at any time after the date of this Deed, Novartis and / or any other member of the Novartis Group disposes of or transfers assets to a Third Party Purchaser such
that: 

  

	 	(i)	it or they would no longer be able to sell and transfer all or substantially all of the Business as at the date of this Deed to the Purchaser at Option Closing, Clause 2.1.1 shall no longer apply with the effect that
Novartis (and the members of the Novartis Group) may no longer exercise the Put Option with respect to the Option 1 Assets; 

  

	 	(ii)	it or they would no longer be able to sell and transfer all or substantially all of the Cell-based Influenza Business as at the date of this Deed to the Purchaser at Option Closing, Clauses 2.1.2 and 2.1.4 shall no
longer apply with the effect that Novartis (and the members of the Novartis Group) may no longer exercise the Put Option with respect to the Option 2 Assets, or a combination of the Option 2 Assets and some or all of the Option 4 Assets; and / or

  

	 	(iii)	it or they would no longer be able to sell and transfer all or substantially all of the Egg-based Influenza Business as at the date of this Deed to the Purchaser at Option Closing, Clauses 2.1.3 and 2.1.5 shall no
longer apply with the effect that Novartis (and the members of the Novartis Group) may no longer exercise the Put Option with respect to the Option 3 Assets, or a combination of the Option 3 Assets and some or all of the Option 4 Assets.

  

	5.4	Novartis’s obligations in relation to insurance 

 Without prejudice to the
generality of Paragraph 5.2.1, between the date of this Deed and Option Closing, Novartis shall or shall procure that the relevant members of the Novartis Group shall maintain in force all Influenza Group Insurance Policies and all Novartis Group
Insurance Policies for the benefit of the Influenza Group Businesses and Influenza Group Companies. 
  

	5.5	Novartis’s obligations in relation to cash, Intra-Group Non-Trade Payables and Receivables and Third Party Indebtedness 

From the Option Exercise Date and prior to Option Closing, Novartis shall seek to minimise the amounts which would, but for this Paragraph 5.5,
otherwise fall to be treated as: 
  

	 	(i)	Intra-Group Non-Trade Payables; 

  

	 	(ii)	Intra-Group Non-Trade Receivables; 

  

	 	(iii)	Influenza Group Companies Cash Balances; and 

  

	 	(iv)	Third Party Indebtedness. 

  
  

51 

 Execution Version 
  

in each case to the extent reasonably possible, taking into account the consequences of any such reduction for the Novartis Group. 

 

	5.6	Novartis’s Obligations in Relation to Books and Records 

 Without prejudice to the
generality of Paragraph 5.2.1, from the Option Exercise Date and prior to Option Closing, Novartis shall, and shall procure that its Affiliates shall, allow the Purchaser and its respective agents, upon reasonable notice, reasonable access to, and
to take copies of, the books, records and documents of or relating in whole or in part to the Influenza Group, provided that the obligations of Novartis under this Paragraph shall not extend to allowing access to information which is:
(i) reasonably regarded as confidential to the activities of Novartis and the Novartis Group otherwise than in relation to the Influenza Group; or (ii) commercially sensitive or other information relating to the Option Assets if such
information cannot be shared with the Purchaser prior to Option Closing in compliance with Applicable Law (though Novartis shall seek to share such information with the Purchaser to the extent and in such a manner as would comply with Applicable
Law). 
  

	5.7	Affiliate Contracts 

  

	 	5.7.1	Other than as provided in the Ancillary Agreements and subject to Paragraph 8.6, Novartis and the Purchaser shall procure that: 

 

	 	(i)	the Cash Pooling Arrangements; and 

  

	 	(ii)	each Affiliate Contract in force immediately prior to Option Closing, other than any Surviving Affiliate Contract, 

  

	 	  	shall terminate prior to Option Closing and each counterparty thereto shall, effective as of Option Closing, settle all outstanding financial obligations arising out of such Affiliate Contracts and unconditionally
release and irrevocably discharge each other party thereto from (i) any and all further obligations to perform or any further performance of the various covenants, undertakings, warranties and other obligations contained in such Affiliate
Contract and (ii) any and all claims and Liabilities whatsoever arising out of, in any way connected with, as a result of or in respect of such Affiliate Contract. 

 

	 	5.7.2	As soon as practicable following the Option Exercise Date, and in any event within one month of the Option Exercise Date, Novartis shall provide a copy of each Affiliate Contract that is material to the Influenza
Group and is in writing to the Purchaser. Within two months of the Option Exercise Date, the Purchaser shall notify Novartis of the services provided under the Affiliate Contracts from the Novartis Group which the Purchaser reasonably requires in
order to operate the business of the Influenza Group as it is carried on at the Option Exercise Date to continue to receive on the same terms as contained in the relevant Affiliate Contract for a maximum period of 6 months following Option Closing
provided that such services are not addressed by the Ancillary Agreements. 

  

	5.8	Tax Groups 

  

	 	5.8.1	Novartis shall take all reasonable steps to procure that any Tax Consolidation existing between any member of the Novartis Group and any Influenza Group Company be terminated on or before Option Closing, so far as
permitted by the applicable law, or otherwise on the earliest date on which such termination is permitted under applicable law, and Novartis and the Purchaser shall take such action as is necessary to procure or effect this, including timely
submitting any necessary Tax documents. 

  
  

52 

 Execution Version 
  

 

	 	5.8.2	Pending the taking effect of the action referred to in Paragraph 5.8.1, and for so long thereafter as may be necessary, the Purchaser shall (subject to the provisions of the Tax Indemnity) procure that such
information is provided to Novartis as may reasonably be required to enable any relevant member of the Novartis Group to make all Tax Returns and other filings required of it in respect of the Tax Consolidation. 

 

	 	5.8.3	Novartis and the Purchaser shall cooperate in good faith to take, and procure that each member of the Novartis Group and the Purchaser’s Group takes, all reasonable procedural or administrative steps
(including the making of elections and filings with relevant Tax Authorities) which are reasonably necessary to procure the minimisation of the extent to which Tax liabilities of members of the Novartis Group (other than Influenza Group Companies)
can be assessed on members of the Purchaser’s Group or on Influenza Group Companies. 

  

	 	5.8.4	Novartis shall take all reasonable steps to ensure that Chiron Technologies Limited and Chiron Pharmaceuticals Limited are finally liquidated, and cease to exist, before the Option Closing Date.

  

	6	Option Closing 

  

	6.1	Date and Place 

 Option Closing shall take place at 11.59 p.m. (Central European Time) in
at the offices of Freshfields Bruckhaus Deringer, 65 Fleet Street, London EC4Y 1HS (other than in respect of any Local Transfer Documents agreed between the parties to be executed in another jurisdiction) on the last Business Day of the month in
which fulfilment or waiver of the last of the condition(s) set out in Paragraph 4.1 to be fulfilled or waived takes place, except that: 
  

	 	6.1.1	where the last day of such month is not a Business Day, the Option Closing shall instead take place on the first Business Day of the following month; and 

 

	 	6.1.2	where less than five Business Days remain between such fulfilment or waiver and the last Business Day of the month, Option Closing shall take place: 

 

	 	(i)	on the last Business Day of the following month; 

  

	 	(ii)	where the last day of such month is not a Business Day, the Option Closing shall instead take place on the first Business Day of the month following the month referred to in Paragraph 6.1.2(i); or 

 

	 	(iii)	at such other location, time or date as may be agreed between the Purchaser and Novartis in writing, 

provided that in determining the date on which the last of the conditions set out in Paragraph 4.1 is fulfilled or waived, the date shall be
the date on which the last of the conditions set out in Paragraphs 4.1.1, 4.1.2, 4.1.3, 4.1.4, 4.1.5 and 4.1.8 is fulfilled or waived unless any of the conditions set out in Paragraphs 4.1.6 and 4.1.7 is not fulfilled or waived on that date, in
which case the date shall then be the first following date on which all of the conditions set out in Paragraphs 4.1.6 and 4.1.7 are fulfilled or waived. 

  
  

53 

 Execution Version 
  

	6.2	Option Closing Events 

  

	 	6.2.1	On Option Closing, the parties shall comply with their respective obligations specified in Appendix 15. Novartis may waive some or all of the obligations of the Purchaser as set out in Appendix 15 and the
Purchaser may waive some or all of the obligations of Novartis as set out in Appendix 15. 

  

	 	6.2.2	The parties acknowledge that the transfer of Product Approvals and Product Applications to the Purchaser or other members of the Purchaser’s Group may be subject to the approval of applicable Governmental
Entities, and that, notwithstanding anything in this Deed to the contrary, each Product Approval and Product Application shall continue to be held by the relevant member of the Novartis Group from the Option Closing Date until the relevant PA
Transfer Date. 

  

	 	6.2.3	The parties shall perform their respective obligations with respect to: 

  

	 	(i)	the transfer of the Product Approvals, Product Applications and Pipeline Product Approvals as set out in Appendix 8; 

  

	 	(ii)	the transfer of Contracts (other than Product Approvals, Product Applications and Pipeline Product Approvals) and the Transferred Intellectual Property Contracts as set out in Appendix 9 and the treatment of Shared
Business Contracts; and 

  

	 	(iii)	to the extent the Purchaser has elected to have the Relevant Part of a Shared Business Contract transferred to it, the separation of each Shared Business Contract as set out in Appendix 9. 

 

	6.3	Payment on Option Closing 

  

	 	6.3.1	On Option Closing the Purchaser shall pay (for itself and on behalf of each relevant member of the Purchaser’s Group in accordance with Paragraph 15.6) an amount in cleared funds, to Novartis to the Purchase
Price Bank Account, which is equal to the sum of: 

  

	 	(i)	the Headline Price; 

  

	 	  	plus 

  

	 	(ii)	the Estimated Influenza Group Companies’ Cash Balances and the Estimated Intra-Group Non-Trade Receivables; 

  

	 	  	minus 

  

	 	(iii)	the Estimated Third Party Indebtedness; 

  

	 	  	minus 

  

	 	(iv)	the Estimated Intra-Group Non-Trade Payables; 

  

	 	 	minus 

  

	 	(v)	any Estimated Employee Benefit Adjustment; 

  

	 	 	minus 

  

	 	(vi)	the Estimated Tax Adjustment. 

  
  

54 

 Execution Version 
  

 

	6.4	Notifications to determine payments on Option Closing 

  

	 	6.4.1	Five Business Days prior to Option Closing, Novartis shall notify the Purchaser of 

  

	 	(i)	the Estimated Influenza Group Companies’ Cash Balances; 

  

	 	(ii)	the Estimated Third Party Indebtedness; 

  

	 	(iii)	the Estimated Intra-Group Non-Trade Receivables; 

  

	 	(iv)	the Estimated Intra-Group Non-Trade Payables; 

  

	 	(v)	any Estimated Employee Benefit Adjustment; and 

  

	 	(vi)	the Estimated Tax Adjustment, 

 and shall at the same time provide to the Purchaser reasonable
supporting calculations and information to enable the Purchaser to review the basis on which the estimates have been prepared. 
  

	 	6.4.2	Novartis’s notification pursuant to Paragraph 6.4.1 shall specify the relevant debtor and creditor for each Estimated Intra-Group Payable and Estimated Intra-Group Receivable. 

 

	 	6.4.3	Immediately following Option Closing: 

  

	 	(i)	the Purchaser shall procure that each Influenza Group Company repays to the relevant member of the Novartis Group the amount of any Estimated Intra-Group Non-Trade Payables and shall acknowledge on behalf of each Group
Company the payment of the Estimated Intra-Group Non-Trade Receivables in accordance with Paragraph 6.4.3(ii); and 

  

	 	(ii)	Novartis shall procure that each relevant member of the Novartis Group repays to the relevant Influenza Group Company the amount of any Estimated Intra-Group Non-Trade Receivables and shall acknowledge on behalf of each
relevant member of the Novartis Group the payment of the Estimated Intra-Group Non-Trade Payables in accordance with Paragraph 6.4.3(i). 

  

	 	6.4.4	The repayments made pursuant to Paragraph 6.4.3 shall be adjusted in accordance with Paragraphs 7.3 and 7.4 when the Option Closing Statement becomes final and binding in accordance with Paragraph 7.2.1.

  

	6.5	Breach of Option Closing Obligations 

  

	 	6.5.1	If any party fails to comply with any material obligation in Paragraphs 6.2 or 6.3 or Appendix 15 in relation to Option Closing, the Purchaser, in the case of non-compliance by Novartis, or Novartis, in the case
of non-compliance by the Purchaser, shall be entitled (in addition to and without prejudice to all other rights or remedies available) by written notice to Novartis or the Purchaser to fix a new date for Option Closing which, except as agreed by the
parties, shall be the last day of the month next ending or, if that day is not a Business Day, the first Business Day falling after that day, in which case the provisions of Appendix 15 shall apply to Option Closing as so deferred, but provided such
deferral may only occur once. 

  
  

55 

 Execution Version 
  

 

	 	6.5.2	Option Closing shall occur only once and shall only be effective if it is in respect of all of the Business to be transferred to the Purchaser under this Deed. 

 

	7	Post-Option Closing Adjustments 

  

	7.1	Option Closing Statements 

  

	 	7.1.1	Novartis shall procure that as soon as practicable following Option Closing there shall be drawn up a draft of the Option Closing Statement (the “Draft Option Closing Statement”) in accordance
with Appendix 16 in relation to the Influenza Group Companies and Influenza Group Businesses, on a combined basis. 

  

	 	7.1.2	The Option Closing Statement shall be drawn up as at the Effective Time. 

  

	7.2	Determination of Option Closing Statement 

  

	 	7.2.1	The Draft Option Closing Statement as agreed or determined pursuant to paragraph 1 of Part 1 of Appendix 16: 

  

	 	(i)	shall constitute the Option Closing Statement for the purposes of this Deed; and 

  

	 	(ii)	shall be final and binding on the parties. 

  

	 	7.2.2	The Influenza Group Companies’ Cash Balances, the Third Party Indebtedness, the Intra-Group Non-Trade Receivables, the Intra-Group Non-Trade Payables and the Tax Adjustment shall be derived from the Option
Closing Statement. 

  

	7.3	Adjustments to Purchase Price 

  

	 	7.3.1	Influenza Group Companies’ Cash Balances: 

  

	 	(i)	if the Influenza Group Companies’ Cash Balances are less than the Estimated Influenza Group Companies’ Cash Balances, Novartis shall repay to the Purchaser an amount equal to the deficiency; or

  

	 	(ii)	if the Influenza Group Companies’ Cash Balances are greater than the Estimated Influenza Group Companies’ Cash Balances, the Purchaser shall pay to Novartis an additional amount equal to the excess.

  

	 	7.3.2	Intra-Group Non-Trade Receivables: 

  

	 	(i)	if the Intra-Group Non-Trade Receivables are less than the Estimated Intra-Group Non-Trade Receivables, Novartis shall repay to the Purchaser an amount equal to the deficiency; or 

 

	 	(ii)	if the Intra-Group Non-Trade Receivables are greater than the Estimated Intra-Group Non-Trade Receivables, the Purchaser shall pay to Novartis an additional amount equal to the excess. 

 

	 	7.3.3	Third Party Indebtedness 

  

	 	(i)	if the Third Party Indebtedness is greater in magnitude than the Estimated Third Party Indebtedness, Novartis shall repay to the Purchaser an amount equal to the excess; or 

  
  

56 

 Execution Version 
  

 

	 	(ii)	if the Third Party Indebtedness is less in magnitude than the Estimated Third Party Indebtedness, the Purchaser shall pay to Novartis an additional amount equal to the deficiency. 

 

	 	7.3.4	Intra-Group Non-Trade Payables: 

  

	 	(i)	if the Intra-Group Non-Trade Payables are greater in magnitude than the Estimated Intra-Group Non-Trade Payables, Novartis shall repay to the Purchaser an amount equal to the excess; or 

 

	 	(ii)	if the Intra-Group Non-Trade Payables are less in magnitude than the Estimated Intra-Group Non-Trade Payables, the Purchaser shall pay to Novartis an additional amount equal to the deficiency. 

 

	 	7.3.5	Tax Adjustment 

  

	 	(i)	if the Tax Adjustment is greater than the Estimated Tax Adjustment, Novartis shall repay to the Purchaser an amount equal to the difference; or 

 

	 	(ii)	if the Tax Adjustment is less than the Estimated Tax Adjustment, the Purchaser shall pay to Novartis an additional amount equal to the difference. 

 

	7.4	Adjustments to repayment of Intra-Group Non-Trade Payables and Intra-Group Non-Trade Receivables 

Following the determination of the Option Closing Statement pursuant to Paragraph 7.2 and paragraph 1 of Part 1 of Appendix 16, if the amount
of any Intra-Group Non-Trade Payable and/or any Intra-Group Non-Trade Receivable contained in the Option Closing Statement is greater or less than the amount of the corresponding Estimated Intra-Group Non-Trade Payable or Estimated Intra-Group
Non-Trade Receivable, then Novartis and the Purchaser shall procure that such adjustments to the repayments pursuant to Paragraph 6.4.3 are made as are necessary to ensure that (taking into account such adjustments) the actual amount of each
Intra-Group Non-Trade Payable and each Intra-Group Non-Trade Receivable has been repaid by each Group Company to the relevant member of the Novartis Group or by the relevant member of the Novartis Group to the relevant Group Company, as the case may
be. 
  

	7.5	Interest 

 Any payment to be made in accordance with Paragraph 7.3 shall include interest
thereon calculated from the Option Closing Date to the date of payment at a rate per annum of LIBOR. 
  

	7.6	Payment 

  

	 	7.6.1	Any payments pursuant to Paragraph 7.3 or 7.4, and any interest payable pursuant to Paragraph 7.5, shall be made on or before the Final Payment Date. 

 

	 	7.6.2	Where any payment is required to be made pursuant to Paragraph 7.3 or Paragraph 7.5 (in relation to a payment pursuant to Paragraph 7.3) the payment made on account of the Purchase Price shall be reduced or
increased accordingly. 

  

	 	7.6.3	Where any payment is required to be made pursuant to Appendix 12, the payment made shall be deemed to be a reduction to the Purchase Price. 

  
  

57 

 Execution Version 
  

 

	8	Post-Option Closing Obligations 

  

	8.1	Indemnities 

  

	 	8.1.1	Indemnity by the Purchaser against Assumed Liabilities 

 The Purchaser hereby undertakes
to Novartis (for itself and on behalf of each other member of the Novartis Group and their respective directors, officers, employees and agents) that, with effect from Option Closing, the Purchaser will indemnify on demand and hold harmless each
member of the Novartis Group and their respective directors, officers, employees and agents against and in respect of any and all Assumed Liabilities. 
  

	 	8.1.2	Indemnities by Novartis 

 Subject to Paragraph 8.1.3, Novartis hereby undertakes to the
Purchaser (for itself and on behalf of each other member of the Purchaser’s Group and their respective directors, officers, employees and agents) that, with effect from Option Closing, Novartis will indemnify on demand and hold harmless each
member of the Purchaser’s Group and their respective directors, officers, employees and agents against and in respect of any and all: 
  

	 	(i)	Excluded Liabilities; and 

  

	 	(ii)	Liabilities, including legal fees, to the extent they have arisen or arise (whether before or after Option Closing) as a result of or otherwise relate to any act, omission, fault, matter, circumstance or event
undertaken, occurring or in existence or arising before Option Closing so far as related to: (A) any breach of any anti-bribery warranty, including without limitation those set forth in paragraphs 9.1 through 9.6 of Appendix 18, not being true
and correct when made; (B) any government inquiries or investigations involving Novartis, its Affiliates or its associated persons; (C) save to the extent in existence as at the date of this Deed any limitation, restriction or other
reduction in drug registrations, licenses, listings or marketing approvals, government pricing or reimbursement rates relating to the Products including specifically the value of lost future profits as a result of any such limitation, restriction or
reduction; or (D) any other claim, litigation, investigation or proceeding to the extent related to any of the foregoing (A) to (C), including but not limited to costs of investigation and defense and legal fees. 

 

	 	8.1.3	Limitations on Indemnities 

 Subject to Paragraph 8.1.4, Novartis shall not be liable
under Paragraph 8.1.2 in respect of: 
  

	 	(i)	any Time-Limited Excluded Liability unless a notice of a claim in respect of the matter giving rise to such liability is given by the Purchaser to Novartis within ten years of Option Closing, provided that this
sub-Paragraph (i) shall not apply in respect of any claim by the Purchaser which relates to: 

  

	 	(a)	a Product Liability; 

  

	 	(b)	a Governmental Liability; 

  

	 	(c)	a Clinical Trials/Data Liability; 

  
  

58 

 Execution Version 
  

 

	 	(d)	an IP Liability; or 

  

	 	(e)	an Excluded Asset; 

  

	 	(ii)	any claim if and to the extent that the relevant Liability is included in the Option Closing Statement; or 

  

	 	(iii)	any individual claim (or a series of claims arising from similar or identical facts or circumstances) where the liability (disregarding the provisions of this Paragraph 8.1.3(iii)) in respect of any such claim or series
of claims does not exceed US$10 million, provided that, for the avoidance of doubt, where the Liability in respect of any such claim or series of claims exceeds US$10 million, the Liability of Novartis shall be for the whole amount of such claim(s)
and not just the excess. 

  

	 	8.1.4	Disapplication of limitations 

 None of the limitations contained in Paragraph 8.1.3
shall apply to any claim to the extent that such claim which arises or is increased, or to the extent to which it arises or is increased, as the consequence of, or which is delayed as a result of, fraud by any member of the Novartis Group or any
director, officer or employee of any member of the Novartis Group. 
  

	8.2	Conduct of Claims 

  

	 	8.2.1	Assumed Liabilities 

  

	 	(i)	If Novartis becomes aware after Option Closing of any claim by a third party which constitutes or may constitute an Assumed Liability, Novartis shall as soon as reasonably practicable: 

 

	 	(a)	give written notice thereof to the Purchaser, setting out such information as is available to Novartis as is reasonably necessary to enable the Purchaser to assess the merits of the potential claim; 

 

	 	(b)	take all appropriate actions to preserve evidence; and 

  

	 	(c)	provide the Purchaser with periodic updates on the status of the claim upon request and shall not admit, compromise, settle, discharge or otherwise deal with such claim without the prior written agreement of the
Purchaser (such agreement not to be unreasonably withheld or delayed). 

  

	 	(ii)	Novartis shall, and shall procure that each Share Seller and Business Seller shall, take such action as the Purchaser may reasonably request to avoid, dispute, resist, appeal, compromise, defend or mitigate any claim
which constitutes or may constitute an Assumed Liability subject to Novartis and each Share Seller and Business Seller being indemnified and secured to their reasonable satisfaction by the Purchaser against all Liabilities which may thereby be
incurred. In connection therewith, Novartis shall make or procure to be made available to the Purchaser or their duly authorised agents on reasonable notice during normal business hours all relevant books of account, records and correspondence
relating to the Influenza Group Businesses which have been retained by the Novartis Group (and shall permit the Purchaser to take copies thereof at its expense) for the purposes of enabling the Purchaser to ascertain or extract any information
relevant to the claim. 

  
  

59 

 Execution Version 
  

 

	 	8.2.2	Excluded Liabilities 

  

	 	(i)	If the Purchaser becomes aware after Option Closing of any claim by a third party which constitutes or may constitute an Excluded Liability or relates to an Excluded Liability or any investigations related thereto,
regardless of whether the Purchaser believes that such claim would be made against a member of the Purchaser’s Group or a member of the Novartis Group, the Purchaser shall as soon as reasonably practicable: 

 

	 	(a)	give written notice thereof to Novartis, setting out such information as is available to the Purchaser as is reasonably necessary to enable Novartis to assess the merits of the potential claim; 

 

	 	(b)	take all appropriate actions to preserve evidence; and 

  

	 	(c)	provide Novartis with periodic updates on the status upon request and shall not admit, compromise, settle, discharge or otherwise deal with such claim without the prior written agreement of Novartis (such agreement not
to be unreasonably withheld or delayed). 

  

	 	(ii)	The Purchaser shall take such action as Novartis may reasonably request to avoid, dispute, resist, appeal, compromise, defend or mitigate any claim which constitutes or may constitute an Excluded Liability subject to
the Purchaser being indemnified and secured to its reasonable satisfaction by Novartis against all Liabilities which may thereby be incurred. 

  

	 	(iii)	In addition, where any such claim or investigation involves a Governmental Entity, the Purchaser shall, subject to Applicable Law, the requirements of the Relevant Governmental Entity and Novartis providing any
appropriate confidentiality undertaking in favour of the Purchaser’s Group, provide to Novartis, at least five Business Days in advance (or, where not possible, as soon as reasonably possible), any analyses, appearances, presentations,
memoranda, briefs, arguments, opinions and proposals they or their agents make or submit to a Governmental Entity. Without limiting the foregoing, the parties agree, subject to the Applicable Law and the requirements of the relevant Governmental
Entity and Novartis providing an appropriate confidentiality undertaking in favour of the Purchaser’s Group, to: 

  

	 	(a)	give Novartis reasonable advance notice of all meetings with any Governmental Entity; 

  

	 	(b)	give Novartis an opportunity to participate in each of such meetings; 

  

	 	(c)	to the extent practicable, give Novartis reasonable advance notice of all substantive oral communications with any Governmental Entity; 

 

	 	(d)	if any Governmental Entity initiates a substantive oral communication, promptly notify Novartis of the substance of such communication; 

 

	 	(e)	provide Novartis with a reasonable advance opportunity to review and comment upon all substantive written communications (including any substantive correspondence, analyses, presentations, memoranda, briefs, arguments,
opinions and proposals) that the Purchaser or its agents intend to make or submit to a Governmental Entity in connection with such claim; 

  
  

60 

 Execution Version 
  

 

	 	(f)	provide Novartis with copies of all substantive written communications to or from any Governmental Entity; and 

  

	 	(g)	not advance arguments with the Governmental Entity without prior agreement of Novartis that would reasonably be likely to have a significant adverse impact on Novartis, 

provided however, that the Purchaser shall not be required to comply with paragraph (b) above to the extent that the Governmental Entity
objects to the participation of a party, or with paragraph (e) or (f) above to the extent that such disclosure may raise regulatory concerns (in which case, the disclosure may be made on an outside counsel basis). 

 

	 	(iv)	Other than in respect of any claim to the extent it relates to an IP Liability, a Commercial Practices Liability or a Governmental Liability (other than in respect of any Liability arising solely by virtue of a breach
of any Contract with any Governmental Entity which breach does not also constitute a breach of Applicable Law), Novartis shall be entitled at its own expense and in its absolute discretion, by notice in writing to the Purchaser, to take such action
as it shall deem necessary to avoid, dispute, deny, defend, resist, appeal, compromise or contest any such claim (including making counterclaims or other claims against third parties) in the name of and on behalf of the Purchaser or other member of
the Purchaser’s Group concerned and to have the conduct of any related proceedings, negotiations or appeals. In taking action on behalf of any member of the Purchaser’s Group as permitted by this Paragraph 8.2, Novartis shall, in good
faith, take into account and have due regard to any reputational matters or issues arising out of the claim for any member of the Purchaser’s Group or any of their respective directors, officers, employees or agents which are brought to its
attention by the Purchaser or a member of the Purchaser’s Group. 

  

	 	(v)	Without limitation to Novartis’s rights pursuant to Paragraph 8.10, the Purchaser shall make or procure to be made available to the Novartis or its duly authorised agents on reasonable notice during normal business
hours full and free access to all relevant books of account, records and correspondence relating to the Influenza Group which are in the possession of the Purchaser or any member of the Purchaser’s Group (and shall permit Novartis to take
copies thereof) for the purposes of enabling Novartis to ascertain or extract any information relevant to the claim. 

  

	 	(vi)	The Purchaser shall, and shall procure that each other member of the Purchaser’s Group shall, on reasonable notice from Novartis, give such assistance to Novartis as it may reasonably require in relation to the
claim including providing Novartis or any member of the Novartis Group and its representative and advisers with access to and assistance from directors, officers, managers, employees, advisers, agents or consultants of the Purchaser and/or of each
other member of the Purchaser’s Group (collectively, the “Relevant Persons”) and the Purchaser will use its reasonable endeavours to procure that such Relevant Persons comply with any reasonable requests from Novartis and
generally co-operates with and assists Novartis and other members of Novartis Group. 

  
  

61 

 Execution Version 
  

 

	 	(vii)	When seeking assistance under Paragraph 8.2.2(v) and (vi), Novartis, or any other relevant member of the Novartis Group, shall use reasonable endeavours to minimise interference with the Purchaser and the
Purchaser’s Group’s conduct of the relevant business or the performance by the Relevant Persons of their employment duties. 

  

	8.3	Release of Guarantees 

  

	 	8.3.1	The Purchaser shall use reasonable endeavours to procure as soon as reasonably practicable after Option Closing, the release of Novartis or any member of the Novartis Group from any securities, guarantees or
indemnities given by or binding upon Novartis or any member of the Novartis Group in respect of the Assumed Liabilities or in connection with a liability of any of the Influenza Group Companies (other than an Excluded Liability). Pending such
release, the Purchaser shall indemnify Novartis and any member of the Novartis Group against all amounts paid by any of them (acting reasonably) pursuant to any such securities, guarantees or indemnities in respect of such Assumed Liabilities or
such liability of the Influenza Group Companies (other than an Excluded Liability). 

  

	 	8.3.2	Novartis shall use reasonable endeavours to procure by Option Closing or, to the extent not done by Option Closing, as soon as reasonably practicable after Option Closing, the release of the Influenza Group
Companies from any securities, guarantees or indemnities given by or binding upon the Influenza Group Companies in respect of any liability of Novartis or any member of the Novartis Group. Pending such release, Novartis shall indemnify the Influenza
Group Companies against all amounts paid by any of them (acting reasonably) pursuant to any such securities, guarantees or indemnities in respect of such liability of Novartis which arises after Option Closing. 

 

	8.4	Transferred Accounts Payable 

 If at any time after Option Closing, Novartis or any of
its Affiliates pays any monies in respect of any Transferred Accounts Payable, then the Purchaser shall pay or procure payment to Novartis (for the relevant Business Seller), as soon as reasonably practicable the amount paid, plus any Taxation
suffered or incurred by the Novartis Group which would not have arisen but for the payment and receipt of such monies. 
  

	8.5	Transferred Accounts Receivable 

 If at any time after Option Closing, a Business Seller
receives any monies in respect of any Transferred Accounts Receivable, then the Business Seller shall pay or procure payment to the Purchaser, as soon as reasonably practicable the amount recovered, less any Taxation suffered or incurred by the
Novartis Group which would not have arisen but for the receipt and payment of such monies. 

  
  

62 

 Execution Version 
  

	8.6	Intra-Group Trading Balances 

 Any Intra-Group Trading Balances shall be settled after
Option Closing in the ordinary course of business and in any event within 60 days of Option Closing. 
  

	8.7	Transfer of Marketing Authorisations 

  

	 	8.7.1	The transfer of the Marketing Authorisations following Option Closing shall take place in accordance with Part 2 of Appendix 8 and the terms of the Manufacturing, Supply and Distribution Agreement.

  

	 	8.7.2	Between the Option Closing Date and the Marketing Authorisation Transfer Date, Novartis agrees to assist the Purchaser in accordance with Part 4 of Appendix 8 in respect of any tenders relating to the Products.

  

	8.8	Wrong Pockets Obligations 

  

	 	8.8.1	Except as provided in Appendices 3, 8, 9, 10 and 11, if any property, right or asset forming part of the Influenza Group (other than any property, right or asset expressly excluded from the sale under this Deed)
has not been transferred to the Purchaser or to another member of the Purchaser’s Group and should have transferred pursuant to the terms of this Deed, Novartis shall procure that such property, right or asset (and any related liability which
is an Assumed Liability) is transferred to the Purchaser, or to such other member of the Purchaser’s Group as the Purchaser may nominate which is reasonably acceptable to Novartis, as soon as practicable and at no cost to the Purchaser.

  

	 	8.8.2	If, following Option Closing, any property, right or asset not forming part of the Influenza Group (other than any property, right or asset expressly included in the sale under this Deed) is found to have been
transferred to the Purchaser or to another member of the Purchaser’s Group and should not have transferred pursuant to the terms of this Deed, the Purchaser shall procure that such property, right or asset is transferred to the transferor or
another member of the Novartis Group nominated by Novartis which is reasonably acceptable to the Purchaser as soon as practicable and at no cost to Novartis. 

  

	8.9	Covenant not to sue 

  

	 	8.9.1	Novartis hereby undertakes not to enforce, at any time after Option Closing, any Out of Scope Patent against the Purchaser’s Group in relation to the Purchaser’s Group carrying on the Business as at the
date of Option Closing. 

  

	 	8.9.2	The Purchaser hereby undertakes not to enforce, at any time after Option Closing, any Influenza Patent against the Novartis Group in relation to the Novartis Group carrying on the Novartis Group Retained Business
as at the date of Option Closing. 

  

	8.10	The Purchaser’s Continuing Obligations 

  

	 	8.10.1	The Purchaser shall procure that as soon as practicable after Option Closing, each of the Influenza Group Companies shall change its name so that it does not contain any of the Novartis Restricted Marks or any
name which is likely to be confused with the same and shall provide Novartis with appropriate evidence of such change of name. 

  
  

63 

 Execution Version 
  

 

	 	8.10.2	Except as provided in the Ancillary Agreements, the Purchaser shall not, and shall procure that no member of the Purchaser’s Group shall, after Option Closing, use any of the Novartis Restricted Marks or any
confusingly similar name or mark, any extensions thereof or developments thereto in any business which competes with Novartis’s business, or any other business of Novartis or any member of the Novartis Group in which the Novartis Restricted
Marks are used for a minimum period of five (5) years following Option Closing and thereafter for so long as any member of the Novartis Group continues to retain an interest in the relevant Novartis Restricted Marks. 

 

	 	8.10.3	The Purchaser shall, and shall procure that the relevant Influenza Group Companies shall, retain for a period of 10 years from Option Closing (and, upon notice from Novartis between 9 and 10 years from Option
Closing, for a further period of 5 years), and not dispose of or destroy the books, records and documents of the Influenza Group to the extent they relate to the period prior to Option Closing and shall, and shall procure that the relevant Influenza
Group Companies shall, if reasonably requested by Novartis, allow Novartis reasonable access to such books, records and documents (including the right to take copies at Novartis’s expense) and to the employees of the Influenza Group or former
employees of the Influenza Group who are employees of any member of the Purchaser’s Group. 

  

	 	8.10.4	During the 90 days following the Option Closing Date, the Purchaser shall provide and cause to be provided to Novartis the information reasonably required to enable Novartis to prepare and audit the standard
monthly reporting forms of the Novartis Group, to the extent that such financial reporting relates to the Influenza Group, in respect of the period prior to the Option Closing and in respect of the calendar month in which the Option Closing occurs.
The Purchaser shall provide such financial reporting in respect of the calendar month in which Option Closing occurs to Novartis within six Business Days of the last day of the relevant month. 

 

	8.11	Novartis’s Continuing Obligations 

 For a period of 10 years from Option Closing
(and, upon notice from the Purchaser between 9 and 10 years from Option Closing, for a further period of 5 years), Novartis shall make or procure to be made available to the Purchaser or their duly authorised agents on reasonable notice during
normal business hours: 
  

	 	8.11.1	all relevant books, accounts, other records and correspondence relating to the Influenza Group which have been retained by the Novartis Group (and shall permit the Purchaser to take copies thereof); and

  

	 	8.11.2	reasonable access to employees of the Novartis Group who have knowledge relating to any of the Products (including any inventor of the Products) for the purposes of the defence, prosecution or enforcement of any
Influenza Group Intellectual Property Rights, or as required by law or a Governmental Entity, provided that the Purchaser shall promptly reimburse Novartis for expenses reasonably incurred by Novartis in relation to providing such access if it
exceeds 25 man hours in aggregate per annum. 

  

	8.12	Manufacturing, Supply and Distribution Agreement 

 If the Manufacturing, Supply and
Distribution Agreement has not been entered into at Option Closing, the provisions of the heads of terms in the Agreed Terms for the “Manufacturing, Supply and Distribution Agreement” as defined in the Vogel SAPA (with any necessary
amendments) shall be binding on the Seller and Purchaser until the earlier of: (i) the date on which the Manufacturing, Supply and Distribution Agreement (as defined in this Deed) is entered into; or (ii) the date on which the Seller no
longer manufactures and supplies Products to the Seller for distribution. 

  
  

64 

 Execution Version 
  

 

	8.13	Transitional Services Agreement 

 If the Transitional Services Agreement has not been
entered into at Option Closing, the provisions of the heads of terms in the Agreed Terms for the “Transitional Services Agreement” as defined in the Vogel SAPA (with any necessary amendments) shall be binding on the Seller and Purchaser
until the earlier of: (i) the date on which the Transitional Services Agreement (as defined in this Deed) is entered into; or (ii) the date on which Novartis no longer provides such transitional services to the Purchaser. 

 

	8.14	Novartis’s Licence under the Out-Licensing Programme 

 Novartis grants (and shall
procure the grant) to the Purchaser of a non-exclusive, irrevocable, royalty-free, non-assignable, sub-licensable licence of the Out-Licensing Programme Intellectual Property Rights solely for use in relation to the Business which shall be
sub-licensable by the Purchaser solely (i) to members of the Purchaser’s Group and (ii) to third parties working with it on the development of the Products. 
  

	8.15	Holly Springs Facility 

 Novartis and the Purchaser shall perform their respective
obligations with respect to the transfer of the facility at the Holly Springs Site as set out in Part 2 of Appendix 17. 
  

	9	Warranties 

  

	9.1	Novartis’s Warranties 

  

	 	9.1.1	Subject to Paragraph 9.2, Novartis warrants (on behalf of the relevant Business Sellers or Share Seller as applicable) to the Purchaser and each member of the Purchaser’s Group to which Shares or other
assets are transferred pursuant to this Deed or any Local Transfer Document, that the statements set out in Appendix 18 are true and accurate as at the date of this Deed. 

 

	 	9.1.2	Subject to Paragraph 9.2, Novartis warrants that that the statements set out in Appendix 18 will be true and accurate as at the Option Exercise Date as if repeated immediately before the Option Exercise Date by
reference to the facts and circumstances subsisting at that date on the basis that any reference in Novartis’s Warranties, whether express or implied, to the date of this Deed (other than any reference to the Disclosure Letter) is substituted
by a reference to the Option Exercise Date. 

  

	 	9.1.3	Novartis may, solely in respect of Novartis’s Warranties given pursuant to Paragraph 9.1.2, make specific disclosures against such Novartis’s Warranties by providing a further letter addressed from it
to the Purchaser (an “Option Exercise Date Disclosure Letter”), provided that any such Option Exercise Date Disclosure Letter: 

  

	 	(i)	shall be delivered to the Purchaser’s Lawyers in substantially final form no less than two Business Days before the intended Option Exercise Date; 

  
  

65 

 Execution Version 
  

 

	 	(ii)	(x) may only contain specific disclosures against Novartis’s Warranties in relation to facts, matters or circumstances occurring or arising after the date of this Deed; and (y) shall not contain any
disclosures against Novartis’s Warranties set out in paragraphs 1, 2.2, 8.2 to 8.4 and 18 of Appendix 18; and 

  

	 	(iii)	shall, save for the restrictions on its contents as set out in this Paragraph 9.1.3, be in substantially the same form and written on substantially the same basis as the Disclosure Letter. 

 

	 	9.1.4	Each of Novartis’s Warranties shall be separate and independent and shall not be limited by reference to any other paragraph of Appendix 18 or by anything in this Deed or any Local Transfer Document or in
the Tax Indemnity. 

  

	 	9.1.5	Novartis does not give or make any warranty as to the accuracy of the forecasts, estimates, projections, statements of intent or statements of opinion provided to the Purchaser or any of its directors, officers,
employees, agents or advisers on or prior to the date of this Deed. 

  

	 	9.1.6	Any Novartis Warranty qualified by the expression “so far as Novartis is aware” or to “Novartis’s Knowledge” or any similar expression shall, unless otherwise stated, be deemed to refer
to the knowledge of the following persons: [***], such persons having made due and reasonable enquiry. 

  

	9.2	Novartis’s Disclosures 

  

	 	9.2.1	Novartis’s Warranties are subject to all matters which are fairly disclosed in: 

  

	 	(i)	this Deed; 

  

	 	(ii)	the Disclosure Letter, in respect of the Novartis’s Warranties given pursuant to Paragraph 9.1.1; or 

  

	 	(iii)	the Disclosure Letter and the Option Exercise Date Disclosure Letter, in respect of the Novartis’s Warranties given pursuant to Paragraph 9.1.2. 

 

	 	9.2.2	References in the Disclosure Letter or the Option Exercise Date Disclosure Letter to paragraph numbers shall be to the paragraphs in Appendix 18 to which the disclosure is most likely to relate. Such references
are given for convenience only and, shall not limit the effect of any of the disclosures, all of which are made against Novartis’s Warranties as a whole. 

  

	9.3	The Purchaser’s Warranties 

  

	 	9.3.1	The Purchaser warrants to Novartis that the statements set out in Appendix 19 are true and accurate as of the date of this Deed. 

 

	*** 	Note: Confidential treatment has been requested with respect to the information contained within the [***] marking. Such portions have been omitted from this filing
and have been filed separately with the Securities and Exchange Commission. 

  
  

66 

 Execution Version 
  

 

	10	Limitation of Liability 

  

	10.1	Application 

  

	 	10.1.1	In respect of the Tax Indemnity, the provisions of this Paragraph 10 shall operate to limit the liability of Novartis only in so far as any provision in this Paragraph 10 is expressed to be applicable to the Tax
Indemnity, and the provisions of the Tax Indemnity shall further operate to limit the liability of Novartis in respect of any claims thereunder. 

  

	 	10.1.2	References to Novartis’s Warranties in Paragraphs 10.2 to 10.5 and 10.7 to 10.9 shall not include the Tax Warranties and the Tax Indemnity shall operate to limit the liability of Novartis and to govern the
claims procedure in respect of any claim under the Tax Warranties in respect of a liability for Tax as if such claim had been a claim in respect of a Tax Liability (as defined in the Tax Indemnity) under the Tax Indemnity. 

 

	10.2	Time Limitation for Claims 

 Novartis shall not be liable under this Deed or any Local
Transfer Document for breach of any Novartis’s Warranty or under the Tax Indemnity in respect of any claim unless a notice of the claim is given by the Purchaser to Novartis specifying the matters set out in Paragraph 11.2: 

 

	 	10.2.1	in the case of a claim under paragraphs 1, 2.1, 2.2.1, 2.2.3 or 2.3 of Appendix 18, within the applicable statutory limitation period; 

 

	 	10.2.2	in the case of any claim under paragraphs 4.1 to 4.10 of Appendix 18, within 6 years of Option Closing; 

  

	 	10.2.3	in respect of claims under the Tax Warranties or the Tax Indemnity, before the date falling six months after the expiry of the period specified by statute during which an assessment of the relevant liability to
tax may be issued by the relevant Tax Authority; and 

  

	 	10.2.4	in the case of any other claim, within two years of Option Closing. 

  

	10.3	Minimum Claims 

  

	 	10.3.1	Novartis shall not be liable under: 

  

	 	(i)	this Deed or any Local Transfer Document for breach of any Novartis’s Warranty in respect of any individual claim (or a series of claims arising from similar or identical facts or circumstances) where the liability
agreed or determined (disregarding the provisions of this Paragraph 10.3) in respect of any such claim or series of claims does not exceed US$250,000; or 

  

	 	(ii)	this Deed for breach of any Tax Warranty or under the Tax Indemnity in respect of any individual claim (or series of claims arising from similar or identical facts or circumstances) where the liability agreed or
determined (disregarding the provisions of this Clause 10.3) in respect of any such claim or series of claims does not exceed US$50,000; 

  

	 	10.3.2	Where the liability agreed or determined in respect of any such claim or series of claims exceeds US$250,000 (in the case of claims falling within paragraph 10.3.1(i)) or US$50,000 (in the case of claims falling
within paragraph 10.3.1(ii)), the liability of Novartis shall be for the whole amount of such claim(s) and not just the excess. 

  
  

67 

 Execution Version 
  

 

	10.4	Aggregate Minimum Claims 

  

	 	10.4.1	Novartis shall not be liable under this Deed or any Local Transfer Document for breach of any Novartis’s Warranty in respect of any claim unless the aggregate amount of all claims for which Novartis would
otherwise be liable under this Deed or any Local Transfer Document for breach of any Novartis’s Warranty (disregarding the provisions of this Paragraph 10.4) exceeds US$2.5 million. 

 

	 	10.4.2	Where the liability agreed or determined in respect of all claims exceeds US$2.5 million, Novartis shall be liable for the aggregate amount of all claims as agreed or determined and not just the excess.

  

	 	10.4.3	For the avoidance of doubt, the Purchaser may give notice of any single claim in accordance with and for the purposes of Paragraph 10.2, irrespective of whether, at the time the notice is given, the amount set
out in Paragraph 10.4.2 has been exceeded. 

  

	10.5	Maximum Liability 

 The aggregate liability of Novartis in respect of: 

 

	 	10.5.1	any breaches of Novartis’s Warranties (other than Novartis’s Warranties contained in paragraphs 1, 2.1, 2.2.1, 2.2.3, 2.3 or 4.1 to 4.10 of Appendix 18) shall not exceed an amount equal to thirty per
cent. of the Headline Price; 

  

	 	10.5.2	any breaches of Novartis’ Warranties contained in paragraphs 4.1 to 4.10 of Appendix 18 shall not exceed an amount equal to sixty per cent. of the Headline Price; and 

 

	 	10.5.3	any breaches of Novartis’s Warranties contained in paragraphs 1, 2.1, 2.2.1, 2.2.3 or 2.3 of Appendix 18 shall not exceed the Headline Price. 

 

	10.6	Contingent Liabilities 

 The Novartis shall not be liable under this Deed or any Local
Transfer Document for breach of any Novartis’s Warranty in respect of which the liability is contingent, unless and until such contingent liability becomes an actual liability and is due and payable (but the Purchaser has the right under
Paragraph 11.1 to give notice of such claim before such time). For the avoidance of doubt, the fact that the liability may not have become an actual liability by the relevant date provided in Paragraph 10.2 shall not exonerate Novartis in respect of
any claim properly notified before that date. 
  

	10.7	Provisions 

 Novartis shall not be liable under this Deed or any Local Transfer Document,
in either case, in respect of any claim for breach of any Novartis’s Warranty, if and to the extent that any allowance, provision or reserve has been properly made in the Option Closing Statement or Statement of Net Assets for the matter giving
rise to the claim and Novartis can demonstrate that the allowance, provision or reserve so made was in respect of such matter. 

  
  

68 

 Execution Version 
  

 

	10.8	Matters Arising Subsequent to this Deed 

 Subject to Paragraph 8.1.2, Novartis shall not
be liable under this Deed or any Local Transfer Document, in either case in respect of any claim for breach of any Novartis’s Warranty, in respect of any matter, act, omission or circumstance (or any combination thereof), to the extent that the
same would not have occurred but for: 
  

	 	10.8.1	Agreed matters 

 any matter or thing done or omitted to be done by Novartis or any
member of the Novartis Group before Option Closing pursuant to and in compliance with this Deed or any Local Transfer Document or otherwise at the request in writing of the Purchaser; or 

 

	 	10.8.2	Changes in legislation 

 the passing of, or any change in, after the Option Closing
Date, any Applicable Law or administrative practice of any government, governmental department, agency or regulatory body having the force of the law including (without prejudice to the generality of the foregoing) any increase in the rates of
Taxation or any imposition of Taxation or any withdrawal of relief from Taxation not in force at the Option Closing Date. 
  

	10.9	Insurance 

 Without prejudice to Paragraph 14, Novartis’s Liability under this Deed
for breach of any Novartis’s Warranty shall be reduced by an amount equal to any loss or damage to which such claim related which has actually been recovered under a policy of insurance held by the Purchaser or an Influenza Group Company (after
deducting any reasonable costs incurred in making such recovery including the amount of any excess or deductible). 
  

	10.10	Purchaser’s Right to Recover 

 If Novartis has paid an amount in discharge of any
claim under this Deed for breach of any Novartis’s Warranty and subsequently the Purchaser recovers (whether by payment, discount, credit, relief, insurance or otherwise) from a third party a sum which indemnifies or compensates the Purchaser
(in whole or in part) in respect of the loss or liability which is the subject matter of the claim, the Purchaser shall pay to Novartis as soon as practicable after receipt an amount equal to (i) the sum recovered from the third party less any
costs and expenses incurred in obtaining such recovery and any Tax on any amounts recovered (or Tax that would have been payable on such amounts but for the availability of any Tax relief), or if less (ii) the amount previously paid by Novartis
to the Purchaser. Any payment made by the Purchaser to Novartis under this Paragraph shall be made or procured by way of further adjustment of the consideration paid by the Purchaser and the provisions of Paragraph 3.3 shall apply mutatis
mutandis. 
  

	10.11	No Double Recovery and no Double Counting 

 A party shall be entitled to make more than
one claim under this Deed arising out of the same subject matter, fact, event or circumstance but shall not be entitled to recover under this Deed or any Local Transfer Document or the Tax Indemnity or otherwise more than once in respect of the same
Losses suffered or amount for which the party is otherwise entitled to claim (or part of such Losses or amount), regardless of whether more than one claim arises in respect of it. No amount (including any relief) (or part of any amount) shall be
taken into account, set off or credited more than once under this Deed or any Local Transfer Document or the Tax Indemnity or otherwise, with the intent that there will be no double counting under this Deed or any Local Transfer Document and the Tax
Indemnity or otherwise. 

  
  

69 

 Execution Version 
  

 

	10.12	Fraud 

 None of the limitations contained in this Paragraph 10 shall apply to any claim
to the extent that such claim which arises or is increased, or to the extent to which it arises or is increased, as the consequence of, or which is delayed as a result of, fraud by any director or officer of any member of the Novartis Group. 

 

	11	Claims 

  

	11.1	Notification of Potential Claims 

 Without prejudice to the obligations of the Purchaser
under Paragraph 11.2, if the Purchaser becomes aware of any fact, matter or circumstance that may give rise to a claim against Novartis under this Deed or any Local Transfer Document for breach of any Novartis’s Warranty other than a Tax
Warranty (ignoring for these purposes the application of Paragraph 11.2 or 11.3), the Purchaser shall as soon as reasonably practicable give a notice in writing to Novartis of such facts, matters or circumstances as are then available regarding the
potential claim. Failure to give notice within such period shall not affect the rights of the Purchaser to make a relevant claim under this Deed or any Local Transfer Document for breach of any Novartis’s Warranty, except that the failure shall
be taken into account in determining the liability of Novartis for such claim to the extent Novartis establishes that the amount of it is increased, or is not reduced, as a result of such failure. 

 

	11.2	Notification of Claims under this Deed 

 Notices of claims under this Deed or any Local
Transfer Document for breach of any Novartis’s Warranty (other than a Tax Warranty) shall be given by the Purchaser to Novartis within the time limits specified in Paragraph 10.2 and shall specify information (giving reasonable detail) in
relation to the basis of the claim and setting out the Purchaser’s estimate of the amount of Losses which are, or are to be, the subject of the claim. 
  

	11.3	Commencement of Proceedings 

 Any claim notified pursuant to Paragraph 11.2 shall (if it
has not been previously satisfied, settled or withdrawn) be deemed to be irrevocably withdrawn 9 months after the relevant time limit set out in Paragraph 10.2 unless, at the relevant time, legal proceedings in respect of the relevant claim have
been commenced by being both issued and served except: 
  

	 	11.3.1	where the claim relates to a contingent liability, in which case it shall be deemed to have been withdrawn unless legal proceedings in respect of it have been commenced by being both issued and served with 9
months of it having become an actual liability; or 

  

	 	11.3.2	where the claim is a claim for breach of a Novartis’s Warranty of which notice is given for the purposes of Paragraph 10.2 at a time when the amount set out in Paragraph 10.4.2 has not been exceeded, in
which case it shall be deemed to have been withdrawn unless legal proceedings in respect of it have been commenced by being both issued and served within 9 months of the date of any subsequent notification to Novartis pursuant to Paragraph 11.1 of
one or more claims which result(s) in the total amount claimed in all claims notified to Novartis pursuant to Paragraph 10.2 exceeding the amount set out in Paragraph 10.4.2 for the first time. 

  
  

70 

 Execution Version 
  

 

	11.4	Conduct of Third Party Claims 

 If the matter or circumstance that may give rise to a
claim against Novartis under this Deed or any Local Transfer Document for breach of any Novartis’s Warranty (other than a Tax Warranty) is a result of or in connection with a claim by a third party (a “Third Party Claim”) then:

  

	 	11.4.1	the Purchaser shall as soon as reasonably practicable give written notice thereof to Novartis and thereafter shall provide Novartis with periodic updates upon reasonable request and shall consult with Novartis so
far as reasonably practicable in relation to the conduct of the Third Party Claim and shall take reasonable account of the views of Novartis in relation to the Third Party Claim; 

 

	 	11.4.2	the Third Party Claim shall not be admitted, compromised, disposed of or settled without the written consent of Novartis (such consent not to be unreasonably withheld or delayed); and 

 

	 	11.4.3	subject to Novartis indemnifying the Purchaser or other member of the Purchaser’s Group concerned against all reasonable costs and expenses (including legal and professional costs and expenses) that may be
incurred thereby, the Purchaser shall, or the Purchaser shall procure that any other members of the Purchaser’s Group shall, take such action as Novartis may reasonably request to avoid, dispute, deny, defend, resist, appeal, compromise or
contest the Third Party Claim, provided that this Paragraph 11.4.3 shall not apply where the claim by the third party relates to matters or circumstances referred to in paragraphs 4 or 9 of Appendix 18 and the Purchaser shall then have the right to
conduct the claim at its discretion (subject to Paragraphs 11.4.1 and 11.4.2), 

 provided that failure to give notice in
accordance with Paragraph 11.4.1 shall not affect the rights of the Purchaser to make a relevant claim under this Deed for breach of any Novartis’s Warranty, except that the failure shall be taken into account in determining the liability of
Novartis for such claim to the extent Novartis establishes that the amount of it is increased, or is not reduced, as a result of such failure. 
  

	12	Restrictive Covenants 

  

	12.1	Non-compete 

 Novartis will not, and undertakes to procure that each member of the
Novartis Group will not, for the period from Option Closing until three years after the Option Closing Date: 
  

	 	12.1.1	be engaged (directly or indirectly) in any business which competes with the Business as it is carried on at the Option Closing Date (the “Restricted Business”), provided that commercial
transactions outside the Restricted Business with a client, customer, supplier, licensor or distributor that is not a member of the Novartis Group shall not be deemed to indirectly violate this Paragraph 12.1.1 by reason of such person being engaged
in the Restricted Business or taking any other action prohibited hereunder; or 

  
  

71 

 Execution Version 
  

 

	 	12.1.2	solicit the custom of any person to whom goods or services have been sold by any member of the Influenza Group in the course of its business during the two years before the Option Closing Date, in each case only
to the extent that such solicitation is in competition with the Business of the Influenza Group as it is carried on at the Option Closing Date. 

  

	12.2	Exceptions to the non-compete 

 The restrictions in Paragraph 12.1 shall not apply to:

  

	 	12.2.1	the Specified Excluded Businesses; 

  

	 	12.2.2	any activities of any nature undertaken or developed by the Novartis Group (other than the Influenza Group) in relation to oncology; 

 

	 	12.2.3	any activities of any nature (or any assets related thereto) contributed by the Novartis Group pursuant to the Consumer Contribution Agreement; 

 

	 	12.2.4	any supply agreements between the Novartis Group (other than the Influenza Group) and the Business, the Vaccines Group Businesses (as defined in the Vaccines SAPA) or GlaxoSmithKline Constellation Limited (or its
Affiliates); 

  

	 	12.2.5	any person at such time as it is no longer a member of the Novartis Group, and any person that purchases assets, operations, subsidiaries or businesses from the Novartis Group if such Person is not a member of
the Novartis Group after such transaction is consummated; 

  

	 	12.2.6	any Affiliate of Novartis in which a person who is not a member of the Novartis Group holds equity interests and with respect to whom a member of the Novartis Group has existing contractual or legal obligations
limiting its discretion to impose non-competition obligations; 

  

	 	12.2.7	the holding of shares in a company or other entity for investment purposes provided Novartis does not exercise, directly or indirectly, Control over that company or entity; 

 

	 	12.2.8	any business activity that would otherwise violate Paragraph 12.1 that is acquired in connection with an acquisition so long as the relevant member of the Novartis Group divests all or substantially all of the
business activity that would otherwise violate Paragraph 12.1 or otherwise terminates or disposes of such business activity, product line or assets of such acquired business that would otherwise violate Paragraph 12.1 within nine months after the
consummation of the relevant acquisition, or such longer period as may reasonably be necessary to comply with Applicable Law (provided that in those circumstances Novartis shall procure that the Restricted Business is disposed of as soon as
reasonably practicable); 

  

	 	12.2.9	passive investments by a pension or employee benefit plan or trust for present or former employees; 

  

	 	12.2.10	financial investments by the Novartis Venture Funds; 

  

	 	12.2.11	investments by the Novartis Foundation for Sustainable Development, or a similar non-profit-based organization; 

  
  

72 

 Execution Version 
  

 

	 	12.2.12	performance of any obligation of the Novartis Group under the Transaction Documents, as amended from time to time in accordance with their terms; or 

 

	 	12.2.13	provision of data or other content to or in connection with business conducted by any person, in each case as required by Applicable Law. 

 

	12.3	Non-solicit 

 Novartis will not, and undertakes to procure that each member of the
Novartis Group will not, for a period of two years after the Option Closing Date, solicit or induce any Restricted Influenza Group Employee to become employed or engaged whether as employee, consultant or otherwise by any member of the Novartis
Group. 
  

	12.4	Exceptions to the non-solicit 

 The restrictions in Paragraph 12.3 shall not apply to the
solicitation, inducement or recruitment of any person: 
  

	 	12.4.1	through the placing of advertisements of posts available to the public generally; 

  

	 	12.4.2	through an employment agency, provided that no member of the Novartis Group encourages or advises such agency to approach any such person; or 

 

	 	12.4.3	who is no longer employed by the Purchaser’s Group. 

  

	12.5	Reasonableness of Restrictions 

 Each undertaking contained in this Paragraph 12 shall be
construed as a separate undertaking and if one or more of the undertakings is held to be against the public interest or unlawful or in any way an unreasonable restraint of trade, the remaining undertakings shall continue to bind Novartis. 

 

	12.6	Definitions 

 For the purposes of this Paragraph: 

“Restricted Influenza Group Employee” means any Transferred Employee who has access to trade secrets or other confidential
information of the Influenza Group with an annual basic salary in excess of US$150,000; and; 
 “Specified Excluded
Businesses” means the businesses and activities of: (i) Roche Holding AG and (ii) Novartis Institutes for BioMedical Research (and other activities of a similar type to those currently conducted by Novartis Institutes for
BioMedical Research). 
  

	13	Confidentiality 

  

	13.1	Announcements 

 No announcement, communication or circular concerning the existence or
the subject matter of this Deed shall be made or issued by or on behalf of any member of the Novartis Group or the Purchaser’s Group without the prior written approval of Novartis and the Purchaser (such consent not to be unreasonably withheld
or delayed). This shall not affect any announcement, communication or circular required by law or any governmental or regulatory body or the rules of any stock exchange on which the shares of any party (or its holding company) are listed but the
party with an obligation to make an announcement or communication or issue a circular (or whose holding company has such an obligation) shall consult with the other parties (or shall procure that its holding company consults with the other parties)
insofar as is reasonably practicable before complying with such an obligation. 

  
  

73 

 Execution Version 
  

 

	13.2	Confidentiality 

  

	 	13.2.1	Subject to Paragraph 13.1 and Paragraph 13.2.2, each of the parties shall treat as strictly confidential and not disclose or use any information received or obtained as a result of entering into this Deed, the
Ancillary Agreements or any agreement entered into pursuant to this Deed which relates to: 

  

	 	(i)	the existence and provisions of this Deed, the Ancillary Agreements and of any other agreement entered into pursuant to this Deed; 

  

	 	(ii)	the negotiations relating to this Deed, the Ancillary Agreements and any such other agreement; 

  

	 	(iii)	(in the case of Novartis) any information relating to the Influenza Group Companies and Influenza Group Businesses following Option Closing and any other information relating to the business, financial or other affairs
(including future plans and targets) of the Purchaser’s Group; or 

  

	 	(iv)	(in the case of the Purchaser) any information relating to the business, financial or other affairs (including future plans and targets) of the Novartis Group including, prior to Option Closing, the Influenza Group
Companies and Influenza Group Businesses. 

  

	 	13.2.2	Paragraph 13.2.1 shall not prohibit disclosure or use of any information if and to the extent: 

  

	 	(i)	the disclosure or use is required by law, any governmental or regulatory body or any stock exchange on which the shares of any party (or its holding company) are listed; 

 

	 	(ii)	the disclosure or use is required to vest the full benefit of this Deed or the Ancillary Agreements in any party; 

  

	 	(iii)	the disclosure or use is required for the purpose of any arbitral or judicial proceedings arising out of this Deed, the Ancillary Agreements or any other agreement entered into under or pursuant to this Deed or to
enable a determination to be made by the Reporting Accountants under this Deed; 

  

	 	(iv)	the disclosure is made to a Tax Authority in connection with the Tax affairs of the disclosing party; 

  

	 	(v)	the disclosure is made to a ratings agency on a confidential basis in connection with the affairs of the disclosing party; 

  

	 	(vi)	the disclosure is made to professional advisers of any party on a need to know basis and on terms that such professional advisers undertake to comply with the provisions of Paragraph 13.2.1 in respect of such
information as if they were a party to this Deed; 

  

	 	(vii)	the information was lawfully in the possession of that party without any obligation of secrecy prior to its being received or held, in either case as evidenced by written records; 

  
  

74 

 Execution Version 
  

 

	 	(viii)	the information is or becomes publicly available (other than by breach of this Deed); 

  

	 	(ix)	the other party has given prior written approval to the disclosure or use; or 

  

	 	(x)	the information is independently developed, 

 provided that prior to disclosure or use of any
information pursuant to Paragraph 13.2.2(i), (ii) or (iii), the party concerned shall, where not prohibited by law, promptly notify the other parties of such requirement with a view to providing the other parties with the opportunity to contest
such disclosure or use or otherwise to agree the timing and content of such disclosure or use. 
  

	14	Insurance 

  

	14.1	No cover under Novartis Group Insurance Policies from Option Closing 

 The Purchaser
acknowledges and agrees that following Option Closing: 
  

	 	14.1.1	neither the Purchaser nor any Influenza Group Company shall have or be entitled to the benefit of any Novartis Group Insurance Policy in respect of any event, act or omission that takes place after Option Closing
and it shall be the sole responsibility of the Purchaser to ensure that adequate insurances are put in place for those Influenza Group Companies and Influenza Group Businesses with effect from Option Closing; 

 

	 	14.1.2	neither Novartis nor any member of the Novartis Group shall be required to maintain any Novartis Group Insurance Policy for the benefit of the Influenza Group; 

 

	 	14.1.3	no Influenza Group Company shall make or shall be entitled to make or notify a claim under any Novartis Group Insurance Policy in respect of any event, act or omission that occurred prior to the Option Closing
Date. 

  

	14.2	Existing claims under Novartis Group Insurance Policies 

 With respect to any claim made
before the Option Closing Date under any Novartis Group Insurance Policy by or on behalf of any Influenza Group Company or in relation to any Influenza Group Business, to the extent that: 

 

	 	14.2.1	neither the Purchaser nor the Influenza Group Companies have been indemnified by Novartis prior to the Option Closing Date in respect of the matter in respect of which the claim was made; or 

 

	 	14.2.2	the Liability in respect of which the claim was made has not been properly provided for in the Option Closing Statement, 

Novartis shall use reasonable endeavours after Option Closing to recover all monies due from insurers and shall pay any monies received (after
taking into account any deductible under the Novartis Group Insurance Policies and less any Taxation suffered on the proceeds and any reasonable out of pocket expenses suffered or incurred by Novartis or any member of the Novartis Group in
connection with the claim) to the Purchaser or, at the Purchaser’s written direction, the relevant Influenza Group Company as soon as practicable after receipt. 

  
  

75 

 Execution Version 
  

 

	15	Other Provisions 

  

	15.1	Further Assurances 

  

	 	15.1.1	Without prejudice to any restriction or limitation on the extent of any party’s obligations under this Deed, each of the parties shall from time to time, so far as each is reasonably able, do or procure the
doing of all such acts and/or execute or procure the execution of all such documents in a form reasonably satisfactory to the party concerned as they may reasonably consider necessary to transfer the Influenza Group to the Purchaser or otherwise to
give the other party the full benefit of this Deed. 

  

	 	15.1.2	The parties shall negotiate in good faith to agree definitive and legally binding documentation in respect of each of the Ancillary Agreements for which heads of terms are in the Agreed Terms on the date of this
Deed, and shall duly execute and deliver such definitive and legally binding documentation in respect of the Ancillary Agreements at Option Closing. 

  

	15.2	Whole Agreement 

  

	 	15.2.1	This Deed and the Ancillary Agreements contain the whole agreement between the parties relating to the subject matter of this Deed at the date hereof to the exclusion of any terms implied by law which may be
excluded by contract and supersedes any previous written or oral agreement between the parties in relation to the matters dealt with in this Deed. 

  

	 	15.2.2	The Purchaser acknowledges that, in entering into this Deed, it is not relying on any representation, warranty or undertaking not expressly incorporated into it. 

 

	 	15.2.3	Each of the parties agrees and acknowledges that its only right and remedy in relation to any representation, warranty or undertaking made or given in connection with this Deed shall be for breach of the terms of
this Deed and each of the parties waives all other rights and remedies (including those in tort or arising under statute) in relation to any such representation, warranty or undertaking. 

 

	 	15.2.4	In Paragraphs 15.2.1 to 15.2.3, “this Deed” includes the Ancillary Agreements and all other documents entered into pursuant to this Deed. 

 

	 	15.2.5	Nothing in this Paragraph 15.2 excludes or limits any liability for fraud. 

  

	15.3	No Assignment 

 No party may without the prior written consent of the other parties,
assign, grant any security interest over, hold on trust or otherwise transfer the benefit of the whole or any part of this Deed. 
  

	15.4	Third Party Rights 

  

	 	15.4.1	Subject to Paragraph 15.4.2, the parties to this Deed do not intend that any term of this Deed should be enforceable, by virtue of the Contracts (Rights of Third Parties) Act 1999, by any person who is not a
party to this Deed. 

  

	 	15.4.2	Certain provisions of this Deed confer benefits on the Affiliates of the Purchaser and the Affiliates of Novartis (each such Affiliate being, for the purposes of this Paragraph 15.4, a “Third
Party”) and, subject to Paragraph 15.4.3, are intended to be enforceable by each Third Party by virtue of the Contracts (Rights of Third Parties) Act 1999. 

  
  

76 

 Execution Version 
  

 

	 	15.4.3	Notwithstanding Paragraph 15.4.2, this Deed may be varied in any way and at any time without the consent of any Third Party. 

 

	15.5	Variation or waiver 

  

	 	15.5.1	No variation of this Deed shall be effective unless in writing and signed by or on behalf of each of the parties. 

  

	 	15.5.2	No failure or delay by a party in exercising any right or remedy provided by Applicable Law or under this Deed or any Ancillary Agreement shall impair such right or remedy or operate or be construed as a waiver
or variation of it or preclude its exercise at any subsequent time and no single or partial exercise of any such right or remedy shall preclude any further exercise of it or the exercise of any other remedy. 

 

	15.6	Method of Payment and set off 

  

	 	15.6.1	Except as set out in Paragraph 15.6.2, payments (including payments pursuant to an indemnity, compensation or reimbursement provision) made or expressed to be made by the Purchaser and Novartis pursuant to this
Deed or any claim for breach of this Deed shall, insofar as the payment or claim relates to or affects any Shares (including the underlying Influenza Group Companies transferred (directly or indirectly) by reason of the transfer of those Shares),
assets or liabilities, transferred pursuant to this Deed and the Local Transfer Documents, be made or received (as the case may be) by: 

  

	 	(i)	Novartis, for itself or as agent on behalf of the relevant Share Seller or the Business Seller (each in respect of the Shares and/or assets and liabilities to be transferred by it pursuant to this Deed and the Local
Transfer Documents); and 

  

	 	(ii)	the Purchaser, for itself or as agent on behalf of the relevant members of the Purchaser’s Group (each in respect of Shares and/or the assets and liabilities to be transferred by it pursuant to this Deed and the
Local Transfer Documents). 

  

	 	15.6.2	The repayment of the Estimated Intra-Group Non-Trade Receivables and the Estimated Intra-Group Non-Trade Payables pursuant to Paragraph 6.4.3 and any adjustments to such repayment pursuant to Paragraph 7.4 shall
be settled by payments between Novartis, on behalf of the relevant members of the Novartis Group, and the Purchaser, on behalf of the relevant Influenza Group Companies. 

 

	 	15.6.3	Any payments pursuant to this Deed shall be made in full, without any set-off, counterclaim, restriction or condition and without any deduction or withholding (save as may be required by law or as otherwise
agreed), except that payments due between Novartis and the Purchaser: 

  

	 	(i)	in relation to repayments of the Estimated Intra-Group Non-Trade Payables and Estimated Intra-Group Non-Trade Receivables pursuant to Paragraph 6.4.3; or 

 

	 	(ii)	in relation to adjustments to those repayments pursuant to Paragraph 7.4, 

  
  

77 

 Execution Version 
  

 

	 	respectively,	shall be discharged to the fullest extent possible by way of set-off against each other. 

  

	 	15.6.4	Any payments pursuant to this Deed shall be effected by crediting for same day value the account specified by Novartis or the Purchaser (as the case may be) on behalf of the party entitled to the payment
(reasonably in advance and in sufficient detail to enable payment by telegraphic or other electronic means to be effected) on or before the due date for payment. 

  

	 	15.6.5	Payment of a sum in accordance with this Paragraph 15.6 shall constitute a payment in full of the sum payable and shall be a good discharge to the payer (and those on whose behalf such payment is made) of the
payer’s obligation to make such payment and the payer (and those on whose behalf such payment is made) shall not be obliged to see to the application of the payment as between those on whose behalf the payment is received. 

 

	15.7	Costs 

  

	 	15.7.1	Subject to Paragraph 15.8, Novartis shall bear all costs incurred by it and its Affiliates in connection with the preparation and negotiation of, and the entry into, this Deed, the Local Transfer Documents, the
Tax Indemnity and the sale of the Influenza Group. 

  

	 	15.7.2	The Purchaser shall bear all such costs incurred by it and its Affiliates in connection with the preparation and negotiation of, and the entry into, this Deed, the Local Transfer Documents, the Tax Indemnity and
the purchase of the Influenza Group. 

  

	15.8	Notarial Fees, Registration, Stamp and Transfer Taxes and Duties 

  

	 	15.8.1	Subject to Paragraph 2.3.5, 2.3.6 and 15.8.2, the Purchaser or the relevant member of the Purchaser’s Group: 

  

	 	(i)	shall bear the cost of half of all notarial fees and all registration, stamp and transfer taxes and duties or their equivalents in all jurisdictions where such fees, taxes and duties are payable as a result of the
transactions contemplated by this Deed the other half of such cost to be borne by Novartis; 

  

	 	(ii)	shall be responsible for arranging the payment of all such fees, taxes and duties, including fulfilling any administrative or reporting obligation imposed by the jurisdiction in question in connection with such payment;
and 

  

	 	(iii)	shall indemnify Novartis or any other member of the Novartis Group against any Losses suffered by Novartis or that member of the Novartis Group as a result of the Purchaser failing to comply with its obligations under
this Paragraph 15.8. 

  

	 	15.8.2	The Purchaser and Novartis shall make or procure the making of such payments to each other (and to each other’s Affiliates) as are necessary to ensure the sharing of cost provided for under Paragraph 15.8.1.

  

	15.9	Interest 

 If any party defaults in the payment when due of any sum payable under this
Deed, the Local Transfer Documents or the Tax Indemnity the liability of that party shall be increased to include interest on such sum from the date when such payment is due until the date of actual payment (as well after as before judgment) at a
rate per annum of two per cent. above LIBOR. Such interest shall accrue from day to day. 

  
  

78 

 Execution Version 
  

 

	15.10	Grossing-up 

  

	 	15.10.1	All sums payable under this Deed, the Local Transfer Documents and the Tax Indemnity shall be paid free and clear of all deductions, withholdings, set-offs or counterclaims whatsoever save only as may be
permitted by Paragraph 15.6.3 or required by law. Subject to Paragraphs 15.10.3 to 15.10.7 if any deductions or withholdings are required by law the party making the payment shall (except in the case of any interest payable under Paragraph 7.5 or
15.9) be obliged to pay to the other party such sum as will after such deduction or withholding has been made leave the other party with the same amount as it would have been entitled to receive in the absence of any such requirement to make a
deduction or withholding, provided that if either party to this Deed shall have assigned or novated the benefit in whole or in part of this Deed or shall, after the date of this Deed, have changed its tax residence or the permanent establishment to
which the rights under this Deed are allocated then the liability of the other party under this Paragraph 15.10.1 shall be limited to that (if any) which it would have been had no such assignment, novation or change taken place. 

 

	 	15.10.2	If either party is or becomes aware of any facts making it reasonably likely that the Purchaser, or any relevant member of the Purchaser’s Group, will be required to deduct or withhold any amount in respect
of the Purchase Price (a “Relevant Tax Deduction”), then that party shall, as soon as reasonably practicable, give notice to the other party (including details of the relevant facts and, so far as possible, details of the rate and
basis of such withholding) provided that for the purposes of this Paragraph 15.10.2, Novartis may assume that the Purchase Price will be paid by (and for) a company resident for Tax purposes only in Belgium. 

 

	 	15.10.3	Novartis and the Purchaser shall, and shall procure that the members of their respective groups shall (at Novartis’s cost), co-operate with each other in good faith and use all reasonable efforts to reduce
or mitigate any Relevant Tax Deduction (or its amount) and/or to enable Novartis or the relevant Share Seller or Business Seller to obtain any available credit or refund in respect of such Relevant Tax Deduction, including, without limitation,
making any available claim under an applicable double taxation treaty. 

  

	 	15.10.4	Without prejudice to the generality of Paragraph 15.10.3, Novartis and the Purchaser shall co-operate in good faith to establish or agree the amount or basis of calculation of any Relevant Tax Deduction prior to
Option Closing (and in this regard the Purchaser shall consider reasonably any relevant information or evidence provided or obtained by Novartis) including, if requested by Novartis and at the Novartis’s expense, by seeking to obtain a ruling
or confirmation from a relevant Tax Authority, or obtaining an opinion from reputable local tax counsel or a firm of accountants of international standing satisfactory to the Purchaser (acting reasonably) and instructed jointly by Novartis and the
Purchaser. 

  
  

79 

 Execution Version 
  

 

	 	15.10.5	The Purchaser shall, or shall procure that the relevant member of the Purchaser’s Group shall, make any Relevant Tax Deduction in the minimum amount required by Applicable Law, provided that:

  

	 	(i)	if a double taxation treaty between the jurisdiction under the laws of which the Relevant Tax Deduction is required and the jurisdiction of residence of Novartis or the relevant Share Seller or Business Seller is in
force, the Purchaser shall (and shall procure that any relevant member of the Purchaser’s Group shall) make any Relevant Tax Deduction in an amount not exceeding the rate specified in such double taxation treaty (which may be nil), provided
that Novartis has provided the Purchaser with such evidence as is required under Applicable Law to establish the entitlement of Novartis (or relevant Share Seller or Business Seller) to the benefit of the applicable treaty; and 

 

	 	(ii)	if an opinion from reputable local counsel or a firm of accountants of international standing has been obtained at the request of Novartis as envisaged by Paragraph 15.10.4, the Purchaser shall (and shall procure that
any relevant member of the Purchaser Group shall) make such Relevant Tax Deduction in an amount or on a basis which is consistent with that opinion (which may result in no withholding or deduction), provided that Novartis has indemnified the
Purchaser and any relevant member of the Purchaser’s Group, to the Purchaser’s reasonable satisfaction, against any Liabilities arising (including any interest and penalties) should such opinion be wholly or partly incorrect.

  

	 	15.10.6	The Purchaser shall promptly provide Novartis with evidence reasonably satisfactory to Novartis that a Relevant Tax Deduction has been made and an appropriate amount paid to the relevant Tax Authority.

  

	 	15.10.7	If any Relevant Tax Deduction is required an additional sum shall be payable in accordance with Paragraph 15.10.1 only if and to the extent that such deduction or withholding would not have been required had the
Purchaser and each member of the Purchaser’s Group making such payment or to which such payment relates been resident for Tax purposes only in Belgium. 

  

	15.11	Notices 

  

	 	15.11.1	Any notice or other communication in connection with this Deed (each, a “Notice”) shall be: 

  

	 	(i)	in writing in English; and 

  

	 	(ii)	delivered by hand, fax, or by courier using an internationally recognised courier company. 

  

	 	15.11.2	A Notice to Novartis shall be sent to such party at the following address, or such other person or address as Novartis may notify to the Purchaser from time to time: 

Novartis AG 
 Postfach 

CH-4002 
 Basel Switzerland 

Fax: +41 613244300 
 Attention:
Head of M&A Legal 

  
  

80 

 Execution Version 
  

with a copy to Novartis’s Lawyers, marked for the urgent attention of James Inglis (delivery of such copy shall not in itself constitute
valid notice). 
  

	 	15.11.3	A Notice to the Purchaser shall be sent to such party at the following address, or such other person or address as the Purchaser may notify to Novartis from time to time: 

GlaxoSmithKline PLC 
 980 Great
West Road 
 Brentford 

Middlesex TW8 9GS 
 United
Kingdom 
 Fax: +44 (0)208 0476904 

Attention: The Company Secretary 

with a copy to the Purchaser’s Lawyers, marked for the urgent attention of Simon Nicholls (delivery of such copy shall not in itself
constitute valid notice). 
  

	 	15.11.4	A Notice shall be effective upon receipt and shall be deemed to have been received: 

  

	 	(i)	at the time of delivery, if delivered by hand or courier; 

  

	 	(ii)	at the time of transmission in legible form, if delivered by fax. 

  

	15.12	Invalidity or Conflict 

  

	 	15.12.1	If any provision in this Deed shall be held to be illegal, invalid or unenforceable, in whole or in part, the provision shall apply with whatever deletion or modification is necessary so that the provision is
legal, valid and enforceable and gives effect to the commercial intention of the parties. 

  

	 	15.12.2	To the extent it is not possible to delete or modify the provision, in whole or in part, under Paragraph 15.12.1, then such provision or part of it shall, to the extent that it is illegal, invalid or
unenforceable, be deemed not to form part of this Deed and the legality, validity and enforceability of the remainder of this Deed shall, subject to any deletion or modification made under Paragraph 15.12.1, not be affected. 

 

	 	15.12.3	If there is any conflict between the terms of this Deed and any of the Ancillary Agreements this Deed shall prevail (as between the parties between this Deed and as between any member of Novartis Group and any
member of the Purchaser Group) unless (i) such Ancillary Agreement expressly states that it overrides this Deed in the relevant respect and (ii) Novartis and the Purchaser are either also parties to that Ancillary Agreement or otherwise
expressly agree in writing that such Ancillary Agreement shall override this Deed in that respect. 

  

	15.13	Counterparts 

 This Deed may be entered into in any number of counterparts, all of which
taken together shall constitute one and the same instrument. Any party may enter into this Deed by executing any such counterpart. Delivery of a counterpart of this Deed by email attachment shall be an effective mode of delivery. 

  
  

81 

 Execution Version 
  

 

	15.14	Governing Law and Submission to Jurisdiction 

  

	 	15.14.1	This Deed and the documents to be entered into pursuant to it, save as expressly referred to therein, and any non-contractual obligations arising out of or in connection with the Deed and such documents shall be
governed by and construed in accordance with English law. 

  

	 	15.14.2	Each of the parties irrevocably agrees that the courts of England and Wales are to have exclusive jurisdiction to settle any dispute which may arise out of or in connection with this Deed and the documents to be
entered into pursuant to it save as expressly referred to therein, and that accordingly any proceedings arising out of or in connection with this Deed and the documents to be entered into pursuant to it shall be brought in such courts. Each of the
parties irrevocably submits to the jurisdiction of such courts and waives any objection to proceedings in any such court on the ground of venue or on the ground that proceedings have been brought in an inconvenient forum. 

 

	15.15	Appointment of Process Agent 

  

	 	15.15.1	Novartis hereby irrevocably appoints Hackwood Secretaries Limited of One Silk Street, London EC2Y 8HQ as its agent to accept service of process in England and Wales in any legal action or proceedings arising out
of this Deed, service upon whom shall be deemed completed whether or not forwarded to or received by Novartis. 

  

	 	15.15.2	Novartis agrees to inform the Purchaser in writing of any change of address of such process agent within 28 days of such change. 

 

	 	15.15.3	If such process agent ceases to be able to act as such or to have an address in England and Wales, Novartis irrevocably agrees to appoint a new process agent in England and Wales and to deliver to the Purchaser
within 14 days a copy of a written acceptance of appointment by the process agent. 

  

	 	15.15.4	Nothing in this Deed shall affect the right to serve process in any other manner permitted by law. 

  
  

82 

 Execution Version 
  

Appendix 1 
 Details of
the Share Seller, Shares etc. 
 (Paragraph 2.1) 
  

					
	(1)	 	(2)	 	(3)
	 Name

of Share Seller
	 	 Name of

Company
	 	Shares
	 Novartis Pharma AG
	 	Novartis Vaccines Holdings Limited	 	92 shares (100%)

  
  

83 

 Execution Version 
  

Appendix 2 
 Company and
Subsidiaries 
  

	1	Particulars of the Company 

  

					
	 Name of Company:
		Novartis Vaccines Holdings Limited
		
	Registered Number:		4679458
		
	Registered Office:		 C/O Novartis Pharmaceuticals UK Limited,

Frimley Business Park, Frimley,
 Camberley, GU16 7SR, United
Kingdom

		
	Date and place of incorporation:		26 February 2003, England and Wales
		
	Issued share capital:		GBP 92 divided into 92 shares of GBP 1 each
			
	Shareholders and shares held:		Novartis Pharma AG		92 (100%)

  

	2	Particulars of the Subsidiaries 

  

					
	 Name of Subsidiary:
		Chiron Technologies Limited
		
	Registered Number:		02977138
		
	Registered Office:		 3 Rivergate, Temple Quay, Bristol,

BS1 6GD, United Kingdom

		
	Date and place of incorporation:		10 October 1994, England and Wales
		
	Issued share capital:		GBP 2 divided into 2 shares of GBP 1 each
			
	Shareholders and shares held:		Novartis Vaccines Holdings Ltd		2 (100%)
		
	 Name of Subsidiary:
		Novartis Vaccines and Diagnostics Limited
		
	Registered Number:		3970089
		
	Registered Office:		 C/O Novartis Pharmaceuticals UK Ltd,

Frimley Business Park, Frimley, Camberley,
 Surrey, GU16 7SR,
United Kingdom

		
	Date and place of incorporation:		11 April 2000, England and Wales

  
  

84 

 Execution Version 
  

 

					
	 Name of Subsidiary:
		Novartis Vaccines and Diagnostics Limited
		
	Issued share capital:		GBP 100 divided into 100 shares of GBP 1 each
			
	Shareholders and shares held:		Novartis Vaccines Holdings Limited		100 (100%)
		
	Name of Subsidiary:		Chiron Pharmaceuticals Limited
		
	Registered Number:		3321428
		
	Registered Office:		 3 Rivergate, Temple Quay, Bristol,

BS1 6GD, United Kingdom

		
	Date and place of incorporation:		14 February 1997, England and Wales
		
	Issued share capital:		 GBP 9,858,543.50 divided into 98,585,435

shares of GBP 0.1 each

			
	Shareholders and shares held:		Novartis Vaccines Holdings Limited		144,000,000 (100%)

  
  

85 

 Execution Version 
  

Appendix 3 
 The
Properties 
 Part 1 

(Company Real Property) 

Part A 
 Company Owned
Real Property 
 None 

Part B 
 Company Leased
Real Property 
  
  

			
	 1                 INFLUENZA GROUP
COMPANY:
		Novartis Vaccines and Diagnostics Limited
		
	 1.1             Property Description: 
		‘Site 2’ – Land on the North side of Speke Boulevard, Liverpool, UK
		
	                    Date and
parties to Lease:
		1 April 1948
		
			 (1)    Home and Communities Agency

		
			 (2)    Novartis Vaccines and Diagnostics Limited
(current tenant)

		
	                    Title
Number:
		MS134921
		
	 1.2             Property Description: 
		‘Site 2’ – Land on the South side of Gaskill Road, Speke, Liverpool, UK
		
	                    Date and
parties to Lease:
		20 February 1952
		
			 (1)    Home and Communities Agency

		
			 (2)    Novartis Vaccines and Diagnostics Limited
(current tenant)

		
	                    Title
Number:
		MS253780

  
  

86 

 Execution Version 
  

			
	 1.3             Property Description:
		‘Site 4’ – Plot 5A Boulevard Industrial Estate (as well as car parking bays and loading area), Liverpool, UK
		
	                    Date and parties to
Lease:
		28 February 2006
		
			 (1)    The Matrix Speke Limited Partnership

		
			 (2)    Novartis Vaccines and Diagnostics Limited (current tenant)

		
	                    Title
Number:
		MS536103
		
	 1.4             Property Description:
		‘Site 3’ – Unit 7, Boulevard Industrial Estate, Liverpool, UK
		
	                    Date and parties to
Lease:
		23 December 2013
		
			 (1)    Medimmune U.K. Limited

		
			 (2)    Novartis Vaccines and Diagnostics Limited

		
	 1.5             Property Description:
		Unit 4 Boulevard Industrial Estate, Speke, Liverpool, UK
		
	                    Date and parties to
Lease:
		18 July 2001
		
			 (1)    Speke-Garston Development Limited

		
			 (2)    Novartis Vaccines and Diagnostics Limited (current tenant)

		
	                    Title
Number:
		MS451073

  
  

87 

 Execution Version 
  

Appendix 3 
 The
Properties 
 Part 2 

(Transferred Real Property) 

Part A 
 Transferred
Owned Real Property 
  

			
	 1               BUSINESS SELLER:
		Novartis Vaccines & Diagnostics, Inc.
		
	 1.1             Property Description:
		85 acre tract, Holly Springs Business Park, US
		
	                  Real Estate ID
Number:
		0348207 and Part of 0347056, Wake County Tax Office
		
	                  Documents:
		Deed - Bk 12119, Pg 2155, Wake County Registry
		
			Declaration of covenants, conditions and restrictions for Holly Springs Business Park
		
	 1.2             Property Description:
		77 acre tract, Holly Springs Business Park, US
		
	                   Real Estate ID
Number:
		Part of 0347056, Wake County Tax Office
		
	                   Documents:
		Deed - Bk 12390, Pg 2295, Wake County Registry
		
			Declaration of covenants, conditions and restrictions for Holly Springs Business Park
		
	 1.3             Property Description:
		14.455 acres, Holly Springs Business Park, US
		
	                   Real Estate ID
Number:
		0005476, Wake County Tax Office
		
	                   Documents:
		Deed - Bk 14464, Pg 320, Wake County Registry
		
			Declaration of covenants, conditions and restrictions for Holly Springs Business Park

 Part B 

Transferred Leased Real Property 
  

			
	 1                BUSINESS SELLER:
		Novartis Vaccines and Diagnostics, Inc.
		
	 1.1             Property Description:
		Parcel L, Holly Springs Business Park, US
		
	                   Date and parties to
Lease:
		24 July 2006
		
			 (1)    Town of Holly Springs

		
			 (2)    Novartis Vaccines and Diagnostics, Inc.

		
	                   Real Estate ID
Number:
		0348208, Wake County Tax Office
		
	                   Documents:
		Bk 12097, Pg 1486, Wake County Registry
		
			Declaration of covenants, conditions and restrictions for Holly Springs Business Park

  
  

88 

 Execution Version 
  

Appendix 3 
 The
Properties 
 Part 3 

Terms relating to the Company Real Property 
  

	1	General Provisions relating to the Company Real Property 

  

	1.1	Interpretation 

 The following further definitions apply in this Part 3 of Appendix 3:

 “Company Landlord” means the person for the time being entitled to the reversion immediately expectant on the termination
of the term granted by a Company Lease; 
 “Company Leased Real Properties” means the leasehold properties identified in
Part B of Part 1 of this Appendix 3, and “Company Leased Real Property” means any one of them; 
 “Company
Leases” means the leases, licence documents or tenancy agreements under which the Company Leased Real Properties are held, including all documents supplemental to them, and “Company Lease” means any one of them; 

“Company Owned Real Properties” means the owned properties as identified in Part A of Part 1 of this Appendix 3 together with
all buildings, structures, fixed plant, fixed machinery and fixed equipment thereon (except as excluded in Paragraph 2.3.2), and “Company Owned Real Property” means any one of them; 

“Company Real Property Longstop Date” means the date on which a court of competent jurisdiction finally determines that a
Company Third Party Consent has been lawfully refused or cannot be obtained and/or that the Purchaser may not acquire (directly or indirectly, acting through a subsidiary) the relevant Company Real Property; and 

“Company Third Party Consents” means all consents, licences, approvals, permits, authorisations or waivers required from any
Company Landlord, superior landlord and/or other third party, including any consents, licences, approvals, permits, authorisations or waivers required by any legislation or regulation or by any statutory, governmental, state, provincial or municipal
bodies or authorities which are required under a Company Lease or otherwise in relation to any change of control, shareholders or directors of the Influenza Group Companies, and “Company Third Party Consent” means any one of them.

  
  

89 

 Execution Version 
  

 

	1.2	Company Third Party Consents 

  

	 	1.2.1	This paragraph 1.2.1 of Part 3 of Appendix 3 applies to those Company Real Properties in relation to which a Company Third Party Consent is required and if such Company Third Party Consent remains to be obtained as at
the Option Closing Date this paragraph 1.2.1 of Part 3 of Appendix 3 shall continue to apply until the relevant Company Third Party Consent shall have been obtained or until the Company Real Property Longstop Date. If any Company Third Party
Consents are required: 

  

	 	(i)	Novartis shall make an application for, and shall use all reasonable endeavours to obtain each Company Third Party Consent as soon as reasonably practicable following the Option Exercise Date and shall at all times keep
the Purchaser informed of progress in obtaining such Company Third Party Consents; 

  

	 	(ii)	the Purchaser shall supply such information and references as may reasonably be required by a Company Landlord, any superior landlord or other relevant third party in connection with a Company Third Party Consent;

  

	 	(iii)	the Purchaser shall be responsible for and undertake to pay, or procure the giving of undertakings to pay the professional and other fees of any Company Landlord, any superior landlord or other relevant person
(including any Tax or disbursements in respect of such fees but excluding any Tax on the actual net income, profit or gains of the Company Landlord, any superior landlord or any other relevant person) properly incurred in connection with any
application for Company Third Party Consents, whether or not such Company Third Party Consents are given; and 

  

	 	(iv)	in respect of the period after Option Closing only, the Purchaser shall enter into such covenants for the payment of the rent under the Company Lease and for the observance and performance of the covenants and
conditions contained in the Company Lease as may reasonably be required by the Company Landlord, any superior landlord or other relevant third party. 

  

	 	1.2.2	Each party shall give written notice to the other party as soon as reasonably practicable after obtaining any Company Third Party Consents which shall be accompanied by a copy of such consent. 

 

	 	1.2.3	Save as set out in paragraph 1.2.1(iii) of this Part 3 of Appendix 3, Novartis shall pay any moneys or provide or procure the giving of any guarantees or other security, in each case as may be lawfully required
by a Company Landlord, superior landlord or other relevant third party in connection with the obtaining of the Company Third Party Consents, provided that the Purchaser shall indemnify and keep indemnified Novartis in an amount equal to:

  

	 	(i)	any moneys required to be paid by Novartis pursuant to this paragraph; and 

  

	 	(ii)	 any Liabilities under any guarantees or other security given or procured by Novartis pursuant to this paragraph and arising out of, or in connection
with, an act or omission on the part of the Purchaser or (following Option Closing) the relevant Influenza Group Company, 

  
  

90 

 Execution Version 
  

and where the Company Landlord, superior landlord or other relevant third party lawfully requires any guarantees or other security to be given by the person who is acquiring a membership interest
in respect of the relevant Influenza Group Company, the Purchaser shall provide or procure the giving of any such guarantees or security. 

Company Third Party Consent not obtained 
  

	 	1.2.4	If a Company Third Party Consent has been refused or otherwise not obtained within twelve months following the Option Closing Date, Novartis and the Purchaser may (acting reasonably) agree that an application is
to be made to a court of competent jurisdiction that the relevant Company Third Party Consent has been unreasonably withheld or delayed. 

  

	 	1.2.5	If an application is to be made to a court of competent jurisdiction pursuant to paragraph 1.2.4 of this Part 3 of Appendix 3: 

 

	 	(i)	the proceedings shall be brought by, and prosecuted at the expense of, the Purchaser; 

  

	 	(ii)	Novartis shall provide all such assistance in connection with such proceedings as the Purchaser (acting reasonably) may require in the interests of obtaining the Company Third Party Consent; and 

 

	 	(iii)	provided that Novartis has complied with its obligation under paragraph 1.2.1(i) of this Part 3 of Appendix 3, the Purchaser shall indemnify and keep indemnified Novartis for any costs and expenses properly incurred in
connection with any such assistance provided by Novartis. 

  

	 	1.2.6	If a Company Third Party Consent has not been obtained by the Company Real Property Longstop Date then Novartis and the Purchaser shall each bear fifty per cent. of any Losses of Novartis and the Purchaser
arising out of or in connection with the failure to obtain such Company Third Party Consent. 

  
  

91 

 Execution Version 
  

Appendix 3 
 The
Properties 
 Part 4 

Terms relating to the Transferred Real Property 
  

	1	General Provisions Relating to the Transferred Real Property 

  

	1.1	Interpretation 

 The following further definitions apply in this Part 4 of Appendix 3:

 “Landlord” means the person for the time being entitled to the reversion immediately expectant on the termination of the
term granted by a Lease; 
 “Leases” means the leases, licences or tenancy agreements under which the Transferred Leased
Real Properties are held by the relevant member of the Novartis Group, including all documents supplemental to them, and “Lease” means any one of them; 

“Letting Document” means any lease, licence or tenancy agreement to which a Transferred Real Property is subject; 

“Licence” means a right in favour of the Purchaser and all persons authorised by it to occupy the Licensed Premises during the
Licence Period pursuant to this Part 4 of Appendix 3; 
 “Licence Fee” means the payments to be made by the Purchaser to the
Novartis Group pursuant to paragraph 1.4.4 of this Part 4 of Appendix 3; 
 “Licence Period” means a period, which may be
different for each of the Licensed Premises, commencing on the Option Closing Date and ending on the earliest of the following dates: 
  

	 	(xxxiii)	the date on which this Deed is terminated by whatever means whether in whole or in relation to the relevant Licensed Premises; 

  

	 	(xxxiv)	the date immediately preceding the date on which the term of the relevant Lease ends by whatever means; 

  

	 	(xxxv)	the date of Property Transfer Completion in relation to the relevant Transferred Real Property; and 

  

	 	(xxxvi)	the Property Longstop Date; 

 “Licensed Premises” means any of the Transferred
Real Properties for which all relevant Property Third Party Consents have not been obtained prior to, or at, the Option Closing Date; 

“Property Agreed Terms” means a transfer in the terms agreed between the relevant Business Seller, the Purchaser and any
relevant third party or determined pursuant to paragraph 1.3.2 of this Part 4 of Appendix 3 and signed for identification by or on behalf of the Business Seller and by or on behalf of the Purchaser from time to time before or after the date of this
Deed, with such alterations as may be agreed from time to time in writing between the relevant Business Seller, the Purchaser and any relevant third party; 

  
  

92 

 Execution Version 
  

“Property Longstop Date” means the date on which a court of competent jurisdiction finally determines that a Property Third
Party Consent has been lawfully refused; 
 “Property Third Party Consents” means all consents, licences, approvals,
permits, authorisations or waivers required from any Landlord, superior landlord and/or other third party, including any consents, licences, approvals, permits, authorisations or waivers required by any legislation or regulation or by any statutory,
governmental, state, provincial or municipal bodies or authorities for or in connection with the transfer of a Transferred Real Property by the Business Sellers to the Purchaser and includes (where the context so admits) Sublease Consents; 

“Property Transfer Completion” means the completion of the transfer of a Transferred Real Property under this Deed, where such
completion does not take place on the Option Closing Date because any relevant Property Third Party Consents have not been obtained on or prior to such date; 

“Property Transfer Completion Date” means the date of Property Transfer Completion in accordance with paragraph 1.7 of this
Part 4 of Appendix 3; 
 “Registered Title” means the registered title relating to a Transferred Real Property; 

“Sublease Consent” has the meaning given to it in paragraph 1.11.2 of this Part 4 of Appendix 3; 

“transfer”, for the purposes of this Part 4 of Appendix 3 only, means in respect of a Transferred Leased Real Property, the
transfer or assignment of the relevant Lease or Leases, and in the case of a Transferred Owned Real Property the transfer thereof, and “a transfer” means and includes any instruments, deeds or agreements effecting such transfer;

 “Transferred Leased Real Properties” means the leasehold properties held by a Business Seller and identified in Part B of
Part 2 of this Appendix 3 and “Transferred Leased Real Property” means any one of them; and 
 “Transferred Owned
Real Properties” means the owned properties identified in Part A of Part 2 of this Appendix 3 together with all buildings, structures, fixed plant, fixed machinery and fixed equipment thereon (except as excluded in Paragraph 2.3.2, and
“Transferred Owned Real Property” means any one of them. 

  
  

93 

 Execution Version 
  

 

	1.2	Each of the Transferred Real Properties and/or the Leases thereof shall be transferred subject to the terms set out in this Part 4 of Appendix 3 and all other applicable terms of this Deed. 

 

	1.3	Pre-Option Closing 

  

	 	1.3.1	Prior to Option Closing, the Business Sellers and the Purchaser shall agree (acting reasonably) the form of all documents on Property Agreed Terms necessary for the transfer of each of the Transferred Real
Properties pursuant to the terms set out in this Part 4 of Appendix 3 and all other applicable terms of this Deed. 

  

	 	1.3.2	Any dispute arising out of or connected with paragraph 1.3.1 of this Part 4 of Appendix 3 which is not resolved by agreement between the parties within nine months of such dispute arising shall be referred for
and resolved by expert determination as follows: 

  

	 	(i)	either the relevant Business Seller or the Purchaser may initiate an expert reference under this provision by proposing to the other party the appointment of an expert (the “Expert”); 

 

	 	(ii)	the Expert shall either be the nearest equivalent to a chartered surveyor in the relevant jurisdiction or (in relation to legal issues) a single QC (or equivalent), in each case with no less than 15 years’
post-qualification experience in commercial real estate in the relevant jurisdiction chosen by agreement between the relevant Business Seller and the Purchaser or, failing agreement within 14 days of the initiation of the reference, by the President
for the time being of the relevant professional body to which the Expert belongs (the “President”) on the application of either the relevant Business Seller or the Purchaser; 

 

	 	(iii)	the relevant Business Seller and the Purchaser shall request that the Expert determines the referred dispute within 10 days of receiving the reference; 

 

	 	(iv)	if the Expert has been appointed but is unable or unwilling to complete the reference, another Expert shall be appointed by agreement between the relevant Business Seller and the Purchaser or, failing agreement within 7
days of the parties being notified that the Expert is unable or unwilling to complete the reference, by the President on the application of either party; 

  

	 	(v)	the Expert shall act as an expert and not as an arbitrator; 

  

	 	(vi)	the relevant Business Seller and the Purchaser shall have the right to make representations and submissions to the Expert, but there will be no formal hearing; 

 

	 	(vii)	the relevant Business Seller and the Purchaser shall make all relevant documents and information within their control available to the Expert; 

 

	 	(viii)	the costs of the Expert shall be borne equally by the relevant Business Seller and the Purchaser; and 

  
  

94 

 Execution Version 
  

 

	 	(ix)	the decision of the Expert shall, in the absence of fraud or manifest error, be final and binding on the parties. 

  

	 	1.3.3	This paragraph 1.3.3 of Part 4 of Appendix 3 applies to those Transferred Real Properties in relation to which a Property Third Party Consent is required and if such Property Third Party Consent remains to be obtained
as at the Option Closing Date this paragraph 1.3.3 of Part 4 of Appendix 3 shall continue to apply until the relevant Property Third Party Consent shall have been obtained or until the Property Longstop Date. If any Property Third Party Consents are
required: 

  

	 	(i)	Novartis or relevant Business Seller shall make an application for, and shall use all reasonable endeavours to obtain each Property Third Party Consent as soon as reasonably practicable following the Option Exercise
Date for the transfer of the Transferred Real Property and shall, at all times, keep the Purchaser informed of progress in obtaining such Property Third Party Consents; 

 

	 	(ii)	the Purchaser shall: 

  

	 	(a)	supply such information and references as may reasonably be required by a Landlord, any superior landlord or other relevant third party in connection with a Property Third Party Consent; 

 

	 	(b)	in respect of the period after Option Closing only, enter into such covenants for the payment of the rent in respect of the Transferred Leased Real Properties and for the observance and performance of the covenants and
conditions on the part of the lessee contained in any Lease as may reasonably be required by the Landlord, any superior landlord or other relevant third party; 

  

	 	(c)	if reasonably required by the Landlord, any superior landlord or other relevant third party, provide a rent deposit or procure that a surety acceptable to such person guarantees the Purchaser’s obligations under
the Lease following the transfer of the relevant Transferred Leased Real Property; and 

  

	 	(d)	be responsible for and undertake to pay, or procure the giving of undertakings to pay the professional and other fees of any Landlord, any superior landlord or other relevant person (including any Tax or disbursements
in respect of such fees but excluding any Tax on the actual net income, profit or gains of the Landlord, any superior landlord or any other relevant person) properly in connection with any application for Property Third Party Consents, whether or
not such Property Third Party Consents are given. 

  

	 	1.3.4	Each party shall give written notice to the other party as soon as reasonably practicable after obtaining any Property Third Party Consents which shall be accompanied by a copy of such consent. 

 

	 	1.3.5	Subject to the Purchaser complying with its obligations under paragraphs 1.3.3(ii)(b) to (d) of this Part 4 of Appendix 3, Novartis shall pay, or shall procure that a member of the Novartis Group pays, any moneys
or provide or procure the giving of any guarantees or other security, in each case as may be lawfully required by a Landlord, superior landlord or other relevant third party in connection with the obtaining of the Property Third Party Consents,
provided that the Purchaser shall indemnify and keep indemnified Novartis in an amount equal to: 

  

	 	(i)	any moneys required to be paid, or procured to be paid, by Novartis pursuant to this paragraph; and 

  
  

95 

 Execution Version 
  

 

	 	(ii)	any Liabilities under any guarantees or other security given or procured by Novartis pursuant to this paragraph and arising out of, or in connection with, an act or omission on the part of the Purchaser.

  

	1.4	Licence 

  

	 	1.4.1	In the event that any Property Third Party Consents are not obtained on or before the Option Closing Date, notwithstanding the terms of the Leases, Novartis shall procure that the relevant Business Seller allows
the Purchaser to occupy the Licensed Premises for the Licence Period relating to the relevant Licensed Premises on the terms set out in this paragraph 1.4 of Part 4 of Appendix 3. 

 

	 	1.4.2	The Purchaser acknowledges that the grant of each Licence may amount to a breach of the terms of the relevant Lease. 

  

	 	1.4.3	The Licence of each Licensed Premises is granted: 

  

	 	(i)	subject to all of the matters to which the relevant Leases relating to the Transferred Leased Real Property are subject; 

  

	 	(ii)	subject to the matters referred to in the Registered Title and the Letting Documents; 

  

	 	(iii)	out of whatever right, title and interest that the relevant Business Seller has in the Licensed Premises and/or under the Leases; 

  

	 	(iv)	in such state of repair and condition as the Licensed Premises may be in as at the date on which the relevant Licence is granted; and 

 

	 	(v)	without making any statement or representation that the relevant Business Seller is entitled to grant it. 

  

	 	1.4.4	From Option Closing and pending Property Transfer Completion, the Purchaser shall pay to the relevant Business Seller a “Licence Fee” equivalent to: 

 

	 	(i)	all rents and other charges (including VAT due thereon under the relevant Lease where payable at the date of this Deed by the relevant Business Seller) payable in respect of the Licensed Premises; and 

 

	 	(ii)	all outgoings (including VAT due thereon under the relevant Lease) (including, but not limited to, rates, service charges, management charges, levies, air-conditioning charges, insurance, heating, electricity, gas,
telecommunications and other services and the cost of complying with fire and other statutory regulations) payable by the relevant Business Seller in respect of the Licensed Premises or charged upon the owner or occupier of the Licensed Premises,

 such payments to be made not less than 10 Business Days before any such sum falls due subject to the relevant Business
Seller giving the Purchaser not less than 10 Business Days’ prior written notice to that effect. To the extent that there has been a prepayment at the Option Closing Date of the amounts in paragraphs 1.4.4(i) and (ii) of this Part 4 of
Appendix 3 by the Novartis Group which is not otherwise accounted for in the Option Closing Statement, the Purchaser shall pay to the relevant member of the Novartis Group within 10 Business Days of written demand an amount equal to the amount of
such prepayment in respect of any period after the Option Closing Date. 

  
  

96 

 Execution Version 
  

 

	 	1.4.5	Throughout the Licence Period, the Purchaser shall, in respect of the Licensed Premises only: 

  

	 	(i)	keep the Licensed Premises in no worse a state of repair than they are in at the Option Closing Date, fair wear and tear excepted; 

  

	 	(ii)	observe and perform the covenants and conditions on the part of the lessee in the relevant Lease under which the relevant Business Seller holds the Licensed Premises (other than in relation to the payment of rent and
other charges paid to the relevant Business Seller as part of the Licence Fee and subject to paragraph 1.4.5(i) of this Part 4 of Appendix 3); and 

  

	 	(iii)	use the Licensed Premises only in accordance with the terms of the Lease of the relevant Licensed Premises and in compliance with the law and regulations where the relevant Licensed Premises is located (save for any
such law or regulation that prohibits the use of the Licensed Premises without a Property Third Party Consent having been obtained). 

  

	 	1.4.6	The Purchaser and each Business Seller agree that: 

  

	 	(i)	the Licence is personal to the Purchaser and may only be exercised by the Purchaser and those authorised by it; 

  

	 	(ii)	(subject to paragraph 1.4.5 of this Part 4 of Appendix 3) the Purchaser and all persons authorised by it are permitted to have the unrestricted use and occupation of the Licensed Premises; and 

 

	 	(iii)	no relationship of landlord and tenant is created as a result of the Licence. 

  

	 	1.4.7	If a Landlord or any other relevant third party commences proceedings, raises any lawful objection or takes any other action in connection with the Purchaser’s occupation or use of any of the Licensed
Premises pending the obtaining of the relevant Property Third Party Consents, the Purchaser and the relevant Business Seller shall meet and negotiate in good faith in order to determine which steps should be taken in respect of the relevant
Transferred Real Property. 

  

	 	1.4.8	Throughout the Licence Period, the Purchaser shall, in respect of the Licensed Premises only, indemnify and keep indemnified each member of the Novartis Group from and against any Licence Fee and any Losses arising from
the Licence and/or as a result of the occupation of the Licensed Premises by the Purchaser. 

  

	 	1.4.9	The Purchaser and the Business Sellers shall each inform the other forthwith of any notice received by it in relation to any of the Licensed Premises from the Landlord or any other third party. 

  
  

97 

 Execution Version 
  

 

	1.5	Determination of Licence 

  

	 	1.5.1	The Licence in relation to any one or more of the Licensed Premises shall determine: 

  

	 	(i)	immediately if the Property Longstop Date occurs; or 

  

	 	(ii)	by the relevant Business Seller giving at least three months’ prior written notice to the Purchaser if the Purchaser fails to make the payment of the Licence Fee for a period of one month or is otherwise in
material breach of the provisions of the Licence for a continuous period of one month following written notification by the relevant Business Seller to the Purchaser of the same, and in either case the Purchaser has failed to remedy the relevant
failure to pay or to remedy the breach prior to the expiry of the three month notice period (or, if the breach is not capable of remedy within such three month period, the Purchaser has failed to commence to remedy the breach within that period and
thereafter failed diligently to continue with such remedy); or 

  

	 	(iii)	if the relevant Landlord in relation to a Transferred Leased Real Property prosecutes forfeiture proceedings (or the nearest local law equivalent) as a result of the occupation by the Purchaser of the Licensed
Premises then the parties shall either: 

  

	 	(a)	agree that the Licence shall determine on a date to be agreed between the parties (acting reasonably); or 

  

	 	(b)	in the absence of such agreement, either party may require a QC (or equivalent) with no less than 15 years’ post-qualification experience in commercial real estate in the relevant jurisdiction to be appointed (such
appointment to be by agreement between Novartis and the Purchaser or, failing agreement, within 14 days, by the President (as defined in paragraph 1.3.2(ii) of this Part 4 of Appendix 3)). Should the QC determine that there is more than a 50% chance
of the proceedings in question resulting in the Lease in question being forfeited (or equivalent), then the Licence shall determine on a date to be agreed between the parties (acting reasonably) in order to afford Novartis the opportunity to apply
for relief from forfeiture or otherwise challenge the proceedings in question on the basis that any breach resulting from the grant of the Licence has been cured, 

provided that this paragraph 1.5.1(iii) shall at all times operate without prejudice to paragraphs 1.4.7, 1.5.1(i) and 1.12. 

 

	 	1.5.2	If, for whatever reason, the Licence Period comes to an end in relation to any of the Licensed Premises then: 

  

	 	(i)	the Licence insofar as it relates to the relevant Licensed Premises shall be severable from the remainder of this Deed and this Deed shall otherwise remain in full force and effect; 

 

	 	(ii)	the Purchaser shall not be entitled to any refund, abatement or reduction of the Purchase Price but shall be entitled to a refund in respect of any Licence Fee prior to the termination of the Licence for the Licensed
Premises and which relates to the period following termination of the Licence; 

  
  

98 

 Execution Version 
  

 

	 	(iii)	it shall not prejudice or affect any claim by any relevant Business Seller in respect of any prior breach of this Deed by the Purchaser in respect of that Licensed Premises; and 

 

	 	(iv)	unless the Licence Period comes to an end due to Property Transfer Completion in respect of the relevant Licensed Premises taking place, the Purchaser shall: 

 

	 	(a)	vacate the Licensed Premises forthwith; 

  

	 	(b)	remove from the Licensed Premises all items belonging to it; 

  

	 	(c)	leave the Licensed Premises in a clean and tidy condition; and 

  

	 	(d)	at the request of the relevant Business Seller, reinstate the Licensed Premises or any part or parts thereof to at least as good a state of repair or condition as at Option Closing, fair wear and tear excepted.

  

	1.6	Option Closing 

  

	 	1.6.1	The transfer of the Transferred Real Property shall only take place on Option Closing to the extent that all necessary Property Third Party Consents in respect of the relevant transfer have been obtained prior to the
Option Closing Date. 

  

	 	1.6.2	The Purchase Price shall be paid on the Option Closing Date in accordance with this Deed even if any necessary Property Third Party Consents have not then been obtained and not all the Transferred Real Property
is transferred on the Option Closing Date. 

  

	 	1.6.3	Completion of the transfer of the Transferred Real Property shall take place at such place (or places) as the parties may agree. 

 

	1.7	Property Transfer Completion 

 Property Transfer Completion in respect of a Transferred
Real Property shall take place on the date falling 15 Business Days following the grant of all relevant Property Third Party Consents for such Transferred Real Property or on such other date as the parties shall agree acting reasonably (but not
before the Option Closing Date). 
  

	1.8	General Transfer Provisions 

  

	 	1.8.1	Novartis shall procure that the relevant members of the Novartis Group shall transfer the Transferred Real Property to the Purchaser subject to the terms set out in this Part 4 of Appendix 3 and all other applicable
terms of this Deed on the Option Closing Date or (if later) Property Transfer Completion. 

  

	 	1.8.2	The Transferred Real Property is sold subject to the Letting Documents (if any) but otherwise with vacant possession together with all buildings, structures, fixed plant, fixed machinery and fixed equipment thereon
except as excluded in Paragraph 2.3.2. 

  
  

99 

 Execution Version 
  

 

	 	1.8.3	The transfer of each Transferred Real Property shall contain covenants with the relevant Business Seller by the Purchaser to comply with: 

 

	 	(i)	the obligations arising from the matters mentioned in the Registered Title; and 

  

	 	(ii)	obligations on the part of the landlord arising under the Letting Documents (if any), 

 insofar
as the relevant Business Seller may remain liable directly or indirectly for them after the Option Closing Date or Property Transfer Completion (as the case may be) and to indemnify the relevant member of the Novartis Group against any
non-compliance and a further covenant by the Purchaser to indemnify the relevant Business Seller against any liability arising under an authorised guarantee agreement (or equivalent) entered into by the relevant member of the Novartis Group. 

 

	 	1.8.4	The transfer of each Transferred Real Property shall be on the nearest equivalent terms that exist under local (national) law to a transfer of real property in England and Wales made with full title guarantee
save that where it is a Transferred Leased Real Property the covenant set out in Section 4(2)(b) of the Law of Property (Miscellaneous Provisions) Act 1994 shall not extend to the imposition on the transferor of liability for any subsisting
breach of obligation relating to the physical state of the Transferred Leased Real Property. 

  

	 	1.8.5	On the Option Closing Date or Property Transfer Completion (as the case may be) in respect of each of the Transferred Real Properties: 

 

	 	(i)	Novartis shall procure that the relevant Business Seller delivers to the Purchaser a duly executed transfer in respect of the relevant Transferred Real Property on Property Agreed Terms; and 

 

	 	(ii)	the Purchaser shall deliver to Novartis a duly executed transfer in respect of the relevant Transferred Real Property on Property Agreed Terms. 

 

	 	1.8.6	The Purchaser shall, at its own cost and expense, procure that all transfers are duly stamped, filed or registered at the relevant registries on a timely basis and within the statutory period (if any) and the
relevant Business Seller shall promptly assist the Purchaser with any requisitions or enquiries raised in relation thereto. 

  

	1.9	Subjections 

 Notwithstanding anything contained in this Deed: 

 

	 	1.9.1	Each of the Transferred Real Properties is transferred subject to and (where appropriate) with the benefit of the following matters (to the extent applicable under the laws of the relevant jurisdiction):

  

	 	(i)	any unregistered interest which overrides first registration under Schedule 1 of the Land Registration Act 2002 (the “2002 Act”) and any interest which fall within Section 11(4)(c) of the 2002 Act
and any unregistered interests which override registered dispositions under Appendix 3 of the 2002 Act or their local jurisdiction equivalent (if any); 

  
  

100 

 Execution Version 
  

 

	 	(ii)	such unregistered interests as may affect that Transferred Real Property to the extent and for so long as they are preserved by the transitional provisions of Schedule 12 of the 2002 Act or its local jurisdiction
equivalent (if any); 

  

	 	(iii)	all matters contained or referred to in the Letting Documents; 

  

	 	(iv)	all matters contained or referred to in the Property, Proprietorship and Charges registers (or equivalent entries and registers) of the Registered Title relating to that Transferred Real Property (except fixed and
floating charges securing money or liabilities); 

  

	 	(v)	all exceptions, reservations, rights, easements, quasi-easements, wayleaves, rent charges, covenants, conditions, declarations, leases, tenancies (including statutory tenancies), licences and agreements affecting the
same; 

  

	 	(vi)	(in the case of a leasehold property) the rents, covenants and conditions reserved by or contained in the Lease under which the same is respectively held; 

 

	 	(vii)	all local land charges (whether or not registered before the date of this Deed) and all matters capable of registration as local land charges (whether or not actually registered) or their local jurisdiction equivalent
(if any); 

  

	 	(viii)	all notices served and orders, demands, proposals, or requirements made by any local or other public or competent authority; 

  

	 	(ix)	all actual or proposed orders, directions, plans, notices, instruments, charges, restrictions, conditions, agreements or other matters arising under any statute relating to town and country planning and any laws and
regulations intended to control or regulate the construction, demolition, alteration or change of use of land or buildings or to preserve or protect the environment; and 

 

	 	(x)	matters which are fairly disclosed by the Disclosure Letter. 

  

	 	1.9.2	The Purchaser is deemed to acquire with full knowledge of the matters referred to in paragraph 1.9.1 of this Part 4 of Appendix 3. 

  

	 	1.9.3	The Business Sellers shall procure that any and all financial charges affecting the Transferred Real Properties will be discharged on or before the date on which such Transferred Real Property is to be
transferred to the Purchaser, and shall provide to the Purchaser such evidence as the Purchaser may reasonably require in order to satisfy itself that such discharge has been effected and to remove any notices or entries in respect of such charges
from any relevant register. 

  

	 	1.9.4	The Business Sellers do not give any warranty as to the use or area of any of the Transferred Real Properties and shall not be required to define the boundaries of any of the Transferred Real Properties. The
transfer of the Transferred Real Properties shall not be annulled, nor shall any compensation be allowed or payable, in respect of any error in respect of any such matters. 

  
  

101 

 Execution Version 
  

 

	 	1.9.5	On the date on which the transfer of each Transferred Real Property is completed, Novartis shall deliver, to the Purchaser (or such other third party as the Purchaser may reasonably direct) all of the original documents
in the possession of the Business Sellers or relevant member of the Novartis Group in respect of each of the Transferred Real Properties. 

  

	 	1.9.6	The Purchaser shall not raise any requisition on matters arising after the date of this Deed, except where the subject matter of the requisition is registered at the Land Registry (or equivalent local registry) after
the date of this Deed and does not relate to any matter referred to in paragraph 1.9.1 of this Part 4 of Appendix 3. 

  

	 	1.9.7	To the extent that deposit guarantees have been given by the Novartis Group in respect of any Transferred Real Property and/or insofar as the Novartis Group retains any residual or ongoing liabilities or obligations
(including performance guarantees) in connection with the Transferred Real Property, the Purchaser shall use all reasonable endeavours to procure that the Novartis Group is released from all deposit guarantees and all other residual or ongoing
liabilities or obligations and, insofar as the counterparties thereto shall properly and lawfully refuse to give any such release, the Purchaser shall indemnify and keep indemnified Novartis (or the relevant member of the Novartis Group) in an
amount equal to any Liabilities under any such residual or ongoing liabilities or obligations arising out of, or in connection with, an act or omission on the part of the Purchaser. 

 

	1.10	Insurance 

 The Business Sellers shall maintain their existing insurance (if any) on the
Transferred Real Properties and shall cancel such insurance with effect from the Option Closing Date or, if later, the date of Property Transfer Completion (as the case may be) unless agreed otherwise with the Purchaser. 

 

	1.11	Grant of Sublease 

 If a Business Seller is unable to obtain a Property Third Party
Consent from a Landlord for the transfer of a Transferred Leased Real Property the provisions of this paragraph 1.11 of Part 4 of Appendix 3 shall apply: 
  

	 	1.11.1	where a Lease permits a sublease to be granted without the requirement for any Property Third Party Consent from the Landlord, the relevant Business Seller shall grant to the Purchaser a sublease of the Transferred
Leased Real Property on the same rent and other terms and conditions as the Lease of the Transferred Leased Real Property with such changes as are appropriate and agreed between the relevant Business Seller and the Purchaser acting reasonably and
the term of the sublease shall be the term of such Lease less one day; and 

  

	 	1.11.2	where the Transferred Leased Real Property is held by the relevant Business Seller from a Landlord on terms which require the consent of the Landlord to: 

 

	 	(i)	the grant of a sublease; or 

  

	 	(ii)	 the terms on which a sublease is granted, 

  
  

102 

 Execution Version 
  

Novartis or the relevant Business Seller shall use all reasonable endeavours to obtain such consent (“Sublease Consent”) from such Landlord. Where the relevant Business Seller is
able to obtain the appropriate Sublease Consent (or, where applicable, the court of competent jurisdiction referred to in paragraph 1.12.1 of this Part 4 of Appendix 3 declares that the Sublease Consent has been unreasonably withheld or delayed),
the relevant Business Seller shall grant to the Purchaser a sublease of the Transferred Leased Real Property on the same rent and other terms and conditions as the Lease of the Transferred Leased Real Property with such changes as are appropriate
and agreed between the relevant Business Seller and the Purchaser acting reasonably and the term of the sublease shall be the term of such Lease less one day. 
  

	1.12	Property Third Party Consent not obtained 

  

	 	1.12.1	If a Property Third Party Consent (and, where applicable, a Sublease Consent) has been refused or otherwise not obtained within twelve months following the Option Closing Date, Novartis and the Purchaser may (acting
reasonably) agree that an application is to be made to a court of competent jurisdiction that the relevant Property Third Party Consent has been unreasonably withheld or delayed. 

 

	 	1.12.2	If an application is to be made to a court of competent jurisdiction pursuant to paragraph 1.12.1 of this Part 4 of Appendix 3: 

  

	 	(i)	the proceedings shall be brought and prosecuted by Novartis; and 

  

	 	(ii)	the Purchaser shall provide all such assistance in connection with such proceedings as Novartis (acting reasonably) may require in the interests of obtaining the Property Third Party Consent; and 

 

	 	(iii)	provided that Novartis has complied with its obligations under paragraphs 1.3.3(i) and 1.11.2 of this Part 4 of Appendix 3, the Purchaser shall indemnify and keep indemnified Novartis for any costs and expenses properly
incurred by Novartis in bringing and prosecuting proceedings under this paragraph. 

  

	 	1.12.3	If a Property Third Party Consent has not been obtained by the Property Longstop Date then Novartis and the Purchaser shall each bear fifty per cent. of any Losses of Novartis and the Purchaser arising out of or in
connection with the failure to obtain such Property Third Party Consent. 

  

	1.13	Obligations on the Business Sellers 

 In this Part 4 of Appendix 3, any reference to an
obligation on the part of the Business Sellers (or any of them, as the case may be) shall be read as if it were an obligation on the part of Novartis to procure performance of such obligation by the Business Seller or Business Sellers in question.

  
  

103 

 Execution Version 
  

Appendix 4 
 Influenza
Group Intellectual Property Rights and Influenza Group Intellectual 
 Property Contracts 

(Paragraph 2.3) 
 [This
appendix has been intentionally left blank as at the date of this Deed. 
 This appendix shall be populated prior to the Option
Exercise Date] 
 Part 1 
 Influenza Group
Intellectual Property Rights 
 Part 2 

Influenza Group Intellectual Property Contracts 
 Part
3 
 MF59® Intellectual Property Rights 

Part 4 
 MF59® Intellectual Property Rights Contracts 

  
  

104 

 Execution Version 
  

Appendix 5 

[Intentionally Left Blank] 
  

 
  
  

  
  

105 

 Execution Version 
  

Appendix 6 

[Intentionally Left Blank] 
  

 
  
  

  
  

106 

 Execution Version 
  

Appendix 7 
 Permitted
Encumbrances 
 (Paragraph 1.1) 
  

	1	Co-owned Influenza Group Intellectual Property Rights. 

  
  

 
  

  
  

107 

 Execution Version 
  

Appendix 8 
 Product
Approvals and Product Applications 
 Part 1 

Terms relating to the Product Approvals and Product Applications 

 

	1	General Provisions 

  

	1.1	The Purchaser shall do all things necessary to effect the transfer of each Product Approval and Product Application, including complying with requirements and requests of Governmental Entities with respect to the
transfer of each Product Approval and Product Application. 

  

	1.2	The Marketing Authorisations shall be transferred in accordance with Part 2 of this Appendix 8. 

  

	2	Product Applications 

  

	2.1	The Purchaser shall file or cause to be filed applications for the transfer of each Product Application in each country or territory in which such transfer is required to be submitted as soon as possible after the
Option Closing Date. 

  

	2.2	Pending the transfer of each Product Application Novartis shall, and shall cause the relevant members of the Novartis Group to: 

  

	 	2.2.1	upon reasonable request from the Purchaser and at the Purchaser’s expense, reasonably cooperate and coordinate with the Purchaser in relation to the transfer of the Product Applications, including by providing the
Purchaser with regulatory documentation concerning the Products owned or controlled by Novartis or any of its Affiliates; 

  

	 	2.2.2	perform such acts and services as may be requested by the Purchaser that are reasonably necessary or required by any Governmental Entity to maintain or renew any Product Application or are reasonably necessary for the
Purchaser to pursue the regulatory approval for any Product Application, including conducting any studies, including clinical and stability studies, concerning the Products; and 

 

	 	2.2.3	notify the Purchaser as soon as is reasonably practicable of any written communication received by Novartis or any member of the Novartis Group with respect to any Product Application and shall consult with the
Purchaser with respect to such communication and take into account the Purchaser’s views as to the form and content of any communication with any Governmental Entity concerning such Product Application. 

 

	3	Fees and expenses 

 From and after the Option Closing Date, the Purchaser shall promptly
reimburse the relevant members of the Novartis Group for all maintenance and renewal fees and similar fees paid, and all out of pocket expenses reasonably incurred in connection with the satisfaction of any commitments or obligations by such members
of the Novartis Group with respect to each Product Approval and each Product Application. 

  
  

108 

 Execution Version 
  

	4	Notification 

 As soon as Novartis or the Purchaser or any of their respective Affiliates
receives notification, if any, of impending approval or approval of the transfer of a Product Application from a Governmental Entity, the notified party or the party whose Affiliate was notified shall inform the other party of the expected date of
appointment or transfer and actual date of appointment or transfer of that Product Application. 
  

	5	Responsibility for transfer 

 Notwithstanding any other provision of this Deed, neither
Novartis nor any of its Affiliates shall have any Liability to the Purchaser in the event that the transfer of any Product Application alone results in any further obligations, commitments or Liabilities in relation to such Product Application. 

  
  

109 

 Execution Version 
  

Appendix 8 
 Product
Approvals and Product Applications 
 Part 2 

Transfer of Marketing Authorisations 
  

	1	Marketing Authorisation Transfer and Marketing Authorisation Re-registration 

  

	1.1	Novartis and the Purchaser hereby agree they will each use, and will procure that their respective Affiliates will use, all reasonable endeavours to ensure that, as soon as reasonably practicable after the Option
Closing Date: 

  

	 	1.1.1	subject to paragraph 1.1.2, each Marketing Authorisation shall be transferred in accordance with Applicable Law by the Marketing Authorisation Holder to the Marketing Authorisation Transferee (“Marketing
Authorisation Transfer”); and 

  

	 	1.1.2	where Applicable Law does not permit Marketing Authorisation Transfer, a new marketing authorisation shall be registered in the name of the Marketing Authorisation Transferee to replace the existing Marketing
Authorisation (“Marketing Authorisation Re-registration”) and Novartis shall procure that the relevant Marketing Authorisation Holder takes all necessary steps to withdraw, abandon, cancel or allow to lapse the superseded Marketing
Authorisation as soon as practicable after the Marketing Authorisation Re-registration Date. 

  

	1.2	Any Marketing Authorisation Transfer or Marketing Authorisation Re-registration (as applicable) shall each be effected on a Market-by-Market basis (such that there shall not be any staggered Marketing Authorisation
Transfer or Marketing Authorisation Re-registration (as the case may be) on a Product-by-Product basis in any Market), unless otherwise agreed between Novartis and the Purchaser. 

 

	1.3	With effect from the Option Closing Date until the Marketing Authorisation Transfer Date or the Marketing Authorisation Re-registration Date (as applicable), Novartis shall procure that each Marketing Authorisation
Holder shall hold the Marketing Authorisation(s) in its name but for the account, risk and benefit of the relevant Marketing Authorisation Transferee. 

Submission of MA Documentation 
  

	1.4	Without prejudice to paragraph 1.5, the Purchaser shall be responsible for preparing and submitting, or for procuring that there is prepared and submitted (in any such case at the Purchaser’s cost and expense), all
notices, applications, submissions, reports and any other instruments, documents, correspondence or filings necessary to complete Marketing Authorisation Transfer or Marketing Authorisation Re-registration (as applicable) (the “MA
Documentation”). The MA Documentation shall be prepared in accordance with Applicable Law as soon as reasonably practicable. 

  

	1.5	At Novartis’s election, the Purchaser shall procure that advanced drafts of the MA Documentation are submitted to Novartis so as to allow Novartis and/or the Marketing Authorisation Holder a reasonable opportunity
to provide comments on such MA Documentation before it is submitted to the relevant Governmental Entity. The Purchaser shall incorporate all comments on such drafts as may reasonably be made by Novartis and/or the Marketing Authorisation Holder
PROVIDED THAT the Purchaser shall not be obliged to incorporate any comments if the Purchaser considers, acting reasonably that to do so would materially delay Marketing Authorisation Transfer or Marketing Authorisation Re-registration (as
applicable). 

  
  

110 

 Execution Version 
  

 

	1.6	Where under Applicable Law the MA Documentation is required to be submitted to the relevant Governmental Entity: 

  

	 	1.6.1	by the Marketing Authorisation Holder, the Purchaser shall procure that the finalised MA Documentation is provided to Novartis after such MA Documentation is finalised in accordance with paragraph 1.5 above and Novartis
shall, in turn, procure that the Marketing Authorisation Holder submits such MA Documentation to the relevant Governmental Entity (the timing and date of such submission to be agreed with the Purchaser) and Novartis shall promptly thereafter advise
the Purchaser of such submission and provide a copy of the relevant MA Documentation (in the form submitted) to the Purchaser; and 

  

	 	1.6.2	by the Marketing Authorisation Transferee, the Purchaser shall procure that the relevant Marketing Authorisation Transferee submits the finalised MA Documentation to the relevant Governmental Entity as soon as
reasonably practicable after such MA Documentation is finalised in accordance with paragraph 1.5 above and the Purchaser shall promptly thereafter advise Novartis of such submission and provide a copy of the relevant MA Documentation (in the form
submitted) to Novartis. 

  

	1.7	From the Option Closing Date, Novartis shall procure that the relevant Marketing Authorisation Holder shall, as soon as reasonably practicable, sign any notices, applications, submissions, reports and other instruments,
documents, correspondence or filings presented to it by the Purchaser or the relevant Marketing Authorisation Transferee that are necessary to effect Marketing Authorisation Transfer or Marketing Authorisation Re-registration (as applicable). The
Marketing Authorisation Holder shall: 

  

	 	1.7.1	provide notice of its consent to a Marketing Authorisation Transfer or Marketing Authorisation Re-registration if required by any Governmental Entity; 

 

	 	1.7.2	provide to the Purchaser or the relevant Marketing Authorisation Transferee any information or other data or technical or other information in its possession that relates to the relevant Marketing Authorisation and that
is required by a relevant Governmental Entity or otherwise reasonably required by the Purchaser or the relevant Marketing Authorisation Transferee to assist the Purchaser or the relevant Marketing Authorisation Transferee to effect the relevant
Marketing Authorisation Transfer or Marketing Authorisation Re-registration; and 

  

	 	1.7.3	in the event of any request for information or any query from any relevant Governmental Entity in respect of Marketing Authorisation Transfer or the Marketing Authorisation Re-registration (as applicable), the relevant
party receiving such request or query shall provide copies of any such request or query to Novartis or, as the case may be, to the Purchaser. The Purchaser shall be responsible for preparing, or shall be responsible for procuring that there is
prepared, (at the Purchaser’s cost and expense) any response to such a request or query with the intention that such request or query shall be dealt with as promptly and efficiently as possible. In advance of finalising any such response, the
Purchaser shall procure that the relevant response is submitted to the Novartis so as to allow Novartis and/or the relevant Marketing Authorisation Holder a reasonable opportunity to provide comments on such response before it is submitted to the
Governmental Entity. 

  
  

111 

 Execution Version 
  

	 	
The Purchaser shall procure that relevant Marketing Authorisation Transferee (i) shall submit the response to the relevant Governmental Entity as soon as reasonably practicable after the
same has been finalised in accordance with this paragraph 1.7.3 and (ii) shall provide a copy of the relevant response (in the form submitted) to Novartis. 

  

	2	Obligations Pending Marketing Authorisation Transfer Or Marketing Authorisation Re-Registration 

  

	2.1	Unless otherwise required by Applicable Law or a relevant Governmental Entity (or unless otherwise agreed in writing by Novartis and the Purchaser), from the Option Closing Date until the applicable Marketing
Authorisation Transfer Date or Marketing Authorisation Re-registration Date: 

  

	 	2.1.1	Novartis shall: 

  

	 	(i)	maintain in force (or procure that there is maintained in force) each Marketing Authorisation, and shall not voluntarily amend, cancel or surrender any Marketing Authorisation unless requested to do so in writing by the
Purchaser or required to do so by any Applicable Law or any Governmental Entity; 

  

	 	(ii)	with the Purchaser’s consent (not to be unreasonably withheld or delayed) progress (or procure that there is progressed) any registrations, variations or renewals to Marketing Authorisations initiated by Novartis
(or any other member of Novartis’s Group) prior to the Option Closing Date or withdraw them upon the request of the Purchaser; 

  

	 	(iii)	procure that each Marketing Authorisation Holder shall comply with the terms of any Marketing Authorisation and shall notify the Purchaser as soon as reasonably practicable of the details of any variations or renewals
initiated following the Option Closing Date; 

  

	 	(iv)	inform the Purchaser of any impending renewals of Marketing Authorisations as at the Option Closing Date and the parties shall discuss in good faith to what extent any such renewal will be pursued or withdrawn (it being
agreed that the Purchaser shall have the final decision in any such matter); 

  

	 	(v)	not without the consent of the Purchaser, initiate any additional variations or amendments to the Marketing Authorisations, except to the extent required by any Governmental Entity or where failure to do so would breach
Applicable Law; and 

  

	 	(vi)	consider in good faith any request by the Purchaser to apply for a new marketing authorisation in respect of a Product PROVIDED THAT if Novartis agrees to submit such application, any costs or expenses incurred by
Novartis in making such application shall be for the Purchaser’s account and shall constitute MA Costs; 

  
  

112 

 Execution Version 
  

 

	 	2.1.2	without prejudice to the generality of the foregoing paragraph 2.1.1(iii), the Purchaser acknowledges and agrees that each Marketing Authorisation Holder shall be entitled to do (or to procure that there is done) any or
all of the following (and the Purchaser acknowledges that, where the relevant Marketing Authorisation Holder so chooses and unless otherwise agreed, responsibility for each of the following activities shall rest with the relevant Marketing
Authorisation Holder): 

  

	 	(i)	pharmacovigilance activities related to the Marketing Authorisations, which activities shall be conducted in accordance with Applicable Law, the Pharmacovigilance Agreement and the standards, policies and procedures of
Novartis’s Group from time to time in force; and 

  

	 	(ii)	conducting any and all communications with a Governmental Entity in respect of a Marketing Authorisation (including, without limitation to the generality of the foregoing, attending any meetings with relevant
Governmental Entities and filing and submitting all reports and other documents which it reasonably considers necessary to be submitted in order to comply with Applicable Law or its obligations under this Deed), PROVIDED THAT responsibility for
(a) the costs of preparation of any such documents, reports and/or filings shall be borne by the Purchaser (or the relevant Marketing Authorisation Transferee) to the extent such costs are reasonably necessary, and (b) the submission of MA
Documentation shall be the responsibility of the Purchaser in accordance with paragraph 1.4 above, PROVIDED THAT Novartis shall ensure that the Purchaser is kept fully and promptly informed of any such communications or submissions in advance, to
the extent reasonably practicable; and 

  

	 	2.1.3	Novartis shall procure that each Marketing Authorisation Holder shall act in accordance with the reasonable instructions of the Purchaser or the Marketing Authorisation Transferee in respect of each Marketing
Authorisation in respect of which such Marketing Authorisation Holder is the holder, PROVIDED THAT no Marketing Authorisation Holder shall be obliged to comply with such instructions to the extent the same: (i) infringe the terms of the
relevant Marketing Authorisation(s); or (ii) are otherwise inconsistent with the provisions of the Pharmacovigilance Agreement relating to Novartis; 

  

	 	2.1.4	the Purchaser shall only request artwork changes to the extent such changes are required in order to comply with Applicable Law; 

  

	 	2.1.5	the Purchaser shall submit to Novartis (or shall procure that there is submitted) written details (in such form and with such supporting materials as Novartis may reasonably request) of any new, amended or proposed
advertising and promotional activity or training materials in respect of any Product Commercialised pursuant to any Marketing Authorisation (including (without limitation) any material reasonably requested by Novartis in order to validate new and/or
amended promotional or training materials), and the Purchaser acknowledges and agrees that no such advertising, promotional or training activity shall be implemented, undertaken or otherwise commenced without the prior written consent of Novartis
(for itself and on behalf of the relevant Marketing Authorisation Holder), such consent not to be unreasonably withheld. The Purchaser further agrees and acknowledges that, if it so chooses, Novartis shall be entitled to assume responsibility for
obtaining (or procuring that there is obtained) the consent(s) and approval(s) of any relevant Governmental Entity required for such new, amended or proposed advertising and promotional activity or training activity; and 

  
  

113 

 Execution Version 
  

 

	 	2.1.6	to the extent permitted by the terms of the relevant Marketing Authorisation, the Purchaser or any other member of the Purchaser’s Group shall Commercialise the Product(s) which are the subject of such Marketing
Authorisation (notwithstanding that such Marketing Authorisation is held in the name of the relevant Marketing Authorisation Holder and, for the avoidance of doubt, the proceeds of any such Commercialisation shall be for the benefit of the
Purchaser’s Group) and the Purchaser shall: 

  

	 	(i)	indemnify each member of Novartis’s Group against any and all actions, claims, demands, investigations, judgments, proceedings, liabilities, loss, damages, payments, costs and expenses arising in relation to the
Commercialisation of the Products by the Purchaser or any other member of the Purchaser’s Group under this paragraph 2.1.6; and 

  

	 	(ii)	procure that such Product(s) are Commercialised in compliance with the terms of the relevant Marketing Authorisation and/or the requirements of the relevant Governmental Entity. 

 

	3	New and Pending Marketing Authorisations in Respect of the Products 

  

	3.1	If, at any time prior to Option Closing, any member of the Novartis Group is granted or otherwise comes to hold any marketing authorisation which relates exclusively to one or more Products (a “New Marketing
Authorisation”) then: 

  

	 	3.1.1	Novartis undertakes to the Purchaser to notify the Purchaser as soon as reasonably practicable following the date on which the relevant member of Novartis’s Group is granted, or becomes entitled to, the New
Marketing Authorisation; and 

  

	 	3.1.2	the provisions of paragraphs 1 and 2 above shall apply to that new Marketing Authorisation. 

  

	3.2	Where a member of Novartis’s Group has submitted to any Governmental Entity any application relating to the grant of a new marketing authorisation in respect of the Influenza Group which is pending or in process as
at the Option Exercise Date (a “Pending Marketing Authorisation”): 

  

	 	3.2.1	Novartis shall continue to be responsible for preparation and submission of all documents required to register such Pending Marketing Authorisation but, following Option Closing, it shall do so at the Purchaser’s
cost and shall pass responsibility for such Pending Marketing Authorisation to the Purchaser (or such member of the Purchaser’s Group as the Purchaser may nominate) as soon reasonably possible after Option Closing, subject to Applicable Law;

  

	 	3.2.2	from the Option Closing Date, the provisions of paragraph 1 shall apply mutatis mutandis to any registration process for any Pending Marketing Approval. 

 

	4	MA Costs 

 From the Option Closing Date, the Purchaser shall be responsible for all
necessary costs of preparation and submission of MA Documentation and, save as expressly provided in this Deed, any other necessary costs incurred by Novartis or a member of Novartis’s Group in connection with the maintenance and any
variations, amendments and renewals of the Marketing Authorisations relating to the Products or for any matter requested by the Purchaser pursuant to this Part 2 of Appendix 8 and for all fees and costs reasonably incurred by the relevant member of
Novartis’s Group in complying with its obligations in respect of a Marketing Authorisation Transfer or Marketing Authorisation Re-registration (“MA Costs”). 

  
  

114 

 Execution Version 
  

 

	5	Obligations following Marketing Authorisation Transfer or Marketing Authorisation Re-Registration 

  

	5.1	On and from the relevant Marketing Authorisation Transfer Date or Marketing Authorisation Re-registration Date (as applicable), the Purchaser shall procure that each Marketing Authorisation Transferee shall assume and
be solely responsible for: 

  

	 	5.1.1	all obligations as the holder of such Marketing Authorisation including (subject to the terms of the Pharmacovigilance Agreement) pharmacovigilance activities related to such Marketing Authorisation; 

 

	 	5.1.2	all activities and actions required by Applicable Law in connection with such Marketing Authorisation; and 

  

	 	5.1.3	any and all outstanding commitments and obligations to the relevant Governmental Entities with respect to the relevant Marketing Authorisation, save for any such commitments or obligations arising from a breach of this
Deed by Novartis. 

  

	5.2	In the event that, following Marketing Authorisation Transfer or Marketing Authorisation Re-registration in respect of any Product, Novartis wishes to apply for a marketing authorisation in respect of a retained
product, the Purchaser shall (and shall procure that the relevant Marketing Authorisation Transferee shall) co-operate with and provide all reasonable assistance to Novartis (or the relevant member of Novartis’s Group) at Novartis’s costs
as may be reasonably required for the purposes of applying for such new marketing authorisation, including (without limitation) providing Novartis (or the relevant member of Novartis’s Group) and/or any Governmental Entity with such access to
Marketing Authorisation Data or such other data or technical or other information as is reasonably requested by the relevant Governmental Entity or is otherwise reasonably required by Novartis or the relevant member of the Novartis Group.

  
  

115 

 Execution Version 
  

Appendix 8 
 Product
Approvals and Product Applications 
 Part 3 

List of Products, Products Under Registration and Pipeline Products 

Products 
  

	1.	Aflunov 

  

	2.	Agriflu Republic of South Korea (Copy product of Agrippal) 

  

	3.	Agrippal 

  

	4.	Agrippal Pediatric 

  

	5.	Araflu for Saudi Arabia (copy product of Agrippal) 

  

	6.	Celtura 

  

	7.	Certat (Copy Product of AGRIPPAL) 

  

	8.	Dotaricin (Copy Product of FLUAD) 

  

	9.	FLUAD 

  

	10.	Fluvirin 

  

	11.	Fluxvir for Argentina (copy product of Fluad) 

  

	12.	Focetria 

  

	13.	Foclivia 

  

	14.	INFLUPOZZI ADIUVATO 

  

	15.	Influpozzi Subunità 

  

	16.	Optaflu 

  

	17.	Prepandemic Influenza vaccine (H5N1) 

  

	18.	Satixeo 

  

	19.	Vantaflu Republic of South Korea (Copy product of Fluad) 

  

	20.	Viraflu for Argentina (copy product of Agrippal) 

  

	21.	Viraflu Pediatric for Argentina (copy product of Agrippal Pediatric) 

 Products under Registration 

 

	1.	Agrippal – in Brunei and Venezuela 

  

	2.	Agrippal Pediatric – in Mexico 

  

	3.	Fluxvir Pediatric for Argentina (copy product of Fluad Pediatric) – new presentations in Argentina 

  
  

116 

 Execution Version 
  

Pipeline Products 
  

	1.	All lifecycle management programs, geographic expansion, or age extensions for Products 

  

	2.	QIV Cell Culture Influenza Vaccines 

  

	3.	Adjuvanted QIV Egg Based Influenza Vaccines 

  
  

117 

 Execution Version 
  

Appendix 8 
 Product
Approvals and Product Applications 
 Part 4 

Tenders 
 From Option Closing until the
Marketing Authorisation Transfer Date in any Market, Novartis shall, and shall procure that each member of the Novartis Group and the relevant Marketing Authorisation Holder shall, to the extent permitted by Applicable Law: 

 

	(i)	inform the Purchaser in writing of any Call for New Tender as soon as reasonably practicable following receipt; and 

  

	(ii)	co-operate with and provide reasonable assistance to the Purchaser (or the relevant member of the Purchaser’s Group) for the purposes of responding to the Call for New Tender or otherwise applying for a new tender;
and 

  

	(iii)	where Applicable Law requires such responses or applications to be made by the Marketing Authorisation Holder, Novartis shall procure that the Marketing Authorisation Holder submits such responses or applications on
behalf of the Purchaser PROVIDED THAT the Purchaser shall indemnify Novartis and/or the relevant Marketing Authorisation Holder (as the case may be) for any and all costs, expenses and liabilities suffered or reasonably incurred by Novartis and/or
the Marketing Authorisation Holder in complying with or as a result of the provisions of this paragraph. 

  
  

118 

 Execution Version 
  

Appendix 9 
 Transferred
Contracts 
 (Paragraph 2.3) 
  

	1	Separation of Shared Business Contracts 

  

	1.1	Following the Option Exercise Date and prior to Option Closing, Novartis and the Purchaser shall discuss and agree in good faith a process to identify all material Shared Business Contracts 

 

	1.2	Novartis shall use all reasonable efforts to maintain relationships under the Shared Business Contracts and continue to operate the Shared Business Contracts, including without limitation fulfilling all its obligations
under the Shared Business Contracts, in the same manner as it has for the twelve months prior to this Deed. 

  

	1.3	The Purchaser may, by notice to Novartis at any time prior to the Marketing Authorisation Transfer Date in respect of the relevant Product in the relevant territory, elect to take the rights and obligation of the
Relevant Part of any Shared Business Contract. 

  

	1.4	If the Purchaser makes an election under paragraph 1.3 above, Novartis and the Purchaser shall use all reasonable endeavours to procure that an arrangement is entered into with the relevant counterparty to each Shared
Business Contract, the effect of which shall be that, with effect from whichever is the later of Marketing Authorisation Transfer Date and the date of the relevant arrangement, the benefit and burden of the Relevant Part is severed from such Shared
Business Contract and an agreement or arrangement equivalent to such Shared Business Contract is entered into between the relevant counterparty and a member of the Purchaser’s Group (or the Relevant Part of the Shared Business Contract is
sub-licensed to such Purchaser) (a “Separation”). For the avoidance of doubt, no part of any such Shared Business Contract shall be severed and transferred to any Purchaser in so far as it relates to Novartis’s Retained
Business, any product other than the Products or any Excluded Asset. 

  

	2	Obligation to obtain Third Party Consents 

  

	2.1	In relation to any Transferred Contract (excluding, for the purposes of this Appendix 9, any US Government Contract, Product Approval or Product Application) or Transferred Intellectual Property Contract or MF59® Intellectual Property Rights Contracts or Co-Owned Influenza Group Intellectual Property Right or Transferred Plant or Equipment which is not assignable or sub-licensable without a Third Party
Consent or a Separation of a Shared Business Contract which is not separable without a Third Party Consent, this Deed, shall not be construed as an assignment, an attempted assignment, a sub-licensing or an attempted sub-licensing and Novartis and
the Purchaser shall each use reasonable endeavours both before and after Option Closing to obtain all necessary Third Party Consents as soon as possible and shall keep each other informed of progress in obtaining such Third Party Consents. Novartis
shall deliver to the Purchaser, on Option Closing or, if later, as soon as possible after receipt, any Third Party Consent. 

  

	2.2	In connection with the obtaining of any Third Party Consent referred to in paragraph 2.1, the Purchaser shall supply to Novartis such information as may be reasonably requested by Novartis or any relevant third party.

  
  

119 

 Execution Version 
  

	2.3	Save as otherwise provided in this Deed, the cost of any fee demanded by the third party as consideration for giving the Third Party Consent shall be borne by the Purchaser, provided that: 

 

	 	2.3.1	the cost is agreed in advance by the Purchaser (such agreement not to be unreasonably withheld or delayed); and 

  

	 	2.3.2	no party shall be required to bear any internal or administrative costs of the other party in relation to any Third Party Consent. 

  

	3	Obligations until Third Party Consents are obtained/where Third Party Consents are refused 

  

	3.1	Subject to paragraph 3.2, the Purchaser shall assume, carry out, perform and discharge Novartis’s and the Business Seller’s obligations arising under the Transferred Contracts, Transferred Intellectual
Property Contracts, MF59® Intellectual Property Rights Contracts, Co-Owned Influenza Group Intellectual Property Rights, Transferred Plant and Equipment and the Relevant Part of the Shared
Business Contracts as from Option Closing. 

  

	3.2	In respect of any Transferred Contract, Transferred Intellectual Property Contract, MF59® Intellectual Property Rights Contract, Transferred Plant and Equipment,
Relevant Part of Shared Business Contract or Co-Owned Influenza Group Intellectual Property Right, from Option Closing until the relevant Third Party Consent has been obtained as contemplated by paragraph 2.1 or where the Third Party Consent has
been refused: 

  

	 	3.2.1	the relevant Business Seller shall hold on trust to the extent it is lawfully able to do so or, where it is not lawfully able to do so or where holding on trust is not possible under local law or otherwise
impracticable, the relevant Business Seller and the Purchaser shall make such other arrangements between themselves to provide to the Purchaser the benefits of the Contract (other than amounts corresponding to any Tax Liability by the relevant
Business Seller in respect of amounts due under or in respect of the Transferred Contract, Transferred Intellectual Property Contract, MF59® Intellectual Property Rights Contract, Relevant
Part of Shared Business Contract, Transferred Plant and Equipment or Co-Owned Influenza Group Intellectual Property Right including the enforcement at the cost and for the account of the Purchaser of all rights of the relevant Business Seller
against any other party thereto; 

  

	 	3.2.2	to the extent that the relevant Business Purchaser is lawfully able to do so, the Purchaser shall perform the relevant Business Seller’s obligations under the Contract as agent or sub-contractor and shall indemnify
Novartis and the relevant Business Seller if the Purchaser fails to do so. To the extent that the Purchaser is not lawfully able to perform such obligations, Novartis shall procure that relevant Business Seller shall, (subject to being indemnified
by the Purchaser for any Losses Novartis or the relevant Business Seller may incur in connection therewith) do all such things as the Purchaser may reasonably require to enable due performance of the Transferred Contract, Transferred Intellectual
Property Contract, MF59® Intellectual Property Rights Contract, Transferred Plant and Equipment or Relevant Part of the Shared Business Contract and the Purchaser shall indemnify the relevant
Business Seller in respect thereof. 

  

	4	Failure to Obtain Third Party Consents 

  
  

120 

 Execution Version 
  

 

	4.1	If a Third Party Consent is refused or otherwise not obtained on terms reasonably acceptable to the Purchaser within 18 months of Option Closing, or in the case of a Separation, 18 months of the Marketing Authorisation
Transfer Date: 

  

	 	4.1.1	Novartis shall be entitled to procure the termination of the Transferred Contract, Transferred Plant and Equipment, Transferred Intellectual Property Contract,
MF59® Intellectual Property Rights Contract or Relevant Part of the Shared Business Contract and the obligations of the parties under this Deed in relation to such Transferred Contract,
Transferred Intellectual Property Contract or Relevant Part of the Shared Business Contract shall cease forthwith; 

  

	 	4.1.2	references in this Deed to the Transferred Contracts, Transferred Intellectual Property Contracts, MF59® Intellectual Property Rights Contracts, Transferred Plant
and Equipment or Relevant Part of the Shared Business Contracts and the Influenza Group Businesses (other than in this paragraph 4) shall be construed as excluding such Transferred Contract, Transferred Intellectual Property Contract, MF59® Intellectual Property Rights Contract, Transferred Plant and Equipment or Relevant Part of the Shared Business Contract; and 

 

	 	4.1.3	Novartis and the Purchaser shall use all reasonable efforts to put in place alternative arrangements so as to give the Purchaser equivalent benefits or rights as would have been enjoyed under the terminated Transferred
Contract, Transferred Intellectual Property Contract, MF59® Intellectual Property Rights Contract, Relevant Part of the Shared Business Contract or Co-Owned Influenza Group Intellectual
Property Right. 

  
  

121 

 Execution Version 
  

Appendix 10 
 Employees

 (Paragraph 2.4.1) 
  

	1	Information and consultation 

  

	1.1	At such time as the parties agree to be appropriate following the Option Exercise Date, Novartis and the Purchaser or the relevant member of the Purchaser’s Group shall jointly communicate to the Employees an
agreed notice which shall, other than to the extent the parties agree otherwise: 

  

	 	1.1.1	inform the Employees that following Option Closing those Employees who continue to be employed in the Business would be employed by the Purchaser or relevant member of the Purchaser’s Group; and 

 

	 	1.1.2	comply with the requirements of any applicable national law. 

 For the avoidance of doubt, the
parties may agree to issue such notice to different Employees or categories of Employees at different times and in different forms. 
  

	1.2	Notwithstanding the operation of paragraph 1.1 above, Novartis and the Purchaser agree to comply with any more onerous notice requirements imposed by local laws. 

 

	1.3	The Purchaser (on its own behalf and on behalf of any relevant member of the Purchaser’s Group) shall provide Novartis (for itself and any relevant member of the Novartis Group) with such information and assistance
at such times as Novartis may reasonably request or as may be reasonably necessary for Novartis or any other member of the Novartis Group to comply with any formal or informal requirement to inform or consult with the Employees, a relevant trade
union, a relevant works council, or any other employee representatives in connection with the matters contemplated by this Deed (which formal or informal requirements Novartis hereby undertakes to comply or procure compliance with). Where reasonably
necessary to ensure compliance with any formal or informal requirements or obligations to inform or consult with Employees, a relevant trade union, a relevant works council or any other employee representatives in connection with the matters
contemplated by this Deed, Novartis (for itself and for each member of the Novartis Group) and the Purchaser (for itself and for each member of the Purchaser’s Group) agree that the Purchaser or relevant member of the Purchaser’s Group
shall cooperate with and participate in any information, negotiation and/or consultation process as reasonably required by Novartis. 

  

	1.4	As soon as practicable following the Option Exercise Date, the Purchaser agrees to provide on a timely basis such information, in writing, in respect of its existing terms and conditions of employment as may reasonably
be required by Novartis so as to facilitate Novartis’s information and consultation exercise with its Employees in respect of the matters set out in this Deed. 

 

	2	Influenza Business Employees 

  

	2.1	General 

  

	 	2.1.1	The Purchaser shall (or shall procure that the relevant member of the Purchaser’s Group shall) fulfil all its duties and obligations under Applicable Law in relation to the Influenza Business Employees. Where the
provisions of local law do not provide for an automatic transfer of the employment of the Influenza Business Employees to the Purchaser or a relevant member of the Purchaser’s Group with effect from (and including) the Option Closing Date, then
paragraph 2.2 below shall apply. Where the provisions of local law do provide for an automatic transfer of employment of the Relevant Influenza Business Employees to the Purchaser or the relevant member of the Purchaser’s Group with effect from
(and including) the Option Closing Date, then paragraph 2.3 below shall apply. 

  
  

122 

 Execution Version 
  

 

	 	2.1.2	The parties acknowledge and agree that: 

  

	 	(i)	any Deferred Employee shall be treated for all purposes under this Deed as if such Deferred Employee were an Influenza Business Employee or an Influenza Group Company Employee (as appropriate); and 

 

	 	(ii)	the Purchaser’s obligations under this Appendix 10 shall apply in respect of each Deferred Employee in the same way as they do to each Influenza Business Employee or Influenza Group Company Employee (as
appropriate); and 

  

	 	(iii)	if any Deferred Employee accepts an offer of employment made by the Purchaser under paragraph 2.2.1 below or becomes an employee of an Influenza Group Company after the Option Closing Date, such Deferred Employee shall
further be treated for all purposes under this Deed as a Transferred Employee. 

  

	 	2.1.3	For the avoidance of doubt, this paragraph 2 shall not apply to any Excluded Employee, who will remain employed by Novartis or the relevant member of the Novartis Group. 

 

	2.2	Where no automatic transfer of employment 

  

	 	2.2.1	In such timescale as the parties may agree, but in any event at least 30 Business Days prior to the Option Closing Date, the Purchaser or relevant member of the Purchaser’s Group shall make an offer to each
Influenza Business Employee employed by Novartis or a member of the Novartis Group to employ him or her under a new contract of employment to commence with effect from (and including) the Option Closing Date provided that such employee continues to
be an Influenza Business Employee until the Option Closing Date. Save as otherwise agreed with Novartis (such agreement not to be unreasonably withheld), the offer to be made will be on the same terms and conditions (including as to period of
continuous employment) as were provided to that Influenza Business Employee immediately prior to the Option Closing Date. The Purchaser shall keep Novartis updated throughout the offer process on when offers are made and accepted or rejected.

  

	 	2.2.2	If the Influenza Business Employee wishes to accept the offer of employment from the Purchaser or the relevant member of the Purchaser’s Group, then Novartis shall (or shall procure that the relevant member of the
Novartis Group shall), insofar as it is permitted by Applicable Law, waive the requirement on the Influenza Business Employee concerned to give any period of notice of termination of his or her employment under the terms of his or her employment so
as to allow the Influenza Business Employee to commence employment with the Purchaser or relevant member of the Purchaser’s Group with effect from (and including) the Option Closing Date. 

  
  

123 

 Execution Version 
  

 

	2.3	Where automatic transfer of employment 

 If the Transfer Regulations do not or are found
not to or are alleged not to apply to any person who is a Relevant Influenza Business Employee and to whom paragraph 2.2 does not apply, the Purchaser agrees that following Option Closing: 

 

	 	2.3.1	in consultation with Novartis, the Purchaser or relevant member of the Purchaser’s Group shall within 10 Business Days of being so requested by Novartis (as long as the request is made no later than 3 months after
Option Closing) (or if the Purchaser so chooses), make such Relevant Influenza Business Employee an offer in writing to employ him or her under a new contract of employment subject to, and to take effect upon, a date agreed between the parties and
such employee; and 

  

	 	2.3.2	save as otherwise agreed with Novartis (such agreement not to be unreasonably withheld) the offer to be made will be on the same terms and conditions (including as to period of continuous employment) as were provided to
that Relevant Influenza Business Employee immediately prior to the Option Closing Date. 

  

	3	Wrong-pocket arrangements for persons other than Relevant Employees 

  

	3.1	If the contract of employment of any person other than a Relevant Employee is found or alleged to have effect upon Option Closing as if originally made with the Purchaser or another member of the Purchaser’s Group
(including any Influenza Group Company) as a consequence of this Deed, or if any Influenza Group Company employs any person who does not work wholly or substantially in the Business, Novartis agrees that following Option Closing: 

 

	 	3.1.1	in consultation with the Purchaser, Novartis or relevant member of the Novartis Group may within 10 Business Days of being so requested by the Purchaser (as long as the request is made no later than 3 months after
Option Closing) (or if Novartis so chooses), make to that person an offer in writing to employ him or her under a new contract of employment subject to, and to take effect upon, the termination referred to below; and 

 

	 	3.1.2	the offer to be made will be on the same terms and conditions (including as to period of continuous employment) as were provided to that person immediately prior to the Option Closing Date. 

 

	3.2	After the expiry of the 10 Business Days referred to at paragraph 3.1 above, and provided that the relevant member of the Purchaser’s Group takes such steps as are legally possible to terminate the employment of
the person concerned as soon as reasonably practicable after becoming aware of the finding or allegation referred to at paragraph 3.1 above (either by giving notice or transferring the person by agreement to be concluded between the relevant member
of the Purchaser’s Group, the person concerned and the relevant member of the Novartis Group), Novartis shall be responsible for and shall indemnify and keep indemnified the Purchaser (for itself and as trustee for any relevant member of the
Purchaser’s Group) against all Losses from time to time made, suffered or incurred by the Purchaser (or any other member of the Purchaser’s Group) as a result of: 

 

	 	3.2.1	the actual or alleged transfer to a member of the Purchaser’s Group and (regardless of whether there has been such a transfer) any employment liabilities relating to such person; 

  
  

124 

 Execution Version 
  

 

	 	3.2.2	employing such person on and from the Option Closing Date until such termination (up to the time reasonably expected to have achieved such termination in accordance with the terms of the contract of employment and
Applicable Law) but subject to a maximum period of 6 months unless prevented by the terms of the contract of employment or Applicable Law; and 

  

	 	3.2.3	such termination. 

  

	3.3	The parties agree to co-operate in good faith to minimise the Losses which are subject to the indemnity referred to in paragraph 3.2 above.  

 

	4	Employment liabilities 

  

	4.1	All wages, salaries, employer’s liabilities in respect of associated Taxes and other periodic outgoings in respect of the Transferred Employees which relate to a period: 

 

	 	4.1.1	after the Option Closing Date shall be borne or discharged by the Purchaser or relevant member of the Purchaser’s Group; and 

  

	 	4.1.2	on or before the Option Closing Date shall be borne or discharged by Novartis or relevant member of the Novartis Group. 

  

	4.2	Novartis shall (for itself and for each member of the Novartis Group) indemnify and keep indemnified the Purchaser (for itself and as trustee for each other member of the Purchaser’s Group) against all
Losses (ignoring any amount in respect of Employee Benefits, as to which see Appendix 11) in respect of: 

  

	 	4.2.1	the employment of any Employee at any time prior to the Option Closing Date (excluding any Transferred Employee Benefit Liabilities (as defined in Appendix 11) which the Purchaser agrees to assume in accordance with
Appendix 11); 

  

	 	4.2.2	any termination of the employment of any Employees prior to the Option Closing Date including, but not limited to, all claims relating to severance, termination pay, pay in lieu of notice of termination and similar
obligations (excluding any liability arising directly as a result of any breach of the commitments set out in paragraph 5 or 6 below by the Purchaser or a member of the Purchaser’s Group and any act or omission by the Purchaser or any member of
the Purchaser’s Group in relation to any Employee before Option Closing as a result of which that Employee treats his employment as having been terminated prior to the Option Closing Date); 

 

	 	4.2.3	any amount which becomes payable to any Employee or benefit to which any Employee becomes entitled by reason of this Deed or the matters it contemplates, including any change of control or other payment or benefit (and
including any enhancement of severance terms on a subsequent termination of employment but excluding any Losses relating to any share-based incentive schemes, as to which see paragraph 11 below); 

 

	 	4.2.4	any failure by Novartis or any other member of the Novartis Group to comply with any obligation to inform or consult with employee representatives in connection with the matters contemplated by this Deed (other than as
a result of any failure set out in paragraph 4.3.3 below); and 

  
  

125 

 Execution Version 
  

 

	 	4.2.5	any breach by Novartis or any other member of the Novartis Group of paragraph 4.1.2 above or paragraph 4.4, 4.5 or 10 below. 

  

	4.3	The Purchaser shall (for itself and for each member of the Purchaser’s Group) indemnify and keep indemnified Novartis (for itself and as trustee for each other member of the Novartis Group) against all
Losses (ignoring any amount in respect of Employee Benefits, as to which see Appendix 11) in respect of: 

  

	 	4.3.1	the employment of any of the Transferred Employees on and after the Option Closing Date (including, without limitation, any changes to terms and conditions of employment by the Purchaser or any other member of the
Purchaser’s Group); 

  

	 	4.3.2	any termination of the employment of any Transferred Employees on and after the Option Closing Date including, but not limited to, all claims relating to severance, termination pay, pay in lieu of notice of termination
and similar obligations except as contemplated under paragraph 3.2 above; 

  

	 	4.3.3	any failure by the Purchaser or any other member of the Purchaser’s Group to provide information and reasonable assistance to Novartis to enable Novartis or any other member of the Novartis Group to comply with any
obligation to inform or consult with employee representatives in connection with the matters contemplated by this Deed; 

  

	 	4.3.4	any breach by the Purchaser or any other member of the Purchaser’s Group of paragraph 4.1.1 above or paragraph 4.4 or 4.5 below; and 

 

	 	4.3.5	any act or omission by the Purchaser or any member of the Purchaser’s Group in relation to any Employee before Option Closing as a result of which that Employee treats his employment as having been terminated prior
to the Option Closing Date. 

  

	4.4	Any amount payable to or in respect of any Transferred Employee after Option Closing (including without limitation amounts paid under paragraph 4.5 below) which (ignoring vesting conditions and any amount payable
in respect of Employee Benefits or otherwise in accordance with Appendix 11) is referable to the period prior to Option Closing is payable by Novartis (for itself or on behalf of the relevant Share Seller or Business Seller). Responsibility for
amounts payable which are only partly referable to the period prior to Option Closing (again ignoring vesting conditions) is to be shared between Novartis (for itself or on behalf of the relevant Share Seller or Business Seller) and the Purchaser
(for itself or on behalf of the relevant member of the Purchaser’s Group) such that Novartis bears S per cent. of the cost and the Purchaser bears P per cent., where S is the percentage of the period by reference to which
the amount was earned which fell on or before the Option Closing Date and P is the percentage of that period which falls after the Option Closing Date. The Purchaser shall, or shall procure that such other member of the Purchaser’s Group
shall, pay such amounts when due to the relevant Transferred Employees on or after Option Closing and shall deduct and/or pay and account for any Tax payable or accountable for by the employer in respect of such amounts. Novartis covenants to
reimburse the Purchaser in respect of any such amount (or S per cent. of it where relevant), including any Tax payable or accountable for by the employer in respect of such amount, within 30 days of receiving notification that it has been paid to
the extent such amounts are not reflected in the Option Closing Statement. Novartis will provide the Purchaser with all information and documentation reasonably necessary to allow such payments to be made. 

  
  

126 

 Execution Version 
  

 

	4.5	Following the Option Closing Date: 

  

	 	4.5.1	the Purchaser shall, or shall procure that a member of the Purchaser’s Group shall, pay a pro-rated cash bonus of an amount advised by Novartis to the Purchaser to each Transferred Employee who participated in an
annual cash bonus plan immediately before the Option Closing Date in their first payroll payment after the Option Closing Date; and 

  

	 	4.5.2	where Novartis is able to determine performance, any such bonus payment made to such eligible employees by the Purchaser or a member of the Purchaser’s Group will be based on Novartis’s determination of
performance to the Option Closing Date and pro-rated to the Option Closing Date; or 

  

	 	4.5.3	where Novartis is unable to determine performance (either business or individual), for example, because the Option Closing Date occurs near the start of the bonus year, Novartis shall calculate any such bonus payment
based on a deemed achievement of performance conditions at target level pro-rated to the Option Closing Date; and 

  

	 	4.5.4	as soon as reasonably practicable after the Option Closing Date, the Purchaser shall, or shall procure that such other member of the Purchaser’s Group shall, provide such information as Novartis requires in order
for Novartis to calculate the Tax payable or accountable for by the employer in respect of such bonus payments; and 

  

	 	4.5.5	the Purchaser shall, or shall procure that such other member of the Purchaser’s Group shall, deduct and/or account for any Tax payable or accountable for by the employer in respect of such bonus payments; and

  

	 	4.5.6	Novartis shall reimburse the Purchaser for the aggregate bonuses advised by Novartis to the Purchaser which are paid pursuant to this paragraph 4.5 along with the employer’s social security contributions due in
respect of such payments to the extent such amounts are not reflected in the Option Closing Statement. 

  

	5	Protection of terms and conditions and termination rights post-Option Closing 

  

	5.1	Without prejudice to paragraph 5.4 below, the Purchaser shall procure that for a period of 24 months following the Option Closing Date: 

 

	 	5.1.1	each Transferred Employee will (for so long as such Transferred Employee continues in the same role with any member of the Purchaser’s Group save that the Purchaser shall not seek to demote any Transferred Employee
to avoid the application of this provision) continue to receive at least the same basic salary; 

  
  

127 

 Execution Version 
  

 

	 	5.1.2	each Transferred Employee will continue to receive contractual benefits (but excluding Employee Benefits and any share-based incentive schemes or other long-term incentive plans) which the Purchaser reasonably considers
to be substantially comparable, taken as a whole, to the contractual benefits (but excluding Employee Benefits and any share-based incentive schemes or other long term incentive plans) of such Transferred Employee immediately prior to the Option
Closing Date; and 

  

	 	5.1.3	no Transferred Employee will suffer a change to his overall employment terms (whether contractual or otherwise) and including, without limitation, any related to length of service (but excluding Employee Benefits and
any share-based incentive schemes or other long-term incentive plans), which, when taken as a whole viewed in the round (including to the extent relevant alongside any other changes being made at the same time to that Transferred Employee’s
employment terms), would in the Purchaser’s reasonable opinion acting in good faith be regarded as materially detrimental. 

  

	5.2	The Purchaser confirms that, following the Option Closing Date and for so long as the Transferred Employees continue in the employment of any member of the Purchaser’s Group, the Transferred Employees will be
eligible to participate in those share-based incentive schemes or other long-term incentive plans that are operated by the Purchaser or relevant members of the Purchaser’s Group from time to time for employees of equivalent status, subject
always to the rules of such share-based incentive schemes or long-term incentive plans and any qualifying conditions. 

  

	5.3	Novartis shall provide or shall cause to be provided to any member of the Purchaser’s Group such information reasonably requested in writing by any member of the Purchaser’s Group to enable the Purchaser to
comply with its obligations in paragraph 5.1 above. 

  

	5.4	If the employment of any Transferred Employee is terminated by reason of redundancy within 24 months following the Option Closing Date, the Purchaser shall procure that there shall be provided to such Transferred
Employee benefits which are equivalent to those provided under such redundancy and severance policies and benefits (whether contractual or otherwise and giving due credit to the Transferred Employees for any additional service or earnings from the
Option Closing Date onwards) (but excluding Employee Benefits) as were applicable in respect of the particular Transferred Employee immediately prior to the Option Closing Date, to the extent that such policies and benefits are notified in writing
to the Purchaser prior to the Option Closing Date. If, at any time during the 24 month period immediately following the Option Closing Date, the Purchaser places any Transferred Employee into a redundancy selection process, the Purchaser undertakes
that, in determining such selection, it will or will procure that the relevant member of the Purchaser’s Group will take no account of the costs of dismissal of any person within the relevant selection pool (including such Transferred
Employee). 

  
  

128 

 Execution Version 
  

 

	5.5	For the avoidance of doubt, the provisions of this paragraph 5 are without prejudice to the operation of any rule of law in relation to the terms and conditions of employment of the Transferred Employees.

  

	6	Benefits arrangements/service continuity 

  

	6.1	Each Transferred Employee shall have their service with the Novartis Group and their respective predecessors recognised under any employee benefit plans or arrangements of the Purchaser’s Group for all
purposes of eligibility, vesting and accrual of benefits to the extent past service was recognised for such Transferred Employee under a comparable plan or arrangement immediately prior to the Option Closing Date. Notwithstanding the foregoing,
nothing in this paragraph 6.1 shall be construed to require recognition of service for the purposes of calculation of Employee Benefits or that would result in: 

 

	 	6.1.1	any additional liability being assumed by the Purchaser’s Group in respect of Employee Benefits other than subject to and in accordance with the provisions of Appendix 11; 

 

	 	6.1.2	duplication of benefit; 

  

	 	6.1.3	recognition of service for any purposes under any plan or arrangement for which participation, service and/or benefits accrual is frozen or any post-retirement medical plan; or 

 

	 	6.1.4	recognition of service under a newly established plan or arrangement for which prior service is not taken into account for employees of the Purchaser’s Group generally. 

 

	6.2	Without limiting the foregoing, with respect to the Transferred Employees, the Purchaser shall, or shall cause such other member of the Purchaser’s Group to, be responsible for all paid time off benefits,
including vacation pay, sick pay, banked leave, flexitime and other payments for time off of normal work hours accrued by the Transferred Employees up to the Option Closing Date, provided that, if the value of such matters (excluding normal accrued
but untaken annual leave for the year current as at Closing) would exceed US$7.5 million if accrued for in a balance sheet in accordance with IFRS, then Novartis shall compensate the Purchaser for such matters (again excluding normal accrued but
untaken annual leave for the year current as at Option Closing) by paying the Purchaser an amount equal to that value, less any amount actually accrued and transferred to the Purchaser for such matters. 

  
  

129 

 Execution Version 
  

 

	6.3	With respect to any welfare plan maintained by the Purchaser or any other member of the Purchaser’s Group in which Transferred Employees are eligible to participate after the Option Closing Date, the
Purchaser shall: 

  

	 	6.3.1	waive all limitations as to pre-existing conditions, exclusions, evidence of insurability provisions, waiting periods with respect to such participation and coverage requirements or similar provisions under a
Purchaser’s benefit plans that are welfare plans (as defined in section 3(1) of ERISA or any equivalent Applicable Law) applicable to such employees to the extent such conditions, exclusions and waiting periods or other provisions were
satisfied or did not apply to such employees under welfare plans maintained by Novartis or other members of the Novartis Group prior to the Option Closing Date; and 

 

	 	6.3.2	provide each Transferred Employee with credit for any co-payments and deductibles paid prior to the Option Closing Date in satisfying any analogous deductible or out-of-pocket requirements to the extent
applicable under any such plan in the year in which Option Closing occurs, to the extent credited under the welfare plans maintained by Novartis or other members of the Novartis Group prior to the Option Closing Date. 

 

	7	US Transferred Employees 

  

	7.1	To the extent the Purchaser or any other member of the Purchaser’s Group maintains a health care and dependent care flexible spending account arrangement pursuant to section 125 or 129 of the Code
(collectively, “FSAs”), the Purchaser will use commercially reasonable efforts to honour the elections of all Transferred Employees who are employed in the United States and/or covered by US Benefit Plans (“US Transferred
Employees”) under the FSAs of any relevant member of the Novartis Group (“Relevant Employer’s FSAs”), as in effect immediately prior to the Option Closing Date, and the Purchaser will use commercially reasonable
efforts to assume responsibility for administering all reimbursement claims of US Transferred Employees with respect to the calendar year in which the Option Closing Date occurs that are submitted for payment on or after the Option Closing Date,
whether arising before, on or after the Option Closing Date, under the Purchaser’s FSAs. As soon as practicable but no more than 45 days following the Option Closing Date, Novartis will cause to be transferred to the Purchaser an amount in cash
equal to (i) the sum of all contributions to the Relevant Employer’s FSAs with respect to the calendar year in which the Option Closing Date occurs by or on behalf of the US Transferred Employees prior to the Option Closing Date, reduced
by (ii) the sum of all claims incurred in the calendar year in which the Option Closing Date occurs that are submitted to the Relevant Employer for payment prior to the Option Closing Date and paid by the Relevant Employer’s FSAs with
respect to such US Transferred Employees prior to the date of such cash transfer to the Purchaser; provided, however, if this calculation results in a negative number, then the Purchaser will pay to Novartis (on behalf of the Relevant Employer) as
soon as practicable following the end of the calendar year in which the Option Closing Date occurs, the amount by which (ii) exceeds (i). 

  
  

130 

 Execution Version 
  

 

	7.2	With effect on and from the Option Closing Date, the Purchaser shall, or shall procure that such other members of the Purchaser’s Group shall, assume the responsibility and obligation to provide COBRA continuation
coverage to all US Transferred Employees whose employment is terminated after the Option Closing Date and their eligible dependents. 

  

	8	Shared Employees 

 After the date of this Deed, Novartis shall identify any Shared
Employees who work wholly or substantially in the Business but who are not Influenza Group Company Employees or Influenza Business Employees. In consultation with the Purchaser, Novartis will procure that an Influenza Group Company will offer
employment to any such employee before the Option Closing Date, to take effect from immediately before the Option Closing Date (provided that such employee continues to work wholly or substantially in the Business until the Option Closing Date) or,
where that is not reasonably practicable or there is no Influenza Group Company in the country in which the employee works, the Purchaser shall treat such employee as if he or she were an Influenza Business Employee (provided that such employee
continues to work wholly or substantially in the Business until the Option Closing Date) and the provisions of this Appendix 10 will apply to him or her and further provided, however, that these arrangements will apply to no more than 10 full time
equivalent employees. 
  

	9	International Assignees 

 Where Applicable Law does not provide for the automatic
transfer of employment of any International Assignee and/or the other terms governing their international assignment, the Purchaser shall assume and agree to be bound by the individual contract of employment and such other terms governing their
international assignment including any tax equalisation agreement entered into between an International Assignee and a member of the Novartis Group provided that such employee becomes a Transferred Employee and Novartis has disclosed to the
Purchaser the template international assignment terms of the Novartis Group prior to the Option Closing Date. 

  
  

131 

 Execution Version 
  

 

	10	Liability for retention arrangements 

 Novartis or any other member of the Novartis Group
has or will put in place certain retention arrangements (in the form of cash) to retain key employees in connection with the matters contemplated by this Deed. To the extent that details of such retention arrangements are disclosed to the Purchaser
prior to the Option Closing Date, and in respect of arrangements put in place after the date of this Deed, with the agreement of the Purchaser, the Purchaser shall, or shall procure that such other member of the Purchaser’s Group shall, make
the cash retention payments when due to the relevant Transferred Employees on or after Option Closing and shall deduct and/or pay and account for any Tax payable or accountable for by the employer in respect of such cash payments. Novartis covenants
to reimburse the Purchaser in respect of any cash retention payments, whether or not disclosed (including any Tax payable or accountable for by the employer in respect of such payments), which are put in place prior to the Option Closing Date.
Novartis acknowledges that the Purchaser may ask Novartis to put in place more generous retention arrangements than those proposed by Novartis (including, where practicable, putting in place retention arrangements which last for a period of at least
six months following Option Closing) and will not unreasonably withhold consent to such arrangements provided that any incremental cost of such arrangements over and above the cost of Novartis’s own proposals will be for the Purchaser’s
account. Novartis will provide the Purchaser with all information and documentation reasonably necessary to allow such payments to be made. 
  

	11	Share-based incentive schemes 

  

	11.1	This paragraph 11 applies notwithstanding any other provision of this Deed. 

  

	11.2	Subject to paragraph 11.10, Novartis undertakes to use its best endeavours to ensure that share-based awards held by Transferred Employees pursuant to a share-based incentive scheme operated by Novartis or another
member of the Novartis Group (“Relevant Awards”) shall be treated in a manner consistent with the “good leaver treatment” in the share-based incentive schemes operated by the Purchaser, to the extent possible under the
relevant plan rules and any Applicable Law. Where Relevant Awards are subject to performance (or other) conditions and it is not possible to determine whether or not such conditions have been met at the applicable early vesting date (or within a
reasonable period thereafter), Novartis and the Purchaser agree that performance shall be deemed “on target”. 

  
  

132 

 Execution Version 
  

For the avoidance of doubt: 
  

	 	(A)	where necessary and subject to (B), Novartis shall rely on the exercise of existing discretions in the relevant plan rules and (provided the approval of Novartis’s shareholders is not required) shall be expected to
amend the relevant plan rules to achieve the “good leaver treatment”; 

  

	 	(B)	Novartis (or relevant member of the Novartis Group) shall not take any action which would require shareholder approval or which could trigger any significant legal, Tax or operational issues for the relevant Transferred
Employee (including the loss of any Tax-favourable treatment), the Novartis Group or the Purchaser’s Group. 

 For the
purposes of this paragraph 11.2, the “good leaver treatment” shall be that: 
  

	 	(C)	Relevant Awards shall not lapse or be forfeited as a result of Option Closing except to the extent that they do not vest in accordance with (D) and/or (E) below; 

 

	 	(D)	Relevant Awards shall vest early as a result of Option Closing and shall be time pro-rated to take account of the reduced period of time, as a proportion of the original vesting period, that the relevant Transferred
Employee worked within the Novartis Group (calculated on the basis of the number of years of service as at the Option Closing Date, where part years of service are rounded up); and 

 

	 	(E)	Relevant Awards that vest after the Option Closing Date shall remain subject to any relevant performance (or other) conditions, adjusted as necessary to take account of Option Closing and measured up to the applicable
early vesting date. 

 For the purposes of this paragraph 11.2, “on target” performance shall not be construed as
permitting share-based awards to vest in full. 
  

	11.3	Novartis agrees to indemnify the Purchaser (or relevant member of the Purchaser’s Group) for any Liabilities borne by the Purchaser’s Group in connection with the Relevant Awards, including any Tax. The
Purchaser agrees to use its best endeavours to seek any applicable Tax relief in respect of the Relevant Awards and to indemnify Novartis in respect of any Tax relief obtained provided always that Novartis provides the Purchaser with any information
that the Purchaser may reasonably request in this respect in a timely manner. 

  
  

133 

 Execution Version 
  

 

	11.4	Subject to paragraph 11.5, Novartis undertakes to inform the Purchaser of the vesting or exercise (as applicable) of the Relevant Awards and to provide, in a timely manner, details of the Relevant Awards that so
vest or are exercised so that the Purchaser’s Group can make any applicable withholdings for Tax and to pay any Tax for which the Purchaser’s Group is liable in respect of the Relevant Awards to the relevant Tax Authority within any
applicable timescale. 

  

	11.5	To the extent permitted under the relevant plan rules and any Applicable Law, Novartis undertakes to sell such number of the shares underlying the Relevant Awards as may be necessary for the sale proceeds to
satisfy any applicable Tax withholdings and to pay such amounts to the Purchaser in sufficient time for the Purchaser to pay such Tax to the relevant Tax Authority within any applicable timescale, provided always that the Purchaser provides Novartis
with any information that Novartis may reasonably request in this respect in a timely manner. 

  

	11.6	Novartis undertakes to procure that each relevant member of the Novartis Group will pay any Tax for which such member is liable in respect of the Relevant Awards to the relevant Tax Authority within any
applicable timescale. 

  

	11.7	Novartis undertakes to procure the completion of any relevant Tax Return in respect of the Relevant Awards and to procure the submission of any such Tax Return to the relevant Tax Authority within any applicable
timescale. 

  
  

134 

 Execution Version 
  

 

	11.8	This paragraph shall apply where Relevant Awards lapse or are forfeited (or will lapse or be forfeited) either in whole or in part as a result of Option Closing. As soon as practicable following Option Closing
(and, in any event, by the later of 30 days from the Option Closing Date and 30 days from the first date after the Option Closing Date when the granting of share-based awards is not prevented by dealing restrictions, subject in both cases to the
relevant plan rules and any Applicable Law), the Purchaser (or member of the Purchaser’s Group) shall grant each relevant Transferred Employee a share-based award over shares in the capital of the Purchaser substantially equal in value (valued
as at the date of grant) to the value of the portion of their Relevant Awards which lapsed or was forfeited (or will lapse or be forfeited) as a result of Option Closing (valued as at the Option Closing Date), where relevant, disregarding any loss
(or expected loss) of Tax-favourable treatment (each a “Compensation Award”). To the extent that (i) it could reasonably have been expected that any related matching share award and/or free share award would have been granted
to a Transferred Employee following Option Closing in connection with any Relevant Award which lapsed or was forfeited (or will lapse or be forfeited) as a result of Option Closing (each a “Relevant Matching Award”), and
(ii) such Relevant Matching Award has not been granted (or will not be granted) as a result of Option Closing, on or around the date on which such Relevant Matching Award would, in the ordinary course of business, have been made by Novartis (or
a member of the Novartis Group), the Purchaser (or member of the Purchaser’s Group) shall grant each relevant Transferred Employee a share-based award over shares in the capital of the Purchaser substantially equal in value (valued as at the
date of grant) to the value of such Relevant Matching Award (valued as at the date of grant of the related Matching Award, defined below), where relevant, disregarding any loss (or expected loss) of Tax-favourable treatment (each a “Matching
Award”), subject to the relevant plan rules and any Applicable Law. 

 Such Compensation Awards shall be granted
pursuant to the rules of whichever share-based incentive plan operated by the Purchaser’s Group at the time of grant the Purchaser considers most closely aligned to the share-based incentive plan operated by the Novartis Group pursuant to which
the related Relevant Award had been granted (or related Relevant Matching Award would have been granted) but will vest according to a vesting schedule substantially similar to the vesting schedule that would have otherwise applied to the related
Relevant Award or related Relevant Matching Award if Option Closing had not occurred. In such cases: 
  

	 	(a)	the Purchaser undertakes to seek any applicable Tax relief in respect of the Compensation Awards and Matching Awards and to indemnify Novartis in respect of 50 per cent of any Tax relief obtained, provided always
that Novartis provides the Purchaser with any information that the Purchaser may reasonably request in this respect in a timely manner; 

  

	 	(b)	where a Compensation Award or Matching Award is granted in the form of a restricted share award, the Purchaser undertakes to obtain a valid election pursuant to section 431 of the Income Tax (Earnings and Pensions) Act
2003 (or, as applicable, any similar Tax election that is available pursuant to any Applicable Law in another jurisdiction), provided that, if either party makes representations to the other party to waive this obligation in respect of certain
Compensation Awards or certain Matching Awards and the other party consents to such waiver (such consent not to be unreasonably withheld), this paragraph (b) shall not apply in respect of such Compensation Awards or Matching Awards; and

  
  

135 

 Execution Version 
  

 

	 	(c)	Novartis agrees to indemnify the Purchaser (or relevant member of the Purchaser’s Group) for any Liabilities borne by the Purchaser’s Group in connection with such Compensation Awards and Matching Awards,
including any Tax, provided that: 

  

	 	(i)	Novartis shall not indemnify the Purchaser (or relevant member of the Purchaser’s Group) to the extent that the Purchaser (or member of the Purchaser’s Group) compensates Transferred Employees for any loss (or
expected loss) of Tax-favourable treatment in respect of Relevant Awards or for any Liabilities to Tax as contemplated in paragraph 11.9 below; and 

  

	 	(ii)	Novartis only agrees to indemnify the Purchaser (or member of the Purchaser’s Group) to a maximum of 50 per cent of the total of (i) the value of the portion of such Relevant Awards that lapsed or was
forfeited (or will lapse or be forfeited) as a result of Option Closing, (ii) the value of the Relevant Matching Awards, and (iii) any related Liabilities, including any Tax; 

 

	 	(iii)	for the avoidance of doubt, Novartis shall not indemnify the Purchaser (or any member of the Purchaser’s Group) for any lapse or forfeiture (or expected lapse or forfeiture) due to a failure to meet any applicable
performance (or other) conditions. 

 For these purposes, the compensation in respect of the portion of a Relevant Award which
lapsed or was forfeited (or will lapse or be forfeited) as a result of Option Closing shall not exceed the difference between (i) the value of the Relevant Award which could reasonably have been expected to vest on the normal vesting date but
for Option Closing (subject, where applicable, to performance (or other) conditions), and (ii) the value of the Relevant Award which actually vested (or will vest) as a result of Option Closing. 

For the purposes of this paragraph 11.8: 
  

	 	(a)	the portion of a Relevant Award which lapsed or was forfeited (or will lapse or be forfeited) as a result of Option Closing shall be valued on the basis of the average price of an ordinary share in the capital of
Novartis over the five trading days immediately prior to Option Closing; 

  

	 	(b)	the value of a Compensation Award to be granted shall be valued on the basis of the average price of an ordinary share in the capital of the Purchaser over the five trading days immediately prior to the date of grant;

  

	 	(c)	the value of a Relevant Matching Award shall be valued on the basis of the average price of an ordinary share in the capital of Novartis over the five trading days immediately prior to the date of grant of the related
Matching Award; 

  

	 	(d)	the value of a Matching Award to be granted shall be valued on the basis of the average price of an ordinary share in the capital of the Purchaser over the five trading days immediately prior to the date of grant; and

  

	 	(e)	any currency conversion shall be made in accordance with Clause 1.10 of this Deed. 

  
  

136 

 Execution Version 
  

 

	11.9	To the extent that any payment to a Transferred Employee (whether by the Novartis Group or by the Purchaser’s Group) would trigger Liabilities to Tax under section 280G of the United States Internal Revenue
Code (“Section 280G”), the relevant Transferred Employee shall be allowed to choose whether to accept the full payment (and pay any relevant Section 280G Tax) or to receive such lower payment as may be necessary in order
to fall below the Section 280G threshold for Tax. To the extent that any similar Tax would arise pursuant to any Applicable Law in another jurisdiction, this paragraph 11.9 shall apply mutatis mutandis.

  

	11.10	This paragraph shall apply where: (i) a Transferred Employee would, in the ordinary course of business, have been granted a share-based award pursuant to a share-based incentive scheme operated by Novartis
or another member of the Novartis Group on the basis of performance criteria linked to the Novartis Group’s 2014 financial year (which may, for the avoidance of doubt, be business and/or individual performance criteria and assessment) (each a
“2014 Performance Award”), and (ii) Option Closing occurs prior to the grant of such 2014 Performance Award. As soon as practicable following Option Closing (and, in any event, by the later of 30 days from the Option Closing
Date and 30 days from the date when the value of each 2014 Performance Award has been determined), Novartis shall notify the Purchaser in writing of the value of each 2014 Performance Award and under which share-based incentive plan operated by the
Novartis Group the related 2014 Performance Award would have been granted. As soon as practicable following the receipt of such notice (and, in any event, by the later of 30 days from the receipt of such notice and 30 days from the first date
following the receipt of such notice when the granting of share-based awards is not prevented by dealing restrictions, subject in both cases to the relevant plan rules and any Applicable Law), the Purchaser (or member of the Purchaser’s Group)
shall grant each relevant Transferred Employee a share-based award over shares in the capital of the Purchaser substantially equal in value (valued as at the date of grant) to the value of the 2014 Performance Award which would have been granted but
for the occurrence of Option Closing. Such 2014 Performance Awards shall be granted pursuant to the rules of whichever share-based incentive plan operated by the Purchaser’s Group at the time of grant the Purchaser considers most closely
aligned to the share-based incentive plan operated by the Novartis Group pursuant to which the related 2014 Performance Award would have been granted. In such cases: 

 

	 	(a)	the Purchaser undertakes to seek any applicable Tax relief in respect of the 2014 Performance Awards and to indemnify Novartis in respect of any Tax relief obtained, provided always that Novartis provides the Purchaser
with any information that the Purchaser may reasonably request in this respect in a timely manner; 

  

	 	(b)	where a 2014 Performance Award is granted in the form of a restricted share award, the Purchaser undertakes to obtain a valid election pursuant to section 431 of the Income Tax (Earnings and Pensions) Act 2003 (or, as
applicable, any similar Tax election that is available pursuant to any Applicable Law in another jurisdiction), provided that, if either party makes representations to the other party to waive this obligation in respect of certain 2014 Performance
Awards and the other party consents to such waiver (such consent not to be unreasonably withheld), this paragraph (b) shall not apply in respect of such 2014 Performance Awards; and 

  
  

137 

 Execution Version 
  

	 	(c)	Novartis agrees to indemnify the Purchaser (or relevant member of the Purchaser’s Group) for any Liabilities borne by the Purchaser’s Group in connection with such 2014 Performance Awards, including any Tax.

 The grant of a 2014 Performance Award to a Transferred Employee shall be taken into account by the Purchaser when
determining the extent to which that Transferred Employee shall participate in incentive arrangements (other than any Compensation Award or Matching Award) operated by the Purchaser’s Group following Option Closing. 

For the purposes of this paragraph 11.10: 
  

	 	(a)	the value of a 2014 Performance Award to be granted shall: (i) be determined by Novartis acting reasonably and in good faith, (ii) be consistent with past practice and with the level of similar awards granted
to employees remaining in service within the Novartis Group, (iii) take into account the relevant business and/or individual performance criteria linked to the Novartis’s Group’s 2014 financial year, and (iv) if Option Closing
occurs before 31 December 2014, be time pro-rated to take account of the reduced period of time, as a proportion of the Novartis’s Group’s 2014 financial year, that the relevant Transferred Employee worked within the Novartis Group
(calculated on the basis of the number of complete months of service as at the Option Closing Date); 

  

	 	(b)	the number of shares to be placed under a 2014 Performance Award shall be valued on the basis of the average price of an ordinary share in the capital of the Purchaser over the five trading days immediately prior to the
date of grant; and 

  

	 	(c)	any currency conversion shall be made in accordance with Clause 1.10 of this Deed. 

  

	11.11	This paragraph shall apply if any member of the Novartis Group’s corporate executive team (or similar body) is a Transferred Employee (each a “CET Member”). The treatment of share-based
awards held by CET members shall be determined by the remuneration committee of the board of directors of Novartis (acting reasonably and in good faith and following informal consultation with the Purchaser), subject to the rules of any relevant
share-based incentive scheme and any Applicable Law, and the provisions of paragraph 11.8 shall apply. 

  
  

138 

 Execution Version 
  

Appendix 11 
 Employee
Benefits 
 (Paragraph 2.4.2) 
 In
this Appendix 11: 
 “Employee Benefits” means benefits to or in respect of any current or former employee, including without limitation,
any pension, early retirement, disability, death benefit, long service awards, termination indemnity (such as Italian TFR) or post-retirement medical benefits or deferred compensation linked to retirement, disability or death benefits or old age
part-time benefits (such as German ATZ) and jubilee payments. 
 “Employee Benefit Liabilities” means liabilities and obligations (whether
funded or unfunded) in respect of any employee benefit promise, scheme, plan, fund, program, policy, practice or other individual or collective arrangement providing Employee Benefits. 

“Novartis Funding Assumptions” means, in relation to any Transferred Employee Benefits, if there is a local obligation or practice prior to
the date of this Deed to pre-fund or externally fund those Transferred Employee Benefits to a funding target which is determined by reference to a method and assumptions other than IFRS (such as would, for example, be the case in relation to UK
HMRC-registered defined benefit pension obligations), then that method and those assumptions as in force in relation to those Transferred Employee Benefits immediately prior to the date of this Deed (so, taking the example of UK defined benefit
obligations, this would be the method and assumptions used to determine the relevant plan’s technical provisions as at the date of this Deed – regardless of whether the plan is in fact fully funded on that basis at any relevant time). 

“Novartis IFRS Assumptions” means, in relation to any Transferred Employee Benefits, the method and assumptions used by the Novartis Group
(or the most relevant member thereof) most recently prior to the date of this Deed to value those Transferred Employee Benefits for IFRS accounting purposes. 

“Partial Liquidation Longstop Date” means, in relation to each of Novartis Pensionskasse 1, Novartis Pensionskasse 2, and Kaderkasse
Novartis, the earlier of (i) the date after Option Closing on which the plan undergoes partial liquidation, and (ii) 12 months after Option Closing. 

“Purchaser Funding Assumptions” means, in relation to any Transferred Employee Benefits, where a member of the Purchaser’s Group
provides, in the same country, a similar or comparable benefit programme to the programme to which the Transferred Employee Benefits relate (regardless of differences in the terms of entitlement of accrual etc), and there is a local obligation or
practice prior to the date of this Deed to pre-fund or externally fund those similar or comparable benefits to a funding target which is determined by reference to a method and assumptions other than IFRS (such as would, for example, be the case in
relation to UK HMRC-registered defined benefit pension obligations), then that method and those assumptions as in force in relation to those similar or comparable benefits immediately prior to the date of this Deed (so, taking the example of UK
defined benefit obligations, this would be the method and assumptions used to determine the relevant plan’s technical provisions as at the date of this Deed – regardless of whether the plan is in fact fully funded on that basis at any
relevant time). 

  
  

139 

 Execution Version 
  

“Purchaser IFRS Assumptions” means, in relation to any Transferred Employee Benefits, where a member of the Purchaser’s Group provides,
in the same country, a similar or comparable benefit programme to the programme to which the Transferred Employee Benefits relate (regardless of differences in the terms of entitlement of accrual etc), the method and assumptions used most recently
prior to the date of this Deed to value those similar or comparable benefits by the Purchaser’s Group (or any relevant member thereof) for IFRS accounting purposes. 

“Swiss Actuary” means an actuary: (a) who can reasonably be viewed: (i) as independent of both the Purchaser and Novartis; and
(ii) as familiar with Swiss pension issues; and (b) whom the Purchaser and Novartis have agreed should be jointly appointed by them for the purposes of determining the Swiss Assumptions or who in default of such agreement has been
appointed by the Swiss Association of Actuaries or other industry body of actuaries in Switzerland as agreed by Novartis and the Purchaser. 

“Swiss Assumptions” means, in relation to any Transferred Employee Benefits in Switzerland, the Novartis IFRS Assumptions adjusted: 

 

	 	(a)	by replacing any assumed “cash balance” annuity conversion rate in the Novartis IFRS Assumptions with a conversion rate which the Swiss Actuary certifies to the Purchaser and Novartis as representing a
reasonable estimate of the likely effective overall blended conversion rate which will apply in relation to the Transferred Employee Benefits in question, having regard to the changes to the rate which can (having regard to longevity projections,
legal and governance constraints around Swiss pension structures and such other matters as the Swiss Actuary considers relevant) in the Swiss Actuary’s opinion reasonably be expected to occur during the expected service lives of the Transferred
Employees to whom the Transferred Employee Benefits relate, and weighting the impact of those changes by reference to the ages of the relevant employees (and so the extent to which the changes will in fact operate to reduce the effective liability
on the Purchaser); and 

  

	 	(b)	by removing any reserve for death or disability benefits to the extent that the Swiss Actuary certifies to the Purchaser and Novartis that it constitutes a reserve for liabilities to and in respect of the relevant
Transferred Employees which could reasonably be externally insured by the Purchaser without introducing a new ongoing cost on the Purchaser which was not reflected in the Accounts. 

  
  

140 

 Execution Version 
  

For the purposes of each of the Purchaser Funding Assumptions, the Purchaser IFRS Assumptions, the Novartis Funding Assumptions, the Novartis IFRS Assumptions
and the Swiss Assumptions, any economic and financial assumptions which are based (whether expressly or implicitly) on yields, rates or indices shall be updated for the purposes of such definitions to take account of those yields, rates or indices
as at Option Closing (or the latest practicable time prior to Option Closing). 
  

	1	Except to the extent otherwise requested by Novartis and expressly agreed by the Purchaser before Option Closing (such Purchaser agreement not to be unreasonably withheld to the extent that it is not reasonably possible
for Novartis or its Affiliates to retain the relevant Employee Benefit Liabilities – for example, where an Influenza Group Company operates its own standalone arrangement, liability for which cannot lawfully be assumed by another member of the
Novartis Group, or where liability unavoidably transfers by operation of law under European Council Directive 2001/23/EC or its local implementing legislation), any Employee Benefit Liabilities in respect of service in the Influenza Group or with
any member of the Novartis Group (including any Influenza Group Company) or in any plan or arrangement in which any member of the Novartis Group (including any Influenza Group Company) participates or has participated: 

 

	 	(a)	(in the case of a Transferred Employee) prior to Option Closing; or 

  

	 	(b)	(in the case of any other person) at any time, 

 (together, “Pre-Closing EB
Liabilities”) will stay with or be assumed by Novartis or its Affiliates (excluding any Influenza Group Company) and Novartis shall fully indemnify the Purchaser and its Affiliates (which for the avoidance of doubt in the period from Option
Closing includes any Influenza Group Company) against any such Employee Benefit Liabilities and against any liabilities and obligations to or in respect of any plan or arrangement for the provision of Employee Benefits in which any member of the
Novartis Group (including any Influenza Group Company) participates or participated prior to Option Closing. For the avoidance of doubt, the Purchaser’s agreement under this paragraph 1 may, if the Purchaser so determines, relate only to
certain specified categories or tranches of Pre-Closing EB Liabilities under a particular benefit programme (in other words, it does not need to be “all or nothing”), in which case it is only those specified Pre-Closing EB Liabilities
which are excluded from the scope of the Purchaser’s indemnity entitlement hereunder. 
  

	2	Where and to the extent that the Purchaser agrees under paragraph 1 that any Pre-Closing EB Liabilities may transfer to or remain with the Purchaser and/or its Affiliates (which for the avoidance of doubt in the
period from Option Closing includes any Influenza Group Company) (such Pre-Closing EB Liabilities being the “Transferred Employee Benefit Liabilities” and the benefits to which they relate being the
“Transferred Employee Benefits”), the Purchaser will be compensated in respect of such Transferred Employee Benefit Liabilities as set out in the rest of this Appendix 11. Subject to being so compensated but without prejudice to
paragraphs 9 and 11, the Purchaser shall, or shall procure that its relevant Affiliate shall, assume, with a full discharge for Novartis and its Affiliates, the Transferred Employee Benefit Liabilities. 

  
  

141 

 Execution Version 
  

Without limiting the Purchaser’s obligation not unreasonably to withhold consent under paragraph 1 above, the Purchaser acknowledges its
agreement to the principle that the post-retirement medical healthcare plan to which it admits US Transferred Employees who immediately before Option Closing were members of such a plan will take account of periods of employment with the Novartis
Group to the extent previously recognised under the equivalent Novartis Group plan for the purposes of determining eligibility, contributions, and vesting; therefore, subject to appropriate identification during the period before Option Closing of
such liabilities and to the operation of the compensation mechanism set out in this Appendix 11, they will become Transferred Employee Benefit Liabilities. 

Without limiting the Purchaser’s obligation not unreasonably to withhold consent under paragraph 1 above, the parties hereby acknowledge
that it would not be reasonably possible for Novartis or its Affiliates to retain those Pre-Closing EB Liabilities which attach to the Influenza Group Companies in relation to the Chiron UK Pension Scheme (formerly known as the “Powderject
Pension Scheme”) (the “Agreed UK Scheme”). So, subject to appropriate identification during the period before Option Closing of such liabilities and to the operation of the compensation mechanism set out in this Appendix 11,
and the liabilities will become Transferred Employee Benefit Liabilities and, for the avoidance of doubt, the Agreed UK Scheme will transfer to the Purchaser. Novartis acknowledges that the Purchaser’s agreement to this is expressly based on
Novartis’s belief, as confirmed to it by the Purchaser, that the following documents relate to the Agreed UK Scheme: 
  

	 	A.	the document titled “Chiron UK Pension Scheme - Actuarial Report as at 31 December 2012” and signed for identification purposes on or around 22 April 2014 by Eleanor Hart of Slaughter and May
and John Gordon of Linklaters LLP; and 

  

	 	B.	the 2001 rules (when the Agreed UK Scheme was called the Powderject Pension Scheme) which were disclosed to the Purchaser prior to the date of this Deed, 

and that if either of these beliefs should not be correct, then it will be reasonable for the Purchaser to refuse to agree that the Pre-Closing
EB Liabilities associated with the Agreed UK Scheme should become Transferred Employee Benefits Liabilities and instead to require Novartis to procure that the Influenza Group Companies have no further liabilities to or in respect of the Agreed UK
Scheme prior to Option Closing. 

  
  

142 

 Execution Version 
  

 

	3	The value of the Transferred Employee Benefit Liabilities shall be determined on employee census data and plan provision as at Option Closing: 

 

	 	A.	in relation to any Transferred Employee Benefits in Switzerland, the Swiss Assumptions; and 

  

	 	B.	in relation to any other Transferred Employee Benefits, the Novartis IFRS Assumptions, PROVIDED that if any of the following values is available and is greater than the value derived using the Novartis IFRS
Assumptions then that value will be used instead (and if more than one of these values is available then the one which would place the greatest value on the relevant Transferred Employee Benefit Liabilities will be used): 

 

	 	(i)	if a member of the Purchaser’s Group provides, in the same country, a similar or comparable benefit programme to the programme to which the Transferred Employee Benefits relate (regardless of differences in the
terms of entitlement of accrual etc), the value which is midway between the value based on the Novartis IFRS Assumptions and the Purchaser IFRS Assumptions; 

  

	 	(ii)	if there is a local obligation or practice prior to the date of this Deed to pre-fund or externally fund the Transferred Employee Benefits to a funding target which is determined by reference to a method and assumptions
other than IFRS, the value derived using the Novartis Funding Assumptions; and 

  

	 	(iii)	if there is both: (i) a local obligation or practice prior to the date of this Deed to pre-fund or externally fund the Transferred Employee Benefits to a funding target which is determined by reference to a method
and assumptions other than IFRS; and (ii) a member of the Purchaser’s Group provides, in the same country, a similar or comparable benefit programme to the programme to which the Transferred Employee Benefits relate (regardless of
differences in the terms of entitlement of accrual etc), the value which is midway between the value based on the Novartis Funding Assumptions and the Purchaser Funding Assumptions. 

The market value as at Option Closing of any underlying assets related to the Transferred Employee Benefit Liabilities which are or are to be
transferred as per paragraph 8 below will be deducted from the value of the Transferred Employee Benefit Liabilities to the extent such assets are or will be available to the Purchaser or its Affiliates to meet such liabilities and the remaining
value of the Transferred Employee Benefit Liabilities (if any) is the “Employee Benefit Indemnification Amount”. Such determination shall be carried out on a country-by-country basis and, where necessary, on a plan-by-plan basis.
For the avoidance of doubt, in relation to Switzerland, the calculation shall, if partial liquidation occurs in relation to any of the Transferred Employee Benefit Liabilities by the Partial Liquidation Longstop Date, make allowance for the assets
thereby transferred assuming that they will be available to meet such liabilities. If any Employee Benefit Indemnification Amount is greater than the estimate of such amount determined for the purposes of the Estimated Employee Benefit Adjustment
(or, where no such estimate was made, greater than zero), Novartis shall pay or procure payment, by way of a reduction in the Purchase Price attributable to the Shares or the particular part of the Influenza Group to which the payment relates, an
amount equal to the difference (or, where no such estimate was made, such amount) to the Purchaser, or at the request of the Purchaser to an Affiliate of the Purchaser, as compensation for the Transferred Employee Benefit Liabilities. If any
Employee Benefit Indemnification Amount is less than the estimate of such amount determined for the purposes of the Estimated Employee Benefit Adjustment (if any), the Purchaser shall pay an amount equal to the difference to Novartis. 

  
  

143 

 Execution Version 
  

 

	4	Novartis and its Affiliates shall, within 45 days after Option Closing (or, in the case of Switzerland, 45 days after the Partial Liquidation Longstop Date), provide its actuary, the Swiss Actuary and the actuary
chosen by the Purchaser with all relevant plan, asset, assumptions and employee census information needed to calculate the Employee Benefit Indemnification Amounts in respect of any Transferred Influenza Business Employees. The actuary chosen by
Novartis shall provide the actuary chosen by the Purchaser with its calculation of the Employee Benefit Indemnification Amounts (including, but not limited to, any supporting documentation on which it relied as well as the methodologies it employed
in calculating the Employee Benefit Indemnification Amounts), on a plan-by-plan basis, within 90 days following Option Closing (or, in the case of Switzerland, 90 days after the Partial Liquidation Longstop Date). The actuary chosen by the Purchaser
shall review the calculation of the Employee Benefit Indemnification Amounts of Novartis’s actuary within 120 days following Option Closing (or, in the case of Switzerland, 120 days after the Partial Liquidation Longstop Date). The Employee
Benefit Indemnification Amounts shall be determined, on a plan-by-plan basis, by mutual agreement between the parties within 180 days following the Option Closing Date (or, in the case of Switzerland, 180 days after the Partial Liquidation Longstop
Date). 

  

	5	If the parties cannot agree on any Employee Benefit Indemnification Amount within the 180-day period referred to in paragraph 4, the parties shall appoint within 5 days an independent actuary acceptable to both
parties, or such actuary shall be selected by the President of the Institute and Faculty of Actuaries in the UK if they cannot agree, and the independent actuary thus appointed shall review their calculations and, within 75 days after appointment,
render a final and binding decision on the amount of that Employee Benefit Indemnification Amount, and, in making such decision, shall be limited to adopting the position taken by either one of the parties. The cost of any independent actuary shall
be borne jointly by the parties. 

  

	6	In connection with the procedures referred to in this Appendix 11, the parties shall provide each other and the actuaries referred to in this Appendix 11 with access to the relevant business records and other
relevant documents and information as may reasonably be requested. All documents, records and information provided for the purposes of this Appendix 11 must be accurate and complete in all material respects. 

  
  

144 

 Execution Version 
  

 

	7	Each Employee Benefit Indemnification Amount shall be paid by Novartis (by way of a reduction in the Purchase Price attributable to the Shares or the particular part of the Influenza Group to which the payment
relates) within 14 days following its final determination. Novartis may make an accelerated or advance payment at its own discretion (which, for the avoidance of doubt, includes in relation to each Employee Benefit Indemnification Amount so much (if
any) of the Estimated Employee Benefit Adjustment as Novartis notified pursuant to Paragraph 6.4 of Schedule 1 was intended to relate to that Employee Benefit Indemnification Amount). Each Employee Benefit Indemnification Amount shall include
interest calculated from (and including) the Option Closing Date to (and including) the date of payment at a rate per annum of LIBOR (but where amounts are prepaid or paid in stages or treated as paid via inclusion in the Estimated Employee Benefit
Adjustment then the interest will cease to accrue on so much of the Employee Benefit Indemnification Amount as has been paid). Such interest shall accrue from day to day. Any such payment shall be made in US dollars (and any underlying values shall
be expressed in US dollars) and any currency other than US dollars shall be converted into US dollars at the exchange rates determined in accordance with Clause 1.10 of this Deed on the Option Closing Date. 

 

	8	To the extent (if any) that there are any Transferred Employee Benefit Liabilities which prior to Option Closing were externally funded by assets held in a trust or other vehicle established for the purposes of
meeting such Transferred Employee Benefit Liabilities, the Purchaser will, if requested by Novartis before Option Closing and unless it is not reasonably practicable to do so, establish or nominate a trust or other vehicle which is capable of
receiving a transfer of assets from the pre-Option Closing trust or other vehicle to the extent that such assets relate to the Transferred Employee Benefit Liabilities. 

 

	9	If, within one year of Option Closing, Novartis or the Purchaser notifies the other that the membership or other benefit data (the “Data”) used for calculating any Employee Benefit
Indemnification Amount may be inaccurate, then a “Data Dispute” has arisen and the following provisions shall apply: 

  

	 	(a)	On such notification, Novartis shall procure that its actuary and the Purchaser shall procure that its actuary consult each other with a view to agreeing whether the Data is inaccurate and if so, what the accurate Data
should be. If Novartis’s actuary and the Purchaser’s actuary agree that the Data is inaccurate, they will jointly certify this to be the case and advise on what the accurate Data should be. The notification is deemed to have occurred on
the date of the certification. 

  

	 	(b)	If Novartis’s actuary and the Purchaser’s actuary fail to agree whether the Data is inaccurate within 60 days of the notification by one party to the other that the Data may be inaccurate, paragraph 5 shall
apply mutatis mutandis. The notification is deemed to have occurred when the independent actuary advises that the Data is inaccurate and what the accurate Data should be. 

 

	 	(c)	On the occurrence of the Data Dispute, Novartis and the Purchaser shall respectively procure that a valuation of the relevant Employee Benefit Indemnification Amount is carried out in accordance with paragraphs 3 and 4
(mutatis mutandis) but on the basis of the accurate Data as agreed under paragraph (a) or determined under paragraph (b). 

  

	 	(d)	If as a consequence of paragraph (c), Novartis has paid to the Purchaser an amount which on the basis of the further valuation is not payable, such amount (the “Overpayment”) shall be repaid within 21
days of the amount of the Overpayment being agreed or determined. Any such payment shall bear interest calculated from (and including) the date the Overpayment was made to (and including) the date the payment is made in full in accordance with this
paragraph (d) at a rate per annum of LIBOR. Such interest shall accrue from day to day. 

  
  

145 

 Execution Version 
  

 

	 	(e)	If as a consequence of paragraph (c), Novartis has not paid to the Purchaser an amount which on the basis of the further valuation is payable, such amount (the “Outstanding Amount”) shall be paid within
21 days of the amount of the Outstanding Amount being agreed or determined. Any such payment shall bear interest calculated from (and including) the Option Closing Date to (and including) the date the payment is made in full in accordance with this
paragraph (e) at a rate per annum of LIBOR. Such interest shall accrue from day to day. 

  

	10	Except as otherwise agreed by Novartis, the Purchaser shall where a trust or other vehicle has been established under paragraph 8, procure that all of the assets transferred as envisaged by paragraph 8 are paid
into such trust or other vehicle. If, after such payment or transfer, or after payment of an Employee Benefit Indemnification Amount or after making an Estimated Employee Benefit Adjustment, the Purchaser and/or its Affiliates achieves a reduction
in its liability to any Tax in respect of or in connection with the payment or transfer, the Purchaser shall pay to Novartis (for itself or on behalf of the relevant Share Seller or Business Seller as applicable), within 30 days after the Purchaser
would otherwise have been liable to pay the saved Tax, a sum equal to the amount of that Tax reduction by way of an increase in the Purchase Price in respect of the relevant Shares or the particular part of the Influenza Group. This paragraph 10
applies for a period of four years following the later of the date on which a transfer of assets is made, or payment of any Employee Benefit Indemnification Amount or Estimated Employee Benefit Adjustment is made to the Purchaser. 

 

	11	Novartis covenants with the Purchaser to pay to the Purchaser an amount equal to any cost, claim or liability incurred by any member of the Purchaser’s Group which it is or becomes liable to make on or at
any time after Option Closing by reason of any change or purported change made to the terms of any Transferred Employee Benefits prior to Option Closing proving to be or have been legally ineffective or by reason of such terms and/or benefits
failing to comply with any mandatory legal requirements (excluding any obligation to equalise guaranteed minimum pensions in the United Kingdom). Novartis shall not be liable under this paragraph 11 in respect of any individual claim (or a series of
claims arising from similar or identical facts or circumstances) unless the liability in respect of such claim or series of claims exceeds US$100,000. If the Purchaser becomes aware of any fact, matter or circumstance that may give rise to a claim
against Novartis under this paragraph 11, the Purchaser shall as soon as reasonably practicable give notice in writing to Novartis of such facts, matters or circumstances as are then available regarding the potential claim. Failure to give such
notice within such period shall not affect the rights of the Purchaser to make a relevant claim under this paragraph 11, except that Novartis shall not be liable for any increase in the amount of such claim arising from such failure. The latest date
on which the Purchaser may give notice of a claim under this paragraph 11 is the fourth anniversary of the Option Closing Date. 

  

	12	Notwithstanding any general provision to the contrary in Appendix 10 and subject to being compensated in accordance with this Appendix 11, the Purchaser shall admit Transferred Employees in the United States who
participated in a post-retirement medical plan immediately prior to Option Closing to its own post-retirement medical plan. Subject to being compensated in accordance with this Appendix 11, periods of employment with the Novartis Group (including,
without limitation, any current or former Affiliate of Novartis, to the extent previously recognised under the applicable benefit plan arrangement provided by the Novartis Group), shall be taken into account for the purposes of determining, as
applicable, the eligibility for participation, contributions, and vesting for any employee under such post-retirement medical plan. 

  
  

146 

 Execution Version 
  

 

	13	Notwithstanding any general provision to the contrary in Appendix 10, the US Transferred Employees shall, as of the Option Closing Date, become eligible to participate in a US tax-qualified defined contribution
plan to the extent such plan is sponsored by the Purchaser or a relevant member of the Purchaser’s Group. The Purchaser agrees that it will use commercially reasonable efforts to cause such plan to accept rollovers of the account balances of
the US Transferred Employees (including participant loan promissory notes) from the relevant employer’s tax-qualified retirement plans; provided that (i) the Purchaser will not be required to accept any such rollovers that might result in
material liability to the Purchaser or may otherwise cause the relevant plan to cease to qualify under Section 401(a) of the Code and (ii) the Purchaser will not be required to amend any plan to permit participant loans. 

 

	14	The parties agree that where any Transferred Employee has accrued defined contribution benefits prior to Option Closing in a Novartis Group arrangement then: 

 

	14.1	Novartis shall use commercially reasonable efforts to procure the vesting of those benefits (if they would otherwise lapse as a result of Option Closing); 

 

	14.2	the parties shall, provided this will not impose unreasonable administrative burdens on the Purchaser’s Group, co-operate in good faith to procure a transfer of the account balances of such Transferred Employee
from the Novartis Group arrangement to a Purchaser’s Group arrangement; and 

  

	14.3	for the avoidance of doubt, the Purchaser will comply with the provisions of paragraph 6.1 of Appendix 10. 

  
  

147 

 Execution Version 
  

Appendix 13 
 Allocation
of Purchase Price 
 (Paragraphs 3.3 and 7.6) 
  

	1	Novartis and the Purchaser agree that the Purchase Price (and any adjustments thereto) and the Assumed Liabilities shall be allocated for Tax purposes among the Shares and the Influenza Group Businesses in accordance
with Applicable Law (the “Allocation”). 

  

	2	From the Option Exercise Date and prior to the Option Closing Date and subject always to paragraph 1, Novartis and the Purchaser shall negotiate in good faith to reach an agreement as to the Allocation of the Purchase
Price and the Assumed Liabilities to the Shares, and to any Influenza Group Businesses that are subject to transfer Taxes or VAT, or where a valuation of a particular Influenza Group Business prior to Option Closing is otherwise required by
Applicable Law (each a “Required Item”). 

  

	3	Failing agreement between the parties on the Allocation in respect of any Required Item in accordance with this Appendix 13, the Allocation shall be determined by the Reporting Accountants on the application of Novartis
or the Purchaser. Paragraphs 1.7 to 1.13 of Part 1 of Appendix 16 shall apply mutatis mutandis to the engagement and determination of the Reporting Accountants pursuant to this paragraph 3. 

 

	4	Novartis and the Purchaser shall negotiate in good faith to further allocate the Purchase Price and Assumed Liabilities among the Influenza Group Businesses for which an allocation was not agreed prior to Option Closing
within 90 calendar days after the Option Closing Date. If Novartis and the Purchaser reach written agreement within such 90 day period, the Allocation, as so amended, shall become binding upon Novartis and the Purchaser as the “Final
Allocation Schedule”. 

  

	5	Novartis and the Purchaser shall, and shall procure that each of their Affiliates will, file all Tax Returns in a manner consistent with the Final Allocation Schedule, unless otherwise required by Applicable Law, and
shall take no position inconsistent with the Final Allocation Schedule in any proceedings before any Governmental Entity or otherwise. 

  

	6	If Novartis and the Purchaser are unable to agree to an Allocation pursuant to paragraph 4, the matter shall be determined by the Reporting Accountants on the application of Novartis or the Purchaser. Paragraphs 1.7 to
1.13 of Part 1 of Appendix 16 shall apply mutatis mutandis to the engagement and determination of the Reporting Accountants pursuant to this paragraph 6. 

  
  

148 

 Execution Version 
  

Appendix 14 
 VAT 

(Paragraph 3.4) 
  

	1	VAT: Records 

  

	1.1	Novartis may, on or before the date of Option Closing, obtain a direction from the relevant Tax Authority for the retention and preservation by it of any VAT records relating to its period of ownership of the relevant
part of the Influenza Group and, where any such direction is obtained, Novartis shall: 

  

	 	1.1.1	preserve the records to which that direction relates in such a manner and for such period as may be required by the direction or by Applicable Law; and 

 

	 	1.1.2	allow the Purchaser, upon the Purchaser giving reasonable notice, reasonable access to and copies of such records where reasonably required by the Purchaser for its Tax purposes. 

 

	1.2	If no such direction as is referred to in paragraph 1.1 above is obtained on or before the date of Option Closing and any documents in the possession or control of a member of Novartis’s Group are required by law
to be preserved by the Purchaser, Novartis shall, as soon as reasonably practicable after Option Closing, deliver such documents to the Purchaser. 

  

	2	VAT: Going Concern - EU Member States 

  

	2.1	Novartis and the Purchaser shall use reasonable endeavours (including, for the avoidance of doubt, the making of an election or application in respect of VAT to any Taxation Authority or entering into a written
agreement) to secure that, to the extent reasonably possible, the sale of all or any part of the Influenza Group Businesses, so far as carried on in the European Union, is treated as neither a supply of goods nor a supply of services for the
purposes of the laws governing VAT in each relevant member state. 

  

	2.2	Each Business Seller shall have the right to seek a ruling from the relevant Tax Authority as to whether the sale of all or part of the Influenza Group Businesses, so far as carried on in the relevant member
state, should be treated as neither a supply of goods nor a supply of services for the purposes of the laws governing VAT in that member state and to account for VAT (and accordingly to seek an additional payment from the Purchaser under Paragraph
3.4.3) in accordance with that ruling. Novartis shall not be obliged to challenge (or to procure that any relevant Business Seller challenges) that ruling unless required to do so by the Purchaser. If the Purchaser wishes to challenge, or to require
the relevant Business Seller to challenge, any such ruling it may do so, provided that it bears the full cost of, and agrees to indemnify the relevant Business Seller in respect of any loss arising from or in connection with, that challenge and that
such challenge shall not affect the date on which VAT must be paid to Novartis under paragraph 4 below. 

  

	2.3	Insofar as no ruling has been obtained from a relevant Tax Authority prior to Option Closing, Novartis shall determine in good faith if (or the extent to which) VAT is payable in respect of the sale of the
Influenza Group Businesses and shall be entitled to charge (or not to charge) VAT to the Purchaser in accordance with such determination. 

  

	3	VAT: Going Concern - non-EU Jurisdictions 

  
  

149 

 Execution Version 
  

 

	3.1	To the extent that any state outside the European Union provides for relief or exemption from VAT on the transfer of a business or a company or treats such a transaction as being non-taxable for VAT purposes,
Novartis and the Purchaser shall use reasonable endeavours (including, for the avoidance of doubt, the making of an election or application in respect of VAT to any Tax Authority or entering into a written agreement) to secure such relief, exemption
or treatment, to the extent reasonably possible, as regards the sale of all or part of the Influenza Group Businesses (insofar as the business of the Influenza Group is carried on in the relevant state) under this Deed. 

 

	3.2	The relevant Business Seller shall have the right to seek a ruling from the relevant Tax Authority as to whether the sale of all or part of the Influenza Group Businesses, so far as the business of the Influenza
Group is carried on in the relevant state, is eligible for a relief or exemption or is otherwise eligible to be treated as non-taxable for the purposes of the laws governing VAT in that state and to account for VAT (and accordingly seek an
additional payment from the Purchaser under Paragraph 3.4.3) in accordance with that ruling. Novartis shall not be obliged to challenge (or to procure then the relevant Business Seller challenges) that ruling unless required to do so by the
Purchaser. If the Purchaser wishes to challenge, or to require the relevant Business Purchaser to challenge, any ruling it may do so, provided that it bears the full cost of, and agrees to indemnify the relevant Business Seller in respect of any
loss arising from or in connection with, that challenge and that such challenge shall not affect the date on which VAT must be paid to Novartis under paragraph 4 below. Insofar as no ruling has been obtained from a relevant Tax Authority prior to
Option Closing, Novartis shall determine in good faith if (or the extent to which) VAT is payable in respect of the sale of the Influenza Group Businesses and shall be entitled to charge (or not to charge) VAT to the Purchaser in accordance with
such determination. 

  

	4	VAT: Time, Manner and Currency of Payment 

  

	4.1	Any amounts which the Purchaser is obliged to pay to Novartis under this Deed in respect of VAT shall be paid by the Purchaser, on its own account or on behalf of another member of the Purchaser’s Group, to
Novartis or to such member of the Novartis Group as Novartis may direct. Such amounts shall be paid in the currency in which the VAT in question must be accounted for to the relevant Tax Authority. 

 

	4.2	Subject to any provision or express agreement to the contrary, any amounts in respect of VAT payable in any jurisdiction in respect of the transfer at Option Closing of any of the Influenza Group Businesses or Shares
shall be paid in accordance with paragraph 4.1 above at Option Closing against production of a valid VAT invoice (or equivalent, if any). 

  

	4.3	Notwithstanding any other provision of this Deed, the Purchaser shall not be liable to account to Novartis or any member of the Novartis Group for or in respect of penalties or interest arising solely from the failure
of Novartis or any other member of the Novartis Group to account promptly for VAT to the relevant Tax Authority following Novartis having been placed in the appropriate amount of funds for that purpose by the Purchaser. 

  
  

150 

 Execution Version 
  

Appendix 15 
 Option
Closing Obligations 
 (Paragraph 6) 
  

	1	General Obligations 

  

	1.1	Novartis’s Obligations 

 On Option Closing, Novartis shall deliver or make available
to the Purchaser the following: 
  

	 	1.1.1	the Tax Indemnity duly executed by Novartis; 

  

	 	1.1.2	the Ancillary Agreements (other than, if they have not been agreed, the Transitional Services Agreement and the Manufacturing, Supply and Distribution Agreement) duly executed by the relevant members of the Novartis
Group; 

  

	 	1.1.3	a valid power of attorney or such other evidence reasonably satisfactory to the Purchaser that Novartis, and each of its relevant Affiliates, are authorised to execute the Tax Indemnity, the Ancillary Agreements and the
Local Transfer Documents (including, where relevant, any notarial deeds referred to in this Deed), in each case to the extent that they are parties thereto; and 

  

	 	1.1.4	the statutory books of the Influenza Group Companies (which shall be written up to but not including the Option Closing Date), the certificate of incorporation (and certificate of incorporation on change of name) and
common seal (if any) of each Influenza Group Company and share certificates (or other documents of title) in respect of all the issued share capital of each Influenza Group Company. 

In addition, Novartis shall, if requested by the Purchaser by notice in writing not less than five Business Days prior to the Option Closing
Date: 
  

	 	(i)	procure any then present directors and officers (if any) of each Influenza Group Company resign their offices to take effect at the Option Closing Date as such and to relinquish any rights which they may have under any
contract of employment with any Influenza Group Company or under any statutory provisions (including any right to damages or compensation for breach of contract, loss of office, redundancy or unfair dismissal or on any other account whatsoever) and
to confirm that no agreement or arrangement is outstanding under which any Influenza Group Company has or could have any obligation to any of them including in respect of remuneration or expenses; 

 

	 	(ii)	procure the present auditors of each Influenza Group Company to resign their office as such, such resignations to take effect as at the Option Closing Date; and 

 

	 	(a)	procure board meetings of the relevant Influenza Group Companies are held, or written resolutions of the board are passed, at or by which: 

 

	 	(b)	it shall be resolved that each of the transfers relating to the Shares shall, so far as possible, be approved for registration and any person nominated by the Purchaser shall be appointed director, such appointments to
take effect on the Option Closing Date. 

  
  

151 

 Execution Version 
  

 

	1.2	The Purchaser’s Obligations 

 On Option Closing, the Purchaser shall deliver or make
available to Novartis the following: 
  

	 	1.2.1	the Tax Indemnity duly executed by the Purchaser; 

  

	 	1.2.2	the Ancillary Agreements (other than, if they have not been agreed, the Transitional Services Agreement and the Manufacturing, Supply and Distribution Agreement) duly executed by the relevant members of the
Purchaser’s Group; and 

  

	 	1.2.3	evidence reasonably satisfactory to Novartis that the Purchaser, and each of its relevant Affiliates, are authorised to execute the Tax Indemnity, the Ancillary Agreements and the Local Transfer Documents (including,
where relevant, any notarial deeds referred to in this Deed), in each case to the extent that they are parties thereto. 

  

	2	Transfer of the Shares and Influenza Group Businesses 

  

	2.1	General Transfer Obligations 

 On Option Closing or such other date as agreed between the
parties, Novartis shall procure that the Share Seller and Business Sellers shall, and the Purchaser shall, execute and/or deliver and/or make available Local Transfer Documents and take such steps as are required to transfer the Shares and Influenza
Group Businesses in accordance with this Deed. 
  

	2.2	Specific Transfer Obligations 

 For the purposes of compliance with paragraph 2.1,
Novartis and the Purchaser shall, between the Option Exercise Date and Option Closing, negotiate in good faith any and all Local Transfer Documents and other such steps as are required to transfer the Shares and Influenza Group Businesses in
accordance with this Deed. 

  
  

152 

 Execution Version 
  

Appendix 16 
 Post Option
Closing Adjustments 
 (Paragraph 7) 

Part 1 
 Preparation of
Option Closing Statement 
  

	1	Preparation 

  

	1.1	No later than 60 days following Option Closing, Novartis shall deliver to the Purchaser the Draft Option Closing Statement. Prior to such delivery, Novartis shall so far as is practicable consult with the Purchaser with
a view to reducing the potential areas of disagreement. 

  

	1.2	In order to enable Novartis to prepare the Draft Option Closing Statement, the Purchaser shall keep up-to-date and, subject to reasonable notice, make available to Novartis’s representatives and to Novartis’s
accountants all books and records relating to the Influenza Group during normal office hours and co-operate with them with regard to the preparation, review and agreement or determination of the Draft Option Closing Statement. The Purchaser agrees
to make available the services of the employees of the Influenza Group to assist Novartis in the preparation, review and agreement or determination of the Draft Option Closing Statement. 

 

	1.3	In order to allow the Purchaser to review the Draft Closing Statement, Novartis shall, subject to reasonable notice, make available to the Purchaser’s representatives and to the Purchaser’s accountants all
books and records relating to the Vaccines Group during normal office hours and co-operate with them with regard to their review of the Draft Closing Statement. Novartis agrees to make available the services of the employees of Novartis and its
Affiliates to assist the Purchaser in its review of the Draft Closing Statement. 

  

	1.4	If the Purchaser does not within 60 days of presentation to it of the Draft Option Closing Statement give notice to Novartis that it disagrees with the Draft Option Closing Statement or any item thereof, such notice
stating the reasons for the disagreement in reasonable detail and specifying the adjustments which, in the Purchaser’s opinion should be made to the Draft Option Closing Statement (the “Purchaser’s Disagreement Notice”),
the Draft Option Closing Statement shall be final and binding on the parties for all purposes. If the Purchaser gives a valid Purchaser’s Disagreement Notice within such 60 days, Novartis and the Purchaser shall attempt in good faith to reach
agreement in respect of the Draft Option Closing Statement and, if they are unable to do so within 30 days of such notification, Novartis or the Purchaser may by notice to the other require that the Draft Option Closing Statement be referred to the
Reporting Accountants (an “Appointment Notice”). 

  

	1.5	Within 30 days of the giving of an Appointment Notice, Novartis may by notice to the Purchaser indicate that, in the light of the fact that the Purchaser has not accepted the Draft Option Closing Statement in its
entirety, it wishes the Reporting Accountants to consider matters relating to the Draft Option Closing Statement in addition to those specified in the Purchaser’s Disagreement Notice, provided that such matters as are related to the matters
specified in the Purchaser’s Disagreement Notice and that the notice states in reasonable detail the reasons why and in what respects Novartis believes that the Draft Option Closing Statement should be altered in respect of such matters (the
“Novartis’s Disagreement Notice”). 

  
  

153 

 Execution Version 
  

 

	1.6	The Reporting Accountants shall be engaged jointly by Novartis and the Purchaser on the terms set out in this paragraph 1 and otherwise on such terms as shall be agreed; provided that neither Novartis nor the Purchaser
shall unreasonably (having regard, inter alia, to the provisions of this paragraph 1) refuse its agreement to terms proposed by the Reporting Accountants or by the other party. If the terms of engagement of the Reporting Accountants have not been
settled within 45 days of their identity having been determined (or such longer period as Novartis and the Purchaser may agree) then, unless Novartis or the Purchaser is unreasonably refusing its agreement to those terms, those accountants shall be
deemed never to have become the Reporting Accountants and new Reporting Accountants shall be selected in accordance with the provisions of this Deed. 

  

	1.7	Except to the extent that Novartis and the Purchaser agree otherwise, the Reporting Accountants shall determine their own procedure but: 

 

	 	1.7.1	apart from procedural matters and as otherwise set out in this Deed shall determine only: 

  

	 	(i)	whether any of the arguments for an alteration to the Draft Option Closing Statement put forward in the Purchaser’s Disagreement Notice or Novartis’s Disagreement Notice is correct in whole or in part; and

  

	 	(ii)	if so, what alterations should be made to the Draft Option Closing Statement in order to correct the relevant inaccuracy in it; 

  

	 	1.7.2	shall apply the accounting principles, policies, procedures, practices and estimation techniques as set out in Part 2 of this Appendix; 

 

	 	1.7.3	shall make their determination pursuant to paragraph 1.7.1 as soon as is reasonably practicable; 

  

	 	1.7.4	the procedure of the Reporting Accountants shall: 

  

	 	(i)	give Novartis and Purchaser a reasonable opportunity to make written and oral representations to them; 

  

	 	(ii)	require that each party supply the other with a copy of any written representations at the same time as they are made to the Reporting Accountants; 

 

	 	(iii)	permit each party to be present while oral submissions are being made by the other party; and 

  

	 	(iv)	for the avoidance of doubt, the Reporting Accountants shall not be entitled to determine the scope of their own jurisdiction. 

  

	1.8	The Reporting Accountants shall send Novartis and the Purchaser a copy of their determination pursuant to paragraph 1.7.1 within one month of their appointment. Such determination: 

 

	 	1.8.1	shall be made available to Novartis and the Purchaser in writing; and 

  

	 	1.8.2	unless otherwise agreed by Novartis and the Purchaser, shall include reasons for each relevant determination. 

  
  

154 

 Execution Version 
  

 

	1.9	The Reporting Accountants shall act as experts and not as arbitrators and their determination of any matter falling within their jurisdiction shall be final and binding on Novartis and the Purchaser save in the
event of manifest error (when the relevant part of their determination shall be void and the matter shall be remitted to the Reporting Accountants for correction). In particular, their determination shall be deemed to be incorporated into the Draft
Option Closing Statement. 

  

	1.10	The expenses (including amounts in respect of VAT) of the Reporting Accountants shall be borne as they shall direct at the time they make any determination under paragraph 1.7.1(i) or, failing such direction,
equally between the Purchaser and Novartis. 

  

	1.11	Novartis and the Purchaser shall co-operate with the Reporting Accountants and comply with their reasonable requests made in connection with the carrying out of their duties under this Deed. In particular,
Purchaser shall keep up-to-date and, subject to reasonable notice, make available to Novartis’s representatives, Novartis’s accountants and the Reporting Accountants all books and records relating to the Influenza Group during normal
office hours as Novartis or the Reporting Accountants may reasonably request during the period from the appointment of the Reporting Accountants down to the making of the relevant determination. 

 

	1.12	Nothing in this Appendix 16 shall entitle a party or the Reporting Accountants access to any information or document which is protected by legal professional or litigation privilege, provided that neither
Novartis nor the Purchaser shall be entitled to refuse to supply such part or parts of documents as contain only the facts on which the relevant claim or argument is based. 

 

	1.13	Each party and the Reporting Accountants shall, and shall procure that its accountants and other advisers shall, keep all information and documents provided to them pursuant to this paragraph 1 confidential and
shall not use the same for any purpose, except for disclosure or use in connection with the preparation of the Draft Option Closing Statement, the proceedings of the Reporting Accountants or another matter arising out of this Deed.

  
  

155 

 Execution Version 
  

Part 2 
 Option Closing
Statement Principles 
 This Part 2 of Appendix 16 comprises the specific rules, principles, policies and practices, without limitation, for preparing
the Option Closing Statement. 
 The Option Closing Statement sets out the Influenza Group Companies’ Cash Balances, the Third Party Indebtedness, the
Intra-Group Non-Trade Receivables, the Intra-Group Non-Trade Payables and the Tax Adjustment, in each case as prepared in accordance with the specific rules, principles, policies and practices set forth in this Part 2 of Appendix 16. The Option
Closing Statement shall be prepared in the form of the Illustrative Option Closing Statement in Part 3 of this Appendix 16. 
 For the avoidance of doubt,
the Option Closing Statement as referred to in this Part 2 of Appendix 16 shall inclusively apply to each of the Draft Option Closing Statement and the Option Closing Statement. 

 

	1	Option Closing Statement Rules 

  

	1.1	The Option Closing Statement shall be prepared as follows: 

  

	 	1.1.1	in accordance with the specific accounting treatments set out in paragraph 2 of this Part 2 of Appendix 16; and, subject thereto 

 

	 	1.1.2	adopting the same accounting principles, methods, procedures and practices utilized in preparing the Statement of Net Assets, as detailed in the Statement of Net Asset Rules, applied on a consistent basis using
consistent estimation methodologies and judgments and with consistent classifications as were used to prepare the Statement of Net Assets; and subject thereto 

  

	 	1.1.3	in accordance with IFRS. 

  

	1.2	For the avoidance of doubt, paragraph 1.1.1 shall take precedence over paragraphs 1.1.2 and 1.1.3, and paragraph 1.1.2 shall take precedence over paragraph 1.1.3. 

 

	2	Specific requirements 

  

	2.1	Cut-off 

 The Option Closing Statement (including the Draft Option Closing Statement)
shall not take into account any additional events and any additional information that becomes available after the statement time up to the date that such Option Closing Statement is prepared. 

  
  

156 

 Execution Version 
  

 

	2.2	Change of Ownership 

 The Option Closing Statement shall not be adjusted for any charges,
provisions, reserves or write-offs in respect of any costs, liabilities or charges that may be incurred by the Influenza Group prior to or after the Option Closing as a consequence of the change of ownership of the Influenza Group or any changes in
the management strategy, direction or priority or possible closure of any part of the Influenza Group by the Purchaser after Option Closing, whether or not resulting from the change in ownership. 

 

	2.3	Deferred Tax 

 The Option Closing Statement (including the Draft Option Closing
Statement) shall not take into account or provide for deferred Tax. 
  

	2.4	Other Taxes 

 The Option Closing Statement (including the Draft Option Closing Statement)
shall take account of or provide for all income taxes and sales taxes, to which lines BS14_120 Taxes other than income taxes (Liability account) and BS13_108 Value added tax receivable apply. 

  
  

157 

 Execution Version 
  

Part 3 
 Illustrative
Option Closing Statement 
  

					
	 	  	Influenza Group
Illustrative Closing
Statement	 
	 Target Group Companies’ Cash Balances (BS01_180 Cash & cash equivalents)
	  	 	[    	] 
		
	 Intra-Group Non-Trade Receivables (BS01_050 Total financing and loans to subsidiaries / JV)
	  	 	[    	] 
		
	 Third Party Indebtedness, comprising:
	  			
	 BS01_511 Financial Debt – long term
	  	 	[    	] 
	 BS01_651 Financial Debt – short term
	  	 	[    	] 
		
	 Intra-Group Non-Trade Payables
	  	 	[    	] 
	 BS01_516 Financing from subsidiaries / JV:
	  	 	[    	] 
	 BS01_518 Loans from subsidiaries / JV:
	  	 	[    	] 
		
	 Tax Adjustment, comprising
	  	 	[    	] 
	 BS13_190 Current income tax receivables
	  	 	[    	] 
	 BS01_660 Income taxes payable
	  	 	[    	] 
		  	  
	  
	 
	 Balancing payment required:
				
		  	  
	  
	 

  
  

158 

 Execution Version 
  

Appendix 17 
 US
Government Contracts 
 Paragraphs 1.1 and 8.15 

Part 1 
 List of US
Government Contracts 
  

	1	HHS 101C (Contract No: HHSO100200900101C) 

  

	2	HHS CIADM (Contract No: HHSO100201200003I) 

  

	3	Flu Cell Culture Contract (Contract No: HHSO100200600012C) 

  

	4	Antigen Sparing Contract (Contract No: HHSO100200700030C) 

  

	5	2014 CDC Adult Flu (Contract No: 200-2014-57655) 

  

	6	2014 CDC Pediatric Flu (Contract No: 200-2014—57659) 

  

	7	DLA Flu (Contract No: SPM2DP-13-D-0004) 

  

	8	Federal Supply Schedule (Contract No: V797P-2134D) 

  

	9	Community Economic Development Agreement with North Carolina Economic Investment Committee 

  

	10	Grant Agreement with Wake County, North Carolina 

  

	11	Economic Development Agreement with the Town of Holly Springs, North Carolina 

  

	12	Development Agreement Regarding Infrastructure Construction and Fee Reimbursement with the Town of Holly Springs, North Carolina – Recorded in Bk 12097, Pg 1497, Wake County Registry, as amended by First
Amendment to Development Agreement Regarding Infrastructure Construction and Fee Reimbursement recorded in Bk 14473, Pg 2755, Wake County Registry 

  

	13	HHS Stockpile Contract (Contract No: HHSO100201200014I) 

  

	14	HHS 061C (Contract No: HHSO100201000061C) 

  
  

159 

 Execution Version 
  

Part 2 
 Holly Springs
Facility 
  

	1	Obligation to Obtain US Government Consent 

  

	1.1	Unless the parties agree otherwise, in relation to all US Government Contracts which require formal novation pursuant to 48 C.F.R. Subpart 42.12 (the “Applicable FAR Regulations”), Novartis and the
Purchaser shall obtain all US Government consents necessary for such novation as soon as possible and shall keep each other informed of progress in obtaining such consents. Novartis shall deliver to the Purchaser, on Option Closing, or, if such
consents have not been received at Option Closing, as soon as possible after receipt, copies of any such consent executed by the appropriate parties. 

  

	2	Obligations of the Parties 

  

	2.1	Each party shall use all reasonable endeavours to procure the novation of the US Government Contracts in accordance with this Part 2. The Parties shall perform their respective obligations under the Applicable FAR
Regulations in order to consummate the novation of the US Government Contracts. 

  

	2.2	Without limitation of and subject to the Applicable FAR Regulations: 

  

	 	(a)	Novartis shall begin discussions with the Responsible Contracting Officer (as defined in the Applicable FAR Regulations) as soon as reasonably practicable after the Option Exercise Date, and in doing so shall use its
reasonable endeavours to identify any possible issues with, or objections to, the Transaction and/or the proposed novation of US Government Contracts that the Responsible Contracting Officer and/or US Government might raise; 

 

	 	(b)	the parties shall use their reasonable endeavours to negotiate, as soon as reasonably practicable after the Option Exercise Date and, in any event, no less than 45 Business Days before the intended Option Closing Date,
documentation in Agreed Terms to be entered into as at the Option Closing Date providing for such sub-contracting arrangements as would customarily apply in a transaction such as the Transaction during the period between closing and the novation of
contracts in accordance with the Applicable FAR Regulations and consistent with the following principles: 

  

	 	(i)	during the relevant period, the Purchaser will perform Novartis’s obligations under the relevant US Government Contracts to the extent permissible under the Federal Acquisition Regulations (“FAR”);

  

	 	(ii)	during the relevant period, Novartis will perform its obligations under the relevant US Government Contracts to the extent necessary to entitle it to payment from the US Government for the work performed under such
contracts; and 

  

	 	(iii)	any payments made by the US Government during the relevant period in respect of the relevant contracts shall promptly be paid over to the Purchaser; 

 

	 	(c)	where US Government consent is required before implementing the sub-contracting arrangements described in sub-paragraph (b) above and such consent is not obtained prior to Option Closing, the parties shall put in
place an arrangement between them which achieves substantially the same economic effect as would have been achieved had the sub-contracting arrangements described in sub-paragraph (b) been implemented; 

  
  

160 

 Execution Version 
  

 

	 	(d)	if, following escalation to the senior management of Novartis and Purchaser, the parties do not reach agreement on the documentation referred to in sub-paragraph (b) within the 45 Business Day time period specified
in sub-paragraph (b), any remaining dispute as to the contents of such document may be referred (on the application of either party) for determination by such independent law firm of international standing with extensive experience in advising in
relation to contracts with the US Government, as the parties shall agree or, failing agreement, such firm as is appointed on application by either party by the President of the American Bar Association (the “Firm”). The Firm shall
be requested to make its decision within 30 Business Days of confirmation and acknowledgement by the Firm of its appointment (or such later date as the parties and the Firm agree in writing). The following provisions shall apply once the Firm has
been appointed: 

  

	 	(i)	the parties shall each prepare a written statement within seven days of the Firm’s appointment on the matters in dispute which (together with the relevant supporting documents) shall be submitted to the Firm for
determination and copied at the same time to the other; 

  

	 	(ii)	following delivery of their respective submissions, the parties shall each have the opportunity to comment once only on the other’s submission by written comment delivered to the Firm not later than seven days
after receipt of the other’s submission and, thereafter, neither party shall be entitled to make further statements or submissions except insofar as the Firm so requests (in which case it shall, on each occasion, give the other party (unless
otherwise directed) five days to respond to any statements or submission so made); 

  

	 	(iii)	in giving his/her determination, the Firm shall state his/her reasons for his/her determination; and 

  

	 	(iv)	the Firm shall act as an expert (and not as an arbitrator) in making his/her determination which shall, in the absence of manifest error or fraud, be final and binding on the parties (subject to the Firm’s
determination being compatible with Applicable Law) and, without prejudice to any other rights which they may respectively have under this Deed, the parties expressly waive, to the extent permitted by Applicable Law, any rights of recourse they may
otherwise have to challenge it; 

  

	 	(e)	the parties shall each be responsible for their own costs in connection with the novation of the US Government Contracts. The fees and expenses of the Firm, if appointed, shall be borne equally between the parties or in
such other proportions as the Firm shall determine. 

  
  

161 

 Execution Version 
  

 

	 	(f)	the parties shall prepare and provide (or cause to be prepared and provided) to the Responsible Contracting Officer (as defined in the Applicable FAR Regulations) for Novartis Vaccines and Diagnostics Inc., as promptly
as practicable, and in any event within two months of Option Closing, audited balance sheets of: 

  

	 	(i)	Novartis Vaccines and Diagnostics Inc. as of immediately prior to Option Closing; 

  

	 	(ii)	Novartis Vaccines and Diagnostics Inc. as of immediately following Closing; 

  

	 	(iii)	the Purchaser as of immediately prior to Option Closing; and 

  

	 	(iv)	the Purchaser as of immediately following the Option Closing; and 

  

	 	(g)	the parties shall provide the following information to the Responsible Contracting Officer: 

  

	 	(i)	all information required under 48 C.F.R. § 42.1204(e)-(f), including an opinion of legal counsel for the transferor and transferee stating that the transfer was properly effected under Applicable Law and the
effective date of transfer; and 

  

	 	(ii)	any other relevant information requested by the Responsible Contracting Officer. 

  

	2.3	The provisions of Paragraph 4.2.5 shall apply mutatis mutandis to this Part 2 of Appendix 17. 

  
  

162 

 Execution Version 
  

Appendix 18 Warranties given under Paragraph 9.1 
  

	1.	Authority and Capacity 

  

	1.1	Incorporation 

 Novartis and each Share Seller and Business Seller is validly existing
and is a company duly incorporated and registered under the law of its jurisdiction of incorporation. 
  

	1.2	Authority to enter into Deed 

  

	 	1.2.1	Novartis and each Share Seller and Business Seller has the legal right and full power and authority to enter into and perform this Deed, any Ancillary Agreement to which it is a party and any other documents to be
executed by it pursuant to or in connection with this Deed or any Ancillary Agreement. 

  

	 	1.2.2	The documents referred to in paragraph 1.2.1 will, when executed, constitute valid and binding obligations on Novartis and each Share Seller and Business Seller in accordance with their respective terms.

  

	 	1.2.3	Except as referred to in this Deed, Novartis: 

  

	 	(i)	is not required to make any announcement, consultation, notice, report or filing; and 

  

	 	(ii)	does not require any consent, approval, registration, authorisation or permit, 

 in each case
in connection with the performance of this Deed or any other document referred to in paragraph 1.2.1. 
  

	 	1.2.4	The execution and delivery of the documents referred to in paragraph 1.2.1 and the performance by Novartis, each Share Seller and each Business Seller of their respective obligations under them, will not:

  

	 	(i)	result in a breach of any provision of the memorandum or articles of association or by laws or equivalent constitutional document of the relevant member of the Novartis Group; 

 

	 	(ii)	result in a breach of, or constitute a default under, any instrument or contract to which the relevant member of the Novartis Group is party or by which the relevant member of the Novartis Group is bound where such
breach is material to their ability to perform their obligations under such documents; 

  

	 	(iii)	result in a breach of any existing order, judgment or decree of any court, Governmental Entity by which the relevant member of the Novartis Group is bound and where such breach is material to their ability to perform
their obligations under such documents. 

  
  

163 

 Execution Version 
  

	1.3	Authorisation 

 Novartis and each Share Seller and Business Seller has taken, or will
have taken by Option Closing, all corporate action required by it to authorise it to enter into and to perform this Deed, any Ancillary Agreement to which it is a party and any other documents to be executed by it pursuant to or in connection with
this Deed or any Ancillary Agreement. 
  

	2	Influenza Group 

  

	2.1	Organisation and Standing of the Influenza Group Companies 

  

	 	2.1.1	Appendix 2 sets out a complete and accurate list of each of the Influenza Group Companies, together with its jurisdiction of organisation, its authorised and outstanding capital stock or other equity interests, all of
which equity interests are held by Novartis or an Affiliate of Novartis unless otherwise stated in Appendix 2. 

  

	 	2.1.2	Each Influenza Group Company is duly incorporated, validly existing and in good standing, under the laws of its jurisdiction of organisation and has all necessary corporate power under its constitutional documents to
conduct its portion of the Business as at the date of this Deed. 

  

	2.2	The Shares 

  

	 	2.2.1	Either Novartis or one of its Affiliates is the legal and beneficial owner of the Shares. 

  

	 	2.2.2	There is no option, right to acquire, mortgage, charge, pledge, lien or other form of security or Encumbrance or equity on, over or affecting the Shares or the shares, capital stock or other equity interests in the
Subsidiaries or any of them and there is no agreement or commitment to give or create any. 

  

	 	2.2.3	All of the Shares and all of the shares, capital stock or other equity interests in the Subsidiaries have been duly authorised and validly issued and are fully paid and non-assessable. There are no options, warrants,
rights, convertible, exercisable or exchangeable securities, “phantom” stock rights, stock appreciation rights, stock-based performance units, commitments, Contracts, arrangements or undertakings of any kind to which any of the Influenza
Group Companies is a party or by which it is bound obligating any of the Influenza Group Companies to issue, deliver or sell, or cause to be issued, delivered or sold, additional shares of capital stock or other equity interests in, or any security
convertible into, or exercisable or exchangeable for, any capital stock of, or other equity interest in, such Influenza Group Company. 

  

	 	2.2.4	There are no outstanding Contracts to which any of the Influenza Group Companies is a party or is otherwise bound to repurchase, redeem or otherwise acquire any shares, capital stock or other equity interest of such
Influenza Group Company. 

  

	 	2.2.5	None of the Shares, and the shares, capital stock and other equity interests in the Subsidiaries is subject to and was not issued in violation of any purchase option, call option, right of first refusal, pre-emptive
right, subscription right or similar right or any provision of Applicable Law or the constitutional documents of the Influenza Group Companies. 

  
  

164 

 Execution Version 
  

 

	2.3	The Assets 

 Save in relation to the Transferred Intellectual Property Rights, either
Novartis or another member of the Novartis Group has good and valid title to the assets listed in Paragraph 2.3.1 free and clear of all Encumbrances other than Permitted Encumbrances. 

 

	2.4	Accounts 

 The Accounts of the Company and Novartis Vaccines and Diagnostics Limited:

  

	 	2.4.1	were prepared in accordance with accounting practices generally accepted in the jurisdiction of incorporation of the relevant Influenza Group Company at the time they were audited; and 

 

	 	2.4.2	show, in accordance with applicable legal requirements: 

  

	 	(i)	the assets and liabilities of the relevant Influenza Group Company at the Accounts Date; and 

  

	 	(ii)	of the profits or losses of the relevant Influenza Group Company for the accounting period ended on the Accounts Date. 

  

	2.5	Statement of Net Assets 

  

	 	2.5.1	Appendix 22 sets out the Statement of Net Assets. 

  

	 	2.5.2	The Statement of Net Assets was prepared for the purposes of the transactions contemplated by this Deed and in accordance with the Statement of Net Assets Rules and, so far as Novartis is aware on that basis the
penultimate column of the Statement of Net Assets fairly presents, in all material respects, the financial position of the Influenza Group as of the date thereof, subject to year-end audit adjustments and the absence of footnote discussions and
similar presentation items therein. For the purposes of this paragraph 2.5.2, “in all material respects” shall be construed as having a materiality threshold of US$50m. 

 

	2.6	Changes Since 31 December 2013 

 Except as a result of the execution and delivery of
this Deed and other than as contemplated by Paragraph 2.3.5 or Paragraph 5, from 31 December 2013 to the date of this Deed: 
  

	 	2.6.1	the Business of the Influenza Group has been conducted in all material respects in the ordinary and usual course; 

  

	 	2.6.2	the Influenza Group has not entered into any material contract or commitment outside the ordinary course of business as conducted prior to 31 December 2013; and 

 

	 	2.6.3	to Novartis’s knowledge, there has been no event or circumstance arising which is reasonably likely to have had a material adverse effect. 

 

	2.7	Third Party Indebtedness and financial instruments 

 None of the Influenza Group
Companies: (i) has any Third Party Indebtedness exceeding $1 million (other than short term bank borrowings in the ordinary course of business) or (ii) is a party to any financial instruments (including any swaps or derivatives). 

  
  

165 

 Execution Version 
  

	3	Real Property and Key Sites 

  

	3.1	Company Real Properties 

  

	 	3.1.1	The Company Real Properties are the only material freehold, leasehold or other immovable property in any part of the world owned, used or occupied by the Influenza Group Companies or in respect of which any Influenza
Group Company has any estate, or any material interest, right or liability. 

  

	 	3.1.2	Each of the Company Real Properties is used and occupied for the purpose of the business of a member of an Influenza Group Company. 

  

	 	3.1.3	A member of the Novartis Group is solely legally and beneficially entitled to such Company Real Property. 

  

	 	3.1.4	No person has or will have any right to possession, occupation or use of such Company Real Property in a manner that has or will have a material adverse effect on the use of, or operations at, such Company Real
Property. 

  

	 	3.1.5	There are no mortgages or charges affecting any of the Company Real Properties other than those registered in the relevant Land Register. 

 

	 	3.1.6	There are no material outstanding disputes, actions, claims or demands in respect of any Company Real Property, nor has Novartis or any member of the Novartis Group received any notice threatening the same.

  

	 	3.1.7	In respect of each Company Leased Real Property, all material covenants and conditions contained in the Company Lease have been observed and performed to date. 

 

	3.2	Transferred Real Properties 

  

	 	3.2.1	The Transferred Real Properties are the only material freehold, leasehold or other immovable property in any part of the world owned or occupied by the Influenza Group Businesses or in respect of which any Influenza
Group Business has any estate, or any material interest, right or liability. 

  

	 	3.2.2	Each of the Transferred Real Properties is used and occupied for the purpose of the business of the Influenza Group Business. 

  

	 	3.2.3	A member of the Novartis Group is solely legally and beneficially entitled to such Transferred Real Property. 

  

	 	3.2.4	No person has or will have any right to possession, occupation or use of such Transferred Real Property in a manner that has or will have a material adverse effect on the use of, or operations at, such Transferred Real
Property. 

  

	 	3.2.5	There are no mortgages or charges affecting any of the Transferred Real Properties other than those registered in the relevant Land Register. 

 

	 	3.2.6	There are no material outstanding disputes, actions, claims or demands in respect of any Transferred Real Property, nor has Novartis or any member of the Novartis Group received any notice threatening the same.

  

	 	3.2.7	In respect of each Transferred Leased Real Property, all material covenants and conditions contained in the Lease have been observed and performed to date. 

  
  

166 

 Execution Version 
  

	3.3	Key Sites 

  

	 	3.3.1	The Key Sites are the only properties used or occupied by the Novartis Group for the purpose of Manufacturing in respect of the Business. 

 

	 	3.3.2	No consents, licences, approvals, permits, authorisations or waivers are required from any Landlord, superior landlord or other third party to transfer any Key Site to the Purchaser (or any other member of the
Purchaser’s Group) regardless as to whether such transfer occurs directly (through a change of ownership of the relevant key site) in the case of the Holly Springs Site or indirectly (through the transfer of the Influenza Group Companies) in
the case of the Liverpool Site. 

  

	 	3.3.3	There is no circumstance which would entitle any third party to exercise a right of power of entry or to take possession which would materially adversely restrict the continued possession, enjoyment or existing use of
each Key Site and there are no material restrictive conditions of servitude or public easements attaching to each Key Site. 

  

	 	3.3.4	No member of the Novartis Group has had any notice from any competent authority to make any alteration, repair or addition to any Key Site, including with regards to the disposal of effluent or the state of buildings or
the number of legally required parking spaces which is presently outstanding. 

  

	4	Intellectual Property and Information Technology 

  

	4.1	Appendix 4 sets out, as of the Option Exercise Date, complete and accurate details of Registered Influenza Group Intellectual Property Rights and the Registered
MF59® Intellectual Property Rights, including for each such item, as applicable, (i) the identity of the record owner, (ii) the registration or application number, and (iii) the
jurisdiction of issuance or registration. 

  

	4.2	In relation to Products which are material to the Business, all documents and instruments necessary to maintain and preserve any extension of patent terms including Patent Term Extensions and patent term
adjustments in relation to: (i) the Registered Influenza Group Intellectual Property Rights; (ii) the Registered MF59® Intellectual Property Rights; and (iii) any Registered
Intellectual Property Rights licensed under any Influenza Group Intellectual Property Contracts or MF59® Intellectual Property Rights Contracts for which Novartis controls the prosecution and
maintenance; and in each case, where such applications have a reasonable prospect of success, have been validly executed, delivered and filed in a timely manner with the appropriate Governmental Entity. 

 

	4.3	Each of the Patents: (i) included within the Registered Influenza Group Intellectual Property Rights and the Registered MF59® Intellectual Property
Rights for the Products which are material to the Business; and (ii) to Novartis’s Knowledge, included within the Registered Intellectual Property Rights licensed under the Influenza Group Intellectual Property Contracts for Products which
are material to the Business, in each case, correctly identifies by name each inventor thereof as determined in accordance with the Applicable Law of each jurisdiction in which such Patent issued and/or is pending. 

 

	4.4	To Novartis’s Knowledge, the Patents forming part of: (i) the Registered Influenza Group Intellectual Property Rights; (ii) the Registered
MF59® Intellectual Property Rights; and (iii) the Registered Intellectual Property Rights licensed under the Influenza Group Intellectual Property Contracts, in each case, for the
Products which are material to the Business are subsisting, valid and enforceable and have not lapsed or been abandoned. 

  
  

167 

 Execution Version 
  

	4.5	All renewal, application and other registry fees required for the maintenance, prosecution and enforcement of the Registered Influenza Group Intellectual Property Rights and the Registered MF59® Intellectual Property Rights relating to Products that are material to the Business have been paid. 

  

	4.6	Appendix 4 sets out, as of the Option Exercise Date, a complete and accurate list of each material Influenza Group Intellectual Property Contract and MF59®
Intellectual Property Rights Contract. Neither Novartis nor any of its Affiliates has given, or received, written notice to terminate any material Influenza Group Intellectual Property Contract or
MF59® Intellectual Property Rights Contract, and neither Novartis nor any Affiliate of Novartis is in default of any material Influenza Group Intellectual Property Contract or MF59® Intellectual Property Rights Contract. To Novartis’s Knowledge, no third party is in default under any material Influenza Group Intellectual Property Contract or MF59® Intellectual Property Rights Contract. 

  

	4.7	Novartis and its Affiliates between them own all Registered Influenza Group Intellectual Property Rights and Registered MF59® Intellectual Property Rights
free of all Encumbrances except Permitted Encumbrances. Novartis and its Affiliates have taken reasonable steps to protect the confidentiality of Proprietary Information and Know-How relating to the Products. 

 

	4.8	To Novartis’s Knowledge: (i) the conduct of the Business as currently conducted does not infringe or misappropriate the Intellectual Property Rights of any third party; and (ii) there is no
material judicial, administrative or arbitral action, suit, hearing, inquiry, investigation or other proceeding (public or private) before any Governmental Entity pending against Novartis or any of its Affiliates in which it is alleged that the
conduct of the Business as currently conducted by Novartis and its Affiliates infringes or misappropriates any Intellectual Property Rights of any third party. Neither Novartis nor any of its Affiliates has received any written notice of such
infringement or misappropriation. 

  

	4.9	To Novartis’s Knowledge, no third party is infringing or misappropriating any Influenza Group Intellectual Property Rights, MF59® Intellectual
Property Rights or Proprietary Information and neither Novartis nor its Affiliates have made any such claims against any such persons, nor, to Novartis’s knowledge is there any basis for such a claim. 

 

	4.10	The Influenza Group Intellectual Property Rights, the Intellectual Property Rights licensed under the Influenza Group Intellectual Property Contracts, the
MF59® Rights and the Intellectual Property Rights licensed under the Purchaser Intellectual Property Licence Agreement constitute all the material Intellectual Property Rights used in the
conduct of the Business as currently conducted by Novartis and its Affiliates on a worldwide basis; provided however, that the foregoing is not a representation of non-infringement, non-misappropriation, or any other non-violation of Intellectual
Property Rights of any third party, which representation is solely set out in paragraph 4.8 above. 

  

	4.11	All Information Technology necessary for the Business to be conducted in all material respects as it is carried on at the date of this Deed is: (i) Owned Information Technology; (ii) is Transferred
Information Technology; or (iii) will be provided by Novartis and its Affiliates to the Purchaser and the Business under the Transitional Services Agreement. 

 

	4.12	The Business has not, in the 12 months prior to the date of this Deed, experienced any material disruption in its operations as a result of any failure of its Information Technology.  

  
  

168 

 Execution Version 
  

	5	Contracts 

  

	5.1	No Influenza Group Company or Business Seller is a party to or subject to any Contract, transaction, arrangement, understanding or obligation (other than in relation to any Property, lease or contract of employment,
Information Technology or Intellectual Property Right) which is material to the business of the Influenza Group and which: 

  

	 	5.1.1	is not in the ordinary course of business or is unduly onerous; 

  

	 	5.1.2	is not on an arm’s length basis; 

  

	 	5.1.3	has an unexpired term or likely duration of 10 years or more; 

  

	 	5.1.4	restricts its freedom to carry on its business in any part of the world in such manner as it thinks fit; 

  

	 	5.1.5	involves an aggregate outstanding expenditure by it of more than US$50 million, exclusive of VAT; 

  

	 	5.1.6	can be terminated in the event of a change of underlying ownership or control of an Influenza Group Company; or 

  

	 	5.1.7	involves the supply of goods and services, the aggregate sales value of which (exclusive of VAT) will be more than 5 per cent of turnover of the Influenza Group (exclusive of VAT) for the preceding financial year.

  

	5.2	Save in relation to any Influenza Group Intellectual Property Contract, no Influenza Group Company is in material default under any material Contract to which it is party and no third party is in material default under
any material Contract to which an Influenza Group Company is party and, to the Novartis’s knowledge, there are no circumstances in either case likely to give rise to such a material default. 

 

	5.3	Save in relation to any Influenza Group Intellectual Property Contract, no Business Seller is in material default under any material Contract to which it is party and no third party is in material default under any
material Contract to which a Business Seller is party and, to the Novartis’s knowledge, there are no circumstances in either case likely to give rise to such a material default. 

 

	6	Joint Ventures etc. 

 No Influenza Group Company or Business Seller is, or has agreed to
become, a member of any joint venture, consortium, partnership or other unincorporated association (other than a recognised trade association in relation to which the Influenza Group Company or Business Seller has no liability or obligation except
for the payment of annual subscription or membership fees). 

  
  

169 

 Execution Version 
  

	7	Agreements with Connected Parties 

  

	7.1	There are no existing contracts or arrangements material to the business of the Influenza Group between, on the one hand, any Business Seller or Influenza Group Company and, on the other hand, Novartis, the Share Seller
or any Business Seller other than on normal commercial terms in the ordinary course of business. 

  

	7.2	No Affiliate Contract is required to run the Business and the termination of any Affiliate Contract will not, when taken together with the rights and services under the Ancillary Agreements and for the respective terms
thereof, have a material effect on the Business. 

  

	7.3	The Influenza Group Companies do not currently carry on any Novartis Group Retained Business. 

  

	8	Sufficiency of Influenza Group 

  

	8.1	Each of the assets listed in Paragraph 2.3.1 is owned both legally and beneficially by Novartis or its Affiliates and each of those assets capable of possession is, save where in the possession of third parties in the
ordinary course of business, in the possession of Novartis or its Affiliates. 

  

	8.2	Save for Permitted Encumbrances, no option, right to acquire, mortgage, charge, pledge, line or other form of security or Encumbrance (excluding licences of Intellectual Property or Know-How) or equity on, over or
affecting the whole or any part of the assets listed in Paragraph 2.3.1 is outstanding and, save in relation to Permitted Encumbrances, there is no agreement or commitment entered into by any member of the Novartis Group to give or create any and no
claim has been made against any member of the Novartis Group by any person entitled to any. 

  

	8.3	The Influenza Group Businesses and the assets of the Influenza Group Companies, when taken together with the rights and services under the Ancillary Agreements and for the respective terms thereof: 

 

	 	(i)	comprise all of the assets required to carry out the Business in substantially the same manner as it has been during the twelve months prior to the date of this Deed; and 

 

	 	(ii)	are sufficient in all material respects to carry out the Business after Option Closing substantially as conducted by Novartis and its Affiliates as of the date of this Deed, 

provided however, that the foregoing is not a warranty of non-infringement, non-misappropriation or any other non-violation of Intellectual
Property Rights of any third party, which warranty is solely set out in paragraph 4.8. 
  

	8.4	So far as Novartis is aware, the US Government Contracts set out in Part 1 of Appendix 17 comprise the only US Government Contracts in relation to the Business at the Holly Springs Site conducted in substantially the
same manner as it has been during the twelve months prior to the date of this Deed. 

  

	9	Compliance with Laws, Permits and Anti-Bribery 

  

	9.1	None of Novartis or its Affiliates is in breach of any Applicable Law where such breach is reasonably likely to be material to the Influenza Group. 

 

	9.2	Neither Novartis nor any of its Affiliates has received any written notice from any Governmental Entity that it is not in compliance (or any warning letter that it may not be in compliance) with any Applicable Law or is
not in possession of any permits, licences, certificates or other authorisations or consents of a Governmental Entity in each case as is necessary for the conduct of the Business of the Influenza Group in all material respects as presently conducted
(each a “Permit” and, collectively, the “Permits”), except where such non-compliance or non-possession does not remain outstanding or uncured as of Option Closing or would not reasonably be expected to have a material effect on
the Business. 

  
  

170 

 Execution Version 
  

 

	9.3	With respect to the Influenza Group, since 1 January 2009, neither Novartis nor any of its Affiliates, nor any of their respective directors, officers or employees and, to Novartis’s Knowledge, no
Seller Partner has, directly or indirectly: (i) used any corporate funds for any unlawful contribution, gift, entertainment or other unlawful expense relating to political activity or to influence official action; (ii) made or offered to
make any unlawful payment to any foreign or domestic government official or employee, or agent, political party or any official of such party, or political candidate from corporate funds; (iii) made or offered to make any bribe, rebate, payoff,
influence payment, money laundering, kickback or other unlawful payment; or (iv) violated or is in violation of any provision of any applicable Anti-Bribery Law; and with respect to the Influenza Group, Novartis and its relevant Affiliates have
instituted and maintain policies and procedures reasonably designed to ensure compliance with applicable Anti-Bribery Law. 

  

	9.4	With respect to the Influenza Group, neither Novartis nor any of its Affiliates, nor any of their respective directors, officers or employees and, to Novartis’s Knowledge, no Seller Partner: (i) is currently
the subject of, nor has it been since 1 January 2009, the subject of, any action alleging a violation, or possible violation, of any Anti-Bribery Law, or been since 1 January 2009, the recipient of a subpoena, letter of investigation or
other document alleging a violation, or possible violation, of any Anti-Bribery Law, or (ii) has, since 1 January 2009, improperly or inaccurately recorded in any books and records (A) any payments, cash, contributions, gifts,
hospitalities or entertainment to a foreign or domestic government official, employee of an enterprise owned or controlled in whole or in part by any foreign government, official of a foreign or domestic political party or campaign, or a foreign or
domestic candidate for political office; or (B) other expenses related to political activity or lobbying. 

  

	9.5	With respect to the Influenza Group, since 1 January 2009, neither Novartis nor any of its Affiliates, nor any of their respective directors or officers, and, to Novartis’s Knowledge, none of their respective
employees has received notice that any such person is or has been alleged to be in violation of any sanctions administered by the Office of Foreign Assets Control of the U.S. Department of the Treasury or by the U.S. Department of State or
equivalent measures of the United Kingdom, European Union, or the United Nations (the “Sanctions Law”). With respect to the Influenza Group, neither Novartis nor any of its Affiliates, nor any of their respective directors or
officers, and, to Novartis’s Knowledge, none of their respective employees has conducted any of their business activities whatsoever with, or for the benefit of, a government, national or legal entity to the extent such actions would violate
any Sanctions Law. None of the execution, delivery and performance of this Deed and the direct or indirect use of proceeds from any transaction contemplated hereby or the fulfilment of the terms hereof will result in a violation by any person of any
Sanctions Law. 

  

	9.6	Each member of the Novartis Group, in connection with the Products, the Product Approvals, the Product Applications, the Transferred Contracts and the Transferred Intellectual Property Contracts requires its Service
Providers to act in accordance with the requirements of applicable Anti-Bribery Law and uses all reasonable endeavours to procure that they do so. Each such Service Provider has in place policies, systems, controls and procedures designed to
prevent, and which are reasonably expected to continue to prevent, it and its Associated Persons from violating applicable Anti-Bribery Law. 

  
  

171 

 Execution Version 
  

 

	10	Product Approvals 

  

	10.1	Novartis or one of its Affiliates is the registered holder of each of the Product Approvals. All material Product Approvals held by Novartis or its Affiliates are in full force and effect. No material deficiencies have
been asserted by any applicable Governmental Entity with respect to any Product Approval or Product Filing, nor, to Novartis’s knowledge, are there any facts or circumstances that would be likely to lead to such assertions being made.

  

	10.2	Each Product was and is being researched, developed, manufactured, marketed or sold in all material respects in accordance with the specifications and standards contained in the relevant Product Approval and the related
Marketing Authorisation Data and in accordance with Applicable Law. 

  

	10.3	Neither Novartis or any of its Affiliates has received any written notice that any Governmental Entity with jurisdiction over the Products has commenced or will commence any action: (i) to withdraw the approval of
any Product or otherwise revoke or materially amend any Product Approval or Marketing Authorisation Data; or (ii) enjoin production, marketing or sale of any Product and, to Novartis’s knowledge, no such action has been threatened.

  

	10.4	All application and renewal fees due and payable with respect to all material Product Approvals have been paid. 

  

	10.5	All preclinical and clinical investigations with respect to the Products are being and have been conducted in compliance with Applicable Laws in all material respects. Novartis and its Affiliates have not, and to
Novartis’s Knowledge, none of its Product Partners or any other third party under any Licensed Intellectual Property Contract has received since 1 January 2009, any written notices or other correspondence from any Governmental Entity with
respect to any on-going clinical or pre-clinical studies or tests of any Product requiring the termination, suspension or material modification of such studies or tests. 

 

	10.6	None of Novartis or its Affiliates or, to Novartis’s Knowledge, any Product Partner or any other third parties pursuant to any Licensed Intellectual Property Contract, has any knowledge of any adverse event,
arising since the date three years prior to the date of this Deed, reportable with respect to the safety or efficacy of any Product which is expected to be material. 

 

	11	Product Recall 

  

	11.1	No Product (or any component thereof) has been recalled, suspended, withdrawn, seized, discontinued or the subject of a refusal to file, clinical hold, deficiency or similar action letter (including any correspondence
questioning data integrity) as a result of any action by any Governmental Entity, by Novartis or any of its Affiliates; nor are any such actions pending or under consideration (or any facts, conditions, or circumstance known) by Novartis or any of
its Affiliates, or, to Novartis’s Knowledge, by any Governmental Entity. There is not, to Novartis’s Knowledge, pending or threatened litigation anywhere in the world seeking the recall, withdrawal, suspension, seizure or discontinuance of
any of the Products. 

  
  

172 

 Execution Version 
  

	12	Product Liability 

 The Products sold by the Business during the Product Liability
Relevant Period have complied in all material respects with all applicable product specifications and have been Manufactured in all material respects in accordance with applicable requirements of then current GMP and any Applicable Law, except for
any such non-compliance that has not had, and would not reasonably be expected to have, a materially adverse impact on the relevant Product. 
  

	13	Taxes 

  

	13.1	Each Influenza Group Company and each Tax Group to which it belongs has, and every member of the Novartis Group with an interest in the Influenza Group has in respect of the Influenza Group, duly, and within any
appropriate time limits, filed all Tax Returns required to be filed and has maintained all records required to be maintained for tax purposes in relation to the assets comprised in the Influenza Group; all such information was and remains complete
and accurate in all material respects and all such Tax Returns were complete and accurate in all material respects and were made on the proper basis. 

  

	13.2	There are no Tax liens on any asset comprised in the Influenza Group Businesses (other than Permitted Encumbrances). 

  

	13.3	No Influenza Group Company and no Tax Group to which an Influenza Group Company belongs is currently under audit or examination by a Tax Authority that could result in the assessment of a material amount of Tax
and neither Novartis nor any Influenza Group Company (nor any Tax Group to which an Influenza Group Company belongs) has received notice from a Tax Authority of any dispute or disagreement outstanding or contemplated at the date of this Deed with
any Tax Authority regarding liability or potential liability to any Tax recoverable from any Influenza Group Company or regarding the availability of any relief from Tax to any Influenza Group Company and, so far as Novartis is aware, there are no
circumstances which make it likely that any such dispute or disagreement will commence. 

  

	13.4	The Disclosure Letter lists every written agreement that an Influenza Group Company has entered into, in each case, which is currently in force, to have its Tax affairs dealt with on a consolidated basis and for
any Tax sharing arrangement (including without limitation any arrangement under which Tax losses or Tax reliefs are surrendered or agreed to be surrendered or claimed) in respect of the profits, gains or losses of that Influenza Group Company with
any company not being another Influenza Group Company. 

  

	13.5	No Influenza Group Company, and no Tax Group to which an Influenza Group Company belongs, has received or requested any extension of time to file a Tax Return that remains unfiled or has granted or requested a waiver or
extension of a limitation on any period for audit and examination or assessment and collection of Tax for any taxable period as to which Tax could be assessed. 

  

	13.6	No member of the Novartis Group with an interest in the Influenza Group has received notice from a Tax Authority of, and so far as Novartis is aware, there is not any dispute or disagreement outstanding at the
date of this Deed with any Tax Authority regarding the proper method of computing the profits of the Influenza Group (or any part of it) for Tax purposes or the proper treatment for VAT purposes of any supplies of goods or services made (or treated
as made) in the course of the Influenza Group and, so far as the Novartis is aware, there are no circumstances which make it likely that any such dispute or disagreement will commence. 

  
  

173 

 Execution Version 
  

 

	13.7	So far as the Novartis is aware, no Influenza Group Company benefits from any preferential Tax regime, granted by law or by special authorisation issued by any Tax Authority or by any other authority, which would in
whole or in part be withdrawn as a result of the signature of this Deed. 

  

	13.8	So far as Novartis is aware, no Tax Authority has within the past three years operated or agreed to operate any special arrangement (being an arrangement which is not based on relevant legislation or any published
practice) in relation to any assets comprised in the Influenza Group. 

  

	13.9	In respect of all documents which establish or are necessary to establish the title of the relevant member of the Novartis Group to each material asset comprised in the Influenza Group, or by virtue of which the
relevant member of the Novartis Group has any right in respect of each such asset, all applicable stamp duties, transfer taxes, registration charges or similar duties or charges have been duly paid. 

 

	13.10	So far as Novartis is aware, other than any payments which are of a nature or type (such as expenditure on business entertainment or marketing) which are not deductible for Tax purposes by reason of a general
restriction on deductibility applicable to payments of that nature or type under the laws of the jurisdiction in which the relevant Influenza Group Company is resident for Tax purposes or carries on its business, no Influenza Group Company is under
any obligation to make any future payment which will not be deductible for Tax purposes in an amount which, if the payment were deductible for Tax purposes, would reduce the Tax liability of the relevant Influenza Group Company by an amount
exceeding US$5 million. 

  

	13.11	The country of incorporation which is given in Appendix 2 for each Influenza Group Company is also the Tax residence of each Influenza Group Company is the only country whose Tax Authorities seek to charge Tax on the
worldwide profits or gains of that Influenza Group Company and no Influenza Group Company has, within the past three years, carried on the Business of the Influenza Group through a permanent establishment in any other country. 

 

	14	Environmental Matters 

  

	14.1	To Novartis’s Knowledge, each Business Seller (with respect to its conduct of the Business and any Transferred Real Property) and Influenza Group Company is in compliance in all material respects with all
Environmental Laws. 

  

	14.2	To Novartis’s Knowledge, each Influenza Group Company and each Business Seller (with respect to its conduct of the Business and any Transferred Real Property) possesses all material Permits required under
applicable Environmental Laws necessary to conduct its portion of the Business. 

  

	14.3	To Novartis’s Knowledge, no Influenza Group Company nor any Business Seller (with respect to its conduct of the Business and any Transferred Real Property) has received any written notice alleging a material
violation of any Environmental Laws, other than matters that have been resolved in all material respects. 

  
  

174 

 Execution Version 
  

	14.4	To Novartis’s Knowledge, no Influenza Group Company nor any Business Seller (with respect to its conduct of the Business and any Transferred Real Property) has received any written notice or claim alleging
that it is or may be liable to any person in any material respect under any applicable Environmental Law as a result of a release or threatened release of any Hazardous Substance at any Transferred Real Property, other than matters that have been
resolved in all material respects. 

  

	14.5	To Novartis’s Knowledge, no Influenza Group Company nor any Business Seller (with respect to its conduct of the Business and any Transferred Real Property) is a party to any pending proceedings relating to
any Environmental Laws, other than proceedings that would not reasonably be expected to have a material adverse effect.  

  

	15	Employees 

  

	15.1	The Employees are all employed by an Influenza Group Company or a Business Seller and work wholly or substantially in the Business.  

 

	15.2	The Disclosure Letter contains a true, complete and correct list of the following information in respect of each Influenza Business Employee and each Influenza Group Company Employee as of 17 April 2014
(organised by country and, in relation to any Influenza Group Company, by legal employer): (A) employee identification details; (B) date of birth; (C) employment status (part-time or full-time); (D) employment start date;
(E) base salary; (F) target annual incentive for 2014 (and actual bonus for 2013); and (G) target long-term incentive for 2014 (and actual long-term incentive for 2013).  

 

	15.3	In each of the Material Employee Jurisdictions except as would not be reasonably expected to have a material adverse effect: 

 

	 	15.3.1	as of the date of this Deed there is not, and in the two years prior to the date of this Deed there has not been, nor to Novartis’s Knowledge is there pending or threatened, any labour strike, dispute, work
stoppage or lockout by any group of either Influenza Business Employees or Influenza Group Company Employees; 

  

	 	15.3.2	no trade union or works council is recognised in any way for bargaining, information or consultation purposes in relation to any of the Influenza Business Employees or Influenza Group Company Employees and no collective
bargaining negotiations, whether voluntary or mandatory, are currently taking place with respect to any of the Influenza Business Employees or Influenza Group Company Employees and, as of the date of this Deed, no Influenza Group Company or Business
Seller is a party to any agreement (whether legally binding or not) with any trade union or works council affecting any Influenza Business Employee or Influenza Group Company Employee and there is no existing dispute with any such representative
body (or, to Novartis’s Knowledge, pending or threatened) in relation to the Business; 

  

	 	15.3.3	there is no material litigation, claim or other dispute existing, nor to the Novartis’s Knowledge, pending or threatened by or in respect of any Employees (or any former employees of the Influenza Group Companies)
in respect of their employment or any matter arising from their employment; and 

  

	 	15.3.4	no Influenza Group Company or Business Seller has, within the 2 years prior to the date of this Deed, closed any plant or facility, effectuated any layoffs of employees or implemented any early retirement, separation or
similar programme in each case in violation of the WARN Act, nor has any Influenza Group Company or Business Seller announced any such action or programme for the future. 

  
  

175 

 Execution Version 
  

	15.4	To Novartis’s Knowledge, and subject to the next sentence, no Influenza Group Company Employee will, as a result of the entering into of this Deed or Option Closing, be entitled to receive any payment or benefit
which he would not otherwise be entitled to receive (including, without limitation, an enhanced severance package on a subsequent termination) or be entitled to treat either such event as amounting to a breach of his terms and conditions of
employment or to treat himself as redundant or dismissed or released from any obligation. This warranty shall not apply to any retention arrangements (in the form of cash or shares) put in place by Novartis or any member of the Novartis Group to
retain key employees in connection with the matters contemplated by this Deed as described in paragraphs 10 and 11 of Appendix 10, or any arrangement relating to the share-based incentive schemes of the Novartis Group pursuant to paragraph 11 of
Appendix 10. 

  

	15.5	Since the Statement of Net Assets Date, no material change has been made, announced or proposed to the emoluments or other terms of employment of any Employee, and no such change, and no negotiation or request for such
a change, is due or expected within 12 months from the date of this Deed, and the employing company is under no obligation to make such a change (with or without retrospective operation) other than any arrangement relating to the share-based
incentive schemes of the Novartis Group pursuant to paragraph 11 of Appendix 10. 

  

	16	Employee Benefits 

  

	16.1	The Disclosure Letter contains a true, complete and correct list of all bonus, staff incentives (including any share-based incentive schemes), redundancy or other benefits payable on termination of employment (whether
voluntary or involuntary but excluding arrangements required in accordance with Applicable Law), ill-health, Employee Benefits or other benefits which are the material benefits available to the Influenza Business Employees and the Influenza Group
Company Employees in the Material Employee Jurisdictions. To Novartis’s Knowledge, other than any arrangement relating to the share-based incentive schemes of the Novartis Group pursuant to paragraph 11 of Appendix 10, no Influenza Group
Company or Business Seller has made any promises or commitments to make available any additional benefits to the Influenza Business Employees and the Influenza Group Company Employees in the Material Employee Jurisdictions, or to modify or change in
any material way any existing benefits in the Material Employee Jurisdictions, or to continue or maintain the level of any existing benefits generally for any period, which in each case could reasonably be expected to have a material adverse effect.

  

	16.2	The Disclosure Letter contains true and complete copies of all documents of any written benefit schemes, plans or arrangements referred to in paragraph 16.1 above applicable to either Influenza Business Employees or
Influenza Group Company Employees in the Material Employee Jurisdictions containing material terms (including governing documents, and for benefit plans that are not share-based incentive schemes, related trust agreements or other funding documents)
and a true, complete and correct summary of the material terms of any unwritten benefit schemes, plans or arrangements referred to in paragraph 16.1 above. 

  
  

176 

 Execution Version 
  

 

	16.3	Benefit Plans 

  

	 	16.3.1	In the Material Employee Jurisdictions all benefit and compensation schemes, plans, funds, contracts, policies, agreements or arrangements (other than the US Benefit Plans and any schemes, plans, funds, contracts,
policies, agreements or arrangements operated by any Governmental Entity) (A) operated by or on behalf of an Influenza Group Company or Business Seller, with respect to Influenza Group Company Employees or Influenza Business Employees or
current or former employees or directors of an Influenza Group Company, (B) in respect of which any Influenza Group Company or Business Seller, with respect to Influenza Group Company Employees or Influenza Business Employees, Novartis or any
member of the Novartis Group contributes or has contributed or (C) in respect of which any Influenza Group Company or Business Seller, with respect to Influenza Group Company Employees or Influenza Business Employees, has any liability (whether
actual or contingent), including, but not limited to, plans providing Employee Benefits or during periods of sickness or disablement, or any deferred or incentive compensation, welfare, healthcare, medical, stock or stock-related award plans,
including individual pension commitments, “jubilee” pension benefits and retirement and termination indemnity arrangements, (such schemes, plans, funds, contracts, policies, agreements and arrangements hereinafter being referred to as
“Non-US Benefit Plans”) and the US Benefit Plans have been administered in accordance with their terms and are in compliance with Applicable Law, except for any failures to so administer or be in compliance that, individually
and in the aggregate, would not reasonably be expected to have a material adverse effect. All required filings for all Benefit Plans have been made on time and with the appropriate Governmental Entity, except for any failures to timely file that,
individually and in the aggregate, would not reasonably be expected to have a material adverse effect. As of the date of this Deed, there is no existing, pending or, to the Novartis’s Knowledge, threatened material litigation, claim or other
dispute relating to Benefit Plans. 

  

	 	16.3.2	The Influenza Group Companies or Business Sellers, with respect to Influenza Group Company Employees or Influenza Business Employees in each Material Employee Jurisdiction, (A) are in material compliance with all
Applicable Law respecting employment, employment practices, terms and conditions of employment, occupational health, safety, wages and hours, (B) have withheld all amounts required by Applicable Law, collective bargaining agreements or the
Benefit Plans to be withheld from the wages, salaries or other payments to the Influenza Group Company Employees or the Influenza Business Employees and former employees of the Influenza Group Companies, (C) in respect of the Influenza Group
Company Employees or Influenza Business Employees or former employees of the Influenza Group Companies, are not liable under any applicable provisions of the Benefit Plans and any Applicable Law for any arrears, wages, Taxes, other than payments not
yet due, or any penalty for failure to comply with the foregoing and (D) are not liable under any applicable provisions of the Benefit Plans and any Applicable Law for any payment to any trust or other fund or to any Governmental Entity with
respect to unemployment compensation benefits, workers compensation, social security or other benefits for Influenza Group Company Employees or Influenza Business Employees or former employees of the Influenza Group Companies, other than payments
not yet due, except, in each case, for any failures to comply, failures to withhold or liabilities that, individually and in the aggregate, would not reasonably be expected to have a material adverse effect. 

  
  

177 

 Execution Version 
  

 

	 	16.3.3	All material contributions that the Influenza Group Companies or Business Sellers, with respect to Influenza Business Employees or the Influenza Group Company Employees in a Material Employee Jurisdiction, are required
to make to any Benefit Plan in respect of the period on or before the date of this Deed have been fully and timely paid when due. 

  

	17	Litigation 

  

	17.1	No Influenza Group Company or Business Seller is involved whether as claimant or defendant or other party in any claim or Proceeding (other than as claimant in the collection of debts arising in the ordinary course of
its business none of which exceeds US$5 million) which is material to the Business. 

  

	17.2	To Novartis’s Knowledge, no such claim or Proceeding of material importance is pending or threatened by or against any Influenza Group Company or Business Seller. 

 

	18	Insolvency 

  

	18.1	No order has been made and no resolution has been passed for the winding up of any Share Seller or any Business Seller, or for the appointment of any administrator, receiver (including administrative receiver) or
liquidator (provisional or otherwise) over the whole or any part of the property, assets and/or undertaking of any Share Seller or any Business Seller. 

  

	18.2	No petition has been presented or meeting convened for the purpose of considering a resolution or resolution circulated for the winding up of any Share Seller or any Business Seller, or for the appointment of any
administrator, receiver (including administrative receiver) or liquidator (provisional or otherwise) over the whole or any part of the property, assets and/or undertaking of any Share Seller or any Business Seller. 

 

	18.3	Neither any Share Seller nor any Business Seller has stopped payment or suspended payment of its debts generally, is insolvent or deemed unable to pay its debts as they fall due. 

 

	18.4	Neither Chiron Technologies Limited nor Chiron Pharmaceuticals Limited, each of which is in the process of liquidation, owns any assets in relation to the Business. 

 

	19	Insurance 

 All material insurance policies relating to the Influenza Group are in full
force and effect and, to Novartis’s Knowledge, no notice of cancellation, termination or default has been received with respect to any such insurance policy. All premiums due and payable on such policies covering periods up to Option Closing
have been paid in full or accrued. 
  

	20	Consents and Licences 

  

	20.1	All governmental and quasi-governmental licences, consents, permissions, waivers, exceptions and approvals required for carrying on the Business of the Influenza Group, the absence of which, individually or in the
aggregate, would be material to the Influenza Group, are in force and, to Novartis’s Knowledge, no written notice has been received by Novartis or any member of the Novartis Group which indicates that any such licence, consent, permission,
waiver, exception or approval is likely to be revoked or which may confer a right of revocation. 

  
  

178 

 Execution Version 
  

	21	Delinquent and Wrongful Acts 

  

	21.1	To Novartis’s Knowledge, no member of the Novartis Group has, during the Product Liability Relevant Period, committed any criminal or illegal act which relates to the Influenza Group Companies or the Influenza
Group Businesses. 

  

	21.2	No member of the Novartis Group has, during the Product Liability Relevant Period, received notification that any investigation or inquiry is being or has been conducted by any supranational, national or local
authority or governmental agency specifically related to the Influenza Group, which is material in respect of the Influenza Group. 

  

	22	Compliance 

  

	22.1	No member of the Novartis Group has received in the Product Liability Relevant Period any written notification or written claim (in each case, which remains outstanding) that it has conducted the Business of the
Influenza Group with respect to the research, development, manufacturing, distribution and sale of the Products in a manner which does not in any respect comply with all Applicable Law, or which in any respect is defective or dangerous, where the
pursuit of any such notification or claim is, or would reasonably be expected to be, material in respect of the Influenza Group. 

  

	22.2	So far as Novartis is aware, the Influenza Group has, and has during the Product Liability Relevant Period been, operated in all material respects in compliance with all Applicable Law or standards and to
Novartis’s Knowledge there are no circumstances that could involve or lead to a material violation of any material Applicable Law or standards. 

  

	23	Pipeline Products 

  

	23.1	Novartis or one of its Affiliates is the registered holder of each of the Pipeline Product Approvals, and the benefit of each Pipeline Product Approval can be transferred to the Purchaser (or another member of
the Purchaser’s Group) regardless as to whether such transfer occurs directly (whether by way of transfer, reissuance or any other equivalent mechanism under Applicable Law of the relevant jurisdiction) or indirectly (through the transfer of
the Influenza Group Companies). 

  

	23.2	All development activities in relation to the Pipeline Products have been conducted in the ordinary course and in accordance with all Applicable Law and standards and to Novartis’s Knowledge there are no
circumstances relating to the development of the Pipeline Products that could involve or lead to a material violation of any material Applicable Law or standards. 

 

	23.3	No material regulatory, clinical or safety event has occurred in relation to the Pipeline Products and no member of the Novartis Group has received any notification or claim from any person of any such event (or the
possibility of any such event). 

  

	24	Manufacturing Licences and Manufacture 

  

	24.1	All Manufacturing Licences which are material to the Influenza Group, are in effect and are validly held by a member of the Novartis Group and during the Product Liability Relevant Period, to Novartis’s Knowledge,
no member of the Novartis Group has received any written notice of any suit, action or proceeding regarding the revocation or modification of any such Manufacturing Licence. 

  
  

179 

 Execution Version 
  

 

	24.2	No directive, order or notice has been given to Novartis or any member of the Novartis Group by any relevant regulatory authority to update, modify, amend, vary, supplement or delete any process and/or
methodology relevant to the manufacture at the Key Sites of any Product currently manufactured at the Key Sites and, so far as Novartis is aware, no such directive, order or notice is pending. 

 

	25	No Industrial Action 

 To Novartis’s Knowledge, there is no industrial action
currently taking place, threatened or expected which is, or is expected to be, material to the Business. 
  

	26	Ongoing Clinical Trials 

 Appendix 21 contains a complete list of all Ongoing Clinical
Trials. 

  
  

180 

 Execution Version 
  

Appendix 19 
 Warranties
given by the Purchaser under Paragraph 9.3 
  

	1	Authority and Capacity 

  

	1.1	Incorporation 

 The Purchaser is validly existing and is a company duly incorporated and
registered under the law of its jurisdiction of incorporation. 
  

	1.2	Authority to enter into Deed 

  

	 	1.2.1	The Purchaser and each member of its Group has the legal right and full power and authority to enter into and perform this Deed and any Ancillary Agreement to which it is a party and any other documents to be executed
by it pursuant to or in connection with this Deed or any Ancillary Agreement. 

  

	 	1.2.2	The documents referred to in paragraph 1.2.1 will, when executed, constitute valid and binding obligations on the Purchaser and each member of its Group in accordance with their respective terms. 

 

	 	1.2.3	Except as referred to in this Deed the Purchaser: 

  

	 	(i)	is not required to make any announcement, consultation, notice, report or filing; and 

  

	 	(ii)	does not require any consent, approval, registration, authorisation or permit, 

 in each case
in connection with the performance of this Deed or any other document referred to in paragraph 1.2.1. 
  

	 	1.2.4	The execution and delivery of the documents referred to in paragraph 1.2.1 and the performance by the Purchaser and each member of its Group of their respective obligations under them, will not: 

 

	 	(i)	result in a breach of any provision of the memorandum or articles of association or by laws or equivalent constitutional document of the relevant member of the Purchaser’s Group; 

 

	 	(ii)	result in a breach of, or constitute a default under, any instrument or contract to which the relevant member of the Purchaser’s Group is party or by which the relevant member of the Purchaser’s Group is bound
where such breach is material to their ability to perform their obligations under such documents; 

  

	 	(iii)	result in a breach of any existing order, judgment or decree of any court, Governmental Entity by which the relevant member of the Purchaser’s Group is bound and where such breach is material to their ability to
perform their obligations under such documents. 

  

	1.3	Authorisation 

 The Purchaser has taken, or will have taken by Option Closing, all
corporate action required by it to authorise it to enter into and to perform this Deed and any Ancillary Agreement to which it is a party and any other documents to be executed by it pursuant to or in connection with this Deed or any Ancillary
Agreement. 

  
  

181 

 Execution Version 
  

Appendix 20 
 Pre-Option
Closing Obligations 
 (Paragraph 5.2) 

Part 1 
 Novartis
Restrictions 
 The actions for the purposes of Paragraph 5.2.2 are: 
  

	1	amend or otherwise modify the constitutional documents of any Influenza Group Company other than minor or administrative amendments or modifications which are not adverse to the Business or to the Purchaser of
any member of the Purchaser’s Group; 

  

	2	create, allot or issue, or grant an option or right to subscribe for or purchase, any share capital or other securities or loan capital of any Influenza Group Company; 

 

	3	repay, redeem or repurchase any share capital, or other securities of any Influenza Group Company; 

  

	4	make any acquisition or disposal which has a value in excess of US$10 million, exclusive of VAT; 

  

	5	grant any guarantee or indemnity for the obligations of any person which has a value in excess of US$5 million (other than in the ordinary course of trading); 

 

	6	dispose of, or agree to dispose of, any material asset or material stock at below market value other than in the ordinary course of business; 

 

	7	acquire or agree to acquire any share, shares or other interest in any company, partnership or other venture, other than an investment of 5 per cent or less of the total shares or interest in such company,
partnership or venture and provided the investment is not more than US$5 million; 

  

	8	enter into, extend, amend, give notice to terminate or vary in any material respect any lease of real property or change the existing use of such property which is material to the Influenza Group;

  

	9	cease, compromise or settle any dispute including litigation, arbitration or administrative proceedings in relation to (or otherwise compromise or settle) any claim by Pfizer which relates to any form of
meningococcal vaccine (Group B) whether adjuvanted, combined or otherwise (or any similar product) of Pfizer or enter into any licensing arrangements with Pfizer in relation to such products or Intellectual Property Rights relevant to them;

  

	10	enter into any borrowing facility which has a value in excess of US$10 million; 

  

	11	enter into any off-balance sheet finance arrangements; 

  

	12	sell, lease, license, transfer or dispose of, or create any Encumbrance over, any material assets of the Influenza Group other than (i) in the ordinary course of business (including any sale of inventory);
or (ii) any Permitted Encumbrance; 

  
  

182 

 Execution Version 
  

 

	13	(a) terminate, materially amend (or amend in any respect in relation to a Product or Pipeline Product which is material to the Business) or grant any material waiver under (or any waiver in relation to a Product
or Pipeline Product which is material to the Business) any Influenza Group Intellectual Property Contract or MF59® Intellectual Property Rights Contract other than in the ordinary course of
business, or (b) terminate any Transferred Contract other than in the ordinary course of business or terminate any Contract held by the Influenza Group Companies other than in the ordinary course of business; 

 

	14	fail to comply in all material respects with all Applicable Laws, Product Approvals, Pipeline Product Approvals and Marketing Authorisations applicable to the operation of the Business; 

 

	15	assign, dispose of, license (save in respect of non-exclusive licences relating to Novartis’s research, development or Commercialisation of the Products) or abandon any material Influenza Group Intellectual
Property Rights or material MF59® Intellectual Property Rights (or any Registered Influenza Group Intellectual Property Rights or Registered
MF59® Intellectual Property Rights in respect of a Product or Pipeline Product which is material to the Business), or cease to prosecute or otherwise dispose of, fail to maintain, defend or
pursue applications for any material Registered Influenza Group Intellectual Property Rights or Registered MF59® Intellectual Property Rights (or any Registered Influenza Group Intellectual
Property Rights or Registered MF59® Intellectual Property Rights in respect of a Product or Pipeline Product which is material to the Business) in each case other than in the ordinary course
of business;  

  

	16	save where requested in writing by the Purchaser or required by any applicable Governmental Entity, cancel or surrender or materially amend (or amend in any respect in relation to a Product or Pipeline Product
which is material to the Business) any applications, submissions or filings with respect to Registered Influenza Group Intellectual Property Rights or Registered MF59® Intellectual Property
Rights, in each case other than in the ordinary course of business; 

  

	17	instigate, cease, compromise or settle any litigation or arbitration proceedings related to the Influenza Group in relation to a claim for which the potential liability attaching thereto is in excess of US$5
million; 

  

	18	make any material amendment to any Marketing Authorisation, Manufacturing Licence or Environmental Permit, in each case except to the extent required by: (a) Applicable Law; (b) any Governmental Entity,
or (c) the standards, policies and procedures of the Novartis Group as then in force; 

  

	19	enter into or amend in any material respect any Transferred Contract, or incur any commitment, which is not capable of being terminated without compensation at any time with twelve months’ notice or less or
which is not in the ordinary course of business, or which involves or may involve total annual expenditure in excess of US$10 million, exclusive of VAT; 

  

	20	enter into any contract which would materially restrict the freedom of the Influenza Group to operate in any part of the world; 

  
  

183 

 Execution Version 
  

 

	21	take any steps to increase or reduce the proportion of time spent working in the Business by any employee of any member of the Novartis Group or to transfer the employment of any Employee to another member of the
Novartis Group or to employ or offer to employ or engage any new persons in the Business other than in the ordinary course of business consistent with past practice and subject to an aggregate increase of not more than 2.5 per cent. in total
staff costs of the Business per annum, provided that this restriction shall not apply to the redeployment of any Influenza Group Company Employee who is not wholly or substantially engaged in the Business before the Option Closing Date to
employment with another member of the Novartis Group; 

  

	22	make, or commit to make, any changes to the terms and conditions of employment (including pension fund commitments or any increase to remuneration) or to any employee benefit plan of any Employee, other than
(a) those required by Applicable Law or (b) pursuant to normal annual pay reviews in the ordinary course of business consistent with past practice and subject to an aggregate increase of not more than five per cent. in total staff costs of
the Business per annum or (c) retention arrangements in the form of cash or shares to retain key employees in connection with the matters contemplated by this Deed as described in paragraphs 10 and 11 of the Appendix 10, or (d) those
changes to the share-based incentive schemes made for the purpose of complying with paragraph 11 of Appendix 10;  

  

	23	make any promises or commitment to any Employees or employee representative body concerning the matters contemplated by this Deed or offer or otherwise give any assurances to any Employees as to the possibility
of continued employment with the Purchaser’s Group after Option Closing; 

  

	24	make any change or commitment to make any change to the terms of any redundancy policy or practice applying to the Employees (including amounts payable on redundancy); 

 

	25	enter into (where there is no existing agreement) or materially amend any collective bargaining agreement or other contract with a labour organisation, works council or employee organisation to create new or
additional obligations for any member of the Novartis Group, in each case in relation to the Business; and 

  

	26	undertake any recall or withdrawal of any Product (other than in the ordinary course of business or to comply with Applicable Law). 

  
  

184 

 Execution Version 
  

Part 2 
 Novartis
Obligations 
  

	1	Obligations to be Satisfied prior to the Option Closing 

 At least five Business Days
prior to the Option Closing Date, Novartis shall provide the Purchaser with a list of any required actions that must be taken within three (3) months after Option Closing with respect to the payment of any registration, maintenance, or renewal
fees or the filing of any documents, applications or certificates in order to maintain any Registered Influenza Group Intellectual Property Rights and Registered MF59® Intellectual Property
Rights in full force and effect. Upon the Purchaser’s reasonable request, Novartis shall execute and deliver assignment agreements and other transfer documentation, including, where applicable, duly executed assignments of such Intellectual
Property Rights for recording with the applicable Governmental Entity, and to take such further actions, in each case at the Purchaser’s reasonable cost and expense and as may be required, to give effect to the foregoing assignments. 

 

	2	Obligations from the Date of the Deed to the Option Closing 

 The requirements for the
purposes of Paragraph 5.2.3 are: 
  

	2.1	so far as permitted by Applicable Law, Novartis shall procure that each member of the Novartis Group informs the Purchaser promptly if Novartis becomes aware of, or has reasonable grounds for suspecting any
violation of Anti-Bribery Law which is reasonably likely to have an impact on the Influenza Group, and 

  

	2.2	carry out capital expenditure in relation to any site operated by the Influenza Group where the Products are manufactured in a manner materially consistent (and within a variance of 10 per cent. in
aggregate) with Novartis’s capital expenditure programme for the Business as at the date of this Deed;  

  

	2.3	maintain and keep any Registered Influenza Group Intellectual Property Rights and Registered MF59® Intellectual Property Rights and ensure that all filings
and notifications required to be made in respect of the same are made in accordance with past practice; 

  

	2.4	progress, in accordance with past practice any applications, submissions, filings or other correspondence relating to the grant of new Registered Influenza Group Intellectual Property Rights and Registered MF59® Intellectual Property Rights; 

  

	2.5	progress, in accordance with past practice during the Product Liability Relevant Period, any applications, submissions, filings or other correspondence initiated by such member of the Novartis Group relating to
the grant of new Manufacturing Licences and Environmental Permits in respect of the Influenza Group; 

  
  

185 

 Execution Version 
  

 

	2.6	continue to promote, market and Commercialise the Products in accordance with past practice during the Product Liability Relevant Period and do not materially accelerate or increase the quantity of Products
distributed to the relevant distributors and/or wholesalers, in each case except in respect of a bona fide increase in demand for the relevant Product by the relevant distributor and/or wholesaler which has not been stimulated in any way by
discounts, rebates, claw-backs or the like outside of the ordinary course of business or the grant of preferred terms offered by the Novartis Group outside of the ordinary course; 

 

	2.7	not discontinue or cease to operate or materially reduce the resources applied to any part of the Business; 

  

	2.8	maintain the level of Manufacturing Stocks and Manufacturing Inventory held for use in the Business materially in accordance with the Novartis Group’s operating policies as applied to the Influenza Group
from time to time in force; 

  

	2.9	maintain the level of In-Market Inventory held for use in the Business materially in accordance with the Novartis Group’s operating policies as applied to the Influenza Group from time to time in force;

  

	2.10	use all reasonable endeavours to ensure that the manufacture of the Products by the Novartis Group comply with Applicable Law;  

 

	2.11	use all reasonable endeavours to ensure that the Products sold by the Business comply with Applicable Law;  

  

	2.12	continue to conduct the Ongoing Clinical Trials in accordance with GCP and the Novartis Group’s policies and procedures; 

 

	2.13	notify the Purchaser in writing of any actual safety or quality issue in respect of any Product or the manufacture of any Product (as soon as reasonably practicable after becoming aware of the same) which issue
the relevant member of the Novartis Group, acting reasonably and in good faith, considers material in the context of the manufacture or commercialisation of such Product; 

 

	2.14	so far as permitted by Applicable Law, report periodically to the Purchaser concerning the status of the Business, including delivering to the Purchaser as soon as reasonably practicable each month:

  

	 	2.14.1	an update on material commercial developments in relation to the Business and the Products during the previous month; 

  

	 	2.14.2	the gross profit for each Product in respect of the previous month; and 

  

	2.15	a report on the month-end in-trade inventory in respect of each Product for the previous month prepared in the ordinary course of business consistent with past practice, together with a comparison against the
comparable period of trading for the prior year; and 

  

	2.16	shall or shall procure that each member of the Novartis Group continues to respond to any Calls For Tender in accordance with past practices in the relevant market. 

  
  

186 

 Execution Version 
  

Part 3 
 Exceptions

 Paragraphs 5.1 and 5.2 shall not operate so as to prevent or restrict the declaration, making or payment of any dividend or other distribution to
shareholders. 

  
  

187 

 Execution Version 
  

Appendix 21 
 Ongoing
Clinical Trials 
 (Paragraph 1.1) 
  

	1	Ongoing interventional trials 

 [***] 

 

	2.	Ongoing observational trials 

 [***] 

 
  

	***	Note: Confidential treatment has been requested with respect to the information contained within the [***] marking. Such portions have been omitted from this filing and have been filed separately with the Securities and
Exchange Commission. 

  
  

188 

 Execution Version 
  

Appendix 22 
 Statement of
Net Assets 
 (Paragraph 1.1) 

Part 1 
 Statement of Net
Assets Rules 
 Part 1 

Statement of Net Assets Rules 
 Part 1 of
Appendix 22 comprises the Statement of Net Assets Rules. 
 Part 2 of Appendix 22 sets forth, for illustrative purposes only, a computation of the Statement
of Net Assets as of the close of business on 31 December 2013 (the “Statement of Net Assets”). 
  

	1	Preparation of the Statement of Net Assets 

  

	1.1	Period 

 The Statements of Net Assets is prepared as of the close of business on the
final day of the relevant calendar month. 
  

	1.2	Translation of Reporting Entity’s Statements of Net Assets 

 A reporting entity
reports in local currency. All reports are translated into US Dollars by Novartis for reporting purposes. The Statement of Net Assets is translated with the period-end exchange rates which are the rates provided by Novartis Group Treasury and are
based on Bloomberg’s mid-morning CET exchange rates and are published in the Group Treasury section of the Novartis intranet. 
  

	1.3	Novartis Reporting System and Materiality: 

  

	 	1.3.1	Financial information is obtained from the Financial Consolidation & Reporting System of Novartis and the supporting general ledgers are prepared in accordance with Novartis’s Accounting Manual (the
“NAM”). The Financial Consolidation & Reporting System is the system of record for Novartis external reporting. References in the Statement of Net Assets included as part 2 of this Appendix 23 shown as “BS01 lines
010-671” relate to the groupings shown in Novartis’s monthly reporting form “BS01 – Balance sheet”. 

  
  

189 

 Execution Version 
  

 

	 	1.3.2	For Novartis’s reporting purposes, the financial reporting of a legal entity is separated into a divisional part, which includes operating items and a corporate part, which mainly captures the amounts
related to taxes, post-employment benefit obligations and most of the financial assets and liabilities. The Statement of Net Assets contains the business of the Vaccines division (including the Business) as included in Novartis’s segment
reporting (column C - “Vaccines Divisional Reported Statement of Net Assets”), and items of the corporate Statement of Net Assets for the Vaccines Group Companies (as defined in the Vaccines SAPA) (Column D – “Vaccines Statement
of Net Assets of the Corporate part of the Vaccines Group Companies” and items related to the Statement of Net Assets for the Novartis Vaccines Institute for Global Health (column E – “Statement of Net Assets of the part of Novartis
Vaccines Institute for Global Health”) as well as adjustments for certain items which are either excluded from or added to the transaction (columns F -“Excluded items”). A US$10 million threshold was applied. Column H shows the impact
of the Business which is excluded from the transaction contemplated by the Vaccines SAPA. For the purpose of the carve out of the influenza business allocations have been made based on management’s best estimate of the contribution of the
Business. For Receivables own BU (BS01_130) and Payables own BU (BS01_620) items related to the entity in Liverpool, which will not transfer have been added back into the statement of net assets. For other entities amounts related to the Business
have not been added back in as they are offsetting each other. Payables and Receivables to Other BU’s related to the Business have been left in the statement of net assets as they are not expected to be material on a net basis. A materiality
threshold of US$50 million applies to the Business. 

  

	 	1.3.3	The Statement of Net Assets has been prepared as follows: 

  

	 	(i)	in accordance with the specific accounting treatments set out below; and, subject thereto, 

  

	 	(ii)	adopting the same accounting principles, methods, procedures and practices utilized in preparing the consolidated financial statements of Novartis AG as described in the Novartis Accounting Manual applied on a
consistent basis using consistent estimation methodologies and judgments and with consistent classifications and, subject thereto, 

  

	 	(iii)	in accordance with IFRS. 

  

	 	1.3.4	For the avoidance of doubt, paragraph 1.3.3(i) shall take precedence over paragraphs 1.3.3(ii) and 1.3.3(iii), and paragraph 1.3.3(ii) shall take precedence over paragraph 1.3.3(iii). 

 

	2	Specific Policies 

 The following supplement the description in the NAM for certain items
included in the Vaccines Group (as defined in the Vaccines SAPA) Statement of Net Assets: 
  

	2.1	Non-Current assets 

  

	 	2.1.1	Property, plant and equipment (BS01_010) 

 For the purpose of the Vaccines Divisional
Statement of Net Assets an amount of US$122 million is included for assets which are not dedicated to the Vaccines Group and will not transfer to the purchaser under the Vaccines SAPA (as reflected in Column F). These assets comprise all property,
plant and equipment located in Emeryville, California and in Pernambuco, Brazil. 

  
  

190 

 Execution Version 
  

 

	 	2.1.2	Financial assets &– subsidiaries/JV (BS01_040) 

 This line reflects equity
investments that Vaccines Group Companies hold in other Vaccines Group Companies. These relationships have been eliminated in the Statement of Net Assets (as reflected in Column F). 

 

	 	2.1.3	Total financing and loans to subsidiaries/JV (BS01_050) 

 This line represents financing
owed by any member of the Novartis Group to a Transferred Subsidiary. For the purpose of the Statement of Net Assets balances within the Vaccines Group have been excluded (as reflected in Column F). 

 

	2.2	Current Assets: 

  

	 	2.2.1	Trade receivables (BS01_120) 

 An amount of US$51 million of trade receivables is
excluded from this Statement of Net Assets (as reflected in Column F) as it relates to non-Vaccines business activity such as licence fee receivables related to HCV and HIV patents. 

 

	 	2.2.2	Receivables own BU (BS01_130) 

 Column C of the Statement of Net Assets represents
receivables against other entities within the Vaccines division, which are offset by an equivalent amount in the line Payables own BU. These amounts have been eliminated in Column F of the Statement of Net Assets. 

 

	 	2.2.3	Receivables own BU – Corporate and Institute for Global Health (BS01_130) 

 Columns
D and E of the Statement of Net Assets represent receivables against other members of the Novartis Group as well as other Vaccines Group Companies. The receivables against other Vaccines Group Companies have been eliminated in Column F of the
Statement of Net Assets. 
  

	 	2.2.4	Receivables other BU’s (BS01_140) 

 Receivables recognized on this line are due
from members of the Novartis Group operating in the Pharmaceuticals and Sandoz segments which are selling vaccines in markets where the Vaccines Group is not represented. The receivable of the Vaccines Institute for Global Health relates to a
Transferred Subsidiary and has therefore been eliminated. 
  

	 	2.2.5	Other current assets (BS01_160) 

 An amount of US$5 million is related to current assets
of the divested Diagnostics business, which did not transfer to the purchaser of the Diagnostics business. They are excluded from the Statement of Net Assets as they do not relate to the activities of the Vaccines Group (as reflected in Column F).
Furthermore, an amount of US$1 million is related to assets of the plant in Pernambuco, Brazil which will not be transferred and has therefore been excluded (as reflected in Column F) from the Statement of Net Assets. 

  
  

191 

 Execution Version 
  

 

	 	2.2.6	Prepaid share-based payments (BS01_161) 

 An asset for prepaid share-based compensation
is recognized to reflect Novartis’s internal charge-out mechanism for its equity settled share-based compensation plans. For entities settling the charge for the shares at the beginning of the vesting period, it reflects the expense yet to be
recognized for the unvested part of a share-based compensation plan. This asset has been excluded (as reflected in Column F) and is not reflected in the Statement of Net Assets. 

 

	2.3	Long-term Liabilities: 

  

	 	2.3.1	Total financing and loans from subsidiaries/JV (BS01_520) 

 This line represents
financing received from any member of the Novartis Group. For the purpose of the Statement of Net Assets, balances within the Vaccines Group have been excluded (as reflected in Column F). 

 

	 	2.3.2	Other non-current liabilities (BS01_540) 

 Column F excludes net liabilities for
post-employment benefits of US$90 million included in the corporate part of the Vaccines Group Companies as their treatment is addressed separately in Appendix 11. 
  

	2.4	Current Liabilities: 

  

	 	2.4.1	Trade payables (BS01_610) 

 An amount of US$11 million included in this line relates to
the construction of the plant in Pernambuco, Brazil which will not be transferred and has therefore been excluded (as reflected in Column F) from the Statement of Net Assets. 
  

	 	2.4.2	Payables own BU (BS01_620) 

 Column C of the Statement of Net Assets represents payables
against other entities within the Vaccines division, which are offset by an equivalent amount in the line Receivables own BU. These amounts have been eliminated in the Statement of Net Assets. 

  
  

192 

 Execution Version 
  

 

	 	2.4.3	Payables own BU – Corporate (BS01_620) 

 Column D of the Statement of Net Assets
represents payables against other Vaccines Group Companies as well as payables against other members of the Novartis Group. The corporate payables against Vaccines Group Companies have been eliminated in Column F of the Statement of Net Assets. 

 

	 	2.4.4	Payables other BU’s (BS01_630) 

 Payables recognized on this line are due to
members of the Novartis Group, except for a payable recognized by the Vaccines Institute for Global Health, which is owed to a Vaccines Group Company and has therefore been eliminated. 

 

	 	2.4.5	Accrued and other current liabilities (BS01_670) 

 An amount of US$35 million is related
to short- term liabilities of the divested Diagnostics business, which did not transfer to the purchaser of this Diagnostics business. They are excluded from the Statement of Net Assets (as reflected in Column F) as they do not relate to the
activities of the Vaccines Group. Furthermore, an amount of US$3 million relates to the construction of the plant in Pernambuco, Brazil, which will not be transferred and has therefore also been excluded (as reflected in Column F) from the Statement
of Net Assets. An amount of US$1 million relates to legal fees for litigation not related to the Vaccines Group. 
  

	 	2.4.6	Accrued share-based payments (BS01_671) 

 A liability for share-based compensation is
recognized to reflect Novartis’s internal charge-out mechanism for its equity-settled share-based compensation plans. For entities settling the charge for the shares after the vesting period, it reflects the expense recognized for the vested
part of a share based compensation plan. This liability has been excluded (as reflected in Column F) and is not reflected in the Statement of Net Assets. 

  
  

193 

 Execution Version 
  

Part 2 
 Statement of Net
Assets 
 All amounts in $ thousands 
  

																					
	 	 	 Column A
	 	 Column B
	 	 Column C
	 	 Column D
	 	 Column E
	 	 Column F
	 	 Column G
	 	 Column H
	 	Column I	 
	 	 	 Vaccines
Dataroom
balance
sheet

Dec 31,
2013
	 	 Adjustments*
	 	 Vaccines
Divisional

Reported
 Statement
of
Net
Assets at
Dec 31,
2013
	 	 Vaccines
Statement
of Net
Assets
of
the
Corporate
part of the
Vaccines
Group
Companies
	 	 Statement
of Net
Assets
of
the part of
Novartis
Vaccines
Institute
for Global
Health
	 	 Excluded
items
	 	 Vaccines
Group
Statement
of Net
Assets

Dec 31,
2013
	 	 Influenza
business
	 	Vaccines
Group
(excl.
Influenza
business)
Statement
of Net
Assets
Dec 31,
2013	 
										
	 BS01_010 Property, plant and equipment
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	 	778,011	  
	 BS01_020 Intangible assets
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	 	1,853,635	  
	 BS01_034 Financial assets_ associated companies
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	 	777	  
	 BS01_035 Financial assets - 3rd parties and loans to AC
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	 	17,981	  
	 BS01_040 Financial assets & subsidiaries//JV
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	 	0	  
	 BS01_042 Deferred tax assets
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	 	78,951	  
	 BS01_044 Other non-current non-financial assets
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	 	23,129	  

  

	***	Note: Confidential treatment has been requested with respect to the information contained within the [***] marking. Such portions have been omitted from this filing and have been filed separately with the Securities and
Exchange Commission. 

  
  

194 

 Execution Version 
  

 

																					
	 BS01_050 Total financing and loans to subsidiaries / JV
		[***]		[***]		[***]		[***]		[***]		[***]		[***]		[***]		 	58,563	  
	BS01_110 Total inventories		[***]		[***]		[***]		[***]		[***]		[***]		[***]		[***]		 	400,663	  
	 BS01_120 Trade receivables (3rd parties and AC)
		[***]		[***]		[***]		[***]		[***]		[***]		[***]		[***]		 	335,387	  
	BS01_130 Receivables own BU		[***]		[***]		[***]		[***]		[***]		[***]		[***]		[***]		 	21,818	  
	 BS01_130 Receivables own BU – Corporate and Institute for Global Health
		[***]		[***]		[***]		[***]		[***]		[***]		[***]				 	865	  
	 BS01_140 Receivables other BU’s
		[***]		[***]		[***]		[***]		[***]		[***]		[***]		[***]		 	20,419	  
	 BS01_160 Other current assets(3rd parties and AC)
		[***]		[***]		[***]		[***]		[***]		[***]		[***]		[***]		 	70,208	  
	 BS01_161 Prepaid share-based payments
		[***]		[***]		[***]		[***]		[***]		[***]		[***]		[***]		 	0	  
	 BS01_180 Cash & cash equivalents
		[***]		[***]		[***]		[***]		[***]		[***]		[***]		[***]		 	4,393	  
	Total Assets		[***]		[***]		[***]		[***]		[***]		[***]		[***]		[***]		 	3,664,799	  
	 Bs01_511 Financial debt – long-term
		[***]		[***]		[***]		[***]		[***]		[***]		[***]		[***]		 	8	  

  

	***	Note: Confidential treatment has been requested with respect to the information contained within the [***] marking. Such portions have been omitted from this filing and have been filed separately with the Securities and
Exchange Commission. 

  
  

195 

 Execution Version 
  

 

																					
	 BS01_520 Total financing and loans from subsidiaries// JV
		[***]		[***]		[***]		[***]		[***]		[***]		[***]		[***]		 	680,633	  
	 BS01_535 Deferred tax liabilities
		[***]		[***]		[***]		[***]		[***]		[***]		[***]		[***]		 	92,072	  
	 BS01_540 Other non-current liabilities (3rd parties and AC)
		[***]		[***]		[***]		[***]		[***]		[***]		[***]		[***]		 	54,438	  
	 BS01_610 Trade payables (3rd parties and AC)
		[***]		[***]		[***]		[***]		[***]		[***]		[***]		[***]		 	176,115	  
	 BS01_620 Payables own BU
		[***]		[***]		[***]		[***]		[***]		[***]		[***]		[***]		 	15,056	  
	 BS01_620 Payables own BU – Corporate
		[***]		[***]		[***]		[***]		[***]		[***]		[***]		[***]		 	3,239	  
	 BS01_630 Payables other BU’s
		[***]		[***]		[***]		[***]		[***]		[***]		[***]		[***]		 	40,675	  
	 BS01_651 Financial debt – Short-term (3rd parties and AC)
		[***]		[***]		[***]		[***]		[***]		[***]		[***]		[***]		 	1,395	  
	 BS01_660 Income taxes payable
		[***]		[***]		[***]		[***]		[***]		[***]		[***]		[***]		 	55,060	  
	 BS01_670 Accrued and other current liabilities (3rd parties and AC)
		[***]		[***]		[***]		[***]		[***]		[***]		[***]		[***]		 	240,559	  
	 BS01_671 Accrued share-based payments
		[***]		[***]		[***]		[***]		[***]		[***]		[***]		[***]		 	0	  

  

	***	Note: Confidential treatment has been requested with respect to the information contained within the [***] marking. Such portions have been omitted from this filing and have been filed separately with the Securities and
Exchange Commission. 

  
  

196 

 Execution Version 
  

 

																					
	 Total Liabilities
		[***]		[***]		[***]		[***]		[***]		[***]		[***]		[***]		 	1,359,250	  
	 Net Assets
		[***]		[***]		[***]		[***]		[***]		[***]		[***]		[***]		 	2,305,549	  

  

	*	The difference for BS01_010 Property, plant and equipment relates to the plant built in Pernambuco Brazil, which had been excluded in the dataroom balance sheet. 

The difference for BS01_160 Other current assets is composed of other current assets related to the Diagnostics business, but which have not been transferred
to Grifols; these were excluded in the dataroom balance sheet. 
 Line BS01_620 and Line BS01_630 have been combined into the line Intercompany payable in
the dataroom balance sheet and items related to Pernambuco have been excluded. 
 The difference for BS01_670 Accrued and other current liabilities is
composed of items related to the Diagnostics business, which have not been transferred to Grifols and were therefore excluded in the dataroom balance and items related to the Plant in Pernambuco, which have also been excluded in the dataroom balance
sheet. 
  
  

	***	Note: Confidential treatment has been requested with respect to the information contained within the [***] marking. Such portions have been omitted from this filing and have been filed separately with the Securities and
Exchange Commission. 

  
  

197 

 Execution Version 
  

Attachment 1: Purchaser Intellectual Property Licence – Agreed Terms 

Novartis shall grant the Purchaser a licence on terms consistent with the following Agreed Terms. 

 

			
	 Flu Licence

 

	Definitions		 Each of “Affiliate”, “Business”, “Option Closing”, “Intellectual Property
Rights”, “Out-Licensing Programme Intellectual Property Rights”, “Novartis Group”, “Novartis Marks” and “Transferred Intellectual Property Rights” have the meanings given
to them in the Put Option Deed (relating to all or part of the Influenza Business of the Novartis Group).
  

“Licensed IP Rights” means Intellectual Property Rights not transferred to the Purchaser under the Put Option Deed, which are owned by, or
licensed (to the extent it has a right to sub-license) to, any member of the Novartis Group as at the date of Option Closing and related to, used in or held for use in the Business excluding: (i) the Transferred Intellectual Property Rights; (ii)
the Out-Licensing Programme Intellectual Property Rights; and (iii) the Novartis Marks.

	
	Retained IP Licence - licence from Novartis to the Purchaser of retained IP
		
	Licence Grant		 Novartis entity(ies) grant[s] to the Purchaser entity(ies) an exclusive, irrevocable, fully paid-up, royalty-free, freely-assignable (with
notification to be provided after assignment other than to Affiliates), worldwide licence or sub-licence, with a right to sub-license (with notification to be provided after grant of sub-licence other than to Affiliates), of the Licensed IP
Rights:
  
 (A) for research and development purposes; and

 
 (B) to use, manufacture, have manufactured, promote, distribute, market, sell, have sold,
offer for sale, import, export and otherwise commercialise any products and services,
  

in relation to the Business.

		
	Term		Perpetual
		
	Prosecution and maintenance		 Licensor shall:
  

•  pay renewal fees and take all reasonable actions to maintain registered Licensed IP Rights;

 
 •  not surrender or allow to lapse
all registered Licensed IP Rights;
  

•  use reasonable endeavours to prosecute to grant any applications for registered Licensed IP Rights;
and
  
 •  keep Licensee
reasonably informed of all actions relevant to the Licensee’s rights and allow Licensee the opportunity to comment on any such actions and/or filings.
  

If the Licensor wishes to take any action in derogation of the obligations above, it shall provide the Licensee with [30] days’ prior notice giving the
Licensee the option to take over the prosecution or maintenance of the relevant Licensed IP Rights.
  

If the Licensor wishes to abandon any Licensed IP Right, Licensee will have a right of first refusal to take on that Licensed IP Right.

 Boilerplate 
 The
Purchaser Intellectual Property Licence Agreement boilerplate provisions shall be conformed to those of the Put Option Deed, including variation and waiver; costs; notarial fees, registration, stamp and transfer taxes and duties; notices; invalidity
or conflict; counterparts; and governing law and submission to jurisdiction. 

  
  

1 

 Execution Version 
  

Table of Contents 
  

					
	Contents	  	Page	 
		
	 1       Interpretation and amendment post signing
	  	 	17	  
		
	 2       Sale and Purchase of the Influenza Group
	  	 	38	  
		
	 3       Consideration
	  	 	44	  
		
	 4       Conditions
	  	 	46	  
		
	 5       Pre-Option Closing
	  	 	49	  
		
	 6       Option Closing
	  	 	53	  
		
	 7       Post-Option Closing Adjustments
	  	 	56	  
		
	 8       Post-Option Closing Obligations
	  	 	58	  
		
	 9       Warranties
	  	 	65	  
		
	 10     Limitation of Liability
	  	 	67	  
		
	 11     Claims
	  	 	70	  
		
	 12     Restrictive Covenants
	  	 	71	  
		
	 13     Confidentiality
	  	 	73	  
		
	 14     Insurance
	  	 	75	  
		
	 15     Other Provisions
	  	 	76	  
		
	 Appendix 1 Details of the Share Seller, Shares etc. (Paragraph 2.1)
	  	 	83	  
		
	 Appendix 2 Company and Subsidiaries
	  	 	84	  
		
	 Appendix 3 The Properties Part 1 (Company Real Property)
	  	 	86	  
		
	 Appendix 3 The Properties Part 2 (Transferred Real Property)
	  	 	88	  
		
	 Appendix 3 The Properties Part 3 Terms relating to the Company Real Property
	  	 	89	  
		
	 Appendix 3 The Properties Part 4 Terms relating to the Transferred Real Property
	  	 	92	  

  
  

2 

 Execution Version 
  

					
	 Appendix 4 Influenza Group Intellectual Property Rights and Influenza Group Intellectual Property Contracts (Paragraph 2.3)
		 	104	  
		
	 Appendix 5 [Intentionally Left Blank]
		 	105	  
		
	 Appendix 6 [Intentionally Left Blank]
		 	106	  
		
	 Appendix 7 Permitted Encumbrances (Paragraph 1.1)
		 	107	  
		
	 Appendix 8 Product Approvals and Product Applications Part 1 Terms relating to the Product Approvals and Product Applications
		 	108	  
		
	 Appendix 8 Product Approvals and Product Applications Part 2 Transfer of Marketing Authorisations
		 	110	  
		
	 Appendix 8 Product Approvals and Product Applications Part 3 List of Products, Products Under Registration and Pipeline
Products
		 	116	  
		
	 Appendix 8 Product Approvals and Product Applications Part 4 Tenders
		 	118	  
		
	 Appendix 9 Transferred Contracts (Paragraph 2.3)
		 	119	  
		
	 Appendix 10 Employees (Paragraph 2.4.1)
		 	122	  
		
	 Appendix 11 Employee Benefits (Paragraph 2.4.2)
		 	139	  
		
	 Appendix 13 Allocation of Purchase Price (Paragraphs 3.3 and 7.6)
		 	148	  
		
	 Appendix 14 VAT (Paragraph 3.4)
		 	149	  
		
	 Appendix 15 Option Closing Obligations (Paragraph 6)
		 	151	  
		
	 Appendix 16 Post Option Closing Adjustments (Paragraph 7)
		 	153	  
		
	 Appendix 17 US Government Contracts Paragraphs 1.1 and 8.15
		 	159	  
		
	 Appendix 18 Warranties given under Paragraph 9.1
		 	163	  
		
	 Appendix 19 Warranties given by the Purchaser under Paragraph 9.3
		 	181	  
		
	 Appendix 20 Pre-Option Closing Obligations (Paragraph 5.2)
		 	182	  
		
	 Appendix 21 Ongoing Clinical Trials (Paragraph 1.1)
		 	188	  
		
	 Appendix 22 Statement of Net Assets (Paragraph 1.1)
		 	189	  

 Attachment 1 Purchaser Intellectual Property Licence – Agreed Terms 

  
  

3 

 Execution Version 
  

Schedule 2 
 Option 2
Assets 
  

	3	Following entry into this Deed, the parties shall discuss and agree, in good faith and acting reasonably, the amendments that are necessary to Schedule 1 to reflect that the Option 2 Assets that are being bought and
sold rather than the Business (the “Option 2 Changes”) (recognising that the Option 2 Changes to Schedule 1 may be required in addition to other changes pursuant to Schedule 4). 

 

	3.1	Set-out in paragraph 2 of this Schedule 2 is a non-exhaustive list of the Option 2 Changes. If the parties reach agreement on the Option 2 Changes, a document signed by each party setting out Option 2 Changes shall be
supplementary to this Schedule 2 and treated as though it were set out in paragraph 2 of this Schedule 2. If, following appropriate escalation to their respective senior management, the parties do not reach agreement within 60 Business Days
following 29 May 2014, any remaining dispute as to the Option 2 Changes may be referred (on the application of either party) for determination by such independent commercial Queen’s Counsel (based in London and who has been a Queen’s
Counsel for at least five years) as the parties shall agree or, failing agreement, such Queen’s Counsel as is appointed on application by either party by the Chairman of the Bar Council in London from time to time (the “QC”).
The QC shall be requested to make his/her decision within 30 Business Days of confirmation and acknowledgement by the QC of his/her appointment (or such later date as the parties and the QC agree in writing). The following provisions shall apply
once the QC has been appointed: 

  

	 	3.1.1	the QC shall be instructed that, in making his/her determination, no inference should be drawn from the fact that amendments/additions that are proposed by a party for inclusion were not included in this Schedule 2 at
the date of this Deed; 

  

	 	3.1.2	the parties shall each prepare a written statement within seven days of the QC’s appointment on the matters in dispute which (together with the relevant supporting documents) shall be submitted to the QC for
determination and copied at the same time to the other; 

  

	 	3.1.3	following delivery of their respective submissions, the parties shall each have the opportunity to comment once only on the other’s submission by written comment delivered to the QC not later than seven days after
receipt of the other’s submission and, thereafter, neither party shall be entitled to make further statements or submissions except insofar as the QC so requests (in which case it shall, on each occasion, give the other party (unless otherwise
directed) five days to respond to any statements or submission so made); 

  

	 	3.1.4	in giving his/her determination, the QC shall state his/her reasons for his/her determination; and 

  

	 	3.1.5	the QC shall act as an expert (and not as an arbitrator) in making his/her determination which shall, in the absence of manifest error or fraud, be final and binding on the parties and, without prejudice to any other
rights which they may respectively have under this Deed, the parties expressly waive, to the extent permitted by law, any rights of recourse they may otherwise have to challenge it. 

 

	 	3.1.6	The parties shall each be responsible for their own costs in connection with the review and agreement or determination of the contents of this Schedule 2. The fees and expenses of the QC shall be borne equally between
the parties or in such other proportions as the QC shall determine. 

  
  

4 

 Execution Version 
  

 

	4	For the avoidance of doubt, if the Put Option is exercised in respect of the Option 2 Assets then in respect of the Option 2 Assets: 

 

	4.1	the Headline Price in paragraph 3.1.1 shall be US$80 million; 

  

	4.2	the Minimum Claims figure in paragraph 10.3.1 (i) shall be US$80,000; 

  

	4.3	the Aggregate Minimum Claims figure in paragraph 10.4.1 shall be US$800,000; 

  

	4.4	the Maximum Liability in paragraph 10.5.1 shall be 30% of the Headline Price of US$80 million; 

  

	4.5	the Maximum Liability in paragraph 10.5.2 shall be US$80 million; and 

  

	4.6	paragraph 12 of Schedule 1 shall only apply from such time as Novartis no longer has any interest in the Business (and shall then apply for the stated periods). 

 

	5	If the Put Option is exercised in respect of the Option 2 Assets all provisions of Schedule 1 relating to intellectual property and intellectual property contracts shall be amended to achieve the following:

  

	5.1	Novartis entity(ies) shall: 

  

	 	5.1.1	assign to the Purchaser all Intellectual Property Rights and, subject to Appendix 9 (Transferred Contracts), all Intellectual Property Contracts, Predominantly Related to the Business (the “Transferred
Business IPR” and the “Transferred Intellectual Property Contracts” respectively. 

  

	 	5.1.2	grant the Purchaser entity(ies) a licence on terms consistent with the following Agreed Terms. 

  

			
	Licence		An exclusive, irrevocable, fully paid-up, royalty-free, freely-assignable (with notification to be provided after assignment other than to Affiliates), worldwide licence or sub-licence, with a right to sub-license (with
notification to be provided after grant of sub-licence other than to Affiliates), of the Licensed IP Rights (defined in the row below):
		
			 (A) for research and development purposes; and

		
			 (B) to use, manufacture, have manufactured, promote, distribute, market, sell, have sold, offer for sale, import, export and otherwise commercialise any
products and services,

		
			in relation to the Business.
		
	Licensed IP Rights		Intellectual Property Rights not transferred under Clause 3.1.1 above, which are owned by, or licensed (to the extent it has the rights to sub-license) to, any member of the Novartis Group as at the date of Option Closing and
related to, used in or held for use in the Business excluding: (i) the Transferred Intellectual Property Rights; (ii) the Out-Licensing Programme Intellectual Property Rights; and (iii) the Novartis Marks.
		
	Term and Termination		Perpetual

  
  

5 

 Execution Version 
  

 

			
	Prosecution and maintenance		 Licensor shall:
  

•    pay renewal fees and take all reasonable actions to maintain registered Licensed IP
Rights;
  
 •    not
surrender or allow to lapse all registered Licensed IP Rights;
  

•    use reasonable endeavours to prosecute to grant any applications for registered Licensed
IP Rights; and
  

•    keep Licensee reasonably informed of all actions relevant to the Licensee’s
rights and allow Licensee the opportunity to comment on any such actions and/or filings.
  

If the Licensor wishes to take any action in derogation of the obligations above, it shall provide the Licensee with [30] days’ prior notice giving the
Licensee the option to take over the prosecution or maintenance of the relevant Licensed IP Rights.
  

If the Licensor wishes to abandon any Licensed IP Right, Licensee will have a right of first refusal to take on that Licensed IP Right.

		
	Boilerplate		The boilerplate provisions shall be conformed to those of the Put Option Deed, including variation and waiver; costs; notarial fees, registration, stamp and transfer taxes and duties; notices; invalidity or conflict;
counterparts; and governing law and submission to jurisdiction.

  

	5.2	The Purchaser entity(ies) shall grant back to Novartis entity(ies) a licence on terms consistent with the following Agreed Terms. 

  

			
	Licence		 An irrevocable, fully paid-up, royalty-free, freely-assignable (with notification to be provided after assignment other than to
Affiliates), worldwide licence or sub-licence, with a right to sub-license (with notification to be provided after grant of sub-licence other than to Affiliates), of the Licensed IP Rights (defined in the row below):

 
 (A) for research and development purposes; and

 
 (B) to use, manufacture, have manufactured, promote, distribute,
market, sell, have sold, offer for sale, import, export and otherwise commercialise any products and services,
  

that will be:
  

(i) exclusive in relation to the retained business; and
  

(ii) non-exclusive in relation to the Business.

		
	Licensed IP Rights		Transferred Business IPR and a sub-licence of the Transferred Intellectual Property Contracts (to the extent it has the rights to sub-license) transferred under this Deed.

  
  

6 

 Execution Version 
  

 

			
	Term and Termination		Perpetual
		
	Prosecution and maintenance		 Licensor shall:
  

•    pay renewal fees and take all reasonable actions to maintain registered Licensed IP
Rights;
  
 •    not
surrender or allow to lapse all registered Licensed IP Rights;
  

•    use reasonable endeavours to prosecute to grant any applications for registered Licensed
IP Rights; and
  

•    keep Licensee reasonably informed of all actions relevant to the Licensee’s
rights and allow Licensee the opportunity to comment on any such actions and/or filings.
  

If the Licensor wishes to take any action in derogation of the obligations above, it shall provide the Licensee with [30] days’ prior notice giving the
Licensee the option to take over the prosecution or maintenance of the relevant Licensed IP Rights.
  

If the Licensor wishes to abandon any Licensed IP Right, Licensee will have a right of first refusal to take on that Licensed IP Right.

		
	Boilerplate		The boilerplate provisions shall be conformed to those of the Put Option Deed, including variation and waiver; costs; notarial fees, registration, stamp and transfer taxes and duties; notices; invalidity or conflict;
counterparts; and governing law and submission to jurisdiction.

  
  

7 

 Execution Version 
  

Schedule 3 
 Option 3

  

	6	Following entry into this Deed, the parties shall discuss and agree, in good faith and acting reasonably, the amendments that are necessary to Schedule 1 to reflect that the Option 3 Assets that are being bought and
sold rather than the Business (the “Option 3 Changes”) (recognising that the Option 3 Changes to Schedule 1 may be required in addition to other changes pursuant to Schedule 4). 

Paragraph 1.1 of Schedule 2 applies mutatis mutandis in relation to agreeing the Option 3 Changes as if set out in this Schedule 3. 

 

	7	For the avoidance of doubt, if the Put Option is exercised in respect of the Option 3 Assets, then in respect of the Option 3 Assets: 

 

	7.1	the Headline Price in paragraph 3.1.1 shall be US$145 million; 

  

	7.2	the Minimum Claims figure in paragraph 10.3.1 (i) shall be US$145,000; 

  

	7.3	the Aggregate Minimum Claims figure in paragraph 10.4.1 shall be US$1,450,000; 

  

	7.4	the Maximum Liability in paragraph 10.5.1 shall be 30% of the Headline Price of US$145 million. 

  

	7.5	the Maximum Liability in paragraph 10.5.2 shall be US$145 million; and 

  

	7.6	paragraph 12 of Schedule 1 shall only apply from such time as Novartis no longer has any interest in the Business (and shall then apply for the stated periods). 

 

	8	Paragraph 3 of Schedule 2 applies mutatis mutandis in relation to agreeing the Option 3 Changes as if set out in this Schedule 3. 

  
  

8 

 Execution Version 
  

Schedule 4 
 Option 4
Products Terms 
  

	9	Option 4 

 The following table sets out the Option 4 Assets. No other assets or liabilities shall
transfer in respect of the Option 4 Assets. Where there are references to a Third Party Purchaser, Novartis shall procure that the Third Party Purchaser agrees to provide the specified services to the Purchaser in the event of an exercise of the Put
Option in respect of the Option 4 Assets. 
  

			
	 Term
	  	 Description

	 Products
	  	 The Option 4 Assets shall be such of the following products as Novartis shall specify:

1. Agrippal (Europe)
 2. Agrippal (Canada)

3. Agrippal (South Korea)
 4. Agrippal (Brazil)

5. Agrippal (India)
 6. Agrippal (Colombia)

7. Agrippal (Mexico)
 8. Agrippal (Australia)

9. Agrippal (all ex-Europe and ex-Canada jurisdictions)
 10.
Agrippal (global)
 11. Fluvirin (US)
 12. Fluvirin (UK)

13. Fluvirin (global)
 14. Fluvirin (all ex-US and ex-UK
jurisdictions)
 15. Fluad (US)
 16. Fluad (Europe)

17. Fluad (Mexico)
 18. Fluad (Canada)

19. Fluad (South Korea)
 20. Fluad (Brazil)

21. Fluad (Colmbia)
 22. Fluad (Argentina)

23. Fluad (all ex-US and ex-Europe jurisdictions)
 24.
Optaflu/Flucelvax (US)
 25. Optaflu/Flucelvax (Europe)
 26.
Optaflu/Flucelvax (South Korea)
 27. Optaflu/Flucelvax (Brazil)

28. Optaflu/Flucelvax (Australia)
 29. Optaflu/Flucelvax (all
ex-US and ex-Europe discussions)

  
  

9 

 Execution Version 
  

			
	 Term
	  	 Description

		  	 30. Optaflu/Flucelvax (Argentina)
 30b.
Optaflu/Flucelvax (India)
 31. QIVc (USA)
 32. QIVc
(Europe)
 33. QIVc (South Korea)
 34. QIVc (India)

35. QIVc (China)
 36. QIVc (Brazil)

37. QIVc (Argentina)
 38. QIVc (Chile)

39. aQIV (US)
 40. aQIV (UK)

41. Egg pipeline (US)
 42. Egg pipeline (Europe)

43. Egg pipeline (all jurisdictions except US and Europe)
 44.
Cell pipeline (US)
 45. Cell pipeline (Europe)
 46. Cell
pipeline (all jurisdictions except US and Europe)

		
	Headline Price	  	US$100 per Product
		
	Transitional Manufacturing and Supply Agreement	  	Until Purchaser can manufacture relevant Products, Novartis or Third Party Purchaser to supply Product to Purchaser on terms consistent with the Agreed Terms for the Manufacturing, Supply and Distribution Agreement (as defined in
the Vaccines SAPA) (with any necessary amendment) until such time as the full form Manufacturing, Supply and Distribution Agreement (as defined in the Vaccines SAPA) is agreed, in which case, the terms that will apply will be that full form
agreement (with any necessary amendments)
		
	Transitional Services	  	Novartis or Third Party Purchaser to provide transitional services to Purchaser on terms consistent with the Agreed Terms for the Transitional Services Agreement (as defined in the Vaccines SAPA) (with any necessary amendment)
until such time as the full form Transitional Services Agreement (as defined in the Vaccines SAPA) is agreed, in which case, the terms that will apply will be that full form agreement (with any necessary amendments)

  
  

10 

 Execution Version 
  

			
	 Term
	  	 Description

	IP	  	Paragraph 3 of Schedule 2 applies mutatis mutandis in relation to agreeing the Option 4 Changes as if set out in this Schedule 4 with references to “Business” in Paragraph 3 of Schedule 2 being read here as if
these references were references to “Products” (i.e. such of the above listed products in this Schedule 4 as Novartis has specified).
		
	Marketing Authorisation	  	Novartis or Third Party Purchaser to distribute Products on behalf of Purchaser until Purchaser has obtained Marketing Authorisation, on the same basis as set out in Schedule 1.

  

	10	Following entry into this Deed, the parties shall discuss and agree, in good faith and acting reasonably, the amendments that are necessary to Schedule 1 to reflect that the Option 4 Assets that are being bought and
sold rather than the Business (the “Option 4 Changes”) (recognising that the Option 4 Changes may be required in addition to other changes pursuant to Schedules 2 or 3). 

Paragraph 1.1 of Schedule 2 applies mutatis mutandis in relation to agreeing the Option 4 Changes as if set out in this Schedule 4. 

 

	11	For the avoidance of doubt, if the Put Option is exercised in respect of the Option 4 Assets, then in respect of the Option 4 Assets: 

 

	11.1	the Headline Price in paragraph 3.1.1 shall be as set out in the table above (based on the number of Products in respect of which Option 4 has been exercised); 

 

	11.2	the Minimum Claims figure in paragraph 10.3.1 (i) shall be £100; 

  

	11.3	the Aggregate Minimum Claims figure in paragraph 10.4.1 shall be £1,000; 

  

	11.4	the Maximum Liability in paragraph 10.5.1 shall be 30% of the aggregate Headline Price for the relevant Option 4 Assets ; 

  

	11.5	the Maximum Liability in paragraph 10.5.2 shall be the aggregate Headline Price for the relevant Option 4 Assets; and 

  

	11.6	paragraph 12 of Schedule 1 shall only apply from such time as Novartis no longer has any interest in the Business (and shall then apply for the stated periods). 

 

	12	For the avoidance of doubt, if the Put Option is exercised in respect of the Option 4 Assets, paragraphs 8.1.2, 8.1.3 and 8.1.4 shall apply in respect of the Option 4 Assets. 

  
  

11 

 Schedule 2 

Amended Disclosure LetterAgreement 
 [***]

  
  
  

[**** Note: Confidential treatment has been requested with respect to the information contained within the [***] marking. Such portions, consisting of 156
pages, have been omitted from this filing and have been filed separately with the Securities and Exchange Commission.**]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00241-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00241-of-00352.parquet"}]]